03/35026

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 1 August 2002 (01.08.2002)

PCT

(10) International Publication Number WO 02/059377 A2

(51) International Patent Classification7:

- -

- (21) International Application Number: PCT/US02/02242
- (22) International Filing Date: 24 January 2002 (24.01.2002)
- (25) Filing Language:

English

C12Q 1/68

(26) Publication Language:

English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US

- (71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225A Gateway Boulevard, South San Francisco, CA 94080-7019 (US).
- (72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

- (74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Best Available Copy

110000

(54) Title: METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.



METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

15

BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

5

10

15

20

25

30

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), none are currently approved for breast cancer therapy in the US.

5

10

15

20

25

30

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

5

10

15

20

25

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

5

10

15

20

25

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

5

10

15

20

25

30

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist.

Preferably, the agent inhibits breast cancer.

5

10

15

20

25

30

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

25

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

Definitions

5

10

15

20

25

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster, cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

5

10

15

20

25

30

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

5

10

15

20

25

30

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

5

10

15

20

25

30

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (*see, e.g.*, the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

5

10

15

20

25

30

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

10

15

20

25

30

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and 10 polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, 15 Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & 20 Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid 25 analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and 5 linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

5

10

15

20

25

30

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

10

15

20

5

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

25

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

10

15

20

25

30

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times

background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

5

10

15

20

25

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include *in vitro*, *in vivo*, and *ex vivo* activities.

5

10

15

20

25

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed. 1994).

5

10

15

20

25

30

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'₂, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The F(ab)'₂

may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

10

15

20

25

Identification of breast cancer-associated sequences

10

15

20

25

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

10

15

20

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are up-regulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g.,

European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ).

U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and treatment of breast cancer is hereby expressly incorporated by reference.

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

5

10

15

20

25

Informatics

5

. 10

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

5

10

15

20

25

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis:

Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999);

Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

5

10

15

20

25

30

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

10

15

20

25

30

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

Use of breast cancer nucleic acids

5

10

15

20

25

30

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

10

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

20

5

10

15

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

25

30

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

5

10

15

20

25

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

10

15

20

25

30

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip™ technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

Expression of breast cancer proteins from nucleic acids

5

10

15

20

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast

cancer proteins are used to make a variety of expression vectors to express breast cancer

proteins which can then be used in screening assays, as described below. Expression vectors

and recombinant DNA technology are well known to those of skill in the art (see, e.g.,

Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are

used to express proteins. The expression vectors may be either self-replicating

extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

5

10

15

20

25

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, supra).

5

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez & Hoeffler, *supra*). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

5

15

20

25

30

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to

optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

5

10

15

20

25

30

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

5

10

15

20

25

Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

10

15

20

25

30

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al., Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem. 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

Antibodies to breast cancer proteins

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

10

15

20

25

30

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5

10

15

20

25

30

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

10

15

20

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al., J. Immunol. 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all

10

15

20

25

30

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

10

15

20

25

30

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

15

20

25

30

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Selectivity of binding is also important.

Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

10

15

20

25

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

PCT/US02/02242

5

10

15

20

25

30

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

5

10

15

20

25

30

In another preferred method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein.

In a preferred embodiment, in situ hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

5

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein..

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out in Table 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype.

Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity.

Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

5

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et al., J. Med. Chem. 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

5

10

15

20

25

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

10

15

20

25

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

30

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

5

10

15

20

25

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

5

10

15

20

25

Assays to identify compounds with modulating activity can be performed in vitro. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

5

10

15

20

25

30

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon TM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

5

10

15

20

25

30

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ¹²⁵I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

5

10

15

20

25

30

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

5

10

15

20

25

30

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed., 1994), herein incorporated by reference. See also, the methods section of Garkavtsev et al. (1996), supra, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (³H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (³H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (³H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

Growth factor or serum dependence

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

5

10

15

20

25

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with ¹²⁵I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A . Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10⁶ cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of breast cancer

5

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothicate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

Ribozymes

5

10

15

20

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g.,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

Methods of identifying variant breast cancer-associated sequences

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et al., eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

10

15

20

25

30

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

5

10

15

20

25

30

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

5

10

15

20

25

30

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

25.

10

5

Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

5

10

20

25

30

Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

10

15

20

25

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing. They are next centrifuged at <8000 rpm (<7500 x g) for 5 minutes at 4°C.

The RNA wash is decanted. The pellet is carefully transferred to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H₂0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A⁺ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

5

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H₂0 at 1ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Oiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

15

20

10

5

First Strand cDNA Synthesis

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNAl. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1

25 hour.

30

Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H₂0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

In vitro Transcription (IVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 1.5 ul T7 10xUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μl
Random Hexamers (1 μg/μl): 4 μl
H₂O: μl
14 μl

5

10

25

Incubate the above 14 µl mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μ l 50X dNTP mix: 0.6 μ l H₂O: 2.4 μ l Cy3 or Cy5 dUTP (1mM): 3 μ l

Sapar (DDI)

SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min., 42°C. Then, 1 µl SSII is added and incubated for another hour before being placed on ice.

16 µl

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25 μ l each of 100mM dATP, dCTP, and dGTP; 10 μ l of 100mM dTTP to 15 μ l H₂O.]

RNA degradation is performed as follows. Add 86 µl H₂O, 1.5 µl 1M NaOH/

2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 µl TE/sample spin at 7000 g
for 10 min, save flow through for purification. For Qiagen purification, suspend u-con
recovered material in 500 µl buffer PB and proceed using Qiagen protocol. For DNAse
digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min.
Incubate at 5 min 95°C to denature the DNAse.

10

15

Sample preparation

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H₂0. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H₂O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H₂O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H₂O. Dry slides and scan at appropriate PMT's and channels.

TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

10								
	Pkey:		Unique Eos probeset identifier number					
	ExAcon:			Exemplar Accession number, Genbank accession number				
	Unigene			bridene number				
	Unigene Title:			Jrigene gene title				
15		I IUE.						
13	R1:		Kauo o	A LICOTUSTI CI	east tissue to tumor			
					•			
			_					
	Picey	ExAccn	ι	JnigenelD	UnigeneTitie		R1	
							_	
20	100472	D90084	-	ts.1023	pyruvate dehydrogenase (lipoamide) alpha		5	
	100499	T51986	1	ts.283108	hemoglobin, gamma G		10	
	100545	M55405			gb:Homo sapiens mucin (MUC-3) mRNA, part		5	
	100549	BE1420	19 F	ts.222056	Homo saplens cDNA FLJ11572 fis, clone HE		10	
	100613	X52078	H	ls.101047	transcription factor 3 (E2A immunoglobul		5	
25		BE25903			Ewing sarcoma breakpoint region 1		5	
		X16841			neural cell adhesion molecule 1		5	
		A03758	•		NM_000477*Homo sapiens albumin (ALB), m		10	
		L27065			gbd-luman neurofibromatosis 2 (NF2) mRNA,		5	
		M60832		le 2/0220	collagen, type VIII, alpha 2		5	
30		BE37972		ls.83213	fatty acid binding protein 4, adipocyte		10	
30		AJ25056		ts.82749	transmembrane 4 superfamily member 2		5	
				ts.2099			5	
		M90424			lipocalin 1 (protein migrating faster th		10	
		NM_001		ts.460	activating transcription factor 3			
25		NM_006		ts.75678	FBJ murine osteosarcoma viral oncogene h		10	
35		X03350	-	ts.4	alcohol dehydrogenase 1B (class I), beta	1	10	
		M21305			gbd-luman alpha satellite and satellite 3	·	10	
•		N98569		1s.76422	phospholipase A2, group IIA (platelets,		10	
		M27826			endogenous retroviral protease		10	
	101634	AV6502	62 H	ts.75765	GRO2 oncogene	ŧ	5	
40	101736	M74447	ŀ	ts.502	transporter 2, ATP-binding cassette, sub	Į.	10	
	102208	U22961			gbd-turnan mRNA clone with similarity to L	Ş*	10	
	102297	NM_001	504 H	ts.198252	G protein-coupled receptor 9		5	
	102450	U48251	ŀ	ls.75871	protein kinase C binding protein 1		10	
	102515	U89337			tenascin XB		10	
45	102571	U60115	H	ts.239069	four and a half LIM domains 1		5	
		AA31353			gb:EST185419 Colon carcinoma (HCC) cell		10	
		NM 006		ts.76461	retinol-binding protein 4, interstitial		10	
		AA8292			serum amyloid A1		10	
·		X98065		ts.54433	tenascin R (restrictin, Janusin)		5	
50		AA0819			gb:zn26d06.r1 Stratagene neuroepithelium		10	
20		AA1261			gb:zm78c07.r1 Stratagene neuroepithelium		5	
		AA13710		P 336304	Homo sapiens, clone MGC:16638, mRNA, com		10	
				1s.8719	hypothetical protein MGC1136		5	
		AA3262					5	
EE		AB0410		18.57771	kallikrein 11 (KLK11; TLSP; PRSS20; hipp			
55		R50727		ts.336970	— - ·		10	
		AA42212			gbczv26h12,r1 Soares_NhHMPu_S1 Homo sapi		5	
		AL35395			hypothetical protein DKFZp434P0531		10	
		F06638		ts.12440	Homo sapiens done 24734 mRNA sequence		10	
		AA42618			gb:zw11e09.r1 Soares_NhHMPu_S1 Homo sapi		5	
60	104492	N73185	H	ts.94285	EST		10	
	104506	N91071	ŀ	ls.109650	ESTs		10	
	104511	N99542		ts.572	orosomucoid 1		5	
		AI49876	3 H	Hs.203013	hypothetical protein FLJ12748		10	

10

	104536	R24024	Hs.158101	Homo saplens cDNA FLJ14673 fis, clone NT	5
		Y11312	Hs.132463	phosphoinositide-3-kinase, class 2, beta	5
	104659	AW969769	Hs.105201		5
		AA009764	Hs.190380	ESTs	10
5	104711	AA017245	Hs.32794	ESTs	10
	104731	AA019300	Hs.125070	ESTs, Moderately similar to 154374 gene	10
		AI039243	Hs.278585	ESTs	5
		Al298208	Hs.28805		10
	105036	AA130390		hypothetical protein FLJ20898	10
10		R61532		hypothetical protein FLI22938	5
		AW970043	Hs.238039	hypothetical protein FLJ11090	5
		AA221036		gb:zr03f12_r1 Stratagene NT2 neuronal pr	10
		AA421973		ESTs, Wealdy similar to T25731 hypotheti	5
1.5		BE242857			5 10
15		N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	5
		AL359624	Hs.11387		10
		Al803651	Hs.191608		5
		AW976171		hypothetical protein FLJ22233	10
20		A1085846		KIAA1808 protein DKFZP434N061 protein	10
20		AL042069 AW235928	Hs.313182		10
		AA135688	Hs.10083		10
		AA906434	Hs.3776	zinc finger protein 216	5
		AW054888	Hs.25682		10
25		Al458623	12000	ghttk04g09.x1 NCI_CGAP_Lu24 Homo sapiens	5
~~		Al983730	Hs.26530	· · · · · · · · · · · · · · · · · · ·	5
		Al347578		hypothetical protein MGC2605	5
		AF128847		Indolethylamine N-methyltransferase	5
	106991	AJ223811	Hs.30127	hypothetical protein	5
30	107103	Al446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	5
	107124	AB006532		RecQ protein-like 4	10
	107148	A1005036		GS1999full .	10
		AF127026	Hs.5394	myosin IA	10
25		AB020672		KIAA0865 protein	10
35		AI905985	Hs.111805		10
		U51704		ESTs, Moderately similar to ALU8_HUMAN A	5 5
		W26652	Hs.6163	PTEN induced putative kinase 1	10
		W28516		hypothetical protein MGC11308	10
40		AL042425 A1092790		hypothetical protein PRO2389 hypothetical protein FLJ14529	5
40		W38002	15.334703	Empirically selected from AFFX single pr	10
		N53167	Hs.47623	• •	10
		W96141	Hs.220687		10
		AA017462	Hs.269244		10
45		BE621721		hypothetical protein FLJ12387 similar to	10
		AA025060	Hs.61246		10
		BE271708	Hs.95110	ESTs, Wealdy similar to A55943 1-phospha	10
	107888	AA025836	Hs.191637	ESTS	5
	107997	AL049176	Hs.82223	chordin-like	10
50		AA043675	Hs.62633		10
		AA093668		muscleblind (Drosophila)-like	5
		AA012881	Hs.72531		10
		AA059473	Hs.66783		10 5
E E			Hs.144269		5
55		AA070500		gbzm70h03.s1 Stratagene neuroepithelium gbzf79b12.s1 Soares_pineal_gland_N3HPG	10
		AA071193	Un erroe	macrophage receptor with collagenous str	5
		NM_006770	Hs.67726	gb:zm86a01.s1 Stratagene ovarian cancer	10
		AA075124		gb:zm97c09.s1 Stratagene colon HT29 (937	10
60		AA079079 AA085383		gbzzn13g03.s1 Stratagene hNT neuron (937	10
UU		AA074897		gb:zm65a05.r1 Stratagene ovarian cancer	10
		AA934589	Hs.49696	ESTs	5
	108662	AF117646	Hs.156637	Cas-Br-M (murine) ectropic retroviral tr	5
		AA121820	Hs.74569	KIAA0842 protein	10
65		AA126583	Hs.158725	ESTs	10
	108827	Al273692	Hs.110470		10
	109123	AI028376	Hs.73232		10

PCT/US02/02242

	109389	AA101325	Hs.86154	hypothetical protein FLJ12457	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	5
		R40604		ESTs, Wealdy similar to MCAT_HUMAN MITOC ring finger protein 24	10 10
5		A1094674 H46749	Hs.30524 Hs.31540	. .	10
•		W22165	Hs.22586	ESTs	· 5
		AW294162		UDP-N-acetyl-alpha-D-galactosamine:polyp	10
		H51276	Hs.13526	hypothetical protein FLJ12688	10 5
10		H52576 H72639	Hs.167608	gbcyt85e08.r1 Soares_pineal_gtand_N3HPG FSTe	5
10		H60593	Hs.124990		10
		AL044174		patched (Drosophila) homolog	10
		AI753316	Hs.26034		5
15		N66616	Hs.138629	H.sapiens mRNA for subtetomentc repeat s gb:tr34b07.x1 NCL_CGAP_Ov23 Homo sapiens	5 10
13		A1798376 AJ224864	Hs.9688	leukocyte membrane antigen	5
		AA641636	Hs.37477	ESTs, Weakly similar to T46908 hypotheti	5
		R00144	Hs.189771		10
~~		Al168511		gb:ow90h09.s1 Soares_fetal_liver_spleen_	10
20		R16733 R26065	Hs.20499	ESTs gb:yh39d03.s1 Soares placenta Nb2HP Homo	10 5
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
		R42333	Hs.302292		10
		AL117490		Ras-associated protein Rap1	10
25		NM_006668	Hs.25121		10 5
-		R51889 R31094	Hs.24990 Hs.24378	ESTs	10
		R77302	16.24010	gbcyi75h08.s1 Soares placenta Nb2HP Homo	10
		BE618629	Hs.268809		5
30		T98628	Hs.191290		5
		Al057205 AA581428	Hs.14584 Hs.5021	ESTs EST	5 10
		T16837	Hs.4241	ESTs	5
		T51588		gbcyb27e06.s1 Stratagene fetal spleen (9	10
35		T54659		Homo saplens cDNA FLJ11465 fls, clone HE	5
		AA743563	Hs.10305		5 10
		AW207424 N92359	Hs.332594 Hs.14518	ESTs, Moderately similar to A48752 B-cel	10
		R16763	Hs.268679		5
40		AA913635		Homo sapiens cDNA FLJ20812 fis, clone AD	10
		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5 10
		Al791905 Al244311	Hs.95549 Hs.26912	hypothetical protein ESTs	10
		W07586	Hs.8045	ESTS	3
45		W86195		gb:zh54e05.s1 Soares_fetal_liver_spteen_	- 10
,		Z39319	Hs.27347	EST	10
		AB018263 AA745978	Hs.28273	tumor necrosis factor receptor superfamil ESTs	5 5
		AA020738	115.20213	gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50		AA034378	Hs.267319	endogenous retroviral protease	5
		AA065096		gb:zm50a02.s1 Stratagene fibroblast (937	5
		AA081507	11. 07000	gbczn05b10.r1 Stratagene hNT neuron (937	5 5
		AA234826 AA234462	Hs.87386 Hs.87350	EST ESTs	5
55		AK000725	Hs.50579	hypothetical protein FLJ20718	3
	115666	AF173081	Hs.178215	Vertebrate LIN7 homolog 1, Tax Interacti	5
		AB020649	Hs.74569	KIAA0842 protein	5
		AA398841 AI478427	Hs.39850	hypothetical protein FLJ20517 esophageal cancer related gene 4 protein	10 10
60		AL133916	Hs.43125 Hs.172572	hypothetical protein FLJ20093	10
-		AA463902	Hs.13522	ESTs, Wealdy similar to 138022 hypotheti	5
		AW968703	Hs.30085	hypothetical protein FLJ23186	5
		AW410377	Hs.41502	hypothetical protein FLJ21276	5 10
65		AW194253 BE314852	Hs.68607 Hs 168694	ESTs Homo saptens clone 23763 unknown mRNA, p	5
	• • • • •	F10528	Hs.70001	ESTs, Moderately similar to JC6169 nucle	5
	117058	AW801806		gb:IL5-UM0070-110400-062-g07 UM0070 Homo	5

PCT/US02/02242

	117151	AI803656	Hs.42373	ESTs	5
		N20468		gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
		A1472863	Hs.43387	ESTs	5
		N34417	Hs.44584		3
5		N26627		ESTs, Wealdy similar to JC4124 pregnancy	5
		N40551		Homo sapiens Ets-1 binding protein (E1B)	10
		N49285	Hs.182391		10 10
		AW263476	Hs.44268 Hs.279472		5
10		BE222341 N53145	115.21 341 2	gb;yv55i09.s1 Soares fetal liver spleen	3
10		AW955696	Hs.90960	ESTS	10
		A)078236	Hs.49688		5
		N70907	Hs.230619		10
		AL122040	Hs.102981	Homo sapiens mRNA; cDNA DKFZp434G1972 (f	3
15	118902	AA993527	Hs.293907	hypothetical protein FLJ23403	5
		A)160570	Hs.252097	pregnancy specific beta-1-glycoprotein 6	3
		AF142419	Hs.15020		5
		AA514422	Hs.221849		† 5 10
20		AK002001	Hs.51305		10 5
20		T77892	Hs.90949	gb;yd20f04.s1 Soares fetal liver spleen EST	5
		T81824 W38051	N3.30343	Empirically selected from AFFX single pr	10
		AL049798	Hs 80552	dematoportin	3
		AF086332	Hs.58314		10
25		AF088061	Hs.159690		5
	119835	AF086429	Hs.58429	ESTs	- 5
	119923	AW803308	Hs.62954	ferritin, heavy polypeptide 1	5
		U34249	Hs.337461	Human putative zinc finger protein (ZNFB	5
~~		AL042725		gb:DKFZp434B1822_r1 434 (synonym: htes3)	10
30		AW136934	Hs.97162		5 5
		AA907743	Hs.142373		5
		AA401695 AA405763	Hs.97334	Homo sapiens cDNA FLJ20470 fis, clone KA	5
		AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35		AK000229	Hs.98017		10
-		AA447555	Hs.99116		10
		AA458945	Hs.95898		10
	122771	AW135093		ESTs, Highly similar to G100_HUMAN 110 K	5
40		AA609122		Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5
40		Al024595	Hs.97508	a disintegrin and metalloproteinase doma	5
		AA621529		gbcaf47a02.s1 Soares_total_fetus_Nb2HF8_	10 5
		H62570 H83465		gb:yr44a01.r1 Soares fetal liver spleen gb:ys91a11.s1 Soares retina N2b5HR Homo	5
		AK001527	He 163053	hypothetical protein FLJ10665	5
45		NM_014312		cortic al thymocyte receptor (X. laevis	10
		T98199	Hs.48403		10
		BE299567		ESTs, Moderately similar to ALU8_HUMAN A	5
	125284	NM_002666	Hs.103253	perlipin	10
		BE256206	Hs.17775		5
50	128484	AA485421		ESTs, Weakly similar to ALU7_HUMAN ALU S	10
				potassium intermediate/small conductance	10
		R44214	Hs.101189		5 5
		C16161 AA193106		hypothetical protein PRO2543 chromosome 11 open reading frame 23	10
55		H39537		eukaryotic translation elongation factor	10
33		AW150717		STAT induced STAT inhibitor 3	10
		N62889	Hs.107242	Homo sapiens cDNA FLJ12965 fis, clone NT	10
		AA443323		BPOZ protein	5
		AA056483	Hs.301463	Human Chromosome 16 BAC clone CIT987SK-A	5
60		NM_013403	Hs.108665		10
		AL117472		SH3-domain protein 5 (ponsin)	5
		A1146494		ESTs, Weakly similar to IRX2_HUMAN IROQU	3
		U40714		tyrosyl-IRNA synthetase	5
C F		AA530892		dual specificity phosphatase 1	5 10
65		BE617015 AF110141		ESTs, Moderately similar to T17372 plasm WAS protein family, member 2	10
		NM_003877		STAT induced STAT inhibitor-2	5
	123300	. 417_VVVV) /	15.10170	OTTO BROOKS OTTO BESIDENCE	•

					c
		X06828		von Willebrand factor	5 10
		AW245805		claudin 5 (transmembrane protein deleted	5
		W37944	Hs.4007	Sarcolemnal-associated protein	10
E		BE061069		KIAA0467 protein	10
5		AF020038		isocitrate dehydrogenase 1 (NADP+), solu	10
		BE222078	Hs.113069		5
		BE622468		ESTs, Wealdy similar to 138022 hypotheti ESTs, Wealdy similar to 138022 hypotheti	5
		Al304966	Hs.12457	hypothetical protein FLJ10814	10
10		AK001676 AK000956	Hs.13209		5
10		Al338993	Hs.134535		5
		AJ251760		quanine nucleotide binding protein (G pr	5
		NM 000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
		NM_001158		amine oxidase, copper containing 2 (reti	5
15		M62402		insulin-like growth factor binding prote	10
LJ		AA452006	Hs.333199		5
		W80711		Homo saplens mRNA for KIAA1727 protein,	5
		D88435		cyclin G associated kinase	10
		AI241084	Hs.154353	nonselective sodium potassium/proton exc	5
20		AA435746		gb:zt79e03.s1 Soares_testis_NHT Homo sap	5
	130400	V00517	Hs.283108	hemoglobin, gamma G	10
	130436	NM_001928	Hs.155597	D component of complement (adipsin)	10
	130478	X72308	Hs,251526	small inducible cytokine A7 (monocyte ch	5
	130480	BE222978	Hs.15760		10
25	130494	AW390834	Hs.75874	pregnancy-associated plasma protein A	5
	130563	BE270472		HSPC015 protein	10
		AL110226		DKFZP434H204 protein	10
		Al652143		hypothetical protein FLJ13111	5
20		A1769067	Hs.127824	ESTs, Weakly similar to T28770 hypotheti	3 10
30		AA993269		Homo saplens, done IMAGE:3875012, mRNA	10
		NM_006691			5
		AA232075	Hs.18259		10
		AF263462	Hs.18376 Hs.18441		5
35		N41322 M81349	Hs.1955	serum amyloid A4, constitutive	10
33		BE048821	Hs.20144		10
		AB040935	Hs.23954		10
		AA360419		inositol(myo)-1(or 4)-monophosphatase 1	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	. 10
40		AW939251	Hs.25647		10
		AKD00393	Hs.25817	BTB (POZ) domain containing 2	5
	131341	AF110908	Hs.297660	TNF receptor-associated factor 3	5
	131406	H83294	Hs.284122	Wnt inhibitory factor-1	5
	131489	BE394648	Hs.27414	hypothetical protein	5
45		AW966881	Hs.41639	, .	10
		BE559681	Hs.30736		5
		AA829286		serum amyloid A1	10
		AA443966	Hs.31595		10 10
50		H69342		TRABIO protein	5
50		AA021258	Hs.32753		5
		BE244961		FE65-LIKE 2	10
	131828	AJ000263 AW294659	Hs.34054	kerafin, hair, basic, 6 (monilethrix) Homo sapiens cDNA: FLJ22488 fis, clone H	5
		AJ003112	Hs.34780	doublecortex; lissencephaly, X-linked (d	5
55	424040	AK000010		hypothetical protein FLJ20003	10
"	422445	HB1604		KIAA0798 gene product	5
	422177	X80818		giutamate receptor, metabotropic 4	5
	122296	AA467752	Hs.195161		5
	132426	AW118072	Hs.89981	diacytolycerol kinase, zeta (104kD)	10
60	132477	S68874		prostaglandin E receptor 3 (subtype EP3)	5
	132675	A1291496	Hs.5476	Homo saplens, clone IMAGE:3530123, mRNA,	10
	132796	NM_006283		transforming, acidic coiled-coil contain	10
	132898	W28548	Hs.224829		10
	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
65	132953	BE175645	Hs.321264	LBP protein 32	5
	133116	BE563966	Hs.6529	ESTs, Wealty similar to 178885 serine/th	5
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10

	133130	AF052138	Hs.6580	Homo saplens cDNA: FLJ23227 fts, clone C	5
		AA668224	Hs.6634	Homo sapiens cDNA: FLJ22547 fis, clone H	5
		AW956781	Hs.293937		5
		NM_002776	Hs.69423	kalikrein 10 (KLK10) (PRSSL1) (nes1)	5
5		AA207059	110.00120	gb:zq80h09.s1 Stratagene hNT neuron (937	5
		AF017987	Hs.7306	secreted frizzled-related protein 1	5
		H21497	Hs.7471	BBP-like protein 1	5
		L02321	Hs.75652	glutathlone S-transferase M5	5
		H26904	Hs.75736	apolipoprotein D	5
10		N71725		hemoglobin, alpha 2	10
	-	T85626	Hs.76239		5
	134007	AF072441	Hs.7840	calcineurin binding protein 1	10
	134055	D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
	134111	Al372588	Hs.8022	TU3A protein	10
15	134117	AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10
	134177	BE243319	Hs.79672	KIAA0652 gene product	5
	134308	AW905827	Hs.81454	ketohexokinase (Iructokinase)	10
	134361	BE549343	Hs.82208	acyl-Coenzyme A dehydrogenase, very long	5
	134369	AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
20	134449	L34155	Hs.83450	laminin, alpha 3 (niceln (150kD), kalini	5
	134467	Al190413	Hs.8373	ESTs	10
	134496	M64936		gb:Homo sapiens retinoic acid-inducible	10
	134510	NM_002757	Hs.250870	mitogen-ectivated protein kinase kinase	10
	134550	M26315	Hs.85258		10
25	134577	BE244323	Hs.85951		5
		U73394	Hs.166085	killer cell immunoglobulin-like receptor	5
		AL008583		dynein, axonemal, light polypeptide 4	5
		D10216	Hs.89394		5
20		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10
30		T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10
		T87521	Hs.261457		5
		NM_003394	Hs.91985	. •	10
		H22570		hypothetical protein FLJ20093	5
25		AA302517	Hs.92732		5
35		X04430	Hs.93913		10 10
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5
		U76456 AB002361	Hs.96633	tissue inhibitor of metalloproteinase 4 KIAA0363 protein	5
		U83171	Hs.97203		5
40		AA416829	Hs.191597		<i>i</i> 5
70		AA905406	Hs.9905	ESTs, Weakly similar to unnamed protein	3
		X55019	Hs.99975	cholinergic receptor, nicotinic, delta p	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5
		H39537	Hs.75309	eukaryotic translation elongation factor	₫ 5
45		AW245805		claudin 5 (transmembrane protein deleted	5
		M62402		insulin-like growth factor binding prote	¹ 5
		NM_006691	Hs.17917	extracellular link domain-containing 1	10
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	3
		AF017987	Hs.7306	secreted frizzled-related protein 1	5
50		N71725		hemoglobin, alpha 2	5
_	134369	AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
	135066	X04430	Hs.93913	Interleukin 6 (interferon, beta 2)	10
•		AL036557	Hs.95910	putative lymphocyte GO/G1 switch gene	5
	322580	AK001852	Hs.274151		5
55	408790	AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
	418043	AW377752	Hs.83341	AXL receptor tyrosine kinase	5
		BE208364	Hs.29283	ESTs, Wealthy similar to LIGHU proteoglycan link	5
		AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10
	449826	U85642	Hs.138506	ESTs	5
60		RC_H15814_s YEL024w/RIP1		Human apM1 mRNA for GS3109 (novel adipose specific EST - YEL024w/RIP1	c collagen 3

TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

4	Λ	
1	υ	

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession	Genhank accession numbers

15	Accession:	Genban	k accession numbers
	Pkey	CAT Number	Accessions
20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA07404 AA074794 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041 AA065148 AA071310 AA101144 AA079669 AA078931 AA078209 AA070928 AA068994 AA068817 AA076187 AA069053 AA131489 AA071308 AA063317 AA070158 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895
25		•	AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929
30	124215 117058 110455 111168	1597154_1 1219924_1 46874_1 38585_1	H62570 H59063 AW801806 H50434 BE086530 H52576 AF085971 H52172 ATP8876 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384
35			AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 Al829309 AW991957 N66951 AA527374 H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
40	111498 104340 103747 134496 Al684569	411008_1 46289_10 117944_1 46501_1 AA257011	Al168511 Al022712 AA700366 R07371 R07324 AA426189 F15201 AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311
45	103750 105239	118365_1 34624_1	AK079277 AI241318 BE327710 AW975215 AW898268 AA884990 BE327514 AA126129 AA126033 AA082561 AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16869
50	120379	34624_3	AL042725 BED63316 AW975610 AA457591 BED62092 AI655202 AA714296 AI267264 AI075321 AA223286 AA071122 AA227849 AA216700 AI698002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868 AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
55	114624 106851 108392 100545	111686_1 322947_1 113549_1 22955_11	AA081507 AA070071 AA070840 AA084362 Al488623 AA639708 AA485409 R22065 AA485570 AA075124 AA075208 M55405 AW752552 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495
60	100654 100702 102208	tigr_HT2969 tigr_HT3413 6735_9	X51363 X51364 X51365 L27065 U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 AI378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101

N70806 AI141254 AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 AH33207 AH32980 AH33214 AUG64826 AUG61615 AH33473 AH74852 AH33404 Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 A1110799 D17107 NM_000477 AF190168 R50724 A1248416 A1207432 A1133684 A1133345 A1174710 AM33290 AM33304 AM74948 AI207484 AM10717 AF074624 AM14515 AF063516 AM10642 AM14559 AM14498 AM14759 5 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 A1174748 A1114663 A1133104 A1132999 A1133100 A1064925 A1064979 A1133063 AA343347 T69091 AA233989 T39772 AJ444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AJ400677 AJ091136 AA334608 T57411 Z20979 N56507 T87485 AM33622 AA343370 T40075 T69671 T53849 T74820 AF075316 AM10818 T40121 T57381 AM114468 10 AA332728 T51362 AH14589 R06691 AH 10629 AF063503 AH40543 AA334681 AA332720 AA343262 T73513 T86549 A1114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 A1174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 15 AA501730 T39931 T39682 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005018 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W5Z763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W88731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 20 AM89471 AA005147 AM78102 AI207662 AM92792 AI768421 AI064737 AW051713 AA936693 AM33117 AI766232 AI913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 A1823482 A1114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363 T78943 A1823481 AA845518 AA719124 AA883454 T68850 T69115 A1935509 A1150977 T62890 T71374 T68294 A1174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 25 MUS2657 175984 T69118 W82684 A114860 T62093 T61797 A152233 T73322 H92881 T56018 T61811 T57232 A1336158 T61821 T69457 T62900 T62912 T72917 T46885 A1702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 A187111 T64308 T62071 T69427 A1114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 30 T67751 A1774983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864 AA621529 123941 genbank_AA621529 genbenk_N53145 118049 N53145 AA313538 U88895 U88902 102800 14782_20 35 104106 AA422123_j_stAA422123_j R26065 111738 genbank_R26065 genbank_T51588 113149 T51588 genbank_W86195 genbank_AA070500 W86195 113958 108335 AA070500 genbank_AA071193 40 AA071193 108351 108441 genbank_AA079079 AA079079 124276 genbank H83465 H83465 M21305 101447 entrez_M21305 genbank_N20468 117226 N20468 45 genbank_AA207059 AA207059,AA207241 133379 119366 genbank_T77892 T77892 NOT_FOUND_entrez_W38051 W38051 119528 112588 genbank_R77302 R77302 114449 genbank_AA020736 AA020736 50 114576 genbank_AA065096 AA065096 107459 W38002 s at W38002 s AA435746 130339 genbank_AA435746

PCT/US02/02242 WO 02/059377

TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue.

Pkey: ExAccn: UnigenelD: Unigene Title: R1: 10

Unique Eos probeset identifier number Exemptar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

100499 T51986 Hs.283108 Hemoglobin, gamma G 10	15	Pkey	ExAccn	UnigenelD	Unigene Tittle	1	R1
100549 BE142019 Hs.222056 Homo seplens cDNA FLJ11572 fls, clone HE 10 100674 A03758 Hs.83573 Hs.83213 Hs.450 Hs.75678 Hs.75678 Hs.75678 Hs.75678 Hs.75678 Hs.75678 Hs.75678 Hs.75678 Hs.76421 Hs.76461 Hs.75679 Hs.75679 Hs.75679 Hs.75679 Hs.75679 Hs.76422 Hs.76421 Hs.76461 Hs.36970 Hs.266391 Hs.36970 Hs.266391 Hs.36970 Hs.266391 Hs.266391 Hs.266391 Hs.266391 Hs.266391 Hs.266391 Hs.266391 Hs.36980 Hs.369980 Hs.36980 Hs		100499	T51986	Hs.283108	hemoglobin, gamma G		10
100654 A03758 Hs.3213 Hs.420 E379727 Hs.3213 E379727 Hs.460 E379727 Hs.460 E379727 Hs.460 E379727 Hs.460 E379727 Hs.460 E379727 Hs.460 E379727 Hs.470 Hs.470 E37972 Hs.470 Hs.470 E37972 Hs.470 Hs.470 E37972 Hs.470 Hs				• • • • • • • • • • • • • • • • • • • •			10
101184 NM_001674							10
101184 NM_001674	20	100971	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte		10
101367 X03350 Hs.4 alcohol dehydrogenase 1B (class I), beta 10 gbd-human alpha satelille and satelille 3 10 lot		101184	NM_001674	Hs.460			10
101367 X03350				Hs.75678	FBJ murine osteosarcoma viral oncogene h		10
101451 N98569				Hs.4	alcohol dehydrogenase 1B (class I), beta		10
101511 M27826		101447	M21305		gbd-furnan alpha satellite and satellite 3		10
101736 M74447	25	101461	N98569				
102208 U22961 Hs.75871 gbtHuman mRNA clone with similarity to L 10 102800 AA313538 gbtEST185419 Colon carcinoma (HCC) cell 10 102900 AA829286 Hs.332053 serum amyloid A1 102990 AA829286 Hs.332053 serum amyloid A1 10 103812 AA137107 Hs.326391 Homo saplens, clone MGC:16638, mRNA, com 10 104109 A1.353957 Hs.284181 hypothetical protein DKFZp434P0531 10 104492 N73185 Hs.94285 ESTs 10 104506 N91071 Hs.109650 ESTs 10 104506 N91071 Hs.109650 ESTs 10 104731 AA019300 Hs.283013 hypothetical protein FL.112748 10 104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10 105239 AA221036 Hs.26362 ESTs Highly similar to T00391 hypothetical protein 10 106051 AA135688 Hs.26362 ESTs 10 106379 AL042069 Hs.119021 DKFZP434N061 protein 10 106491 AA135688 Hs.25632 KlAA1808 protein 10 107314 AB105632 Hs.313182 ESTs 10 106491 AA135688 Hs.25632 KlAA1808 protein 10 107214 AB006532 Hs.313420 Hs.334305 Hs.334305 Hs.35686 Hs.25682 KlAA1808 protein 10 107474 AB006532 Hs.314180 Hs.35998 Homo saplens mRNA for KlAA1863 protein, 10 107447 W28516 Hs.175411 KlAA0865 protein 10 107447 W28516 Hs.19510 ESTs Homo saplens mRNA for KlAA1863 protein, 10 107447 W28516 Hs.175411 KlAA0865 protein 10 107447 W28516 Hs.175411 KlAA0865 protein 10 107447 W28516 Hs.195110 ESTs Homo saplens mRNA for KlAA1863 protein, 10 107447 W28516 Hs.175411 KlAA0865 protein 10 107447 W28516 Hs.175411 KlAA0865 protein 10 107447 W28516 Hs.195110 ESTs Wealdy similar to A55943 1-phospha 10 107447 W28516 Hs.25954 Hs.301062 UDP-N-acotyl-abha-0-galactosamine polyto 10 10 10 10 10 10 10 1							
102450 U48251 Hs.75871 protein kinase C binding protein 1 10 gbEST185419 Colon carcinoma (HCC) cell 10 102890 AA313538 Hs.332053 senum amyloid A1 102990 AA829286 Hs.332053 senum amyloid A1 10 103912 AA137107 Hs.366391 Homo saplens, clone MGC:16638, mRNA, com 10 104109 AL353957 Hs.284181 hypothetical protein DKFZp434P0531 10 104250 F06638 Hs.12440 Homo saplens clone 24734 mRNA sequence 10 104506 N91071 Hs.109650 ESTs 10 104506 N91071 Hs.109650 ESTs 10 104506 N91071 Hs.3263794 ESTs 10 104711 AA017245 Hs.32794 ESTs 10 104711 AA017245 Hs.32794 ESTs 10 104711 AA019300 Hs.125070 ESTs 10 105036 AA130390 Hs.25549 hypothetical protein FLJ12748 pbc.25549 hypothetical protein FLJ120898 10 10632 AV28866 Hs.191608 ESTs 10 10633 Al085846 Hs.25522 KIAA1808 protein 1 10 106341 AW2345928 Hs.119021 DK-727434N061 protein 1 10 106341 AW235928 Hs.119021 DK-727434N061 protein 1 10 106351 AW235928 Hs.119021 DK-727434N061 protein 1 10 107124 AB006532 Hs.313182 ESTs 10 107124 AB006532 Hs.313182 ESTs 10 107124 AB006536 Hs.333405 GS1999ful 10 107447 W28516 Hs.19104 Hs.25695 hypothetical protein MGC-11308 hg.07447 W28516 Hs.19104 Hs.25695 hypothetical protein MGC-11308 hg.07447 W28516 Hs.19104 Hs.25695 hypothetical protein MGC-11308 hg.07447 W28516 Hs.19104 hg.07447 W28516 Hs.191021 DK-727434N061 protein 1 10 107424 AB006532 Hs.31442 Hs.333405 GS1999ful 10 107447 W28516 Hs.19104 Hs.25695 hypothetical protein MGC-11308 hg.07447 W28516 Hs.19104 Hs.25695 hypothetical protein MGC-11308 hg.07447 W28516 Hs.19104 Hs.26954 hg.08659 protein 1 10 107447 W28516 Hs.19104 Hs.26954 hg.08659 protein PRO2289 1 10 107447 W28516 Hs.19104 Hs.26954 hg.08659 protein PRO2289 1 10 107447 W28516 Hs.19104 hg.08659 protein PRO2289 1 10 107447 W28516 Hs.19104 Hs.26954 hg.08659 protein PRO2289 1 10 107447 W28516 Hs.19104 hg.08659 protein PRO2289 1 10 107447 W28516 Hs.26954 hg.08659 protein PRO2289 1 10 1074				Hs.502			
102800 AA313538							
102857 NN_006744	20			Hs.75871			
102990 AA829286 Hs.332053 Serum amyloid A1 10 103747 AA081995 103812 AA137107 Hs.326391 Homo saplens, clone MGC:16638, mRNA, com	30						
103747 AA081995							
103812 AA137107				Hs.332053			
104093 R50727				11- 000004			
104109 AL353957 Hs.284181 hypothetical protein DKFZp434P0531 10	25						
104250 F06638	33						
104492 N73185 Hs.94285 EST 10 104506 N91071 Hs.109650 ESTs 10 104532 Al498763 Hs.203013 hypothetical protein FLJ12748 10 104577 AA009764 Hs.190380 ESTs 10 104711 AA017245 Hs.32794 ESTs 10 104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10 105005 Al298208 Hs.28805 ESTs 10 105036 AA130390 Hs.25549 hypothetical protein FLJ20898 10 105239 AA221038 ESTs 10 106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10 106181 Al803651 Hs.191608 ESTs 10 106283 Al085846 Hs.25522 KIAA1808 protein 10 106491 AA135688 Hs.1083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25682 Homo sapiens, clone IMAGE:4139786, mRNA, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.334305 GS1999ful 10 107214 AF127028 Hs.334305 GS1999ful 10 107331 Al905985 Hs.11805 ESTS 10 107477 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTS, Weakly similar to A55943 1-phospha 10 10831 AA071193 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 10743 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 10743 AW2494162 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 10743 AW2494162 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
104506 N91071 Hs.109650 ESTs 10 104677 AA009764 Hs.190380 ESTs 10 104677 AA017245 Hs.32794 ESTs 10 104731 AA013000 Hs.125070 ESTs, Moderately similar to 154374 gene 10 105005 A1298208 Hs.28805 ESTs 10 105005 A1298208 Hs.28805 ESTs 10 105036 AA130390 Hs.25549 hypothetical protein FLJ20898 10 105039 AA221038 gbc30312.1 Stratagene NT2 neuronal pr 10 105028 A1085846 Hs.91608 ESTs 10 106283 A1085846 Hs.25522 KIAA1808 protein FLJ20898 10 106283 A1085846 Hs.25522 KIAA1808 protein FLJ20898 10 106491 AA135688 Hs.10083 Hs.119021 DKFZP434N061 protein 10 106491 AA135688 Hs.10083 Hs.0083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054866 Hs.25562 Homo sapiens mRNA for KIAA1863 protein, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.5394 myosin IA 10 107214 AF127028 Hs.5394 myosin IA 10 107331 Al905985 Hs.11805 EST5 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTS, Weekly similar to 55943 1-phospha 10 108518 AA071193 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.39100 UDP-N-acetyl-alpha-D-galactosamine.polypo 10							
40 104532 A4498763							
104677 AA009764 Hs.190380 ESTs 10 104731 AA017245 Hs.32794 ESTs 10 104731 AA019300 Hs.125070 ESTs, Moderately similar to 154374 gene 10 105005 A1298208 Hs.28805 ESTs 10 105036 AA130390 Hs.25549 hypothetical protein FLJ20898 10 105239 AA221038 gbzx03f12_r1 Stratagene NT2 neuronal pr 10 106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10 106181 A1803651 Hs.191608 ESTs 10 106283 A1085846 Hs.25522 KIAA1808 protein 10 106379 AL042069 Hs.119021 DKFZP434N061 protein 10 106491 AA135688 Hs.10033 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25682 Homo sapiens, clone IMAGE:4139786, mRNA, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.5394 myosin IA 10 107214 AB005036 Hs.334305 GS1999full 10 107214 AB005036 Hs.37411 KIAA0865 protein 10 107331 A1905985 Hs.11805 ESTS 10 107467 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weekly similar to A55943 1-phospha 10 108351 AA0771193 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 110433 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 10P-N-acetyl-alpha-D-galactosamine:Dolyo 10	40						
104711 AA017245 Hs.32794 ESTs 10 104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10 105005 AI288208 Hs.28805 ESTs 10 105036 AA130390 Hs.25549 Hs.25845 ESTs 10 105239 AA221038 Hs.25549 gbzz03f12_r1 Stratagene NT2 neuronal pr 10 106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypothetic 10 106181 AI803651 Hs.191608 ESTs 10 106283 AI085846 Hs.25522 KIAA1808 protein 10 106283 AI085846 Hs.25522 KIAA1808 protein 10 106491 AA135688 Hs.10031 DKFZP434N061 protein 10 106491 AA135688 Hs.10033 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107124 AF127028 Hs.5394 myosin IA 10 107242 AB020672 Hs.175411 KIAA0865 protein 10 107331 AI905985 Hs.11805 ESTS 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weekly similar to A55943 1-phospha 10 108351 AA071193 109546 F01449 Hs.26954 Hb.301062 UDP-N-acetyl-alpha-D-galactosamine:polypo 10	70				•		
104731 AA019300 Hs.125070 ESTs, Moderately similar to I54374 gene 10 105005 Al298208 Hs.28805 ESTs 10 105036 AA130390 Hs.25549 hypothetical protein FL;20898 10 105239 AA221038 ESTs hypothetical protein FL;20898 10 106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10 106181 Al803651 Hs.191608 ESTs 10 106283 Al085846 Hs.25522 KlAA1808 protein 10 106283 Al085846 Hs.25522 KlAA1808 protein 10 106379 AL042069 Hs.119021 DKG-ZP434N061 protein 10 106491 AA135688 Hs.303182 ESTs 10 106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25662 Homo sapiens mRNA for KlAA1863 protein, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.334305 GS1999full 10 107214 AF127028 Hs.334305 GS1999full 10 107242 AB020672 Hs.175411 KlAA0865 protein 10 107331 Al905985 Hs.111805 ESTS 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weakly similar to 54374 gene 10 10 10433 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKG-Zp762G123 (fr 10 10433 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKG-Zp762G123 (fr 10 10433 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKG-Zp762G123 (fr 10 10433 AW294162 Hs.26954 Homo sapiens mRNA; cDNA DKG-Zp762G123 (fr 10 10433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-qualactosamine.polyo							
105005 Al298208							
105036 AA130390							
105239 AA221036 gbza03f12_r1 Stratagene NT2 neuronal pr 10	45						
106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypotheti 10 106181 Al803651 Hs.191608 ESTs 10 106283 Al085846 Hs.25522 KIAA1808 protein 10 106379 AL042069 Hs.119021 DKFZP434N061 protein 10 106491 AAV35698 Hs.313182 ESTs 10 106491 AAV35688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.334305 GS1999full 10 107214 AF127028 Hs.5394 myosin IA 10 107242 AB002672 Hs.175411 KIAA0865 protein 10 107331 Al905985 Hs.11805 ESTs 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weekly similar to A55943 1-phospha 10 108351 AA071193 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosammerodyp 10				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
106181 Al803651 Hs.191608 ESTs 10 106283 Al085846 Hs.25522 KIAA1808 protein 10 106379 AL042069 Hs.119021 DKG-ZP434N061 protein 10 106451 AW235928 Hs.313182 ESTs 10 106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 106782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10 107124 AB006532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.334305 GS1999ful 10 107214 AF127028 Hs.5394 myosin IA 10 107242 AB020672 Hs.175411 KIAA0865 protein 10 107331 Al905985 Hs.111805 ESTS 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weekly similar to A55943 1-phospha 10 108351 AA071193 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp7625123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosammer.polypo 10				Hs.6382			
106283 Al085846							10
50 106379 AL042069 Hs.119021 DKFZP434N061 protein 10 106451 AW235928 Hs.313182 EST5 10 106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 10 105782 AW054886 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 10 107124 AB008532 Hs.31442 RecQ protein-like 4 10 107214 AF127028 Hs.5394 myosin IA 10 107214 AF127028 Hs.5394 myosin IA 10 107331 AI905985 Hs.11805 EST5 10 107447 W28516 Hs.19210 Hs.11805 EST5 10 107477 W28516 Hs.9210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTS, Weekly similar to A55943 1-phospha 10 10854 A071193 109546 F01449 Hs.26954 Homo sapiens mRNA cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosammer.polypo 10					KIAA1808 protein		10
106491	50	106379	AL042069	Hs.119021			10
106782 AW054886		106451	AW235928	Hs.313182	ESTs		10
107124		106491	AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,		10
55 107148 Al005036 Hs.334305 GS1999full 10 107214 AF127028 Hs.5394 myosin IA 10 107242 AB020672 Hs.175411 KIAA0865 protein 10 107331 Al905985 Hs.111805 ESTs 10 107447 W28516 Hs.19210 hypofinetical protein MiGC11308 10 107451 AL042425 Hs.283976 hs.95110 ESTs, Weakly similar to A55943 1-phospha 10 108351 AA071193 Hs.25110 Hs.26194 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine:polypo		106782	AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,		10
107214		107124	AB006532	Hs.31442			10
107242 AB020672 Hs.175411 KIAA0865 protein 10 107331 AI905985 Hs.111805 ESTs 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107872 BEZ71708 Hs.95110 ESTs, Weakly stmilar to A55943 1-phospha 10 108351 AA071193 Hs.26354 Hs.9512 Scares_pinea_gland_N3HPG 10 109346 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine.polyp 10	55	107148	Al005036	Hs.334305	GS1999full		10
107331 Al905985 Hs.111805 ESTs 10 107447 W28516 Hs.19210 hypothetical protein MGC11308 10 107871 AL042425 Hs.283976 hypothetical protein PRO2389 10 107872 BEZ71708 Hs.95110 ESTs, Weakly similar to A55943 1-phospha 10 108351 AA071193 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine.polyp 10		107214	AF127026	Hs.5394	myosin IA		10
107447 W28516 Hs. 19210 hypothetical protein MGC11308 10		107242	AB020672	Hs.175411	KIAA0865 protein		10
60 107451 AL04245 Hs.283976 hypthetical protein PRO2389 10 107872 BEZ71708 Hs.95110 ESTs, Weekly similar to A55943 1-phospha 10 108351 AA071193 gbzf79b12.s1 Soares pinest gland_N3HPG 10 109546 F01449 Hs.26954 Homo saplens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine.polyp 10		107331	A1905985	Hs.111805	ESTs		10
107872 BEZ71708 Hs.95110 ESTs, Weakly similar to A55943 1-phospha 10 108351 AA071193 gbzf79b12.s1 Soares pineal gland_N3HPG 10 109546 F01449 Hs.26954 Homo saplens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine.polyp 10		107447	W28516	Hs.19210			10
108351 AA071193 gbzf79b12.s1 Scares_pineat_gland_N3HPG 10 109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine.polyp 10	60			Hs.283976			10
109546 F01449 Hs.26954 Homo sapiens mRNA; cDNA DKFZp762G123 (fr 10 110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine:polyp 10				Hs.95110			
110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-galactosamine:polyp 10					gbzz79b12.s1 Soares_pineal_gland_N3HPG		
110433 AW294162 Hs.301062 UDP-N-acetyl-alpha-D-gatactosamine:polyp 10 patiched (Drosophila) homolog 5		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Homo sapiens mRNA; cDNA DKFZp762G123 (fr		
OD 110976 AL044174 Hs.159526 patiched (Drosophila) homolog 5	<i></i>				UDP-N-acetyl-alpha-D-galactosamine:polyp		
	65	110976	AL044174	Hs.159526	patched (Drosophila) homolog		5

	111168	AJ798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo saplens	10
	111651	R16733	Hs.20499	ESTs	10
	111803	AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
_	114484	AA034378	Hs.267319	endogenous retroviral protease	10
5	125284	NM_002666	Hs.103253	perilipin	10
	128850	AA193106	Hs.180817	chromosome 11 open reading frame 23	5
	128903	AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
	129346	AF110141	Hs.288908	WAS protein family, member 2	10
	129381	AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10	129516	AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
	129554	BE222078	Hs.113069	ESTs	10
	130085	M62402	Hs.274313	Insulin-like growth factor binding prote	10
	130243	D88435	Hs.153227	cyclin G associated kinase	10
	130400	V00517	Hs.283108	hemoglobin, gamma G	10
15	130436	NM_001928	Hs.155597	D component of complement (adipsin)	10
	130563	BE270472	Hs.279900	HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
	130683	AA993269	Hs.17872	Homo saplens, clone IMAGE:3875012, mRNA	10
	130689	NM_006691	Hs.17917	extracellular link domain-containing 1	10
20	130689	AA046747	Hs.17917	extracellular link domain-containing 1	10
	130718	N70196	Hs.18376	KIAA1319 protein	10
	130798	M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
	131184	AB040935	Hs.23954	cerebral cell adhesion molecule	10
25	131282	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	131328	AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
	131543	AW966881	Hs.41639	programmed cell death 2	10
		AA829286	Hs.332053	serum amyloid A1	10
	131785	H69342	Hs.26320	TRABID protein	10
30		AJ000263	Hs.278658	keratin, hair, basic, 6 (monitethrix)	10
		AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
	132675	A1291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
		W28548	Hs.224829	ESTs	10
		NM_004235	Hs.7934	Kruppel-like factor 4 (guf)	10
35		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
		AF017987	Hs.7306	secreted frizzled-related protein 1	10
		H26904	Hs.75736	apolipoprotein D	10
		AF072441	Hs.7840	calcineurin binding protein 1	10
40		D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40		Al372588	Hs.8022	TUSA protein	5
		AA081846	Hs.7921	Homo saplens mRNA; cDNA DKFZp566E183 (fr	5
		BE243319	Hs.79672	KIAA0652 gene product	10
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (10
45		M64936	11. 050000	gbd-lomo sapiens retinoic acid-inducible	10 10
43		NM_002757	Hs.250870	mitogen-activated protein kinase kinase	
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
		NM_003394	Hs.91985	wingless-type MMTV integration site famil	10 10
50		X04430	Hs.93913	Interleudin 6 (interferon, beta 2)	10
30		AW580227	Hs.47860	neurotrophic tyrosine khase, receptor, type 2	10
	4466/4	AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10

TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigeneID's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

	tor scq	dences e	omprising each cluster are listed in the Accession column.
10			
	Pixev:	Unlaue	Eos probasal Identifier number
	CAT numb		Auster number
	Accession:		nk eccession numbers
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-	
15			
	Pixey	CAT number	Accessions
	111168	38585_1	AJ798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567
	*****		AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384
20			AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718
			AA157719 AA100472 AA100774 AA130758 AA157705 AA157730 AA157715 AA053624 AW849581 AW854566 C05254
			AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215
			AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659
			BE081531 H59570
25	103747	117944_1	AA081995 AA101099
	134498	46501_1	MS4936 AI025512 AI382987 BE051777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 AI269283 T40311
		_	Al684569 AA257011 Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627
			AW869639 BE081833 BE000520 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241
30			AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904
			C16859
	100654	fgr_HT2969	A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22861 V00494 V00495
			X51363 X51364 X51365
35	102208	6735_9	U22951 AA203523 AA503337 AH74733 AH92802 C05092 AA035357 AH90619 AH99244 AB28450 AA602295 AB78195
33			A1209170 A1185653 A1127795 A1183846 H77389 A1589465 AA629390 H94305 A1018388 R68584 AA027196 A1745413
			AI685092 AU93426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101
			N70805 AH41254 A1393191 A4401237 A1080709 A1093400 W84549 T90806 R00012 W01413 AA630557 A1378348 A1559265
			AA877103 W84464 AA625146 R68379 A1133207 A1132980 A1133214 A1064826 A1061615 A1133473 A1174852 A1133404 A1133272 V00484 M12523 M12523 A1207526 A1133120 A1064802 A1174993 A1114729 A1061645 A1084716 A1084959 H77388
40			T85705 AF075298 Al110799 D17107 NM, 000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710
-10			AN33290 AN33304 AN74948 AN207484 AN110717 AF074624 AN114515 AF063516 AN110642 AN114559 AN114498 AN114759
			A1207568 AID64980 A174753 A114666 R69184 R00011 A1064997 T60601 A1207701 T71735 AA385318 H73569 T60496
			H94399 AH33158 T74675 AA484750 T73413 T56909 R50261 T72061 N80533 T51189 T74936 AI207490 AH32925 AI064701
			A1174748 A1114663 A1133104 A1132999 A1133100 A1054925 A1064979 A1133063 AA343347 T68091 AA233989 T39772
45			Al444620 T52280 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 A091136 AA334608 T57411 Z20979
			N56507 T87485 Al133622 AA343370 T40075 T68871 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468
			AA332728 T51362 AH 14589 R05691 AH 10529 AF063503 AH 40543 AA334661 AA332720 AA343262 T73513 T86549
			AH14840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39895 AH74786
			Al132926 R09237 Al064638 Al133660 T60398 T88753 T55930 T92126 Al444602 T60998 Al114792 H93911 Al133106
50			R10779 Al085020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567
			H71080 T73217 AA343950 AH74743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842
			AA501730 T39931 T39862 T40136 AA334904 T71425 H77784 R00874 Al085049 T84512 T55918 Al207595 T39951
			AADD5016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AL114676 ADD64778 AAD35710 W52763 AL114786
			T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675
55			AA343592 T53838 T46869 T64721 T55508 W05241 T54019 T57845 T60513 T48364 AF075308 W85731 T82851 T48269
			H54053 T73211 Al114590 T48317 T55985 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T96666 Al203974
			Al189471 AACO5147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646
			T83962 AI055112 AI207689 AI174684 AI207702 T81475 AI133325 AI032512 AA701169 AI936354 AI114720 AI433289
60			AAC46980 AB23482 AI114536 AAB60651 AW242644 R07469 AW300438 AI133416 AW271670 AB91363 T78943 AB23481
OU			AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318
			AIDS4689 T56624 T69010 T68982 T68302 AI332829 T72908 AID64819 AI205880 T62895 T69430 T95111 AA025050 T73330
			W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158

PCT/US02/02242 WO 02/059377

5

102800 108351 101447

TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

10	Pkey:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigeneiD:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of normal breast tissue to tumor

5

1,

15					
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	101336	NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10.0
	102208	U22961		gbd-luman mRNA clone with similarity to L	10.0
20	102990	AA829286	Hs.332053	serum amytoid A1	10.0
	111168	A1798376		gbdr34b07.x1 NCL_CGAP_Ov23 Homo sapiens	10.0
		AA593731	Hs.325823	ESTs. Moderately similar to ALU5_HUMAN A	10.0
	130085		Hs.274313	insulin-like growth factor binding prote	10.0
		BE048821	Hs.20144	small inducible cytoldine subfamily A (Cy	10.0
25		AW966881	Hs.41639	programmed cell death 2	10.0
	133120		Hs.65424	tetranectin (plasminogen-binding protein	10.0
	134758		Hs.89538	cholesteryl ester transfer protein, plas	10.0

TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey: Unique CAT mumber: Gene Accession: Genb

Unique Eos probeset identifier number

Gene cluster number Genbank accession numbers

15 Pitey CAT number Accessions

1022086735_9

20

25

30

35

40

45

50

55

BE081531 H59570 U22951 AA203623 AA503337 A1174733 A1192802 C06092 AA035357 A1190519 A1199244 A1828450 AA602295 A1378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al585092 AK093426 AK623873 AK074570 N50096 AA047486 N25060 AA327614 AK042512 AK383957 AA156873 AK333101 N70806 AK141254 AL383191 AI401237 AL080709 AL09340D W84549 T90806 R00012 W01413 AA630557 AL378348 AL559265 AA877103 W84464 AA625146 R68379 AH33207 AH32980 AH33214 AD64826 AD61615 AH33473 AH174852 AH33404 AH33272 VO0494 M12523 M12523 AIZ07526 Al133120 AI064802 Al174993 Al114729 AI061645 AI064716 AI064959 H77388 T85705 AF075298 Al110799 D17107 NW_000477 AF190168 R50724 AI248416 AI207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 AI207484 AI110717 AF074624 AI114515 AF063516 AI110642 AI114559 AI114498 AI114759 AI207568 AI064980 AI174753 Al114666 R69184 R00011 Al034997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al084925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133051 T50850 Al400577 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69871 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R08691 Al110829 AF083503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 AH32926 R09237 AD64838 AH33660 T60398 T88753 T5593D T92126 Al/44602 T60998 Al/14792 H93911 Al/33106 R10779 Al055020 T90925 T50889 D17029 Al/33703 AA/33805 AH33040 AH33017 AK064857 AH10730 AF074637 AK207567 H71080 T73217 AA343950 AH74743 AA334224 AA334281 R05592 T64739 T40163 T60528 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AKOS5049 T84512 T55918 AK207595 T39951 AACOS016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AK114676 AI054778 AA035710 W5Z763 AI114786 T83584 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305875 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57845 T60513 T48364 AF075308 W85731 T82851 T48269 H54053 T73211 AH14550 T48317 T55935 T74857 R84228 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 AH33117 AI766232 AI913646 T83952 AI035112 AI207689 AH74684 AI207702 T81475 AH33325 AI032512 AA701169 AI936354 AI114720 AI433289 AA046980 AB23482 AI114536 AA860551 AW242644 R07469 AW300438 AI133416 AW271670 AI591363 T78943 A1823481 AA845518 AA719124 AA883454 T68850 T69115 A1935509 A1150977 T62890 T71374 T68294 A1174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AH14860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290

Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412

T64300 T28321 T55864

TABLE 4: Figure 4 from BRCA 001 US

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number

Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

	ExAcon:		Exemplar Accession number, Genbank accession number					
10	UnigenelD:		Unigene number					
	Unigene Title:		Inigene gene title					
	R1:		Ratio of tumor	to normal breast tissue				
15	Pkey	ExAccn	UnigeneiD	Unigene Title	R1			
•	100113	NM 001	269Hs.84746	chromosome condensation 1	2.3			
		X02308	Hs.82962	thymidylate synthetase	2.9			
		D12485	Hs.11951		1.9			
20			9 Hs.2471	KIAA0020 gene product	1.9			
		D13666		osteoblast specific factor 2 (fasciclin Hike) (periostin)	7.5			
		H60720		KIAA0101 gene product	9.2			
		W44671	Hs.124	gene predicted from cDNA with a complete coding sequence	1.6			
			34 Hs.217493		2.0			
25		D38521		KIAA0077 protein	1.5			
				S100 calcium-binding protein A11 (calgizzarin)	13.5			
				KIAA0090 protein	5.1			
		D50920		KIAA0130 gene product	1.9			
	100335	AW2475	29 Hs.6793	platelet-activating factor acetylhydrolase, Isoform Ib, gamma subunit (29kD)	2.7			
30	100364	NM 004	341Hs.154868	carbamoyi-phosphate synthetase 2, aspartate transcarbamytase, and dihydrocrotase	2.0			
	100372	NM_014	791Hs.184339	KIAA0175 gene product	2.6 ⁻			
	100393	D84145	Hs.39913	novel RGD-containing protein	3.2			
	100400	AW9543	24 Hs.75790	phosphatidylinositol glycan, class C	1.5			
	100418	D86978	Hs.84790	KIAA0225 protein	2.0			
35	100482	M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9			
	100518	NM_004		desmoptatin (DPI, DPII)	1.9			
		L05424		CD44 antigen (homing function and Indian blood group system)	5.7			
		L05424		CD44 antigen (homing function and Indian blood group system)	9.0			
		L05424		CD44 antigen (homing function and Indian blood group system)	7.6			
40			35 Hs.740	PTK2 protein tyrosine kinase 2	53.2			
				ribosomal protein L24	1.8			
			6 Hs.1657	estrogen receptor 1	1.6			
				general transcription factor IIH, polypeptide 2 (44kD subunit)	5.9			
4-			2 Hs.297939		1.7			
45			4 Hs.180789		1.7			
				ublquitin protein Ilgase E3A (human papilioma virus E6-associated protein, Angelman syndrome)	1.5			
			Hs.79172		6.3			
			5 Hs.76480	ubiquitin-like 4	11.4			
50		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5 reductase)	1.6			
50		J05070	HS.151/38	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	8.2			
		J05614	11. 7500	gbd-luman proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0			
		N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6			
		L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danios syndrome ty				
E E	101161	NM_UU0	262Hs.37044	peripherin	16.9			
55				core-binding factor, beta subunit	2.0 1.8			
			6 Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)				
			7 Hs.82916	chaperonin containing TCP1, subunit 6A (zeta 1)	1.7			
			6 Hs.78802	glycogen synthase kinase 3 beta	1.9 1.5			
<i>6</i> 0	101249	L18964	Hs.1904	protein kinase C, lota	5.2			
60	101332	J04088		topoisomerase (DNA) II alpha (170kD)				
		J04088		topoisomerase (DNA) II alpha (170kD)	3.4 6.3			
		AI494299		COX17 (yeast) homolog, cytochrome c oxidase assembly protein	6.3 4.2			
			11 Hs.78996	proliferating cell nuclear antigen gb:Human Alu repeats in the region 5' to the small nuclear rib	4.2 1.9			
65	101443	M21259	546Hs.1846	tumor protein p53 (Li-Fraumen) syndrome)	1.6			
UJ	(014/0	14IACTOOR	A-10119' 10-10	minu brown boo feet iminan shimans)	1.0			

	101478	NM_002890)Hs.758	RAS p21 protein activator (GTPase activating protein) 1	2.5
	101483	M24486	Hs.76768	procottagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	5.5
		J04977	Hs.84981	X-ray repair complementing detective repair in Chinese harnster cells 5 (double-strand-break rejoin	ing 2.1
				proteasome (prosome, macropain) 26S subunit, ATPase, 3	1.6
5		NM_012151		coagulation factor VIII-associated (intronic transcript)	5.7
9		AF064853		guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
					5.6
		AF064853		guanine mucleotide binding protein (G pr	2.4
		BE391804		guanylate binding protein 1, interferon-inducible, 67kD	
4.0				protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10		M74099		cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
	101759	M80244	Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	5.0
	101767	M81057	Hs.180884	carboxypeptidase B1 (fissue)	14.4
	101782	AA306495	Hs.1869	phosphoglucomutase 1	5.2
		AW409747		stress-Induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15				S100 calcium-binding protein A7 (psortasin 1)	8.9
				peroxisomal membrane protein 3 (35kD, Zeliweger syndrome)	3.2
	101070	AA17837A	He 243888	nuclear autoantigenic sperm protein (histone-binding)	1.6
				glycoprotein hormones, alpha polypeptide	31.3
					1.8
20		AF182645		IK cytokine, down-regulator of HLA II UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminytiransferase 1 (GalNAc-T	
20		U41514	Hs.80120		8.4
		Al904232		prohibitin	
				protein tyrosine kinase 9	1.3
	102036	BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	2.0
	102083	T35901	Hs.75117	interlaukin enhancer binding factor 2, 45kD	1.6
25	102083	T35901	Hs.75117	Interleukin enhancer binding factor 2, 4	1.3
			Hs.182366	heat shock protein 75	1.4
		NM_001809		centromere protein A (17kD)	1.8
				death associated protein 3	4.6
				polymerase (DNA directed), delta 2, regulatory subunit (50kD)	4.3
30		AA829978			6.7
J U					4.3
		U24389	Hs.65436		1.9
				heterochromatin-like protein 1	
				karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	4.4
				protein kinase C-like 2	2.7
35				chromobox homolog 1 (Drosophila HP1 beta)	1.5
	102339	BE378432	Hs.95577	cyclin-dependent kinase 4	2.3
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member B2	2.0
				bacutoviral IAP repeat-containing 2	3.2
		U39840		hepatocyte nuclear factor 3, alpha	2.0
40		U33635		PTK7 protein tyrosine kinase 7	6.2
-10				deoxyguanosine kinase	1.5
		U48705		discoidin domain receptor family, member 1	6.9
					1.8
		NM_00135			1.5
45		U50939	Hs.61828		
45				origin recognition complex, subunit 3 (yeast homolog)-like	3.3
	102494	Al188137	Hs.75193	COP9 homolog	21
	102501	AF217197	Hs.74562	slah binding protein 1; FBP interacting repressor; pyrimidine tract binding splicing	3.2
	102522	BE250944	Hs.183556	solute carrier family 1 (neutral amino acid transporter), member 5	2.8
	102532	AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50	102564	U59423	Hs.79067	MAD (mothers against decapentaplegic, Drosophila) homolog 1	2.3
		W81489		RAB31, member RAS oncogene family	5.3
		U60808		CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1	2.1
	402581	ALI077228	Ha 77256	enhancer of zeste (Drosophila) homolog 2	1.6
	40000	U61232		tutulin-specific chaperone e	2.1
55	102002	UD IZGZ	HS-32073	COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
55	102617	AW 101433	HS. 190/0/	COLA (COLAMBINA highinolandeur? vignacher? incurred) ainmir a	
	102618	AU3/6/2	HS.810/1	extracellular matrix protein 1	5.8
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3
	102683	NM_002270	OHs.168075	karyopherin (importin) bela 2	1.8
	102676	BE262989	Hs.12045	putative protein	2.3
60	102687	NM_007019	9Hs.93002	ubiquitin carrier protein E2-C	4.3
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, type II	6.0
	102696	BE540274	Hs.239	forthead box M1	4.2
	102704	AU077058	Hs 540RO		1.9
	102704 40270E	T97490	Hs.50002	small inducible cylotine subfamily A (Cys-Cys), member 19	23
65	102700	AB014460		nth (E.coti endonuclease III)-like 1	1.2
U)	102/30	DESESSA4	TH 300/4	pyridoxal (pyridoxine, vitamin B6) kinase	6.4
		BE252241	113/20041		1.6
	702872	U90549	FIS.430//4	high-mobility group (nonhistone chromosomal) protein 17-like 3	

TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and inRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	Unique Eos pr
	CAT number:	Gene cluster r
	Accession:	Genbank acce

Unique Eos probeset identifier number

Gene cluster number Genbank accession numbers

1	5	Phey	CAT	number	Accessions
---	---	------	-----	--------	------------

AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 111168 38585_1 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 20 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AB29309 AW991957 N56951 AA527374 H66215 AA045564 A1694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 U22961 AA203623 AA503337 AH74733 AH92802 C06092 AA035357 AH90619 AH99244 AB2B450 AA602296 AB378195 1022086735_9 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027195 Al745413 Al685092 25 AK093426 AK623873 AK074570 N50096 AA047486 N25060 AA327614 AK042512 AK383957 AA156873 AK333101 N70806 AK141254 AC3R3191 AJ401237 AID80709 AID9340D W84549 T90806 R00012 W01413 AA630557 AI376348 AI559265 AA877103 W84464 AA625146 R68379 A1133207 A1132980 A1133214 AD64826 AD61615 A1133473 A1174852 A1133404 A1133272 V00494 M12523 M12523 A1207526 A1133120 A1064802 A1174993 A1114729 A1061645 A1064716 A1064959 H77388 T85706 AF075298 A1110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 30 ALZO7484 AL110717 AF074624 AL114515 AF063516 AL110642 AL114559 AL114498 AL114759 ALZO7568 AL064980 AL174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60498 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 AI207490 AI132925 AI064701 AI174748 AI114663 AI133104 AI132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 AM33061 T50850 AM00677 AM91136 AA334608 T57411 Z20979 N56507 T87485 AM33622 AA343370 T40075 35 T69871 T53849 T74820 AF075316 AM10818 T40121 T57381 AM14468 AA332728 T51362 AM14589 R05691 AM10629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 AH32926 R09237 AH064838 AH33660 T60398 T88753 T55930 T92126 AM44602 T60998 AM14792 H93911 AM33106 R10779 AD66020 T90925 T50889 D17029 AM33703 AA333805 A1133D40 A1133017 A1064857 A1110730 AF074637 A1207567 H71080 T73217 AA343950 A1174743 AA334224 AA334281 40 R05692 T64739 T40163 T60528 T81661 T73179 R01842 AA501730 T39931 T39562 T40136 AA334904 T71425 H77784 R00874 ALCGSD49 T84512 T55918 AL207595 T39951 AACCSD16 T60361 T69176 T73356 T58795 T61233 T39955 T60612 Al114676 AIG64778 AAG35710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305875 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W89731 T82851 T48269 H54053 T73211 AM14590 T48317 T55885 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 AM89471 AA005147 AM78102 Al207662 AM92792 Al768421 Al064737 AW051713 AA936693 45 Al133117 AL766232 AI913646 T83962 AL065112 AL207689 Al174684 AL207702 T81475 Al133325 AL032512 AA701169 AI936354 AI114720 AI433289 AAD46980 AI823482 AI114536 AAB60651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 A1823481 AA845518 AA719124 AA883454 T68850 T69115 A1935509 A1150977 T62890 T71374 T68294 A1174774 T67411 T68318 AID64689 T56624 T69010 T68982 T68302 AI332829 T72908 AID54819 AI205880 T62895 T69430 T95111 50 AA025050 T73330 W52657 T71984 T69118 W92684 AM14860 T62093 T61797 AL522333 T73322 H92981 T56018 T61811 T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73468 H69872 N53869 T68447 D11809 D12412 55 T64300 T28321 T55864

TABLE 4: Figure 4 from BRCA 001 US

Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number
EXAcon: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of tumor to normal breast tissue

15	Pkey	ExAcen	UnigenelD	Unigene Title	R1
	100113	NM_001269	9Hs 84746	chromosome condensation 1	2.3
		X02308	Hs.82962	thymidylale synthetase	2.9
		D12485		ectonucleotide pyrophosphatase/phosphodiesterase 1	1.9
20		BE185499		KIAA0020 gene product	1.9
20		D13666		osteoblast specific factor 2 (fasciclin Hike) (perfostin)	7.5
		H60720	Hs.81892	KIAA0101 gene product	9.2
		W44671	Hs.124	gene predicted from cDNA with a complete coding sequence	1.6
				annexin A2	2.0
25		D38521		KIAACO77 protein	1.5
				S100 calcium-binding protein A11 (calgizzarin)	13.5
				KIAA0090 protein	5.1
		D50920		KIAAD130 gene product	1.9
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)	2.7
30	100364	NM 00434	1Hs.154868	carbamoyl-phosphate synthetase 2, asparlate transcarbamylase, and dihydroorotase	2.0
	100372	NM 01479	1Hs.184339	KIAA0175 gene product	2.6
		D84145		novel RGO-containing protein	3.2
	100400	AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5
	100418	D86978	Hs.84790	KIAA0225 protein	2.0
35	100482	M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9
	100518	NM_00441	5Hs.74316	desmoplakin (DPI, DPII)	1.9
	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	5.7
	100667	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	9.0
	100668	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	7.6
40	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	100685	AA328229	Hs.184582	ribosomal protein L24	1.8
		AA383256		estrogen receptor 1	1.6
				general transcription factor IIH, polypeptide 2 (44kD suburiti)	5.9
				cathepsin B	1.7
45	100892	BE245294	Hs.180789	S164 protein	1.7
				ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)	1.5
		AA157634		solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5	6.3
		AX000405	Hs.76480	ubiquitin-like 4	11.4
	100999	H38765	Hs.80706	diaphorase (NADH/NADPH) (cylochrome b-5 reductase)	1.6
50		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	8.2
		J05614		gbd-luman proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0
		N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6
	101093	L06419	Hs.75093	procollagen-lystne, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danios syndrome ty	
	101161	NM_00626	2Hs.37044	peripherin	16.9
55				core-binding factor, beta subunit	2.0
	101216	AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	1.8
	101228	AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (zeta 1)	1.7
	101247	AA132666		glycogen synthase kinase 3 beta	1.9
	101249	L18964	Hs.1904	protein kinase C, lota	1.5
60	101332	J04088		topoisomerase (DNA) II alpha (170kD)	5.2
	101332	J04088		topoisomerase (DNA) II elpha (170kD)	3.4
	101352	Al494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxidase assembly protein	6.3
	101396	BE267931	Hs.78996	proliferating cell nuclear antigen	4.2
	101445	M21259	MI . 45 * 5	gbd human Alu repeats in the region 5 to the small nuclear rib	1.9
65	101470	NM 00054	6Hs.1846	tumor protein p53 (Ll-Fraumeni syndrome)	1.6

	101478	NM_002890	Hs.758		2.5
	101483	M24486	Hs.76768		5.5
	101540	J04977	Hs.84981	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoin	ing 2.1
_	101573	AW248421	Hs.250758		1.6
5	101580	NM_012151	Hs.83363	coagulation factor VIII-associated (intronic transcript)	5.7
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-inducible, 67kD	2.4
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha Isoform	1.3
10		M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
	101759	M80244	Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	5.0
				carboxypeptidase B1 (tissue)	14.4
		AA306495		phosphoglucomutase 1	5.2
		AW409747			8.6
15				S100 calcium-binding protein A7 (psortasin 1)	8.9
10	101810	NM 000318	Hs 180612	peroxisornal membrane protein 3 (35kO, Zellweger syndrome)	3.2
	101879	AA17637A	Hs 243886	nuclear autoantigenic sperm protein (histone-binding)	1.6
	101013	ΔΔΔΔ1787	Hs 119689	glycoprotein hormones, alpha polypeptide	31.3
		AF182645		IK cytokine, down-regulator of HLA II	1.8
20			Hs.80120	UDP-N-acetyl-alpha-D-galactosamins:polypeptide N-acetylgalactosaminyttransferase 1 (GalNAc-T	
20		Al904232		prohibijin	8.4
		BE245149		protein tyrosine kinase 9	1.3
		BE250127			2.0
		T35901	Hs.75117		1.6
25				Interleukin enhancer binding factor 2, 4	1.3
23		T35901	Hs.75117	heat shock protein 75	1.4
					1.8
	102123	NM_001809	7713.1009 Us. 450697	centromere protein A (17kD)	4.6
				death associated protein 3 polymerase (DNA directed), delta 2, regulatory subunit (50kD)	4.3
30		AW950852			6.7
3 0		AA829978			4.3
		U24389	Hs.65436		1.9
				heterochromatin-like protein 1	4.4
				karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	2.7
25	102302	AA306342	MS.091/1	protein kinase C-like 2	1.5
35				chromobox homolog 1 (Drosophila HP1 beta)	2.3
		BE378432			2.0
		U37519	Hs.87539		3.2
				bacutoviral IAP repeat-containing 2	2.0
40		U39840		hepatocyte nuclear factor 3, alpha	6.2
40		U33635		PTK7 protein tyrosine kinase 7	
				deoxyguanosine kinase	1.5
		U48705		discoidin domain receptor family, member 1	6.9
				2,4-dienoyl CoA reductase 1, mitochondrial	1.8
4-	102488	U50939	Hs.61828	amytoid beta precursor protein-binding protein 1, 59kD	1.5
45				origin recognition complex, subunit 3 (yeast homolog)-like	3.3
				COP9 homolog	2.1
		AF217197			3.2
				solute carrier family 1 (neutral amino acid transporter), member 5	2.8
			Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50		U59423		MAD (mothers against decapentaplegic, Drosophila) homolog 1	23
		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
	102580	U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatidate cytidylyttransferase) 1	2.1
				enhancer of zeste (Drosophila) homolog 2	1.6
	102582	U61232	Hs.32675	tubulin-specific chaperone e	2.1
55	102617	AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3
				karyopherin (importin) bela 2	1.8
	102676	BE262989	Hs.12045	putative protein	23
60	102687	NM_00701	9Hs.93002	ubiquitin carrier protein E2-C	4.3
	102689	U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, type ti	6.0
	102696	BE540274	Hs.239	forkhead box M1	4.2
				BRCA1 associated RING domain 1	1.9
		T97490		small inducible cytokine subfamily A (Cys-Cys), member 19	23
65	102750	AB014460			1.2
55				pyridoxal (pyridoxine, vitamin B6) kinase	6.4
		U90549		high-mobility group (nonhistone chromosomal) protein 17-like 3	1.6

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (beta)	5.6 2.0
	102831	AA262170	Hs.80917	adaptor-related protein complex 3, sigma 1 subunit	1.3
				WW domain-containing protein 1	· 4A
_				plasminogen activator, urokinase	1.9
5		BE440142		signal recognition particle 19kD small muclear ribonucleoprotein polypeptide A'	2.4
	102335	BE561850	MS.8U5U0	small muchan ruboniutaeoprocean purpenter A methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyttetrahydrofolate c	yclohydrolase2.7
•	102968	AUU/0011	IIS. 1040/2	non-metastatic cells 1, protein (NM23A) expressed in	•••
			Hs.2707	G1 to S phase transition 1	5.2
10	102303	AWENDATA	Hs 117950	multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
10	103038	AA926960	Hs.334883	CDC28 protein kinase 1	2.5
	103060	NM 005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
	103080	AU077231	Hs 82932	cyclin D1 (PRAD1: parathyroid adenomatosis 1)	3.1
			Hs.179729	collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasta)	2.4 3.5
15	103177	BE244377	Hs.48876	famesyl-diphosphate famesyltransferase 1	9.9
	103178	AA205475	Hs.275865	ribosomal protein S18	1.3
	103179	NM_001777	7Hs.82685	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	20
		X69636	Hs.334731	Homo saplens, clone IMAGE:3448306, mRNA, partial cds	1.6
	103185	NM_00682	5Hs.74368	transmerribrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment	25
20	103191	AA401039	Hs.2903	protein phosphalase 4 (formerly X), catalytic subunit	2.2 '
	103193	NM_004760	5Hs.75724	coatomer protein complex, subunit beta 2 (beta prime) DEAD/H (Asp-Gtu-Ala-Asp/His) box polypeptide 1	6.3
		NM_00493		monokine induced by gamma interferon	8.8
		X72755	Hs.77367	chaperonin containing TCP1, subunit 3 (gamma)	3.0
25		BE275607 X75962	HS. 1700	tumor necrosis factor receptor superfamily, member 4	1.8
25		Al369285		death-associated protein	5.6
		NM_00154		immature colon carcinoma transcript 1	1.9
		A1803447		email nuclear ribonucleopmiein polypeptide G	2.5
	103349	X89059		gbt-Lapiens mRNA for unknown protein expressed in macrophage	1.6
30	103376	AL036166	Hs.323378	coated vesicle membrane renteln	1.8 2.3
		X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glutamate gamma-semialdenyde synthetase)	4.0
		X94563		gbH saplens dibitatop gene exon 1 & 2.	1.3
	103430	BE564090	Hs.20716	translocase of inner mitochondrial membrane 17 (yeast) homolog A	5.6
				myeloid/lymphold or mixed-lineage leukemia 3	5.1
35	103505	AL031224	Hs.33102	transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	
				protessome (prosome, macropain) subunit, beta type, 8 (large multifunctional protesse 7) phospholnositide-3-kinase, catalytic, alpha polypeptide	2.0
	103588	NM_00621	8H\$.85/U1	priosprioriosuses-Sariassi, caranjus, apria polytepiate SRY (sex determining region Y)-box 9 (campornelic dysplasia, autosomal sex-reversal)	1.3
	103613	NM_00034	DHS.Z310	polymerase (RNA) II (DNA directed) polymeriide K (7.0kD)	2.0
40	103621	PE3/2/00	Un 279672	membrane component, chromosome 11, surface marker 1	2.3
40	103022	ANDUSUUS AIRTRRRS	He 206381	growth factor receptor-bound protein 2	1.3
	402740	AI 435304	He R7RR	hynothetical nrotein FLJ10849	1.8
	10375	AIN15709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586t2022 (from clone DKFZp586t2022)	1.3
•	103780	AA094752	Hs.169992	hynothetical 43.2 Kd protein	7.5
45		H26531	Hs.7367	Homo esolone RTR domaio ominio (RDPL) mRNA, paniai CQS	1.2
••	10379	7 AAD80912		gbczn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cONA cione 5' similar	1.5 1.5
	10381	AI042582	Hs.181271	CGI-120 protein	1.5
	10385	5 W02363	Hs.302267	hypothetical protein FLJ10330	6.5
	10388	B AK001278	Hs.105737	hypothetical protein FLI10416 similar to constitutive photomorphogenic protein 1	2.9
50	10405	2 NM_00240	17Hs.97644	mammaglobin 2	1.4
	10407	9 AA251242	Hs.103238	ESIS	5.6
	10417	4 AA478984	Hs.6451	PRO0659 protein	1.6
	10422	7 ABUUZ343	HS.50530	protocadherin alpha 9 GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55	10427	5 AI/519/U	H3.10100/	polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
55	10432	0 PE3/8/00	115.1000/0	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.6
		3 R83113	Hs.1432	protein kinase C substrate 80K-H	5.2
	10442	2 AB037762			1.2
	10440	2 AUGR763	Hs.203013	hypothetical protein FLJ12748	2.1
60	10456	3 AL117403	Hs.306189	DKFZP434F1735 protein	1.2
-	10/66	7 A1239923	Hs.30098	ESTs	1.3
	10475	7 AJ694413	Hs.332649	olfactory receptor, family 2, subfamily 1, member 6	2.3
	10480	4 AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	. 1.3 2.3
	10480	6 AB023175	5 Hs.22982	KIAAD958 protein	2.3 10.9
65	10482	7 AW05200	6 Hs.8551	PRP4/STKWD splicing factor	5,6
	10484	6 Al250789	Hs.32478	ESTs	12.3
	10485	A AANA1276	3 Hs.154729	3 -phosphoinositide dependent protein kinase-1	124

	104867	AA278898	Hs.225979	hypothetical protein similar to small G proteins, especially RAP-2A	2.0
		T78044	Hs.28893	Homo saplens mRNA; cDNA DKFZp564O2364 (from clone DKFZp564O2364)	1.3
	104896	AW015318	Hs.23165	ESTS	17.7
_	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5				NS1-associated protein 1	1.7
		AA026880		prolactin receptor	1.4
	104930	AF043467	Hs.32893	neurexophilin 2	2.2
		NM_015310		KIAA0942 protein	5.0
10		Y12059	Hs.278675	bromodomain-containing 4	1.4 2.4
10		AL136877		SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	23
•		AL136877	HS,50/08	SMC4 (structural maintenance of chromoso Homo sapiens, Similar to RIKEN cDNA 2010317E24 gene, clone IMAGE:3502019, mRNA, partial	
		A)199268			1.3
		AA937934		milochondrial GTP binding protein	3.5
15		BE379584	He 3/1780	dolichyl-diphosphociigosaccharide-protein glycosyttransferase	5.5
IJ		AF098158		chromosome 20 open reading frame 1	3.3
•		AI050715		E2F transcription factor 5, p130-binding	2.2
		AA127818	113.2.01	gbzzt12a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:501674 3*	6.8
		AA907305	Hs 36475	ESTs	2.5
20		AB037716		KIAA1295 protein	2.2
~~				speckle-type POZ protein	3.8
		AA151342			9.5
		AA147884		Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716	5.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
25		Z78407	Hs.27023	vesicle transport-related protein	2.2
		BE387350	Hs.33122	KIAA1160 protein	1.6
		AW975433		ESTs	6.3
	105127	AA045648	Hs.301957	nudix (nucleoside diphosphate linked moiety X)-type motif 5	2.1
	105141	AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransterase, isoenzyme A	2.7
30				hypothetical protein NUF2R	1.9
				S164 protein	1.7
		AA191512		Homo sapiens cDNA FLJ11309 fis, clone PLACE1010076	4.8
		AA071276		KIAA0859 protein	1.9 2.8
25		AA263143		RAD51-interacting protein	1.9
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	8.0
		AA700122		sentrin-specific protease	1.8
				KIAA0779 protein	8.2
		NM_01601		CGI-68 protein hypothetical protein FLJ21918	5.0
40		AW887701		hypothetical protein FLI20628	2.5
70				hypothetical protein FLJ10326	2.2
				membrane protein CH1	2.3
				interleukin enhancer binding factor 3, 90kD	5.4
				Npw38-binding protein NpwBP	1.6
45	105400	AF198620	Hs.65648	RNA binding motif protein 8A	1.6
		AA252395		gb:zs12g10.s1 NCL_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685026 3', mRNA sequence	e. 5.0
	105507	BE268348	Hs.226318	CCR4-NOT transcription complex, subunit 7	1.6
	105529	AA113449	Hs.32471	hypothetical protein FLJ20364	1.3
		AB023179		KIAA0962 protein	3.4
50		AA262640			9.3
				hypothetical protein FLJ14299	1.4
		AA579535		hypothetical protein FLI20452	10.9 2.9
				splicing factor 3b, subunit 1, 155kD	1.7
e e	105608	AMMONOR	HS.20/003	hypothetical protein FLJ12475	1.4
55				fetal Alzheimer antigen	1.7
		AK000892		glucocorticoid modulatory element binding protein 1 caseln kinase 1, gamma 2	5.5
				hypothetical protein FLJ20059	9.4
		AW499988			2.0
60		R26944	Hs. 180777	Homo saptens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	1.7
UU	405743	BE246502	Hs 9598	sema domain, immunoglobulin domain (lg), transmembrane domain (TM) and short	2.6
		AW151952			1.5
		Al123118			1.3
				synovial sarcoma, translocated to X chromosome	1.6
65				transcriptional unit N143	2.2
	105826	AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3
	105856	Al262106	Hs.12653	ESTs	2.4

	405500	. = 4 = 4000	11-004400	how after the all and a land	2.9
	105858	AF151060	HS.201428		1.4
		AK001708	HS.322/1		5.2
		AF016371		pepedyt protyr isomerase i i toycoopiumi i i y	1.7
~	106000	AW194426	HS.ZU/Z0	EDIS	2.8
5		AW081202		ESTs	1.4
		AA477956		downstream neighbor of SON	1.4
		AL157441	HS.17004	CONTAMINATION ESTS, Moderately similar to ALUB_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	1.6
	1000/8	AA130158	NS. 1997 7	hypothetical protein FLJ14681	8.6
10	400440	ADDOCCOA	Un:44042	MAARORE omtein	1.6
10	100140	AA251303	He 200052	Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, clone MGC:13155, mRNA, complete co	ls 10.
	400271	ARM377A9	He 24336	KIAA1321 protein	1.3
		Y10043	He 19114	high-mobility group (nonhistone chromosomal) protein 4	3.6
		AL043114	He 22410	FSTs Wealdy similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15	106350	AK001404		curfin R2	5.7
13		AW390282		transmembrane 7 superfamily member 2	6.3
	106381	APPRINTE	Hs 24106	KIAA1483 protein	6.5
	106389	AW748420	Hs.6236	Homo saniens cDNA: FLJ21487 ffs. clone COL05419	2.2
	106457	AF119256	Hs.27801	zinc finger protein 278	2.7
20		D63078	Hs.186180	Homo saniens cDNA: FLJ23038 fis. clone LNG02039	2.3
		AA454036		FSTs	1.6
	106586	AA243R37	Hs.57787	ESIS	1.6
	106589	AK000933	Hs.28661	PRINTED SOCIETIES CENTRA CENTRON I INC. COCKS CENTRON VOCA	2.4
	106610	AA458882	Hs.79732	fibulin 1	7.9 7.7
25	106624	NM_00359	5Hs.26350	PROTECTION SAME MANAGEMENT ASSET	1.8 1.8
	106650	AL049951	Hs.22370		1.3
	106669	AV657117	Hs.184164	C212' INFOCUSION SELECT ON 200031 OPERA 10 GOODS CONTROL OF THE PARTY	4.5
	106713	BE614802	Hs.184352	11V10V103:0120 D10V201 1 L2 122-13	1.3
	106717	AA600357	Hs.239489	1M1 CARDING BIRING 92200 GIGG LARADHUR SI INDOCE.	1.6
30	108723	BE388094	Hs.21857	EDIS	5.7
	106795	AF174487	Hs.293753	DG-S-(REGIST) AND MICH MORE IN THE PROPERTY OF	16.2
	106829	AW959893	Hs.27099	hypothetical protein FLJ23293 similar to ARL-6 interacting protein-2	1.5
	106831	BE564871	Hs.29463	Calmar's Latent horant a forcest leaves and a	22
25	106846	AB037744	HS.34892	NAA 1323 piotest	1.3
35			HS.JUU031	hypothetical protein Homo saptens, clone IMAGE:3343149, mRNA, partial cds	16.B
		N49809		GLO02 protein	1.5
	100000 400000	W79171	Ha 222024	transcription factor BWAL2	2.2
	400000	AM001271	He 296323	serum/glucocorticoid regulated kinase	3.3
40	100020	AK000511	Hs 6294	hypothetical protein DKFZp434L1435 similar to valyi tRNA synthetase	6.8
70	106973	BE156256	Hs 11923		6.6
		AL043152		KIAAC2CC3 gene product	4.8
	106978	AW631480	Hs.8688	ESTs	6.0
	107004	AA146872	Hs.300700	hypothetical protein FLJ20727	1.3
45	107029	AF264750	Hs.288971	mwelald/wmahold or mixed-lineage leutemia 3	1.8
	107071	AW385224	Hs.35198	ectonucleofide pyrophosphatase/phosphodiesterase 5 (putative function)	1.7
	107113	AKD00733	Hs.23900	GTPase activating protein	2.5 1.7
	107125	AK000512	Hs.69388	hypothetical protein PLJ20505	4.6
	107136	AV661958	Hs.8207	GKOO1 protein	3.3
50	107136	AV661958	Hs.8207	GK001 protein	2.0
		AK001455		Down syndrome critical region gene 2	6.3
	107151	AW378065	Hs.8687	ESTs	33.5
		AW391927		KIAA1288 protein	5.2
~~		BE122762		ESTS	6.1
55	107197	W15477	Hs.64639	glioma pathogenesis-related protein	17.4
	107221	AW888411	HS.81915	leukemia-associated phosphoprotein p18 (statiumin) ESTs, Moderately similar to 138759 zinc fingerfieucine zipper protein [H.saplens]	7.4
	107243	BE219716	H3.34/2/	E212' MODESTRIES STIEST IN 1201.22 Still Hillians Stiest In Society Still Hillians	1.8
				nuclear receptor co-repressor/HDAC3 complex subunit translocase of outer mitochondrial membrane 70 (yeast) homolog A	6.6
60	107203	D80341	Hs.21198		
60		BE379594		ESTs, Moderately similar to YOJ1_CAEEL HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN	2.5
		N95657	Hs.6820 Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	1.7
	10/250	N95657 BE277457			3.2
	10/ <i>2</i> 5	1 662/145/ 5 163174	He 10270	Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324)	2.0
65	10/310 4072E/	NM Mes	APPS 3468	zinc finger protein 193	5.0
UJ	10130	AMSGGGU) Hs 267632	2 TATA element modulatory factor 1	1.2
	107481	AA307703	Hs.27976	kinesin family member 4A	1.6
				•	

5.3

					20
	107529	BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3.0
	107554	AA001386	Hs.59844	ESTs CONTAMBIATION	1.3
	107681	BE379594	Hs.49136	ESTS, Moderately similar to ALUT_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.1
_	107777	AAN1R5R7	He 303055 .	FSTs. Weakly similar to ALU1 HUMAN ALU SUBPAMILY J SEQUENCE CONTAMINATION	8.4
5				horazzenii Antrado-Agren currinci noralen permusi erremusi et memor e	2.5
	107901		Hs.335952		1.6
	107901		Hs.335952		2.2
	107922	BE153855	Hs.61460	lg superfamily receptor LNIR	6.7
	107974	AW956103	Hs.61712	pyruvate dehydrogenase kinase, iscenzyme 1	
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member	1.3
	108230	AA054224	Hs.59847	ESTs .	7.1
	108274	AF129535	Hs.272027	F-bax only protein 5	2.5
	108296	N31256	Hs.161623	ESTs .	3.5
	108496	AA083069	Hs.339659	ESTs	3.4
15	108607	BE300380	Hs.69476	Homo saplens cDNA FLJ12758 fis, clone NT2RP2001328	1.6
	108621	AA101809	Hs.182685	ESTS	1.7
		AW022410			9.8
	108647	BE546947		homeo box C10	7.2
	108695	AB029000	Hs.70823	KIAA1077 protein	1.3
20	108717	AA122393	Hs.70811	hypothetical protein FLI20516	2.7
	108740	A)089575	Hs.9071	progesterone membrane binding protein	1.8
	108828	AK001693	Hs.273344	DKFZP56400463 protein	1.5
		AL121500	Hs.178904	ESTS	2.1
	108872	H06720	Hs.111680	endosulfine alpha	5.3
25		AI801235		ESTS	4.0
	108894	AK001431	Hs.5105	hypothetical protein FLJ10569	5.6
	108955	AA149754	Hs.195155	Homo saplens amino acid transport system N2 (SN2) mRNA, complete cds	1.6
				homeo box (expressed in ES cells) 1	6.2
~~		AA152178		hypothetical protein FLJ10633	1.7
30		AB028987		KIAA1064 protein	1.4
		AA156542	Hs./212/	ESTs gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu re	
		AA157811	11 mos4s		2.9
		AA164293		ESTS	1.6
25	109101	AW608930	MS.52104	hypothetical protein FL 120618	3.2
35	109112	AWATSTSO	HS.201824	hypothetical protein FLJ13782 hypothetical protein FLJ22104	1.7
				riypoureucas protein Pt.222 104 zinc finger protein 281	2.6
	109139	AJ132592	115.00101	RAB6 Interacting, kinesin-like (rabkinesin 6)	2.9
	109166	AA219691	HS./ 3023	highly expressed in cancer, rich in leucine heptad repeats	2.0
40	109190	BE566742	100 000 PTC	potential nuclear protein C5ORF5; GAP-like protein	5.3
40	109213	NM_016603 AW958181	3013.02133 LL: 400000		5.7
	100220	A11077794	Lie 170285	nucleoporin 214kD (CAIN)	5.3
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.4
		AA375752		Homo sapiens mRNA; cDNA DKFZp586F1822 (from clone DKFZp586F1822)	2.9
45		AF153201		C2H2 (Kruppel-type) zinc linger protein	1.3
47	100010	AA213506	He 115000		2.9
	100301	AI nocres	He 184245	KIAA0929 protein Msx2 interacting nuclear target (MINT) homolog	1.5
		HB3603	Hs.40408		2.2
		N30531	Hs.42215		3.0
50		Al160029		FSTs	1.9
50	400446	AA232103	He 189915	FSTs	1.8
	100450	ARD33069	Hs 173042	KIAA1143 protein	3.7
	100400	NM_01531	0Hs 6763	KIAAD942 protein	3.2
	100400	AW074143	Hs 87134	•	2.0
55		L40027	Hs 118890	glycogen synthase kinase 3 alpha	2.1
"		F02614	Hs.27319		1.4
		R71264	Hs.16798		1.3
		H11938	Hs.21907		2.0
	11005	AASOROAA	Hs.279009	matrix Gla protein .	2.5
60	11000	AA603840	Hs.29956	KIAA0460 protein	1.7
JU	11000	T07353	U- 704R	FSTq	2.9
	440420	R51853	Hs.226429	ESTS. Wealty similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7
	11012	NM 01452	14Un 47007	CU2 domain hinding ambin A	4.2
	1107/	A1668594	Hs.176588	ESTS, Weakly similar to CP4Y_HUMAN CYTOCHROME P450 4A11 PRECURSOR (H.saplens)	4.2
65	11024	N41744	Hs.19978	CGI-30 protein	1.3
0.5	11025	H28428	Hs.32406	ESTs, Wealty similar to 138022 hypothetical protein [H.sapiens]	2.2
	11031	BE256986	Hs.11896	hypothetical protein FLJ12089	2.1

	110330	Al288666	Hs.16621	DKFZP4341116 protein	6.2
•	110501	H55748		gb:yg94a01.s1 Soares fetal liver splean 1NFLS Homo sapiens cDNA clone IMAGE:203400 3'	6.1
		H55915	Hs.210859	hypothetical protein FLJ11016	6.1
		H57330	Hs.37430	• • •	6.3
5		AK001160		hypothetical protein FLJ10298	1.3
_		T97586	Hs.18090	ESTS	1.8
		AB007902	Hs.32168	KIAA0442 protein	1.6
		AW190338		hypothetical protein MGC11256	7.6
		AL138077		hypothetical protein FLJ12707	2.5
10	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3
	110765	AK000322	Hs.18457	hypothetical protein FLJ20315	5.5
	110769	BE000831	Hs.23837	Homo sepiens cDNA FLJ11812 fls, clone HEMBA1006364	2.1
	110799	A1089660	Hs.323401	dpy-30-like protein	1.5
	110805	T25829	Hs.24048	FK506 binding protein precursor	6.6
15	110813	AA767373	Hs.35669		5.7
	110820	R33261	Hs.6614	ESTs, Wealthy similar to A43932 much 2 precursor, intestinal [H.saptens]	3.4
	110840	N31598	Hs.12727	hypothetical protein FLJ21610	1.7
	110844	AJ740792	Hs.167531	methylcrotonoyi-Coenzyme A carboxytase 2 (beta)	1.7
	110854	BE612992	Hs.27931	hypothetical protein FLJ10607, similar to glucosamine-phosphate N-acetyltransferase	4.7
20	110856	AA992380		gb:ol37g06.s1 Soares_testis_NHT Homo saptens cDNA clone 3' similar to contains element	2.3
	110885	BE384447	Hs.16034	hypothetical protein MGC13186	3.5
	110897	AL117430	Hs.6880	DKFZP434D156 protein	2.2
		BE092285			2.6
		H04360		ESTs, Moderately similar to reduced expression in cancer [H.sapiens]	1.9
25		NM_005864		signal transduction protein (SH3 containing)	6.7
				DKFZP564O123 protein	2.0
	110981	AK001980	Hs.24284	ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2	1.3
				UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	1) 1.
		N63823		ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30				hypothetical protein	2.1
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170	23
		R67419		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	3.7
				Homo saplens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122)	7.5
25				asporin (LRR class 1)	7.1
35				Homo saplens cDNA FLJ20738 fis, clone HEP08257	6.7
				Homo sapiens cDNA FLI20738 fis, clone HE	3.3
		N67603		ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.saplens]	3.6 1.5
		AW139408			2.6
40				KIAA1361 protein	4.6
40				KIAA1866 protein	7.9
		N90956		nypounda product action	6.9
		AA778711		eultaryotic translation initiation factor 1A	5.0
				KIAA1265 protein	3.8
45		Al523913 T99755	Hs.334728		1.2
43					5.1
		H58589		Homo saplens cDNA FLJ11027 fis, clone PLACE1004114	2.2
					2.8
		N94606			2.2
50					2.1
50					5.1
		W46342			8.4
	111452	R02354	Hs.15999		2.7
	111486	Al051194	Hs 227978		6.5
55	111549	W90638	Hs 20321	ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	1.4
-	111585	R10720	Hs.20670		1.6
		R52656			1.6
	111870	AB037834			24
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)	10.6
60		AW083791			6.6
-		NM_015310			5.1
		R41823	Hs.7413		28
	112244	AB029000			14.6
		R46071			9.0
65	112456	NM_01624	3Hs.232076		1.4
	112464	AW007287	Hs.28538		1.4
		AJ742756			3.2

	112513	R68425	Hs.13809	hypothetical protein FLJ10648	2.0	
	112752	AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	
		AK000004		Homo saplens mRNA for FLI00004 protein, partial cds	6.6	
		T10258	Hs.5037	EST	1.5	
5		AW970826		KIAA1557 protein	3.2	
,		R61388	Hs.6724	ESTs	6.0	
					6.4	
		Z44718		glucocorticoid receptor DNA binding factor 1	1.2	
		AK000272		hypothetical protein FLJ20265	5.6	
4.0		AA737033		ESTs, Moderately similar to 2115357A TYKI protein [M.musculus]		
10	112996	BE276112	Hs.7165	zinc finger protein 259	2.0	
	113047	A¥571940	Hs.7549	ESTs	1.9	
	113049	AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein, partial cds	2.4	
		T40707	Hs.270862	ESTs	1.3	
		T57317		obyh51a03.s1 Stratagene fetal spieen (937205) Homo sapiens cDNA clone IMAGE:74668 3',	1.7	
15		T63857		gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence	2.8	
1.7			He 11440	DKFZP564O123 protein	1.3	
	443277	A14/07/10/0	Ue 11774	protein (peptidyl-protyl cis/trans isomerase) NIMA-interacting, 4 (parvulin)	3.2	
					1.2	
			Hs.179808		5.9	
^^		Al467908		ESTs	2.0	
20		H59588	Hs.15233			
	113554	AW503990	Hs.142442	HP1-BP74	3.6	
	113647	AA813887	Hs.188173	Homo sepiens cDNA FLJ12187 fis, clone MAMMA1000831	1.3	
	113702	T97307		gb:ye53h05.s1 Soares fetal liver spicen 1NFLS Homo sapiens cDNA clone IMAGE:121497 3',	4.4	
	113722	AV653556	Hs.184411	albumin	1.3	
25		AW499665		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member	5 1.2	
~~			Hs.10590		13.4	
		AL359588		hypothetical protein DKFZp762B226	1.7	
				chitoblase, di-N-acetyi-	1.3	
			Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone COL01832	3.3	
20	113000	W44735		Homo sapiens conn. FLI22044 fis, done HEP09141	3.1	
30		BE207480			3.2	
		H13325		hypothetical protein DKFZp761O17121	2.3	
			Hs.24809	hypothetical protein FLJ10826		
	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellular matrix protein 2	11.3	
	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subunit, non-ATPase, 11	2.7	
35	113870	AL079314	Hs.16537	hypothetical protein, similar to (U06944) PRAJA1	6.1	
	113885	AW959486	Hs.21732	ESTs	6.6	
		AW953484		hypothetical protein FLJ22041 similar to FK506 binding proteins	1.9	
		W87544			1.2	
				Homo sapiens cONA FLJ11562 fis, clone HEMBA1003197	5.4	
40	114022	A1826386	He 164478	hypothetical protein FLJ21939 similar to 5-azacytidine induced gene 2	9.4	
70			Hs.7910		1.8	
					1.5	
				fucose-1-phosphate guarrylyftransferase	1.8	
	114220	AB028968	HS./909	KIAA1045 protein		2.3
	114253	BE149866	HS.14831	Homo septens, Stimilar to zinc finger protein 136 (clone pHz-20), clone MGC:10647, mRNA, comp	4.4	2.0
45		AL117518		KIAA0978 protein	1.4	
				KIAA0306 protein	15.8	
	114292	A1815395	Hs.184641	fatty acid desaturase 2	1.9	
	114309	AA332453	Hs.20824	CGI-85 protein	2.4	
	114392	AA249590	Hs.100748	ESTs, Wealthy similar to A28996 proline-rich protein M14 precursor - mouse [M.musculus]	1.8	
'50	114407	BE539976	Hs.103305	Homo saniens mRNA: cDNA DKFZo434B0425 (from clone DKFZp434B0425)	1.2	
-		H37908	Hs 271616	ESTs, Wealty similar to ALUB_HUMAN ALU SUBFAMILY SX SEQUENCE	5.5	
	114463	A) 420247	He ADADO	KIAA0872 protein	5.2	
	444464	A1004749	Un 100607	Homo saptens, Similar to RIKEN cONA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial		
					1.8	
	1144/1	AAU28U/4	HS.104613	RP42 homolog	1.D Th 12.8	
55	114480	BE066778	HS.1516/8	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyitransferase 6 (GalNAc-1	0) 13.4	
	114671	AA766268	Hs.2662/3	hypothetical protein FLJ13346	1.9	
	114698	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	3.5	
	114730	A1373544	Hs.331328	Intermediate filament protein syncollin	3.8	
	114767	A1859865	Hs.154443	minichromosome maintenance deficient (S. cerevisiae) 4	1.6	
60 ·	114774	AV656017	Hs.184325	CGI-76 protein	3.1	
	11/1708	AA159181	Hs.54900	serologically defined colon cancer antigen 1	3.5	
	44/980	AI 157545	Hs.42179	bromodomain and PHD finger containing, 3	4.3	
	114000	AA226477	Hs.76591	KIAAC887 protein	7.1	
	114050	DEE20404	II- E224	hypothetical protein	1.3	•
65	114896	BE539101	r15.3324	nypoineucas protein gbzz/29/02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:723771 3', mRNA s	onitonee	1.5
65	114911	AA236672	11. 4665	GRATES IN SOCIES OVERY MINISTRUMON FROM SAPIRIES COMM GROUP INMOSTAL 2011 12, HIRAM S	2 A	1.4
	114930	AA237022	Hs.188717	ES18	2.0	
	114938	AA242834	Hs.58384	ESIS	2.9	

	114965	Al733881	Hs.72472	BMP-R1B	2.3
				dachshund (Drosophila) homolog	1.3
	115038	AA252360	Hs.87968	toll-like receptor 9	1.6
	115061	Al751438	Hs.41271	Homo saplens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5	115062	AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5 1.5
		A1670847		hypothetical protein	2.8
	115121	A1634549	Hs.88155	ESTs	2.5
	115206	AW183695	Hs.186572	ESTS	1.5
				hypothetical protein FLJ10116	1.3
10	115239	BE251328	HS./3297	hypothetical protein FLJ10881 ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4
	115242	AUGOGACO	HS.200132	hypothetical protein FLJ11301	1.5
		AW972872			2.4
				hypothetical protein FLJ10461	6.2
15		AI215069		ESTs	6.6
IJ	115468	AA314349	Hs.48499		7.4
	115471	AK001376	Hs.59346	hypothetical protein FLJ10514	1.4
	115479	AW301608	Hs.278188	ESTs. Moderately similar to 154374 gene NF2 protein [H.saptens]	4.0
	115496	AW247593	Hs.71819	eukaryotic translation initiation factor 4E binding protein 1	16.3
20	115500	Y14443	Hs.88219	zinc finger protein 200	5.0 2.5
	115553	AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5 6.1
	115581	A1540842	Hs.61082	ESTs	2.9
	115587	BE081342	Hs.283037	HSPC039 protein	5.3
25		AA399477	Hs.67896	7-60 protein solute carrier family 2 (facilitated glucose transpórter), member 10	4.7
25					10.0
	115652	BE093589	MS.301/0	hypothetical protein FL123468 Homo sapiens, clone MGC:16063, mRNA, complete cds	12.7
	110000	ALU46269 Al138785	115.200099 Ue 40607	ESTs	2.0
	145676	AA953006	He 88143	ESTS	3.0
30		AA625132		hynothetical protein FLJ21615	1.7
50		AF231023			6.8
		BE395161		proteasome (prosome, macropaln) subunit, beta type, 2	1.7
		AI950339			2.6
	115811	NM_01543	4Hs.48604	DKFZP434B168 protein	21
35	115823	AI732742	Hs.87440	ESTs	2.1 1.3
•	115837	Al675217	Hs.42761	ESTs	4.4
				hypothetical protein MGC5370	7.2
		AW062629			1.2
40		N55669		mitochondrial ribosomal profein L13	5.5
40	110941	Al867451 AB037753	He 67767	hypothetical protein FLJ20739 . KIAA1332 protein	9.8
	44E003	DE275/60	He 66493	Down syndrome critical region gene 5	1.4
	116003	VI 320023	Hs 57664	Homo saptens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
	116108	AA770688	Hs.28777	H2A histone family, member L	1.8
45	116134	BE243834	Hs.50441	CGI-04 protein	1.4
15		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0584 [H.saplens]	1.2
	116195	AW821113	Hs.72402	ESTs	21
	116238	AV660717	Hs.47144	DKFZP586N0819 protein	1.7
	116246	AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7 1.7
50	116262	A1936442	Hs.59838	hypothetical protein FL/10808	1.9
	116298	AI955411	Hs.94109	Homo saplens cONA FLJ13634 fs, clone PLACE1011133	4.9
	116318	AF097645	Hs.58570	deleted in cencer 1; RNA helicase HD8/DICE1	1.4
				Homo saplens cDNA FLJ11663 fis, done HEMBA1004631	1.9
55	116336	AL133033 AK000290	115.4004	KIAA1UZo protein dipepiidyl pepiidase 8	1.5
55	110339	AA407120	He 184771	nuclear factor I/C (CCAAT-binding transcription factor)	1.9
	110330	Al149586	Hs.38125	Interferon-induced protein 75, 52kD	1.9
		N50174	Hs.46765		6.1
	116368	N90466	Hs.71109	KIAA1229 protein	1.6
60	116417	AW499664	Hs.12484	Human clone 23826 mRNA sequence	7.4
50	116436	AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1
	.116462	AF218313	Hs.236828	putative helicase RUVBL	1.5
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	21
	116470	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	1.2
65	116575	AA312572	Hs.6241	phosphoinostide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.5
	116637	AK001043	Hs.92033	integrin-linked kinase-associated serine/threonine phosphatase 2C	2.7 2.3
	116640	X89984	Hs.211563	B B-cell CLL/lymphoma 7A	2.0

				nyposicacai procein mootor co	1.4	
	116705	AW074819	Hs.12313	Hisporicing Morest (F) 14000	3.4	
				CO15, Freday Strate to ROOLE Hypotholine protein protein protein proteins	2.9 8.3	
_		AW068115		ngi)cari	1.7	
5	116926		Hs.290830	ES18	3.4	
	117034			1 1 Passociated sector 2	5. 4 5.2	
			HS.42315			5.5
	117247		11- 404000	gbcyx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264803 3', mRNA se	1.5	0.0
10	11/2/6	N71183	HS.121606		2.0	
10				House achieve and it is seen to the first the seen of	20	
•	11/30/	A1041/93	Hs.42502		21	
				Hit DO'th free board is decourse free one beautiful manners	2.7	
			Hs.40173	LUI3	1.4	
15	117412			South Carles Killing to (increasing and autoperato), manage	3.4	
13		N34895	Hs.44532 Hs.44648	dition de la constant	3.4	
				CGI-12 protein	3.0	
				zinc finger protein 281	1.9	
	117879	NS4706	He 303025	chromosome 11 open reading frame 24	1.8	
20				huturate induced transcript 1	5.7	
20				hypothetical protein MGC5370	5.9	
	117911	Al 137379	Hs 47125	hypothetical protein FLJ13912	1.7	
		Y10518		hypothetical protein FLJ20048	1.7	
				KIAA1785 protein	5.4	
25		N54321	Hs.47790	EST	5.2	
			Hs.293264	ESTs	2.6	
	118429	AA243332	Hs.74649	cytochrome c oxidase subunit Vic	2.5	
	118472	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1	•
			Hs.50102	rapa-2 (rapa gene)	1.2	
30	118509	N22617	Hs.43228	Homo saplens cDNA FLJ11835 fis, clone HEMBA1006595	1.5	
	118528	Al949952	Hs.49397	ESTs	7.4	
	118656	A1458020	Hs.293287	ESTs	2.5	
	118670	AA332845	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	1.2	
~-			Hs.50187	KIAA1287 protein	2.1 5.2	
35		AA199688		ghzzi75g09.r1 Strategene hNT neuron (937233) Homo saptens cDNA clone IMAGE:647488 5		
	118925	N92293	Hs.206832	ESTS, Moderately similar to ALUB HUMAN ALU SUBFAMILY SX SECUENCE CONTAMINATION	36	
	118984	Al668709	Hs.240722	ESTs, Moderately similar to ALUS_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	4.8	
				bladder cancer overexpressed protein	1.7	
40				KIAA1710 protein	22	
40			Hs.3657		1.6	
		AW453069		activity-dependent neuroprotective prote	1.4	
		N57568	Hs.285363 Hs.48028		25.1	
			1Hs.155478		1.6	
45	110230	AM 17240	He 320838	ESTs, Wealdy similar to A47582 B-cell growth factor precursor [H.sapiens]	1.3	
73		T65004	Hs.163561		8.4	
				nucleolar protein NOP5/NOP58	6.7	
			Hs.170042	ESTS	24	
			Hs.55513	ESTs	2.1	
50		W37933		Empirically selected from AFFX single probeset	1.9	
	119601	AX000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp6671103 (from clone DKFZp6671103)	3.7	
				hypothetical protein FLJ11350	3.0	
	119676	AA243837	Hs.57787	ESTS	1.4	
	119682	W61019	Hs.57811	ESTs	1.2	
55		AB032977	Hs.6298	KIAA1151 protein	1.8	
	119780	NM_01682	5Hs.191381	hypothetical protein	3.1	
	119789	BE393948	Hs.50915	kalillrein 5 (KLK5; KLK-L2; stratum comeum typtic enzyme)	9.2	
	119805	AJ223810	Hs.43213	ESTs, Wealthy similar to IEFS_HUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP	3.6	
	119818	AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	
60	119863	AA081218	Hs.58608	Homo sapiens cDNA FL114208 fis, clone NT2RP3003157	2.7	
	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danios syndrome type IV, autosomal dominant)	2.6	
			Hs.58963		2.7 1.2	
		W57554		lymphold nuclear protein (LAF-4) mRNA	1.∡ 45.7	
CE		H26735		Homo sapiens done PP1498 unknown mRNA	45.7 1.2	
65				uncharacterized bone marrow protein BM033	38.9	
				fibroblast growth factor 128	9.6	
	120209	AW131940) Hs.104030	teols	J.U	

	120274	AA177051		gb:nc02z02.s1 NCL_CGAP_Pr3 Homo saplens cDNA clone IMAGE:194 similar to contains Alu	4.6
		AA190577		gbrzp52g02.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 3', mRNA sequence	2.0
	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	1.8
	120297	AA191384	Hs 104072	ESTs, Wealty similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	15.2
5		AA195517			5.5
•		AA195651			6.4
	120323	AK000292	Hs 278732	hypothetical protein FLJ20285	16.1
		N85785	He 181165	eutraryotic translation elongation factor 1 alpha 1	2.9
	120342	AWASDESS	He ASOSR	hypothetical protein DKFZp4341143	5.7
10	120242	AA210722	He 10415R	FSTs	4.5
10	120040 120240	AVAIDEDARI	He 55180	hypothetical protein	16.8
		R06859	Lie 403177	ESTs, Wealthy similar to 138022 hypothetical protein [H.saplens]	5.0
	120002	A CONTRACT	13. 150 17 £	putative purinergic receptor	28.1
	120330	AA219305	Us 40/400	ECT CCT	12.4
15	1203/1	AA219303 AA228026	13,107130	EOI ECTo	4.0
13	120002	AA220020	III. 422422	FSH primary response (LRPR1, rat) homolog 1	9.7
	120363	ALIUSSOS	TES. 123 122	hypothetical protein DKFZp434D0127	32.6
	120385	AWYSOSOOS	IIS, 104040	Hippotessa process ora apromotias	3.1
	120388	AA232874	HS. 104240	ESTS, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	121.7
20	120389	AW96/985	HS.320012	eukaryotic translation initiation factor 4E	12.5
20	120396	AA134006	HS./9300	CURATYOUG UZISKUUN PRODUCAN KAKA 4L.	7.2
	120404	ABU23230	HS.9042/	KIAA1013 protein	11.4
	120418	AW966893	MS.20013	Homo saplens mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F1323)	1.9
	120423	AA236453	HS.189/8	Homo sapiens cDNA: FLJ22822 fis, clone KAIA3968 gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	19.4
~~	120472	Al950087		GOOWGIDOUXXI NOT COMP TO IX LOUISO SANSIE COLAN CIONE 2 , HILVAN SECTIONICE	5.4
25		AA251973			10.4
		AA253170	Hs.964/3	gbzzr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:682387 3*, mRNA sequen	
		AA256837			9.4
		BE047718			2.4
~~	120520	AA258601	Hs.161731	EST	2.5
30	120535	BE350244	Hs.96547	ESIS	5.2
	120551	AA279160	Hs.111407	Homo saptens, clone IMAGE:3613029, mRNA, partial cds	14.4
	120570	AA280679	Hs.271445	ESTs, Wealthy similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	10.2
	120582	BE244830	Hs.284228	ZNF135-like protein	2.1
	120590	AW372799	Hs.125790	leucine-rich repeal-containing 2	7.5
35				N-acety/glucosamine-phosphate mutase	2.5
	120619	AW965339	Hs.111471	ESTS	52.0
			Hs.173518	M-phase phosphoprotein homolog	
	120539	AA286942		gbzs56i05.s1 NCL CGAP_GCB1 Homo saptens cDNA clone IMAGE:701505 3' similar to contains	5.0
	120648	AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	2.2
40	120653	AW063659	Hs.191649	ESTs	2.2
				6.2 kd protein	1.9
		BE536739	Hs.109909	ESTs	
	120695	AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	40.0
		AI821539			2.5
45		AW449855			5.9
	120718	AA292747	Hs.97296	ESTs	2.9
	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B cell growth factor [H.saplens]	7.0
	120774	A1608909	Hs.193985	ESTS	7.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848 protein	6.8
50	120809	AA346495		gb:EST52657 Fetal heart II Homo saplens cDNA 3' end similar to EST containing O family repeat,	4.4
	120938	AA386260	Hs.104632	EST	4.4
	120977	AA398155	Hs.97600	ESTs	4.4
	120984	BE262951	Hs.99052	ESTs	5.6
	120985	A1219896	Hs.97592	ESTs	1.2
55	121011	AA398360	Hs.97608	EST	3.1
	121026	A1439713	Hs.165295	i ESTs	3.5
•	121081	AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
	121133	AA363307	Hs.97032	ESTs	3.7
	121176	AL121523	Hs.97774	ESTs	1.7
60 .	121223	A1002110	Hs.97169	ESTs, Wealty similar to dJ667H12.2.1 [H.sapiens]	2.9
	121320	AAAAAAAAAA	Hs.301927	7 c6.1A	1.9
	121340	AW056081	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
	424409	AAAOR137	He 98019	EST	6.0
	121/170	AA410190	Hs 98076	ESTs. Weakly similar to A47582 B-cell growth factor precursor [H.Sapiens]	7.4
65	121450	AAANEARA	Hs.10536	Horno saplens, clone MGC:18257, mRNA, complete ods	6.9
5 5	121750	AW971063	Hs 29288	P ESTs	1.8
	121402	. ATTO 1000	, , DEGEROO	minute and indused 14	10.5

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
			Hs.97900		14.4
			Hs.194417		13.1
			Hs.97887		28.0
5			Hs.181510	ESTs	6.2
•		AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:727563 3', mRNA sequence	. 2.6
			Hs.98142		7.4
		AA412497	.,	gbzt95g12.s1 Soares_testis_Ni+T Homo sapiens cDNA clone IMAGE:730150 3' similar to contains	:2.8
			Hs.98098		3.5
10 .		AA416568	113.0000	gbzzu05c10.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	6.1
10			He 20712	spermine synthase	3.9
			Hs.98247		2.2
			Hs.126065		4.2
•	121022	AAA24527	Lie 179072	Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023)	7.8
15	121000	AAA19160	He REDAY	Homo sapiens cDNA FLJ13558 fs, done PLACE1007743	2.0
1.7			Hs.110286		4.7
	121706			hypothetical protein FLJ11585	12.7
	121700	AAA10225		Homo sapiens cDNA FLJ11953 fls, done HEMBB1000883	8.1
	121/14	AIDADEOZ	Hs.98325	ECTs	1.8
20					4.0
20			Hs.180744		7.1
			Hs.97514		19.5
	121/48	RE030311	TS-Z34343	hypothetical protein NUFZR	7.9
				KIAA1196 protein	1.7
25			Hs.161008		6.6
25				hypothetical protein FLJ22501	10.5
	121/80	AM30//4	Hs.98376 Hs.98434	E015	5.8
					3.8
			Hs.218289		5.0
30				ESTs, Highly similar to KIAA1048 protein [H.saplens]	2.7
30			Hs.2799	serine/threonine kinase 23	2.3
					2.9
			Hs.293044		5.0
			Hs.98459	gbczw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3*	7.2
35	121911	AA427950	Un 202406	ESTs, Moderately similar to A46010 X-linked retinopathy protein (H.saplens)	2.5
33					2.3
			Hs.98611		3.4
	127983	AAZS0/OU	TIS. 100 191	hypothetical protein FLJ14904 Homo saplens, clone IMAGE:2822295, mRNA, partial cds	11.4
				nemo-Eko kinase	3.8
40	121990	AA210863	Hs.98668		6.4
40					2.2
				Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	6.5
			Hs.98706	ESTS, Weakly similar to ALUS_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
		W92142			9.1
45				ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	13.1
43			Hs.98750		1.5
			Hs.104921	gbzt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5, mRNA sequence	3.3
		AA398838	No 00042		5.6
			Hs.98842 Hs.29417		5.1
50					5.6
J U	1///20/	AMAJOO19	Hs.98899	EQ13	5.8
•			Hs.104947		2.0
			Hs.99010	ESTs	7.3
		AA443794			12.2
55	122369	AAAASSSS	Hs.303222	EOIS EOT-	5.0
55	1223/1	AABOBOO	Hs.178222	EQ18	7.6
	1223/2	AAA46UU6	Hs.336677	ENI	25
	1223/8	ABUSZUAN	HS.21300	hypothetical protein DKFZp762K2015	2.8
	122405	AA4465/2	Hs.303223	EOI EOTo	7.3
<i>6</i> 0	122412	AA446869	Hs.119316	EOIS	1.9
60	122415	AA446918	Hs.99088	EOI FOTO A fadorata la cialita de cialita de MAAGOCC (IL) combono)	6.8
	122418	AA446966	HS.99090	ESTs, Moderately similar to KIAA0766 [H.sapiens]	
	122440	AW505139	HS.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
	122446	AA447603	Hs.99123	ENI Com	1.8
~-	122448	AA447626	Hs.99127	E21	3.5
65	122458	A1266159	Hs.104980	ESIS	1.5
	122460	AW418788	Hs.99148	ESTs, Weakly similar to \$43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
	122464	AA448158	Hs.99152	ESI	4.8

	122400	AA448349	Llo 238451	PS1	6.1	
	122490	AA448417	He 104990	FSTq	5.4	
	122432	Papancay	He 234863	Home saries cDNA FL J12082 fis. clone HEMBB1002492	1.3	
	122510	AA449232	He 99195	FST9	11.2	
5	122530	AW050741	Hs 40368	adantor, related protein complex 1, signa 2 Subunii	10.1	
,	122547	AA779725	Hs.164589	ESTs	2.5	
		AA194055			1.9	
		AA452578			9.5	
	122572	MARSTALA	He 99287	FST	11.0	
10	122586	AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516	3.4	
	122587	AB040893	Hs.6968	KIAA1460 protein	20	
	122598	AI028173	Hs.99329	ESTs	1.7	
	122599	AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	
	122602	AA411925	Hs.301960	ESTs	4.6 61.5	
15	122607	AA453518	Hs.98023	ESTs	10.7	
		AA453630			107.3	
	122616	AA453638	Hs.161873	ESTS	121.4	
	122617	Al681535	Hs.148135	serine/fireonine kinase 33	31.1	
	122618	AA453641		gbzz48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3, mRNA sequence	5.6	
20	122622	AA453987	Hs.144802	ESIS	8.5	
		AA456859			10.4	
	122762	Al376875	Hs.105119	ESIS	81.8	
	122829	AW204530	HS.99500	Homo saplens cDNA FLJ10658 fis, clone NT2RP2006052	3.6	
25	122834	AA461492	HS.95040	HORID SEPREIS CLARA FLUTOCOD IIS, CIGILE AT 21 4 2000002	4.5	
25	122836	AA460581	HS.230330	ESTs, Weakly similar to putative p150 [H.sapiens]	2.7	
	122837	AA460584	HS.290000	EGL!	75.3	
	122000	AACOOOSE AACOOOSE	IP- 063E	NIMA (never in mitosis gene a)-related kinase 6	7.7	
	122009	ANDOUZE ANDOOTA	115.3023 14e 75357	Sro-like-adapter	5.8	
30	122000	AA335721	He 119394	FSTs	1.3	
50	122001	BE539656	Hs 283705	ESTS	4.1	
	122888	AF005216	He 115541	Janus knase 2 (a protein tyrosine kinase)	5.3	
	122870	AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone COLF7179	9.9	
	122872	AW081394	Hs.97103	ESTs	5.3	
35	122879	AA769410	Hs.128654	ESTs	13.9 11.5	
	122907	AA470074	Hs.169896	ESTs	1.7	
	122916	AA470140	Hs.229170	EST	5.0	
	122981	AA478951	Hs.105629	ESTs	15.4	
	123013	AW968324	Hs.17384	ESTS	2.8	
40	123016	AW338067	Hs.323231	Homo saplens cDNA FLJ11946 ffs, clone HEMBB1000709	8.7	
	123034	AL359571	HS.44004	ninein (GSK3B interacting protein)	8.8	
				ESTs, Wealdy similar to KIAA1395 protein [H.sapiens]	3.9	
	123082	AA485360 Al343652	HS. 100001	EDIS	3.8	
45	123000	AA486256	Ub. 102510	E313	7.4	
43	123110	Pに303042	Lib 265849	myomegalin	2.8	
	123117	T52027	He 271705	ESTs, Weakly similar to 138022 hypothetical protein [H.saplens]	2.4	
	123137	AIDR15R2	Hs 324179	Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434	15.6	
	123136	AW451999	Hs.194024	ESTs	5.1	
50	123149	AI734179	Hs.105676	ESTs	23.8	
•	400450	AMMONTE	1 LL 9709CD	LCTo	5.2	9.3
	123258	AA490929	Hs.105274	r core week, elemente disect di biann decit attor de Milloux Spindle Aggement i ind	sapiensj	9.3
	123315	AA496369)	gb:zy/37d10.s1 Soares ovary tumor NbHOT Homo saplens cDNA clone IMAGE:755827 3' similar	6.9	
	123369	AA504757	Hs.105738	ESTs .	3.6	
55	123394	AA731404	Hs.105510	ESTs	3.7	
	123433	AW45092	2 Hs.112478	B ESTs	7.4	
	123466	AA599042	Hs.112503	SEST		
	123470	AW30328	5 Hs.303632	Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene similar	5.2	
<i>-</i> 0	123471	AB021644	Hs.197219	2 zinc finger protein 14 (KOX 6)	1.7	
60				Homo saplens, clone IMAGE:4098694, mRNA, partial cds	1.6	
	12348	N95059	Hs.55098	ESIS	2.4	
	12348	BEU19072	. HS.3348U	2 Homo saplens cDNA FLJ14680 fis, clone NTZRP2004242, weakly similar to 5 KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	2.2	
	123500	AVVJUUJU	o ms.133341 1	gbraf12a12.s1 Soares_testis_NHT Homo sapiens cDNA ctone 3', mRNA sequence	7.8	
65	12361	AA609170 AA602964	, l	about the second of the second	2.8	
65	1/301	3 AA609364	, 1	glorida/CIZ-S1 NCL_CGAP_F12 holi to sapiens con control in MAGE:743441 3' similar to contra glozu/1d09.s1 Soares_lestis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similar to contra	ins Alu.	1.7
	1/2300	NAMEDEUD NAMEDEUD	He 10519	7 kinesin protein 9 gene	5.7	
	1230/4	7 (1)403003	1 100 100 10			

	123735	NM_013241	Hs.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
	123753	AA609955	Hs.234951	Huntingtin interacting protein E	30.6	
_			Hs.261915	EST, Wealthy similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.saplens]	2.1	
5	123811	AA620586		ghrae60g05.s1 Stratagene lung carcinoma 937218 Homo saplens cDNA clone IMAGE:951320 3	2.7 6.2	
	123951	AB012922	Hs.173043	metastasis-associated 1-like 1	0.2 4.4	
				choline dehydrogenase .	7.0	
				ralA binding protein 1	8.1	
10		Al147155			3.7	
10	124070	AI950314	HS.154/62	HIV-1 rev binding protein 2	1.2	
	124074	H05635	HS.294030	topolsomerase-related function protein 4-2	3.1	
	1241/8	BE463721	MS.9/101	putative G protein-coupled receptor ESTs, Weakly stmilar to AF161356 1 HSPC093 [H.saplens]	5.7	
	124203	AA3/2/90	HS.209339	EQ12' AGENDA SIMINI ID VL. 10 1200 1 LOL COSS (i resolvere)	3.1	
15		AA640891		KIAA0265 protein	3.5	
13		D87454 Al267847	113, 102,000	gb:aq49a10.x1 Stantey Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
			He 7535	COBW-like protein	2.8	
	124330	AE155000	He 279780	NY-RENI-18 antinen	7.1	
		N34059	113.21 37 00	gbyv28h09.s1 Soares fetal liver spieen 1NFLS Homo sapiens cDNA clone 3' similar to contains A	lu 3.3	
20	124428	H13540	Hs.82202	ribosomal protein L17	2.9	
	124440	AA532519	Hs.129043	Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
	124466	R10084	Hs.113319	khosin heavy chain member 2	2.6	
		N53935		gb:yv59d09.s1 Soares fetal liver spicen 1NFLS Homo sapters cDNA clone 3', mRNA sequence	7.9	
		H79433	Hs.268997		7.8	
25	124515	AA669097	Hs.109370	ESTs	3.3	
	124608	N71076	Hs.102800	ESTs, Wealthy similar to neuronal thread protein AD7o-NTP [H.saplens]	4.5	
	124631	NM 01405	3Hs.270594	FLVCR protein	3.2	
				Homo saplens cDNA FLJ13533 fis, clone PLACE1006371	5.8	
				hypothetical protein	9.3	
30				sorting nexin 17	3.5 6.1	
			Hs.313054		8.3	
		AW297702			5.6	
	124661	R48170	Hs.78436	ESTS, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
35					5.7	
3 3		R09166 R22952			11.3	
	124733 124781	AARTATER	He 93560	Homo sapiens mRNA for KIAA1771 protein, partial cds	9.0	
	12476R	AW368528	Hs 100855	FSTs	8.1	
	12/775	DA1779	He 100878	FSTs	4.9	
40	124777	R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	2.8	
••	124788	R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone HSi15005	5.1	
	124809	AL355722	Hs.106875	Homo sapiens EST from clone 35214, full insert	4.2	
				hypothetical protein FLJ22604	14.2	
	124812	R47948	Hs.188732	ESTs	7.9	
45				Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
		AA501669			2.3 2.7	
		AW975868			2.3	
		R63652			23.9	
50		R65763			2.0	
50	124863	AUSTECO	MS.12/900	bromodomain-containing 1	4.4	
	124876	Ar1504ZZ	13.2/US	GDP-mannose pyrophosphorylase A hypothetical protein FLJ22242	2.7	
			Hs.101883		5.7	
		H37941 AW296713			32.4	
55		A1076343	He 173030	ESTs, Weekly similar to ALLIB_HUMAN (III ALLI CLASS B WARNING ENTRY (I) [H.sapiens]	22.8	
<i>J J</i>		R99978	He 268892	ESTs, Moderately similar to B34087 hypothetical protein [H.saplens]	6.1	
		A)078645	Hs.431	murine leukemia viral (bmi-1) oncogene homotog	1.9	
		T40841	Hs.98681	EST8	4.5	
		T59338	Hs.269463	ESTs, Weekly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60		179815	Hs.279793		5.0	
		T79956	Hs.100588		135.3	
	125056	T81310	Hs.100592		5.4	
		A1472068	Hs.286236	KJAA1856 protein	5.6	
		T96595	Hs.302270	ESTS, Weakly similar to ALUF_HUMAN IIII ALU CLASS F WARNING ENTRY III [H.sapiens]	1.8	
65	125115	T97341		gbcye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' simi	tar to 9	9.6
		Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end	or the gene 1	1.5
	425447	W38150		Emphically solocted from AFFX single nonbeset	1.7	

	125161	W44657	Hs.144232	EST	10.7
	126240	V VESUBES	He 131375	ESTs, Moderately similar to ALUB_HUMAN IIII ALU CLASS B WARNING ENTRY III [H.sapiens]	1.3
					9.4
				timeless (Drosophita) homolog	1.5
_		AW401809		KIAA1150 protein	8.0
5	125280	Al123705	Hs.106932	ESTS	
	125298	AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 ffs, clone HEP01068	1.5
				scaffold attachment factor B	5.9
				YY1 transcription factor	1.2
			Hs.7138	cholinergic receptor, muscarinic 3	6.4
1Λ					14.3
10		AW409701		baculoviral IAP repeat-containing 5 (survivin)	2.4
•				vacuolar proton pump della polypeptide	
				a disintegrin and metalloproteinase domain 10	9.1
	127050	AW411066	Hs.274351	CGI-89 protein	17.D
				Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947	128
15			Hs.161623		7.3
13				KIAA0276 protein	3.1
					1.3
				KIAA0276 protein	9.4
	128522	BE173977	HS.10098	putative nucleolar RNA helicase	1.5
	128527	AA504583	Hs.101047	transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	
20	128528	R39234	Hs.251699	ESTs, Wealthy similar to IDN4-GGTR14 [H.saplens]	2.8
	128595	U31875	Hs.272499	short-chain alcohol dehydrogenase family member	121
	128599	NM 015366	Hs.102336	Rho GTPase activating protein 8	2.3
	128604	AIR70000	He 102397	GIOT-3 for gonadotropin inducible transcription repressor-3	1.3
	400000	MIDI SUSS	Un 402440	zinc finger protein	7.1
25					1.3
25	120025	ABU3/841	HS.1U2002	hypothetical protein ASH1	3.2
	128629	AL096748	Hs.102708	DKFZP434A043 protein	
	128639	AW582962	Hs.102897	CGI-47 protein	2.0
	128656	AA458542	Hs.10326	coatomer protein complex, subunit epsilon	1.4
	128656	AA458542	Hs.10326	coatomer protein complex, subunit epsilo	1.3
30	128658	RF397354	Hs 324830	distinguia toxin resistance oxidein required for dighthamide biosynthesis (Saccharomyces)-like 2	2.4
50	120000	AA075ARG	He 103441	Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete of	ds 7.
				hypothetical protein MGC5576	7.7
		W27939			3.8
			HS.ZZ59//	nuclear receptor coactivator 3	1.6
~-		Y15221		small inducible cytokine subfamily B (Cys-X-Cys), member 11	
35		T85231		tubulin, beta 5	7.6
	128717	AK001564	Hs.104222	hypothetical protein FLJ10702	5.5
	128733	BE147740	Hs.104558	ESTs, Moderately similar to 138022 hypothetical protein (H.sapiens)	2.7
				RP42 homolog	2.8
				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40	120/42	A1470402	115.231331	actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
40	128/46	AI4/0163	HS.323392	SCOT LEADER PROCESS 2/3 CONTINUES, SUBJUM 4 (20 MJ)	2.8
				PDZ-binding kinase; T-cell originated protein kinase	
	128772	BE302796		thymidine kinase 1, soluble	5.3
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypeptide F	53.9
	128797	NM 002975	5Hs.105927	stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45	128808	AW630942	Hs.106061	RD RNA-binding protein	2.6
				nuclear prelamin A recognition factor	2.2
				valosin-containing protein	5.9
	120000	AMOORTO	115.100007	Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6
					2.2
~ ^				hypothetical protein FLJ13855	
50	128854	BE159181	Hs.168232	hypothetical protein FLJ13855	1.9
	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	3.0
	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	2.2
				ATPase, Ca++ transporting, type 2C, member 1	1.5
		F34856		Homo saplens, clone MGC:16362, mRNA, complete cds	13.3
55		R57988		epithelial protein lost in neoplasm beta	4.7
<i>))</i>					1.4
				programmed ceil death 5	1.9
		R67419		Homo sapiens cDNA FL.112900 fis, clone NT2RP2004321	
		Y13153		kymurenine 3-monooxygenase (kymurenine 3-hydroxytase)	7.2
	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase domain 12 (melirin alpha) (ADAM-12)	2.4
60	128958	AW139032	Hs.107376	hypothetical protein DKFZp434N035	1.3
-	422050	AISR0197	Hs 107381	hypothetical protein FLJ11200	10.9
	420000	AWHENCH?	Hs.107418	FSTe	1.4
	120500	VILL 120091	113.10/410	ECT.	1.3
	128970	AI3/56/2	Hs.165028	NOC C	14.0
	128975	BE560779	HS.284233	NICE-5 protein	
65	128979	AW271217	Hs.281434	Homo sapiens dDNA FLJ14028 fis, clone HEMBA1003838	1.6
	128995	AJ816224	Hs.107747	DKFZP566C243 protein	1.9
		A1950087		gb:wq05c02_x1 NCl_CGAP_Kid12 Homo saplens cDNA clone 3', mRNA sequence	2.9

	420004	AL DA ACTE	Un 472004	VIA ACEZO mentole	3.8
				KIAA0530 protein	2.5
				KIAA0530 protein	3.4
	129032	R80088	Hs.108104	ubiquilin-conjugating enzyme EZL 3	5.0
_	129076	AW296806	Hs.326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens]	
5	129078	Al351010	Hs.102267	lysosomal	2.1
	129088	AA744610	Hs.194431	palladin .	17.1
	129095	L12350	Hs.108623	thrombospondin 2	2.7
	129096	AA463189	Hs 288906	WW Domain-Containing Gene	20.9
	129097	RF243933	Hs 108642	zinc finger protein 22 (KOX 15)	3.0
10	120007	AF146074	He 108660	ATP-binding cassette, sub-family C (CFTR/MRP), member 5	5.8
ıv				hypothetical protein MGC2747	5.9
					6.3
				KIAA0050 gene product	1.8
				hypothetical protein PRO2577	2.1
			Hs.183299		3.2
15				latexin protein	5.8
				KIAA1415 protein	8.0
				osteoglycin (osteoInductive factor, mimecan)	2.9
	129228	U40714	Hs.239307	tyrosyl-tRNA synthetase	3.2
	129229	AF013758	Hs.109643	polyadenylate binding protein-interacting protein 1	
20	129254	AA252468	Hs.1098	DKFZp434J1813 protein	2.6
	129255	Al961727	Hs.109804	H1 histone family, member X	7.3
		W26392	Hs.110080	ESTs, Wealty similar to S13495 pregnancy zone protein [H.sapiens]	9.6
			Hs.110122		1.2
		AA287239	He 5518	Homo saptens cDNA FLJ11311 fis, clone PLACE1010102	5.1
25		H75334		F-box only protein 9	4.6
23	120010	DEC44402	H= 270860	melanoma-associated antigen recognised by cytotoxic T lymphocytes	7.6
			Un 440720	solute carrier family 12 (sodium/potassium/chloride transporters), member 2	6.7
	123302	U30246	TS. 1107-30	Homo sapiens clone 23785 mRNA sequence	8.6
					1.4
20				SAR1 protein	2.0
30	129372	NM_01603	9HS.1108U3	CGI-99 protein	7.4
				pituitary turnor-transforming 1 Interacting protein	5.0
			Hs.317584		2.5
			Hs.317584		10.2
	129423	AA204686	Hs.234149	hypothetical protein FLJ20647	
35	129449	A1096988	Hs.111554	ADP-ribosylation factor-like 7	8.0
	129453	AW974265	Hs.111632	Lsm3 protein	3.2
	129482	AA188185	Hs.289043	spindlin	6.7
			Hs.289043		3.6
				hypothetical protein AL110115	7.1
40	129515	AF255303	Hs.112227	membrane-associated nucleic acid binding protein	2.5
				delta-tubulin	3.2
				hypothetical protein FLJ14784	7.5
			Hs.7845	and the state of t	6.8
				hypothetical protein MGC2/52 chromosome 1 open reading frame 8 processin induced protein	2.0
45				Citolitization tobal loaning	1.6
43		F08282			6.8
	12958/	H14718	HS.11500	Human clone 23589 mRNA sequence	1.4
				postmeiotic segregation increased 2-like 9	7.3
	129591	N57423	HS.179898	HSPC055 protein	9.0
	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombin conversion accelerator)	1.6
50	129596	AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	2.2
	129628	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	
	129628	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	1.4
	129629	AK000398	Hs.11747	hypothetical protein FLJ20391	3.8
	129649	AD000092	Hs.16488	caireficulin	3.3
55	129675	NM 01552	56Hs_172180	KIAA0440 protein	13.4
55		U03749		gb:Human chromogranin A (CHGA) gene, promoter an	14.
			Hs 77873	B7 homolog 3	2.6
	42070	ARRANA	He 12035	ESTs, Wealthy similar to 138022 hypothetical protein [H.sapiens]	7.4
	12310	AA4EE94A	12459	APMCF1 protein	2.0
cn	129/2	MAIDOZ14	, ∏3.1∠13∠ 4£Un 944£~	eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	1.7
60			IURS.∠ I 1033	o tunarjunu uzusidudi inudani idulu 2, sublim 4 (german, 4204)	8.3
	12972	H15474		3 fatty acid desaturase 1	1.8
	12977	AWU16/6	HS.12457	hypothetical protein FLJ10814	5.4
	129779	AA394090	Hs.12460	Homo septens clone 23870 mRNA sequence	1.7
	129800	AF052112	Hs.12540	lysosomal	1.7
65	12980	AB023148	3 Hs.173373	3 KIAA0931 protein	
	12981	BE565817	Hs.26498	hypothetical protein FLJ21657	3.1
		A ANA ARCE	20020	CaDAID apporably defection 4 homolog	1.8

	129861	AL049999	Hs.85963		2.2
				nunt-related transcription factor 1 (acute myelold leukemia 1; aml1 oncogene)	1.7
	129869	A1222069	Hs 13015	hypothetical protein similar to mouse Dnaji1	2.7
				gamma-tuturin complex protein 2	4.5
5				PAI-1 mRNA-binding protein	1.8
J					2.5
		AA412195		Lord	1.8
	_			dynamin 1-like	1.3
				zinc finger protein 36 (KOX 18)	
				activating transcription factor 6	4.0
10	130010	AA301116	Hs.142838	nucleotar phosphoprotein Nopp34	1.6
	130081	AA287325	Hs.14713	ESTs	4.0
	130082	S73265	Hs.1473	gastrin-releasing peptide	1.8
	130097	AL046962	Hs.14845	forkhead box O3A	2.8
	130100	Al 135561	Hs.14891	hynothetical protein FLJ21047	2.3
15		X53002		integrin, beta 5	2.3
10	130112	AA916785	Hs 180610	splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)	3.0
				splicing factor proline/glutamine rich (21
	_	L76937		Werner syndrome	1.8
			115.130777 116.21626	bibulin, gamma 1	6.1
20	130133	AA311420	NS-21000	ESTS, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.sapiens]	
20					1.3
		D80001		KIAA0179 protein	2.0
		R85367		splicing factor, arginine/serine-rich 2, interacting protein	3.2
	130241	AL035588		MyoD family inhibitor	
	130242	X79201		synovial sarcoma, translocated to X chromosome	5.4
25	130249	D81983	Hs.322852	GAS2-related on chromosome 22	4.8
	130263	NM_002497	7Hs.153704	NIMA (never in mitosis gene a)-related kinase 2	1.4
	130287	AA479005	Hs.154036	tumor suppressing subtransferable candidate 3	2.6
	130310	AB011121	Hs.154248	amyotrophic lateral scienosis 2 (Juvenile) chromosome region, candidate 3	6.3
		Z19084		MAUF1 protein	6.2
30				nuclear receptor interacting protein 1	2.4
J				pulative methyliransferase	3.4
	120257	NA 01244	112 277801	bromodomain adjacent to zinc finger domain, 2A	8.5
		AL135301			1.4
				RNA binding motif protein 9	3.3
35		A1077464			1.8
33	130393	N89487	MS. 100281	KIAA0005 gene product	3.4
	130399	AW374106	HS.150306	hypothetical protein MGC2840 similar to a putative glucosyltransferase	2.3
	130407	BE385099	HS.334/2/	hypothetical protein MGC3017	2.7
	130409	NM_001197	7Hs.155419	BCL2-interacting killer (apoptosis-inducing)	
			Hs.155489	NS1-associated protein 1	1.8
40		U63630		protein kinase, DNA-activated, catalytic polypeptide	2.3
	130448	BE513202	Hs.15589	PPAR binding protein	3.9
	130455	D90041	Hs.155956	N-acetyltransferase 1 (arytamine N-acetyltransferase)	33.6
	130455	D90041	Hs.155956	N-acetytransferase 1 (arytamine N-acety	4.6
	130471	AL121438	Hs.183706	adducin 1 (alpha)	2.7
45	130485	BE245851	Hs.180779	H2B histone family, member B	5.0
		U49844	Hs.77613	etada telangiectasia and Rad3 related	4.3
		L38951	Hs 180446	karyopherin (importin) beta 1	1.6
	130503	BE208491		KIAA0618 gene product	16.1
		L32137	Lie 15R4	cartilage oligomeric matrix protein (pseudoachondroplasia, epiphyseal dysplasia 1, multiple)	6.1
50			Hs.1584	cartilage of gomeric matrix protein (pse	5.3
20	130311	L32137	NS. 1004		2.1
				hypothetical protein FLJ12910	7.8
		U64675		RAN binding protein 2-like 1	1.5
	130544	AA321238	Hs.4310	euleanyotic translation initiation factor 1A	
	130553	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4
55	130556	A1907018	Hs.15977	Empirically selected from AFFX single probeset	4.7
	130567	AA383092	Hs.1608	replication protein A3 (14kD)	7.9
	130568	AA232119	Hs.16085	putative G-protein coupled receptor	3.3
		AF083208		apoptosis antagonizing transcription factor	1.2
		AB007891		KIAAD431 protein	5.6
60		AL042210		hypothetical protein DKFZp762N2316; KIAA1803 protein	1.4
J		AA609738		ESTs	1.5
		A1354355		down-regulator of transcription 1, TBP-binding (negative cofactor 2)	1.3
				dutamine-fructose-6-phosphate transaminase 1	12.1
		M90516	Hs.1674		24
<i>CE</i>	130517	M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	15.9
65	130618	AA383439	HS. 16758	Spir-1 protein	
	130667	BE246961	Hs.17639	Homo saplens ubiquitin protein ligase (UBE38) mRNA, partial cds	13,9
	130674	AL048842	Hs. 194019	atractin	1.5

					- 4
	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4
		AA652501	Hs.13561	hypothetical protein MGC4692	5.0
	130693	R68537	Hs.17962		2.0
			Hs.279762	bromodomain-containing 7	1.8
5	130714	Al348274	Hs.18212	DNA segment on chromosome X (unique) 9879 expressed sequence	2.0
	130730	AB007920	Hs.18586	KIAAO451 gene product	3.7
	130744		Hs.18747	POP7 (processing of precursor, S. cerevisiae) homolog	3.1
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	1.4
	130757	AL036067	Hs.18925	protein x 0001	5.7
10	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1), member 1	5.1
	130789	AK000355	Hs.8899	strtuin (sitent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
	130815	AB018298	Hs.19822	SEC24 (S. cerevisiae) related gene lamily, member D	1.5
	130836	J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15.7
	130841	AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, done ADXA01732	2.8
15	130843	AA447492	Hs.20183	ESTs, Wealty similar to AF164793 1 protein x 013 [H.sapiens]	1.5
	130844	U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.4
•	130855	AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7
	130861	NM_016578	Hs.20509	HBV pX associated protein-8	1.9
	130879	NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.16)	1.4
20	130880	BE514434	Hs.20830	kinesin-like 2	2.1
	130892	AL120837	Hs.20993	high-glucose-regulated protein 8	2.4
	130898	AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7
		BE409769	Hs_21189	DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
	130919	N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture antigen) binding protein	2.3
25	130944	BE382657	Hs.21486	signal transducer and activator of transcription 1, 91kD	5.4
		N39842	Hs.301444		2.2
	130992	BE398091	Hs.74316	desmoplakin (DPI, DPII)	1.8
	130993	T97401	Hs.21929		1.6
	131005	AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6
30	131028	A1879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP), gamma	1.2
	131042	A1826288	Hs.171637	hypothetical protein MGC2628	1.6
	131046	AA321649	Hs.2248	smail inducible cytokine subfamily B (Cys-X-Cys), member 10	7.4
	131046	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	3.0
		H23230	Hs.22481		1.7 5.1
35		AA194422		myosin VI	2.5
		AA194422		myosin VI	7.1
	131070	N53344	Hs.22607	ESTs	2.0
		AA749230		dollichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (1.9
40	131076	AA749230	Hs.26433	dolicinyl-phosphate (UDP-N-acetylglucosam	7.0
40				COX15 (yeast) homolog, cytochrome c oxidase assembly protein	1.9
		NM_00654		nuclear receptor coactivator 2	5.8
		BE280074		cyclin B1	2.0
	131206	AW138839	HS.24210	ESTs	7.0
A ==				CGI-26 protein	7.5
45		H62087	Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	2.9
		N47468	Hs.59757		3.5
	131233	D89053	H3.256012	fatty-acid-Coenzyme A ligase, long-chain 3	2.8
	131243	AW383256	H3.24/52	spectrin SH3 domain binding protein 1	2.8
50				thioredaxin domain-containing	5.6
50	13124/	AL043100	HS.32019U	faity acid amide hydrolase	5.7
		AA251716	HS.23/2/	ESTS	1.3
		X80038		Homo sapiens clone F19374 APO E-C2 gene cluster	5.0
				CGI-76 protein	1.8
E E	131320	AADUDD91	HS.140000	splicing factor (CC1.3)	2.6
55	131339	AH028030	HS-20012	Nijmegen breakage syndrome 1 (nibrin) Nijmegen breakage syndrome 1 (nibrin)	2.6
	131339	APU50090 AW293165	175-23012 Un 442424	Militaria meneria shimona i (man)	5.4
	1313/5	AWZSU100	115.143134 115.49200	mitochondriai ribosomai protein L20	5.3
	131390	BE209300	Us 270020	HINDOMORDIEN HOUSONEN FORM EZO	2.2
<i>6</i> 0	131410	BEZ39110	いろん/3030 アレト 4040で7	HSPC168 protein SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
60	131412	NM_UTZZ4	/ 178.12902/ Lla 20250	DELETION PROPERTY STATISTICS AND ADDRESS OF THE PROPERTY OF TH	1.4
	131429	ALUABSUZ	ITS.ZD/20	hypothetical protein FLJ21908	1.7
	131458	BE297567	HS-2/04/	hypothetical protein FLJ20392	2.0
	131475	AA392841	115.2/203	KÍAA1458 protein	2.6
CE	131501	AV661958	115.02U/	GK001 protein	1.6
65	131501	AV661958	173.0 <i>201</i>	GK001 protein Homo sapiens cDNA: FLI21333 fis, clone COL02535	2.0
	131511	AR/JZ103	HS.2/000	UDP-glucose dehydrogenase	1.6
	131528	AUU/04U8	rts.∠0309	OPL-Rimmer naulannikamer	

	131532	BE268278	Hs.28393	hypothetical protein MGC2592	7.4
	131543	AW966881	Hs.41639	programmed cell death 2	2.2
	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1
_	131562	NM_003512	Hs.28777	H2A histone family, member L	1.7 5.1
5	131564		Hs.28792	Homo saplens cDNA FLJ11041 fis, clone PLACE1004405	1.8
	131564			Homo sapiens cDNA FLJ11041 fis, clone PL	5.0
			Hs.271623	nucleoporin 50kD	1.8
		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.3
	131622		Hs.29692	Homo saplens cDNA FLI11436 fis, clone HEMBA1001213	2.2
10		AB037791		hypothetical protein FLJ10980	1.9
		AB037791		hypothetical protein FLJ10980 HSPC182 protein	2.9
		AW410601 AW960597		ESTs	1.3
				KIAA0854 protein	2.8
15	131669		Hs.3041	uracii-DNA giyoosylase 2	2.8
1.5		BE559681		KIAA0124 protein	5.6
		AA642831		putative DNA binding protein	2.9
	131722		Hs.311	phosphoribosvi pyrophosphate amidotransferase	3.4
		AK001641		inhibitior of kappa light polypeptide gene enhancer in B-ceits, kinase complex-associated protein	3.8
20	131760		Hs.3164	nucleobindin 2	2.9
	131760		Hs.3164	nucleobladin 2	2.8
	131763	AI878932	Hs.317	topoisomerase (DNA) !	3.4
	131772	AA382590	Hs.170980	KIAA0948 protein	25.5
			Hs.169474	DKFZP586.00119 protein	5.5 2.4
25	131787	D87077	Hs.196275	KIAA0240 protein	7.9
	131793	AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fls, clone NT2RP2002439	1.4
			Hs.32317	high-mobility group 20B	4.1
	131798			adenovirus 5 E1A binding protein	4.2
30		U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
5 0		U28838 Al251317			5.1
		AA083764		hypothetical protein MGC3178	5.8
		BE502341		ESTs	13.7
		BE502341	Hr 3403	ESTe .	2.4
35	131887	W17064	Hs.332848	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member	1 3.
-	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, complete cds	6.7
	131900	AAD99014	Hs.231029	Homo saptens, clone MGC:15961, mRNA, com	2.0
	131904	AF078866	Hs.284296	Homo saplens cDNA: FLJ22993 fis, clone KAT11914	5.5
	131905	AA179298	Hs.3439	stomatin-like 2	11.3 1.7
40	131913	AW207440	Hs.185973	degenerative spermatocyte (homolog Drosophila; lipid desaturase)	5.2
	131916	AA025976	Hs.34569	ESTS .	2.7
				anaphase promoting complex subunit 11 (yeast APC11 homolog)	5.3
		BE541211			23
15		BE252983 AA355113		ublquifin specific protease 1 x 001 protein	1.5
45				hypothetical protein FLJ20039	23
		W79283	Hs.35962		1.4
				hynothelical protein MDS025	3.5
		U90441	Hs.3622	procellagen-proline, 2-cooglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide It	6.5
50		AA503020			2.4
		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
		H56995	Hs.37372	Homo saptens DNA binding peptide mRNA, partial cds	3.2
		AF193844		COP9 complex subunit 7a	5.8
	132062	BE266155	Hs.3832	ctathrin-associated protein AP47	1.5
55		NM_00226		karyopherin alpha 3 (importin alpha 4)	3.7
		BE171921		ESTs	1.4
		AV646076		ESTs .	5.8
	132116	AW960474	Hs.40289	ESTS	1.7 3.3
6 0		AA857025		kinesin-like 1	3.3 14.7
60		NM_00446		fibroblast activation protein, alpha	5.5
		AA206153		mitochondrial ribosomal protein L37	4.4
	132194	R42432	Hs.4212	ESTS	2.2
		NM_UU476 BE206939		synaptosomal-associated protein, 29kD E2F transcription factor 6	2.2
65	13/201 13272E	AVRERATT	He #2656	KIAA1681 protein	7.8
UJ	132233 1323AN	AR01R324	Hs 42676	KIAA0781 protein	1.5
	132252	A1566004	Hs.141269	Homo saplens cDNA; FLJ21550 fts, clone COL06258	1.3
				• • • • • • • •	

					E 7
	132266	AA301228	Hs.43299	hypothetical protein FLJ12890	5.7
	132273	AA227710	Hs.43658	DKFZP586L151 protein	4.2
				hypothetical protein FLJ13089	2.1
					1.5
_				solute carrier family 2 (facilitated glucose transporter), member 10	10.0
5	132294	AB023191	Hs.44131	KIAA0974 protein	
	132298	NM_015986	Hs.7120	cytokine receptor-like molecule 9	1.9
		AW405882		cortistatin	9.2
			Hs.44856	hypothetical protein FLJ12116	2.0
				hypothetical protest i to 12 i i o	6.5
				heterogeneous nuclear ribonucleoprotein D-like	
10	132370	AW572805	Hs.46645	ESTs .	. 3.8
	132374	AF155582	Hs.46744	core1 UDP-galactosetN-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase	1.5
		Al279892		sorting nextn 14	12.5
					28.3
		AA312135		HSPCO34 protein	1.9
		AL135094			
15		AA100012		hypothetical protein FLJ12085	1.9
	132452	AW973521	Hs.247324	mitochondrial ribosomal protein S14	6.1
		AB011084			1.7
					8.6
		AW169847			5.2
		Al224456	HS.4934	H.sapiens polyA site DNA	
20		X16660	Hs.119007	RAB4, member RAS oncogene family	1.4
	132518	AW885606	Hs.5064	ESTs	6.1
		T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	3.3
				SEC22, vesicle trafficking protein (S. cerevisiae) like 1	2.0
		AA306105			2.9
		AA454132		mitochondrial ribosomal protein L16	22
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	
	132543	BE568452	Hs.5101	protein regulator of cytokinesis 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevisiae, homolog of	1.7
				TH1 drosophila homolog	7.1
		AW631437		· · · · · · · · · · · · · · · · · · ·	2.2
		AK001484		CGI-45 protein	2.2
30	132611	AA345547	Hs.53263	hypothetical protein FLJ13287	
	132612	H12751	Hs.5327	PRO1914 protein	6.8
	132616	RF262677	Hs 283558	hypothetical protein PRO1855	14.0
		AI796870			11.4
25	-			Line Seguine at a monoconto A (annato) cono aspisación de conociones de la conocione de la con	1.9
		U51127	Hs.54434		2.6
35	132668	AB018319	Hs.5460	KIAA0776 protein	
	132692	AW191962	Hs.249239	collagen, type VIII, alpha 2	2.0
	132715	F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645	1.5
		NM_00460		Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
	422724	A14477CE	LL EE ADD	geranylgeranyl diphosphate synthase 1	2.4
40			11320430	L D Mark - M. M. C. C. A. P. A.	12.4
40	132/31	Al189075	HS.3018/2	hypothetical protein MGC4840	14,6
	132744	AA010233	Hs.55921	glutamyl-prolyl-tRNA synthetase	
	132760	AA125985	Hs.56145	thymosin, beta, identified in neuroblastoma cells	2.7
		Y10275		phosphoserine phosphatase	3.0
				KIAA0493 protein	2.3
AE					1.8
45				GDP dissociation inhibitor 2	3.7
		Al026701		KIAA0310 gene product	
	132807	U07418	Hs.57301	mutil. (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)	1.8
	132810	AB007944	Hs.5737	KIAA0475 gene product	5.9
	132813	RE313625	He 57435	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	8.7
50	400045	AIDAEAGG	13- 67476	sex comb on midleg homolog 1	6.4
J U			INS.DI TIO	SEX CONTROLLED OF INSTRUMENT	3.6
		N27852		tousted-like kinase 2	
	132821	AJ251595	Hs.169610	CD44 antigen (homing function and Indian blood group system)	2.8
	132833	U78525	Hs.57783	eultaryotic translation initiation factor 3, subunit 9 (eta, 115kD)	14.6
	432842	NM MASS	AN- 279771	Homo sapiens clone PP1596 unknown mRNA	1.6
55			U- 5044	chromosome 21 open reading frame 59	2.5
"		F12200	115.0011	Letter annual hindre 4	1.4
	132851	U09716	HS.28/912	lectin, mannose-binding, 1	4.2
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	
	132869	AW963217	Hs.203961	ESTs, Moderately similar to AF116721 89 PRO2168 [H.saplens]	2.8
				KIAA1266 protein	2.0
60	420075	ARA OOAGE	nua 50647	Rho-associated, colled-coll containing protein kinase 2	1.6
UU	10/0/0	DESCRIPTION	VI 50001/	I MATTER PA and a regions DAIA cutoffees forther 4 from about a combatt	1.4
				U2(RNU2) small nuclear RNA auxiliary factor 1 (non-standard symbol)	
		AW503667			5.4
	132902	A1936442	Hs.59838	hypothetical protein FLJ10808	6.1
	132012	AW732760	Hs 187579	Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1
65			Lin COSET	Homo saptens cDNA FLJ13598 fis, clone PLACE1009921	2.8
UJ		W78714	113.0023/	The section within the Winner State and the section of the section	6.1
		T79136		Homo sapiens mRNA for KIAA1724 protein, partial cds	
	132941	Al817165	Hs.6120	hypothetical protein FLJ13222	10.3

	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
	132952	AI658580	Hs.61426	Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial cds	2.2
		AA576635		CGI-48 protein	4.9
				Homo sapiens cDNA FLJ11392 fis, done HEMBA1000575	2.7
5		AA035446		The state of the s	5.3
•				RNA binding motif protein 3	3.2
		AA040696			1.3
				done HQ0310 PRO0310p1	3.0
	133012	AARATRA3	He 62711	Homo saciens, clone IMAGE:3351295, mRNA	10.3
10	133015	A.I002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminytransferase 7 (GaliNAc-T	7) 2.
		AI439688		hypothetical protein FLJ20886	1.3
		AI065016		Homo sapiens clone FLB3344 PRO0845 mRNA, complete cds	6.0
		AW500374		PRO0149 protein	5.3
		BE247441		protein with polyglutamine repeat; calcium (ca2+) homeostasis endoplasmic reticulum protein	4.9
15		AK001628		KIAA0483 protein	3.5
10		AA808177		ESTs	13.1
	133134	AF198620	Hs 65648	RNA binding motif protein 8A	1.3
			Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA, partial cds	2.2
				mitogen-activated protein kinase 1	1.3
20				hypothetical protein MGC2745	17.1
20		AW955632			1.8
			Hs.66718	RAD54 (S.cerevisiae)-like	4.9
				hypothetical protein FLJ20671	3.1
		AI801777		ESTS	4.4
25	133233	AWDEARED	No 206287	Homo saptens, Similar to bromodomain-containing 4, clone IMAGE:3542455, mRNA, partial cds	1.7
<i></i>		A1492924		golgi phosphoprotein 1	6.0
				ADP-ribosylation factor-likė 1	1.5
	133254	AIRR7421	He 273330	Homo saplens, clone IMAGE:3544662, mRNA, partial cds	1.4
				zinc finger protein	5.6
30	133268	ANAGESTR1	Hs 293937	ESTs, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9
30				GM2 ganglioside activator protein	4.7
				NRAS-related gene	5.0
		AA102670			2.7
		179526		integral type I protein	9.3
35		AL390127		Knippel-like factor 13	4.4
<i>JJ</i>		BE257758		acid cluster protein 33	1.8
		Al016521		v-aid murine thyrnoma viral oncogene homolog 1	5.5
		AA292811		non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)	2.7
		AF231919		KIAA0539 gene product	1.7
40		AF245505		DKFZP56411922 protein	1.8
70		BE313555		KIAA1224 protein	1.7
		Al950382		phosphatidylserine receptor	1.3
		AW103364		Inhibin, beta A (activin A, activin AB alpha polypeptide)	16.1
				hypothetical protein HT023	12.2
45		ALD31591		phosphotidylinositol transfer protein, beta	10.4
73	133452	NIM 002750	1Hs 274382	protein kinase, interferon-inducible double stranded RNA dependent	1.2
		Al659306		protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
		AW964804		hypothetical protein FLJ22237	11.1
		W45623	Hs.74571	ADP-ribosylation factor 1	2.8
50		AL037159		proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	2.9
J U				damage-specific DNA binding protein 1 (127kD)	2.5
		AU077050		transin	1.5
		X75346	Hs.75074	miliogen-activated protein kinase-activated protein kinase 2	2.1
		BE391579		Fas-activated serine/threonine kinase	1.3
55	133594	AW460781	Hs. 172589	nuclear phosphoprotein similar to S. cerevisiae PWP1	2.2
<i>J J</i>		AA393273		transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
	133500	NM_00288	5Hs.75151	RAP1, GTPase activating protein 1	5.7
		NM_00489		H2A histone family, member Y	25.5
		NM 00204		glycyl-IRNA synihetase	15.8
60		NM_00040		exostoses (multiple) 2	3.3
J V		U25849	Hs.75393	acid phosphatase 1, soluble	1.6
	133600	AV661185	Hs 75574	mitochondriał ribosomal protein L19	4.1
		L27841	Hs.75737		1.5
	422777	AWORDOTA	Hs 279009	matrix Gla protein	6.3
65	1331 E.L. 422754	AMACOSTO	Hs 334787	Homo sapiens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
0 5		T52946		RAE1 (RNA export 1, S.pombe) homolog	1.7
	133131 422750	DESTATE	He 181357	laminin receptor 1 (67kD, ribosomal protein SA)	1.8
	133100	DCE: 1100	, 10. 14 1601	minimizer combined at fast smoothers become as A	_

	4227CE	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteoblast)	1.5
					3.5
		AA557660			
	133784	BE622743	Hs.301064	arfapin 1	6.8
	133791	M34338	Hs.76244	spermidine synthase	2.6
5	133797	AL133921	Hs.76272	retinoblastoma-binding protein 2	1.4
•		D50525	Hs.699	peptidylprolyl Isomerase B (cyclophilln B)	8.0
				putative human HLA class II associated protein I	13.5
					2.2
		AA147026		ESTS	
	133850	W29092	Hs.7678	cellular retinoic acid-binding protein 1	1.8
10	133859	U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.0
	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	2.8
				KIAA0097 gene product	6.7
		AB012193			2.5
					3.0
		U30872		centromere protein F (350/400kD, mhostn)	
15	133922	U30825	Hs.77608	splicing factor, arginine/serine-rich 9	1.4
	133924	D86326	Hs.325948	vesicle docking protein p115	5.4
				SMC1 (structural maintenance of chromosomes 1, yeast)-like 1	4.9
		L17128		gamma-glutamyl carboxylase	3.7
					12.1
00				adaptor-related protein complex 3, mu 2 subunit	
20	133959	X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	9.7
	133976	Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor gene activator)	3.1
	133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, actin dependent regulator of chromatin	1.3
				regulator of G-protein signalling 12	9.7
				RNA binding protein; AT-rich element binding factor	2.4
25					2.5
		D31764		sorting nextin 17	
	134070	NM_003590			1.3
		U41060		LIV-1 protein, estrogen regulated	4.2
	134129	NM 014742	2Hs.79305	KIAA0255 gene product	2.2
		H86504	Hs. 173328	protein phosphatase 2, regulatory subunit B (B56), epsilon isoform	5.0
30				KIAA0160 protein	3.2
					2.5
		AF107463		splicing factor 30, survival of motor neuron-related	2.1
		NM_00028		perodsomal biogenesis factor 7	
	134219	NIM_000402	2Hs.80206	glucose-6-phosphate dehydrogenase	9.1
	134234	BE300078	Hs.80449	Homo saplens, clone IMAGE:3535294, mRNA, partial cds	2.8
35	134275	AJ878910	Hs.3688	cisplatin resistance-associated overexpressed protein	1.8
				immunoglobulin superfamily, member 3	2.0
				Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HSU90909	2.5
		AW502505			2.8
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	
	134324	AB029023	Hs.179946	KIAA1100 protein	10.4
40	134326	AW903838	Hs.81800	chondrolfin sulfate proteoglycan 2 (versican)	1.9
		N92036	Hs.81848	RAD21 (S. pombe) homolog	2.6
		NM_00492		SEC24 (S. cerevisiae) related gene family, member C	2.3
		AW291946		interleutin 6 signal transducer (gp130, oncostatin M receptor)	13.0
				meanagement or signate transfer some statement of the sta	8.8
4 =		AA339449		phosphoribosylglychamilde formyltransferase, phosphoribosylglycinamide synthetase,	
45	134376	XD6560	Hs.82396	2',5'-oligoadenylata synthetasa 1 (40-46 kD)	1.5
	134379	AW362124	Hs.323193	hypothetical protein MGC3222	8.1
	134384	Al589941	Hs.8254	Homo sapiens, Similar to tumor differentially expressed 1, clone IMAGE:3639252, mRNA, partial of	xds 2.6
		AA417383			4.1
				ysosomai	1.7
50		AA456539			2.6
50		AA334551		sperm specific antigen 2	
		AW067903		collagen, type XI, alpha 1	1.3
	134411	BE272095	Hs.167791	reficulocalbin 1, EF-hand calcium binding domain	3.2
	134415	AJ750762	Hs.82911	protein tyrosine phosphatase type IVA, member 2	1.9
	134421	A11077196	Hs 82985	collagen, type V, alpha 2	10.3
55			Hs.83023	peroxisomal biogenesis factor 11B	2.4
"	134424	Z44190			1.2
		AA112036		KIAA0252 protein	
	134447	M58603	Hs.83428	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	1.6
	134470	X54942	Hs.83758	CDC28 protein kinase 2	21
	134480	NM_00500	DHs.83916	Emphrically selected from AFFX single probeset	5.3
60		X82153	Hs.83942	cathepsin K (pycnodysosiosis)	2.5
50	121102	VOT 100			21
	134498	AW246273	10.04101	Michaelle and Shalles	
	134513	AA425473	HS.04429	KIAA0971 protein	3.8
				hypothetical protein FLJ10709	2.4
	134520	BE091005	Hs.74861	activated RNA polymerase II transcription cofactor 4	6.7
65	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.3
55		BE244323			5.5
					5.8
	134302	AA927177	13,000	And which to begin ministry broken i	

	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.2
		AF035119	Hs.8700	deleted in liver cancer 1	2.0
	134632	X78520	Hs.174139	chloride channel 3	2.3
_	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	1.4 72.9
5		AA256106		ESTs ·	8.5
		BE391929		transmembrane protein 4	6.0
			Hs.88251	aryisuliatase A	4.3
	134692	NM_003474	HS,8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha) anaphase-promoting complex subunit 10	2.3
10		BE161887	Hs.890	lysosomal	6.7
10		Y14768 AA852985			2.3
	134713	AF129536	Ha 284226	F-box only protein 6	2.9
				ring finger protein 22	6.6
		X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell receptor	. 23
15	134751	AW630803	Hs.89497	lamin B1	6.2
	134790	BE002798	Hs.287850	Integral membrane protein 1	1.9
	134806	AD001528	Hs.89718	spermine synthase	1.8 1.4
	134834	AW451370	Hs.8991	adaptor-related protein complex 1, gamma 2 subunit	1.4
~~	134850	Al701162	Hs.90207	hypothetical protein MGC11138 5-aminolmidazole-4-carboxamide ribonucleotide formyttransferase/IMP cyclohydrolase	5.6
20		BE268326	HS.SUZ80		2.8
	134859	D26488		KIAA0007 protein 15 kDa setenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fis, clone NT2RP3002255	1.7
		AW885909		PRO1073 protein	2.1
25	134955	AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	1.3
23	134971	Al097346	Hs.286049	phosphoserine aminotransferase	2.1
	134975	R50333	Hs.92186	Lernan coiled-coil protein	2.3
	135011	AB037835	Hs.92991	KIAA1414 protein	1.6
	135022	NM_00040	8Hs.93201	glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	3.9 6.2
30				hypothetical protein FLJ12619	2.0
		AW503733		KIAA1488 protein p53-inducible ribonucleotide reductase small subunit 2 homolog	1.3
		AB036063			7.1
	135095	AF027219	HS.3943	zinc finger protein 36 (KOX 18)	3.2
35	135453	AV001256 AV093155	He 95420	JM27 protein	2.5
33	135181	RF250865	Hs. 279529	px19-like protein	1.4
	135199	AA477514	Hs.96247	transfin-associated factor X	5.0
	135207	N26427	Hs.9634		6.1
	135214	T78802	Hs.96560		4.6 5.6
40		BE463721		putative G protein-coupled receptor	3.5
		A)028767		ESTs ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2
		AW291023		geranylgeranyl diphosphate synthase 1	2.6
		AJ088775		GE36 gene	5.3
45	135274	AA150320	Hs 9800	protein kinase Njmu-R1	9.1
43		AI090838		ESTs	2.4
	135307	AI743770	Hs.98368	ESTs, Wealty similar to KIAA0822 protein [H.sapiens]	13.3
	135321	Al652069	Hs.98614	ribosome binding protein 1 (dog 180kD homolog)	26
_	135354	AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE proteins)	8.3
50			Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HEMBA1003959	1.5 4.9
		U05237		fetal Abzhelmer antigen	2.0
		X78592	Hs.99915		2.6
		R50333	Hs.92186	Leman coiled-coil protein	1.4
55		ABU37835 NM_00040		KIAA1414 protein glycerol-3-phosphate delaydrogenase 2 (mi	1.6
<i>.</i>				is hypothetical protein FLJ12619	1.4
		AW503733		KIAA1488 protein	1.8
		AB036063			2.5
	135095	AF027219	Hs.9443	zinc finger protein 202	1.5
60	135098	AA081258	Hs.132390	zinc finger protein 36 (KOX 18)	2.1
		Al093155		JM27 protein	4.4 14.9
		BE250865			1.3
		AA477514		transin-associated factor X	1.7
CF		N26427 178802	Hs.9634 Hs.96560	ESTs, Highly similar to C10_HUMAN PUTATI	6.1
65	155414	BE463721			2.7
		A1028767		B ESTs	12.2

					76
		AW291023		CO13, Western Service to Action to A	7.6 1.8
		A1088775		Geranish calamorphism opposes a	4.1
		AA446460 AA150320			1.2
5		AN 150320 A1090838		Diction Ministry	4.8
,		AI743770		ESTs, Weakly similar to KIAA0822 protein	5.8
		Al652069			12.3
	135354	AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.7
	135361	AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	7.9
10		U05237	Hs.99872	fetal Alzheimer antigen	1.9 13.9
				androgen receptor (dihydrotestosterone r	5.3
	302256	AA857131	Hs.171595		2.2
	3022/6	AWU5//36	HS.32391U	HER2 receptor tyrosine kinase (c-erb-b2, HSPC070 protein	1.4
15				MSTP033 protein	5.2
1.7		R43191	Hs. 101248	Homo saplens clone IMAGE:32553, mRNA seq	2.3
		AA808229			2.8
	317781	NM 007057	7Hs.42650	ZW10 interactor	2.0
				rab3 GTPase-activating protein, non-cata	5.5
20				Gotpl apparatus protein 1	1.4 1.3
				nucleosome assembly protein 1-like 1	2.9
	322474	AF118083	HS.29494	PRO1912 protein hypothetical protein	1.6
	322550	AF202100	He 104613	RP42 homolog	1.8
25	407827	BE278431	Hs.40323	8UB3 (budding uninhibited by benzimidazo	1.6
	408196	AL034548	Hs.43627	SRY (sex determining region Y)-box 22	6.1
	408813	A1580090		RNA helicase family	5.6
		R73727		ESTs, Wealdy similar to T32527 hypotheti	2.6 2.4
20		AB000115			1.5
30				SFRS protein kinase 1 UBX domain-containing 1	4.2
	4 14040 A16080	A11304434	He ROGRA	high-mobility group (nonhistone chromoso	23.6
		R57256	Hs.82037	TATA box binding protein (TBP)-associate	5.8
	418283	S79895	Hs.83942	cathepsin K (pycnodysostosis)	1.3
35			OHs.85273	refinoblastoma-binding protein 6	1.6
		U72937		alpha thalassemialmental retardation syn	2.3 1.6
		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	3.5
				MCT-1 protein retinoic acid repressible protein	4.9
40	42182R	AWR91965	Hs.279789	histone deacetylase 3	3.1
-10	421983	Al252640	Hs.110364	peptidytprotyl isomerase C (cyclophilin	1.9
	422052	AA302744	Hs.104518	ESTs	2.4
				putative heme-binding protein	4.1
AE		AF165883	Hs.298229	prefoldin 2	7.0 4.9
45		W67883		paternally expressed 10 (PEG10; KIAA105	3.4
	423102 425284	AFISKKR	Hs. 155040	zinc finger protein 217 NS1-associated protein 1	2.1
	426372	BE304680	Hs.169531	DEADIH (Asp-Glu-Ala-Asp/His) box polypep	7.5
	428049	AW183765	Hs.182238	GW128 protein	1.7
50	428477	AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	2.4
		AB001636		DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	3.8 5.6
		AK001333		Homo sapiens hepatocellular carcinoma-as	2.0
	441560	F13386	Hs.7888	Homo saptens clone 23736 mRNA sequence skb1 (S. pombe) homotog	7.5
55	440000 446000	AF 10/0/2	He 334822	hypothetical protein MGC4485	2.2
33	440555	AI017574	Hs.17409	cystelne-rich protein 1 (Intestinal)	2.8
	447778	BE620592	Hs.71190	ESTs, Wealty similar to \$16506 hypotheti	1.7
	448873	NM_00367	7Hs_22393	density-regulated protein	5.9
		W68520	Hs.331328	Intermediate filament protein syncolin	5.6
60	450701	H39960	Hs.288467	Homo saplens cDNA FLJ12280 fs, clone MA	1.4 4.7
			MS.184//1	muclear factor VC (CCAAT-binding transc transcription factor	2.9
	452401 452544	N78223	175. 100 100 Lie 285185	i Homo sapiens cDNA FLJ20845 fis, clone AD	12.1
	452511 453457	AF077036	Hs.31989	DKFZP586G1722 protein	4.7
65	453658	BE541906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	1.3
-	100833	AF135168	Hs.108802	N-ethylmalelmide-sensitive factor	3.2
	102481	U50360		gb:Human catcium, catmodulin-dependent p	6.2

WO 02/059377

	102827	BE244588	He 6456	chaperonin containing TCP1, subunit 2 (b	7	1.9
		BE270465		protein kinase C, zeta	2	2.0
				cdk inhibitor p21 binding protein	5	5.3
				hypothetical protein FLJ10697	2	2.0
5			Hs.87889	helicase-moi	5	5.7
J .			Hs.287820	***************************************		1.3
		M10905	Hs.75875	ublquitin-conjugating enzyme E2 variant		29
		AL034423		splicing factor (CC1.3)		1.7
		BE065136		collagen, type IV, alpha 3 (Goodpasture		2.4
10		X80031	Hs.530	Rho-associated, coiled-coil containing p		5.2
10		R62676	Hs.17820			1.5
	129917	M30773	HS.278540	protein phosphatase 3 (formerly 2B), reg		11.0
	130182		Hs.192053	ubiquitin-conjugating enzyme E2G 2 (homo		3.3
				eukaryotic translation initiation factor		1.3
		NM_01656		TBX3-iso protein		3.2
15	131853		Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		14.3
	131881	AW361018		upstream regulatory element binding prot		3.0
		N52298	Hs.55608	hypothetical protein MGC955		2.7
		X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.3
		H19886		gb:ym57a05.r1 Soares adult brain N2b5H		ري 7.4
$\Delta \Lambda$	440040	A14M404E0	11- 200044	Home england a MAR ET 142MR file chang HE		

TABLE 4A

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10			_r	,					
10	Pkey:		nique Eos probe	set Identifier	r number				
	CAT nur		Gene cluster number						
	Accessio	on: Ge	enbank accessi	on numbers					
15					•				
13	Pkev	CAT numb	er Accession	s	·				
		3068615	AA609170						
		371681_1	AA602964	AA609200					
20		16505	M21259	1000F4					
		656394_1	A1267847 N						
		1642364_1							
		1657509_1	N53935 N5 U50360	3930					
25		3128128 11052 <i>-2</i>	X89059						
2,5		19346_14		N33063 N21	1418 H79958 R21911 H79957				
	110000	10070_17	103797	109699 1	AARR0912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA113892				
			AA083821 A	A134801 AA	AD82953 AAUT0343 AA062835 AAUT5419 AA063293 AA071252 AAUT8900 AA062836 AW974305				
	120280	160212 1	AA190577						
30		328626 1	T63857 AV	V971220 AA4	A93469 T63699				
	120472	44573_2	A1950087 I	170208 R970	040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671				
			AA908598	AA251875 A	AB20501 AB20632 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517				
			Al219788 /	1A884444 NS	92578 F13493 AAS27794 AI560251 AW874068 AL134043 AW235363 AA563345 AW008282 AA488964				
25			AA283144	Al890387 Al	1950344 A1741346 A1689062 AA282915 AW102898 A1872193 A1763273 AW173586 AW150329 A1653832				
35			AJ762688 /	AND 111 AND	A488892 A3356394 AW103813 A1539642 AA642789 AA856975 AW505512 A1961530 AW629970 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874				
			BE512661	AMIZIOSSI I	NIGES3338 ABS5509 AWZ76905 ABS33006 AA972584 AA908741 AW072629 AW513996 AA293273				
			A A OCC 750	1772UJUUZ M 1175628 N22	2388 HB4729 H60052 T92487 AID22058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269				
			EMS31 HS	3489 W3718	81 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005				
40	129019	44573_2	A1950087 I	170208 R970	040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967871				
			AA908598	AA251875 A	AB20501 AB20532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517				
			A1210788	ARRAMA NO	192578 F13493 AA927794 A1560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964				
			AA283144	A1890387 A1	1950344 A1741346 A1689062 AA282915 AW102898 A1872193 A1763273 AW173586 AW150329 A1653832				
			Al762688 /	4A988777 AJ	A488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970				
45			BE612881	AW276997 /	AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW981101 AA251669 AA251874				
			Al819225 /	AW205862 A	NE83338 AI858509 AWZ76905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273				
			AA969759	N75628 N22	2388 HB4729 H60052 T92487 A1022058 AA780419 AA551005 W80701 AW613456 A1373032 Al564269 B1 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005				
•	400000	0000	F00531 HB	13466 W3/10 A1047002 A	81 W76802 R00036 ANO2233 R07640 AA300207 RW939301 1632201 64603 A953664 AA404613 AA428771 BE280542 AW194691 AJ927301 AJ740458 AJ796100 AJ935603 AW052210				
50	120695	9683_3			A425910 AID17004 AI241295 AA402816 AA291468				
30	422400	275673_1	AA398838		MISSO TO VIDIT OUT MIST 1250 HATTOED TO MASS 1700				
		283769 1			AAA17233 AA442223				
		305217_1	AA453641		# 1111 Edw 7 *** include				
		150431 1	AA157811						
55		genbank A		AA609364					
		genbank A		AA620586					
	125115	genbank_T	97341	T97341					
			ND_entrez_W3		W38150				
		382979_1	AA199686						
60		genbank_A		AA177051					
		genbank_T		T57317					
	120504	genbank_A		AA258837					

120639 genbank AA286942

120809 genbank_AA346495 AA346495 113702 genbank_T97307 129680 23162_1 U0 T97307 U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 5 AW03850 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AAA31410 AA854232 W39212 W15214 AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C05286 AA319661 AA405992 10 101045 entrez_J05614 J05614 117247 genbank N21032 110501 genbank H55748 103392 entrez_X94563X94563 105032 genbank AA127818 15 W37933 119513 NOT_FOUND_entrez 105445 genbank 121514 genbank AA252395 AA412112 AA412497 121558 genbank 121911 genbank AA427950 20 123315 714071_1 AA496369 AA496646 114911 genbank 409487 1134778_1 AA236672 H19886 AW402806 T10231

TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

10

Pkey: Unique Eos probeset identifier number
Exacon: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of lumor to normal breast tissue

	Dhan	ExAccn	UnigeneiD	UnigeneTitle	R1
15	Pkey	EARLOWI	omgaren	ongenoriae	
13	100114	XU5308	Hs.82962	thymidylate synthetase	29
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
		H60720	Hs.81892	KIAA0101 gene product	9.2
		AW247529		platetet-activating factor acetylhydrola	2.7
20	100666		Hs.169610	CD44 antigen (homing function and Indian	5.7
20	100667		Hs.169610	CD44 antigen (homing function and Indian	9
	100668		Hs.169610	CD44 antigen (homing function and Indian	7.6
		AW502935		PTK2 protein tyrosine kinase 2	53.2
		AK000405		ubiquitin-like 4	11.4
25	101031		Hs.151738	matrix metalloproteinase 9 (gelatinase 8	8.2
23	101045		, , , , , , , , , , , , , , , , , , , ,	gbd-luman proliferating cell nuclear anti	5
	101332		Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4
		AM94299	Hs.16297	COX17 (yeast) homolog, cylochrome c oxid	6.3
		NM 01215		congulation factor VIII-associated (intr	5.7
30		AF064853		quanine nucleotide binding protein (5.6
50		M81057	Hs.180884	carboxypeptidase B1 (lissue)	14.4
		AA586894		\$100 calcium-binding protein A7 (psortas	8.9
		NIM 00031		percodsomal membrane protein 3 (35kD, Ze	3.2
		AJ904232	Hs.75323	prohibitin	8.4
35		BE258602		heat shock protein 75	1.4
55		BE313280		death associated protein 3	4.6
		AW950852		polymerase (DNA directed), delta 2, regu	4.3
		AA829978		JTV1 gene	6.7
		U24389	Hs.65436	lysosomal	4.3
40		AA306342	Hs.69171	protein kinase C-like 2	2.7
	102348	U37519	Hs.87539	aldehydie dehydrogenase 3 family, member	2
		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
		U48705	Hs.75562	discoldin domain receptor family, member	6.9
	102568	W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
45	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
	102687	NM_00701	9Hs.93002	ubiquitin carrier protein E2-C	4.3
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6
	102704	AU077058	Hs.54089	BRCA1 associated RING domain 1	1.9
	102705	T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3
50	102801	BE252241	Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinas	6.4
	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6
	103060	NM 00594	0Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5
	103080	AU077231	Hs.82932	cyclin D1 (PRAD1: parathyrold adenomatos	3.1
	103178	AA205475	Hs.275865	ribosomal protein S18	9.9
55	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8
	103238	Al369285	Hs.75189	death-associated protein	5.6
	103547	Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7
	103549	BE270465	Hs.78793	protein kinase C, zeta	7.9
			Hs.105737	hypothetical protein FLJ10416 similar to	6.5
60	104325	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.3
		AW052006		PRP4/STK/WD splicing factor	10.9
	104846	A1250789	Hs.32478	ESTs	5.6
			Hs.154729	3-phospholnositide dependent protein kin	12.3
	104867	AA278898	Hs.225979	hypothetical protein similar to small G	2

	404000	*********	th marc	FOT-	17.7
		AW015318 AW408164		ESTs transcription factor 19 (SC1)	5
		AW958157		NS1-associated protein 1	1.7
		AA026880		prolactin receptor	1.4
5	104974	Y12059	Hs.278875	bromodomain-containing 4	1.4
		Al199268	Hs.19322		7.2
		AF098158		chromosome 20 open reading frame 1	3.3
		AA907305		ESTs	2.5 9.5
10		AA151342	Hs.35156	CGI-147 protein Homo sapiens cDNA FLJ11027 fis, clone PL	2.2
10		H58589 AF167570		Interleukin enhancer binding factor 3, 9	5.4
		AA262640		unknown	9.3
		BE616694		hypothetical protein FLJ14299	1.4
	105658	AA985190	Hs.246875	hypothetical protein FLJ20059	9.4
15		AW151952		hypothetical protein FLJ20739	1.5
		AF151066		hypothetical protein	2.9 5.2
		AF016371		peptidyl protyl isomerase H (cyclophilin	6.8
		AA533491 AK001404		hypothetical protein FL./14681 cyclin B2	5.7
20		AW390282	:	transmembrane 7 superfamily member 2	6.3
20		AA458882		fibulin 1	7.9
	106624	NM_003595	Hs.26350	tyrosytprotein sulfotransferase 2	7.7
		BE614802		hypothetical protein FLJ12549	4.5
25		AW959893		hypothetical protein FLJ23293 similar to	16.2
25		AB037744		KIAA1323 protein Horno sapiens, clone IMAGE:3343149, mRNA	2.2 16.8
		N49809 BE156256	Hs.11197	hypothetical protein	6.6
		AF264750		myeloid/lymphoid or mixed-lineage leukem	1.8
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1
30		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4
		L42612	Hs.335952	keratin 68	2.5
		BE153855		lg superfamily receptor LNIR	2.2
		AW956103		pyruvate dehydrogenase kinase, isoenzyme	6.7 7.1
35		AF129535 BE546947		F-box only protein 5 homeo box C10	9.8
55		AB029000		KIAA1077 protein	7.2
		AK001431		hypothetical protein FLJ10569	4
	109011	AA156542	Hs.72127	ESTs	1.4
40		AA164293		ESTs	2.9
40		AA375752		Homo sapiens mRNA; cDNA DKFZp586F182	3.2
		NM_015310 Al668594	JHS.6763 Hs.176588	KIAA0942 protein ESTs, Wealdy similar to CP4Y_HUMAN CYT(
		A1288666	Hs.16621	DKFZP434116 protein	6.2
		H55748	,	gbcyg94a01.s1 Soares fetal liver spicen	6.1
45		AW190338	Hs.28029	hypothetical prolein MGC11256	7.6
		BE044245	Hs.30011	hypothetical protein MGC2963	9.3
		AA992380		gbxx137g06.s1 Soares_testis_NHT Homo sap	
		NM_00586		signal transduction protein (SH3 contain ESTs, Moderately similar to Z195_HUMAN Z	6.7 2.6
50		N63823 AK000136	Hs.269115	asporin (LRR class 1)	7.1
30		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
		AA778711		eulcaryotic translation initiation factor	6.9
	111392	W46342	Hs.325081	Homo saptens, clone IMAGE:3659680, mRNA	l, 8.4
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016	(fr 10.6
55	112244	AB029000	Hs.70823	KIAA1077 protein	14.6
	112995	AA737033	HS./100	ESTs, Moderately similar to 2115357A TYK	5.6 13.4
	113///	BE266947 Al269096	Hs.135578	zinc finger protein 313 chitobiase, di-N-acetyi-	1.3
	113751	BE207480		Homo sapiens cDNA: FLJ22044 fis, clone H	3.1
60	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3
00	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7
	113870	AL079314		hypothetical protein, similar to (U06944	6.1
	113923	AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9
<i>(</i>	114275	AW515443	Hs.308117	KIAA0308 protein	15.8
65	114895	AA236177 AI733881		KIAA0887 protein	7.1 2.3
	114905	AI753881 AI751438	Hs.72472 Hs.41271	BMP-R1B Homo sapiens mRNA full length insert cDN	ىك 11.8
	110001	מטרו טווה	10.712/1	I IONO SOPICIO HEAVA ION CHIGH RECEITOR	1143

	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
		BE545072		hypothetical protein FLJ10461	6.2
		BE093589		hypothetical protein FLJ23468	10.6
		AF231023			6.8
5		Al867451	Hs.46679	hypothetical protein FLJ20739	5.5
,		AB037753		KIAA1332 protein	9.8
		AL359053		Homo sapiens mRNA full length insert cDN	2.4
				Human done 23826 mRNA sequence	7.4
		AW499664	Hs.83484	SRY (sex determining region Y)-box 4	2.1
10		Al272141		integrin-linked kinase-associated serine	2.7
10		AK001043			5.2
		Al393666	Hs.42315	p10-binding protein	5.7
		AF161470	•	butyrate-induced transcript 1 ESTs	7.4
		Al949952	Hs.49397 Hs.287820	ES1S Sibronectin 1	5.7
15		M10905		ESTs	1.4
15		BE539706	Hs. 163561	ESTs	8.4
		T65004		nucleolar protein NOP5/NOP58	6.7
		AL117554		kalikrein 5 (KLK5; KLK-L2; stratum com	9.2
		BE393948 H26735	Hs.91668	Homo saplens clone PP1498 unknown mRNA	
20		AA131376		fibroblast growth factor 12B	38.9
20		AA191384		ESTs, Weakly similar to Z195_HUMAN ZINC	
		AA195651		ESTs	6.4
		AK000292		hypothetical protein FLJ20285	16.1
		AW969481		hypothetical protein	16.8
25		AF000545		putative purinergic receptor	28.1
23		AA219305		EST	12.4
		AL109983		FSH primary response (LRPR1, rat) homolo	9.7
		AW969665		hypothetical protein DKFZp434D0127	32.6
		AW967985		ESTs, Moderately similar to ALU7_HUMAN A	21.7
30		AA134006		eukaryotic translation initiation factor	12.5
50		AW966893		Horno sapiens mRNA; cDNA DKFZp586F132	3 (f 11.4
		Al950087		gb:wq05c02.x1 NCL_CGAP_Kid12 Homo sapi	
		AA253170	Hs.96473	EST	10.4
		AA280679		ESTs, Wealthy similar to ALU1_HUMAN ALU S	S 14.4
35		BE244830		ZNF135-like protein	10.2
		AA282074		N-acetylglucosamine-phosphate mutase	7.5
		AW407987		M-phase phosphoprotein homolog	52
•	120695	AA976503		gb:oq30a04.s1 NCL_CGAP_GC4 Homo sapie	ns 46.8
	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	5.9
40	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
	120774	A1608909	Hs.193985	ESTs	7.8
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	
	120809	AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.4
		BE262951		ESTs	5.6
45		AA398721		ESTs, Highly similar to 137550 mismatch	5.4
		AA406137		EST	6
		AA494172		ESTs	13.1
		AA402515		ESTs	28
50		AA416653	Hs.181510	ESTs	6.2
50					7.4
		AA412477	Hs.98142	EST	Λ n
	121558	AA412497		gbczt95g12.s1 Soares_testis_NHT Homo sap	2.8
	121558 121655	AA412497 AA421537	Hs.178072	gb:zt95g12.s1 Soares_testis_NHT Homo sap Homo saplens mRNA; cDNA DKFZp434B102	3 (f 7.8
	121558 121655 121744	AA412497 AA421537 AA398784	Hs.178072 Hs.97514	gbczt95g12.s1 Soares_testis_NHT Homo sap Homo saplens mRNA; cDNA DKFZp434B102 ESTs	3 (f 7.8 7.1
EE	121558 121655 121744 121748	AA412497 AA421537 AA398784 BE536911	Hs.178072 Hs.97514 Hs.234545	gbzzi95g12.s1 Soares_testis_NHT Homo sap Homo saplens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R	3 (f 7.8 7.1 19.5
55	121558 121655 121744 121748 121773	AA412497 AA421537 AA398784 BE536911 AB033022	Hs.178072 Hs.97514 Hs.234545 Hs.158654	gbzz95g12.s1 Soares_testis_NHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein	3 (f 7.8 7.1 19.5 7.9
55	121558 121655 121744 121748 121773 121832	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797	Hs.178072 Hs.97514 Hs.234545 Hs.158654 Hs.98434	gbzzi95g12.s1 Scares_testis_NiHT Homo sap Homo sapieris mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs	3 (f 7.8 7.1 19.5 7.9 5.8
55	121558 121655 121744 121748 121773 121832 121839	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691	Hs.178072 Hs.97514 Hs.234545 Hs.158654 Hs.98434 Hs.191606	gbzzi95g12.s1 Soares_testis_NiHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein	3 (f 7.8 7.1 19.5 7.9 5.8 5
55	121558 121655 121744 121748 121773 121832 121839 121882	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376	Hs.178072 Hs.97514 Hs.234545 Hs.158654 Hs.98434 Hs.191606	gbzzi95g12.s1 Soares_testis_Ni-HT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5
	121558 121655 121744 121748 121773 121832 121839 121882 121911	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950	Hs.178072 Hs.97514 Hs.234545 Hs.158654 Hs.98434 Hs.191606 Hs.98459	gbzzi95g12.s1 Soares_testis_NiHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzzw50f02.s1 Soares_total_fetus_Nb2HF8_	3 (f7.8 7.1 19.5 7.9 5.8 5 5
55 60	121558 121655 121744 121748 121773 121832 121839 121882 121911 121999	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950 AA430211	Hs.178072 Hs.97514 Hs.224545 Hs.158654 Hs.98434 Hs.191606 Hs.98459 Hs.98668	gbzzi95g12.s1 Soares_testis_Ni-HT Homo sap Homo saplens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KJAA1196 protein ESTs ESTs, Highly similar to KJAA1048 protein ESTs gbzw50f02.s1 Soares_total_fetus_Nb2HF8_ EST	3 (f7.8 7.1 19.5 7.9 5.8 5 7.2 6.4
	121558 121655 121744 121748 121773 121832 121839 121882 121911 121999 122013	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950 AA430211 AA431085	Hs. 178072 Hs. 97514 Hs. 234545 Hs. 158654 Hs. 98434 Hs. 191606 Hs. 98459 Hs. 98668 Hs. 98706	gbzzi95g12.s1 Scares_testis_NiHT Homo sap Homo sapiers mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KUAA1198 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzzw50f02.s1 Scares_total_fetus_Nb2HF8_ EST ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5 7.2 6.4 6.5
	121558 121655 121744 121773 121832 121839 121882 121911 121999 122013	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA4267950 AA430211 AA431085 W92142	Hs. 178072 Hs. 97514 Hs. 234545 Hs. 158654 Hs. 191606 Hs. 98459 Hs. 98668 Hs. 98706 Hs. 271963	gbzzi95g12.s1 Soares_testis_NiHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzzw50f02.s1 Soares_total_fetus_Nb2HF8_ EST ESTs ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5 5 7.2 6.4 6.5 S 13.1
	121558 121655 121744 121748 121773 121832 121839 121882 121911 121999 122013 122036	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950 AA430211 AA431085 W92142 AA443794	Hs. 178072 Hs. 97514 Hs. 27514 Hs. 23645 Hs. 158654 Hs. 191606 Hs. 98459 Hs. 98668 Hs. 98706 Hs. 271963 Hs. 98390	gbzzi95g12.s1 Soares_testis_NiHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzwi50f02.s1 Soares_total_fetus_Nb2HF8_ EST ESTs ESTs, Weakly similar to ALU5_HUMAN ALU : ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5 5 7.2 6.4 6.5 S 13.1 7.3
60	121558 121655 121744 121773 121832 121839 121882 121911 121999 122013 122033 122356	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950 AA430211 AA431085 W92142 AA443794 AA868555	Hs. 178072 Hs. 97514 Hs. 234545 Hs. 158654 Hs. 198634 Hs. 191606 Hs. 98459 Hs. 98706 Hs. 271963 Hs. 271963 Hs. 178222	gbzzi95g12.s1 Soares_testis_Ni-HT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzzw50f02.s1 Soares_total_fetus_Nb2HF8_ EST ESTs ESTs, Weakly similar to ALU5_HUMAN ALU : ESTs ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5 7.2 6.4 6.5 S 13.1 7.3
	121558 121655 121744 121773 121832 121839 121882 121911 121991 122013 122036 122371 122372	AA412497 AA421537 AA398784 BE536911 AB033022 AW340797 AA425691 AA426376 AA427950 AA430211 AA431085 W92142 AA443794	Hs. 178072 Hs. 97514 Hs. 234545 Hs. 158654 Hs. 191606 Hs. 98459 Hs. 98668 Hs. 98706 Hs. 271963 Hs. 178222 Hs. 336677	gbzzi95g12.s1 Soares_testis_NiHT Homo sap Homo sapiens mRNA; cDNA DKFZp434B102 ESTs hypothetical protein NUF2R KIAA1196 protein ESTs ESTs, Highly similar to KIAA1048 protein ESTs gbzwi50f02.s1 Soares_total_fetus_Nb2HF8_ EST ESTs ESTs, Weakly similar to ALU5_HUMAN ALU : ESTs	3 (f7.8 7.1 19.5 7.9 5.8 5 5 7.2 6.4 6.5 S 13.1 7.3

	122492	AA448417	Hs.104990		5.4
	122510	AA449232	Hs.99195		11.2
		AW959741			10.1
_	122572	AA452601	Hs.99287		11
5		AA453518			61.5
		AA453630			10.7
		AA453638	Hs.161873		107.3
		AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	
		AA453987		—- · · ·	5.6
10		AA456859			8.5
•		AW204530			81.8
		AA460584			75.3 5.0
			Hs.75367		5.8 5.3
1.5		AF005216		omino remon e la broner d'acces mine	ວ.ວ 11.5
15		AA470074		ESTs Homo sapiens cDNA FLJ11946 fis, clone HE	
		AW338067			8.7
		AL359571		,	5.1
		AW451999 AW601773		ESTs	5.2
20		AA731404		ESTS	3.6
20		AA599042		EST	7.4
		BE019072		Homo sapiens cDNA FLJ14680 fis, clone NT	
		AA609170	1 ISSUE TOUR	gb:af12a12.s1 Soares_testis_NHT Homo sap	
		NM 013241	Hs 95231	FH1/FH2 domain-containing protein	10
25		AA609955		Huntingtin Interacting protein E	30.6
			Hs.270016	ESTs	8.1
		Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
		AA532519	Hs.129043	Human DNA sequence from clone 989H11 on	7.8
	124656	AW297702	Hs.102915	ESTs	8.3
30	124683	AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITO	
		R22952	Hs.268685	ESTs	11.3
		AA374756		Homo sapiens mRNA for KIAA1771 protein,	9
		AW368528		ESTs	8.1
25		R43543	Hs.100912	Homo saplens cDNA: FLJ22726 fis, clone H	5.1
35		R46068	Hs.288912	hypothetical protein FLJ22604	14.2 7.9
		R47948	Hs.188732	ESTs Homo sapiens cDNA FLJ13558 fis, clone PL	6.6
		AA418160	Hs.101477	EST	23.9
		R65763 AW296713		ESTS	32.4
40		A1076343	Hs.173939	ESTs, Wealdy similar to ALUB_HUMAN IIII	22.8
70		R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1
	125051		Hs.100588	EST	135.3
		TB1310	Hs.100592	ESTs	5.4
		AJ472068	Hs.286236	KIAA1856 protein	5.6
45		T97341		gb:ye57e05.s1 Soares fetal liver spleen	9.6
	125280	Al123705	Hs.106932	ESTS	8
	127274	AW966158	Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
	128528	R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8
	128670	AA975486	Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	
50		W27939	Hs.103834	hypothetical protein MGC5576	7.7
		BE302796		thymidine kinase 1, soluble	5.3
		N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9
	128797			stem cell growth factor; lymphocyte secr	13.3 3
55		AA419008		chromosome 22 open reading frame 3 Homo septens, done MGC:16362, mRNA, co	
33		F34856	Hs.292457 Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	
		Y13153 BE560779	Hs.284233	NICE-5 protein	14
		Al816224	Hs.107747	DKFZP566C243 protein	1.9
		Al950087		gbawg05c02.x1 NCI_CGAP_Kid12 Homo sapi	
60		AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti	5
50		AA744610		palladin	17.1
	129096	AA463189	Hs.288906	WW Domain-Containing Gene	20.9
		N57532	Hs.109315	KIAA1415 protein	5.8
		BE614192		melanoma-associated antigen recognised b	7.6
65	129362	U30246	Ha.110736	solute carrier family 12 (sodium/potassi	6.7
	129372	NM_01603	9Hs.110803	CGI-99 protein	2
			LA 237EUA	LV16	_

	120/192	AA188185	Hs.289043	spindlin	6.7
		W01296	Hs.11360	hypothetical protein FLJ14784	7.5
		H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8
		AK000398		hypothetical protein FLJ20391	3.8
5		AD000092	*	caireticulin	3.3
_		U03749	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:Human chromogranin A (CHGA) gene, pro	14.1
	129689	AW748482	Hs.77873	B7 homolog 3	2.6
	129702	Al304966	Hs.12035	ESTs, Wealthy similar to 138022 hypotheti	7.4
	129720	AA156214	Hs.12152	APMCF1 protein	2
10	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6
	130097	AL046962	Hs.14845	forkhead box O3A	2.8
	130135	AA311426	Hs.21635	tubulin, gamma 1	6.1
	130211	NM_00335	8Hs.23703	ESTs, Moderately similar to CEGT_HUMAN (
	130242	X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4
15		NM_01344		bromodomain adjacent to zinc finger doma	8.5
		W56119	Hs.155103	eultaryotic translation initiation factor	11
		BE513202		PPAR binding protein	3.9
		D90041	Hs.155956	N-acetyttransferase 1 (arytamine N-acety	33.6
20		AL121438		adducin 1 (alpha)	2.7
20		BE208491		KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1 7.8
		U64675	Hs.179825	RAN binding protein 2-like 1	14.4
		AF062649	Hs.15977	pituitary tumor-transforming 1	4.7
25		AJ907018 AA383092		Empirically selected from AFFX single pr replication protein A3 (14kD)	7.9
25		AF083208		apoplosis antagonizing transcription fac	1.2
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
		BE246961		Homo sapiens ubiquitin protein ligase (U	13.9
		R68537	Hs.17962	ESTs	2
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.1
		AL036067		protein x 0001	5.7
		BE514434		kinesin-like 2	2.1
	130944	BE382657	Hs.21486	signal transducer and activator of trans	5.4
	131046	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4
35	131060	AA194422	Hs.22564	myosin Vi	5.1
	131099	AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7
		NM_01656		TBX3-iso protein	3.3
		BE280074		cyclin B1	5.8
40		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40		AL080080		thioredoxin domain-containing	2.8
		X80038	Hs.339713	Homo saplens clone F19374 APO E-C2 gene	
		AL389951		nucleoporin 50kD	5 29
		AW410601 AA642831		HSPC182 protein putative DNA binding protein	29
45		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransi	3.4
43		X76732	Hs.3164	nucleobindin 2	29
		AW966127		Homo sapiens cDNA FLJ14656 fis, clone NT	
		BE502341		ESTs	13.7
	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, co	m 8.7
50	131905	AA179298	Hs.3439	stomatin-like 2	11.3
	131941	BE252983	Hs.35086	ublquitin specific protease 1	2.3
	131971	BE567100	Hs.154938	hypothetical protein MDS025	3.5
	132180	NM_00446	0Hs.418	fibroblast activation protein, alpha	14.7
		NM_00478		synaptosomal-associated protein, 29kD	7.8
55		AA227710		DKFZP586L151 protein	10
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2
		AB023191		KIAA0974 protein	2
		AW067708		heterogeneous nuclear ribonucleoprotein	12.5
<i>4</i> 0		AW572805 AA312135		ESTs	28.3
60		AA312135 AA100012		HSPCO34 protein	6.1 8.6
		AW169847		hypothetical protein FLJ12085 KIAA1634 protein	6.1
		AA454132		mitochondrial ribosomal protein L16	7.1
		AW631437		TH1 drosophila homolog	14
65		A1796870		DNA segment on chromosome X (unique) 990	
05		NM_00460		Siggren syndrome antigen A2 (60kD, ribon	3.7
		N52298	Hs.55608	hypothetical protein MGC955	14.3
	,			// · · · · · · · · · · · · · · · · · ·	—

					c 0
	132731	Al189075	Hs.301872	hypothetical protein MGC4840	5.9
			Hs.55921	alutamyl-protyl-tRNA synthetase	6.4
					14.6
		AA459713		Imam to brown.	2.5
	132798	A1026701	Hs.5716	(Alama to Boue brosser	
5	132810	AB007944	Hs.5737		4.2
-	132833		Hs.57783	eukaryotic translation initiation factor	6.1
				Homo sapiens clone PP1596 unknown mRNA	
	132842	NM_016154			0.4
	132851	U09716	Hs.287912	trong transco priemilit .	6.1
	132891	BE267143	Hs.59271	U2(RNU2) small nuclear RNA auxillary fac	2.7
10			Hs.6120	hypothetical protein FLJ13222	2.1
ΙO				Homo sapiens cDNA FLJ11392 fis, clone HE	35
		AA034365			4.2
	132980	AA040696	Hs.62016	LOTO	1.3
	132004	AA112748	Hs.279905	clone HQ0310 PRO0310p1	17.1
		AJ439688	Hs.6289		4.4
10.					4.4
15 [.]	133177		Hs.66718	In the A forest events and	
	133208	A1801777	Hs.6774		5.5
	133254	Al567421	Hs.273330	Homo saplens, clone IMAGE:3544662, mRNA	, 1.3
		Al160873	Hs.69233	zinc finger protein	16.1
				ESTs, Weakly similar to FXD2_HUMAN FORK	
	133268	AW956781	H9.29393/		40.4
20	133285	M76477	Hs.289082	GM2 ganglioside activator protein	10.4
	133390	A1950382	Hs.72660		5.7
		AW103364	i	inhibin, beta A (activin A, activin AB a	25.5
				proteasome (prosome, macropain) 26S subu	1.7
		AL037159		protessorie (prosonie, metropeni) zoo sand	2.6
	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	
25	133621	NM_004893	3Hs.75258	H2A histone family, member Y	13.5
	133720		Hs.75737	pericentriolar material 1	6.7
				laminin receptor 1 (67kD, ribosomal prot	5.4
	133/60	BE271766	HS. 10133/		12.1
	133784	BE622743	HS.301064	arfaptin 1	
	133791	M34338	Hs.76244	spermidine synthase	9.7
30		AL133921	Hs.76272	retinoblastoma-binding protein 2	1.3
50			Hs.699	peptidytorolyt isomerase B (cyclophilin	9.7
		D50525		- Pulsa - Hada and binding protein 1	4.2
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	
	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5
		U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1
35		D86326	Hs.325948	vesicle docking protein p115	1.8
22					10.4
		X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	
	133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
	133997	Al824113	Hs.78281	regulator of G-protein signalling 12	13
		BE300078		Horno sapiens, clone IMAGE:3535294, mRNA	10.3
40	104204	A111004040	11-02005	Interleukin 6 signal transducer (gp130,	6.7
40		AW291946			5.5
		X06560	Hs.82396	2,5-oligoadenylate synthetase 1 (40-46	
	134379	AW362124	Hs.323193	hypothetical protein MGC3222	5.8
		AW067903		collagen, type XI, alpha 1	72.9
	101100	A11007000	U- 0200E	collagen, type V, alpha 2	6.7
4 =		AU077196		Carling the colored from ACEV single or	6.2
45	134480	NM_00500	UHS.83916	Empirically selected from AFFX single pr	
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	1.4
		AW411479		FK506-binding protein 4 (59kD)	2.8
		AW630803		lamin B1	6.1
	134731	MMOSIBLE	113,00737		1.2
	134790	BE002/98	Hs.287850	integral membrane protein 1	
50	134806	AD001528	Hs.89718	spermine synthase	2.6
		AI701162	Hs.90207	hypothetical protein MGC11138	9.1
		_ :	Hs.90315	KIAA0007 protein	13.3
		D26488		phosphoserine aminotransferase	2
	134971	Al097346	Hs.286049		14.9
	135181	BE250865	Hs.279529	px19-like protein	
55		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTAT	1.7
55		AI028767	Hs.262603	ESTs	12.2
	130240	ANDONO		ESTs, Wealdy similar to A46010 X-linked	7.6
	13525/	AW291023		ES15, Weary Shimai to Moore America	
	135307	A1743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.8
		Al652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3
60	425254	AAAECAEA	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.7
60				androgen receptor (dihydrotestosterone r	13.9
		X78592	Hs.99915	umojai iedau jaijulesiosialis i	5.3
	302276	AW057738	3 Hs.323910	HER2 receptor tyrostne kinase (c	
	317781	NM_00705	7Hs.42650	ZW10 interactor	2.8
	274444	AA902256	Hs 78979	Golgi apparatus protein 1	5.5
C E				hypothetical protein	29
65			Hs.177507	nyponesta protein	23
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	
		11100000	11- 40747C		7

			. Hs.155040 Hs.334822	zinc tinger protein 217 hypothetical protein MGC4485	7.5
			112/204087	HARORICATE ROBURI MOCALION	
	450701	H39960	Hs.288467	Homo saplens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	AF077036	Hs.31989	DKFZP586G1722 protein	12.

TABLE 5A

Unique Eos probeset identifier number

10

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

	CAT number Accession:		uster number Ik accession numbers
15	Pkey	CAT number	Accessions
	123615	3068615	AA609170 AD67847 NZ7351
	124385 110856	656394_1 19346_14	ALSO 047 NZ 7351 AA992380 N33063 N21418 H79958 R21911 H79957
20	120472	44573_2	AISSO087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671
		44313_2	AA908598 AA251875 AI820501 AI820532 W87891 TB5904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512
25			AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI533008 AA972584 AA988741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	AIS50087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 185904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AIZ19788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA888964 AA283144 AI890387 AI950344 AI741346 AI689062 AA28915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653822 AI762688 AA988777 AA488892 AI356394 AW103813 AI338642 AA642789 AA856975 AW505512
35			AB61530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005
40			120595 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468
	122618	305217_1	AA453641 AA454061
		genbank_T973	
45	120809 129680	genbank_AA3 23162 1	46495
43	1 <i>29</i> 000	23102_1	AIB58999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214
50			AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AB65540 AA772107 C06286 AA319661 AA405992
	101045	entrez_J05614	
		genbank_H55	
		genbank AA4	
55	121911	genbank_AA4	27950 AA427950

TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

10

Pkey: Unique Eos probeset identifier number

ExAcca: Exemplar Accession number, Genbank accession number

Unigene iD: Unigene number Unigene Title: Unigene gene title

D1.

Unigene gene title Ratio of tumor to normal breast tissue

	Pitey	ExAcen	UnigenelD	UnigeneTitle	R1
15	•		_	•	
	100147	D13866	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
		AW502935		PTK2 protein tyrosine kinase 2	53.2
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9
	102455		Hs.75562	discoldin domain receptor family, member	6.9
20	103206		Hs.77367	monoidne induced by gamma interferon	8.8
		BE246502		sema domain, immunoglobulin domain (lg),	2.6
		AW151952		hypothetical protein FLJ20739	1.5
		AW503807		histone acetyltransferase	1.8
25		A1668594		ESTs, Wealty similar to CP4Y_HUMAN CYTOC	
25				coat protein gamma-cop	3.2
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7
				fibroblast growth factor 128	38.9 15.2
				ESTs, Wealty similar to Z195_HUMAN ZINC	52
30		AA976503	LI2:11:2010	M-phase phosphoprotein homolog gb:og30a04.s1 NCL_CGAP_GC4 Homo sapiens	46.8
30		AA346385	Un annos	SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA402515		ESTs	28
		AA453518		ESTs	61.5
		AA453638			107.3
35		AA453641	112101010	gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
20		AW204530	Hs.99500	ESTs	81.8
		AA460584			75.3
	123753	AA609955	Hs.234961	Huntingtin interacting protein E	30.6
	124385	Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
40	124860	R65763	Hs.101477	EST	23.9
	124930	A1076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN IIII	22.8
	125051	T79956	Hs.100588		135.3
		N71826		small nuclear ribonucleoprotein polypept	53.9
				WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
		AW748482		B7 homolog 3	2.6
				KIAA0618 gene product	16.1
	130511		Hs.1584	cartilage oligomeric matrix protein (pse	6.1
50		AA321649		small inducible cytokine subfamily B (Cy	7.4 2.9
30		AW410601		HSPC182 protein	2.9 2.7
		AF151048		anaphase promoting complex subunit 11 (y fibroblast activation protein, alpha	14.7
		NM_004460 AW572805		ESTs	28.3
				cione HQ0310 PRQ0310p1	17.1
55		AJ439688	Hs.6289	hypothetical protein FLJ20886	4.4
<i>J</i>		Al160873	Hs.69233	zinc finger protein	16.1
		AW103364		inhibin, beta A (activin A, activin AB a	25.5
		Al690916	Hs.178137		1.2
		NM_000402		glucose-6-phosphate dehydrogenase	1.9
60		AW067903		collagen, type XI, alpha 1	72.9
-		AW411479		FK506-binding protein 4 (59kD)	2.8
		R50333	Hs.92186	Leman colled-coil protein	2.6
		BE250865	Hs.279529	px19-like protein	14.9
				hypothetical protein	2.9

TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	
	Picev:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

15

20

5

Pkey CAT number Accessions

124385 656394_1 Al267847 N27351 120695 9683_3 AA976503 Al91780

AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603

AW052210 AA970201 AL633384 AA425910 AL017004 AL241295 AA402816 AA291468

122618 305217_1 AA453641 AA454061

TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	Pkey:	Unique Eos probeset identifier number	
	ExAcon:	Exemplar Accession number, Genbank accession number	
	UnigenelD:	Unigene number	
	Unigene Title:	Unigene gene titte	
	R1:	Ratio of tumor to normal breast tissue	
15	ORF struct info:	Structural characterization of open reading frame for the sequence of the g	ene
		Ab I a from 11 I a conference	D4

	Pkey	ExAcon	UnigeneID	UnigeneTitle	R1	ORF struct info
	100113	NM_001269	Hs.84746	chromosome condensation 1	2.3	TM
20	100114	X02308	Hs.82962	thyrnidylate synthetase	2.9	other
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	1.9	other
		BE185499	Hs.2471	KIAA0020 gene product	1.9	TM
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.6	other
0.5		H60720	Hs.81892	KIAA0101 gene product	9.2	other
25		W44671	Hs.124	gene predicted from cDNA with a complete	1.6	other
		AW015534	Hs.217493	annexin A2	2	other
		D38521	Hs.112396	KIAA0077 protein	1.5	other
		BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	13.5	other
20		BE242802	Hs.154797	KIAA0090 protein	5.1	other
30		D50920	Hs.23106	KIAA0130 gene product	1.9	TM ather
		AW247529	Hs.6793	platelet-activating factor acetylhydrota	2.7 2	other other
		NM_004341	Hs.154868	carbamoyl-phosphate synthetase 2, aspart	2.6	other
		NM_014791	Hs.184339	KIAA0175 gene product novel RGD-containing protein	3.2	other
35		D84145	Hs.39913	phosphatidylinositol glycan, class C	1.5	other
22		AW954324 D86978	Hs.75790 Hs.84790	KIAA0225 protein	2	other
		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein	2.9	other
		NM_004415	Hs.74316 .	desmoplatin (DPI, DPI)	1.9	other
		1.05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	other
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	9	?
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.7	other
		AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2	other
		AF078847	Hs.191356	general transcription factor IIH, polype	6	other
	100892	BE245294	Hs.180789	S164 protein	1.7	?
45	100945	AF002225	Hs.180686	ublquitin protein ligase E3A (human papi	1.5	other
	100969	AA157634	Hs.79172	solute carrier family 25 (mitochondrial	6.3	other
	100988	AK000405	Hs.76480	ubiquitin-like 4	11.4	?
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5	1.6	other
		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.4	other
50		J05614	÷	gbd-tuman profiferating cell nuclear anti	5	?
	101077	N99692	Hs.75227	Empirically selected from AFFX single pr	2.6	other
		L06419	Hs.75093	procellagen-lysine, 2-exoglutarate 5-dio	1.4	?
		AA020956	Hs.179881	core-binding factor, beta subunit	2	TM
		AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	1.8	other
55		AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (1.7	TM
		AA132666	Hs.78802	glycogen synthase kinase 3 beta	1.9	other
		L18964	Hs.1904	protein kinase C, iota	1.5	other
		J04088	Hs.156346	topolsomerase (DNA) II alpha (170kD)	5.3	other
<i>c</i> n		AJ494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	4.2	other
60		BE267931	Hs.78996	proliferating cell nuclear entigen	1.9	TM
		M21259	Un 4040	gbdHuman Alu repeats in the region 5' to	1.6	TM
		NM_000546	Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	2.5	other
	101478	NM_002890	Hs.758	RAS p21 protein activator (GTPase activa	5.5	other

	101483 M24486	Hs.76768	procollagen-proline, 2-cooglutarate 4-di	2.1	other
	101540 J04977	Hs.84981	X-ray repair complementing defective rep	1.6	other
	101573 AW248421	Hs.250758	proteasome (prosome, macropaln) 26S subu	5.7	other
5	101580 NM_012151		coagulation factor VIII-associated (Intr	1.8	other
,	101592 AF064853 101621 BE391804	Hs.91299 Hs.62661	guanhe nucleotide binding protein (G pr	5.6	7
	101702 AW504089	Hs.179574	guanylate binding protein 1, interferon- protein phosphatase 2 (formerly 2A), reg	2.4	other
	101734 M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	1.3 2.1	other ?
	101759 M80244	Hs.184601	solute carrier family 7 (cationic amino	5	TM
10	101767 M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS.
	101782 AA306495	Hs.1869	phosphoglucomutase 1	5.2	other
	101805 AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H	8.6	other
	101806 AA586894	Hs.112408	S100 calclum-binding protein A7 (psortas	8.9	SS,TM
16	101810 NM_000318		peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15	101879 AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
	101911 AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
	101920 AF182645 101973 U41514	Hs.8024 Hs.80120	IX cytokina, down-regulator of HLA II	1.8	other
	102009 BE245149	Hs.82643	UDP-N-acetyl-alpha-D-galactosamine:polyp protein tyrosine kinase 9	2.4	other
20	102036 BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi	1.3 2	other ?
	102083 T35901	Hs.75117	Interleukin enhancer binding factor 2, 4	1.6	other
	102107 BE258602	Hs.182366	heat shock protein 75	1.4	other
	102123 NM_001809	Hs.1594	centromere protein A (17kD)	1.8	other
~~	102165 BE313280	Hs.159627	death associated protein 3	4.6	7
25	102198 AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.4	?
	102217 AA829978	Hs.301613	JTV1 gene	6.7	other
	102220 U24389	Hs.65436	lysosomal	4.4	TM
	102234 AW163390 102260 AL039104	Hs.278554 Hs.159557	heterochromatin-like protein 1	1.9	TM
30	102302 AA306342	Hs.69171	karyopherin alpha 2 (RAG cohort 1, impor protein kinase C-like 2	4.4 2.7	other ?
	102330 BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
	102339 BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
	102348 U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	TM
	102349 AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2	other
35	102369 U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2	other
	102374 U33635	Hs.90572	PTIC7 protein tyrosine kinase 7	6.2	other
	102391 AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
	102455 U48705 102465 NM 001359	Hs.75562	discoidin domain receptor family, member	7	other
40	102488 U50939	Hs.81548 Hs.61828	2,4-dienoyl CoA reductase 1, mitochondri amyloid beta precursor protein-binding p	1.8	SS,
	102489 AL080116	Hs.74420	origin recognition complex, subunit 3 (y	1.5 3.3	? other
	102494 AJ188137	Hs.75193	COP9 homolog	2.1	other
	102501 AF217197	Hs.74562	slah binding protein 1; FBP interacting	3.2	other
	102522 BE250944	Hs.183556	solute carrier family 1 (neutral amino a	2.8	?
45	102532 AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	?
	102564 U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
	102568 W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	other
	102580 U60808 102581 AU077228	Hs.152981 Hs.77256	CDP-diacytglycerol synthase (phosphatida	21	other
50	102582 U61232	Hs.32675	enhancer of zeste (Drosophila) homolog 2 tubulin-specific chaperone e	1.6	?
-	102617 AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	2.1 1.8	other other
	102618 AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
	102627 AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	other
	102663 NM_002270	Hs.168075	karyopherin (Importin) beta 2	1.8	TM
55	102676 BE262989	Hs.12045	putative protein	2.3	other
	102687 NM_007019	Hs.93002	ubiquitin carrier protein E2-C	4.4	?
	102689 U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	7
	102698 BE540274	Hs.239	forkhead box M1	4.2	other
60	102704 AU077058 102705 T97490	Hs.54089 Hs.50002	BRCA1 associated RING domain 1 small inducible cytokine subfamily A (Cy	1.9	other
v	102755 AB014460	Hs.66196	nih (E.coli endomuciease (II)-like 1	23	SS,TM
	102801 BE252241	Hs.38041	pyrkloxal (pyrkloxine, vitamin B6) kinas	1.2 6.5	TM other
	102812 U90549	Hs.236774	high-mobility group (nonhistone chromoso	0.5 1.6	other
	102827 BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	TM
65	102844 AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
	102868 X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
	102925 BE440142	Hs.2943	signal recognition particle 19kD	1.9	other

				Warnet and Warnet and Sandanad	2.4	?
		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept		
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2	7
5		AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
•		AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
			Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5	other
		NM_005940			3.1	other
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos		
	103089	D31152	Hs.179729	collegen, type X, alpha 1 (Schmid metaph	2.4	other
10	103177	BE244377	Hs.48876	famesyl-diphosphate famesyltransferase	3.5	other
	103178	AA205475	Hs.275865	ribosomal protein S18	9.9	?
		NM_001777	Hs.82685	CD47 antigen (Rh-related antigen, Integr	1.3	other
		X69636	Hs.334731	Homo saplens, clone IMAGE:3448306, mRNA,	2	other
			Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15		NM_006825			2.5	other
15		AA401039	Hs.2903	protein phosphatase 4 (formerly X), cata		TM
	103193	NM_004766	Hs.75724	coatomer protein complex, subunit beta 2	2.2	
	103194	NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8	TM
	103223	BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20		X75962	Hs.129780	turnor necrosis factor receptor superfami	1.8	other
20		Al369285	Hs.75189	death-associated protein	5.6	TM
					1.9	7
		NM_001545	Hs.9078	immature colon carchoma transcript 1		other
		A1803447	Hs.77496	small nuclear ribonucleoprotein polypept	2.5	
	103349	X89059		gb:H.sapiens mRNA for unknown protein ex	1.6	other
25	103376	AL036166	Hs.323378	coated vesicle membrane protein	1.8	other
	103391	X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	other
		X94563		gb:H.saplens dbl/acbp gene exon 1 & 2.	4	TM
		BE564090	Hs.20716	translocase of inner mitochondrial membr	1.3	other
		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7	?
20			Hs.33102	transcription factor AP-2 beta (activati	5.1	other
30		AL031224				?
		Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7	
	103588	NM_006218	Hs:85701	phosphoinositide-3-ktnase, catalytic, al	2	other
	103613	NM_000346	Hs.2316	SRY (sex determining region Y)-box 9 (ca	1.3	?
	103621	BE379766	Hs,150675	polymerase (RNA) II (DNA directed) polyp	2	other
35	103622	AA609685	Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
-		AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
		Al015709	Hs.172069	Homo saplens mRNA; cDNA DKFZp58612022 (f	1.3	other
			Ha.169992		7.6	?
		AA094752		hypothetical 43.2 Kd protein	1.3	SS,TM
40		H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) m		
40		AA080912		gb:zn04d03.r1 Stratagene hNT neuron (937	1.6	other
	103813	A1042582	Hs.181271	CGI-120 protein	1.6	other
	103855	W02363	Hs.302267	hypothetical protein FLJ10330	1.6	other
	103886	AK001278	Hs.105737	hypothetical protein FLJ10416 similar to	6.6	TM
	104052	NM_002407	Hs.97644	mammaglobin 2	2.9	other
45		AA251242	Hs.103238	ESTs	1.4	other
		AA478984	Hs.6451	PRO0659 protein	5.6	TM
		AB002343	Hs.98938	protocadherin aipha 9	1.6	other
					5.4	other
		AI751970	Hs.101067	GCN5 (general control of amino-acid synt		other
		BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	
50	104370	AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, done NT	1.6	other
	104423	R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
	104482	AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
	104667	A1239923	Hs.30098	ESTs	1.4	other
		AJ694413	Hs.332649	olfactory receptor, family 2, subfamily	2.4	other
55		A1858702	Hs.31803	ESTs, Wealty similar to N-WASP [H.sapien	1.4	other
"				KIAA0958 protein	2.4	other
		AB023175	Hs.22982	COD 40004MD on Fring freds	10.9	other
		AW052006	Hs.8551	PRP4/STK/WD splicing factor		
		Al250789	Hs.32478	ESTs	5.7	other
		AA041276	Hs.154729	3-phospholnositide dependent protein kin	12.3	?
60	104867	AA278898	Hs.225979	hypothetical protein stmilar to small G	2.1	other
	104871	T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp56402364 (f	1.4	other
		AW015318	Hs.23165	ESTs	17.7	other
		AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
		AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65					1.5	other
65		AA026880	Hs.25252	prolactin receptor		
		AF043467	Hs.32893	neurexophilin 2	23	other
	104973	NM_015310	Hs.6763	KIAA0942 protein	5.1	other

	104974	Y12059	Hs.278675	bromodomain-containing 4	1.5	other
	104975	AL136877	Ha.50758	SMC4 (structural maintenance of chromoso	2.4	other
	104978	Al199268	Hs.19322	Homo saplens, Similar to RIKEN cDNA 2010	7.3	other
_	104979	AA937934	Hs.321062	ESTs	1.3	other
5	104994	AI499930	Hs.334885	mitochondrial GTP binding protein	3.6	?
	105009	BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
	105012	AF098158	Hs.9329	chromosome 20 open reading frame 1	3.4	other
		Al050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
••		AB037716	Hs.26204	KIAA1295 protein	2.2	other ?
10		BE242899	Hs.129951	speckle-type POZ protein	3.9	TM
		AA151342	Hs.12677	CGI-147 protein	9.5 5.7	other
		AA147884	Hs.9812	Homo septens cDNA FLJ14388 fis, clone HE	2.2	other
	105088		Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
1.5	105095		Hs.27023	vesicle transport-related protein	1.6	other
15	_	BE387350	Hs.33122	KIAA1160 protein	6.4	?
		AW975433	Hs.36288	ESTs nudix (nucleoside diphosphate linked mol	2.2	other
		AA045648	Hs.301957	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
		AA164687 AW976357	Hs.177576 Hs.234545	hypothetical protein NUF2R	2	other
20		BE245294	Hs.180789	S164 protein	1.7	other
20		AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
		AA071276	Hs.19469	KIAA0859 protein	2	TM
		AA263143	Hs.24596	RAD51-interacting protein	2.9	?
		N99673	Hs.3585	ESTs, Wealthy similar to AF126743 1 DNAJ	1.9	TM
25		AA700122	Hs.3355	sentrin-specific protease	8.2	?
~~		AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
		NM_016015	Hs.8054	CGI-68 protein	8.4	other
		BE264645	Hs.282093	hypothetical protein FLJ21918	5.1	other
		AW887701	Hs.32356	hypothetical protein FLJ20628	2.6	other
30	105374	BE242803	Hs.262823	hypothetical protein FLJ10326	2.2	TM
	105387	AW592146	Hs.108636	membrane protein CH1	2.3	SS,TM
	105393	AF167570	Hs.256583	Interleuidin enhancer binding factor 3, 9	5.5	SS,
		BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6	other
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	1.6	other
35		AA252395		gb:zs12g10.s1 NCL_CGAP_GCB1 Homo saplens	5.1	?
		BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6 1.3	other other
		AA113449	Hs.32471	hypothetical protein FLJ20364	3.5	other
		AB023179	Hs.9059	KIAA0962 protein	9.3	other
40		AA262640	Hs.27445	unknown hypothetical protein FLJ14299	1.4	other.
40		BE616694	Hs.288042 Hs.18490	hypothetical protein FLJ20452	10.9	TM
		AA579535 AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
		Al808201	Hs.287863	hypothetical protein FLJ12475	1.7	?
		AA280072	Hs.99872	fetal Alzheimer antigen	1.4	other
45		AK000892	Hs.4069	glucocorticold modulatory element bindin	1.7	TM
40		AW302245	Hs.181390	casein kinase 1, gamma 2	5.6	other
		AA985190	Hs.246875	hypothetical protein FLJ20059	9.4	other
		AW499988	Hs.27801	zinc finger protein 278	2	TM
		R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50	105743	BE246502	Hs.9598	sema domain, Immunoglobulln domain (lg),	2.7	other
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	7
	105759	Al123118	Hs.15159	chemokine-like factor, alternatively spi	1.3	other
		Al267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
		AA741336	Hs.152108	transcriptional unit N143	2.2	other
55		AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3	other
		Al262106	Hs.12653	ESTs	2.4	other other
		AF151066	Hs.281428	hypothetical protein	2.9	other
		AK001708	Hs.32271	hypothetical protein FLJ10846	1.4	other
C 0		AF016371	Hs.9880	peptidyi prolyi isomerase H (cyclophilin	5.3 1.7	other
60		AW194426	Hs.20726	ESTs Homo saplens, clone IMAGE:2989558, mRNA,	2.8	other
		AW081202	Hs.12284		1.4	other
		AA477956	Hs.26268	ESTs downstream neighbor of SON	1.4	other
		AL157441	Hs.17834	ESTs, Moderately similar to ALUB_HUMAN A	1.6	?
65		AA130158	Hs.19977	hypothetical protein FLJ14681	6.9	other
65		AA533491 AB006624	Hs.23317 Hs.14912	KIAA0286 protein	1.6	other
		AA251393	Hs.289052	Homo saptens, Similar to RIKEN cDNA 5430	10.8	?
	1002.7 1	*AFT 1000	·		•	

	106288	AB037742	Hs.24336	KIAA1321 protein	1.3	other
	106300	Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
	106333	AL043114	Hs.22410	ESTs, Wealthy strillar to A54849 collagen	5.5	SS,
	106350	AK001404	Hs.194698	cyclin B2	5.8	other
5	108359	AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
	106381	AB040916	Hs.24106	KIAA1483 protein	6.6	other
	106389	AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
	106457	AF119256	Hs.27801	zinc finger protein 278	2.7	other
	106470	D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone L.	2.3	other
10		AA243837	Hs.57787	ESTs	1.6	other
- •	106589	AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
	106610	AA458882	Hs.79732	fibulin 1	8	SS,
	106624	NM 003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8	other
	106650	AL049951	Hs.22370	Homo saplens mRNA; cDNA DKFZp56400122 (f	1.8	other
15		AV657117	Hs.184164	ESTs. Moderately similar to S65657 alpha	1.3	TM
		BE614802	Hs. 184352	hypothetical protein FLJ12549	4.6	other
		AA600357	Hs.239489	TIA1 cytotoxic granute-associated RNA-bi	1.3	other
		BE388094	Hs.21857	ESTs	1.6	SS,
		AF174487	Hs.293753	Bcl-2-related ovarian killer protein-lik	5.7	other
20		AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
20		BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5	other
		AB037744	Hs.34892	KIAA1323 protein	22	other
		AF151031	Hs.300631	hypothetical protein	1.3	other
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA,	16.8	other
25		W79171	Hs.9567	GL002 protein	1.5	TM
23		AA861271	Hs.222024	transcription factor BMAL2	2.2	other
		AK001838	Hs.296323	serum/glucocorticoid regulated kinase	3.4	other
		AK000511	Hs.6294	hypothetical protein DKFZp434L1435 simil	6.8	?
		BE156256	Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS,
20		AA146872	Hs.300700 ·	hypothetical protein FLJ20727	1.3	other
			Hs.288971	myeloid/lymphoid or mixed-lineage leukem	1.8	other
		AF264750	Hs.35198	ectoructeotide pyrophosphatase/phosphodi	1.7	other
		AW385224	Hs.23900		2.5	other
35		AK000733		GTPase activating protein	1.7	other
33		AK000512	Hs.69388	hypothetical protein FLJ20505	4.7	other
		AV661958	Hs.8207	GK001 protein	2	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	6.4	TM
		AW378065	Hs.8687	ESTS	33.5	other
40		AW391927	Hs.7946	KIAA1288 protein	5.2	?
40		BE122762	Hs.25338	ESTS		other
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1	other
		AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (17.4	
		BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc	7.4	? other
15		AW263124	Hs.315111	nuclear receptor co-repressor/i-IDAC3 comp	1.8° 6.7	
45		D60341	Hs.21198	translocase of outer mitochondrial membr		other other
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5 3.2	TM
		BE277457	Hs.30661	hypothetical protein MGC4508		TM
		T63174	Hs.193700	Homo saplens mRNA; cDNA DKFZp586l0324 (f	2 5	-
50		NM_006299	Hs.96448	zinc finger protein 193	1.2	? other
30		AW299900	Hs.267632	TATA element modulatory factor 1	1.6	other
		AA307703	Hs.279766	kinesin family member 4A		TM
•		BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3 1.4	other
		AA001386	Hs.59844	ESTS	2	
E E		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.3	SS,TM ?
55		AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.2	
		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4	TM
		L42612	Hs.335952	keralin 6B	2.5	other
		BE153855	Hs.61460	lg superfamily receptor LNIR	2.3	other
C 0		AW956103	Hs.61712	pyruvata dehydrogenase kinase, isoenzyme	6.8	other
60		AL121031	Hs.159971	SWI/SNF related, matrix associated, acti	1.6	other
		AA054224	Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
		N31256	Hs.161623	ESTS	2.6	other
~~	108496	AA083069	Hs.339659	ESTS	3.6	other
65	108607	BE300380	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	3.5	other
		AA101809	Hs.182685	ESTs	1.7	other
	108634	AW022410	Hs.69507	ESTs	1.8	SS,TM

		BE546947	Hs.44276	homeo box C10	9.8	other
	108695	AB029000	Hs.70823	KIAA1077 protein	7.3	other
	108740	Al089575	Hs.9071	progesterone membrana binding protein	2.8	7
	108828	AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5		AL121500	Hs.178904	ESTs	1.6	TM
,		H06720	Hs.111680	endosulfine alpha	2.2	other
		Al801235	Hs.48480	ESTs	5.4	other
					4.1	TM
		AK001431	Hs.5105	hypothetical protein FLJ10569		7
• •		AA149754	Hs.195155	Homo saplens amino acid transport system	5.7	-
10		AA151708	Hs.171980	homeo box (expressed in ES cells) 1	1.7	other
	108987	AA152178	Hs.23467	hypothetical protein FLJ10633	6.3	other
	109002	AB028987	Hs.72134	KIAA1064 protein	1.7	other
	109011	AA156542	Hs.72127	ESTs ·	1.5	other
	109026	AA157811		gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15		AA164293	Hs.72545	ESTs	3	other
~~		AW608930	Hs.52184	hypothetical protein FLJ20618	1.6	SS.
		AW419196	Hs.257924	hypothetical protein FLJ13782	3.3	TM
					1.7	other
		AKD00684	Hs.183887	hypothetical protein FLJ22104	2.7	other
20		AJ132592	Hs.59757	zinc finger protein 281		
20		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	•	TM
	109198	BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
	109213	NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-II	5.4	other
	109220	AW958181	Hs.189998	ESTs	5.8	other
	109233	AU077281	Hs.170285	nucleoportn 214kD (CAIN)	5.3	other
25		N99673	Hs.3585	ESTs, Wealdy similar to AF126743 1 DNAJ	1.4	other
		AA375752	Hs.82719	Homo saplens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other
		AA213506	Hs.115099	EST	3	?
			Hs.184245	KIAA0929 protein Msx2 interacting nuclea	1.5	other
20		AL096858			2.2	SS,
30		H83603	Hs.40408	homeo box C9	3.1	TM
		N30531	Hs.42215	protein phosphatase 1, regulatory subuni		
		A)160029	Hs.61438	ESTs	2	?
	109445	AA232103	Hs.189915	ESTs	1.8	other
	109450	AB032969	Hs.173042	KIAA1143 protein	3.8	other
35	109468	NM_015310	Hs.6763	KIAA0942 protein	3.3	other
	109478	AW074143	Hs.87134	ESTs	2	TM
	109570	L40027	Hs.118890	glycogen synthase kinase 3 alpha	2.1	other
	109662	F02614	Hs.27319	ESTs	1.4	other
		R71264	Hs.16798	ESTs	1.3	other
40		H11938	Hs.21907	histone acetyltransferase	2	other
		AA503041	Hs.279009	matrix Gla protein	2.5	other
		AA603840	Hs.29956	KIAA0460 protein	1.7	other
		T07353	Hs.7948	ESTs	2.9	other
				ESTs, Weakly similar to ALU1_HUMAN ALU S	1.7	SS.
45		R51853	Hs.226429		4.3	other
45		NM_014521	Hs.17667	SH3-domain binding protein 4	4.3	?
		A1668594	Hs.176588	ESTs, Wealthy similar to CP4Y_HUMAN CYTOC		other
		N41744	Hs.19978	CGI-30 protein	1.3	
		H28428	Hs.32406	ESTs, Wealdy similar to 138022 hypotheti	2.2	other
		BE256986	Hs.11896	hypothetical protein FLJ12089	2.1	other
50	110501	H55748		gb:yq94a01.s1 Soares fetal liver spieen	6.1	?
	110504	H55915	Hs.210859	hypothetical protein FLJ11016	6.1	TM
	110525	H57330	Hs.37430	EST	6.4	other
	110568	AK001160	Hs.5999	hypothetical protein FLJ10298	1.3	?
		T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
55		AW190338	Hs.28029	hypothetical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
				hypothetical protein MGC2963	9.3	?
		BE044245	Hs.30011			
<i>(</i> 0		AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60	110769	BE000831	Hs.23837	Homo saplens cDNA FLJ11812 fis, clone HE	21	TM
		A1089660	Hs.323401	dpy-30-like protein	1.5	TM
		T25829	Hs.24048	FK506 binding protein precursor	6.7	TM
		AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
		R33261	Hs.6614	ESTs, Wealdy similar to A43932 much 2 p	3.4	other
65	110840	N31598	Hs.12727	hypothetical protein FLI21610	1.7	TM
	110844	Al740792	Hs.167531	methylcrotoncyl-Coenzyme A carboxylase 2	1.7	other
		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			· · · · · · · · · · · · · · · · · · ·		

	110856	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3	other
	110885	BE384447	Hs.16034	hypothetical protein MGC13186	3.5	?
	110897	AL117430	Hs.6880	DKFZP434D156 protein	2.2	?
_	110915	BE092285	Hs.29724	hypothetical protein FLJ13187	2.6	SS,
5	110918		Hs.24283	ESTs, Moderately similar to reduced expr	1.9	TM
		NM_005864	Hs.24587	signal transduction protein (SH3 contain	6.7	other
		AKD02180	Hs.11449	DKFZP564O123 protein	2	other
		AK001980	Hs.24284	ADP-ribosyttransferase (NAD+; poly(ADP-r	1.3	other
		AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	?
10	111125	N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
		AB037807	Hs.83293	hypothetical protein	2.1	TM
	111164		Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
	111172		Hs.21851	Homo saplens cDNA FLJ12900 fis, clone NT	3.7	other
		AL050166	Hs.26295	Homo saplens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15		AK000136	Hs.10760	asportn (LRR class 1)	7.1	other
		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fls, clone HE	6.8	other
	111189		Hs.272130	ESTs, Wealthy similar to S65824 reverse t	3.6	SS,
		AW139408	Hs.152940	ESTs	1.5	other
••		AB037782	Hs.15119	KIAA1361 protein	2.6	other
20		AA852773	Hs.334838	KIAA1866 protein	4.7	other
	111239		Hs.17230	hypothetical protein FLJ22087	7.9	?
		AA778711	Hs.4310	eukaryotic translation initiation factor	7	other
		AB033091	Hs.74313	KIAA1265 protein	5	other
05		AJ523913	Hs.34504	ESTs	3.8	other
25	111318		Hs.334728	ESTS	1.2	TM
		AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1 2.2	other
	111352		Hs.35156	Homo saplens cDNA FLJ11027 fis, clone PL		other ?
		AM78658	Hs.94631	brefeldin A-Inhibited guanine nucleofide	2.8 2.2	other
20	111384		Hs.288969	HSCARG protein	2.1	other
30		AK000987	Hs.169111	oxidation resistance 1	2.7	TM
	111452		Hs.15999	ESTs	6.6	other
		Al051194	Hs.227978	EST Madaminh similar in 7DE1 LittliAN 7	1.4	other
		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN Z	1.6	?
25		R10720	Hs.20670	EST	1.6	other
35		R52656	Hs.21691	ESTS	2.4	other
		AB037834	Hs.18685	Homo sapiens mRNA for KIAA1413 protein,	10.6	other
		BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr	6.6	TM
		AW083791	Hs.21263	suppressor of potassium transport defect KIAA0942 protein	5.1	other
40	112134	NM_015310	Hs.6763 Hs.7413	ESTs; calsyntenin-2	2.8	other
40		AB029000	Hs.70823	KIAA1077 protein	14.6	other
	112388		Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA,	9	other
		NM 016248	Hs.232076	A kinase (PRKA) anchor protein 11	1.4	other
		AW007287	Hs.28538	Homo sapiens cDNA: FLJ21086 fis, done C	1.4	TM
45		AI742756	Hs.26079	ESTs	3.2	other
43	112513		Hs.13809	hypothetical protein FLJ10648	2	TM
		AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	other
		AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein,	6.6	other
	112923		Hs.5037	EST	1.5	?
50		AW970826	Hs.6185	KIAA1557 protein	3.2	other
50	112958		Hs.6724	ESTs	6.1	other
	112966		Hs.102548	glucocorticold receptor DNA blinding fact	6.5	other
		AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	other
		AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6	other
55		BE276112	Hs.7165	zinc finger protein 259	2	other
-		AJ571940	Hs.7549	ESTs	1.9	other
		AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein,	24	TM
		T40707	Hs.270862	ESTs	1.3	SS,
		T57317		gb:yb51a03.s1 Stratagene fetal spleen (9	1.7	other
60		T63857		gb:yc16e01.s1 Stratagene lung (937210) H	2.8	other
		AK002180	Hs.11449	DKFZP564O123 protein	1.3	other
-		AW971049	Hs.11774	protein (peptidyl-protyl cis/trans isome	3.2	other
		AA688021	Hs.179808	ESTs	1.2	other
		Al467908	Hs.8882	ESTs	6	other
65		H59588	Hs.15233	ESTs	2	SS,
	113647	AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MA	1.3	SS,
		T97307		gbcye53h05.s1 Soares fetal liver spicen	4.4	other
				· · · · · · · · · · · · · · · · · · ·		

	113750	AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	
		BE266947	Hs.10590	zinc finger protein 313	13.4	other	•
		AL359588	Hs.7041	hypothetical protein DKFZp762B226	1.7	other	
		Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5		W44735	Hs.9286	Homo saplens cDNA: FLJ21278 fis, clone C	3.3	other	
,		BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
		H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
		AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
			Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10		T26483		proteasome (prosome, macropain) 26S subti	2.7	other	
10		W57902	Hs.90744		6.1	other	
		AL079314	Hs.16537	hypothetical protein, similar to (U06944 ESTs	6.6	other	
		AW959486	Hs.21732		1.9	?	
		AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.2	other	
15		W87544	Hs.268828	ESTS	5.4	other	
13		Al539519	Hs.120969	Homo sapiens cDNA FLJ11562 fis, clone HE	9.4	other	
		Al825386	Hs.164478	hypothetical protein FLJ21939 similar to	1.8	other	
		AB029551	Hs.7910	RING1 and YY1 binding protein	1.5	other	
		AF017445	Hs.150926	fucose-1-phosphate guanylyttransferase	1.8	other	
20		AB028968	Hs.7989	KIAA1045 protein	2.3	other	
20		BE149866	Hs.14831	Homo saplens, Similar to zinc finger pro	2.3 1.4	TM	
		AL117518	Hs.3686	KIAA0978 protein		06 protein 15.8	other
		AW515443.co		Hs.306117		TM	ouici
		Al815395	Hs.184641	fatty acid desaturase 2	1.9		
25		AA332453	Hs.20824	CGI-85 protein	2.4 1.9	other other	
25		AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r			
		BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (f	- 1.3 5.6	TM other	
		H37908	Hs.271616	ESTS, Weakly similar to ALUB_HUMAN ALU S		TM	
		AL120247	Hs.40109	KIAA0872 protein	5.3 1.3	other	
30		AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110 RP42 homolog	1.9	7 7	*
30		AA028074	Hs.104613		13.4	other	
		BE066778 AA766268	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	2	other	
			Hs.266273	hypothetical protein FLJ13346	3.6	other	
		AA476968	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.9	other	
35		A1373544	Hs.331328	intermediate filament protein syncolin	1.7	other	
33		A1859865	Hs.154443	minichromosome maintenance deficient (S.	3.2	other	
		AV656017	Hs.184325	CGI-76 protein	3.6	other	
		AA159181	Hs.54900	serologically defined colon cancer antig	3.0 4.4	other	
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	7.2	other	
40		AA236177	Hs.76591	KIAA0887 protein	1.3	other	
40		BE539101	Hs.5324	hypothetical protein	1.5	other	
		AA236672	LL 490747	gb:zt29f02.s1 Soares ovary tumor NbHOT H	2	SS,	
		AA237022	Hs.188717	ESTs ESTs	2.9	other	
		AA242834	Hs.58384	BMP-R1B	23	?	
45		AI733881	Hs.72472 Hs.63931		1.3	other	
43		AF102546	Hs.87968	dachshund (Drosophila) homolog	1.6	other	
		AA252360 AI751438	Hs.41271	toll-like receptor 9 Homo saplens mRNA full length insert cDN	11.8	other	^
		Al670847	Hs.5324	hypothetical protein	1.5	other	
		AW183695	Hs.186572	ESTs	2.5	other	
50		AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	other	
50		BE251328	Hs.73291	hypothetical protein FLJ10881	1.3	TM	
		Al368238	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
		AK002163	Hs.301724	hypothetical protein FL/11301	1.5	other	
				- Contract of the Contract of	2.4		
55		AW972872 BE545072	Hs.293736 Hs.122579	hypothetical protein FLJ10461	6.3	SS,	
33		Al215069	Hs.89113	ESTs	6.7	?	
		AA314349	Hs.48499	tumor antigen SLP-8p	7.5	ż	
		AK001376	Hs.59346	hypothetical protein FLJ10514	1.4	TM	
			Hs.278188	ESTs, Moderately similar to I54374 gene	4.1	TM	
60		AW301608	Hs.71819	eukaryotic translation initiation factor	16.3	other	
UU		AW247593		zinc finger protein 200	5	other	
		Y14443	Hs.88219	transcription factor (SMIF gene)	25	other	
		AJ275986	Hs.71414	ESTs	6.2	other	
		A)540842	Hs.61082	HSPC039 protein	2.9	other	
65		BE081342	Hs.283037	7-60 protein	5.3	TM	
65		AA399477	Hs.67896		5.3 4.8	?	
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.6 10.6	other	
	115052	BE093589	Hs.38178	hypothetical protein FLJ23468	10.0	Juka	

	445055	41.040000	U- 200544	Home control done MCC-16063 mPMA com	12.7	TM
		AL048269 Al138785	Hs.288544 Hs.40507	Homo saplens, done MGC:16063, mRNA, com ESTs	2	other
		AA953006	Hs.88143	ESTS	3.1	other
		AA625132	Hs.44159	hypothetical protein FLJ21615	1.7	TM
5		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.9	other
•		BE395161	Hs.1390	proteasome (prosome, macropaln) subunit,	1.7	other
		AI950339	Hs.40782	ESTs	2.7	TM
		NM_015434	Hs.48604	DKFZP434B168 protein	2.1	other
	115823	A1732742	Hs.87440	ESTs	21	other
10	115837	AJ675217	Hs.42761	ESTs	1.3	other
		AJ373062	Hs.332938	hypothetical protein MGC5370	4.4	other
		AW062629	Hs.52081	KIAA0867 protein	7.3	other
		N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2 5.5	other other
1.5		Al867451	Hs.46679	hypothetical protein FLJ20739	9.8	other
15		AB037753	Hs.62767	KIAA1332 protein Down syndrome critical region gene 5	1.4	other
		BE275469 AL359053	Hs.66493 Hs.57664	Homo sapiens mRNA full length insert cDN	2.4	other
		AA770688	Hs.28777	H2A histone family, member L	1.8	other
		BE243834	Hs.50441	CGI-04 protein	1.4	other
20		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
		AW821113	Hs.72402	ESTs	2.1	other
		AV660717	Hs.47144	DKFZP586N0819 protein	1.7	other
	116246	AF265555	Hs.250646	bacutovtral IAP repeat-containing 6	1.7	other
		A1936442	Hs.59838	hypothetical protein FLJ10808	1.8	?
25		Al955411	Hs.94109	Hamo septens cDNA FLJ13634 fis, clone PL	1.9	other
		AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
		AI472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4 1.9	SS, ?
		AL133033	Hs.4084 Hs.44033	KIAA1025 protein	1.5	other
30		AK000290 AA497129	Hs.184771	dipeptidyl peptidase 8 nuclear factor VC (CCAAT-binding transc	1.9	?
30		AJ149586	Hs.38125	interferon-induced protein 75, 52kD	1.9	ż
		N50174	Hs.46765	ESTs	6.1	other
		N90466	Hs.71109	KIAA1229 protein	1.8	?
		AW499664	Hs.12484	Human clone 23826 mRNA sequence	7.4	other
35	116436	AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1	other
	116462	AF218313	Hs.236828	putative helicase RUVBL	1.5	TM
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1	TM
		AA312572	Hs.6241	phosphoinositide-3-kinase, regulatory su	1.5 2.7	other other
40		AK001043	Hs.92033	Integrin-linked kinase-associated serine	2.7	other
40		X89984 A1800202	Hs.211563 Hs.317589	B-cell CLL/lymphoma 7A hypothetical protein MGC10765	1.4	other
		AW074819	Hs.12313	hypothetical protein FLJ14566	3.4	other
		AW152225	Hs.165909	ESTs, Wealthy similar to 138022 hypotheti	2.9	other
		H73608	Hs.290830	ESTs	1.7	TM
45		U72209	Hs.180324	YY1-associated factor 2	3.4	TM
	117132	Al393666	Hs.42315	p10-binding protein	5.2	7
	117247	N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Ho	5.5	TM
		N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
50		AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT	2	other
50		AI041793	Hs.42502	ESTs	2 2.1	other ?
		A1878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.7	TM
		AF150275	Hs.40173 Hs.42645	ESTs solute carrier family 16 (monocarboxylic	1.4	other
		N32536 AF123050	Hs.44532	distribution	3.4	TM
55		N34895	Hs.44648	ESTs	3.4	7
55		BE294925		. CGI-12 protein	3	SS,
		AA121673	Hs.59757	zinc finger protein 281	1.9	other
		N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	other
	117904	BE540675	Hs.332938	hypothetical protein MGC5370	6	?
60	117911	AL137379	Hs.47125	hypothetical protein FLJ13912	1.7	other
		Y10518	Hs.116470	hypothetical protein FLJ20048	1.7	other
		AL110246	Hs.47367	KIAA1785 protein	5.4 5.2	other other
		N54321	Hs.47790	EST	5.2 2.6	other
65		AA453902 AA243332	Hs.293264 Hs.74649	ESTs cytochrome c coddase subunit VIc	2.5	TM
O.S		AA243332 AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1	other
		AJ277275	Hs.50102	rapa-2 (rapa gene)	1.2	other
	1 10400	70411410	I NOW I UL	toba + finha Antol		

	118509	N22617	Hs.43228	Horno sapiens cDNA FLJ11835 fis, clone HE	1.5	other
	118528	Al949952	Hs.49397	ESTs	7.4	?
					2.5	other
		Al458020	Hs.293287	ESTs		
	118670	AA332845	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	1.2	TM
5	118698	AB033113	Hs.50187	KIAA1287 protein	2.1	TM
-		AA199686		gb:zg75g09.r1 Stratagene hNT neuron (937	5.2	other
			I In Access		1.4	other
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A		
	118984	A1668709	Hs.240722	ESTs, Moderately similar to ALUB_HUMAN A	3.6	other
	118986	AF148713	Hs.125830	bladder cancer overexpressed protein	4.9	?
10		W24781	Hs.293798	KIAA1710 protein	1.7	TM
IO						
		AW453069	Hs.3657	activity-dependent neuroprotective prote	22	other
	119265	BE539706	Hs.285363	ESTs	1.4	?
	119279	N57568	Hs.48028	EST	25.1	other
		NM_001241	Hs.155478	cyclin T2	1.6	7
1.5						other
15		Al417240	Hs.320836	ESTs, Wealdy similar to A47582 B-cell gr	1.3	
	119403	AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7	TM
	119478	AJ624342	Hs.170042	ESTs	2.4	other
		AI796730	Hs.55513	ESTs	2.1	other
			112200113		1.9	other
~~		W37933		Empirically selected from AFFX single pr		
20	119601	AK000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp6671103 (fr	3.7	TM
	119602	AW675298	Hs.233694	hypothetical protein FLJ11350	3	other
		AA243837	Hs.57787	ESTs	1.4	other
						7
		W61019	Hs.57811	ESTs	1.2	
	119774	AB032977	Hs.6298	KIAA1151 protein	1.8	TM
25	119780	NM_016625	Hs.191381	hypothetical protein	3.1	other
		BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum com	9.2	other
					3.6	TM
		AJ223810	Hs.43213	ESTs, Wealty similar to IEFS_HUMAN TRANS		
	119818	AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	?
	119863	AA081218	Hs.58608	Homo saplens cDNA FLJ14206 fls, clone NT	2.7	TM
30		AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	2.6	other
50					2.7	other
		AA703129	Hs.58963	ESTs		
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
	120206	H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7	other
	120248	Al924294	Hs.173259	uncharacterized bone marrow protein BM03	1.2	other
35		AW131940	Hs.104030	ESTs	9.6	other
33			113. IU4U3U		-	
	120274	AA177051		gbmc02a02.s1 NCI_CGAP_Pr3 Homo sapiens	4.7	other
	120280	AA190577		gb:zp52g02.s1 Stratagene Hel.a cell s3 93	2.1	other
	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	1.9	TM
		AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2	other
40					5.6	?
40		AA195517	Hs.191643	ESTs		
	120325	AA195651	Hs,104106	ESTs	6.5	other
	120327	AK000292	Hs.278732	hypothetical protein FLJ20285	16.1	other
		N85785	Hs.181165	eukaryotic translation elongation factor	3	other
						other
		AW450669	Hs.45068	hypothetical protein DKFZp4341143	5,8	
45	120345	AA210722	Hs.104158	ESTs	4.6	SS,TW
	120349	AW969481	Hs.55189	hypothetical protein	16.8	other
		R06859	Hs.193172	ESTs, Wealdy similar to 138022 hypotheti	5.1	other
				putative purinergic receptor	28.1	TM
		AF000545	Hs.296433			
	120371	AA219305	Hs.104196	EST	12.4	?
50	120382	AA228026	Hs.38774	ESTs	4.1	TM
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homoto	9.7	TM
				hypothetical protein DKFZp434D0127	32.6	other
		AW969665	Hs.154848	••		
	120388	AA232874	Hs.104245	ESTs	3.2	other
	120389	AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	21.7	other
55		AA134006	Hs.79306	eukaryotic translation initiation factor	12.5	other
-		AB023230	Hs.96427	KIAA1013 protein	7.3	other
		AW966893	Hs.26613	Homo saptens mRNA; cDNA DKFZp586F1323 (f	11.4	other
	120423	AA236453	Hs.18978	Homo sapiens cDNA: FLJ22822 fis, clone K	1.9	other
		AJ950087		gb:wq05c02.x1 NCL_CGAP_Kld12 Homo sapien	19.4	other
60		AA251973	Hs.269988	ESTs	5.5	?
UU						?
		AA253170	Hs.96473	EST	10.4	
	120504	AA256837		gbczr84d10.s1 Soares_NhiHMPu_S1 Homo sapi	4	?
		BE047718	Hs.96545	ESTs	9.4	other
		AA258601	Hs.161731	EST	2.4	other
CE						
65		BE350244	Hs.96547	ESTs	2.5	?
	120551	AA279160	Hs.111407	Homo sapiens, clone IMAGE:3613029, mRNA,	5.3	other
		AA280679	Hs.271445	ESTs, Wealthy similar to ALU1_HUMAN ALU S	14.4	?
	,200,0					

	120582 BE244830	Hs.284228	ZNF 135-like protein	10.2	?
	120590 AW372799	Hs.125790	leucine-rich repeat-containing 2	2.2	?
	120596 AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.6	other
_	120619 AW965339	Hs.111471	ESTs	2.5 52	other
5	120624 AW407987	Hs.173518	M-phase phosphoprotein homolog	32 2.4	other other
	120639 AA286942	No. 440200	gb:zs56f05.s1 NCL_CGAP_GCB1 Homo sapiens Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
	120648 AA287095 120653 AW063659	Hs.140309 Hs.191649	ESTs	2.2	other
	120668 AW969638	Hs.112318	6.2 kd protein	2.2	TM
10	120669 BE536739	Hs.109909	ESTs	1.9	TM
	120695 AA976503		gbxxx30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
•	120696 AJB21539	Hs.97249	ESTs	2.5	other
	120713 AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
	120718 AA292747	Hs.97296	ESTs	2.9	other
15	120750 Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
	120774 Al608909	Hs.193985	ESTS	7.9	other TM
	120807 AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7 4.5	other
	120809 AA346495	Hs.104632	gb:EST52657 Fetal heart II Homo sapiens EST	4.5	?
20	120938 AA386260 120977 AA398155	Hs.97600	ESTs	4.5	other
20	120984 BE262951	Hs.99052	ESTs	5.6	other
	120985 Al219896	Hs.97592	ESTs	1.3	other
	121011 AA398360	Hs.97608	EST	3.2	other
	121026 Al439713	Hs.165295	ESTs	3.6	other
25	121081 AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.5	other
	121133 AA363307	Hs.97032	ESTs	3.8	other
	121176 AL121523	Hs.97774	ESTs	1.7 2.9	TM other
	121223 Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.	1.9	other
30	121320 AA403008 121340 AW956981	Hs.301927 Hs.97910	c6.1A Homo sapiens cDNA FLJ13383 fis, clone PL	3.5	other
30	121408 AA406137	Hs.98019	EST	6.1	7
	121439 AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.5	other
	121450 AA406430	Hs.105362	Homo saplens, clone MGC:18257, mRNA, com	7.1	other
	121452 AW971063	Hs.292882	ESTs	1.8	other
35	121455 H58306	Hs.15165	retinoic acid induced 14	10.5	other .
	121457 W07404	Hs.144502	hypothetical protein FLJ22055	3.5	TM
	121496 AA442224	Hs.97900	ESTs	14.4 13.1	other other
	121505 AA494172	Hs.194417	ESTs ESTs	28	other
40	121508 AA402515 121513 AA416653	Hs.97887 Hs.181510	ESTs	6.3	other
40	121514 AA412112	112.101310	gb:zi69b02.s1 Soares_testis_NHT Homo sap	2.7	SS.
•	121549 AA412477	Hs.98142	EST	7.5	?
	121558 AA412497		gbczt95g12.s1 Soares_testis_NHT Homo sap	2.8	other
	121577 AA411970	Hs.98096	EST	3.5	?
45	121581 AA416568		gbczu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
	121589 AD001528	Hs.89718	spermine synthase	4	other
	121594 AA626010	Hs.98247	ESTs	2.2 4.3	other TM
	121622 AA416931 121655 AA421537	Hs.126065 Hs.178072	ESTs Homo sapiens mRNA; cDNA DKFZp434B1023 (f	7.9	other
50	121682 AA418160	Hs.86043	Homo saplens cDNA FLJ13558 fis, done PL	2	other
30	121690 AV660305	Hs.110286	ESTs .	4.7	?
	121706 U55184	Hs.154145	hypothetical protein FLJ11585	12.7	other
	121714 AA419225	Hs.98269	Homo sapiens cONA FLJ11953 fis, clone HE	8.3	?
	121729 Al949597	Hs.98325	ESTs	1.8	TM
55	121731 AA421041	Hs.180744	ESTs	4.1	TM
	121744 AA398784	Hs.97514	ESTs	7.1 19.5	SS, other
	121748 BE536911	Hs.234545	hypothetical protein NUF2R	8	other
	121773 AB033022 121775 AAA21773	Hs.158654 Hs.161008	KIAA1196 protein ESTs	1.7	other
60	121775 AAA21773 121776 AA292579	Hs.125133	hypothetical protein FLJ22501	6.7·	other
UU	121786 AJ810774	Hs.98376	ESTs	10.5	other
	121832 AW340797	Hs.98434	ESTs	5.9	other
	121836 AA328348	Hs.218289	ESTs	3.9	other
	121839 AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	. 5	other
65	121842 AF027406	Hs.104865	serine/threonine kinase 23	2.7	?
	121847 AA446628	Hs.2799	cartilage linking protein 1	2.3	other
	121871 AW972668	Hs.293044	ESTs	2.9	TM

	121882 AA426376	Hs.98459	ESTs	5 .	other
	121911 AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
	121915 AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
_	121935 AA428647	Hs.98611	EST	2.3	other -
5	121983 AA298760	Hs.180191	hypothetical protein FLJ14904	3.4 11.4	other other
	121985 Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA,	3.8	?
	121995 AA210863 121999 AA430211	Hs.3532 Hs.98668	nemo-like kinase EST	6.5	other
	122009 AW292763	Hs.160822	Homo saplens cDNA: FLJ20863 fis, clone A	2.2	other
10	122013 AA431085	Hs.98706	ESTs	6.6	other
	122036 W92142	Hs.271963	ESTs, Wealthy similar to ALU5_HUMAN ALU S	13.1	other
	122050 AV453076	Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
	122060 AA431738	Hs.98750	EST	13.1	?
	122114 AW161023	Hs.104921	ESTs	1.5 3.4	other other
15	122188 AA398838	Lla 00042	gb:zt80d01.r1 Soares_testis_NHT Homo sap	5.6	other
	122204 AA435936 122246 AA329550	Hs.98842 Hs.29417	EST HCF-binding transcription factor Zhangfe	5.2	other
	122257 AA436819	Hs.98899	ESTs	5.6	other
	122302 AA441801	Hs.104947	ESTs	5.8	other
20	122341 AW601969	Hs.99010	hypothetical protein FLJ22263 similar to	2	other
	122356 AA443794	Hs.98390	ESTs	7.4	SS,TM
	122369 AA443985	Hs.303222	ESTs	12.2	?
	122371 AA868555	Hs.178222	ESTs	5 70	? ?
25	122372 AA446008	Hs.336677	EST hypothetical protein DKFZp762K2015	7.8 2.5	?
25	122378 AB032948 122405 AA446572	Hs.21356 Hs.303223	EST	2.8	TM
	122412 AA446869	Hs.119316	ESTs	7.4	other
	122415 AA446918	Hs.99088	EST	1.9	other
	122418 AA446966	Hs.99090	ESTs, Moderately similar to similar to K	6.9	?
30	122440 AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
	122446 AA447603	Hs.99123	EST	1.8 3.5	TM other
	122448 AA447626	Hs.99127	EST ESTs	3.5 1.5	other
	122458 Al266159 122460 AW418788	Hs.104980 Hs.99148	ESTS, Weakly similar to S43569 R01H10.6	9.7	other
35	122464 AA448158	Hs.99152	EST	4.9	other
55	122490 AA448349	Hs.238151	EST	6.2	?
	122492 AA448417	Hs.104990	ESTs	5.5	other
	122502 AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
40	122510 AA449232	Hs.99195	ESTs	11.2	?
40	122530 AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1 2.5	other SS,
	122547 AA779725 122555 AA194055	Hs.164589 Hs.293858	ESTs ESTs	1.9	other
	122570 AA452578	Hs.262907	ESTs	9.5	other
	122572 AA452601	Hs.99287	EST	11	?
45	122586 AK001910	Hs.99303	Homo saplens cDNA FLJ11048 fis, clone PL	3.4	other
	122587 AB040893	Hs.6968	KIAA1460 protein	2	other
	122598 Al028173	Hs.99329	ESTS	1.7	?
	122599 AL355841	Hs.99330	hypothetical protein FLJ23588	4.4 4.7	? other
50	122602 AA411925	Hs.301960 Hs.98023	ESTs ESTs	61.5	other
50	122607 AA453518 122614 AA453630	Hs.99339	EST	10.7	?
	122616 AA453638	Hs.161873	ESTs	107.3	?
	122617 Al681535	Hs.148135	serine/threonine kinase 33	121.4	other
	122618 AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
55	122622 AA453987	Hs.144802	ESTs	5.6	other
	122717 AA456859	Hs.178358	ESTs	8.5	SS,
	122762 Al376875	Hs.105119	ESTs	10.4 81.8	other ?
	122829 AW2D4530 122834 AA461492	Hs.99500 Hs.99545	ESTs Homo saplens cDNA FLJ10658 fis, clone NT	3.7	?
60	122834 AA460581	Hs.290996	ESTs	4.6	other
UU	122837 AA461509	Hs.293565	ESTs, Wesity similar to putative p150 (H	2.7	TM
	122838 AA460584	Hs.334386	ESTs	75.3	other
	122854 AA600235	Hs.9625	NIMA (never in mitosis gene a)-related k	7.8	other
	122856 Al929374	Hs.75367	Src-like-adapter	5.8	other
65	122861 AA335721	Hs.119394	ESTs	1.3	other
	122866 BE539656	Hs.283705	ESTs	4.2 5.3	other other
	122868 AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	J.J	00101

	122870 AW57	6312	Hs.318722	Homo saptens cDNA: FLJ21766 fis, clone C	9.9	?
	122872 AW08	1394	Hs.97103	ESTs	5.3	other
	122879 AA769		Hs.128654	ESTs	13.9	other
_	122907 AA470		Hs.169896	ESTs	11.5	other TM
5	122916 AA470		Hs.229170	EST	1.7 5	other
	122981 AA478		Hs.105629 Hs.17384	ESTs ESTs	15.4	other
	123013 AW96 123016 AW33		Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	2.8	other
	123034 AL359		Hs.44054	ninein (GSK3B interacting protein)	8.7	other
10	123072 Al382		Hs.104308	ESTs, Wealty similar to KIAA1395 protein	8.8	other
10	123082 AA485		Hs.105661	ESTs	4	7
	123088 Al343		Hs.105667	ESTs	3.8	other
	123110 AA486	5256 I	Hs.193510	EST	7.4	other
	123114 BE304	4942	Hs.265848	myomegalin	2.8	?
15	123131 T5202		Hs.271795	ESTs, Weakly similar to 138022 hypotheti	2.4	other
	123132 AJ061		Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6 5.2	TM other
	123136 AW45		Hs.194024	ESTS	23.8	TM
	123149 AI734		Hs.105676 Hs.270259	ESTs ESTs	5.2	other
20	123152 AW60 123258 AA49		Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL.	9.3	?
20	123315 AA49		115.1002/4	gbczv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
	123369 AA50		Hs.105738	ESTs	7	other
	123394 AA73		Hs.105510	ESTs	3.7	other
	123433 AW45		Hs.112478	ESTs	3.8	other
25	123466 AA59	9042	Hs.112503	EST	7.4	other
	123470 AW30		Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other ?
	123471 AB02		Hs.197219	zinc finger protein 14 (KOX 6)	5.2 1.7	other
	123475 BE43		Hs.250528	Homo sapiens, clone iMAGE:4098694, mRNA,	1.6	other
30	123482 N9503 123486 BE013		Hs.55098 Hs.334802	ESTs Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
30	123508 AW38		Hs.155546	KIAA1080 protein; Golgi-essociated, gamm	2.2	TM
	123615 AA60		1,53,100010	gbcaf12a12.s1 Soares_testis_NHT Horno sap	7.9	other
	123619 AA60			gb:no97c02.s1 NCL_CGAP_Pr2 Homo saplens	2.8	other
	123658 AA60			gb:zu71d09.s1 Soares_testis_NHT Homo sap	1.7	?
35	123674 Al269	609	Hs.105187	kinesin protein 9 gene	5.7	?
	123735 NM_0		Hs.95231	FH1/FH2 domain-containing protein	10	other
	123738 AA60		Hs.112777	EST	5.2 30.6	other
	123753 AA60		Hs.234961	Huntingtin interacting protein E	2.1	TM other
40	123804 AA62 123811 AA62		Hs.261915	EST, Wealdy similar to \$65657 alpha-1C-a obcae60g05.s1 Stratagene lung carcinoma	2.7	other
40	123951 AB01		Hs.173043	metastasis-essociated 1-like 1	6.3	?
	123983 AJ277		Hs.146178	choline dehydrogenase	4.4	other
	124001 L4254		Hs.75447	ralA binding protein 1	7.1	?
	124006 AJ147	155	Hs.270016	ESTs	8.3	SS,
45	124070 AI950		Hs.154762	HIV-1 rev binding protein 2	3.8	other
	124074 H056		Hs.294030	topolsomerase-related function protein 4	1.2	SS,
	124178 BE46		Hs.97101	putative G protein-coupled receptor	3.2	? other
	124203 AA37		Hs.269339	ESTs, Wealty similar to AF161356 1 HSPC0	5.7 3.1	TM
50	124352 AA64 124375 D874		Hs.102406 Hs.192966	ESTS	3.5	other
30	124375 D674 124385 Al267		FIS. 132300	KIAA0265 protein gb:ag49a10.x1 Stanley Frontal NB pool 2	57.1	?
	124390 AA31		Hs.7535	COBW-like protein	2.8	other
	124391 AF15		Hs.279780	NY-REN-18 antigen	7.1	other
	124417 N340			gb:yv28h09.s1 Soares fetal liver spieen	3.3	other
55	124428 H135		Hs.82202	ribosomal protein L17	2.9	other
	124440 AA53		Hs.129043	Human DNA sequence from clone 989H11 on	7.9	other
	124466 R100		Hs.113319	kinesin heavy chain member 2	2.6	TM
	124482 N539		11- 00000T	gb:yv59d09.s1 Soares fetal liver spleen	7.9 7.8	TM other
<i>6</i> 0	124498 H794		Hs.268997	ESTs	7.6 3.3	other
60	124515 AA66		Hs.109370 Hs.102800	ESTs, Weakly similar to neuronal thread	4.6	?
	124608 N710 124631 NM_0		Hs.270594	FLVCR protein	3.2	other
	124634 AI764		Hs.143671	Homo sapiens dDNA FLJ13533 fis, done PL	5.8	other
	124637 AA16		Hs.75798	hypothetical protein	9.3	other
65	124642 AW90		Hs.278569	sorting nextn 17	3.5	other
~~	124649 N925	93	Hs.313054	ESTs	6.1	TM
	124661 R481		Hs.78436	EphB1	5.6	other

	124683 AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	TM
	124712 R09166	Hs.191148	ESTs	5.7	other
	124735 R22952	Hs.268685	ESTs	11.3	?
	124761 AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9	other
5	124768 AW368528	Hs.100855	ESTs	8.3	other
	124775 R41772	Hs.100878	ESTs	4.9	other
	124777 R41933	Hs.140237	ESTs, Wealdy similar to ALU1_HUMAN ALU S	2.8	other
	124788 R43543	Hs.100912	Homo saplens cDNA: FLJ22726 fis, clone H	5.1 4.2	other other
10	124809 AL355722	Hs.106875	Homo sapiens EST from done 35214, full	14.2	other
10	124811 R46068	Hs.288912	hypothetical protein FLJ22604 ESTs	7.9	other
	124812 R47948	Hs.188732 Hs.86043	Homo saplens cDNA FLJ13558 fis, clone PL	6.6	other
	124822 AA418160 124825 AA501669	Hs.336693	ESTs	2.3	SS.TM
	124833 AW975868	Hs.294100	ESTs	2.7	SS,TM
15	124857 R63652	Hs.137190	ESTs	2.3	other
	124860 R65763	Hs.101477	EST	23.9	?
	124863 Al382555	Hs.127950	bromodomain-containing 1	2	other
	124876 AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	SS,
	124878 BE397530	Hs.288057	hypothetical protein FLJ22242	2.7	other
20	124902 H37941	Hs.101883	ESTs	5.7 32.4	other other
	124903 AW296713	Hs.221441	ESTs ESTs, Wealdy similar to ALUB_HUMAN !!!!	22.8	other
	124930 Al076343	Hs.173939 Hs.268892	ESTs, Weardy similar to B34087 hypot	6.1	other
	124942 R99978 124958 Al078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	1.9	other
25	124980 T40841	Hs.98681	ESTs	4.5	?
23	125002 T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
	125047 T79815	Hs.279793	ESTs	5	7
	125051 T79956	Hs.100588	EST	135.3	?
	125056 T81310	Hs.100592	ESTs	5.4	other
30	125101 Al472068	Hs.286236	KIAA1856 protein	5.6	other
	125113 T96595	Hs.302270	ESTs, Wealdy similar to ALUF_HUMAN IIII	1.8 9.6	other ?
	125115 T97341	Un 240767	gb:ye57e05.s1 Soares fetal liver spleen Human DNA sequence from clone RP1-12G14	1.5	TM
	125125 Al222382 125147 W38150	Hs.240767	Empirically selected from AFFX single pr	1.7	?
35	125161 W44657	Hs.144232	EST	10.7	7
33	125249 AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN I	1.3	other
	125255 AF098162	Hs.118631	timetess (Drosophita) homolog	9.4	other
	125279 AW401809	Hs.4779	KIAA1150 protein	1.5	?
	125280 Al123705	Hs.106932	ESTs	8.1	?
40	125298 AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone H	1.5	other
	125660 AW292171	Hs.23978	scaffold attachment factor B	5.9 1.2	other ?
	125827 NM_003403 125891 U29589	Hs.97496 Hs.7138	YY1 transcription factor cholinergic receptor, muscarinic 3	6.5	7
	126005 AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (sur	14.3	ż
45	126202 AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.5	SS,
7.5	126695 AA643322	Hs.172028	a disintegrin and metalloproteinase doma	9.1	SS,TM
	127050 AW411066	Hs.274351	CGI-89 protein	17	other
	127274 AW966158	Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
	128355 AW293012	Hs.161623	ESTs	7.4	SS,
50	128493 D87466	Hs,240112	KIAA0276 protein	3.1 9.4	TM other
	128522 BE173977	Hs.10098	putative nucleolar RNA helicase transcription factor 3 (E2A Immunoglobul	1.5	other
	128527 AA504583 128528 R39234	Hs.101047 Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
	128595 U31875	Hs.272499	short-chain alcohol dehydrogenase family	12.1	TM
55	128599 NM_015366	Hs.102336	Rho GTPase activating protein 8	24	?
33	128604 Al879099	Hs.102397	GIOT-3 for gonzdotropin inducible transc	1.3	other
	128608 BE267994	Hs.102419	zinc finger protein	7.2	other
	128625 AB037841	Hs.102652	hypothetical protein ASH1	1.3	other
	128629 AL096748	Hs.102708	DKFZP434A043 protein	3.2	other
60	128639 AW582962	Hs.102897	CGI-47 protein	2 1.4	TM other
	128656 AA458542 128658 BE397354	Hs.10326	coatomer protein complex, subunit epsilo diptheria toxin resistance protein requi	2.5	other
	128670 AA975486	Hs.324830 Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691 W27939	Hs.103834	hypothetical protein MGC5576	7.8	ż
65	128696 BE081143	Hs.225977	nuclear receptor coactivator 3	3.8	other
J J	128700 Y15221	Hs,103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714 T85231	Hs.179661	tubulin, beta 5	7.8	other

	128717	AKD01564	Hs.104222	hypothetical protein FLJ10702	5.5	other
	128733	BE147740	Hs.104558	ESTs, Moderately similar to 138022 hypot	2.7	TM
	128737	AF292100	Hs.104613	RP42 homolog	2.8	TM
_	128742	AA307211	Hs.251531	proteasome (prosome, macropain) subunit,	4.5	?
5	128746	A1470163	Hs.323342	actin related protein 2/3 complex, subun	2.2	other
	128747	AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
	128772	BE302796	Hs.105097	thyrnidine kinase 1, soluble	5.4	other
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9	TM
	128797	NM_002975	Hs.105927	stem cell growth factor; lymphocyte secr	13.3	other
10	128806	AW630942	Hs.106061	RD RNA-binding protein	2.6	other
•	128814	AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
	128830	BE281170	Hs.106357	valosin-containing protein	6	other
	128835	AKD01731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	1.6	SS,
	128854	BE159181	Hs.168232	hypothetical protein FLJ13855	2.3	other
15	128871	AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, memb	1.5	?
	128906	R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.8	other
	128920	AA622037	Hs.166468	programmed cell death 5	1.4	other
	128925	R67419	Hs.21851	Homo saptens cDNA FLJ12900 fts, clone NT	1.9	other
	128946	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	7.3	?
20	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase doma	2.5	other
	128959	Al580127	Hs.107381	hypothetical protein FLJ11200	1.3	other
	128965	AW150697	Hs.107418	ESTs	1.4	7
	128970	Al375672	Hs.165028	ESTs	1.3	other
	128975	BE560779	Hs.284233	NICE-5 protein	14	other
25	128979	AW271217	Hs.281434	Homo saplens cDNA FLJ14028 fls, clone HE	1.6	TM
	128995	Al816224	Hs.107747	DKFZP566C243 protein	1.9	other
	129019	AI950087		gb:wq05c02.x1 NCl_CGAP_Kid12 Homo sapien	2.9	other
	129021	AL044675	Hs.173081	KIAA0530 protein	3.8	other
	129032	R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4	other
30	129076	AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti	5	other
	129078	Al351010	Hs.102267	lysosomal	2.1	other
	129088	AA744610	Hs.194431	palladin	17.1	other
	129095	L12350	Hs.108623	thrombospondin 2	2.7	other
	129096	AA463189	Hs.288906	WW Domain-Containing Gene	20.9	TM
35	129097	BE243933	Hs.108642	zinc finger protein 22 (KOX 15)	3	other
	129099	AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR	5.8	TM
	129136	W93048	Hs.250723	hypothetical protein MGC2747	6	. other
	129149	AA356620	Hs.108947	KIAA0050 gene product	6.4	TM
	129172	AW162916	Hs.241576	hypothetical protein PRO2577	1.8	TM
40	129192	AA286914	Hs.183299	ESTs	2.1	?
		AA150797	Hs.109276	latedn protein	3.3	SS,TM
	129198	N57532	Hs.109315	KIAA1415 protein	5.9	other
		A1934365	Hs.109439	osteoglycin (osteoinductive factor, mime	8.1	other
		U40714	Hs.239307	tyrosyl-tRNA synthetase	29	other
45		AF013758	Hs.109643	polyadenylate binding protein-interactin	3.3	?
		AA252468	Hs.1098	DKFZp434J1813 protein	2.6	SS,TM
		A1961727	Hs.109804	H1 histone family, member X	7.4	other
		W26392	Hs.110080	ESTs, Wealthy strailar to \$13495 pregnancy	9.6	other
		AI051967	Hs.110122	ESTs STATE OF THE	1.2	other
50		AA287239	Hs.5518	Homo sepiens cDNA FLJ11311 fis, clone PL	5.2	other
		H75334	Hs.11050	F-box only protein 9	4.7	SS,
		BE614192	Hs.279869	melanoma-associated antigen recognised b	7.7	TM
		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7	TM
	129366	BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6	SS,
55		Al686379	Hs.110796	SAR1 protein	1.4	TM
		NM_016039	Hs.110803	CGI-99 protein	2	other
	129403	AF149785	Hs.111126	pitultary tumor-transforming 1 Interacti	7.5	other
		Al267700	Hs.317584	ESTs	5.1	other
		AA204686	Hs.234149	hypothetical protein FLJ20647	10.2	other
60	129482	AA188185	Hs.289043	spindiin	6.8	other
_		AW843633	Hs.306163	hypothetical protein AL110115	7.1	SS,
	129515	AF255303	Hs.112227	membrane-associated nucleic acid binding	2.5	other
		AA769221	Hs.270847	delta-tubulin	3.2	other
		W01296	Hs.11360	hypothetical protein FLJ14784	7.5	other
65	129560	AA317841	Hs.7845	hypothetical protein MGC2752	6.8	other
_	129570	Al923097	Hs.11441	chromosome 1 open reading frame 8	2.1	other
	129575	F08282	Hs.278428	progestin induced protein	1.6	other

	420507	1144740	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
		H14718 BE408300	Hs.301862	postmeiotic segregation increased 2-like	1.4	TM
	129591		Hs.179898	HSPC055 protein	7.4	other
		AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5		AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
_		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	2.2	other
		AD000092	Hs.16488	catreticutin	3.3	other
	129675	NM_015556	Hs.172180	KIAA0440 protein	13.4	other
	129680	U03749		ghdHuman chromogranin A (CHGA) gene, pro	14.1	?
10		AW748482	Hs.77873	B7 homolog 3	2.6	other
		AJ304966	Hs.12035	ESTs, Weakly similar to 138022 hypotheti	7.5 2	TM other
		AA156214	Hs.12152	APMCF1 protein	1.7	TM
		NM_001415	Hs.211539	eukaryotic translation initiation factor	1.8	other
15		AKD01676 AA394090	Hs.12457 Hs.12460	hypothetical protein FLJ10814 Homo saptens clone 23870 mRNA sequence	5.5	TM
13		AF052112	Hs.12540	lysosomal	1.7	?
		AB023148	Hs.173373	KIAA0931 protein	1.2	other
		BE565817	Hs.26498	hypothetical protein FLJ21657	3.1	other
		NM_006590	Hs.12820	SnRNP assembly defective 1 homolog	1.8	other
20		AL049999	Hs.85963	DKFZP564M182 protein	23	other
	129864	Al393237	Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
	129869	Al222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	TM
•		BE514376	Hs.165998	PAJ-1 mRNA-binding protein	1.8	other
0.5		AA412195	Hs.13740	ESTs	2.5 1.8	other ?
25		AW753185	Hs.180628	dynamin 1-like	1.3	other
		U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.6	other
		AA301116 AA287325	Hs.142838 Hs.14713	mucleolar phosphoprotein Nopp34 ESTs	4.1	other
		S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30		ALD46962	Hs.14845	forlinead box O3A	2.8	other
50		AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
		X53002	Hs.149846	integrin, beta 5	2.3	other
		AA916785	Hs.180610	splicing factor proline/glutamine rich (3	other
	130128	L76937	Hs.150477	Werner syndrome	1.8	other
35		AA311426	Hs.21635	tubulin, gamma 1	6.1	other
		NM_003358	Hs.23703	ESTs, Moderately similar to CEGT_HUMAN C	1.6 1.3	other other
		D80001	Hs.152629	KIAA0179 protein	2	other
		R85367	Hs.51957	splicing factor, arginine/serine-rich 2, MyoD family inhibitor	3.2	other
40		AL035588 X79201	Hs.153203 Hs.153221	synovial sarcoma, translocated to X chro	5.4	?
40		D81983	Hs.322852	GAS2-related on chromosome 22	4.9	other
		NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	1.4	other
		AA479005	Hs.154036	turnor suppressing subtransferable candid	2.6	other
	130310	AB011121	Hs.154248	armyotrophic lateral scierosis 2 (Juvenil	6.3	other
45	130353	Z19084	Hs.172210	MUF1 protein	6.2	other
		AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4	other
		AJ224442	Hs.155020	putative methyltransferase	3.5 8.5	TM other
		NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	1.4	other
50		AL135301	Hs.8768 Hs.5011	hypothetical protein FLJ10849 RNA binding motif protein 9	3.3	7
30		A1077464 N89487	Hs.155291	KIAA0005 gene product	1.8	other
	*****	AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
		BE385099	Hs.334727	hypothetical protein MGC3017	2.3	other
	130409	NM_001197	Hs.155419	BCL2-Interacting killer (apoptosis-induc	2.7	TM
55		AF037448	Hs.155489	NS1-associated protein 1	1.8	other
		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
		BE513202	Hs.15589	PPAR binding protein	4	TM
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6	?
<i>c</i> 0		BE245851	Hs.180779	H2B histone family, member B	5 4.4	other other
60		U49844	Hs.77613	ataxia telangiectasia and Rad3 related	4.4 1.6	SS,TM
	130498	L38951 BE208491	Hs.180446 Hs.295112	kanyopherin (Importin) beta 1 KIAA0618 gene product	16.1	other
		L32137	Hs.1584	cartilage oligometic matrix protein (pse	6.1	other
		AW876523	Hs.15929	hypothetical protein FLJ12910	2.1	other
65	130520	AA321238	Hs.4310	eukaryotic translation initiation factor	1.5	other
00		AF062649	Hs.252587	pituliary tumor-transforming 1	14.4	?
		Al907018	Hs.15977	Emptrically selected from AFFX single pr	4.8	other

				•		
	130567	AA383092	Hs.1608	replication protein A3 (14kD)	8	other
		AA232119	Hs.16085	putative G-protein coupled receptor	3.4	other
		AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2	other
•		AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4 1.5	other TM
5		AA609738	Hs.16525	EST8	1.3	other
		Al354355 M90516	Hs.16697 Hs.1674	down-regulator of transcription 1, TEP-b glutamine-fructose-6-phosphate transamin	12.1	TM
		AA383439	Hs.16758	Spir-1 protein	15.9	other
		BE246961	Hs.17639	Homo saplens ublquitin protein ligase (U	13.9	other
10		AL048842	Hs.194019	attractin	1.5	other
	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other
		AA652501	Hs.13561	hypothetical protein MGC4692	5	other
		R68537	Hs.17962	ESTs	2 1.8	other TM
15		AJ271881	Hs.279762 Hs.18212	bromodomain-containing 7 DNA segment on chromosome X (unique) 987	2	TM
15		Al348274 AB007920	Hs.18586	KIAA0451 gene product	3.8	?
		H59896	Hs.18747	POP7 (processing of precursor, S. cerevi	3.2	?
		AF052105	Hs.18879	chromosome 12 open reading frame	1.4	other
		AL036067	Hs.18925	protein x 0001	5.7	other
20	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
	130789	AK000355	Hs.8899	situin (silent mating type information	1.6	other
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS,
		AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, clone AD	2.8 1.5	other other
25		AA447492	Hs.20183 Hs.20191	ESTs, Wealdy similar to AF164793 1 prote seven in absentia (Drosophila) homolog 2	3.5	other
23		U76248 AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7	other
		NM_016578	Hs.20509	HBV pX associated protein-8	1.9	other
		NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
		BE514434	Hs.20830	kinesin-like 2	2.1	TM
30	130892	AL120837	Hs.20993	high-glucose-regulated protein 8	2.5	other
		AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7	other other
		BE409769	Hs.21189	DnaJ (Hsp40) homotog, subfamily A, membe collagen, type IV, alpha 3 (Goodpasture	1.8 2.3	TM
		N79110 BE382657	Hs.21276 Hs.21486	signal transducer and activator of trans	5.4	other
35		N39842	Hs.301444	KIAA1673	2.2	SS,
55		T97401	Hs.21929	EST8	1.6	other
		AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6	?
	131028	AJ879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP),	1.2	other
40		AI826288	Hs.171637	hypothetical protein MGC2628	1.6	other
40		AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4 5.1	? other
		AA194422 N53344	Hs.22564 Hs.22607	myosin VI ESTs	7.1	other
		AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	21	TM
		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c cold	7.1	other
45		NM_006540	Hs.29131	nuclear receptor coactivator 2	1.9	?
	131185	BE280074	Hs.23960	cyclin B1	5.8	?
		AW138839	Hs.24210	ESTS	2	other
		AA885699	Hs.24332	CGI-26 protein	7.1	TM
50		H62087	Hs.31659	thyroid hormone receptor-associated prot zinc finger protein 281	7.6 2.9	? other
50		N47468 D89053	Hs.59757 Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
		AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	7
		AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM
		AL043100	Hs.326190	fatty acid amide hydrolase	5.6	other
55		AA251716	Hs.25227	ESTs	5.8	other
	131283	X80038	Hs.339713	Homo saplens clone F19374 APO E-C2 gene	1.3	other
		AV656017	Hs.184325	CGI-76 protein	5	? TM
		AA505691	Hs.145696	splicing factor (CC1.3) Nilmegen breakage syndrome 1 (nibrin)	1.8 2.6	other
60		AF058696 AW293165	Hs.25812 Hs.143134	ESTs	5.4	other
60	121200	BE269388	Hs.182698	mitochondrial ribosomai protein L20	5.3	other
		BE259110	Hs.279836	HSPC166 protein	2.2	other
		NM_012247	Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human:		2
•	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4	other
65		BE297567	Hs.27047	hypothetical protein FLJ20392	1.7	other
		AA992841	Hs.27263	KIAA1458 protein	2	other
	131501	AV661958	Hs.8207	GK001 protein	2.6	other

	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone C	2	other
	131528	AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
	131532	BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
	131543	AW966881	Hs.41639	programmed cell death 2	2.2	other
5	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
_	131562	NM_003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, done Pt.	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5	other
		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10		R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3	other
		AB037791	Hs.29716	hypothetical protein FLJ10980	2.2	TM
•		AW410601	Hs.30026	HSPC182 protein	3	other
		AW960597	Hs.30164	ESTs	1.3	other
		Al218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracil-DNA glycosytase 2	2.8	other
		BE559681	Hs.30736	KIAA0124 protein	5.6	?
		AA642831	Hs.31016	nutolius DNA binding protein	2.9	?
		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
		AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20		A1878932	Hs.317	topoisomerase (DNA) I	3.4	other
LU		AA382590	Hs.170980	KIAA0948 protein	25.5	other
		D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8	TM
		BE501849	Hs.32317	high-mobility group 20B	1.5	other
25		X86098	Hs.301449	adenovirus 5 E1A binding protein	42	other
43		U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
		U28838	Hs.32935	TATA box binding protein (TBP)-associate	3.5	other
		Al2513.17	Hs.33184	ESTs	5.2	TM
		AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30		BE502341	Hs.3402	ESTs	13.7	other
50		AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
		AA179298	Hs.3439	stomatin-like 2	11.3	other
		AW207440	Hs.185973	degenerative spermatocyte (hornolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTs	5.2	TM
33		AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	· other
		BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
		BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
		AA355113	Hs.35380	x 001 protein	1.5	7
40		AK000046	Hs.267448	hypothetical protein FL120039	2.3	other
,,		W79283	Hs.35962	ESTs	1.4	other
		BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	TM
		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS.TM
15		H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, p	3.3	TM
		BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
		NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
		BE171921	Hs.3991	EST8	1.5	other
50		AV646076	Hs.39959	ESTs	5.8	TM
50		AW960474	Hs.40289	ESTs	1.7	other
		AA857025	Hs.8878	kinesin-like 1	3.4	other
		NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
		R42432	Hs.4212	ESTs	22	other
55		BE206939	Hs.42287	E2F transcription factor 6	1.5	other
55		AV658411	Hs.42656	KIAA1681 protein	5.7	other
		AI566004	Hs.141269	Homo saplens cDNA: FLJ21550 fls, clone C	2.1	other
		AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
		AA227710	Hs.43658	DKFZP586L151 protein	10	other
60		AA653507	Hs.285711	hypothetical protein FLJ13089	2	other
50		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2	other
		AB023191	Hs.44131	KIAA0974 protein	2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
		AW405882	Hs.44205	consistin	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
55	132370	AW572805	Hs.46645	ESTs	28.3	?
	132374	AF155582	Hs.46744	core1 UDP-galactose:N-acety/galactosamin	1.9	other
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			g		

	131511	AA732153	Hs.27865	Homo saplens cDNA: FLJ21333 ffs, clone C	2	other
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
		BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
	131543	AW966881	Hs.41639	programmed cell death 2	2.2	other
5	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
		NM_003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo saplens cDNA FLJ11041 fis, clone Pl.	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5	other
10		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10		R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3 2.2	other TM
-		AB037791` AW410601	Hs.29716 Hs.30026	hypothetical protein FLJ10980 HSPC182 protein	3	other
		AW960597	Hs.30164	ESTs	1.3	other
		Al218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracii-DNA glycosylase 2	2.8	other
		BE559681	Hs.30736	KIAA0124 protein	5.6	?
	131714	AA642831	Hs.31016	putative DNA binding protein	2.9	?
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
		AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20		A1878932	Hs.317	topoisomerase (DNA) I	3.4	other
		AA382590	Hs.170980	KIAA0948 protein	25.5	other
		D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8 1.5	TM other
25		BE501849 X86098	Hs.32317 Hs.301449	high-mobility group 208 adenovirus 5 E1A binding protein	4.2	other
23		U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
		U28838	Hs.32935	TATA box binding protein (TBP)-associate	3.5	other
		Al251317	Hs.33184	ESTs	5.2	TM
		AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30	131885	BE502341	Hs.3402	ESTs	13.7	other
	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
•		AA179298	Hs.3439	stomatin-like 2	11.3	other
25		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTS	5.2 2.8	TM - other
		AF151048 BE541211	Hs.183180 Hs.34804	anaphase promoting complex subunit 11 (y Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
		BE252983	Hs.35088	ubiquitin specific protease 1	2.4	other
		AA355113	Hs.35380	x 001 protein	1.5	7
40		AK000046	Hs.267448	hypothetical protein FLJ20039	2.3	other
		W79283	Hs.35962	ESTs	1.4	other
	131971	BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	TM
A.E		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	3
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
		H56995 BE266155	Hs.37372 Hs.3832	Homo sapiens DNA binding peptide mRNA, p clathrin-associated protein AP47	3.3 1.5	TM other
		NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
		BE171921	Hs.3991	ESTS	1.5	other
50		AV646076	Hs.39959	ESTs	5.8	TM
-	132116	AW960474	Hs.40289	ESTs	1.7	other
	132176	AA857025	Hs.8878	kinesin-like 1	3.4	other
	132180	NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
		R42432	Hs.4212	ESTs	2.2	other
55		BE206939	Hs.42287	E2F transcription factor 6	1.5	other
		AV658411	Hs.42656	KIAA1681 protein	5.7	other
		Al566004 AA301228	Hs.141269	Homo saplens cDNA: FLJ21550 fis, clone C hypothetical protein FLJ12890	2.1 1.5	other other
	,	AA227710	Hs.43299 Hs.43658	DKFZP586L151 protein	10	other
60		AA653507	Hs.285711	hypothetical protein FLJ13089	2	other
00		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2	other
		AB023191	Hs.44131	KIAA0974 protein	2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
	132299	AW405882	Hs.44205	confistation	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
		AW572805	Hs.46645	ESTs	28.3	?
	132374	AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other

		•		•		_		
	133174	AA431620	Hs.324178	hypothetical protein MGC2745	2.7	other		
		AW955632	Hs.66666	ESTs, Weakly similar to \$19560 proline-r	9.3	other		
	133177	X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM		
	133208	A)801777	Hs.6774	ESTs	5.5	TM		
5	133226	AW954569	Hs.296287	Homo saplens, Similar to bromodomaln-con	2.7	other ?		
		AI492924	Hs.6831	golgi phosphoprotein 1	1.7	r other		
	133254	Al567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other		
	133268	AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2	other		
		BE297855	Hs.69855	NRAS-related gene	1.2 1.7	TM		
10		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	11.1	?		
		T79526 `	Hs.179516	Integral type I protein	29	other		
		AL390127	Hs.7104	Kruppel-like factor 13	2.5	?		
		BE257758	Hs.71475	acid cluster protein 33	1.5	other		
1.5		Al016521	Hs.71816	v-aid murine thyrnoma viral oncogene homo non-metastatic cells 5, protein expresse	2.1	other		
15		AA292811	Hs.72050	KIAA0539 gene product	1.3	other		
		AF231919	Hs.18759	DKFZP564l1922 protein	22	other		
		AF245505	Hs.72157 Hs.72660	phosphatidylserine receptor	5.7	TM		
		A1950382	Hs.727	inhibin, beta A (activin A, activin AB a	25.5	other		
20		AW103364 AA305127	Hs.237225	hypothetical protein HT023	3.3	other		
20		AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other		
		NM_002759	Hs.274382	protein kinase, interferon-Inducible dou	4.1	other		
		Al659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other		
		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM		
25		W45623	Hs.74571	ADP-ribosylation factor 1	4	?		
2.5		AU077073	Hs.108327	damage-specific DNA binding protein 1 (1	1.8	?		
		AU077050	Hs.75066	translin	1.5	other		
		X75346	Hs.75074	mitogen-activated protein kinase-activat	3.5	TM		
	133582	BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM		
30	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	TM other		
	133595	AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other		
		NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1 13.5	other		
		NM_004893	Hs.75258	H2A histone family, member Y	2.2	other		
~ =		NM_002047	Hs.75280	glycyl-tRNA synthetase	1.8	other		
35		NM_000401	Hs.75334	exostoses (multiple) 2	2	other	,	
		U25849	Hs.75393	acid phosphatase 1, soluble mitochondrial ribosomal protein L19	2.8	other		
		AV661185	Hs.75574 Hs.75737	pericentriolar material 1	6.8	other		
		L27841 AW969976	Hs.279009	matrix Gla protein	2.5	other		
40		AW402048.c		Hs.334787	Homo s	aplens, Similar to likely ortholog	3.1	TM
40		T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.4	?		
		BE271766	Hs.181357	taminin receptor 1 (67kD, ribosomal prot	5.4	other		
		M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	5 ,	other		
		AA557660	Hs.76152	decorin	3.8 🐔	other		
45		AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1 ∜	?		
		D50525	Hs.699	pepiidylprotyl isomerase B (cyclophilin	9.7	?		
	133842	AW797468	Hs.285013	putative human HLA class II associated p	2.4	other		
	133845	AA147026	Hs.76704	ESTS	2.5	other		
		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5	other ?		
50		AW340125	Hs.76989	KIAA0097 gene product	2.5 2.1	other		
		AB012193	Hs.183874	culin 4A	2.1	TM		
	133922	U30825	Hs.77608	splicing factor, arginine/serine-rich 9 vesicle docking protein p115	1.8	SS,		
	133924	D86326	Hs.325948	SMC1 (structural maintenance of chromoso	2	?		
e e	133929	NM_006306	Hs.211602	gamma-glutarnyi carboxytase	26	other		
55	,	L17128	Hs.77719	adantor-related protein complex 3, mu 2	2.9	other		
		BE244332	Hs.77770	solicing factor 3a, subunit 3, 60kD	10.4	other		
		X81789 S A1908165	Hs.77897 Hs.169946	GATA-binding protein 3 (T-cell receptor	1.9	other		
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6	SS,		
60		7 Al824113	Hs.78281	regulator of G-protein signalling 12	13	other		
w		AB016092	Hs.197114	RNA binding protein; AT-rich element bin	8.8	other		
		5 D31764	Hs.278569	sorting nexth 17	1.5	SS,		
		NM_003590		cullin 3	8.3	other		
		U41060	Hs.79136	LIV-1 protein, estrogen regulated	2.7	other		
65	13412	9 NM_014742	Hs.79305	KIAA(1255 gene product	4.2	other		
	13413	4 H86504	Hs.173328	protein phosphatase 2, regulatory subuni	1.7	other		
	13420	0 BE559598	Hs.197803	KIAA0160 protein	2.6	other		
				170				

	****			* 1		
	134206	AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
	134219	NM_000402	Hs.80206	glucose-6-phosphate dehydrogenase	1.9	other
		BE300078	Hs.80449	Homo sepiens, clone IMAGE:3535294, mRNA,	10.3	SS,
						•
_	134275	A1878910	Hs.3688	cisplatin resistance-associated overexpr	2.5	other
5	134292	Al906291	Hs.81234	immunoglobulin superfamily, member 3	1.3	TM
•		AW502505	Hs.81360	Homo saplens cDNA: FLJ21927 fis, clone H	1.6	TM
	134305	U61397	Hs.81424	ublquitin-like 1 (sentrin)	2.1	TM
	13/33/	AB029023	Hs.179946	KIAA1100 protein	5.3	?
						TM
	134326	AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (vers	2.5	
10	134329	N92036 .	Hs.81848	RAD21 (S. pombe) homolog	3.9	?
			Hs.81964	SEC24 (S. cerevisiae) related gene famili	2.4	TM
		NM_004922				
	134348	AW291946	Hs.82065	Interlaukin 6 signal transducer (gp130,	6.8	TM
	134367	AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	2.3	TM
					5.5	other
	1343/6	X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46		
15	134379	AW362124	Hs.323193	hypothetical protein MGC3222	5.9	TM
		AI589941	Hs.8254	Homo sapiens, Similar to tumor different	2.2	other
	134391	AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	2.1	other
	134395	AA456539	Hs.8262	lysosomal	2.3	other
					72.9	other
	134405	AW067903	Hs.82772	cottagen, type XI, alpha 1		
20	134411	BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium bindin	4.4	other
		AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	2.3	other
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.8	?
	134424	Z44190	Hs.83023	peroxisomal biogenesis factor 11B	2.4	other
				KIAA0252 protein	2.9	other
~~		AA112036	Hs.83419			
25	134447	M58603	Hs.83428	nuclear factor of kappa light polypeptid	6.7	other
	134470	X54942	Hs.83758	CDC28 protein kinase 2	2.4	other
					6.3	?
		NM_005000	Hs.83916	Empirically selected from AFFX single pr		
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	1.9	other
	124409	AW246273	Hs.84131	threonyl-tRNA synthetase	1.8	other
20						
30	134513	AA425473	Hs.84429	KIAA0971 protein	1.4	other
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	1.4	other
		BE091005	Hs.74861	activated RNA polymerase II transcriptio	5.6	other
	• • • • • • • • • • • • • • • • • • • •					
	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.8	?
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	1.7	other
25					1.7	TM
35		AA927177	Hs.86041	CGG triplet repeat binding protein 1		
	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.1	other
		AF035119	Hs.8700	deleted in liver cancer 1	1.3	other
						?
	134632	X78520	Hs.174139	chloride channel 3	2.1	-
	134654	AK001741	Hs.8739	hypothetical protein IRJ10879	2.3	other
40		BE391929	Hs.8752	transmembrane protein 4	4	other
40					-	
	134687	U62317	Hs.88251	aryisulfatase A	6.2	other
	134692	NM_003474	Hs.8850	a disintegrin and metalloproteinase doma	2	other
					1.3	SS,
		BE161887	Hs.88799	anaphase-promoting complex subunit 10		
	134714	Y14768	Hs.890	lysosomai	7.2	7
45		AA852985	Hs.89232	chromobox homolog 5 (Drosophila HP1 alph	3.2	other
43						other
	134/22	AF129536	Hs.284226	F-box only protein 6	2.5	
	134746	X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell	5	other
		AW630803	Hs.89497	lamin B1	6.1	other
	134790	BE002798	Hs.287850	Integral membrane protein 1	5.6	TM
50	134834	AW451370	Hs.8991	adaptor-related protein complex 1, gamma	5.3	other
-					9.1	other
		AJ701162	Hs.90207	hypothetical protein MGC11138		
	134853	BE268326	Hs.90280	5-aminolmidazole-4-carboxamide ribonucle	2.4	other
	134880	A)879195	Hs.90606	15 kDa selenoprotein	2.7	other
				PRO1073 protein	1.5	other
	134925	AW885909	Hs.6975			
55	134955	AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), cat	4.9	other
			Hs.286049	phosphoserine aminotransferase	2	other
		Al097346				
	134975	R50333	Hs.92186	Leman colled-coil protein	2.6	TM
		AB037835	Hs.92991	KIAA1414 protein	1.4	7
				glycerol-3-phosphate dehydrogenase 2 (mi	1.6	?
		NM_000408	Hs.93201			
60	135032	AW301984	Hs.173685	hypothetical protein FLJ12619	1.4	other
		AW503733	Hs.9414	KIAA1488 protein	1.8	other
	135083	AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5	other
		AF027219	Hs.9443	zinc finger protein 202	1.5	TM
			Hs.132390	zinc finger protein 36 (KOX 18)	2.1	other
		AA081258				
65	135153	A1093155	Hs.95420	JM27 protein	4.4	?
		BE250865	Hs.279529	px19-like protein	14.9	?
				The state of the s	1.3	other
	135155	AA477514	Hs.96247	translin-associated factor X		-0101

	135207 N	26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
	135214 17	78802	Hs.96560	hypothetical protein FLJ11656	6.2	other
	135243 BI	E463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
_	135245 AI	028767	Hs.262603	ESTs .	12.2	TM
5	135257 A		Hs.97255	ESTs, Wealdy similar to A46010 X-linked	7.7	TM
	135263 AI		Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	other
	135274 A		Hs.112017	GE36 gene	4.2	SS,
	135294 A		Hs.9800	protein kinase Njmu-R1	1.2 4.9	other other
10	135295 Al		Hs.98006	ESTS	4.9 5.9	?
10	135307 AI		Hs.98368 Hs.98614	ESTs, Wealdy similar to KIAA0822 protein ribosome binding protein 1 (dog 180kD ho	12.3	TM
	135321 Al 135354 A		Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
	135361 A		Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
	135389 U		Hs.99872	fetal Alzheimer antigen	1.9	other
15	135400 X		Hs.99915	androgen receptor (dihydrotestosterone r	13.9	TM
10	302256 A		Hs.171595	HIV TAT specific factor 1	1.6	other
	302276 A		Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
	303135 A		Hs.279474	HSPC070 protein	2.2	TM
	303686 A	K000714	Hs.109441	MSTP033 protein	1.4	SS,
20	310085 R	43191	Hs.101248	Homo saplens clone IMAGE:32553, mRNA seq	5.2	other
	315518 A	A808229	Hs.167771	ESTs	2.3	?
	317781 N	_	Hs.42650	ZW10 Interactor	2.9	?
	320836 A		Hs.197289	rab3 GTPase-activating protein, non-cata	2	other
25	321114 A		Hs.78979	Golgi apparatus protein 1	5.6 1.4	SS, ?
25	322221 N		Hs.179662	nucleosome assembly protein 1-like 1	1.3	other
	322474 A		Hs.29494 Hs.177507	PRO1912 protein	2.9	SS,
	322556 B 323541 A		Hs.104613	hypothetical protein RP42 homolog	1.6	other
	407827 B		Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.8	other
30	408196 A		Hs.43627	SRY (sex determining region Y)-box 22	1.6	other
-	408813 A		Hs.48295	RNA helicase family	6.2	other
	409176 R		Hs.101617	ESTs, Weakly similar to T32527 hypotheli	5.7	other
	409487 H			gbcyn57a05.r1 Soares adult brain N2b5HB5	2.7	other
	413670 A	B000115	Hs.75470	hypothetical protein, expressed in osteo	2.6	.?.
35	414108 A	1267592	Hs.75761	SFRS protein kinase 1	2.4	TM
	414846 A	W304454	Hs.77495	UBX domain-containing 1	2.4	other
	416040 A		Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone	2.3	other
	416980 A		Hs.80684	high-mobility group (nonhistone chromoso	4.2 23.6	TM other
40	417378 R		Hs.82037	TATA box binding protein (TBP)-associate	5.8	other
40	418283 S		Hs.83942 Hs.85273	cathepsin K (pycnodysostosis) retinoblastoma-binding protein 6	1.3	other
	420269 U	M_006910	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
	420802 U		Hs.1334	v-myb avian myelobiasiosis viral oncogen	2.3	?
	421225 A		Hs.102696	MCT-1 protein	1.6	?
45	421642 A		Hs.106346	retinoic acid repressible protein	3.5	othe
	421828 A		Hs.279789	histone deacetylase 3	5	othe
	421983 A	1252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin	3.1	TM
	422052 A	A302744	Hs.104518	ESTs	1.9	TM
		IM_014320	Hs.111029	putative heme-binding protein	2.4	othe
50	423750 A		Hs.298229	prefoldin 2	4.2	?
	424001 W		Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1 2.3	? other
	425182 A		Hs.155040	zinc finger protein 217	3.5	othe
	425284 A 426372 B		Hs.155489 Hs.169531	NS1-associated protein 1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.9	?
55	428049 A		Hs.182238	GW128 protein	7.6	ż
33	428477 A		Hs.11482	splicing factor, arginine/serine-rich 11	1.7	othe
	437562 A		Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.4	othe
	438449 A		Hs.6216	Homo saplens hepatocellular carcinoma-as	3.8	othe
	441560 F		Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	othe
60	445580 A		Hs.12912	slo1 (S. pombe) homolog	2	TM
	446999 A		Hs.334822	hypothetical protein MGC4485	7.6	othe
	447111 A	J017574	Hs.17409	cysteine-rich protein 1 (intestinal)	2.2	other
	447778 B		Hs.71190	ESTs, Wealdy similar to \$16506 hypotheti	29	other
		IM_003677	Hs.22393	density-regulated protein	1.8	othe
65	449687 V		Hs.331328	intermediate filament protein syncollin	5.9 5.7	othe
	450701 H		Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.7 1.4	othe othe
	450703 A	AU11202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.4	Oute

	452461 N7822	23	Hs.108106	transcription factor	4.8	7
	452511 BE408		Hs.285165	Homo sapiens cONA FLJ20845 fis, clone AD	2.9	other
	453157 AF077		Hs.31989	DXFZP586G1722 protein	121	SS,TM
	453658 BE541	1906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other
5	100685 AA328	3229	Hs.184582	ribosomal protein L24	1.8	TM
	100690 AA380	3256	Hs.1657	estrogen receptor 1	1.6	other
	100833 AF135	5168	Hs.108802	N-ethylmalelmide-sensitive factor	1.3	other
	100850 AA836	6472	Hs.297939	cathepsin B	1.7	7
	101161 NM_0		Hs.37044	pertpherin	16.9	other
10	102481 U5036			gitd-luman calcium, calmodulin-dependent p	3.2	other
	102831 AA26		Hs.80917	adaptor-related protein complex 3, sigma	2	? other
•	103549 BE27		Hs.78793	protein kinase C, zeta	8 1.8	
	103749 AL138		Hs.8768	hypothetical protein FLJ10849	2	other ?
1.5	104331 AB04		Hs.279862	cdk inhibitor p21 binding protein hypothetical protein FLJ12748	21	other
15	104532 Al498		Hs.203013		1,2	other
	104563 AL117		Hs.306189	DKFZP434F1735 protein qbcz12a02.s1 Soares_pregnant_uterus_NbH	: 7	?
	105032 AA12 105039 AA90		Hs.36475	ESTs	2.6	'n
	106531 AA45		Hs.8832	ESTs	1.6	other
20	106977 AL043		Hs.50421	KIAA0203 gene product	4.9	other
20	107298 N956		Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
	108717 AA12		Hs.70811	hypothetical protein FLJ20516	1.3	other
	110018 AW57		Hs.104557	hypothetical protein FLJ10697	5.3	TM
	110330 Al288		Hs.16621	DKFZP4341116 protein	6.3	other
25	111391 NM_0	03896	Hs.225939	statyttransferase 9 (CMP-NeuActactosylc	5.1	SS,
	111392 W463	42	Hs.325081	Homo sepiens, done IMAGE:3659680, mRNA,	8.4	other
	113554 AW50	3990	Hs.142442	HP1-BP74	3.7	TM
	113722 AV65		Hs.184411	albumin	1.3	other
20	115008 AK00		Hs.87889	helicase-moi	2	other
30	115062 AA25		Hs.154103	LIM protein (similar to rat protein kina	1.5 2.8	other
	115121 Al634		Hs.88155	ESTs	5.8	TM
	117881 AF16		Hs.260622	butyrate-induced transcript 1 fibronectin 1	5.7	other
	119075 M109 119615 AL03		Hs.287820 Hs.75875	ubiquilin-conjugating enzyme E2 variant	1.3	other
35	120253 AA13		Hs.326401	fibroblast growth factor 12B	38.9	other
JJ	125006 BE06		Hs.145696	splicing factor (CC1.3)	2.9	?
	127609 X800		Hs.530	collagen, type IV, alpha 3 (Goodpasture	1.8	other
	128868 AA41		Hs.106730	chromosome 22 open reading frame 3	3	other
	128891 F348		Hs.292457	Homo saplens, clone MGC:16362, mRNA, com	13.3	other
40	128959 Al580	1127	Hs.107381	hypothetical protein FLJ11200	10.9	other
	129209 R626	76	Hs.17820	Rho-associated, coiled-coll containing p	2.4	other
	129449 Al096	988	Hs.111554	ADP-ribosylation factor-like 7	8.2	TM
	129453 AW97		Hs.111632	Lsm3 protein	3.3	?
	129629 AKDO		Hs.11747	hypothetical protein FLJ20391	3.9	other
45	129917 M307		Hs.278540	protein phosphatase 3 (formerly 2B), reg	5.3 4.6	TM other
	129922 AF04		Hs.13386	gamma-tubulin complex protein 2	4.0	SS.
	129989 AB01		Hs.247433	activating transcription factor 6 ubiquith-conjugating enzyme E2G 2 (homo	4.6	other
	130182 BE26		Hs.192853 Hs.155103	eukaryotic translation initiation factor	11	other
50	130365 W561 130471 AL12		Hs.183706	adducin 1 (alpha)	2.7	other
50	130542 U646		Hs.179825	RAN binding protein 2-like 1	7.9	other
	130586 AB00		Hs.16349	KIAA0431 protein	5.6	TM
	130768 AF25		Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	other
	130992 BE39		Hs.74316	desmonlakin (DPI, DPII)	1.8	TM
55	131047 H232		Hs.22481	ESTs, Moderately similar to A46010 X-lin	1.7	?
	131135 NM_0	016569	Hs.267182	TBX3-iso protein	3.3	TM
	131339 AF05	8696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
	131760 X767	32	Hs.3164	nucleobindin 2	2.9	TM
	131774 BE26	7158	Hs.169474	DKFZP586J0119 protein	5.6	other
60	131853 Al681	1917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
	131881 AW3	61018	Hs.3383	upstream regulatory element binding prot	3.2	TM
	131887 W170	D64	Hs.332848	SW/SNF related, matrix associated, acti	3.2	other
	132031 AF19	G844	Hs.3758	COP9 complex subunit 7a	5.9	?
	132192 AA20	J6153	Hs.4209	mitochondrial ribosomal protein L37	2.2 7.9	TM ?
65	132203 NM_I	UU4/82	Hs.194714	synaptosomal-associated protein, 29kD	4.3	other
	132240 AB01 132348 AW0	はる之年 67709	Hs.42676	KIAA0781 protein heterogeneous nuclear ribonucleoprotein	4.3 12.5	other
-	132340 AWU	01/00	Hs.170311	ISSEMBLEORS INCIDES INCIDENCE CHARRIES	12.0	00104

	132528 T78736	Hs.50758	SMC4 (structural maintenance of chromoso	7.4	?	
	132571 AW674699	Hs.5169	suppressor of G2 allele of SKP1, S. cere	6.9	other	
	132726 N52298	Hs.55608	hypothetical protein MGC955	14,3	?	
_	132863 BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
5	133016 AI439688	Hs.6289	hypothetical protein FLJ20886	4.4	other	
·	133053 Al065016	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	1.8	SS,TM	
	133197 Al275243	Hs. 180201	hypothetical protein FLJ20671	1.8	other	
	133240 AK001489	Hs.242894	ADP-ribosylation factor-like 1	1.8	other	
	133266 Al160873	Hs.69233	zinc finger protein	16.1	other	
10	133285 M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
	133383 BE313555	Hs.7252	KIAA1224 protein	1.5	7	
	133540 AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
	133784 BE622743	Hs.301064	arfaptin 1	12.1	other	
• •	133791 M34338	Hs.76244	spermidine synthase	9.7	other	
15	133850 W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2	SS,	
	133859 U86782	Hs.178761	26S proteasome associated pad1 homolog	2.2	other	
	133881 U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1	other	
	134208 NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
20	134403 AA334551	Hs.82767	sperm specific antigen 2	1.4 1.4	other other	
20	134724 AF045239	Hs.321576	ring finger protein 22	2.6	other	
	134806 AD001528	Hs.89718	spermine synthase	13.3	other	
	134859 D26488	Hs.90315	KIAA0007 protein	3.1	other	
	135193 X95525	Hs.96103	TATA box binding protein (TBP)-associate	1.6	?	
25	AA243007		ESTs ESTs	2.5	SS,	
23	T70541		Human stromelysin-3 mRNA	4.5	other	
	X57766		Homo sapiens clone 23592 mRNA sequence	3.1	other	
	S66431 AA453483		ESTs	4.6	TM	
	R63925		ESTs	1.4	other	
30	AA173417		ESTs	1.9	other	
50	AA280588		ESTs	2.2	other	
	AA504223		ESTs Highly similar to CHROMOSOME	2.4	other	
	AA609996		ESTs Highly similar to Surf-4 protein [M.musculus]	5.5	?	
	F02907	•	ESTs	2.3	TM	
35	AA480103		ESTs Weakly similar to IIII ALU SUBFAMILY J	2.8	TM	
	AA024664		Human NADH:ublquinone oxidoreductase subunit	6.2	other	
	AA251776		ESTs	2.3	other	
	AA399047		ESTs	2.4	other	
	N34059		EST - RC_N34059	3.3	other	
40	U95367		Human GABA-A receptor pi subunit mRNA complet		1.7	TM
	AA490899	•	EST3	3.3	other	
	T54762		ESTs	2.9	?	
	Z41963	•	Homo saplens HP protein (HP) mRNA complete cds		?	
4.5	AA521186		ESTs	1.6	TM	
45	AA400195		ESTS	1.3	other	-46
	AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLASI		2.5	other TM
	AA099589		Homo saplens mRNA for GDP dissociation inhibitor ESTs Wealthy similar to PROCOLLAGEN ALPHA 2		1.6 2.6	TM
	W85712			3.7	other	1 141
50	W45728		ESTs Highly similar to HETEROGENEOUS Human tubulin-folding cofactor E mRNA complete of		2.1	other
30	U61232		ESTs	5.3	other	Olica
	AA425154		ESTs Wealthy similar to ZK1058.4 [C.elegans]	2.6	SS,TM	
	T39176 AA496000		ESTs Treaty shipe to 2K 1000,4 [0.000] also	1.9	SS,	
•	1400450		EST - RC_W38150	1.7	?	
55	W38150 T96595		EST - RC_T96595	1.8	TM	
33	AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	?
	R46025		ESTs	2.8	SS.	•
	AA233177		ESTs	2	other	
	AA338760		ESTs	1.3	?	
60	AA412106		ESTs	6.2	other	
00	L47276		EST - L47276	3.4	other	
	D82307		ESTs Weakly similar to TH1 protein [D.melanogaste		11.4	other
	AA293568		ESTs	1.5	other	
	R37778		ESTs	2.4	other	
65	AA250843		Interferon regulatory factor 5	14.6	?	
	W49521		Human prolyl 4-hydroxylase alpha (II) subunit	6.5	?	
	D80000		Human mRNA for KIAA0178 gene partial cds	2	other	

	R99978	ESTs Weakly similar to line-1 protein ORF2 [H.saplens	} 6.1	7
	AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRet 5.		
	Z38501	ESTs Weakly similar to PROBABLE E5 1.	4 other	
	U37547	Human IAP homotog B (MIHB) mRNA complete cds 3.	2 other	
5	AA479961	ESTs 1.		
•	X57579	Inhibin beta A (activin A activin AB alpha polypeptide)	15.8	7
	AA449071	ESTs 1.	3 TM	
	N51855	ESTs Moderately similar to NAD(+) ADP- 1.		
	AA421213	ESTs Weakly similar to F28F8.3 [C.elegans] 3.		
10	AA355201	ESTs 1.		
10	N78717		5 7	
•	N73808	ESTs 5	7	
	U86782	Human 26S proteasome-associated pad1 2.	2 other	
	AA234817	ESTs 1.		
15	D13666	Homo saciens mRNA for esteablast specific 7.	-	
13	AA236177	ESTs 7.		
	U50648	Protein kinase interferon-inducible double 4.		
	M28211	Homo sapiens GTP-binding protein (RAB4) 2.		
	M20211 AA446949	ESTs 2.		
20	W03007	ESTS 1.	_	
20	W61011	ESTs 1.		
	W87544	ESTs 1.		
		Neuroblastoma RAS viral (v-ras) oncogene homolog 1.		
	X02751	YY1 transcription factor 1.		
25	Z14077	ESTs 1.	_	
25	Z38839	ESTS 1.		
	AA410894	ESTs Highly similar to probable chloride channel 3 [H.s.		other
	AA504499	COLS LIGHT SHINKE IN DIODRING CHARGE CHARGES I I W	ω <i>μ 1-</i> 0	00101

TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

: Gene cluster number

Accession:

Genbank accession numbers

15

20

Pkey CAT number

Accession

102481 31281_-28

U50360

105032 genbank_AA127818

AA127818

409487 1134778_1

H19886 AW402806 T10231

TABLE 8: Figure 8 from BRCA 001-1 US

Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue. Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10							
	Pkey:		Uniqu	e Eos probe	set identifier number		
	ExAccn:		Exem	plar Access	ion number, Genbank accession number		
	Unigene			ene number	·		
	Unigene		Unine	ene gene title	}		
15	R1:				normal body tissue		
	R2:			Ratio of tun	nor to normal breast tissue		
	Pkey	ExAccn	٠.	UnigeneiD	Unigene Title	R1	R2
20	400075	454500	•	11- 004400		1	3.8
20		AF1523			protocadherin gamma subfamily B, 4	1.7	5.3
		AV6522	49		polymerase (DNA directed), beta	0.8	4.8
		D38500	04		postmetotic segregation increased 2-like S100 calcium-binding protein A11 (calgiz	3.2	2.3
		BE16000 Al90711		Hs.71465	squalene epoxidase	3.3	1.4
25		X51501	4	Hs.99949	protactin-induced protein	11.9	0.4
23		AA0195	24	Hs.301946	•	3.8	1.2
		X77343	21		transcription factor AP-2 alpha (activat	9.4	9.4
		X02761			fibronectin 1	3.4	7.8
		AA3832	ce	Hs.1657	estrogen receptor 1	4.4	4.4
30		U01351	30	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9
30		K01160		IS.13112	NM_002122:Homo seplens major histocom		4
		AA3825	24	Hs.250959		0.8	4.1
		NM 002		Hs.78944	regulator of G-protein signalling 2, 24k	1.2	12
		NM_006		Hs.37044	peripherin	3.1	1.1
35		L22524	202	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	4.4	0.6
33		Al18622	0	Hs.83164	collagen, type XV, alpha 1	3.1	3.4
		AW4683	-		S100 calcium-binding protein A8 (calgran	0.9	4.2
		M21305		110.100000	ghd-luman alpha salelije and satellije 3	29.9	0.3
		AA3101		He 160248	cylochrome c	0.8	4.9
40		M33552		Hs.56729	lysosomal	1	5.9
-10		BE5616			H2A histone family, member Z	2.8	4
		M55998	••	10.11010	gbd-luman alpha-1 collagen type I gene, 3	3.1	1.7
		NM_002	291	Hs.82124	laminin, beta 1	1.5	4.1
		AA3506		Hs.83347	angio-associated, migratory cell protein	3.1	1.4
45		AF1122			putative Rab5-interacting protein	1.3	6.9
		AL0363		Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9
		AA3345		Hs.79914	kumican	2.2	3.8
		AF0152		Hs.46452	mammaglobin 1	4.2	0.7
		NM 003			Microfibril-associated glycoprotein-2	1.1	4.2
50		NM_001		Hs.2359	dual specificity phosphatase 4	4.5	0.5
		U96759		Hs.198307		1.4	4.2
	102541	Al37995	4	Hs.79025	KIAA0096 protein	0.9	3.9
	102827	BE2445	B8	Hs.6458	chaperonin containing TCP1, subunit 2 (b	1.5	10.9
	102962	R50032		Hs.159263	collagen, type VI, alpha 2	2.2	6.2
55		AW2935	42	Hs.75309	eulraryotic translation elongation factor	5.6	5.7
		X63629		Hs.2877	cadherin 3, type 1, P-cadherin (placenta	3.7	0.5
		X69089		Hs.79227	myomesin (M-protein) 2 (165kD)	1.3	4
		D38616		Hs.54941	phosphorylase kinase, alpha 2 (liver)	1.3	3.8
		X83492		Hs.82359	turnor necrosis factor receptor superfami	0.8	4.6
60		BE5367	00	Hs.4888	seryl-IRNA synthetase	0.9	8
•		T34708		Hs.272927		1.1	5.1
		Y00815		Hs.75216	protein tyrosine phosphatase, receptor t	3.7	1.2
		Z14244		Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4
	-				•		

	103658	NM_000088	Hs.172928	collagen, type I, alpha 1	3.2	3	
		AA084874		gb:zn13e04.r1 Stratagene hNT neuron (937	0.9	10	
		H24185	Hs.92918		1.9	15.9	
5		AA095971 BE439604		Homo saplens cDNA: FLI22463 fs, clone H ATPase, H+ transporting, lysosomal (vacu	1.2 1.4	3.9 3.9	
,		AW130242		hypothetical protein FKSG44	1.6	4.1	
		AK001913	Hs.7100	hypothetical protein	1.5	4.3	
		AF183810		opposite strand to trichorhinophalangeal	7	7	
		AB040927	Hs.301804	KIAA1494 protein	2	4.6	
10		AB002347		KIAA0349 protein	0.7	4.5	
		AW583693		N-terminal acetyltransferase complex and	3.3	3.3	
		AW365522 AW804296	Hs.103657 Hs.9950	hypothetical protein PRO2219 Sec61 gamma	2.3 3.1	4.2 7	
		AF283775		x 001 protein	4	1.3	
15	104432		Hs.99949		3.8	0.6	
		AW966728	Hs.54642		0.8	6.7	
	104479	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H092	4 (f	1.7	4.8
		W94824		RIKEN cDNA 2010100012 gene	2	7.5	
20		AW630488		professe, serine, 23	1.9	7.4	
20		AF123303	Hs.24713		1.1 1.2	6.3 4	
		R82252 AW270555		protein kinase (cAMP-dependent, catalyti hypothetical protein	1.4	3.9	
		AAS60961		zinc (inger protein 83 (HPF1)	1.5	4.2	
		AA305351		uncharacterized hypothalamus protein HAR	1.1	4.1	
25	104849	A1279065		ribosomal protein S6	1.3	4.6	
		AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
		W70164	Hs.20107		0.8	4.2	E 4
		AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RI		1.7	5.1
30		W03831 W44626	Hs.20597 Hs.30627	host cell factor homolog ESTs	0.8 0.7	5.4 6.8	
50		AW955089		Novel human gene mapping to chomosome 2		1 3.9	
		BE298808	Hs.33363		3.3	3.3	
		AW076098	Hs.74316	desmoplakin (DPI, DPII)	1.2	3.7	
0.5		AB029020		KIAA1097 protein	1.1	5.5	
35 `		Al392640	Hs.18272		3.2	1.4	
		BE613061		Homo sapiens, Similar to RIKEN cDNA 0610		11.4 7.2	
		N39760 BE410438	Hs.8859 Hs.9006	Homo sapiens, Similar to RIKEN cDNA 5830 VAMP (vesicle-associated membrane protei		3.5	
		AF146277		CD2-associated protein	1.2	10	
40		AA313825	Hs.21941		3.6	8.3	
	105182	BE407961	Hs.18271	golgi phosphoprotein 3	1.7	6.8	
		AI554929		ATPase, H+ transporting, lysosomal (vacu	1.1	3.7	
		BE243327		chromosome 22 open reading frame 5	1.5	4	14
45		A1015709 W20027	Hs.23439	Homo sapiens mRNA; cDNA DKFZp586t2022	4.3	1.5 2.9	14
43		W03516	Hs.76698	stress-associated endoplasmic reliculum	1.5	5	
		AA252372	Hs.12144	KIAA1033 protein	1.2	3.6	
		AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fis, clone L.	1.7	15.8	
-0		AI805717		CGI-43 protein	2	4.8	
50		AL037715	Hs.28785		1.3	3.9	
		AB040884		KIAA1451 protein	2.7	11.4	
		AB024334 BE504200	Hs.25001 Hs.30127	tyrosine 3-monooxygenase/tryptophan 5-mo hypothetical protein	1.3 1.7	6.1 4.5	
		AA788948	Hs 16869	ESTs, Moderately similar to CA1C RAT COL		24.6	
55		BE614149		CGI-27 protein	1.8	3.6	
		Al559444	Hs.293960	ESTs	1.9	6.6	
	105831	AA329449	Hs.247302	twisted gastrulation	1.5	4.3	
		AI827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9	
60		BE392914	Hs.30503	Homo sapiens cDNA FLJ11344 fis, done PL		4	
60		AW028485	Hs.26136	hypothetical protein MGC14156 Homo sapiens mRNA; cDNA DKFZp434B092	1.7 n#	7.4 1.2	3.8
		AL137728 AB033075	Hs.12258 Hs.10669	development and differentiation enhancin	ս (։ 1.3	4.6	J.D
		AB030656	Hs.17377	coronin, actin-binding protein, 1C	1.1	5.9	
		A1690586	Hs.29403	hypothetical protein FLJ22060	2	4.6	
65		Al240665	Hs.8895	ESTs	4.1	1.2	
		NM_001329		C-terminal binding protein 2	2.6	7	
	106070	T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	1.4	10.7	

	106083	H62087	Hs.31659	thyroid hormone receptor-associated prot	1.5	3.6	
	106155	AA425414	Hs.33287	nuclear factor VB	5.4	1.2	
	106255	BE613206	Hs.279607	calpastatin	1.8	4	
	106414	BE568205	Hs.28827	miliogen-activated protein kinase kinase	5.1	6.1	
5		AK000274		.HDCMA18P protein	1.2	5.9	
•		AW051564	Hs.28285	patched related protein translocated in	1.8	5.4	
		BE044325		U6 snRNA-associated Sm-like protein	2.3	11.2	
		N88604	Hs.30212	thyrold receptor interacting protein 15	1.2	3.6	
			Hs.5367		0.9	4.4	
10		H09548		ESTs, Weakly similar to 138022 hypotheti			
10		AA459480	Hs.23956	hypothetical protein FLJ20502	1.3	3.6	
		BE387614	Hs.25797	splicing factor 3b, subunit 4, 49kD	1.6	7.3	
		AA741038	Hs.6670	ESTS	1.7	6.1	
	106776	AA206079	Hs.6693	hypothetical protein FLJ20420	1	5.4	
	106866	AA487416	Hs.268231	Homo saplens cDNA: FLJ23111 fls, clone L	1.6	5.4	
15	106868	BE185536	Hs.301183	motecule possessing ankyrin repeats indu	3.3	1.2	
	106887	BE503373	Hs.334335	hypothetical protein FLJ13576	1.4	6.3	
	106940	T85594	Hs.339808	hypothetical protein FLJ10120	3.3	1.8	
	106968	AF216751	Hs.26813	CDA14	3	3	
		BE391904	Hs.12482	glyceronephosphate O-acytransferase	1.7	7.6	
20		BE147611	Hs.6354	stromal cell derived factor receptor 1	1.2	4.3	
20		Al289507		hypothetical protein FLJ23399	1.8	6.5	
		BE172058	Hs.82689		1.2	6.9	
			Hs.22595	hypothetical protein FLJ10637	1.4	3.5	
		BE267795	•		2.6	4.3	
25		AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp			
25		AA011510	Hs.60512	ESTS	1.8	4	
		AA027229	Hs.61329		1.3	3.5	
		AF109219		phosphatidylinositol glycan, class N	1.6	3.5	
		AW368993		Homo saplens clone CDABP0086 mRNA seq		1.8	8.1
		AA291440	Hs.73149	paired box gene 8	1.1	3.5	
30	108081	AA093668	Hs.28578	muscleblind (Drosophila)-like	0.7	5.6	
	108137	Al283611	Hs.263479	ESTs, Weakly similar to HMG1_HUMAN HIG	H	1.2	5.6
	108186	AW068579	Hs.7780	Homo saplens mRNA; cDNA DKFZp564A072	ď)	3.1	6.9
	108215	AJ879238	Hs.299315	collapsin response mediator protein-5; C	1.5	4.6	
	108297	AA333660	Hs.71331	hypothetical protein MGC5350	1.5	4	
35	108339	AW151340	Hs.51615	ESTs. Weakly similar to ALU7_HUMAN ALU	S	6.3	4.7
		AA074374	Hs.67639		1.3	3.8	
		AF086070	Hs.237519		1	3.6	
		AA079487		gb:zm97f08.s1 Stratagene colon HT29 (937	1.5	3.6	
		AA079500		gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	4.3	
40		M23114	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	2	4.9	
70		AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1	3.5	
		AA058522	Hs.185751		1.2	3.6	
		AA036725	Hs.61847	ESTS	1.4	3.6	
45		AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456		glucocorticold receptor DNA binding fact	1.2	, 4	
		BE276891		retinolc acid induced 3	1.3	3.6	
		AA152312	Hs.72047	ESTs	1.1	4.1	
		AI732585	Hs.22394	hypothetical protein FLJ10893	1.2	3.5	
	109097	AA167512		gbczp10f12.s1 Stratagene fetal retina 93	1.3	5	
50	109160	BE220601	Hs.301997	hypothetical protein FLJ13033	4	6.1	
	109244	BE179030	Hs.64239	Human DNA sequence from clone RP5-1174I	V9	1.7	7.4
	109481	AA878923	Hs.289069	hypothetical protein FLJ21016	3.8	7.7	
		AA366263		hypothetical protein FLJ11838	1.9	4	
		AA173942		Homo sapiens mRNA; cDNA DKFZp564H191	6 (f	3.7	1.3
55		BE075297	Hs.6614	ESTs, Wealdy similar to A43932 mucin 2 p	4.6	7.4	
•		AW151660	Hs.31444	ESTs	1.2	3.5	
		AW001579	Hs.9645	Homo sapiens mRNA for KIAA1741 protein,	3.7	3.3	
		NM_014899		KIAA0878 protein	2.8	3.7	
		N21207	Hs.182999		1.6	3.5	
60			Hs.14947			1.2	
JU		BE242691		hypothetical protein DKFZp564K142	3.1	7.5	
		AI753230			1.9		
	111051	A)581293	Hs.12186		2	4	
		AKD01566	Hs.23618	hypothetical protein FLJ10704	1.1	3.8	
		BE301871	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	1	8.2	
65		BE314949	Hs.87128	hypothetical protein FLJ23309	3.3	6.1	
		R27975		ESTs, Moderately similar to S65657 alpha	1.2	5.4	
	444000	AC42479A	Un 25249	Harna canione clara 25104 mDNA comionea	22	ብጸ	

	111903	NM_014906	Hs.166351	KIAA1072 protein	1	5.4
	111951	NM_014927		KIAA0902 protein	1	3.8
		AW137198	Hs.278682	Phosphatidylglycerophosphate Synthase	1.4	3.5
_	112193	R49499	Hs.138238		1.5	3.6
5		NM_003655		ESTs	4.6	2
		AW500106	Hs.23643	serine/threonine protein kinase MASK	3.3	10.5
		Z42387	Hs.83883	transmembrane, prostate androgen induced	3.2	3
		T16971		ESTs, Weakly similar to A43932 mucin 2 p	3.7 4.5	10.8 3.7
10		AF019226	Hs.8036	glioblastoma overexpressed	1.2	4.4
10		AW160683 AF143321	Hs.15572	hypothetical protein hypothetical protein IMAGE 109914	0.9	3.6
•		AL042936		holocytochrome c synthase (cytochrome c	1.1	3.5
		AKD01898	Hs.16740	hypothetical protein FLJ11036	1.2	3.9
		Al075407		ESTs, Moderately similar to 154374 gene	1.7	5.3
15		NM_014214	Hs.5753	inositol(myo)-1(or 4)-monophosphatase 2	0.8	6.1
		W30681		Homo sapiens cDNA: FLJ22130 fis, clone H	1.7	6.2
	113857	AW243158	Hs.5297	DKFZP564A2416 protein	1,2	4.6
	113931	BE255499	Hs.3496	hypothetical protein MGC15749	1.5	4
		W17056	Hs.83623	nuclear receptor subfamily 1, group 1, m	3.8	1
20		AA345519	Hs.9641	complement component 1, q subcomponent,	1.2	4.7
		AJ342493	Hs.24192	Homo sapiens cONA FLJ20767 fis, clone CO		4.3
		BE179882	Hs.336920	•	1.1 1.6	4.3 9.2
		N58309	Hs.19575	CGI-11 protein	1.6	3.7
25		AA075488 Al929382	Un 252602	gb:zm88d01.s1 Stratagene ovarian cancer hypothetical protein FLJ20343	1.4	4
23		T10446	Hs.95388	ESTs	1	4.3
		AB037858		hypothetical protein FLJ10337	1.6	9.2
		AV660012		hypothetical protein FLJ10788	1.4	5.2
		A1683069	Hs.175319		3.7	1
30	115518	BE541042	Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	3,2	4.2
	115648	N36110	Hs.305971	solute carrier family 2 (facilitated glu	1.5	3.9
		AW582258	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	1.3	5.9
		AW410233		YME1 (S.cerevislae)-like 1	1.7	6.6
25		AB037836		KIAA1415 protein	1.5	9.1
35		BE383668	Hs.42484	hypothetical protein FLJ10618	0.9 1.6	4.3 5.5
		BE395293	Hs.94491	hypothetical protein FL/20297 guanine nucleotide binding protein (G pr	3.2	24
		A1129767 Z24854	Hs.42299	ESTs	0.8	4.7
		Al371223	Hs 288671	Homo saplens cDNA FLJ11997 fis, clone HE		3.9
40		AF191018		putative nucleotide binding protein, est	5.5	5.5
,,		AA313607	Hs.58633	Homo saplens cDNA: FLJ22145 fis, clone H	5 -	1.3
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	8.7	4.5
	116578	D21262	Hs.75337	nucleolar and coiled-body phosphprolein	3.2	6.9
	116579	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (3.2	3
45		Al557212	Hs.17132	ESTs, Moderately similar to 154374 gene	3.1	8.3
		H25836		ESTs, Moderately similar to unknown [H.s	3.2	4.5
		N25929	Hs.42500	ADP-ribosylation factor-like 5	7 1.2	5.5 6.2
		N20068		PTPRF interacting protein, binding prote	4.5	2.4
50		M18217	Hs.44597	Homo saplens cDNA: FLJ21409 fls, clone C ESTs	1.4	4.2
50		A1383467 U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.3	0.5
		AF161470		butyrate-induced transcript 1	2.1	5.7
		BE327311	Hs.47166	HT021	3.6	7.7
		N66845		gb:za46c11.s1 Soares fetal liver splean	4.2	0.5
55		AL353944	Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J1111	2 (f	3.5
	118505	N67343		gb:yz50b07.s1 Morton Fetal Cochlea Homo	2.1	3.8
•		AF142419	Hs.15020	homolog of mouse qualding QKI (KH domain		1.5
		BE048061	Hs.37054	ephrin-A3	3	1.1
C C		BE218319	Hs.5807	GTPase Rab14	1.1	5.6
60	119462	BE041667	Hs.314544		1.4	4.3
		A1905687	Hs.2533	EST DVEZDERCRASAD and b	3.2 4.3	1 0.7
		AL050097 BE565849	Hs.14158	DKFZP586B0319 protein-	4.3 3.5	1.9
		AA235207		copine III hypothetical protein DKFZp762F2011	1.5	3.7
65		AW968080		Homo sapiens clone 24630 mRNA sequence		1.4
0.5		AF150208		damage-specific DNA binding protein 1 (1	1.6	6.8
	120867	AA350781	Hs.96967	ESTs	1.1	3.6
	,					

3.3

	121260	BE262956	Un 479202	KIAA0180 protein	1.5	4.1	
					2.2	5.5	
		AA416785		heterogeneous nuclear ribonucleoprofein		3.2	
		AA243499		hypothetical protein FLJ10134	3.4		
_		AF169797	Hs.27413		3.9	3.9	
5		AB032948		hypothetical protein DKFZp762K2015	1.4	7.1	
		AJ718702		major histocompatibility complex, class	1.4	3.7	
	123155	AF121856		sorting nextn 6	1.2	4.9	
	123158	AF161426	Hs.218329	hypoihetical protein	2.4	3.6	
	123327	AA421581	Hs.178443	ESTs	0.9	5.2	
10	123495	W28673	Hs.106747	serine carboxypeptidase 1 precursor prot	1.3	5.1	
		AA608657 `		gb:ae55d04.s1 Stratagene lung carcinoma	2.1	5.2	
		AA608751		gb:ae56h07.s1 Stratagene lung carcinoma	2.1	9.3	
		Al932318	He 188762	ESTs, Moderately similar to H2BL_HUMAN H		3.6	
		AL050184	Hs.21610		1.1	3.5	
15			Hs.7351		1.4	3.8	
13		AF084555		cyclic AMP phosphoprotein, 19 kD		11.2	
		BE563957	Hs.74861	activated RNA polymerase II transcriptio	1.9		
		AB037860		nuclear factor VA	1.5	4.4	
		BE387335		ESTs, Weakly similar to S64054 hypotheti	14.8	11.5	
		AW195237	Hs.7734	hypothetical protein FLJ22174	1.2	6.2	
20	124148	BE300094	Hs.227751	lectin, galactoside-binding, soluble, 1	2.5	12.7	
	124153	AU077333	Hs.160483	erythrocyte membrane protein band 7.2 (s	1	4.1	
	124252	BE613340	Hs.334725	Homo sapiens, Similar to RIKEN cDNA 9430	1.5	8.4	
	124314	AK001552	Hs.215766	GTP-binding protein	1.8	10.2	
		D87454		KIAA0265 protein	1.1	4.8	
25		N39016		ESTs, Wealty similar to ALUC_HUMAN IIII	1.3	4.1	
20		N48000		gb:yy98e12.s1 Soares_multiple_sclerosis_	2.7	4.3	
		D54120	He 14R400	cell division cycle 42 (GTP-binding prot	21	5.7	
			Hs.104573		1	4.1	
		Al393320				4	
20		H66409	Hs.108275		1.4	4	
30		AL036596		A kinase (PRKA) anchor protein 2	0.7		
		AA749315	Hs.77171	minichromosome maintenance deficient (S.	1.1	3.5	
		H60193	Hs.21143		1.4	3.6	
	124659	A1680737		Hemo saplens cDNA FLJ11918 fis, clone HE	_	9.9	
	124737	BE270465	Hs.78793	protein kinase C, zeta	0.7	4	
35	124760	AW408586	Hs.91052	ESTs, Moderately similar to ALU5_HUMAN A	0.9	3.6	
	124763	BE410405	Hs.76288	calpain 2, (m/li) large subunit	1.3	3.9	
	124792	R44357	Hs.48712	hypothetical protein FLJ20736	1.8	4.2	
	124842	R56485		gb:yg93h09.s1 Soares infant brain 1NIB H	1	3.6	
	124940	AF068846	Hs.103804	heterogeneous nuclear ribonucleoprotein	3.2	3.4	
40		Al903210		tubulin, beta polypeptide	1	4:4	
		AL023513		seizure related gene 6 (mouse)-like	0.9	5.2	
		T52700	Hs.110044		0.9	3.5	
		AA610577	Hs.187775		1.2	5	
						1.5	3.
45		BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152		£~	J.,
45		T83731	Hs.3343	phosphoglycerate dehydrogenase	0.9	.8 4 3 7	
		AA973971		gb:oq02h08.s1 NCI_CGAP_Lu5 Horno sapier		1 3.7	
		T91518		gb:ye20f05.s1 Stratagene lung (937210) H	3.2	2.5	
•		AA570056	Hs.122730	ESTs, Moderately similar to KIAA1215 pro	5.3	6.6	
	125154	W38419		gb:zc78a07.s1 Pancreatic Islet Homo sapl	0.9	6.1	
50	125155	AA837043	Hs.143669	ESTs	1.1	4.3	
	125159	AK000669	Hs.274428	TRF2-interacting telements RAP1 protein	1.1	4.1	
	125170	AL020996	Hs.8518	selenoprotein N	1.1	3.8	
•	125181	R40815	Hs.12396	ESTs, Wealdy similar to 2004399A chromos	1	3.6	
	125193	W67577	Hs.84298	CD74 antigen (Invariant polypeptide of m	1.2	7.8	
55		H05635	Hs 294030	topolsomerase-related function protein 4	1	4.9	
00		AW884980		triple functional domain (PTPRF interact	1.3	4.8	
		BE612888		myosin regulatory light chain	1.1	16.1	
		W27235	Hs.64311		1.4	5.3	
					2.4	8.7	
C 0		Z45258		short coiled-coil protein			
60		AW630088		Homo sapiens mRNA; cDNA DKFZp564B126		1.8	4.0
		AW504721		high density lipoprotein binding protein	1.9	3.8	
		AW160399		hypothetical protein	1.4	4.1	
		BE384361		ESTs, Wealdy similar to JC5024 UDP-galac	2	3.7	
	126510	AA057593	Hs.334762	hypothetical protein FLJ14735	1.3	<u>4</u> .1	
65	127095	AA340277	Hs.10248	Homo sapiens cDNA FLJ20167 fis, clone CO	1.3	5_	
	127524	Al243596	Hs.94830		4.3	0.9	
		J04182	Hs.150101		1.5	4.7	

	128453	X02761		fibronectin 1	1.2	4.3	
		T16206		ESTs, Highly similar to LDHH_HUMAN L-LAC		44.4	
		H08379		hypothetical protein DKFZp434N1429	0.6	13.1	
5		NM_005904		MAD (mothers against decapentaplegic, Dr	1.3	4	
5		NM_003478	Hs.101299.	ubiquitin specific protease 18	1 0.8	5.1 4	
		Al185977 NM_014721		KIAA0680 gene product	1.3	3.7	
		AA432202		hypothetical protein FLJ21347	1.4	3.9	
		D87432		solute cerrier family 7 (cationic amino	1.2	3.6	
10		Al246669		WW domain-containing protein 1	0.8	4.1	
		BE246444		hypothetical protein FLJ20396	3	1.6	
	128717	AK001564		hypothetical protein FLJ10702	2.8	4.8	
	128774	AA476220	Hs.54457	CD81 antigen (target of antiproliferativ	1.1	10.6	
4.4		AF026692		secreted frizzled-related protein 4	1	3.8	
15		AA194554	Hs.183434	ATPase, H+ transporting, lysosomal (vacu	5.3	5.3	
		Al638184		Homo saptens clone 23836 mRNA sequence	1	5.3	
		Al917602	Hs.106440		0.8	4.5 3.6	
		AA768242 D60985		hypothetical protein DKFZP566D193 protein	4.6	3.7	
20		Al222020		CocoaCrisp	3	1.5	
20		AK000140		hypothetical protein	0.2	3.9	
		AA622037		programmed cell death 5	2.5	15.2	
		AF155096		hypothetical protein FLJ20585	4	4	
	128930	AA298958	Hs.10724	MDS023 protein	1.2	4.5	
25		AW247536	Hs.10729		1.4	5	
		AW953622		RAB31, member RAS oncogene family	2.3	5.6	
		AB020716		KIAA0909 protein	0.9	3.9	
		AW271217		Homo sapiens cDNA FLJ14028 fis, clone HE		3.6 0.8	3.8
30		AA258924 AI770025		NM_002495*:Homo sapiens NADH dehydrogo hypotheticai protein FLJ22059	1.2	5.7	J.Q
30		C15105		Homo sapiens cDNA FLJ14368 fis, clone HE		9.9	
		AA371156		DKFZP564M112 protein	2.4	3.8	
		Al634522		KIAA1268 protein	1.2	3.8	
	129106	AW504486		sterol regulatory element binding transc	1.2	5.5	
35	129113	BE543205	Hs.288771	DKFZP586A0522 protein	0.5	3.7	
		AB002450		CGI-109 protein	1	5.2	_
		AW881089		Homo saplens mRNA; cDNA DKFZp566M094		1.5	7
		N23018		C-terminal binding protein 2	2.1 0.9	9.7 8.6	
40		AA335362 M18916		Empirically selected from AFFX single pr glucosidase, beta; actd (includes glucos	1.1	3.5	
70		BE542214	Hs.109697		1.1	12.8	
		W57656		ubiquitin-like 5	3.2	5.1	
		Al878857		hematological and neurological expressed	1.9	5.7	
	129243	BE169531		TAK1-binding protein 2; KIAA0733 protein	1.2	6.6	
45	129247	R49920	Hs.109733	CGI-131 protein	1.5	3.5	
		AA344367		Empirically selected from multiple AFFX	1	5.4	
		AA250970	Hs.251946	poly(A)-binding protein, cytoplasmic 1-l	1.3	4.1	
		AF077200	Hs.279813	hypothetical protein	1.6	3.9	
50		AA357185		ras homolog gene family, member H putative L-type neutral amino acid trans	1.8 1.1	4.2 6.1	
J 0		AB007896 AA318224	Hs.110 Hs.296141	• **	2.5	4.8	
		W94197		ribosomal protein L26 homolog	1.6	5.1	
		AF189062	Hs.285976	tumor metastasis-suppressor	1.8	6.5	
		AW511656	Hs.170177	Mels1 (mouse) homolog	0.9	4	
55		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	1.4	9.2	
		BE278964		CGI-111 protein	1	4.8	
		AA318271		hypothetical protein	1	4.1	
		AA016188		hypothetical protein	1.8	10.7	
60		A1498631		fertiin, light polypeptide	1.1	4.8	
60		W92931		heat shock factor binding protein 1 DKFZP547E1010 protein	1.8 · 1	9.3 5	
		AL050260 NM_004477		FSHD region gene 1	1.1	4.2	
•		AA449789		connective tissue growth factor	1.9	6.8	
		Al631811		STRIN protein	1.1	9.7	
65		AA769221	Hs.270847	delta-tubulin	1.1	4.3	
	129545	R18087	Hs.323769	cisplatin resistance related protein CRR	1	4.2	
	129579	AW517695	Hs.286218	Junctional adhesion molecule 1	23	3.5	

	129606	AW968941	Hs.166254	hypothetical protein DKFZp5661133	2.4	4.4
	129819	AA209534	Hs.284243	tetraspan NET-6 protein	3.2	13
	129820	D79338		CCR4-NOT transcription complex, subunit	1.6	4.6
	129621	AL110212	Hs.301005	purine-rich element binding protein B	1.1	5.7
5	129634	AB020335		sel-1 (suppressor of lin-12, C.elegans)-	0.9	4.3
	129663	AJ207406	Hs.11866	translocase of inner mitochondrial membr	1.9	4.8
•	129679	AW889132	Hs.11916	ribokinase	0.9	4.1
	129688	U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
	129691	M26939	Hs.119571	collagen, type til, alpha 1 (Ehlers-Dani	4.7	3.7
10	129712	U46386 .	Hs.12102	sorting nexts 3	1.2	3.6
	129747	AL050272	Hs.12305	DKFZP566B183 protein	1	8.9
	129788	BE397454	Hs.124969	Homo saplens clone 24707 mRNA sequence	1.4	3.6
	129796	BE218319	Hs.5807	GTPase Rab14	2.9	5.1
	129797	M62839	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3	5.1
15	129800	AF052112	Hs.12540	lysosomal	1.6	8.8
	129834	AL080084	Hs.296155	ĆGI-100 protein	0.9	5.3
	129836	AW410233		YME1 (S.cerevisiae)-like 1	1.8	9.9
	129843	NM_014840		KIAA0537 gene product	0.9	3.6
		AA626837		hypothetical protein MGC2594	1.4	9.5
20	129878	Z43161		30 kDa protein	1.1	6.3
	129904	AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	2	5.1
	129976	X14008	Hs.234734		0.9	4.9
	129982	Z14221		gbd-Lsaplens germline transcript of lg h	1.2	3.6
25	130007	R15917	Hs.142570	Homo seplens clone 24629 mRNA sequence	4.3	1.3
	130060	BE277024	Hs.146381	RNA binding motif protein, X chromosome	1.6	3.8
	130064	X57815.comp		Empirically selected from AFFX single pr	1.2	8.2
	130068	M93143	Hs.262869	plasminogen-like	1.4	7.9
	130090	H97878	Hs.132390	zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838	•	0.2	4.6
		W61005	Hs.14896	DHHC1 protein	1.	4.1
		AA916785		splicing factor proline/glutamine rich (1.2	5.3
		T47294		X-box binding protein 1	3.8	0.8
25		NM_005095		zinc finger protein 262	1	4.2
35		BE094848		homogentisate 1,2-dioxygenase (homogenti	0.5	4
		R42678		KIAA0564 protein	1	3.7
		M23115 BE278370	Hs.1526 Hs.15265	ATPase, Ca++ transporting, cardiac muscl	0.4	4.4
		BE301883		heterogeneous nuclear ribonucleoprotein glioblasioma amplified sequence	1.7 1	7.5 5.6
40		U29463	TIS. I DZ/V/	gbd-turnan cytochrome b561 gen	1.2	4.2
40		U92014	He 453537	Homo saplens pTM5 mariner-like transposo	1.3	3.6
		W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
		AB040914		KIAA1481 protein	2.9	7.5
		AW067800		stanniocalcin 2	3.2	0.2
45		AW842182		small inducible cytokine A5 (RANTES)	1.4	10.6
		AW163518		huntingtin interacting protein 2	1.7	11.7
		AA852868		KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3
		AW362955	Hs.15641	Homo sapiens cDNA FLJ14415 fis, clone HE		7.6
50	130479	R44163	Hs.12457	hypothetical protein FLJ10814	0.9	4.1
	130499	AB007915	Hs.158286	KIAA0446 gene product	1	3.8
	130546	Al598022	Hs.193989	TAR DNA binding protein	1.3	4.7
	130568	AA232119		putative G-protein coupled receptor	1.2	9.4
	130606	AI652143	Hs.288382	hypothetical protein FLJ13111	1	4.1
55	130612	BE242873	Hs.16677		1.1	3.6
	130616	AL049963	Hs.284205	up-regulated by BCG-CWS	0.6	3.8
	130623	AL045128	Hs.1691	glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
	130629	AL042896	Hs.1697	ATPase, H+ transporting, lysosomal (vacu	0.9	3.9
		AW073971	Hs.238954	ESTs, Wealty similar to KIAA1204 protein	0.9	6.9
60		Al557212	Hs.17132		2.6	3.9
		AF158555	Hs.239189	giutaminase	1.2	13.8
		AI861791	Hs.278479		1.3	4
		A)831962			2.5	4
C E		AL117508		KIAA0737 gene product	1.3	6.2
65		Al928985			1.4	3.9
	130693	NM 014827		ESTs	3.2	0.8
	130034	ואמבטויוטבו	Hs.17969	KIAA0663 gene product	1.1	4.8

	130696	AA325308	Hs.18016	Homo sapiens mRNA; cDNA DKFZp586H032	4 (f	1.8
		Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
		AW190925	Hs.203559	hypothetical protein FLJ12701	1.2	4.1
	130731	Al932971	Hs.18593	Homo saptens cDNA: FLJ21449 fis, clone C	1.4	6.9
5	130787	AF072813	Hs.252831	reticuton 3	1.2	11.2
	130796	AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
	130808	NM_001761	Hs.1973	cyclin F	1.3	4.1
	130863	Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.2	5.9
	130902	AB037750	Hs.21061	KIAA1329 protein	1 .	3.B
10		AW195747	Hs.21122	hypothetical protein FLJ11830 similar to	1.3	7.9
		BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe		3.7
		BE390905	Hs.21198	translocase of outer mitochondrial membr	1.9	4
		H96115	Hs.21293	UDP-N-acteylglucosamine pyrophosphorylas	1.9	10.3
15		AB023182		KIAA0965 protein	1.5	6.8
15		AA393071		leucine aminopeptidase	1.4	5.5
		AA099923		PEST-containing nuclear protein	1.3	3.8
		BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
		D87436	Hs.166318	•	1.6 4.5	3.5 5
20		AA194422	Hs.22564 Hs.22937	myosin VI	2	3.7
20		AL137682 BE387561	Hs.22981	1-kappa-8-interacting Ras-like protein 2 DKFZP586M1523 protein		4.5
		W27770		ESTs, Weakly similar to T31475 hypotheti	0.9	3.5
		BE620886		GCN1 (general control of amino-acid synt	2.1	4.5
		BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25		AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
		AW953575		p53-Induced protein PIGPC1	4,5	13.5
		X77753	Hs.23582		3.4	0.4
	131156	Al472209	Hs.323117		8.0	4.9
	131164	AW013807	Hs.182265	kerafin 19	3.3	2.4
30	131181	H25094	Hs.293663	ESTs, Moderately similar to 138022 hypot	0.6	4
	131194	AW864222	Hs.24083	KIAA0997 protein	1.4	3.8
	131199	AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341	transcriptional co-activator with PDZ-bi	0.7	4.7
25		Al815486		Homo saplens dDNA FLJ20738 fls, done HE		8.2
35		D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7	3.5
		AW956868		DKFZP564D177 protein	1.3	5.4
		AU077158	Hs.24930	tubulin-specific chaperone a	1.6	4.8
		AU077002	Hs.24950	regulator of G-protein signalling 5 nuclear factor I/A	1.4 3.3	4.4 2.2
40		AI750575 AW293399		nuclear receptor co-repressor 1	1.6	3.9
70		NM_006052	Hs.26146	Down syndrome critical region gene 3	1	11.1
		NM_014810	Hs.92200	KIAA0480 gene product	5	2
		Al452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
		AW960146		hypothetical protein FLJ12888	1	3.5
45		BE270734	Hs.2795	lactate dehydrogenase A	2 .	6.5
		AB040927		KIAA1494 protein	1.5	10.7
	131528	AU076408		UDP-glucose dehydrogenase	1.3	4.7
	131534	AF157326	Hs.184786	TBP-interacting protein	1.3	4.9
	131555	T47364	Hs.278613	Interferon, alpha-inducible protein 27	1.5	8
50	131578	AA936296	Hs.234265	DKFZP586G011 protein	1.8	3.5
	131589		Hs.29191	epithelial membrane protein 2	1.3	8.2
	131609			nuclear protein	2.8	3.9
		BE514605		Horno sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
F F	131670		Hs.10130	20.0	1.3	4.B
55		C19034		Homo saplens cDNA FLJ14175 fis, clone NT		9.7
		AF103798	Hs.30819	hypothetical protein	1.3	5.2
		AW160865	Hs.30888		1.3	7.8
		AF017986 Al805664	Hs.31386	secreted frizzled-related protein 2	10.6 1.1	14.7 3.6
60		AF077036	Hs.31731 Hs.31989	peroxiredado 5 DKFZP586G1722 protein	1.1 1.6	3.7
JU	131791		1 13.3 1303	gbdk.saplens VII-5 gene for immunoglobul	1.1	3.5
	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		1.2
		NM_014874	Hs.3363		0.6	42
		NM_004642	Hs.3436		24	4.9
65		AW207440		(===,	24	6
-		AA772603	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT		9.2
		BE252983	Hs.35086	ubiquitin specific protease 1	0.5	5.2

	131947	Al123939	Hs.182997	ESTs	0.7	4.1
	131961	AA129782	Hs.3576	Homo saplens mRNA full length insert cDN	0.9	4.8
		AW381148		2,3-bisphosphoglycerate mutase	1.1	6.1
					1.3	3.9
5		AF208856		hypothetical protein		
3		AF119665		pyrophosphatase (Inorganic)	3.3	6.9
	131997	AF229181	Hs.136644	CS box-containing WD protein	0.9	5.2
	132006	AW162336	Hs.3709	low molecular mass ubiquinone-binding pr	1.2	3.6
	132063	BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosulfate sy	3.2	1.8
	132065	BE379335	Hs.211594	proteasome (prosome, macropain) 26S subu	1.2	3.6
10		AF217798	Hs.3850	LIS1-Interacting protein NUDEL; endoolig	0.7	5.2
10		A1701457	Hs.38694	ESTs	2	5.3
		NM_016045	Hs.3945	CGI-107 protein	1.2	4.3
		AW960474	Hs.40289	ESTs	3.1	3.1
	132164	A1752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3.7
15	132181	AW961231	Hs.16773	Homo sepiens clone TCCCIA00427 mRNA se	equ	1.2
	132208	AL031709	Hs.241575	hypothetical protein CAB56184	1.4	4.2
		AA306325	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
		BE177330		Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
20		U28831	Hs.44566	KIAA1641 protein	5.9	1.6
20		NM_003542	Hs.46423	H4 histone family, member G	5.8	1.5
	132384	AA312135	Hs.46967	HSPCO34 protein	2.1	9.3
	132397	AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	4.6
	132413	AW361383	Hs.260116	metalloprotease 1 (pitrilysin family)	2	4.9
		AW970859	Hs.313503		1.2	5
25		BE388673	Hs.5086	hypothetical protein MGC10433	2	3.9
23						
		BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
		AF065391		zinc linger protein 265	1.2	4
		AV660538	Hs.284162	60S ribosomal protein L30 isolog	3	1.7
	132585	AF029750	Hs.179600	TAP binding protein (tapasin)	1.8	4.7
30	132602	AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
	132608	AA353044	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		NM_004600	Hs.554	Slogren syndrome antigen A2 (60kD, ribon	4.2	2
		Al264357	Hs.55405	hypothetical protein MGC16212	1.1	5.3
					1.4	
35		AK000868	Hs.5570	hypothetical protein FLJ10006		5.2
33		BE222975	Hs.56205	Insulin induced gene 1	1.1	5.8
		F07424	Hs.279840	zinc finger protein 222	1.3	3.7
	132793	AB020713	Hs.56966	KIAA0906 protein	2.3	6.3
	132805	AW975748	Hs.5724	sclerostin	0.7	7.7
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	1.8	6.2
40	132894	D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 ffs, clone C	1	3.8
		AW118826			-	
			Hs.6093	Homo sapiens dDNA: FLJ22783 fis, clone K	0.7	5.4
		BE263252	Hs.6101	hypothetical protein MGC3178	1.6	4.1
		Al248173	Hs.191460	hypothetical protein MGC12936	1	4.2
45	132984	BE539199	Hs.62112	zinc finger protein 207	1.5	4.4
	132990	X77343	Hs.334334	transcription factor AP-2 alpha (activat	13.9	8.0
	132998	Y00062	Hs.170121	protein tyrosine phosphatase, receptor t	0.6	4.6
	133002	AW499985		ARP2 (actin-related protein 2, yeast) ho	1.5	11.1
		NM_006379			3.5	1
50		AA847843				4.5
50				Homo sapiens, clone IMAGE:3351295, mRNA		
		AW502761			0.9	5.5
		H12028	Hs.6396	jumping translocation breat point	1.7	5.3
	133063	Al654133	Hs.30212	thyroid receptor interacting protein 15	0.6	4.9
	133067	AK000708	Hs.169764	hypothetical protein FLJ20701	1.2	3.5
55		AF089816			1.2	17.5
		AA808177			0.9	5.1
		AV655783			1.1	4.5
		AW955632	Hs.66666		1.5	4.8
		AF231981			5.5	5.9
60		AA464362			1.2	3.7
	133206	AB037773	Hs.6762	hypothetical protein	1.6	8.6
		W32474			2.4	4.8
		AL137480			1	4.2
		AW796524			1.3	3.9
65		BE617892	De Core	only related and the All and the second		5.4
UJ			Hs.6895		1.4	
	133271		ns.203/42		3.1	0.7
	133273	N2/6/2	Hs.69469	dendritic cell protein	2.5	6.5

185

	122207	AW797437	Hs.69771	B-factor, properdin	1.3	4	
		BE297855	Hs.69855	NRAS-related gene	1.4	5	
		AA304961	Hs.699		2.2		
		AJ001388		peptidylprolyl isomerase B (cyclophilin	1.5	6.8	
5		AF116666	Hs.69997	zinc finger protein 238	1.4	4.3 6.3	
,		X04898	Hs.70333		0.2		
				apolipoprotein A-II		3.6	
		U56979		H factor 1 (complement)	0.6	5	
		BE257758	Hs.71475	acid cluster protein 33	1.2	4.2	
10		AF245505	Hs.72157	DKFZP56411922 protein	3.7	5.8	
10		AB007916.		KIAA0447 gene product	1.4	5.1	
		Al738719		hexokinase 2	0.9	6.3	
		AB033061	Hs.73287	and the second s	1.2	3,7	4.0
		AL137663	Hs.7378	Homo saplens mRNA; cDNA DKFZp434G227		0.7	4.8
15		M27749		immunoglobulin lambda-like polypeptide 1	1.1	4.3	
15		AF038962	Hs.7381	voltage-dependent anion channel 3	0.7	4.2	
		Al962602	Hs.74284	hypothetical protein MGC2714	3.1	5.9	
		NM_004415	Hs.74316		4.3	11.5	
		BE562958	Hs.74346	hypothetical protein MGC14353	1.8	19.7	
20		D87452	Hs.74579	KIAA0263 gene product	1.2	5.4	
20		H97991		Emphrically selected from AFFX single pr	1.4	3.9	
		Al929645	Hs.225936		0.8	4.9	
		L37368	Hs.75104	RNA-binding protein S1, serine-rich doma	2	10.8	
		Al423369	Hs.75111	protease, serine, 11 (IGF binding)	2.1	4.5	
25		U10564	Hs.75188	wee1+(S. pombe) homolog	3.3	1.1	
25		BE244334	Hs.75249	ADP-ribosylation factor-like 6 interacti	2.3	5.6	
		Al301740		dihydropyrimidinase-like 2	0.8	13.5	
		H14843		popeye protein 3	1	9.1	
		AJ006239	Hs.75438	quinoid dihydropteridine reductase	0.5	5.8	
20		L77964		mitogen-activated protein kinase 6	1.1	6.9	
30		AW503116		zinc finger protein 146	1.8	3.8	
		Al352558	Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	1.5	11.1	
				heterogeneous nuclear ribonucleoprotein	2	3.9	
		AI018666 ,	Hs.75667	synaptophysin	0.6	3.5	•
35			Hs.75824	KIAA0174 gene product	1.2	7.2	
33			Hs.75847	CREBBP/EP300 Inhibitory protein 1	1.5	5	
			Hs.75873	zyxin	1.2	4.8	
			Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	4.1	
				ADP-ribosyltransferase (NAD+; poly (ADP-	21	3.8	
40			Hs.76285		1.9	12.6	
₩.			Hs.76293 Hs.76297	thymosin, beta 10	2.6 1	6:6 4.9	
			Hs.76325	G protein-coupled receptor kinase 6 step II splicing factor SLU7	0.5	4.5 3.8	
			Hs.7644	H1 histone family, member 2	0.5 1.5	3.0 4.5	
			Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264			5.6
45			Hs.76688		0.3	3.7 4.4	5.0
43			Hs.76704		5.5	2.9	
			Hs.76930		0.6	4.8	
	133887		Hs.77271	protein kinase, cAMP-dependent, catalyti	1	10.2	
			Hs.301497		0.9	4.8	
50			Hs.7753	• •	2.8	10.5	
50			Hs.77542		1.8	5.6	
			Hs.7756		1.5	6.6	
	133947		Hs.77810		1.5	3.8	
					0.9		
55	133987		Hs 174007		2.3	4.3 4.3	
-					3.3	3.4	
	133990		Hs.7822	Homo saplens mRNA; cDNA DKFZp564C1218		1.3	5.7
					1	6.5	J.,
			Hs.78683		1.7	3.6	
60			Hs.7869		1	7.5	
50			Hs.78825		1.2	1.5 4	
			Hs.79069		1.2 2.7	4.8	
			Hs.79086		2.7 3.3	2.1	
	134207				1.3	3.5	
65			Hs.80019		1.7	6.9	
55	134218				0.8	5.3	
	134270				1.4	11.4	
	10.171.0			alumbahulantum horen	***	11.7	

	134277	NM_004369	Hs.80988	cottagen, type VI, alpha 3	2.6	3.5
	134280	NM_000712	Hs.81029	biliverdin reductase A	1.8	5.8
		Al022650	Hs.8117	erbb2-Interacting protein ERBIN	1.1	3.6
_		R00603	Hs.8128	phosphatidylserine decarboxylase	1.1	5.9
5		NM_001430	Hs.8136	endothelial PAS domain protein 1	0.5 1.7	4.8 7.9
		AL037800 D50683	Hs.8148 Hs.82028	selenoprotein T transforming growth factor, beta recepto	0.8	7.6
		X76534	Hs.82226	glycoprotein (transmembrane) nmb	2.2	3.6
		N22687	Hs.8236	ESTs	1.9	3.6
10		AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.5	8.3
10		BE512856	Hs.109051		1.1	3.6
		AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	1.9	4.6
		NM 006416	Hs.82921	solute carrier family 35 (CMP-static aci	1.2	7.5
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.6	8.7
15	134439	Z23024	Hs.138860	Rho GTPase activating protein 1	2	3.9
	134454	NM_013230		CD24 antigen (small cell lung carcinoma	3.5	1.1
		D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
		W84869		eukaryotic translation initiation factor	1.2	5.7
20		AW960673		ATP synthase, H+ transporting, mitochond	1.3	3.9 4.3
20		BE091005	Hs.74861	activated RNA polymerase II transcriptio	1.8 0.8	4.3 5.6
		M23161 AI902899	Hs.84775 Hs.85155	Human transposon-like element mRNA butyrate response factor 1 (EGF-response	1.4	5.0
		Al203545		S-phase response (cyclin-related)	0.8	3.9
		NM 016142		steroid dehydrogenase homolog	1.3	5.7
25		AB033017	Hs.8594	KIAA1191 protein	0.9	3.7
20		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4	6.8
		AW936928	Hs.85963	DKFZP564M182 protein	2.2	4.3
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.6	3.6
	134600	AF078859	Hs.86347	hypothetical protein	2.1	3.5
30	134655	AF265208	Hs.123090	SWI/SNF related, matrix associated, acti	1.7	4.2
		AK000606	Hs.8868	golg! SNAP receptor complex member 1	4.4	0.9
		D17530	Hs.89434	drebrin 1	3.1	1.6
		T51986		hemoglobin, gamma G	0.5	4.6
25		AA428520	Hs.90061	progesterone binding protein	1.3	3.7 17.3
35		J03464	Hs.179573 Hs.66295	collagen, type I, alpha 2	8.7 1.7	4
		AA587775 AB020689	Hs.90419	multi-PDZ-domain-containing protein KIAA0882 protein	3.4	0.9
		Al803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
		AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40		R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
	134934	AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1	4.3
	134970	BE560779	Hs.284233	NICE-5 protein	1.4	10.4
		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	1.6	4.1
45		AB037835	Hs.92991	KIAA1414 protein	1.2	5.6
		AW301984		hypothetical protein FLJ12619	1.7	7.6
		AL034344		forkhead box C1	3.2	0.6
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.2 1.3	4.1 4.8
50		AK001887 AK000967	Hs.93872	protein kinase, AMP-activated, gamma 2 n KIAA1682 protein	2	3.7
30		AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
		AB017363	Hs.94234	frizzled (Drosophila) homolog 1	2.4	4.8
		T97257		ESTs, Moderately similar to 138022 hypot	1.4	5.8
		AA132813	Hs.69559	KIAA1098 protein	1.8	8.5
55 .		BE563088	Hs.9552	binder of Arl Two	1.2	6.8
	135172	AB028956	Hs.12144	KIAA1033 protein	3.1	1.4
	135181	BE250865	Hs.279529	px19-like protein	1.3	7.5
	135222	AA534009	Hs.183487	Interferon stimulated gene (20kD)	1.3	3.8
	135232	AL038812	Hs.96800	ESTs, Moderately similar to ALU7_HUMAN A		3.9
60	135289	AW372569	Hs.9788	hypothetical protein MGC10924 similar to	0.9	8.4
	135290	AA331901		hypothetical protein FLJ10097	1	3.8
	135291	T83882	Hs.97927	ESTs	1.2	3.5
		AA114212	Hs.9930	serine (or cystelne) proteinase inhibito	2.6 2.5	8.9 5.4
65	13030/	Al565004 M16029	Hs.79572	cathepsin D (lysosomal aspartyl protease	0.4	5.4 7.9
65		W79431		ret proto-oncogene (multiple endocrine n ribosomal protein L22	1.5	4.5
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	1.8
		, u uvu-				

	302665	R99693	Hs.224410	Homo sapiens cDNA FLJ12843 fis, clone NT	3.6	3.6			
	302892	AW176909	Hs.42346	calcineurin-binding protein calsardin-1	3.3	1.6			
	302963	AW673106	Hs.151945	mitochondrial ribosomai protein L43	0.9	4.2			
	303131	AW081061	Hs.103180	DC2 protein	3	17.3			
5	303150	AA887146	Hs.8217	stromal antigen 2	6.2	4			
		AA147979		mitochondrial import receptor Tom22	1.2	6.6			
		AA233808		protein kinase, cAMP-dependent, regulato	1	3.5			
		BE616412		junctional adhesion molecule 1	1.5	4.7			
		AA054761		kanyopherin alpha 1 (Importin alpha 5)		. 5.6			
10					1.3	3.5			
10		AA412048		CGI-39 protein; cell death-regulatory pr					
		AW239226	Hs.65450	reticulon 4	1.2	13.9			
		AF279145	Hs.8966	hypothetical protein FLJ21776	2	5.1			
		BE539367		ESTs, Wealthy similar to AF220049 1 uncha	1.3	3.9			
	420186	NM_015925	Hs.95697		1.5	6.2			
15	422055	NM_014320		putative heme-binding protein	2	11.3		•	
	425815	R94023		ESTs, Moderately similar to 138022 hypot	1.7	3.6			
	426218	AF119043	Hs.168005	Homo sapiens cDNA FLJ13372 fis, clone PL	3.3	2.8			
	427397	A)929685	Hs.177656	calmodulin 1 (phosphorylase kinase, delt	1.3	4.7			
		AA523543	Hs.7678	cellular retinoic acid-binding protein 1	1.1	3.7			
20		AA361562		26S proteasome-associated pad1 homolog	3.2	2.5			
20		Al355260		histone deacetylase 3	2.8	22			
		AW501325		Homo saplens mRNA; cDNA DKFZp566M063		1.1	5.2		
					1.8	8.8	V 2.		
		X99209		HMT1 (hnRNP methyltransferase, S. cerevi					
25		R23553		hypothetical protein	1.1	5.6			
25		BE395875		mitochondrial carrier homolog 2	1.5	6.1			
		BE407127	Hs.8997	heat shock 70kD protein 1A	1.3	7.6			
		AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.6	6.5			•
		BE616412	Hs.286218		1.3	3.5			
	437754	R60366	Hs.5822	Homo saplens cDNA: FLJ22120 ffs, clone H	2	5.7	•		
30	440252	BE513940	Hs.6101	hypothetical protein MGC3178	1.1	6.2			
	441471	AL042986	Hs.7857	erythrocyte membrane protein band	0.5	3.7			
		BE281316	Hs.47334	hypothetical protein FLJ14495	2.5	4.9			
		H51066	Hs.23581	leptin receptor gene-related protein	1.1	3.6			
		AW001741		hypothetical protein FLJ10706	1.4	3.5			
35		N73222	Hs.279009	•	4	11.2	•		
55		Al634651	Hs.30250	v-mai musculoaponeurotic fibrosarcoma (a	0.8	5.6			
	402000				1.8	4.8			
		RC_H15847_s	•	peptidytprolyl isomerase B (cyclophilin B)		4.6			
		RC_W84712		calumenin	3.5				
40		X14008_ma1_		lysozyme (renal amytoldosis)	0.9	4.5			
40		RC_H86543_f		ESTs	1.8	6.6			
		H07011		ESTs; Wealdy similar to SAS [H.saplens]	1.8	3.9			
		RC_AA164586	3_S		ESTs	6.2	8.0		
		RC_AA07048	5	Homo sapiens clone 23967	3.4	2.6			
		RC_H98714_s	3	ESTs	1.6	3.5			
45		RC_AA40614	5_5		ESTs	4.6	3		
		AA458584	_	SRY (sex determining region Y)-box 4	3.4	0.4			
		AA031548		cell division cycle 42 (GTP-binding protein; 25	kD)	3.1	3.9		
		X02761		fibronectin 1	3.6	15.2			
		RC_AA487193	2	secreted frizzled-related protein 4	4.7	4			
50		R25326	•	Homo saplens mRNA for putative vacuolar	0.9	5			
JU			2		1.1	8.4			
		RC_AA39380		ESTs; Wealdy similar to (define not					
		RC_AA449333		ESTS	2.9	4.6	4		
		RC_AA287681			ESTs	1.3	4		
		RC_AA490864		ESTs; Highly similar to heat shock factor	1.4	5			
55		RC_C14243_f	f	ESTs; Highly similar to heat shock factor	1.7	5			
		R21443		ESTs	1.6	3.7			
		RC_AA251902	2	Homo sapiens lysophospholipase (LPL1)	2.2	3.8			
		M21121_s		small inducible cytokine A5 (RANTES)	0.9	9.9			
		C00038_s		ESTs	2.8	4.8			
60		Y00503		keratin 19	3.1	1.1			
UU		RC_R27006_f	Ī	ESTs	1.6	3.7			
		RC_AA416886		ESTs; Wealty similar to predicted using	3.1	3.1			
		RC_AA460450		fibroblast growth factor receptor 2 (bacteria-	1.5	3.7			
		RC AA48843				4			
65				ESTs; Wealdy similar to deduced amino acid			15 mDNA: portial arta	15	3.6
65		RC_AA278400	r.J	I have a seal to the seal of t			15 mRNA; partial cds	1.5	J.0
		U28831		Human protein immuno-reactive with anti-PTI-		0.6	47		
		RC_AA199588	5	Homo saplens actin-related protein Arp3 (ARF	' 3)	1.8	4.7		

	AF006082	Homo saplens actin-related protein Arp2 (A	RP2)	1.6	10.9
	RC_H90899	desmoptakin (DPI; DPII)	5.4	5.5	
•	RC_W95070 ·	desmoplakin (DPI; DPII)	5	2.6	
	RC_T90946_f	Human mRNA for KIAA263 gene; complete	cds	1.1	3.9
5	D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
	AA313414_s	ESTs; Wealthy similar to cDNA EST EMBL.	T1157	1.5	5.3
	RC_H73484_s	ESTs; Wealtly similar to similar to Yeast	1.3	6.3	
	AFFX-HUMISGF3A/M979	35_3		23	13.5
	AFFX-HUMRGE/M10098	_5	1.1	7.9	
10	AFFX-M27830_5			0.5	7.4
	AFFX-M27830_5			0.6	5.4
	RC_AA063431_f		ESTs	0.8	4.1
	DC TE2760 f	familia: light nahmanlida	11	37	

TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pikey:

Unique Eos probeset identifier number

CAT number:

Gene cluster number Genbank accession numbers

15

Pkey CAT number Accessions

AA079487 AA128547 AA128291 AA079587 AA079600 108469 116761_1 20 125076 190299_1 AA973971 T88817 AA253263 AA075488 AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519 114636 109698 1 AA074510 AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335 AA078829 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296 AA608657 123526 genbank_AA608657 25 AA608751 123533 genbank_AA608751 125090 genbank_T91518 T91518 125154 genbank_W38419 W38419 118475 genbank_N66845 N66845 118505 genbank_N67343 N67343 30 101046 entrez_K01160K01160 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165

129982 221,267 35

AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AFD62280 M99595 Z47214 Z47232 Z47218 M26995 AFD62184 X65895 L38433 X81731 Z11946 Z47226 AFD62205 AF174D12 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AIZ39353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174087 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00636 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ7008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664

50

60

45

AF068669 AF068666 AF068665 AF06867 AW406702 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 Hb4660 AW402990 AW406534 T93007 AI857980 AW3668899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113

55 108470 genbank_AA079500 AA079500 101447 entrez_M21305 M21305 124447 genbank_N48000 N48000 101624 entrez_M55998 M55998

131791 221_260

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 Al660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043

H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45566 H42605 AI735017 T47421 R48719 H27570 H44599 Al459598 H42347 H41938 H24993 AA345888 H22339 Al538691 AJ012264 AA664201 Al880450 AA327310 Al991250 Al833028 AW001210 Al956075 H30467 AA326915 H41943 Al749266 AJ744441 AA327377 AW512326 AJ735170 HD1634 AI587047 AI571623 AA327486 AA327103 AA327195 AA326973 T28143 5 124842 217726_1 R56485 R37248 R59992 103758 AA084874_f_at X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 130064 221_264 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 AW407182 L03632 AW405058 L03627 AW407470 R7Z738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 10 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063704 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500 15 AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z74694 AF194588 AF194601 U09901 U09911 U09892 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJZ33727 H24657 U09882 S75627 AA573599 AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 20 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF093581 AF103620 AW405934 Al445389 AW383753 AA360256 AF099676 H21654 H39501 Al820828 H53689 25 W26785 AW384496 AW407708 AA541663 AA911602 AI821461 AA588300 AA327050 H42717 AI951280 AA421322 AI923193 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 130232 18831_2 U29463 U05715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 T88946 F10106 AA232161 AA243117 AA158937 AA100864 109097 genbank_AA167512 AA167512

4

TABLE 9: Figure 9 from BRCA 001-2 US

Table 9 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAcon: UnigenelD: Unigene Title:	Unique Eos probeset Identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title
		•

15	Pkey	ExAccn	UnigenelD	UnigeneTitle
	100690	AA383256	Hs 1657	estrogen receptor 1
		BE314524		pulative transmembrane protein
		BE270266		5T4 oncofetal trophoblast glycoprotein
20		AF183810		opposite strand to trichorhinophalangeal syndrome !
20		AW503733		KIAA1488 protein
		AW602166		CEGP1 protein
			Hs.29403	hypothetical protein FLJ22060
		AA425414		nuclear factor VB
25		AW503807		historie acetyltransferase
LJ		BE568205		mitogen-activated protein kinase kinase kinase 2
		BE075297		ESTs. Weakly similar to A43932 much 2 precursor, Intestinal
				Homo saplens clone 25194 mRNA sequence
		AF131784		•
20		Al904232		prohibitin
30		Al272141		SRY (sex determining region Y)-box 4
			Hs.172129	Homo sepiens cDNA: FLJ21409 fis, clone COL03924
		Al905687		EST
		AA243499		hypothetical protein FLJ10134
25		BE387335		ESTs, Weakly similar to S64054 hypothetical protein YGL050w
35		AW953575		p53-induced protein PIGPC1
		AA235448		PRO2000 protein
			Hs.178137	transducer of ERBB2, 1
	302235	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112
	452410	AL133619	Hs.29383	Homo sapiens mRNA; cDNA DKFZp434

TABLE 10: Figure 10 from BRCA 001-3 PCT

5 Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn: UnigenelD:	Unique Eos probeset Identifier number Exemplar Accession number, Genbank accession number Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal body tissue
	R2:	Ratio of 90th percentile tumor to body
15	R3:	Ratio of 75th percentile body to tumor
	R4:	Ratio of tumor to normal breast tissue

	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20						450	••	12.2
		AA130080		proteasome (prosome, macropain) 26S subu	4.2	152	36	
		AA380887		dolichyl-phosphate mannosyltransferase p	9.8	123	13	5
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
0.5		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
25		H60720	Hs.81892	KIAA0101 gene product	4.1	320	· 78	10.6
		D14661	Hs.119	Wilms' turnour 1-associating protein	4.7	119	26	3
		AL037228		D123 gene product	5.1	106	21	9.2
		.BE242284		ademylate cyclase 7	4.7	47	1	4.3
		D26361	Hs.3104	KIAA0042 gene product	4.7	47	4	0.7
30	100219	AW972300	Hs.118110	bone marrow stromal cell antigen 2	3.8	350	93	1.9
	100234	D29677	Hs.3085	KIAA0054 gene product; Helicase	4.1	64	16	3
	100248	NM_01515	6Hs.78398	KJAA0071 protein	3.4	77	23	5.9
	100252	NM_00620	7Hs.170040	platelet-derived growth factor receptor-	4.5	45	4	4
	100260	D38491	Hs.322478	KIAA0117 protein	5.9	59	1	. 2.6
35	100279	D42084	Hs.82007	KIAA0094 protein	3.5	96	28	1.3
	100286	BE247550	Hs.86859	growth factor receptor-bound protein 7	3.1	306	98	1.5
	100294	AA331881	Hs.75454	percocredoxin 3	12.8	128	1	11.7
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrola	4.2	187	44	5.4
		A)878927	Hs.79284	mesoderm specific transcript (mouse) hom	4.5	129	29	3.1
40	100375	D80004	Hs.75909	KIAA0182 protein	3.5	78	23	4.8
		D86957	Hs.80712	KIAA0202 protein	10.2	102	1	4.8
•	• •	D86961	Hs.79299	lipoma HMGIC fusion partner-like 2	4	40	1	3.8
		NM_01473		KIAA0215 gene product	3.2	32	2	2.9
		D86978	Hs.84790	KIAA0225 protein	3.6	36	7	3.2
45		AA013051		topoisomerase (DNA) II binding protein	5.6	76	14	2
		AA347720		KJAA0264 protein	3.5	35	9	3.1
		AF234887		cadherin, EGF LAG seven-pass G-type rece	5.5	145	27	2.2
		D87470	Hs.75400	KJAA0280 protein	3.4	34	1	1.2
		X51501	Hs.99949	protactin-induced protein	22.7	760	34	1.4
50		AA019521		lysosomal	14.4	144	9	4.7
30		NM_00503		plastin 3 (T isoform)	4.1	259	63	1.9
		BE623001		Horno sapiens ribosomal protein L39 mRNA,	3.3	116	36	2.2
		L05424	Hs. 169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
		L05424	Hs. 169610	CD44 antigen (homing function and Indian	3	594	201	23
55		BE207168		nuclear receptor subfamily 2, group F, m	5	82	17	0.9
33	100745		Hs.89603	mucin 1, transmembrane	3.5	37	11	2.8
				general transcription factor IIH, polype	9.7	97	10	7.2
		AF078847	PIS. 191300		3.3	33	1	0.8
		M26460	11-74004	gbd-iomo sapiens (cione 104) retinoblasto		33 477	130	3.1
60		BE563957		activated RNA polymerase II transcriptio	3.7	63	4	5.7
60		X80821	Hs.27973	KIAA0874 protein	6.3	47	1	4.2
		BE245294		S164 protein	4.7	115	30	7.1
		BE297139	HS./9411	replication protein A2 (32kD)	3.8			
		K01160		NM_002122:Homo saplens major histocompat	3.9	390	100	11.1
	101079	BE264901	Hs.250502	carbonic anhydrase VIII	3.9	39	8	3.6

	101084	AW409934	Hs.75528	nucleolar GTPase	4.1	53	13	4
		AW862258		neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_001621		aryl hydrocarbon receptor	11.3	113	8	3.9
_		L20320	Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5		1.22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9 10.7
		AU077288		ADP-ribosylation factor-like 1	4 4.2	110 50	28 12	4.4
		BE545277 BE535511		Ts translation elongation factor, mitoch transmembrane trafficking protein	4.2 6.6	135	21	13.1
-		BE267931		proliferating cell nuclear antigen	6.4	249	39	22.4
10		M21305	115.70550	gbd-turnan alpha satellite and satellite 3	6.5	878	135	0.8
10		NM_000424	Hs.195850	keratin 5 (epidermolysis bullosa simplex	· 4.8	622	130	0.7
		NM_000546		tumor protein p53 (Li-Fraumeni syndrome)	5.1	97	19	9.3
		NM_002890		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
	101484	AA053486	Hs.20315	Interferon-induced protein with tetratri	11.2	112	8	5.9
15		X16896	Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
		BE391804	Hs.62661	guanytate binding protein 1, interferon-	3.6	36	1	2.6
		M55998		gbd-turnan alpha-1 collagen type I gene, 3	3.11	2898	923	2.2
		AA436989		H2A histone family, member A	6.9	103	15	8.4
20		M63256	Hs.75124	cerebellar degeneration-related protein	6.4 9.4	64 94	2 1	4,9 0,3
20		L11690 S70114	Hs.620 Hs.239489	bullous pemphigoid antigen 1 (230/240kD) TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	3.6	824	227	1.4
		M83822	Hs.62354	cell division cycle 4-like	9	144	16	13
		M84605	Hs.957	putative opioid receptor, neuromedin K (3.3	36	11	2.4
25		AW024390		pre-B-cell leukemia transcription factor	5.4	180	34	15.9
	101809	M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
		AA446644		GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
		AL049610		transcription elongation factor A (SII)-	7.3	73	1	5,3
20				calponin 3, acidic	3.8	399	105	3.3
30		BE245149		protein tyrosine kinase 9	4.6	148	32	11.3
		U11313	Hs.75760	sterol carrier protein 2	9.5	95 42	4	8.8 3.4
		NM_001809		centromere protein A (17kD)	4.2 9.3	93	7 4	3.4
		NM_006456 NM_004419		sialytiransferase dual specificity phosphatase 5	5.4	137	26	2.5
35		AA450274		CDC16 (cell division cycle 16, S. cerevi	4.6	151	33	2
-		BE313280		death associated protein 3	9.3	93	5	8
		AL036335		secreted phosphoprotein 1 (osteopontin,	45.7	457	1	39.7
	102211	BE314524	Hs.78776	putative transmembrane protein	3.9	442	114	1.3
••		NM_006769		LIM domain only 4	4.9	49	1	3.6
40		U27185	Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	1	1.3
		NM_001546		inhibitor of DNA binding 4, dominant neg	3.8	163	43	0.5
		AA306342		protein kinase C-like 2	4.5	45 2058	1 243	3.6 1.4
		AF015224 U37519	Hs.87539	mammaglobin 1 aldehyde dehydrogenase 3 family, member	8.5 6.4	428	243 67	2.3
45		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
73		AW602154		E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330		selenophosphate synthetase 2	3.3	111	34	7.5
		NM_001394		dual specificity phosphatase 4	20.2	202	5	1.3
	102544	NM_003937	7Hs.169139	kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50			Hs.146847	TRAF family member-associated NFKB activ	8.2	82	1	6.8
		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
		AL037672		extracellular matrix protein 1	10.2	628	62	17.2
		U67319	Hs.9216	caspase 7, apoptosis-related cystelne pr	5	66	13	5.3
55		NM_002270		karyopherin (Importin) beta 2 eyes absent (Drosophila) homolog 2	6.1	126	21 1	2.4 2.8
33		U71207 U79293	Hs.29279 Hs.159264	Human clone 23948 mRNA sequence	4.5 4.1	45 41	1	2.4
	102742		Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58	1.6
•			Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6
		BE242035		embryonic ectoderm development	3.5	35	1	2.7
60		D85390	Hs.5057	carboxypeptidase D	5.6	56	1	5.3
		BE262386		clones 23667 and 23775 zinc finger prote	4.2	42	7	3.7
			Hs.75730	signal recognition particle receptor ('d	3.2	58	18	5
		NM_002275		keratin 15 .	5.8	753	131	0.4
<i>C</i> 5		BE512730		keratin 18	3.1	815	266	1.7
65		AL119505		activating transcription factor 2	3.2	32	4	2.6
		AU076611		methylene tetrahydrofolate dehydrogenase	5.7 6.6	251 1346	44 239	6.6 5.4
	IWW	Al910275	110.1400	trefoil factor 1 (pS2)	5.6	10-10		V. T

	402000	AMERO 470	Un 4470E0	multifunctional askmontide cimiler to C	5.8	218	38	13
		AW500470		multifunctional polypeptide similar to S lactotransferrin	3.7	1421	388	1.9
		NM_002343 M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; Inters	3.1	94	30	5.8
		AA926960		CDC28 protein kinase 1	3.5	332	94	3.1
5		X63629		cadherin 3, type 1, P-cadherin (placenta	4.8	312	65	30.9
•		X65724	Hs.2839	Nonte disease (pseudoglioma)	5.2	331	64	1.5
	103134		Hs.2839	Nonie disease (pseudoglioma)	4.9	49	5	3.8
		AW583058		serine (or cystalne) proteinase inhibito	3.3	1497	458	2.1
		X72755	Hs.77367	monokine induced by gamma interferon	3.5	796	228	3.2
10	103208	AW411340	Hs.31314	retinoblastoma-binding protein 7	5.6	191	34	3.5
	103226	X75042	Hs.44313	v-rel avian reticuloendotheliosis viral	4.1	53	13	4.9
	103333	AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.4	34	8	2.3
	103346		Hs.5464	thyroid hormone receptor coactivating pr	3.9	43	11	1
		H09366	Hs.78853	uracii-DNA glycosylase	9.3	93	8	8.2
15		NM_005982		sine oculis homeobox (Drosophila) homolo	9.7	97	1	9.3
		AL036166		coated vesicle membrane protein	6.3 4.3	98 77	16 18	9.1 7.2
	103391		Hs.114366	pyrroline-5-carboxylate synthetase (glut	4.9	153	31	2.4
		AW175781		M-phase phosphoprotein 6	4.9	261	53	3.7
20			Hs.180139 Hs.75216	SMT3 (suppressor of milf two 3, yeast) ho protein tyrosine phosphatase, receptor t	3.5	564	162	1.7
20		Y00815 AW408009		alkylglycerone phosphate synthase	3.9	49	13	2.5
		AL133415		vimentin	7.5	136	18	3.4
		BE270266		5T4 oncofetal trophoblast glycoprotein	7.9	79	2	6.9
		BE409838		cadherin 1, type 1, E-cadherin (epitheli	3.3	745	229	1.8
25		AW403814		BCL2-associated athanogene	3.2	41	13	2.8
		NIM 000346		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
	103658	NEM_000088	3Hs.172928	collagen, type I, alpha 1	3.8	1612	429	3.1
	103666	NM_003528	3Hs.2178	H2B histone family, member Q	3.2	32	5	2.8
	103988	AA314389	Hs.42500	ADP-ribosylation factor-like 5	3.2	32	9	2.7
30		AB033112		bromodomain and PHD finger containing, 3	4.9	49	1	4.2
		NM_002407		mammaglobin 2	7.2	498	69	9.3
		AF183810		opposite strand to trichorhinophalangeal	29	290	1	26.8 2.1
		H63349	Hs.98806	hypothetical protein	3.7 5.2	37 52	1	4.3
35		AW880614		RNA binding motif protein, X chromosome	5.2 8	84	11	6.3
33		BE081342 AB012113		HSPC039 protein small inducible cytoldine subfamily A (Cy	5.8	58	1 .	3.2
		AB002367		doublecorfin and CaM kinase-like 1	6.4	64	8	3
		AW583693		N-terminal acetyltransferase complex and	4.7	229	49	7.9
		Al337300	Hs.284123	hypothetical protein MGC4604	3.2	32	7	2.4
40				Homo sapiens cDNA: FLJ21409 fis, clone C	5.3	144	27	13.1
• •		X51501	Hs.99949	prolactin-induced protein	6.9	1494	218	1.3
		R56678	Hs.88959	hypothetical protein MGC4816	7.7	77	8	6.9
	104567	AA040620	Hs.5672	hypothetical protein AF140225	3.7	37	5	2.5
	104590	AW373062	Hs.83623	nuclear receptor subfamily 1, group I, m	6.1	493	81	0.7
45		H47610		gb.yp75i03.s1 Soares fetal liver spleen	3.8	38	4	1.2
		AF123303		hypothetical protein	4.8	231	49	7.3
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	3.4	154	46	3 4.7
		R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti	5	468 82	94 22	3.1
50		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (fr	3.6 14.9	149	1	6.4
30		Al239923	Hs.30098	ESTs macrophage erythroblast attacher	6.3	165	26	3.2
		BE244072 AA027317	HS.200 15	ob:ze97d11.s1 Soares_fetal_heart_NbHH19W	3.8	40	11	3.8
		Al858702	Hs.31803	ESTs, Wealty similar to N-WASP [H.saplen	7.7	\ddot{n}	i	5.1
			Hs.125790	leucine-rich repeat-containing 2	7	70	1	6.5
55		A1250789		ESTs	4.7	201	43	4.5
		AW015318		ESTs	7.4	74	1	6
		AA026880		prolactin receptor	3.9	280	72	3.3
		BE298808		DKFZP434N093 protein	4.2	135	32	4
		AF072873		frizzled (Drosophila) homolog 6	16.2	162	1	4.2
60		AI249502		ESTs	3.8	38	1	2.4
		A1392640		amino acid transporter system A1	3.2	522	165	1.9
		AA121686		ESTs	3.2	32	4	2.9
		Al122691		ESTs	3.7	157	43	3.6
15		AW503733		KIAA1488 protein	5.5	55	1	5.2
65		AB037716		KIAA1295 protein	10.3	103	1	3.9 5.4
		AA148710		hundran	6.6	66 31	1	2.5
	100000	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.1	31	•	2.3

	105091	AA148859	Hs.179909	hypothetical protein FLJ22995	3.2	32	1	3
			Hs.24808	ESTs, Weakly similar to 138022 hypotheti	7.3	73	1	3.8
		AA307279		methyl-CpG binding domain protein 4	4.2	90	22	2.8
_		AL133033		KIAA1025 protein	6	60	6	4.6
5		AW612147		Homo sapiens C1orf19 mRNA, partial cds	3.8	38	2	3.2
		AA313825		AD036 protein	9.3	436	47	5.8
		AA975096		hypothetical protein PRO2849	5.7	57	8	5.3
		AA328102		cytoskeleton associated protein 2	4.5	45	1	3.6
• •		AW952479		tropomodulin 3 (ubiquitous)	4.3	43	1	3.9
10		AB039670		ALEX1 protein	8	80	6	7.3
•		AW997484		KIAA0456 protein	3.9	39	6	3.2
		AA894638		ESTs	3.5	35	7	2.7
	105288		Hs.3585	ESTs, Wealdy similar to AF126743 1 DNAJ	4.5	45	10	0.5
4.5		AK000796		hypothetical protein	3.8	93	25	7.5
15		AA234561		ESTs	2.8	131	47	3.9
		AF151073		hypothetical protein	3.9	79	20	6.5
		AW994032		hypothetical protein FLJ10849	5.1	181	36	15.8
		AW500718		Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3.3
00		AF198620		RNA binding motif protein 8A	6.2	62	6	5.6
20		W20027	Hs.23439	ESTs	3.3	206	63	2.2 8.4
		AL137257		Homo sapiens cDNA: FLJ23015 fis, clone I.	3.2	466	146	
		AL117441		hypothetical protein FLJ13033	16.6	166	8	12.7 3
		AW602166		CEGP1 protein	25.4	508 117	20 13	10.6
25		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (6	1.5
25		AB037829		regulator of nonsense transcripts 2; DKF	3.2 8.3	32 83	3	1.8
		AK001269		hypothetical protein FLJ10407	3.5	73	21	1.6
		AB040884		KIAA1451 protein	5.B	336	58	2
		BE616694		hypothetical protein FLJ14299	3.2	32	1	1
20		AA280072		fetal Alzhelmer antigen Human DNA sequence from clone RP1-233G16		79	17	5.2
30		R35343	Hs.24968		4	75	19	1.7
		AA281279 AA001021		hypothetical protein FLJ14681 thyroid hormone receptor interactor 8	4.5	45	1	3.7
		AW294631		ESTs	3.6	36	i	0.1
			Hs.279789	histone deacetylase 3	6.4	64	8	6
35		NM_014517		upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
رر		A1680737		Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
		AW377314		DKFZP564I052 protein	6.9	69	1	4.4
		AAB34664		nuclear receptor coactivator 2	3.4	34	1	3.1
		BE246502		sema domain, immunoglobulin domain (ig),	3	30	10	0.9
40			Hs.15159	chemokine-like factor, alternatively spl	5.4	54	1	4.4
		H57111	Hs.221132	ESTs	5.3	67	13	5.3
		AW369278		hypothetical protein FLJ20160	4.9	49	1	4.5
		W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
		AA878183		Homo sapiens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45		AF206019		REV1 (yeast homolog)- like	4	40	3	3.2
	105807	AA788946	Hs.16869	ESTs, Moderately similar to CA1C RAT COL	4.7	747	158	5.7
	105823	Al559444	Hs.293960	ESTs	3.9	371	94	4.8
	105832	AW802282	Hs.22265	pyruvate dehydrogenase phosphatase	3.6	68	19	6
	105840	AA601518	Hs.22209	secreted modular calcium-binding protein	4.8	134	28	3.2
50	105851	AJ827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
•	105864	A1640775	Hs.28332	Homo saplens cDNA: FLJ21560 fis, clone C	4.3	43	1	3.7
	105870	AW021691	Hs.101057	GCN5 (general control of amino-acid synt	3.6	36	7	3.1
		AK001708		hypothetical protein FLJ10846	3.4	34	8	2.9
	105886	AK001735		UDP-glucosexylycoprotein glucosyttransfe	3.6	45	13	1.3
55		N25986	Hs.22380	ESTs	3.4	34	1	1.5
		Al240665		ESTs	21.2	212	6	17.4
		AA043039		hypothetical protein	3.9	47	12	4.4
		AL122072		heterogeneous nuclear ribonucleoprotein	4.4	174	40	1.6
		AW952005		hypothetical protein FLJ12903	4.7	47	1	4
60		AA382267	Hs.10653	ESTS	3.4	49	15	4.4
		AA417034		gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	1.2
		BE614474		F-box only protein 22	3.4	116	35	2.2
		NM_00132		C-terminal binding protein 2	3.6	444	125	4.6
· •		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.6	365	103	6.9
65		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	1
		AW379378		protein tyrosine phosphatase, receptor t	3.2	267	83	2.3 3.3
	106126	AA576953	HS.22972	hypothetical protein FLJ13352	3.8	38	1	3.3

	400455	44470444	11. 22207	avalage for doc MD	9.9	483	49	1.8
		AA425414	Hs.34892	nuclear factor I/B KIAA1323 protein	6.7	94	14	8
		W37943 Al244563	Hs.325531	Homo saplens clone 015h12 My015 protein	3.3	95	29	4.4
		AB040896		KIAA1463 protein	3.8	83	22	7.5
5		AI765107	Hs.274422	hypothetical protein FLJ20550	3,3	97	30	6.4
,		AW961393		hypothetical protein FLJ10955	4.5	116	26	4.5
		R98185	Hs.17240	ESTs	7	70	3	1.3
		AB007866		KIAA0406 gene product	3.2	37	12	2.6
		AW977397		ESTS	3.8	38	1	1.9
10		AA447453		Homo saplens mRNA; cDNA DKFZp586M0723 (f16	255	16	6.6
10		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone C	4.9	337	70	2.7
		Z42993	Hs.25320	Homo sapiens clone 25142 mRNA sequence	3.1	72	23	5
		AK000310		hypothetical protein FLJ20303	3.1	165	54	1.6
		AA789081		glioma-amplified sequence-41	3.1	31	1	2.6
15		AB033042		cofactor required for Sp1 transcriptiona	5.5	147	27	4.4
13			Hs.30348	ESTS	4.4	222	51	1.8
		NM_01489		KIAA1116 protein	7.4	74	3	1.7
		AA243837		ESTs	15.2	152	1	12.6
		AKD00933		Homo sapiens cDNA FLJ10071 fis, clone HE	3.8	263	69	3.9
20		AA452379		ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
20		R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
		AW188205		Homo saplens clone 23570 mRNA sequence	5.3	166	32	14.9
		AL049951		Homo saplens mRNA; cDNA DKFZp564O0122 (f5.4	75	14	0.8
		BE296396		DIPB protein	3.6	210	58	4.7
25		N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
2,0		N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
		AA600357		TIA1 cytotoxic granute-associated RNA-bi	4.3	101	24	1.6
		NM_00711		triple functional domain (PTPRF interact	4.6	46	1	4
		AL044182		KIAA0753 gene product	3.5	58	17	1.6
30		AB037744		KIAA1323 protein	5.4	192	36	4.4
-		BE185536		molecule possessing ankyrin repeats indu	3.3	696	214	1.8
		AA149537		hypothetical protein FLJ20477	3.8	38	1	1.6
	106893	AA835868	Hs.25253	mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
	106895	AK001826	Hs.25245	hypothetical protein FLJ11269	3.6	36	1	1.2
35	106897	AF039023	Hs.167496	RAN binding protein 6	4.5	45	1	3.8
	106916	AA134329		Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3
		A1868648	Hs.22315	ESTs	3.5	180	52	2.3 12.5
		AF216751		CDA14	5.5	130	24	1.8
40		AA280722		ESTs, Weakly similar to 138022 hypotheti	3.2	266 298	83 59	4.4
40		AL157479	Hs.23740	KIAA1598 protein	5.1	228 228	69	2.8
		AA598820		gb:ae36h12.s1 Gessler Wilms tumor Homo s	3.3	220 55	18	3.8
		AV650537		succinate-CoA ligase, GDP-forming, beta	3.1 3.1	35 75	24	2.2
		AW401864		programmed cell death 8 (apoptosis-induc	3.1	₽367	119	23
45		AW385224		ectonucleofide pyrophosphatase/phosphodi		₹ 98	25	8.6
45		AL122043		hypothetical protein DKFZp566G1424	3.9 6.3	63	1	5.4
		AB037765		KIAA1344 protein	4.6	71	18	3.6
		AA249096		ESTs .	2.5	392	155	4.3
		AV661958		GK001 protein ESTs	15.6	156	7	10.8
£Λ		AW378065		DKFZP586E1621 protein	4.8	48	8	3.1
50		AL080235		tumor rejection antigen (gp96) 1	3.4	251	74	23.7
		BE172058	Hs.159872	ESTs	3.6	36	6	0.5
		Al290284 AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	4
			·	UDP-N-acetyl-alpha-D-galactosamine:potyp	4.6	199	44	19.2
55		AA186629 BE277457		hypothetical protein MGC4606	12.5	156	13	2.9
33		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586i0324 (f		110	35	9.6
		174445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	2.6
			Hs.262476	S-adenosylmethlonine decarboxylase 1	5.8	151	26	11.4
		ALM2013	Hs.60090	Homo sapiens cDNA FL/13595 fis, clone PL	3.2	32	5	2.1
60		A1580492		hypothetical protein	4.4	73	17	6.2
UU			Hs.173091	ublauitin-like 3	3.5	282	80	3.7
		AW732573		potassium voltage-gated channel, delayed	5.7	85	15	7.8
		AW372451		CGI-79 protein	3.5	35	1	1
		AA054949		ESTs	4.3	43	10	2.7
65		AA025782		ESTs	3.1	31	9	2.2
		AF087999		ESTs	4.7	47	4	4.3
		BE153855		lg superfamily receptor LNIR	9	90	1	5.5
				· · · · · · · · · · · · · · · · · · ·				

		AA036811		LIM domains containing 1	4.5	45	1	3.8
			Hs.159971	SWI/SNF related, matrix associated, acti	6.5	65	2	6
	108055	AJ404672	Hs.334483	hypothetical protein FLJ23571	7.4	74	8	6
_	108063	BE548479	Hs.14838	hypothetical protein FLJ10773	3.4	34	1	2.3
5	108339	AW151340	Hs.51615	ESTs, Wealty similar to ALU7_HUMAN ALU S	18.7	187	1	17
	108467	A1478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
	108539	AA084677	Hs.54558	hypothetical protein FLJ22222	5.7	57	1	4.9
	108634	AW022410	Hs.69507	ESTs	3.2	32	5 .	1.7
		BE546947		homeo box C10	8.7	247	29	5.7
10		AB029000		KIAA1077 protein	3.7	625	168	3.8
		AF133123		general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo saptens clone 24674 mRNA sequence	3.4	34	1	2.8
			Hs.49376	hypothetical protein FLJ20644	3.5	35	1	3.2
		AW295647		hypothetical protein MGC5350	5.3	53	1	2.8
15		AL117452		DKFZP586G1517 protein	4.8	96	20	6.5
13		AK001468			5.4	54	1	4
				anilin (Drosophila Scraps homolog), act	3.1	529	170	4.1
		BE276891		retinoic acid induced 3	3.3	33	5	1.7
			Hs.173648	ESTs, Wealdy similar to Zinc-finger prot		34	1	2.6
20		NM_007240		dual specificity phosphatase 12	3.4			
20		BE062109		chloride channel, calcium activated, fam	3.1	31	8	2
		AW608930		hypothetical protein FLJ20618	3.4	71	21	2.4
		AW419196		hypothetical protein FLJ13782	4.1	334	82	3.4
		AK000684		hypothetical protein FLJ22104	3.3	33	1	2.9
		H89083	Hs.181915	ESTs	4	40	7	1.1
25	109160	BE220601	Hs.301997	hypothetical protein FLJ13033	3.8	233	62	3.8
	109166	AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	8.8	199	23	16.1
	109173	AA179962	Hs.73643	EST	3.2	32	1	2.2
	109178	AW976516	Hs.283707	Homo sapiens cDNA: FLJ21354 fis, clone C	3.2	32	10	2.9
	109235	Al381800	Hs.300684	calcitonin gene-related peptide-receptor	4.9	121	25	10.4
30	109273	AA375752	Hs.82719	Homo saplens mRNA; cDNA DKFZp586F1822 (f	2.9	114	39	9.9
	109292	AW975746	Hs.188662	KIAA1702 protein	7.1	71	1	6.5
	109391	AL096858	Hs.184245	KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
		R98881	Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
		BE543313		hypothetical protein FLJ10520	4.2	56	14	2.2
35		U80736	Hs.110826	trinucleofide repeat containing 9	12.3	123	1	11.3
-		AA878923		hypothetical protein FLJ21016	3.2	286	91	5.7
		AJ631874	Hs.155140	caseln kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
		AA989362		ESTs	5.9	59	10	4.2
	109729		Hs.268740	ESTs	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (I		208	36	1.8
70		AW965076		hypothetical protein 669	5	50	5	4.1
		R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
		AW390822		L-kynurenine/alpha-aminoadipate aminotra	14.2	142	i	9.5
		A1084066	Hs.20072		4.1	41	ż	1.7
45			Hs.133521	myosin regulatory light chain interactin	4.2	58	14	0.8
43				ESTS	3.2	136	43	3.6
		Al796320	Hs.10299	Homo sapiens cDNA FLJ13545 fis, clone PL	6.3	693	110	7. 2
			Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p		913	199	29
		A1668594	Hs.176588		4.6		7	2.8
50		AK000768		hypothetical protein FLJ20761	3.8	38 70		3
50		Al610702	Hs.28212		6.7	78 27	12	_
		H11236	Hs.31034	peroxisornal biogenesis factor 11A	3.7	37	1	21
		AF075089	Hs.36823	ESTs	3.6	36	10	2.5
		H61560		gb:yr22g03.s1 Soares fetal liver spieen	3.3	33	1	1.8
		AA071276		KIAA0859 protein	3.5	35	8	1.9
55		AB007902		KIAA0442 protein	3.6	282	79	1.7
	110721	H97678	Hs.31319	ESTs	4.4	103	24	3.8
		NM_014899		KIAA0878 protein	3.3	138	42	3.6
	110769	BE000831	Hs.23837	Homo saplens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
	110775	N22414		gb:yw39a07.s1 Welzmann Offactory Epithel	5.4	54	1	3.7
60	110787	AA831267	Hs.12244	hypothetical protein FLJ20097	4.7	47	4	4.2
		AI089660	Hs.323401	dpy-30-like protein	5	50	1	4.3
		AL157503		Homo saplens mRNA; cDNA DKFZp586N2424 (f		31	1	2.7
		AF153330		solute carrier family 19 (thiamine trans	8.4	84	1	5.3
		AI740792		methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65		BE612992		hypothetical protein FLJ10607 similar to	7.9	79	i	6.2
00		AW963705		molecule possessing ankyrin repeats indu	3.9	353	90	1.2
		Al433165	Hs.9856	ESTs	3.1	31	1	1.3
	110000	. = 100 100					•	

						000		40.5
		BE092285		hypothetical protein FLJ13187	20.9	209	1	19.5
		BE242691		ESTS	3.4	115	34	2.4
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.5	35	9	3.2
_		H44186	Hs.15456	PDZ domain containing 1	4.3	43	1	2
5		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	5.4	54 72	1 10	4.3 6.1
		AB037807		hypothetical protein	7.2 7.7	77	1	5
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fs, clone OV	<i>7.7</i> 25.1	288	12	6.7
		AK000136		asporin (LRR class 1)	3.9	200 146	37	9.8
10		A)815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	5.5 6.3	63	1	5.8
10		AK002055		hypothetical protein FLJ11193	3.7	119	33	6.7
		AB037782		KIAA1361 protein	3.6	402	112	4.9
		AA852773		KIAA1866 protein	4.3	43	1	1
		AW389845		ESTS	3.3	33	i	1.1
15		AA902656		NIF3 (Ngg1 interacting factor 3, S.pombe	4.8	61	13	5.6
15		AA345644		PAN2 protein hypothetical protein FLJ10540	4.3	43	5	2.2
		AW263155	Hs.6616	ESTs	4.1	41	ĭ	2.6
		W20090 BE314949		hypothetical protein FLJ23309	3.8	425	111	4
		AW160993		hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20		AK000987		oxidation resistance 1	3.4	314	91	24
20		U82670	Hs.9786	zinc finger protein 275	3.5	35 .	1	2.1
		BE071382		hypothetical protein FLJ20170	3.5	105	30	9.6
		AW502285		hypothetical protein FLJ12879	3.2	37	12	3.5
		BE383234		Homo sapiens, cione MGC:15393, mRNA, com	6.2	62	2	5.9
25		AF027208		prominin (mouse)-like 1	8.1	328	41	1.7
20		R40576	Hs.21590	hypothetical protein DKFZp564O0523	4.2	125	30	7.4
		NM_015310		KIAA0942 protein	6.5	65	10	1.5
•		R44538		gb:yg29c02.s1 Soares Infant brain 1NIB H	3.3	33	10	2.3
		R41823	Hs.7413	ESTs; calsyntenin-2	6.1	185	31	6.6
30	112197	NM_00365	5Hs.5637	ESTs	3.5	507	145	3.3
	112198	AJ432672	Hs.288539	hypothetical protein FLJ22191	3.5	40_	12 -	2.5
•	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	112253	R51818		gb:yg77h12.s1 Soares infant brain 1NIB H	4	70	18	6.8
		R53734	Hs.25978	ESTs, Weakly similar to 2109260A B cell	3.7	37	1	3
35		AW972635		hypothetical protein FLJ12671	4.3	45 754	11	4.4
		AA863360		ESTs, Wealdy similar to fatty acid omega	2.8	751	270	1.3
		AK000914		hypothetical protein FLJ10052	3.5	41 42	12	3.7 3.6
		AW969785		Homo sapiens cDNA FLJ11321 fis, done PL	4.2 4.7	42 54	6 12	3.6 4.5
40		R68425	Hs.13809	hypothetical protein FLJ10648	4.8	48	2	3.4
40		AA412205		ESTs transmembrane, prostate androgen induced	4.5	390	87	5.3
		Z42387	Hs.83883	ESTs	3.2	99	31	3.1
		AL134324 Al571940	Hs.7549	ESTs	9.6	124	13	9
		N39342	Hs.103042	microtubule-associated protein 1B	9.1	91	6	8.3
45		AA283057		hypothetical protein FLJ14281	6.5	65	6	4.8
73		T66847	Hs.194040	ESTs. Wealdy similar to 138022 hypotheti	3.5	35	1	1.4
		AW449560		inner mitochondrial membrane peptidase 2	3.5	35	4	3.3
		AI791905	Hs.95549	hypothetical protein	7.6	76	1	4.2
		A1075407	Hs.296083	ESTs, Moderately similar to 154374 gene	3.1	453	148	7
50		AI869372	Hs.17207	Homo saplens cDNA FLJ11922 fls, clone HE	3.6	36	4	2.6
		T97307		gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		AL359588	Hs.7041	hypothetical protein DKFZp762B226	4.6	46	4	4.3
	113791	A1269096	Hs,135578	chitobiase, di-N-acetyl-	3.6	36	1	1.2
	113794	T62849	Hs.11090	membrane-spanning 4-domains, subfamily A	3.3	744	227	2.5
55	113804	BE247683	Hs.14611	dual specificity phosphatase 11 (RNA/RNP	3.3	180	54	2.1
	113808	W44735	Hs.9286	Homo saplens cDNA: FLJ21278 fis, clone C	5.1	51	5_	4.5
	113847	NM_00503	2Hs.4114	plastin 3 (T isoform)	3.2	238	75	2.1
		AA457211		bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
~ 0		AW002834		ESTs	6.1	110	18	10.2
60	113886	W76027	Hs.23920	hypothetical protein FLJ11105	4	48	12	4
		AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
		W17056	Hs.83623	nuclear receptor subfamily 1, group 1, m	4.3	819 123	191	1.2 7
		A1267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fi	4.4	123 44	12	2.3
C F	114030	AI825386	Hs.164478	hypothetical protein FLJ21939 similar to	4.4 4.5	45	6 4	2.6
65			Hs.177534	dual specificity phosphatase 10	3.5	45 35	6	3.2
	114057	AF116653	115.3415Z	Homo sapiens PRO0823 mRNA, complete cds	3.1	31	5	1.5
	114002	AK001612	173.20502	Homo sapiens cDNA FLJ10750 fis, clone NT	Φ.	٠.	•	

							40	
		W57554	Hs.125019		24.2	242 67	10 1	5.6 6.3
		AW384793		Homo saplens mRNA; cDNA DKFZp434E033 (fr	o. <i>1</i> 3.8	73	19	1.8
		AF155661 AF017445		pyrotees conjungations protections	4.4	104	24	5.1
5				isocoo i proopristo gomining	5.7	57	1	4.9
_				Homo saplens mRNA; cDNA DKFZp434B231 (fr	3.3	33	1	2.4
		H15261	Hs.21948	ESTs	4.2	46	11	1.4
	114306	AF100143	Hs.6540	and the same of th	4.5	45	2	3
		AF183810		2,440.1m.epinaago	4.4	44	1 166	3 5.8
10		AW970128		Committee of the commit	4.7 5.2	770 52	3	2.3
		A1521936	Hs.107149	novel protein similar to archaeal, yeast minichromosome maintenance deficient (S.	4.6	196	43	10
		A1859865 AF212848	Hs.154443 Hs.182339	ets homologous factor	13.7	137	1	8.9
		AV656017		CGI-76 protein	3.3	168	51	7.3
15		AA159181		serologically defined colon cancer antig	7.4	137	19	1.8
		AI648602	Hs.55468	ESTs	4.7	57	12	4.7
		AL157545		bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		BE165762		hypothetical protein from BCRA2 region	10.1	111	11 11	10.2 5
20		BE092696		ESTS CMAD DAD	6.4 35.9	67 359	10	29.7
20		AI733881	Hs.72472	BMP-R1B KIAA1376 protein	9.4	94	8	7.3
		AW162998 AA251089	N3.24004	abaso405.s1 NCL_CGAP_GCB1 Homo sapiens		115	1	6.9
		AA329340	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	9	1.1
		AW265668		hypothetical protein FL J12428	5.1	51	1	4.2
25	115061	Al751438	Hs.41271	Homo saptens mRNA full tength insert cDN	4.5	290	65	3.7
		NM_01415		HSPC067 protein	4.8	48 49	1 16	4.4 4.2
		AI623693	Hs.191533	ESTs	3.2 3.3	33	1	3
		AK000219 AW183695		hypothetical protein FLJ20212 ESTs	5.8	58	i	5
30		AW365434		hypothetical protein FLJ10116	5.5	343	62	2.5
30		AI422867	Hs.88594	ESTs	11.2	112	1	10.3
		BE545072	Hs.122579	hypothetical protein FLJ10461	4.5	96	21	7.8
		AK001468		aniilin (Drosophila Scraps homolog), act	5.9	59	1	4.2
20		NM_01231		laucine zipper, down-regulated in cancer	9.8 4.6	98 46	1 2	8.8 1.8
35		AA081395		Homo sapiens cDNA FLJ10366 fis, clone NT Homo sapiens mRNA; cDNA DKFZp564D0472 (44	7	1.1
		AJ088691 N36110	Hs.208414 Hs.305971	solute carrier family 2 (facilitated glu	3.2	372	115	2.1
		AW992356		Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
		W87707	Hs.82085	interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
40		AW992405	Hs.59622	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
		AW899053		F-box only protein 8	3.1	58	19	2.5 28.5
		AW582256		anterior gradient 2 (Xenepus laevis) hom	5.7	368 20	65 8	2.2
		AW338063		zinc-finger protein ZBRK1	3.9 4.2	39 79	19	1.9
45		R50956 BE300266	Hs.159993 He 28035	gycosyltransferase transducin-like enhancer of split 1, hom	5.8	58	1	4.4
43		Al373062	Hs.332938	hypothetical protein MGC5370	6.2	62	1	5.4
		AA291377		ESTs	3.2	40	13	0.7
		AJ745379	Hs.42911	ESTs	8.4	101	12	8.7
		AW673312		hypothetical protein FLJ20331	3.6	36	1	2
· 50			Hs.176376	ESTS	5.1	51	1 8	2
		AL133916		hypothetical protein FLJ20093	3.4 3.5	34 35	8	3.3
		AF126743 AF189011		DNAJ domain-containing putative ribonuclease til	4.5	45	9	3.4
		AW861622		Homo saplens cDNA FLJ14934 ffs, clone PL	5.2	52	4	3.9
55		AW976438		RBP1-like protein	3.8	38	7	2.1
		AV660717		DKFZP586N0819 protein	5.1	198	39	17.9
	116250	N76712	Hs.44829	ESTs, Wealdy similar to 138022 hypotheti	13.3	133	8	3.2
		AA328153		ESTs, Wealdy similar to A Chain A, Cryst	3.3	106	33	9.8
<i>c</i> o		Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fls, clone PL	4.8	179	38 55	2.8 3
60 .		AL133033		KIAA1025 protein	3.2 3.7	173 37	1	1.8
		AL133623 N50174		similar to mouse Xm1 / Dhm2 protein ESTs	3.7 3.9	37 39	10	0.6
		NOU174 AA448588	Hs.46765 Hs 71252	hypothetical protein DKFZp761C169	5.6	106	19	9
		AF191018		putative nucleotide binding protein, est	3.6	256	72	3.7
65		AI654450	Hs.47274	Homo sepiens mRNA; cDNA DKFZp564B176 (fr		119	39	2
	116461	AA313607		Homo sapiens cDNA: FLJ22145 fis, clone H	5.5	315	58	3.1
	116470	AJ272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6

					2.4	24		4.0
	116507		Hs.68501	ESTs leukemia-associated phosphoprotein p18 (3.1 3.3	31 931	4 279	1.9 5.6
	116579 /	AW888411	Hs.241567	RNA binding motif, single stranded inter	3.6	36	1	1.9
	116674		Hs.92127	ESTs	4.5	96	22	6.9
5			Hs.273829	ESTs	4.2	42	1	2.7
	116710		Hs.306088	v-crk avian sarcoma virus CT10 oncogene	7.1	71	9 44	6.9 5.4
		AA741307		hypothetical protein FU20073	4.3 22.8	190 228	9	12.4
	116786	HZ5836 AW362965	Hs.301527	ESTs, Moderately similar to unknown (H.s Homo septens cDNA FLJ14415 fis, clone HE	4.9	108	22	9
10			Hs.101174	microtubule-associated protein tau	4.6	163	35	7.3
10.	116844		Hs.337434	ESTs, Weakly similar to A46010 X-linked	6.9	69	10	2.4
			Hs.130093	ESTs	4.8	48	1	2.5 2.3
	117067		Hs.335797	ESTS	3.3 3.1	33 38	13	1.7
15	117129	H95/85 AW901347	Hs.167652 He 38592	ESTs, Highly similar to 1819485A CENP-E hypothetical protein FLJ23342	4.8	48	1	0.9
13	117170		Hs.42500	ADP-ribosylation factor-like 5	3.1	295	96	27.9
	117209		Hs.306881	MSTP043 protein	3.6	41	12	2.8
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83 21	4.4 1.3
20		AI041793	Hs.42502	ESTS	3.5 17.4	72 174	9	6.9
20	117412 117475		Hs.42645 Hs.93740	solute carrier family 16 (monocarboxylic ESTs, Weakly similar to 138022 hypotheti	3.2	35	11	0.7
		AW341639		hypothetical protein FLJ22059	5	50	1	4.7
	117667		Hs.44708	Ser-Thr protein kinase related to the my	4.5	211 i		5
			Hs.136102	KIAA0853 protein	4.6	46	1	3.8 2.7
25	117873		Hs.46624	HSPC043 protein	3.1 4.9	31 49	1	4.4
		A1521436 AA374756	Hs.38891	ESTs Homo sapiens mRNA for KIAA1771 protein,	5	50	2	3.1
		AI813865	Hs.164478	hypothesical protein FLJ21939 similar to	3.6	89	25	0.9
		AF091434		platelet derived growth factor C	3.2	378	117	2.8
30		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5 3.1	145 199	1 64	2.4 1
	118475		11- 42220	gb:za46c11.s1 Soares fetal liver spleen Homo saplens cDNA FLJ11835 fis, clone HE	3. I	60	5	3.7
	118509	N22017 Al949952	Hs.43228 Hs.49397	ESTs	3.3	81	25	1.5
	118828		Hs.50824	EST, Moderately similar to 154374 gene N	3.4	740	217	2.8
35			Hs.173001	hypothetical protein FLJ13964	4.3	162	38	12.1
	118854		Hs.10450	Homo sapiens cDNA: FLJ22063 fis, clone H	3.4 3.5	118 35	35 1	2.3 2.9
		A1824009		ESTs ESTs	8.4	84	10	0.8
		A)191811 AW292577	Hs.54629 Hs.94445	ESTs	7.3	73	3	5.4
40		N29309	Hs.39288	ESTs	5	50	5	4.7
	118991	NM_01665	7Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7	37 ~~	6	0.5 0.6
	119023		11. 00700	gb:zb82h01.s1 Soares_senescent_fibroblas	3.3 3.3	36 167	11 51	2.6
	119088	R39261 R45175	Hs.90790 Hs.117183	Homo sapiens cDNA; FLJ22930 fis, clone K ESTs	5.3	53	6	2.3
45		H09334	Hs.92482	ESTs	3.7	37	4	3
		AJ061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
	119298	NM_00124	1Hs.155478	cyclin T2	4 3.3	40 571	4 171	1.2 2
		BE048061		ephrin-A3 ribosomai protein L34	3.4	34	3	24
50		T78324	Hs.250895 ' Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
50	119580	AL079310	Hs.92260	high-mobility group protein 2-like 1	8.1	94	12	6.5
	119586	AF088033	Hs.159225	ESTS	3.3	33	8	0.9
	119638	NM_01612	2Hs.56148	NY-REN-58 antigen	3.3	33 54	10 1	0.5 4.1
55	119676	AA243837	HS.57787	ESTS P. coll Ct I Americano 11P (zinc finger pro	5.4 4.6	46	7	0.8
55		AA916317 AI905687	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro EST	3.5	2073	595	2.1
			25Hs.191381	hypothetical protein	4.4	44	1	3.1
	119786	AL133396	Hs.121281	prion protein 2 (dublet)	3.4	34	1	2.5
			Hs.43213	ESTs, Wealdy similar to IEFS_HUMAN TRANS	3.6	36 52	1 6	2.9 1.8
60			Hs.58461	ESTs, Weakly similar to A35659 krueppel-	5.2 3.7	37	4	1.9
			Hs.58698 Hs.272531	ESTs DKFZP586B0319 protein	6.9	162	24	2.6
			Hs.14158	copine III	3.7	590	159	3.8
	120132	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	319	47	2.1
65	120150	BE005771	Hs.153746	hypothetical protein FLJ22490	5.3	53 406	5 24	0.9
	120215	AF109219	Hs.108787	phosphatidylinositol glycan, class N	3.2 3.4	106 34	34 1	3.3 1.7
	120260	AKUUUU61	Hs.101590	hypothetical protein	3,4		•	1.7

	420200	A110000044	II. 200000	humotholical sentals EL 199300	4.2	124	30	1.8
		AW995911 R06859	Hs.193172	hypothetical protein FLJ23399 ESTs, Weakly similar to 138022 hypotheti	7.5	112	15	2.5
		AA223249		abl-interactor 12 (SH3-containing protei	3.3	33	10	2.8
		AW966893	Hs 26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (f		48	1	0.5
5		AA251973		ESTS	3.4	34	4	0.1
_		AW968080		Homo sapiens clone 24630 mRNA sequence	3.9	161	42	2
	120524	AA261852	Hs.192905	ESTs	6.8	68	1	0.2
	120554	AA284447	Hs.271887	ESTs	3.2	32	5	0.6
		BE244580		hypothetical protein FLJ10330	8.5	127	15	1.6
10		AB037744		KIAA1323 protein	3.7	37	1	0.5
		H39599	Hs.294008	ESTS	3.6	36	8	0.2 1.6
		AA703226		Homo saplens mRNA; cDNA DKFZp586B211 (fr		101 54	18 10	2.5
		AA687322		leucine zipper protein FKSG14	5.4 3.2	32	8	3
16		Al952639	Hs.98267	ESTs Homo sapiens cDNA FLJ12727 fis, clone NT	5.3	. 58	11	3.3
15		AW449855 Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
		AA347422		EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
		AL135556		ESTs	3.5	37	11	0.1
		AA481003		ESTs	3.1	31	1	0.4
20		AA398155		ESTS	7.9	79	1	2.7
		A)972375	Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
		AL042981		KIAA1201 protein	3.7	37	10	1
	121176	AL121523	Hs,97774	ESTs	7	70	1	0.9
	121202	AA970946	Hs.97794	ESTs	3.9	39	1	0.2
25	121429	AA406293	Hs.41167	ESTs	3.4	34	1	0.8
		AF044197		B-cell attracting chemoline 1 (CXCL13;	3.5	35 402	1	2.6
		AK000282		hypothetical protein FLJ20275	10.3	103 143	1 41	9.3 2.6
		A)002968	Hs.235402	ESTs, Wealdy similar to T26525 hypotheti	3.5 4.6	46	3	0.8
20		AA412488	Hs.48820	TATA box binding protein (TBP)-associate	4.2	77 77	19	1.4
30		AA412494	HS.98102	chczu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	0.8
		AA416568 Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (i		34	10	0.7
		AA243499		hypothetical protein FLJ10134	2.9	214	74	3.7
		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	3.9	39	1	0.2
35		AA425887		hypothetical protein FLJ14303	4.4	48	11	0.9
50		AV650929		splicing factor (CC1.3)	3.6	150	42	3.2
		A1249368	Hs.98558	ESTs; protease inhibitor 15 (P115)	2.7	864	321	0.6
	121916	AW117207	Hs.98523	ESTs	3.5	35	3	2.3
		AI810721	Hs.95424	ESTs	4.9	49	7	3.7
40		AW794215		KIAA1085 protein	3.2	88	28	1.2 7.5
		AF169797		adaptor protein containing pH domain, PT	126 4.1	126 43	7 11	1.6
		AA436475		membrane-associated nucleic acid binding	3.1	43 31	1	1.0
		Al298368	Hs.150926	fucose-1-phosphate guanylyttransferase ESTs	3.3		16	4
45		AA446189 BE567620		ESTS	3.2	53 291	91	4
43		AA449453		ESTS, Weakly straiter to ALU1_HUMAN ALU S	3.1	31	6	0.8
		AW651706		hypothetical protein FLJ14007	3.5	35	1	3
		AA454149		EST	3.2	32	10	3.1
		AW366286		splicing factor (CC1.3)	3.2	36	11	25
50	122861	AA335721	Hs.119394	ESTs	5.6	108	20	1.8
	122873	AA749382	Hs.118797	ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
		AI718702	Hs.308026	major histocompatibility complex, class	3.7	162	44	12.4
,		AA478446		KIAA1096 protein	7.2	72	1 .	5.7
		AA447871		ESTs, Weekly similar to 138022 hypotheti	4.7	59	13	4.7
55		AW338067		Homo saplens cDNA FLJ11946 fis, clone HE	3.3	207 207	63	3.5 5.5
		AL135185		niban protein	3.8 9.9	207 351	55 36	13.9
			Hs.100686	ESTs, Weakly similar to JE0350 Anterior	4.1	72	18	1.5
			Hs.105273 Hs.293796	ESTs	3.7	41	11	1.6
60			Hs.111496	Homo sapiens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
UU	123992	MACGGGG	Hs.112493	Homo saplens mRNA; cDNA DKFZp564D036 (fi		34	ī	2.6
	123443	BENJOYES	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA.	9.7	102	11	6
	123404	AW179019	Hs.112110	mitochondrial ribosomal protein L42	4.2	42	7	2.9
	122503	AW975051	Hs.293156	ESTs, Wealthy similar to 178885 serine/th	3.9	39	1	3.2
65	123516	AB037860	Hs.173933	nuclear factor I/A	4.3	43	1	3.5
	123518	AL035414	Hs.21068	hypothetical protein	5.8	58	1	4.9
	123523	AA608588		gb:ae54e06.s1 Stratagene lung cardnoma	3.1	927	295	2.1

	122522	AE4EMMR	Lle 409277	damage-specific DNA binding protein 1 (1	5	121	25	5.9
		AF150208 AA608955		ESTs	6.8	68	10	6.1
		AA602964	113.105000	20.0	8.5	85	1	4.3
		BE550112			3.9	39	5	3.7
5		AA706910		ESTs	3.9	60	16	4. B
_		AA425769		Miles of coronmuct incomes as	3.4	80	24	3.8
		AW082862		hypothetical protein FLJ23189	4.5	45	2	3.6
	124006	Al147155	Hs.270016	ESTS	5.8	321	55	17
	124059	BE387335	Hs.283713	ESTs, Wealdy similar to S64054 hypotheti	10.4	880	85	5.3
10	124287	H88296	Hs.5123	Inorganic pyrophosphatase	3.1	41	14	2.7
	124292			Homo sapiens cDNA: FLJ23567 fis, clone L	3.2	32	1	1.5
		AA249027		ribosomal protein S6	10.5	105	1	9.9 12.2
		NM_005402		v-ral simian leukemia viral oncogene hom	12.8	141 31	1	1.8
16		AF283776		Homo saplens mRNA; cDNA DKFZp586C1723 (f	3.3	33	i	1.7
15		AJ821780	Hs.179864	ests ab:ve84c03.s1 Soares fetal liver spleen	4.2	42	ż	3
		R01073	Un 440227	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.4	210	63	3.3
		R41933	Hs.140237 Hs.103804	heterogeneous nuclear ribonucleoprotein	6.5	162	25	14.7
	125079		Hs.271396	ESTs	3.1	31	6	2.4
20		T91518	113,27 1330	gb;ye20905.s1 Stratagene lung (937210) H	3.4	985	286	2.8
20		AA570056	He 122730	ESTs, Moderately similar to KIAA1215 pro	3.6	224	63	4
		AB037742		KIAA1321 protein	6.3	63	6	5
		W38240		Empirically selected from AFFX single pr	3.6	38	11	2.6
		W93048	Hs.250723	hypothetical protein MGC2747	3.1	31	1	2.8
25		AA782536	Hs.122647	N-myristoyitransferase 2	3.2	37	12	3.6
	125279	AW401809	Hs.4779	KIAA1150 protein	13.1	131	1	5.1
	125299	T32982	Hs.102720	ESTs	7.7	81	11	7.6
			Hs.288193	hypothetical protein MGC12217	14.3	143	9 11	13.1 3.2
~~		W72949	Hs,77495	UBX domain-containing 1	3.3 8.2	34 124	15	11.5
30		AL038165		translocase of outer mitochondrial membr	3.7	224	61	21
		AA421691		UDP-glucose ceramide glucosyltransferase	5.7 6.7	67	1	6
			Hs.164950	ESTs acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
		T62641	Hs.278544 Hs.241493	natural killer-tumor recognition sequenc	5.5	63	12	1
35 ·		AW292171		scaffold attachment factor B	4.3	68	16	2.8
33			Hs.191356	general transcription factor IIH, polype	4.8	48	5	4.1
			Hs.75722	ribophorin II	6.8	223	33	2.8
		AA143045		v-kit Hardy-Zuckerman 4 feline sarcoma v	8.3	87	11	0.4
		NM 00340		YY1 transcription factor	11.3	124	11	9.7
40		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (30.6	306	4	26.5
		T30968	Hs.13531	hypothetical protein FLJ10971	4.9	68	14	1.4
		AW090198		KIAA1150 protein	6.4	74	12	6.6
		W78968	Hs.181307	H3 histone, family 3A	5	264	53 1	3.4 2.7
4.5		AA3161B1		six transmembrane epithelial antigen of	3.8	38 36	6	2.9
45			Hs.181297	ESTs	3.6 3.1	31	1	2.5
			Hs.172028	a disintegrin and metalloproteinase doma	4.4	76	18	1
			Hs.102178	syntaxtn 16 hypothetical protein FLJ10936	3.8	38	1	3
		AW663887 AW163483		double ring-finger protein, Dorfin	6.7	155	23	1.4
50			Hs.279609	mitochondrial carrier homolog 2	8.8	110	13	10.5
50		AA129640		ESTs	3.6	36	10	1.9
		T26989	Hs.283664	aspartate beta-hydroxylase	5.5	79	15	4.4
	127167	AA625690	Hs.190272	ESTs	3.1	33	11	2.3
			Hs.128638	ESTs	3.5	35	1	3.1
55	127349	AA412108	Hs.269350	ESTs	4.8	106	22	1
		D60237	Hs.14368	SH3 domain binding glutamic add-rich pr	7.5	75	1	6.5
	127537	AI926047	Hs.162859	ESTs	3.8	38	7	3.4
	127542	AA703684	Hs.245474	ESTs, Moderately similar to ALU5_HUMAN A	3.3	33	9	0.9
	127677	AF175265	Hs.264190	vacuotar protein sorting 35 (yeast homol	4.3	152	35	125
60	127774	AA313839	Hs.119488	cystein-rich hydrophobic domain 2	5.4	73 81	14 16	6.8 1.1
	127999	AW978827	Hs.69851	nucleolar protein family A, member 1 (H/	5.2 3.9	220	57	2.5
	128218	AA186733	Hs.292154	stromal cell protein	3.9 9.4	94	3	5.3
	128309	AND 4968	Hs.279009	matrix Gla protein Homo sapiens mRNA; cDNA DKFZp564B222 (fi		46	8	3.9
65	128470	ALU499/4	Hs.100261 Hs.296251	programmed cell death 4	7.2	72	1	5.8
65	120402	7,0009190 1 A1422E70	Hs.199009	protein containing CXXC domain 2	3.8	38	i	0.9
	120001	NLIODIZ NIMBOARA	3 Hs.100861	hypothetical protein FLJ14600	5.6	73	13	6.1
	120317	Viionan	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,p				

	128530	Al932995	Hs.183475	Homo saplens clone 25061 mRNA sequence	4.2	104	25	7.8
	128579	N25956	Hs.101810	Homo sapiens cDNA FLJ14232 fis, clone NT	3.1	172	55	3.1
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	3.3	105	32	3
_		N48373	Hs.10247	activated leucocyte cell adhesion molecu	7.3	106	15	5
5		D87432	Hs.10315	solute carrier family 7 (cationic amino	3.1	31	1	2.2
		AA307211		proteasome (prosome, macropain) subunit,	3.6	130	36	3.5
		NM_00413 AF026692		granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
		AB011125		secreted frizzled-related protein 4 KIAA0553 protein	17.4 3.1	409 34	24 11	7.8 2.7
10		NM_01472		Ste20-related serine/threonine kinase	3.6	36	5	1.5
10		AK001731		Homo sapiens mRNA; cDNA DKFZp586H0924 (288	87	7.9
		R57988	Hs.10706	epitheliai protein lost in neoplasm beta	11.3	113	8	2.5
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15	129017	AA115333	Hs.107968	ESTs	8.2	82	1	7.4
	129075	BE250162		dihydrofolate reductase	5	50	1	3.3
		L12350	Hs.108623	thrombospondin 2	3.2	814	257	2.4
		N23018	Hs.171391	C-terminal binding protein 2	4.4	44	1	3.8
20		Al132988	Hs.109052	chromosome 14 open reading frame 2	14.2	142	6	9.4
20		AF013758		polyadenylate binding protein-interactin	7.1	71	1	6.2
		BE169531		TAK1-binding protein 2; KIAA0733 protein	5	64 75	13 15	6.3 6.4
		AF220050 NM_01534		uncharacterized hematopoletic stem/proge leptin receptor overlapping transcript-l	5.2 3.7	39	11	3.2
		NM_01491		KIAA0990 protein	9.5	95	ï	8.5
25		AL049538		ras association (RatGDS/AF-6) domain con	7.6	92	12	1.4
		BE220806		Homo saplens clone 23785 mRNA sequence	7.1	150	21	14.5
		BE219987		phosphatidylinositol glycan, class F	3.9	54	14	5.1
		X61959	Hs.207776	aspartylglucosaminidase	3.6	36	1	2.7
	129486	NM_00575	4Hs.220689	Ras-GTPase-activating protein SH3-domain	4	40	4	3.2
30		AW964541		hypothetical protein FLJ21127	4.6	199	44	2.3
		N30436	Hs.11556	Homo saplens cDNA FLJ12566 fts, clone NT	4.2	42	1	3.8
		M26939	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
		BE242144		ATP-binding cassette, sub-family E (OABP	4.8	48	8 30	3.8
35		NM_001419 BE165866		eukaryotic translation initiation factor nuclear receptor subfamily 1, group 1, m	5.8 4.5	171 45	1	2.9 2.4
<i>)</i>		R42216	Hs.12342	Homo sapiens clone 24538 mRNA sequence	5.3	53	9	3.6
		R39246	Hs.239666	Homo saplens dDNA FLJ13495 fis, clone PL	3.1	31	2	2.5
		AB028945		cortactin SH3 domain-binding protein	11.4	114	1	10
		Al222069	Hs.13015	hypothetical protein similar to mouse On	4.7	556	119	4.5
40	129965	T71333	Hs.13854	ESTs	3.1	31	3	3
	129977	NM_00039	9Hs.1395	early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2
		BE061916		chromosome 8 open reading frame 2	6.7	67	1	5.7
		AF027153		solute carrier family 5 (Inositol transp	1	1	1	1
45		AK001635		hypothetical protein FLJ10773	14.6	219	15 434	7.6
43		T47294 AW977534	Hs.149923	X-box binding protein 1 calcium/calmodulin-dependent serine prot	3.1 5.3	1336 53	9	1.4 3.2
		U38847	Hs.151518	TAR (HIV) RNA-binding protein 1	4.2	46	11	1.1
		AB040914		KIAA1481 protein	13.2	331	25	12.4
		AF127577		nuclear receptor interacting protein 1	3.3	354	108	4
50		AL135301		hypothetical protein FLJ10849	8.1	81	9	5.5
	130385	AW067800	Hs.155223	stanniocalcin 2	72.2	722	1	1.9
		BE385099		hypothetical protein MGC3017	6.5	65	4	5.3
		AW163518		huntingtin Interacting protein 2	3.5	79	23	2.5
EE		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55		D90041	Hs.155956	N-acetytransterase 1 (arylamine N-acety	10.8	706	66	9.2
		W19744 AW876523	Hs.180059	Homo sapiens cDNA FLJ20653 fis, clone KA	3.9 3.9	39 39	1	1.9 2.6
		AA383092		hypothetical protein FLJ12910 replication protein A3 (14kD) ^	3.8 4.4	39 44	1	4.1
		AA383256		estrogen receptor 1	32.2	322	i	4.7
60		Al354355	Hs.16697	down-regulator of transcription 1, TBP-b	5.2	251	48	21
-		M90516	Hs.1674	glutamine fructose-6-phosphate transamin	10	100	1	7.6
		AI963376	Hs.12532	chromosome 1 open reading frame 21	3.9	39	1	3.4
	130625	AF176012	Hs.260720	J domain containing protein 1	10.5	105	1	9
		AL161961	Hs.17767	KIAA1554 protein	6.8	129	19	12.1
65		R62676	Hs.17820	Rho-associated, colled-coil containing p	4.1	41	1	3.6
	130693		Hs.17962	ESTs	9.2	234	26	16.8
	130/12	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8

	130723	BE247676	Hs.18442	E-1 enzyme	8.1	81	3	2.8
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	4.9	49	1	4.3
	130780	AA197226	Hs.19347	hypothetical protein MGC11321	3.6	100	28	6.6
_	130863	Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
5	130871	AF080158	Hs.226573	inhibitor of kappa light polypeptide gen	10.5	121	12	1.6
		AL044315		Homo saplens mRNA for KIAA1750 protein,	6	202	34	3.7
	130974	NM_003528	3Hs.2178	H2B histone family, member Q	7.1	100	14	7.5
	130979	NM_012448	iHs.169833	single-stranded-DNA-binding protein	3.2	87	27	1.7
	130987	BE613269	Hs.21893	hypothetical protein DKFZp761N0624	3.5	124	35	6.5
10	130993	T97401 .	Hs.21929	ESTs	4.5	45	1	2.5
	131076	AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	3.2	210	66	3.8
	131085	BE207357	Hs.3454	KIAA1821 protein	3.8	42	11	0.6
	131126	NM_016158	SHs.181326	KIAA1073 protein	6.7	67	6	1.9
	131129	BE541042	Hs.23240	Homo saplens cDNA: FLJ21848 fis, clone H	5.8	115	20	2.5
15		AW953575		p53-induced protein PIGPC1	3.8	585	153	3.7
	131164	AW013807	Hs.182265	keratin 19	5.2	1320	256	3.2
		AA465113		ESTs, Wealdy similar to A34615 profilegg	3.8	38	1	3.3
	131200	BE540516	Hs.293732	hypothetical protein MGC3195	4.8	48	1	4,1
	131216	A1815486	Hs.243901	Homo saplens cDNA FLJ20738 fls, clone HE	6.1	343	56	16.4
20	131245	AL080080	Hs.24766	thioredoxin domain-containing	8	100	13	2.9
	131248	AI038989	Hs.332633	Bardet-Biedi syndrome 2	4	95	24	1.1
		AW206008		Homo sapiens dDNA: FLJ21778 fls, done H	4.6	239	53	3.5
	131319	NM_003153	5Hs.25590	stanniocalctn 1	3.5	402	114	2.1
			Hs.173933	nuclear factor I/A	3.3	775	233	2.4
25		AW293165		ESTS	3.8	38	1 .	3
		AK001123		hypothetical protein FLJ10261	3.9	116	30	0.5
		NM_014810		KIAA0480 gene product	7.6	76	1	5
		AA992841		KIAA1458 protein	5.1	113	22	6.1
		A)452601	Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169	20 63	4.6 18.7
30		AV661958		GK001 protein	3.1	197	1	4.4
		N22120	Hs.75277	hypothetical protein FLJ13910	5.9	59 54	i	3.9
		AL355715		programmed cell death 9 (PDCD9)	5.1 3.8	51 70	21	6.9
		AA093668		muscleblind (Drosophila)-like		79 250	88	3
25		NM_003512		H2A histone family, member L	4	350 381	81	6.4
35		T93500	Hs.28792	Homo saplens cDNA FLJ11041 fis, done PL	4.7 4.6		7	3.8
		AA306477		hypothetical protein FLJ10687	4.6	46 82	26	6.6
		NM_002104		granzyme K (sarine protease, granzyme 3;	3.2 6.7	93	14	8.4
		BE297635		heat shock 70kD protein 9B (mortalin-2)	3.8	53 51	14	1.7
40		AB012124		transcription factor-like 5 (basic helix	7.2	72	4	5.7
40		AW963776		SAR1 protein	21	1561	757	1.7
		AF017986		secreted frizzled-related protein 2	11.7	117	1	10.1
		AA961420		ESTS	4.8	48	i	4.6
		AB014548		KIAA0648 protein	3.2	207	64	5.5
15		D87077	Hs.196275	KIAA0240 protein adenovirus 5 E1A binding protein	3.4	115	34	9.1
45		X86098	Hs.301449 Hs.32990		5.8	91	16	1.4
		W00712	Hs.3321	DKFZP566F084 protein ESTs, Highly similar to IRX1_HUMAN IROQU	4.9	632	129	1.7
		A1681917	Hs.156346	topoisomerase (DNA) il alpha (170kD)	6.8	68	1	5.6
		J04088 AW361018		upstream regulatory element binding prot	4	140	35	1.8
50		BE502341		ESTs	5.7	57	1	4.5
50	131003	AF078866	15.3102 No 204206	Homo sapiens cDNA: FLJ22993 fls, ctone K	5.5	90	17	2.9
		T15803	Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6	95	17	9.1
		BF252983		ubiquitin specific protease 1	7.4	103	14	6.5
		NM_00291		replication factor C (activator 1) 4 (37	3.7	37	1	3.4
55	131943	AK000010	Un 259709	hypothetical protein FLJ20003	3.5	35	i	2.5
33		W79283	Hs.35962	ESTs	5.5	168	31	4.4
	131900	U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
	1313//	AA503020		hypothetical protein FLJ22418	40.2	402	1	4
	131303	A1878910	115.30000 14e 3688	cisptatin resistance-associated overexpr	7.3	73	i	1.2
60	131333	AA121098	He 3838	serum-inducible kinase	22.6	226	10	0.9
UU	132009	NM_01604	5He 30/5	CGI-107 protein	3.1	227	73	16.8
	132059	AW190902	He ANNOR	cysteine knot superfamily 1, BMP antagon	3.5	73	21	6.3
	132109	AW190802 AW960474	110.40030 Lle 40320	ESTs	3.6	141	39	12.6
	132110	NETOUNA NETOUNA	Hs.7972	KIAA0871 protein	4.9	49	1	4.1
65	132343	D52059	Hs.295923	seven in absentia (Drosophila) homolog 1	4.4	53	12	2.1
65	132760	W26406 AI752235		procollagen-lysine, 2-oxoglutarate 5-dio	5	225	45	9.1
	132764	NM_00446	I ELT I E I U	fibroblast activation protein, alpha	10.7	433	41	7.2
	13216	MINICOUPING	U1 10.4 IU	क्षाच्याच्या वर्णाच्यातः (मण्डला, व्यक्षाव	••		•••	

					4-	
	132197 Al699482 Hs.42151	ESTs	3.4	58	17	4
	132256 A1078645 Hs.431	murine leukemia viral (bmi-1) oncogene h	4.2	42	1	2.2 3
	132298 NM_015986Hs.7120	cytokine receptor-like molecule 9	3.4 49.6	34 186	2 10	3 1.5
_	132316 U28831 Hs.44566	KIAA1641 protein	18.6 5.5	323	59	10.5
5	132325 N37065 Hs.44856	hypothetical protein FLJ12116	3.3	979	298	2.2
	132358 NM_003542Hs.46423 132384 AA312135 Hs.46967	H4 histone family, member G HSPCO34 protein	3.6	36	1	3.1
	132388 W32624 Hs.278626	Arg/Abt-interacting protein ArgBP2	5.9	186	32	3.7
	132393 AL135094 Hs.47334	hypothetical protein FLJ14495	4.2	159	38	7.1
10	132407 BE613126 Hs.47783	B aggressive lymphoma gene	4.6	46	1	4.3
	132425 N87549 Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
	132440 AB020699 Hs.112751	KIAA0892 protein	3.3	33	4	2.9
	132465 AW169847 Hs.49169	KIAA1634 protein	8.3	145	18	3.7
	132522 AB023164 Hs.5070	KIAA0947 protein	4.6	46	1	4.4
15	132528 T78736 Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4 4.4
	132530 AA308105 Hs.50785	SEC22, vesicle trafficking protein (S. c	4.9	49 201	17	19.1
	132543 BE568452 Hs.5101	protein regulator of cytokinesis 1	11.8 3.8	201 38	ĭ	3
	132572 Al929659 Hs.237825	signal recognition particle 72kD Homo saplens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20	132592 AW803564 Hs.288850	hypothetical protein DKFZp586F1122 simil	6.1	61	2	5.9
20	132602 AW606927 Hs.5306 132616 BE262677 Hs.283558	hypothetical protein PRO1855	3.4	193	58	12.3
	132617 AF037335 Hs.5338	carbonic anhydrase XII	14.2	390	28	22.5
	132618 AL050025 Hs.279916	hypothetical protein FLJ20151	3.3	909	274	3.2
	132632 AU076916 Hs.5398	quantne monphosphate synthetase	5	50	1	4.1
25	132668 AB018319 Hs.5460	KIAA0776 protein	4.2	171	41	12.6
	132742 AA025480 Hs.292812	ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
	132790 AW242243 Hs.168670	peroxisomal famesylated protein	3.7	37	1	2.2
	132811 U25435 Hs.57419	CCCTC-binding factor (zinc finger protei	7	115	17	5.4
	132852 AL120050 Hs.58220	Homo saplens cDNA: FLJ23005 fis, clone L	3.3	61	19 1	5.1 3.6
30	132856 NM_001448Hs.58367	glypican 4	4.8 12.6	48 126	8	9.9
	132880 BE077155 Hs.177537	hypothetical protein DKFZp761B1514	11	187	17	10.4
	132902 Al936442 Hs.59838	hypothetical protein FLJ 10808 geminin	3.3	108	33	2.6
	132906 BE613337 Hs.234896 132914 AL047045 Hs.60293	Homo sapiens clone 122482 unknown mRNA	3.5	110	32	2.1
35	132968 AF234532 Hs.61638	myosin X	4.1	62	15	4.9
33	132977 AAD93322 Hs.301404	RNA binding motif protein 3	22.1	221	9	17.8
	132990 X77343 Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
	132994 AA112748 Hs.279905	clone HQ0310 PRO0310p1	3	380	127	5.5
	133011 NM_006379Hs.171921	sema domain, immunoglobulin domain (lg),	7.3	271	37	2.3
40	133015 AJ002744 Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427 20	93 1	10.4 3.1
	133070 U92649 Hs.64311	a disintegrin and metalloproteinase doma	3.6 5.2	36 117	23	5
	133091 AK001628 Hs.64691	KIAA0483 protein vacuolar protein sorting 26 (yeast homol	3.1	359	118	2.5
	133192 AA218564 Hs.67052	hypothetical protein FLJ20671	5.1	58	12	5.7
45	133197 Al275243 Hs.180201 133199 AF231981 Hs.250175	homolog of yeast long chain polyunsatura	3	816	275	3.9
43	133221 W32474 Hs.301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
	133240 AK001489 Hs.242894	ADP-ribosylation factor-like 1	8.1	81	1	4.6
	133271 Z48633 Hs.283742	H.sapiens mRNA for retrotransposon	124	124	6	10.8
	133291 BE297855 Hs.69855	NRAS-related gene	3.3	33	1	2.9
50	133294 AJ001388 Hs.69997	zinc finger protein 238	7,9	234	30	18.9
	133350 Al499220 Hs.71573	hypothetical protein FLJ10074	4.6	46	5	3.5 0.7
	133362 AK001519 Hs.7194	CGI-74 protein	5	110	22 227	9.7 3.2
	133370 AF245505 Hs.72157	DKFZP56411922 protein	3.2 4.1	725 374	91	1.1
E E	133407 AF017987 Hs.7306	secreted frizzled-related protein 1	4.3	43	1	3.9
55	133422 AB033061 Hs.73287	KIAA1235 protein Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
	133435 Al929357 Hs.323966 133479 W01556 Hs.238797	ESTs, Moderately similar to 138022 hypot	3.5	35	7	2.1
	133493 AW998046 Hs.194369	arolnine quitamic acid dipeptide (RE) re	3.6	39	11	0.4
	133504 NM_004415Hs.74316	desmoplakin (DPI, DPII)	4.1	640	158	3
60	133517 NM_000165Hs.74471	gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
00	133536 W25797 Hs.177486	amyloid beta (A4) precursor protein (pro	3.2	226	71	2.8
	133578 AU077050 Hs.75066	translin	3.4	178	53	8.8
	133633 D21262 Hs.75337	nucleolar and colled-body phosphprotein	4.7	47	1	4
	133640 AW246428 Hs.75355	ubiquitin-conjugating enzyme E2N (homolo	8.5	85 26	1	7.2 0.4
65	133669 NM_006925Hs.166975	splicing factor, arginine/serine-rich 5	3.6	36 234	1 68	10.7
	133681 Al352558 Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	3.4 9.3	234 93	1	7.8
	133746 AW410035 Hs.75862	MAD (mothers against decapentaplegic, Dr	3.3	33	•	

				N. S. C. C. L. v. O. O.D. varilla also footback	22	560	174	2.6
	133765		Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2 5.4	144	27	13.3
		AA557660		decorin	4.7	47	1	4.1
		BE622743		arfaptin 1	3.3	380	114	4.9
5		NM_002462		myxovirus (inituenza) resistance 1, homo Homo sapiens mRNA; cDNA DKFZp564B1264 (f		304	46	7.8
,		AW630088 AA147026		ESTs	6.2	600	97	4.1
•		AU076964		calumenin	3.3	889	267	5
			ns.7755 Hs.232068	transcription factor 8 (represses Interf	3.7	91	25	2.6
	133990			Homo sapiens mRNA; cDNA DKFZp564C1216 (f		91	27	8.5
10		AA535244		RAB2, member RAS oncogene family	7.8	78	1	5.6
10		NM_005025		serine (or cysteine) proteinase inhibito	5.9	59	1	3.3
		AF091622		KIAA0244 protein	5.8	58	1	4.9
			Hs.173824	thymine-DNA glycosylase	6.4	100	16	4.4
	134089		Hs.79029	ESTs	5.1	51	9	3.8
15		NM 004354		cyclin G2	5	50	1	3.2
		BE513171		mitochondrial ribosomal protein L3	4.8	246	51	3.9
			Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
		NM_014781	Hs.50421	KIAA0203 gene product	4.6	69	15	5.8
			Hs.80612	ublquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20	134257	C05768	Hs.8078	Homo sapiens clone FBD3 Crl-du-chat crit	3.4	34	5	2.6
	134272	X76040	Hs.278614	protease, serine, 15	3.6	36	1	2.8
	134282	R45621	Hs.81057	hypothetical protein MGC2718	6.7	67	9	5.7
	134288	AI022650	Hs.8117	erbb2-interacting protein ERBIN	4.5	137	31	12
		BE538082		ESTs, Moderately similar to A46010 X-lin	5.2	52	1	4.9
25	134326	AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (vers	8.6	568	66	22.4
		AW959281		ESTs	4.8	53	11	3.7
		AW291946		interleuktn 6 signal transducer (gp130,	7.1	71	4	6.4
		NM_001982		v-erb-b2 avian erythroblastic leukernia v	3	68	23	2.8
20		AA339449		phosphoribosylglycinamide formyltransfer	4.4	44	1 34	4.1
30			Hs.8236	ESTs	13.3	445 45	2	6 3.4
		AU077143		minichromosome maintenance deficient (S.	4.5 6	43 60	5	5.9
		AA456539		lysosomal	4.1	301	73	6.1
	134401		Hs.211577	kinectin 1 (kinesin receptor)	4.6	1216	267	4.4
35		AW067903	Hs.82911	collagen, type XI, alpha 1 protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
22	134417			solute carrier family 35 (CMP-sialic aci	4.9	49	3	3.8
	134419	W95642	Hs.82961	trefoil factor 3 (Intestinal)	3.2	1872	592	3.3
		AU077196		collagen, type V, alpha 2	6.3	1075	171	3.8
		U29344	Hs.83190	faity acid synihase	3.3	710	217	2
40		X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12 ·	5.1
		AF061739		protein associated with PRK1	4.8	153	32	4.3
			Hs.84087	KIAA0143 protein	3.1	147	48	12.7
		BE091005	Hs.74861	activated RNA polymerase II transcriptio	3.3	.33	1	2
	134542	M14156	Hs.85112	insufin-like growth factor 1 (somatomedi	4.2	42 39	5	2.6
45		U66615	Hs.172280	SWI/SNF related, matrix associated, acti	3.9		1	2.5
	134590	AW903849	Hs.173840	HUEL (C4orf1)-Interacting protein	3.7	41	11	0.6
	134604			RAP1A, member of RAS oncogene family	5.2	52	1	3
		AW068223		ubiquitin C-terminal hydrolase UCH37	4.9	49	1	3.7
~~		AW299723		bone morphogenetic protein receptor, typ	5.2	52	5	3.5
50				hypothetical protein FLJ10879	6.4	64	1	5.1 10.8
		A1750878	Hs.87409	thrombospondin 1	12.6	126	1 15	2.6
•		AF271212		disrupter of silencing 10	5.4 3.4	81 179	52	1.5
	134/00	AK000606	Hs.88974	golgi SNAP receptor complex member 1 cytochrome b-245, beta polypeptide (chro		143	45	13.9
55		X04011			3.2 7	70	6	6
33		AF129536 BE281128		F-box only protein 6 TONDU	3.1	31	1	23
		Al879195	Hs.90606	15 kDa selenoprotein	5.7	57	i	5
		X87241	Hs.166994	FAT tumor suppressor (Drosophila) homolo	3.2	153	48	4.7
		AL137491		Homo sapiens mRNA; cDNA DKFZp434P1530 (452	114	2
60		AK002085		Homo septens cDNA FLJ11223 fis, clone PL	5.1	150	30	7.2
v		AW968058		nudix (nucleoside diphosphate linked mol	8.2	114	14	9.9
		H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
		AL034344		forkhead box C1	5.4	259	48	1.4
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	3.3	1296	394	2.2
65		AK000967		KIAA1682 protein	3.8	240	64	3.2
		W55956	Hs.94030	Homo sapiens mRNA; cDNA DKFZp586E1824 (f 8.1	101	13	7.9
		AW274526		ovarian carcinoma antigen CA125	3.3	33	1	2.6

•	135117	W\$2493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
-	135144			Autosomal Highly Conserved Protein	7.4	74	5	2,4	
-			Hs.267812	sorting nexth 4	6.6	69	11	6.3	
	135155		Hs.166556	Homo saplens, Similar to TEA domain fami	6.1	61	1	5.1	
5		AB028956		KIAA1033 protein	3.4	88	26	1.4	
,		AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135242			putative G protein-coupled receptor	3.4	169	50	9.1	
					3.4	475	142	2.5	
	135269	NM_00340		YY1 transcription factor	3.1	31	10	1.7	
10	135356			hypothetical protein FLJ11274					
10	135357		Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	
	135389		Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	135397	L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	1	2.4	
	-125400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
	• .	AI471525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast plycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1,6-glucosidase; 4-alpha-glucanotransfera	s	3.1	31	1	26
		Al267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide		7.8	137	18	11.9
		AA044840		stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMIL)	, ···	4.7	151	32	9.3
		AA873285	Hs.137947	ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
		AA305536	12200	"EST176522 Colon carcinoma (Caco-2) cell line	B	3.6	121	34	11.8
•		Al369384		aryfsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs.242396	ESTs: Moderately similar to IIII ALU SUBFAMILY		3.4	107	32	9.9

TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

60
v

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accession	
	123619	371681_1	AA602964 AA6092	00
20	104602	524482_2	H47610 R86920	
	121581	283769_1	AA416568 AA4428	89 AA417233 AA442223
	123523	genbank_AA608588	AA608588	
	100821	tigr_HT4306	M26460 U09116	
	125091	genbank_T91518	T91518	
.25		NOT_FOUND_entrea		N38240
•	118475	genbank_N66845	N66845	
		genbank AA027317		
	106055	genbank_AA417034	AA417034	
	113702	genbank_T97307	T97307	
30	101046	entrez_K01160	K01160	•
	101447	entrez_M21305	M21305	
	101624	entrez_M55998	M55998	
	124677	genbank_R01073	R01073	
	110581	genbank_H61560	H61560	
35	119023	genbank_N98488	N98488	
	110775	genbank_N22414	N22414	
	112092	genbank_R44538	R44538	
	112253	genbank_R51818	R51818	
	107014	genbank AA598820	AA598820	
40	114988	genbank_AA251089	AA251089	

Pkey.

TABLE 11: Figure 11 from BRCA 001-3 PCT

Unique Eos probeset identifier number

5 Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	ExAcon:			on number, Genbank accession number				
	Unigene		ene number					
	. •		ene gene (ille					
	R1:			normal body tissue	. 1			
	R2:			entile turnor to normal body				
15	R3:			entite normal body to tumor				
	R4:	Ratio	of turnor to	normal breast fissue				
	Picey	ExAcon	UnigeneiD	Unigene Title	R1	R2	R3	R4
20	·,		Cinguita					
	100131	D12485	Hs.11951	ectorucleolide pyrophosphatase/phosphodi	13.2	244	19	9.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
		X51501	Hs.99949	protectin-induced protein	22.7	760	34	1.4
	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
25				neuropeptide Y receptor Y1	15.3	153	1	14.1
		NIM 00289		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
			Hs.95243		7.3	73	1	5.3
30				death associated protein 3	9.3	93	5	8
			Hs.46452	mammaglobin 1	8.5	2058	243	1.4
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
		NM_00139		dual specificity phosphatase 4	20.2	202	5	1.3
		U63830		TRAF family member-associated NFKB activ	8.2	82	1.	6.8
35		D85390	Hs.5057	carboxypeptidase D	5.6	56	1	5.3
"			Hs.297753		7.5	136	18	3.4
		NM_00034		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
		AF183810		opposite strand to trichorhinophalangeal	29	290	1	26.8
		Al239923		ESTs	14.9	149	1	6.4
40		Al858702		ESTs, Wealthy similar to N-WASP [H.saplen	7.7	77	1	5.1
				leucine-rich repeat-containing 2	7	70	1	6.5
		AW015318		ESTs	7.4	74	1	6
				frizzled (Drosophila) homolog 6	16.2	162	1	4.2
		AW503733		KIAA1488 protein	5.5	55	1	5.2
45			Hs.22862	ESTS	2.8	131	47	3.9
73				CEGP1 protein	25.4	508	20	3
			Hs.30738	hypothetical protein FLJ10407	8.3	83	3	1.8
		AW377314		DKFZP564I052 protein	6.9	69	1	4.4
		Al240665		EST8	21.2	212	6	17.4
50			Hs.11713	E74-like factor 5 (ets domain transcript	26.3	356	14	1
J 0		AA425414		nuclear factor VB	9.9	483	49	1,8
				KIAA1344 protein	6.3	63	1	5.4
		AB037765			2.5	392	155	4.3
		AV661958		GK001 protein	15.6	156	7	10.8
55		AW378065		ESTS	9	90	ί	5.5
<i>33</i>			Hs.61460	ig superfamily receptor LNIR	18.7	187	i	17
) Hs.51615	ESTS, Weakly similar to ALU7_HUMAN ALU S		334	82	3.4
				hypothetical protein FLJ13782	4.1			
				KIAA1702 protein	7.1	71	1	6.5
<i>c</i> 0	109415	U80736		trinucleofide repeat containing 9	12.3	123	1	11.3
60				L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
		BE075297		ESTs, Wealthy similar to A43932 much 2 p	6.3	693	110	7.2
				hypothetical protein FLJ13187	20.9	209	1	19.5
	111164	N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5

					05.4	000	40	0.7
		AK000136		asporin (LRR class 1)	25.1	288 63	12 1	6.7 5.8
				hypothetical protein FLJ11193	6.3 3.6	402	112	4.9
		BE314949		KIAA 1866 protein hypothetical protein FLJ23309	3.8	425	111	4
5		AB029000		KIAA1077 protein	5.7	567	100	6.7
J		A1571940	Hs.7549	ESTs	9.6	124	13	9
		T97307		gbcye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		W57554	Hs.125019	lymphold nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
10	114768	AF212848 -	Hs.182339	ets homologous factor	13.7	137	1	8.9
			Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.5
		Al733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
		AA251089		gb:zs04f05.s1 NCl_CGAP_GC81 Homo saplens	11.5	115	1	6.9 5
15		AW183695			5.8 7.6	58 144	19	13.9
15		AW992405 Al373062		Homo sapiens, clone IMAGE:3507281, mRNA, hypothetical protein MGC5370	6.2 -	62	1	5.4
		AI272141	Hs.83484	SRY (sex determining region Y)-box 4	1.8	1047		1.6
		H25836		ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
		M18217		Homo saplens cDNA: FLJ21409 fls, clone C	3.9	322	83	4.4
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
	118472	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
	119271	AJ061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
		AJ905687	Hs.2533	EST	3.5	2073		21
05				hypothetical protein FLJ10330	8.5	127	15 1	1.6 9.3
25				hypothetical protein FLJ20275	10.3 2.9	103 214	74	3.7
		AA243499 AA478446	Hs.69559	hypothetical protein FLJ10134 KIAA1096 protein	7.2	72	1	5.7
		AJ073913		ESTs, Wealthy similar to JE0350 Anterior	9.9	351	36	13.9
		AA602964	1 15. 100000	gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
30		AA706910	Hs.112742		3.9	60	16	4.8
		Al147155	Hs.270018		5.8	321	55	17
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
				ribosomal protein S6	10.5	105	1	9.9
25		AW401809		KIAA1150 protein	13.1	131	1	5.1 C
35		AA287921			6.7 30.6	67 306	1 4	6 26.5
		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr matrix Gla protein	7.5	75	1	6.5
		A1954968 A1694143		programmed cell death 4	7.2	72	i	5.8
				secreted frizzled-related protein 4	17.4	409	24	7.8
40		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
••		AA115333			8.2	82	1	7.4
				polyadenylate binding protein-interactin	7.1	71	1	6.2
				KIAA0990 protein	9.5	95	1	8.5
				Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
45		AB028945		cortactin SH3 domain-binding protein	11.4 6.7	114 67	1	10 5.7
				chromosome 8 open reading frame 2 solute carrier family 5 (Inositol transp	1	1	i	1
		AK001635		hypothetical prolein FLJ10773	14.6	219	15	7.6
50				KIAA1481 protein	13.2	331	25	12.4
				stanniocaicin 2	72.2	722	1	1.9
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	6.5	65	4	5.3
	130441	U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55		D90041		N-acetyltransferase 1 (arytamine N-acety	10.8	706	66	9.2
		AA383256		estrogen receptor 1	32.2	322	1	4.7
		M90516	Hs.1674	glutamine fructose-6-phosphate transamin	10 17.5	100 175	1 2	7.6 12.8
				bromodomain-containing 7	3.8	585	153	3.7
		NM_014810		p53-induced protein PIGPC1 KIAA0480 gene product	7.6	76	1	5
60		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7	381	81	6.4
		AA961420		ESTs	11.7	117	1	10.1
		J04088		topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
		AA503020		hypothetical protein FLJ22418	40.2	402	1	4
	132316	U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
~~		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
65				ESTs, Wealthy similar to T33468 hypotheli	6.5	65	1	5.6
		X77343		transcription factor AP-2 alpha (activat	12.7 4.6	311 427	25 93	2.4 10.4
	133013	AJ002744	rts.240315	UDP-N-acetyl-alpha-D-galactosamine:polyp	7.0	741	3 0	10.4

	133199	AF231981	Hs.250175	homolog of yeast long chain polyunsatura	3	816	275	3.9
	133240	AK001489	Hs.242894	ADP-ribosytation factor-like 1	8.1	81	1	4.6
	133271	Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
	133640	AW246428	Hs.75355	ublguitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
_	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134485	X82153	Hs.83942	cathensin K (pycnodysostosis)	34.3	411	12	5.1
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1
10	134880	AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	135029		Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1
		AIQ54QSR		matrix Gla nortein	9.4	94	3	5.3

TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: CAT number: Unique Eos probeset identifier number

Gene cluster number

Accession:

Genbank accession numbers

15

Pkey CAT number Accession

20 123619 371681_1 AA602964 AA609200 113702 genbank_T97307 T97307 114988 genbank_AA251089 AA251089

TABLE 12: Figure 12 from BRCA 001-3 PCT

5 Table 12 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn:		xemplar Acc	obeset Identifier number ession number, Genbank accession number				
	Unigene		Inigene numb					
	Unigene		Inigene gene					•
	R1:	1		to normal body tissue				
1.5	R2:			90 th percentile turnor to body				
15	R3:			75th percentile body to tumor				
	R4:		Ratio of	tumor to normal breast tissue				
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100131	D12485	Hs.11951	phosphodiesterase I (PC-1)	13.2	244	19	9.9
	105500	AW60216	6 Hs.222399	ESTS	25.4	508	20	3
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	114124	W57554	Hs.125019	ESTs	24.2	242	10	5.6
	119771	A1905687	Hs.2533	ESTs	3.5	2073	595	2.1
25	121723	AA243499	Hs.104800	ESTs	2.9	214	74	3.7
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	131148	AW95357	5 Hs.303125	ESTs	3.8	585	153	3.7
	131985	AA503020	Hs.36563	ESTs	40.2	402	1	4
	133199	AF231981	Hs.250175	Homo sapiens clone 23904 mRNA sequence	3	816	275	3.9

PCT/US02/02242 WO 02/059377

TABLE 13: Table 1 from BRCA 001-5 US

Table 13 depicts a preferred group of genes upregulated in breast cancer cells. **5**.

	Pkey:	u	Inimue Eos prob	eset identifier number		-
10	ExAccn:			sion number, Genbank accession number		
10	Unigene		nigene number			
	Unigene		nigene gene tit			
	R1:			normal body tissue		
	••••	•				
15					I .	
	Pkey	ExAccn	UniGene ID	Unigene Title		R1
	, ,					
		M97935		control		16.7
~~		M97935		control		6.3
20		M97935		control		8.3
		M97935		control		14.8
		AB003103		proteasome (prosome; macropain) 26S sub		7.5
			Hs.111783	Lsm1 protein		4.9
25		AF006084		actin related protein 2/3 complex; subunit		4.7
25		AF007875		dolichyl-phosphate mannosyttransferase p		13.4 15.9
		D00596	Hs.82962	thymidylate synthetase		4.6
		D10495	Hs.155342	protein kinase C; delta		4.0 7.5
		D10523	Hs.168669	oxoglutarate dehydrogenase (lipoamide)		4.4
30		D11094 D12485	Hs.61153 Hs.11951	proteasome (prosome; macropain) 26S sub phosphodiesterase l'hudeotide pyrophosp		8.7
20		D12463 D13627	Hs. 15071	chaperonin containing TCP1; subunit 8 (t		9.5
		D13643	Hs.75616	Human mRNA for KIAA0018 gene; comp		6
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin Hike		8.5
		D14657	Hs.81892	KIAA0101 gene product		10.5
35		D14812	Hs.173714	MORF-related gene X		4.6
-		D14878	Hs.82043	D123 gene product		7.9
		D21090	Hs.178658	RAD23 (S. cerevisiae) homolog B		5.6
		D25538	Hs.172199	adenylate cyclase 7		9.9
		D26308	Hs.76289	biliverdin reductase B (flavin reductase (N		4.9
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit		14.2
	100216	D26599	Hs.1390	proteasome (prosome; macropain) subunit		11.3
	100219	D28137	Hs.118110	bone marrow stromal cell antigen 2		5.7
	100227	D28915	Hs.82316	interferon-induced; hepatitis C-associated		5.7
		D31888	Hs.78398	KIAA0071 protein		7.4
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e		5.6
		D49396	Hs.75454	anticoddant protein 1		12.9
		D50525	PIS.699	hypothetical protein		8.4
		D63391	Hs.6793	platelet-activating factor acetylhydrolase;		6.8
50		D63487	Hs.82563	KIAA0153 protein		4.4
50		D78129	Hs.71465	Homo sapiens mRNA for squalene epodd		12.6
		D78514	Hs.78563	ubiquitin-conjugating enzyme E2G 1 (hom		4.6
		D79987	Hs.153479	extra spindle poles; S. cerevisiae; homolo		6.5
		D79997	Hs.184339	KIAA0175 gene product		8.4
55		D80004	Hs.75909	KIAA0182 protein		4.5
<i>)</i>		D82060	Hs.278721	Ke4 gene; mouse; human homolog of		8.1
		D83777	Hs.75137	KIAA0193 gene product		10.7 7.2
		D84145	Hs.39913	novel RGD-containing protein		7.2
		D84557 D86425	Hs.155462 Hs.82733	minichromosome maintenance deficient (m nidogen 2		7.2 5.4
60		D86479	Hs.118397	AE-binding protein 1		3.4 4.3
UU		D86957	Hs.80712	KIAA0202 protein		11.9
		D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp		9.7
		D87464	Hs.10037	KIAA0274 gene product		6.4
		D87465	Hs.74583	KIAA0275 gene product		10
65		D87469	Hs.57652	EGF-like-domain; multiple 2		6.2
0.5	100770	20. 100				-

	100467	D89052	Hs.7476	ATPase; H+ transporting; lysosomal (vacu	7.5
	100468	D89289	Hs.118722	fucosyltransferase 8 (alpha (1;6) fucosyltr	5
	100486	HT1112	Hs.10842	Ras-Like Protein To4	16.9
_	100497	HT1400	Hs.79137	Carboxyi Methyltransferase, Aspartate, A	5.6
5	100618	HT2710	Hs.114599	Collagen, Type VIII, Alpha 1	7.5
		HT3018	Hs.132748	Ribosomal Protein L39 Homolog	4.4
		HT3127	Hs.169610	Epican, Alt. Splice 11	4.6
		HT3938	Hs.169610	Epican, Alt. Splice 12	4.4
10		HT3742	Hs.287820	Fibronectin, Alt. Splice 1	9
10		HT26388	Hs.89603	Mucin 1, Epithelial, Alt. Spilce 9	4.7
		HT4018	Hs.191356	Basic Transcription Factor, 44 Kda Subun	13.7
		HT4343	Hs.278544	Cytosolic Acetoecetyl-Coenzyme A Thio	10.6
		HT4344	Hs.4756	Rad2	5.5 4.1
1.5		HT4392	Hs.183418	Protein Kinase Pitstre, Alpha, Alt. Splice	4
15	100850		Hs.297939	Cathepsin B	4.9
		HT4582	Hs.75113	Transcription Factor Ilia	8.7
	-	HT5158	Hs.5398 Hs.324178	Guanosine 5-Monophosphate Synthase Ras Inhibitor Inf	7.2
	100914		Hs.73946	Endothelial Cell Growth Factor 1	5.9
20	100916 100945		Hs.180686	Oncogene E6-Ap, Papillomavirus	4.6
20		J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin	30.1
		J03589	Hs.76480	ubiquitin-like 4	8.3
		J03909	Hs.14623	Interferon; gamma-inducible protein 30	6.9
		J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom	4.3
25		J04430	Hs.1211	acid phosphatase 5; tartrate resistant	5.9
		J04599	Hs.821	biglycan	5.1
		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B;	37.2
		J05249	Hs.79411	replication protein A2 (32kD)	6.1
		K02405	Hs.73931	Human MHC class II HLA-DQ-beta mRN	4.3
30		K03515	Hs.180532	glucose phosphate isomerase	4.3
	101091	L06132	Hs.149155	voltage-dependent anion channel 1	7.4
	101097	L06797	Hs.89414	chemokine (C-X-C motil); receptor 4 (fus	4.6
	101104	L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPY	18.3
		L12723	Hs.90093	heat shock 70kD protein 4	17.4
35		L13800	Hs.9884	Homo sapiens liver expressed protein gen	7.6
		L19779	Hs.795	H2A histone family; member O	10.9
		L25876	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	7.4
		L29008	Hs.878	sorbitol dehydrogenase	14.6 7.5
40		L33801	Hs.78802	glycogen synthase kinase 3 beta	4.4
40		L38810	Hs.79387	proteasome (prosome; macropain) 26S sub	5.8
		L42572 L47276	Hs.78504 Hs.156346	inner membrene protein; mitochondrial (m Horno saptens (cell line HL-6) alpha topo	18.9
		L77213	Hs.30954	phosphomevalonate kinase	7.5
		L77701	Hs.16297	COX17 (yeast) homolog; cytochrome c ox	9.3
45 .		M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.1
7J .		M15796	Hs.78996	proliferating cell nuclear antigen	8.6
		M16342	Hs.182447	heterogeneous nuclear ribonucleoprotein C	4.5
		M20902	Hs.268571	apolipoprotein C-I	6.1
		M22538	Hs.51299	NADH dehydrogenase (ubiquinone) flavo	8.7
50		M22877	Hs.169248	Human somatic cylochrome c (HCS) gene	4.2
-	101472	M22960	Hs.118126	protective protein for beta-galactosidase (6.5
	101478	M23379	Hs.758	RAS p21 protein activator (GTPase activa	14
		M24594	Hs.20315	interferon-induced protein 56	9.2
		M30818	Hs.926	myxovirus (influenza) resistance 2; homol	5.1
55		M30938	Hs.84981	X-ray repair complementing defective rep	4.7
		M31169		Human propionyl-CoA carboxylase beta-s	5.5
		M31642	Hs.82314	hypoxanthine phosphoribosyltransferase 1	8.5
		M34677	Hs.83363	DNA segment on chromosome X (unique)	4.5
60		M37583	Hs.119192	H2A histone family; member Z	5.7 5.9
60		M60750	Hs.2178	H28 histone family; member A	5.8 43.5
		M60752	Hs.121017	H2A histone family; member A	13.5 4
		M60858	Hs.79110	nucteolin cerebellar degeneration-related protein (62	7.6
		M63256	Hs.75124	protein phosphatase 2 (formerly 2A); regu	4.2
65		M64929	Hs.179574 Hs.239489	TIA1 cytotoxic granute-associated RNA-b	4.5
UJ.		M77142 M77836	Hs.79217	pyrroline-5-carboxylate reductase 1	5.7
		M81057	Hs. 180884	carbonypeptidase B1 (tissue)	21.7
	10110/	NIU IUU/		amanylhohanna /	

	101770 M81601	Hs.78869	transcription elongation factor A (SII); 1	4.6
	101791 M83822	Hs.62354	cell division cycle 4-like	9.7
	101803 M86546	Hs.155691	pre-B-cell leukemia transcription factor 1	5.5
_	101809 M86849	Hs.323733	Homo saplens connexin 26 (GJB2) mRNA	22.5
5	101839 M93036	Hs.692	 membrane component; chromosomal 4; su 	4
	101851 M94250	Hs.82045	midkine (neurite growth-promoting factor	7.6
	101888 M99701	Hs.95243	transcription elongation factor A (SII)-like	11.4
	101973 S82597	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	4.6
4.0	101991 U00968	Hs.166	Human SREBP-1 mRNA; complete cds	4.1
10	102009 U02680	. Hs.82643	protein tyrosine kinase 9	4.4
•	102025 U03911	Hs.78934	mutS (E. coli) homolog 2 (colon cancer; n	4
	102047 U07158	Hs.83734	syntaxin 4A (placental)	6.1
	102051 U07550	Hs.1197	heat shock 10kO protein 1 (chaperonin 10	4.4
15	102083 U10323	Hs.75117	interteuldin enhancer binding factor 2; 45k	10.4
15	102095 U11313	Hs.75760	sterol carrier protein 2	9.5
	102130 U15009	Hs.1575	small nuclear ribonucleoprotein D3 polyp	6.6
	102133 U15173	Hs.155596	BCL2/adenovirus E1B 19kD-interacting p	4.3
	102148 U16954	Hs.75823	ALL1-fused gene from chromosome 1q	6.9
20	102179 U19713	Hs.76364	allograft inflammatory factor 1	4.8
20	102180 U19718	Hs.83551	microfibrillar-associated protein 2	7.2 7.2
	102193 U20758	Hs.313	secreted phosphoprotein 1 (osteopontin; b	4.3
	102198 U21090	Hs.74598	polymerase (DNA directed); delta 2; regu	4.5
	102202 U21931	Hs.574	fructose-bisphosphatase 1	9.9
25	102209 U22970 102211 U23070	Hs.265827	interferon; alpha-inducible protein (clone	4.9
23	102220 U24389	Hs.78776 Hs.65436	putative transmembrane protein lysyl oxidase-like 1	8.5
	102224 U24704	Hs.148495	proteasome (prosome; macropain) 26S sub	5.4
	102234 U26312	Hs.278554	chromobox homolog 3 (Drosophila HP1 g	7.7
	102250 U28014	Hs.74122	caspase 4; apoptosis-related cysteine prot	5.4
30	102260 U28386	Hs.159557	karyopherin alpha 2 (RAG cohort 1; Impo	6.3
50	102261 U28488	Hs.155935	complement component 3a receptor 1	5.7
	102273 U30888	Hs.75981	ubiquitin specific protease 14 (IRNA-guan	6.1
	102298 U32849	Hs.54483	N-myc (and STAT) interactor	4.1
	102302 U33052	Hs.69171	protein kinase C-like 2	4.3
35	102305 U33286	Hs.90073	chromosome segregation 1 (yeast homolo	5.4
	102320 U34683	Hs.82327	glutathione synthetase	4.1
	102330 U35451	Hs.77254	chromobox homolog 1 (Drosophila HP1 b	4
	102348 U37519	Hs.87539	aldehyde dehydrogenase 8	9.4
	102361 U39400	Hs.75859	chromosome 11 open reading frame 4	5.2
40	102362 U39412	Hs.75932	N-ethylmaleimide-sensitive factor attachm	9.3
	102369 U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	7.7
	102395 U41767	Hs.92208	a disintegrin and metalloproteinase domai	10.4
	102409 U43286	Hs.118725	selenophosphate synthetase 2	6.2
4 -	102418 U43923	Hs.79058	suppressor of Ty (S.cerevisiae) 4 homolog	4.1
45	102425 U44772	Hs.3873	palmikoyi-protein thioesterase (ceroid-lipo	4.8
	102457 U48807	Hs.2359	dual specificity phosphatase 4	6.3
	102465 U49352	Hs.81548	2;4-dienoyl CoA reductase 1; mitochondri	9.4
	102495 U51240	Hs.79356	Lysosomal-associated multispanning mem	6.5
50	102534 U56833	Hs.198307	von Hippel-Lindau binding protein 1	8.6 4.3
30	102546 U57877	Hs.3577	succinate dehydrogenase complex; subuni	4.3 6.3
	102549 U58046	Hs.198899	eukaryotic transtation initiation factor 3; s tissue specific transplantation antigen P35	5
•	102557 U58768 102562 U59309	Hs.264428 Hs.75653	fumarate hydratase	6
	400000			ā.4
55	102568 U59877 102580 U60808	Hs.223025 Hs.152981	RAB31; member RAS oncogene family CDP-diacylglycerol synthase (phosphatid	9.1 7.9
55	102581 U81145	Hs.77256	enhancer of zeste (Drosophila) homolog 2	7.6
	102590 U62136	Hs.79300	Homo sapiens enterocyte differentiation a	7
	102591 U62325	Hs.324125	amyloid beta (A4) precursor protein-bindi	4
	102592 U62389	Hs.11223	Human putative cytosolic NADP-depende	5
60	102617 U65928	Hs.198767	Jun activation domain binding projein	6.1
-	102618 U65932	Hs.81071	extracellular matrix protein 1	23.2
	102638 U67319	Hs.9216	caspase 7; apoptosis-related cysteine prot	8.9
	102663 U70322	Hs.168075	karyopherin (importin) beta 2	7.1
	102666 U70660	Hs.279910	ATX1 (antioxidant protein 1; yeast) homo	4.7
65	102679 U72661	Hs.11342	ninjurin 1; nerve injury-induced protein-1	4.7
	102687 U73379	Hs.93002	ubiquitin carrier protein E2-C	7.7
	102704 U76638	Hs.54089	BRCA1 associated RING domain 1	5.6

	102705 U77180	Hs.50002	small inducible cytokine subfamily A (Cy		11.8
	102721 U79241	Hs.118666	Human clone 23759 mRNA; partial cds		15
	102729 U79254	Hs.181311	asparaginyi-tRNA synthetase		5
	102739 U79282	Hs.155572	Human clone 23801 mRNA sequence		6
5	102742 U79293	Hs.159264	Human clone 23948 mRNA sequence		13.1
	102761 U82130	Hs.118910	turnor susceptibility gene 101		7
	102788 U86602	Hs.74407	nucleolar protein p40		4.1
	102790 U87269	Hs.154196	E4F transcription factor 1		7.1
	102801 U89606	Hs.38041	pyridoxal (pyridoxine; vitamin B6) kinase		4.7
10	102808 U90426	·Hs.179606	nuclear RNA helicase; DECD variant of D		7.5
	102817 U90904	Hs.83724	Human clone 23773 mRNA sequence		15.2
	102823 U90914	Hs.5057	carboxypeptidase D		6.6
	102827 U91327	Hs.6456	chaperonin containing TCP1; subunit 2 (b		6
	102838 U94592	Hs.80658	Human uncoupling protein homolog (UCP		6.1
15	102841 U95006	Hs.37616	Human D9 splice variant B mRNA; comp		4.2
	102844 U96113	Hs.324275	Homo sapiens Nedd-4-like ubiquitin-prot		6.8
	102868 X02419	Hs.77274	plasminogen activator, urokinase		4
	102907 X06985	Hs.202833	heme oxygenase (decycling) 1		22.7
••	102919 X12447		aldotase A; fructose-bisphosphate		9.9
20	102929 X13238	Hs.74649	cytochrome c oxidase subunit VIc		5.4
	102973 X16663	Hs.14601	hematopoletic cell-specific Lyn substrate		4.8
	102983 X17620	Hs.118638	non-metastatic cells 1; protein (NM23A)		4.6
	102985 X17644	Hs.2707	G1 to S phase transition 1		20.6
0.5	103003 X52003	Hs.1406	trefoil factor 1 (breast cancer, estrogen-ind		10.7
25	103018 X53296	Hs.81134	interleuidh 1 receptor antagonist		5.8
	103023 X53793	Hs.117950	multifunctional polypeptide similar to SA		4
	103038 X54925	Hs.83169	matrix metalloproteinase 1 (Interstitlal col		7.3
	103060 X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin		17.8 5.6
20	103073 X59417	Hs.74077	proteasome (prosome; macropain) subunit		4.2
30	103075 X59543	Hs.2934	ribonucleotide reductase M1 polypeptide		6.7
	103080 X59798	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomal interleukin enhancer blading factor 1		5.7
	103094 X60787	Hs.296281			5.8
	103105 X61970	Hs.76913	proteasome (prosome; macropain) subunit		4.2
35	103121 X63679 103149 X66363	Hs.4147 Hs.171834	translocating chain-associating membrane PCTAIRE protein kinase 1		12
33	103180 X69433	Hs.5337	Isocitrate dehydrogenase 2 (NADP+); mit		18.9
	103182 X69819	Hs.99995	Intercellular adhesion molecule 3		10.7
	103188 X70040	Hs.2942	macrophage stimulating 1 receptor (c-met		4.1
	103191 X70218	Hs.2903	protein phosphatase 4 (formerly X); cataly		10.7
40	103193 X70476	Hs.75724	coatomer protein complex; subunit beta 2	,	8.2
••	103194 X70649	Hs.78580	DEADAH (Asp-Glu-Ala-AspAHis) box pol		13.7
	103195 X70940	Hs.2642	eukaryotic translation elongation factor 1		13.4
	103206 X72755	Hs.77367	monokine induced by gamma interferon		15.1
	103207 X72790		Human endogenous retrovirus mRNA for	<u>\$</u>	5.3
45	103208 X72841	Hs.31314	retinoblastoma-binding protein 7	Ģ	12.3
	103216 X74262	Hs.16003	retinoblastoma-binding protein 4		4.1
	103226 X75042	Hs.44313	v-rel avian reficuloendofheliosis viral onco		6.9
	103230 X75861	Hs.74637	testis enhanced gene transcript		7.9
	103262 X78565	Hs.289114	hexabrachion (tenascin C; cytotactin)		5
50	103278 X79882	Hs.80680	lung resistance-related protein		5.7
	103297 X81788	Hs.9078	immature colon carcinoma transcript 1		4.6
	103302 X82103	Hs.3059	coatomer protein complex; subunit beta		4.5
	103316 X83301	Hs.324728	SMA5		7.1
~ ~	103330 X85373	Hs.77496	small nuclear ribonucleoprotein polypepti		4
55	103349 X89059		serine/threonine kinase 9		4.7
	103352 X89398	Hs.78853	uracii-DNA glycosylase		5.3
	103364 X90872	Hs.279929	SULT1C sulfotransferase		4
	103374 X91788	Hs.84974	chloride channel; mucleofide-sensitive; 1A		4.2
C D	103380 X92396	Hs.24167	synaptobrevin-like 1		13.6
60	103395 X94754	Hs.279946	methionine-IRNA synthetase		14.2
	103402 X95404	Hs.180370	cofilin 1 (non-muscle)		4.6
	103410 X96506	Hs.295362	DR1-associated protein 1 (negative cofact		8.3
	103420 X97065	Hs.173497	Sec23 (S. cerevisiae) homolog B		4.9
65	103421 X97074	Hs.119591	adaptor-related protein complex 2; sigma		5 7
U)	103427 X97303 103430 X97544	Hs.250655	H.sapiens mRNA for Ptg-12 protein		4.5
	103430 X97544 103438 X98263	Hs.20716	translocase of inner mitochondrial membr M-phase phosphoprotein 6		4.5 4.5
	100400 A30203	Hs.152720	w-birese bijoshijoboraji o		7.0

	400404	VOODOF	th. 70470	tarretta liter amounth feedow 2 months	4.2
		Y00285 Y00796	Hs.76473 Hs.174103	insulin-like growth factor 2 receptor integrin; alpha L (antigen CD11A (p180);	4.5
		Y08991	Hs.83050	phosphatidylinositol 3-kinase-associated p	4.1
	-	Y09912	Hs.33102	transcription factor AP-2 beta (activating	4.5
5		Z14982	Hs.180062	proteasome (prosome; macropaln) subunit	4.3
		Z15115	Hs.75248	topoisomerase (DNA) II beta (180kD)	4
		Z22548	Hs.146354	thloredoxin-dependent peroxide reductase	7.6
		Z29083	Hs.82128	5T4 oncofetal trophoblast glycoprotein	14.6 6.3
10		Z47727 Z48042	Hs.150675 Hs.278672	polymerase (RNA) II (DNA directed) pol membrane component; chromosome 11; s	4.4
10		Z74615	Hs.172928	collagen; type I; alpha 1	5.9
		Z93784		Homo saplens DNA sequence from PAC	4.4
			Hs.278554	chromobox homolog 3 (Drosophila HP1 g	4.9
		AA092898		ESTs; Wealthy similar to R07G3.8 [C.eleg	6.1
15			Hs.198793	KIAA0750 gene product	23.3 4
		AA172215		ESTs; Moderately similar to TRANSCRIP	4.9
		AA236843	Hs.105737	ESTs; Weakly similar to gene 9306 protei ESTs; Weakly similar to unknown [S.cere	7.8
			Hs.239189	ESTS	4.8
20		AA393432		hypothetical protein	5.3
	104115	AA428090	Hs.26102	ESTs	28.7
			Hs.268371	zv68f6.r1 Soares_total_fetus_Nb2HF8_9w	5.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	6.9 5.2
25		AA476564	Hs.76561 Hs.283740	ESTs; Wealdy similar to finger protein HZ ESTs	7.8
23			Hs.114309	ESTS	5.1
		AA486946		Homo sapiens mRNA; cDNA DKFZp564	4.3
		AB000221		small inducible cytokine subfamily A (Cy	12.3
			Hs.168212	kinesin family member 3B	6.2
30		C01687	Hs.7381	ATP synthase; H+ transporting; mitochon	4.2
		C02582	Hs.109253	ESTs; Highly similar to N-terminal acetyl	4.5 4.7
		D52818 D55869	Hs.111680 Hs.284123	endosultine alpha Homo sapiens mRNA full length insert cD	4.2
		H19378	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
35		L44497	Hs.7351	ESTs	4.9
_	104453	M19169	Hs.123114	cystatin SN	11.6
		N33807	Hs.324275	protease; serine; 15	5.6
		R56678	Hs.88959	Human DNA sequence from clone 967N2	6.3 13.6
40		R81003 AA004274	Hs.325820	serine protease; umblical endothelium ESTs	6.3
70			Hs.106106	ESTs	10.1
		AA007145		Homo sapiens mRNA; cDNA DKFZp564	4.3
	104667	AA007234	Hs.30098	ESTs	16,6
4 50			Hs.301553	ESTs; Moderately similar to IIII ALU SU	4.6
45	104767	AA025534	Hs.8852	ESTS	4.8 8.1
		AA027163	Hs.7942 Hs.301871	ESTs ESTs: Moderately similar to cAMP induc	10.9
		AA031357		ESTs; Weakly similar to N-WASP (H-sap	5.5
		AA032147		ESTs	10.4
50	104837	AA039469	Hs.21126	ESTs; Wealdy similar to KIAA0299 [H.s	4.6
			Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	4.3
			Hs.225979	Human gene from PACs 37M17 and 305B	4.5
		AAD53021 AA055809		SCO (cytochrome oxidase deficient; yeast ESTs; Weakly similar to phosphoprotein [4.7 8.8
55		AA057193		ESTs	5.5
"		AA057839		ESTs	4.2
		AA058848		DKFZP434N093 protein	7
	104938	AA064627	Hs.318725	ESTs; Highly similar to CGI-72 protein [H	7.1
<i>c</i> ^			Hs.114218	ESTs	5.7
60		AA074919		ESTs; Wealthy similar to ORF YJL063c [S	4.7 5.5
		AA076572 AA084602		ESTs ESTs	4.3
		AA086071		chromosome-associated polypeptide C	8.3
		AA088228		ESTs	6.2
65	104978	AA088458	Hs.19322	ESTs	6.7
		AA101723		ESTs	9.2
	105002	AA113266	Hs.182704	ESTs; Moderately similar to alternatively	6.9

PCT/US02/02242

) an under transfer	407
	105012 AA116036		chromosome 20 open reading frame 1	10.7 5.7
	105019 AA121879		proteasome (prosome; macropain) subunit ESTs	4.4
	105029 AA126855 105033 AA127964		TP53 target gene 1	6.3
5	105035 AA128486		ESTs	6.5
_	105039 AA130349		ESTs	4
	105062 AA13496		ESTs	4.3
	105076 AA142856		ESTs	6.4
	105087 AA147884	Hs.9812	ESTs	. 9.2
10	105091 AA148859		ESTs; Weakly similar to IIII ALU SUBFA	5.7
	105093 AA149051		ESTs	6.3
	105107 AA152300		DKFZP566G223 protein	6.2
	105127 AA15813		ESTs; Wealty similar to contains similar	5.7 4.2
15	105132 AA15950		HBV associated factor ESTs	4.7
IJ	105143 AA165333 105154 AA17173		methyl-CpG blinding domain protein 4	9
	105162 AA17669		KIAA1025 protein	91
	105186 AA191512		Homo sapiens mRNA; cDNA DKFZp564	19.3
	105209 AA205077		KIAA0980 protein	7.4
20	105223 AA21138		ESTs	5.1
	105252 AA22742		ESTs; Wealtly similar to KIAA0512 prote	11.1
	105253 AA22744	8 Hs.5003	KIAA0456 protein	6.4
	105261 AA22787		MEK partner 1	9.1
~~	105263 AA22792		ESTS	6.7
25	105274 AA22812		ATPase; H+ transporting; lysosomal (vacu	5.3 8.7
	105297 AA23345		transcriptional intermediary factor 1	6. <i>1</i> 7.4
	105309 AA23379 105312 AA23385		ESTs; Wealdy similar to cDNA EST yk38 S-phase kinase-associated protein 2 (p45)	5.8 5.8
	105312 A423509 105342 AA23528		ESTs	4.5
30	105376 AA23655		ESTs; Weakly similar to IIII ALU SUBFA	5.8
20	105386 AA23695		ESTs	5.5
	105397 AA24286		ESTs; Wealty similar to house-keeping p	7.7
*	105399 AA24300	7 Hs.16420	ESTs; Highly similar to SH3 domain-bind	5.6
	105400 AA24305		RNA binding motif protein 8	5.8
35	105404 AA24330		ESTs	9.1
	105409 AA24356		ESTs	4.4 5.1
	105436 AA25217 105483 AA25587		ESTs; Moderately similar to cAMP induc ESTs	4.9
-	105493 AA25626		ESTs	6
40	105495 AA25631		Homo sapiens mRNA; cDNA DKFZp586	5.2
-10	105496 AA25632		DKFZP434N126 protein	8.7
	105500 AA25648		CGI-96 protein	9.5
	105507 AA25667	8 Hs.226318	ESTs; Moderately similar to CCR4-associ	4.1
	105538 AA25886		ring finger protein (C3H2C3 type) 6	4.1
45	105544 AA26195		ESTS	, 8
	105546 AA26203		ESTs; Wealdy similar to 6209.a [D.melan	8.1 4.6
	105549 AA26241		ESTs	4.0 9.1
	105551 AA26247 105560 AA26278		ribonuclease Hi; large subunit ESTs	4.5
50	105565 AA27830		ESTs; Weakly similar to partial CDS [C.e	42
30	105566 AA27832		Homo sapiens clone 24606 mRNA sequen	11.9
	105575 AA27871		ESTs	5.9
	105584 AA27901		ESTs; Wealdy similar to KIAA0665 prote	4.4
	105596 AA27941		ESTs	4
55	105604 AA27978		ESTs; Moderately similar to putative pho	5.6
	105610 AA27999		ESTs; Weakly similar to trithorax homolo	5.3
	105621 AA28086		Homo saptens mRNA; cDNA DKFZp564	4.8
	105627 AA28124		ESTS	7.5 5.9
60	105638 AA28159 105645 AA28213		Homo saplens mRNA for for histone H2B ESTs	5.9 6.4
OU	105650 AA28234		ESTs; Highly similar to HSPC003 [H.sap	11.3
	105666 AA28393		ESTs	4.7
	105674 AA28475		CDW52 antigen (CAMPATH-1 antigen)	8
	105687 AA28680		ESTs	7.1
65	105700 AA28764	3 Hs.35254	ESTs; Wealdy similar to hypothetical pro	4.9
	105705 AA29076		Homo sapiens mRNA; cDNA DKFZp434	8
	105709 AA29126	8 Hs.26761	DKFZP586L0724 protein	6.8

PCT/US02/02242

			•		
	105731 AA292711	1 Hs.29131	ESTs		6.4
	105753 AA299789	Hs.110857	ESTs		7
	105774 AA348014	Hs.23412	EST8		7.1
	105784 AA35077	l Hs.17850	ESTs		13.4
5	105791 AA358038	3 Hs.14368	SH3-binding domain glutamic acid-rich p		4.3
	105807 AA393803	3 Hs.16869	ESTs; Moderately similar to COLLAGEN		5.3
	105808 AA393808	Hs.286131	KIAA0438 gene product		4.1
	105812 AA394126		ESTs: Highly similar to CGI-27 protein [H		14.6
	105813 AA394140		ESTs		4.9
10	105819 AA397920		Homo sapiens mRNA; cDNA DKFZp564		4.9
	105870 AA399623		ESTs		4.8
	105874 AA400074		ESTs		4
	105896 AA400999		Human ring zinc-tinger protein (ZNF127-		4.8
	105934 AA404248		ESTs		5.2
15	105935 AA404277		ESTs; Weakly similar to bisphosphate 3-		4
	105966 AA406105		adaptor-related protein complex 1; gamma		8.3
	105974 AA40632		KIAA0895 protein		4.6
	105990 AA410336		ESTs; Weakly similar to PROBABLE AT		4.5
	105995 AA410510		ESTs		4.9
20	106000 AA410972		ESTS		5.8
	106007 AA411462		ESTs; Wealdy similar to veil 1 [H.sapiens		6.9
	106016 AA411819		KIAA0898 protein		5
	106034 AA412473		ESTs		6.6
	106042 AA412700		ubiquitin-conjugating enzyme E2L 6		4.6
25	106057 AA417067		ESTs		4.5
	106065 AA417558		ESTs		123
	106070 AA417761		Homo sapiens done 24416 mRNA sequen		5
	106103 AA421104		ESTs		15.4
	106126 AA424006		ESTs; Moderately similar to H5AR (M.m.		6.4
30	106154 AA425304		ESTs .		5.1
	106157 AA425367		ESTs		11.1
	106166 AA425872		NADH dehydrogenase (ublquinone) 1 alp		19.3
	106204 AA428024		ESTs		4.7
	106210 AA428239		ESTs		5.7
35	106220 AA428582		ESTs; Moderately similar to metargidin p		7.7
	106236 AA429951		ESTs		8
	106240 AA430074		ESTs; Wealdy similar to Ytr218cp [S.cere		4.4
	106263 AA431462		ESTs		4.9
	106288 AA435538		ESTs		8.8
40	106293 AA435591		signal sequence receptor, gamma (transloc		8.7
	106310 AA436244		ESTs		4.5
	106317 AA436568	Hs.108124	ESTs		4
	106328 AA436705		KIAA0766 gene product		4.4
	106341 AA441798	Hs.5243	ESTs; Moderately similar to piL2 hypoth		23.7
45	106348 AA442253		ESTs		4.7
	106350 AA442763	Hs.194698	cyclin B2		6.1
	106371 AA443923		ÉSTs		6.8
	106389 AA446949	Hs.6236	ESTs		4.7
	106394 AA447223	Hs.25320	Homo sapiens clone 25142 mRNA sequen		4.4
50	106426 AA448282	Hs.16206	ESTs: Wealdy similar to F55C12.5 [C.ele		4.5
	106459 AA449741	Hs.4029	glioma-amplified sequence-41		4.8
	106462 AA449912		ESTs; Highly similar to CGI-77 protein [H		5.2
	106468 AA450047	Hs.14770	ESTs	•	6.8
	106479 AA450351	Hs.75251	ESTs		12.4
55	106494 AA452108		transcription factor AP-2 alpha (activating		4.5
	106503 AA452411		ESTs; Highly similar to mediator [H.saple		5.1
	106507 AA452584		protein phosphatase 1; regulatory (inhibito		4.9
	106533 AA453786	Hs.145998	ESTs		8.3
	106568 AA455970	Hs.28285	paiched related protein translocated in ren		7.6
60	106586 AA456598		ESTs		8.2
	106589 AA456646		ESTs		4.8
	106606 AA457730		Homo sapiens done 23851 mRNA sequen		4.4
	106611 AA458904	Hs.26267	ESTs; Weakly similar to torsinA [H.saple		7
	106614 AA458934		ESTs		4.5
65	106628 AA459657		Homo sapiens clone 23570 mRNA sequen		6.5
-	106637 AA459961		ESTs	•	5.5
	106644 AA460239		ESTs		4.4
					•

	106664	AA460969	Hs.7510	mitogen-activated protein kinase kinase ki	8.4
	106698	AA463745	Hs.29403	ESTs; Weakly similar to PROBABLE AT	5.3
	106719	AA465171	Hs.236844	ESTs	5.6
	106726	AA465339	Hs.3886	ESTS	10.1
5	106747	AA476473	Hs.171957 .	triple functional domain (PTPRF Interacti	10.4
	106759	AA477263	Hs.25584	ESTs	4.2
		AA477717		Interleukin 13 receptor; alpha 1	6.9
			Hs.227913	API5-like 1	5.1
		AA482014		centrin; EF-hand protein; 3 (CDC31 yeast	5.1
10		AA482112		ESTs	4.8
•		AA482548		ESTs	10.3
		AA486183		ESTs; Weakly similar to similar to oxyste	6.2
		AA487228		ESTS	4.5
1.5		AA488872		Homo saplens mRNA; cDNA DKFZp586	7.9
15		AA489101		cocysterol binding protein	6.4
		AA489665		ESTS	4.6 4.2
		AA490323 AA490885		SUMO-1 activating enzyme subunit 1 ESTs	123
			Hs.296323	ESTS	6.2
20		AA496204		ESTs	4
20		AA496347		retinoblastoma-binding protein 7	4.8
		AA496788		KIAA0532 protein	4
		AA504631		ESTs; Weakly similar to hypothetical 43.2	4.4
		AA505141		Human DNA sequence from clone 167A1	5.4
25		AA521121		bromodomain adjacent to zinc finger dom	4.1
	106981	AA521157	Hs.74101	ESTs	5.7
	106998	AA598461	Hs.195464	insulin-like growth factor binding protein	18.7
	107008	AA598710	Hs.23740	ESTS	6.2
	107028	AA599214	Hs.24143	EST8	4.1
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta	5.3
		AA600134		glyceronephosphate O-acyltransferase	4.8
		AA600147		ESTs; Wealdy similar to NADH-cytochro	5.8
		AA600310		programmed cell death 8 (apoptosts-induc	4.9
35		AA609210		ESTs	8.4
33		AA609723 AA609943		ESTs :	8 9.5
		AA620553		flap structure-specific endonuclease 1	4.9
		AA620598		ESTs	5.3
		AA620795		ESTs	4
40		AA620889		ESTs	6.7
		AA621169		ESTs .	19
	107159	AA621340	Hs.10600	ESTs; Wealdy similar to ORF YKR081c [8.1
	107174	AA621714	Hs.25338	ESTs	8.5
	107217	D51095	Hs.35861	DKFZP586E1621 protein	7.2
45		D59971	Hs.25925	ESTs	7.9
		T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	5.6
		T40327	Hs.30661	king resistance-related protein	8.4
		T81665	Hs.278422	DKFZP586G1122 protein	7.5
50		U85625		ribonuclease 6 precursor	4.7
20		U85773 W58247	Hs.154695 Hs.279766	phosphomannomulase 2	4.8 6.3
		Y13936	Hs.17883	Homo saptens kinasin superfamily motor protein phosphatase 1G (formerly 2C); ma	8.3
		AA024835		polassium voltage-gated channel; delayed	7.3
		AA026030		ESTs; Weakly similar to CALPAIN 2; LA	7.3
55	107908	AA026894	Hs.42826	ESTs	4.9
••		AA041341		ESTs	5.4
			Hs.159971	ESTs	8.4
		AAD46424		ESTs; Weakly similar to HYPOTHETICA	6.6
		AA058686		ESTs	7.7
60	108255	AA063157	Hs.172608	ESTS	4
		AA071514		ESTs	4
		AA100694		Human DNA sequence from BAC 15E1 o	5.5
		AA112396		ESTs; Moderately similar to HOMEOBO	14.3
<i>(E</i>		AA115562		Homo sapiens mRNA; cDNA DKFZp564	5.2
65		AA120785		ESTs	5.6
		AA121315	ms./U623	KIAA1077 protein	10.5
	100/33	AA126422		zn84f1.s1 Stratagene lung carcinoma 9372	4.4

	108774 AA128125	Hs.71040	ESTs; Moderately similar to CELL GROW	4.6	
	108828 AA131584	Hs.273344	DKFZP564O0463 protein	5.5	
	108872 AA134063		ESTs	7.2	
	108884 AA134958		ESTS	11.3	3
5	108893 AA135894		retinate acid Induced 3	8.9	
,			EST9	14.7	
	109008 AA156360			4.9	
	109010 AA156460		dual specificity phosphatase 12		
	109011 AA156542		ESTs	4.6	
	109042 AA159525	Hs.71779	Homo sapiens DNA from chromosome 19	7.2	
10	109086 AA166695	.Hs.270737	turnor necrosis factor (ligand) superfamily	4	
	109090 AA167006	Hs.70499	ESTs	5.9	
	109101 AA167708	Hs.52184	ESTs	4.2	
	109112 AA169379		ESTs	4	
	109160 AA179387		DKFZP434N126 protein	4	
15	109166 AA179845		RAB6 interacting; kinesin-like (rabkinesin	13.6	3
10	109178 AA181600		ESTs	11.5	3
	109179 AA181902		ESTs; Weakly similar to IIII ALU SUBFA	5.4	
				6.7	
	109261 AA195255		ESTs	4.9	
20	109270 AA195515		ESTs; Wealdy similar to alternatively spli		
20	109277 AA196332		EST8	5.4	
	109313 AA206800	Hs.86276	ESTs; Moderately similar to zinc finger p	5.5	
	109415 AA227219	Hs.110826	trinucleotide repeat containing 9	20.1	•
	109454 AA232255	Hs.295232	ESTs	4.7	
	109457 AA232904	Hs.63187	ESTs	6.8	
25	109481 AA233342		ESTs; Wealthy similar to WD40 protein C	10.6	3
	109508 AA233892		ESTs; Weakly similar to Illi ALU SUBFA	8	
	109514 AA234087		ESTs; Weakly similar to ORF2: function	8.2	
	109572 F02027	Hs.171937	ESTs	4.8	
	109632 F04165	Hs.235873	ESTs; Weakly similar to K11C4.2 [C.eleg	5.2	
30	109644 F04477	Hs.291531	ESTs; Moderately similar to GLYCERAL	6.6	
50				7.1	
	109703 F09684	Hs.24792	ESTs: Weakly similar to ORF YOR283w	5	
	109726 F10009	Hs.9196	ESTs	4.7	
	109747 F10161	Hs.22969	ESTs		
~~	109799 F10770	Hs.180378	Homo saplens clone 669 unknown mRNA	4.5	
35	109814 F10979	Hs.153106	Homo sapiens clona 23728 mRNA sequen	8.7	
	110189 H20543	Hs.6278	DKFZP586B1621 protein	16.1	_
	110240 H25577	Hs.176588	ESTs; Wealty similar to CYTOCHROME	6.2	
	110280 H29285	Hs.32468	ESTs	4.5	
	110520 H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7	
40	110561 H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	['] 19.	5
	110707 H95079	Hs.15617	ESTs: Weakly similar to IIII ALU SUBFA	6.2	
	110734 H98714	Hs.24131	ESTs	30.	
	110770 N22262	Hs.131705	ESTs	EO	_
			solute carrier family 7 (cationic amino aci	8.2 6.7	
45	110780 N23174	Hs.22891		6.7	
45	110787 N24718	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	5.9	
	110794 N25262	Hs.27931	ESTs		
	110799 N26101	Hs.323401	Human ring zinc-finger protein (ZNF127-	4	
	110818 N29454	Hs.27552	ESTs; Weakly similar to putative p150 (H	4.3	
	110839 N30856	Hs.30246	solute cerrier family 19 (thiamine transpo	121	
50	110844 N31952	Hs.167531	Homo sapiens mRNA full length insert cD	10.	
	110854 N32919	Hs.27931	ESTs	4.7	
	110856 N33063		ESTs; Weakly similar to \$164 [H.sapiens	4.2	
	110860 N33438	Hs.170065	ESTs	12.	5
	110897 N39148	Hs.6880	DKFZP434D156 protein	4	
55	110915 N46252	Hs.29724	ESTs	23.3	2
55			protease inhibitor 1 (anti-elastase); alpha-	4.8	
	110935 N48787	Hs.305979		5.4	
	110970 N51374	Hs.96870	Homo sapiens mRNA full length insert cD	4.7	
	111006 N53375	Hs.166146	Homer; neuronal immediate early gene; 3		
C C	111008 N53388	Hs.7222	ESTs	13.	
60	111018 N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7	
	111084 N59543	Hs.15456	PDZ domain containing 1	8.3	
	111100 N62522	Hs.20450	ESTs	14.2	
	111125 N63823	Hs.269115	ESTs	7.9	
	111132 N64378	Hs.83293	ESTs; Highly similar to unknown function	4.4	
65	111139 N64683	Hs,290943	ESTs	6	
	111164 N66857	Hs.14808	ESTs; Wealthy similar to IIII ALU CLASS	4.1	
	111172 N67102	Hs.21851	Homo sapiens mRNA: cDNA DKFZp586	5.5	
	111114 1901 194				

			•	
	111178 N67227	Hs.24633	ESTs	5.7
	111179 N67239	Hs.10760	ESTs	37
	111181 N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro	5.6 8.7
5	111184 N67437	Hs.243901	Homo saptens mRNA; cDNA DKFZp564 ESTs	7.3
,	111221 N68869 111223 N68921	Hs.15119 Hs.297939	ESTs; Wealdy similar to neogenin (H.sap	9
	111229 N69113	Hs.110855	ESTs	8.9
	111241 N69514	Hs.288880	ESTs; Weakly similar to CGI-82 protein [6.9
	111268 N70481	Hs.26118	Homo sapiens clone 24766 mRNA sequen	4.5
10	111295 N73275.	Hs.21275	ESTs; Weakly similar to ubiquitin-conjug	5.6
	111299 N73808	Hs.24936	ESTs	8.5 6.7
	111336 N79565	Hs.29894	ESTs	6.7 15
	111357 N91023 111370 N92915	Hs.87128 Hs.94631	ESTs brefeldin A-inhibited guanine nucleotide e	5.2
15	111806 R33468	Hs.279008	ESTs	10
13.	111825 R35885	Hs.286148	stromal antigen 1	4.5
	111836 R36228	Hs.25119	ESTs	7. 2
	111890 R38678	Hs.12365	ESTs	17.3
	111923 R39995	Hs.25925	Homo saplens clone 23860 mRNA sequen	7.3
20	111942 R40576	Hs.21590	ESTs	9.2
	111987 R42036	Hs.6763	KIAA0942 protein	10.6 5.3
•	112101 R44793 112134 R46025	Hs.296341	adenytyl cyclase-associated protein 2 ESTs	17.4
	112197 R49482	Hs.7413 Hs.5637	ESTS	4.4
25	112244 R51309	Hs.70823	KIAA1077 protein	11
20	112253 R51818	110,1 0020	Homo sapiens mRNA; cDNA DKFZp566	9.3
	112305 R54822	Hs.26244	ESTs	4.4
	112449 R63802	Hs.124186	ring finger protein 2	6.3
	112483 R66534	Hs.285885	ESTs	4.9
30	112519 R68631	Hs.11861	ESTs	14.3
	112610 R79392	Hs.23643	ESTs	5.2 4.6
	112693 R88741 112751 R93507	Hs.91065 Hs.8207	ESTs; Moderately similar to proliferation ESTs	5.6
	112801 R97486	Hs.157160	protein kinase; DNA-activated; catalytic p	8.7
35	112869 T03313	Hs.4747	dyskeratosis congenita 1; dyskerin	5.9
•-	112871 T03352	Hs.12285	ESTs	5.8
	112908 T10065	Hs.3530	TLS-associated serine-arginine protein	4.1
	112966 T17119	Hs.102548	glucocorticold receptor DNA binding fact	5.7
40	112971 T17185	Hs.83883	ESTs	6.4 9.1
40	112995 T23528 113047 T25867	Hs.7155 Hs.7549	ESTs; Weakly similar to TYKI protein (M ESTs	5.4
	113075 T34660	Hs.6986	ESTs; Wealthy similar to IIII ALU SUBFA	5.7
	113117 T47819	Hs.159153	ESTs	5.8
	113206 T58044	Hs.241471	ESTs; Moderately similar to IIII ALU SU	6.4
45	113248 T63857		yc16e1.s1 Stratagene lung (#93721) Homo	4.6
	113260 T64896	Hs.287420	ESTs	6.9
	113277 T65797	Hs.11774	protein (pepiidyl-protyl cis/trans isomeras	5.6
	113278 T65802	Hs.11135	yc11h10.s1 Stratagene kung (#937210) Ho	4.5 6.4
50	113440 T86121 113523 T90037	Hs.191445 Hs.95549	ESTs ESTs	6.4
30	113604 T92735	Hs.296083	ESTs	8.7
	113702 T97307	16.25000	ESTs; Moderately similar to II!! ALU SU	9.5
	113783 W19222	Hs.7041	ESTs; Weakly similar to IIII ALU SUBFA	5.2
	113794 W37382	Hs.11090	EST8	11.9
55	113808 W44735	Hs.9286	ESTs	16.7
	113811 W44928	Hs.6994	ESTs	4
	113822 W47350	Hs.17466	refinoic acid receptor responder (tazaroten	4.8
	113823 W47388	Hs.55099	rab6 GTPase activating protein (GAP and	4 4.1
60	113836 W56792	Hs.12040 Hs.5297	ESTs; Weakly similar to KIAA0881 prote Homo sapiens mRNA; cDNA DKFZp564	4.3
UU	113857 W65477 113886 W72471	Hs.23920	ESTs	4.6
	113895 W73738	Hs.12921	ESTs	7.1
	113923 W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p	6.8
_	113931 W81205	Hs.3496	ESTS	6.1
65	113950 W85765	Hs.30504	Homo saplens mRNA; cDNA DKFZp434	14
	113970 W86748	Hs.8109	ESTs	15
	114051 W94942	Hs.177534	dual specificity phosphatase 10	5.4

	114057	W96222	Hs.34192	ESTs	4.8
		Z38266	Hs.288649	Homo saplens PAC clone DJ0777023 fro	5.1
		Z38347	Hs.118338	ESTs, Wealdy similar to similar to S. cere	6.2
~		Z38435	Hs.184108	ribosomal protein L21	4.6
5		Z38595	Hs.125019		22
		Z38763	Hs.15740	amyloid beta (A4) precursor protein-bindi	8.8
		Z38814	Hs.27196	ESTs	4
	114162		Hs.22265	ESTs	7.2
10		Z39062	Hs.23740	ESTs	5.3
10	114196		Hs.150926	fucose-1-phosphate guarrylyltransferase	4.4
	114208		Hs.7859	ESTs	5.1 7.2
	114250	Z39898	Hs.13297 Hs.21948	ESTs ESTs	14.7
	114292		Hs.184641	delta-6 fatty acid desaturase	19.4
15		Z40758	Hs.173091	DKFZP434K151 protein	8.9
13		Z41342	Hs.22941	ESTS	13.7
		AA024604		POT-	10.1
			Hs.104613	ESTS :	5.7
			Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	7.3
20			Hs.106469	suppressor of var1 (S.cerevisiae) 3-like 1	4.3
			Hs.293380	ESTs	11.7
			Hs.292833	ESTs	7.3
			Hs.107149	ESTs: Wealthy similar to PTB-ASSOCIAT	6.1
		AA113303		transmembrane 4 superfamily member (te	4.3
25			Hs.110857	ESTs; Highly similar to putative DNA-dir	7.1
	114767	AA148885	Hs.154443	minichromosome maintenance deficient (S	5.3
	114799	AA159323	Hs.109929	ESTs	4.2
	114804	AA160363	Hs.269956	ESTs	4.8
		AA161161		multiple inositol polyphosphate phosphata	7.1
30		AA165313		ESTs	4.4
		AA235035		ESTs; Moderately similar to ubiquitin spe	5
			Hs.196437	ESTs; Weakly similar to R26660_1; parti	16.9
		AA236359		ESTs	5.1
25		AA243012		ESTs	8,5
35		AA250737		ESTs	35.1 5.7
		AA252627		homeo box B5	6.2
		AA252863 AA253217		ESTS ESTS	13
			Hs.198269	NADH dehydrogenase (ubiquinone) 1 atp	28.2
40		AA256486		ESTs	8.8
-10			Hs.279938	ESTs; Weakly similar to supported by GE	4.1
			Hs.284216	ESTS	8.3
			Hs.186572	ESTs	5.1
		AA278650		ESTs; Wealthy similar to similar to the bet	4.6
45			Hs.283732	ESTs	8.3
	115249	AA278961	Hs.71124	ESTs	10.1
	115259	AA279071	Hs.13453	splicing factor 3b; subunit 1; 155kD	9.5
	115285	AA279799	Hs.293736	ESTs	5.8
			Hs.122579	ESTs	5.1
50		AA281793		ESTs	5
			Hs.193063	ESTs	6.1
		AA283198		ESTs	4.9
			Hs.193090	ESTs	5.8
55		AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
23		AA292537		Human DNA sequence from clone 620E1	6.8
		AA331393		ESTs	5.8
		AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7 9.7
		AA399204 AA400247	Hs.283037	ESTs; Highly similar to HSPC039 protein ESTs	8.7 4
60		AA400247 AA400948		ESTs; Weakly similar to zinc finger prote	8.4
00			Hs.305971	ESTs Verany similar to zinc unger prote	5.3
		AA405098		ESTs	16.1
		AA405620		ESTs; Weakly similar to weak similarity t	4.7
			Hs.183056	Human DNA sequence from clone 34B21	5.1
65		AA406546		Homo sapiens mRNA; cDNA DKFZp564	20.5
		AA417102		ESTs	4.8
		AA421560		ESTs	7
	-				

		AA421562		anterior gradient 2 (Xenepus laevis) homo	41.6
		AA428576		ESTs	4.2
	115844	AA430124	Hs.7773	ESTs	11.9
	115875	AA433943	Hs.43946	ESTs; Wealthy similar to Weak similarity	33.5
5	115888	AA435839	Hs.76591	KIAA0887 protein	7.2
	115922	AA441911	Hs.71869	ESTs; Wealdy similar to KIAA0926 prote	5.1
		AA443602		ESTs	4.8
		AA443793		ESTs	8.3
		AA443798		poly(A)-specific ribonuclease (deadenylat	13.5
10			Hs.301048	cofilin 1 (non-muscle)	7.5
10		AA446887		ESTs	8.8
				ESTs	
		AA447687			13.1
		AA449448		ESTs	5.5
16		AA451748		Human DNA sequence from done 718J7	7.5
15		AA452112		thloredoxin-like	12.7
		AA453656		ESTs	7.2
	116097	AA456099	Hs.176376	ESTs	11.8
	116108	AA457566	Hs.28777	ESTs	4.5
	116121	AA459254	Hs.48855	ESTs	4.5
20	116127	AA459703	Hs.279884	v-myc avian myelocytomatosis viral onco	4.3
		AA459956		ESTs; Highly similar to putative ribonucle	7.6
		AA460649		ESTs	4.8
			Hs.108646	ESTS	6.8
		AA478397		ESTs	4.9
25		AA478415		ESTS	4.5
LJ		AA479362		TTIT	4.6
				DKFZP586N0819 protein	
			Hs.250646	ESTs; Highly similar to ubiquitin-conjuga	4
		AA480886		ESTs	18.5
20		AA480975		ESTs	10.8
30		AA481146		ESTs; Wealthy similar to OXYSTEROL-B	9.1
		AA481256		ESTs; Wealdy similar to lysophospholipa	8.4
			Hs.272239	Homo sapiens mRNA; cDNA DKFZp586	7.2
		AA482595		ESTs; Wealty similar to F25B5.3 [C.eleg	11.1
	116282	AA486550	Hs.204501	ESTs; Weakly similar to Wiskott-Aldrich	6.2
35	116298	AA489046	Hs.94109	ESTs	4.9
	116300	AA489194	Hs.159471	ESTs; Weakly similar to snRNP protein B	4.6
	116327	AA490959	Hs.28005	Horno septens mRNA; cDNA DKFZp564	5.8
	116334	AA491457	Hs.48948	ESTs	4.3
	116337	AA496127	Hs.44070	ESTs	8.4
40		AA504116		Homo sapiens mRNA; cDNA DKFZp434	5.3
		AA504806		Horno sapiens clone 23620 mRNA sequen	5.2
		AA609204		KIAA0874 protein	6.6
		AA620313		ESTs; Wealdy similar to KERATIN; TYP	4.5
		C13992	Hs.83484	ESTs	4.5
45			U2'02404		
43		C14088	11-75007	glyceraldehyde-3-phosphate dehydrogena	5.6
		D51272	Hs.75337	nucleolar phosphoprotein p130	4.1
		D51276	Hs.81915	leukemia-associated phosphoprotein p18	5.8
		F02028	Hs.81907	ESTS	4.9
		F03069	Hs.15395	ESTs; Wealthy similar to ARGINYL-TRN	6.1
50	116674		Hs.92127	ESTs	10.6
	116680	F08813	Hs.273829	LINE retrotransposable element 1	4.2
	116700	F09983	Hs.317589	ESTs	13
	116724	F13665	Hs.65641	ESTs	8.5
	116726	F13681	Hs.53913	ESTs	5.6
55		F13779	Hs.165909	ESTs	11.6
	116734		Hs.93796	DKFZP586D2223 protein	5.4
		H11054	Hs.155342	protein kinase C: delta	4.3
		H22566	Hs.30098	ESTs	5.7
	116786		Hs.301527	and the second s	
60	116787			tumor necrosis factor (figand) superfamily	8.8
50	116797		Hs.15641	ESTs	8.6
			Hs.101174	microtubule-associated protein tau	22.2
	.116803		Hs.109701	ESTs; Moderately similar to weak similar	6.7
	116877		Hs.168732	ESTs	6.5
CE	116921		Hs.821	biglycan	20.7
65	117216		Hs.42792	ESTs	4.4
	117232		Hs.61153	ESTs	7.4
	117284	N22162	Hs.183779	ESTs; Wealdy similar to cDNA EST yk33	4.1
				-	

	447244 NO46	Me U_0407	oe EOTo	7.4
	117344 N240			7.4 10.5
	117367 N249			
	117392 N261		A	5.8
E	117394 N262			8.4
5	117412 N267		· · · · · · · · · · · · · · · · · · ·	18.1
	117498 N317			5.8
	117557 N339		• · · · · · · · · · · · · · · · · · · ·	12.3
	117634 N364			4.4
	117639 N369			6
10	117754 N474			7.6
	117852 N494			5.9
	117879 N500			7.9
	117924 N510			7.9
	117950 N513			5
15	117992 N520	100 Hs.1720	39 Homo sapiens mRNA; dDNA DKFZp586	7
	118138 N577	73 Hs.9356) ESTs; Weakly strallar to trg (R.norvegicu	4.8
	118215 N621	195 Hs.7791) 3-hydroxy-3-methylglutaryl-Coenzyme A	13.4
	118229 N623	139 Hs.1662	64 heat shock 90kD protein 1; alpha	5.4
	118265 N628	127 Hs.4864	EST .	4.2
20	118336 N636	i04 Hs.4716	S ESTs	7.2
	118363 N641	68 Hs.4893	B ESTs	6
	118429 N661	58 Hs.7464) ESTs	4.1
	118470 N667	769 Hs.2910	B ESTs	5.4
	118472 N668		ESTs .	10.8
25	118475 N668		ESTs; Wealdy similar to IIII ALU CLASS	4.5
	118493 N671	49 Hs.5011	5 ESTs	5.3
	118528 N678			10.4
	118542 N680			7.9
	118600 N692		ESTs	9.2
30	118695 N717			9.8
	118698 N721			4.3
	118901 N907			8.1
	118952 N929		ESTs; Highly similar to CGI-90 protein [H	12.5
35	118976 N936			5
33	118986 N943			7.3 8.2
	118989 N944 119027 N992			5.2
	119042 R053		ESTs	4
	119075 R364		. ==	6
40	119260 T159			4.1
70	119271 T163			12.1
	119298 T238			5.6
	119302 T257		ESTs	14.3
	119341 T625			4
45	119495 W353			5.3
	119580 W424			5.6
	119602 W462			6.5
	119620 W476	20 Hs.5600	2'-5'oligoadenylate synthelase 3	8.1
	119676 W604	173 Hs.5778		5.5
50	119717 W691	134 Hs.5798	' ESTs	4.6
	119729 W697	747 Hs.9480	KIAA1062 protein	4
	119805 W737	788 Hs.4321	ESTs .	4
	119859 W807	702 Hs.5846		4.8
	119867 W808	52 Hs.2506		4.2
55	119873 W811	129 Hs.4486	Homo saplens mRNA; cDNA DKFZp588	4.8
	119899 W847	67 Hs.5869		5.9
	119940 W867			9
	119943 W868			4.8
	119970 W878			4
60	120131 Z386			4.2
	120150 Z395			11
	120206 Z408		· · ·	8.2
	120241 Z418			15,6
CE		9752 Hs.5672	ESTs; Weakly similar to Similarity to Yea	4.2
65		4168 Hs.2210		6.8
		5651 Hs.10410		. 15.2
	TZUSOZ AAZT	1400 Hs.1931	2 ESTs	6.8

	120428 AA236822 Hs.173694	KIAA1097 protein	5.6
	120524 AA261852 Hs.192905	ESTs	5.6
	120528 AA262107 Hs.104413	ESTs	4.5
_	120571 AA280738 Hs.34892	ESTs	4.9
5	120649 AA287115 Hs.192843	ESTs	4.5
	120655 AA287347 Hs.238205	ESTs	6.7
	120668 AA287833 Hs.292913	ESTs	8.3
	120712 AA292654 Hs.102506	eukaryotic translation initiation factor 2 al	4.6
	120713 AA292655 Hs.96557	ESTs	10.6
10	120724 AA293470 Hs.100747	ESTs	5.4
	120873 AA358015	EST	7.1
	120885 AA365515 Hs.301872	ESTs; Moderately similar to IIII ALU SU	4.6
	120919 AA381125 Hs.301444	ESTs	8.2
	120948 AA397822 Hs.104650	ESTs; Highly similar to similar to mago n	8.6
15	120969 AA398116 Hs.129206	casein kinase 1; gamma 3	10.5
	120977 AA398155 Hs.97600	ESTs	10.9
	121103 AA398936 Hs.97697	EST	7.4
	121291 AA401753 Hs.8186	lung cancer candidate	5.3
	121320 AA403008 Hs.301927	T-cell receptor; alpha (V;D;J;C)	13.5
20	121463 AA411745 Hs.239681	ESTs; Weakly similar to KIAA0554 prote	8.9
	121596 AA416740 Hs.174104	ESTs	22.6
	121723 AA419622 Hs.104800	ESTs; Weakly similar to Mouse 19.5 mRN	8
	121748 AA421171 Hs.234545	ESTs	5.6
	122125 AA434411 Hs.98806	ESTs	5.3
25	122522 AA449444 Hs.98969	ESTs	4
	122655 AA454756 Hs.97837	ESTs	4
	122704 AA456326 Hs.99445	ESTs	6.2
	122782 AA459894 Hs.99472	ESTs	5.3
	122856 AA463740 Hs.75367	Sro-like-adapter	13.1
30	122882 AA465381 Hs.108812	ESTs; Wealthy similar to B0041.5 [C.eleg	5.5
	122928 AA476578 Hs.101840	ESTs	6.3
	122974 AA478625 Hs.194215	ESTs	6
	122997 AA479295 Hs.106290	Kelch motif containing protein	12.5
	123016 AA480103 Hs.323231	ESTs; Wealdy similar to alternatively spli	4.4
35	123107 AA486071 Hs.104207	ESTs	8.3
	123111 AA486273 Hs.191721	ESTs	4.2
	123114 AA486407 Hs.129928	ESTs; Moderately similar to KIAA0454 p	5.2
	123136 AA487449 Hs.194024	ESTs	4.2
	123137 AA487468 Hs.100686	ESTs; Wealtly similar to secreted cement	, 14.6
40	123169 AA488892	ESTs; Weakly similar to Gag-Pol polypro	4.5
	123176 AA489020 Hs.69233	ESTs	5.2
	123338 AA504249 Hs.187585	ESTs	4
	123436 AA598714 Hs.223014	protease; serine; 15	7.3 5.9 4.1
	123442 AA598803 Hs.111496	ESTs	. ∮ 5.9
45	123449 AA598899 Hs.112493	Homo sapiens mRNA; cDNA DKFZp564	
	123494 AA599786 Hs.112110	ESTs	. 4
	123503 AA600121 Hs.293156	ESTs	12.8
	123533 AA608751	ESTs; Weakly similar to !!!! ALU SUBFA	7.9
	123619 AA609200	ESTs	23.1
50	123673 AA609471 Hs.158549	ESTs	6.6
	123729 AA609778 Hs.278672	membrane component; chromosome 11; s	4.7
	123819 AA620636 Hs.112264	ESTs	4
	123960 AA621785 Hs.287733	methylmatonate-semialdehyde dehydroge	7.6
	124000 D57317 Hs.74861	activated RNA polymerase II transcription	4.4
55	124006 D60302 Hs.270016	ESTs	20.6
	124012 D80240 Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
	124021 F02859 Hs.13974	ESTs	4.7
	124049 F10523 Hs.74519	primase; polypeptide 2A (58kD)	4.7
	124059 F13673 Hs.283713	ESTs	7.7
60	124243 H66710 Hs.133525	ESTs ·	5.5
	124308 H93575 Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	11.4
	124314 H94877 . Hs.215766	GTP-binding protein	13.7
	124315 H94892 Hs.288757	v-ral simian leukemia viral oncogene hom	14
	124350 N21359 Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65	124352 N21626 Hs.102406	ESTs	7.2
	124357 N22401	yw37g07.s1 Morton Fetal Cochlea Homo	5.2
	124390 N29325 Hs.7535	ESTs; Highly similar to COBW-like place	7.9

	124438	N40188	Hs.11090	ESTs	9.5
		N48000	113.11050	Homo saplens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
	124539	N63172	Hs.146409	cell division cycle 42 (GTP-binding prote	5.6
5	124626	N74604	Hs.11090	ESTS	12.8
		N79515	Hs.306117	interleukin 13 receptor, alpha 1	6.4
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.3
		R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
10		R01073	11- 440400	ESTs; Wealdy similar to IIII ALU CLASS	5.4 6.6
10		R12405 R40923	Hs.112423 Hs.106604	Homo sapiens mRNA; cDNA DKFZp586 ESTs	4.9
		R41933	HS. (U00U4	ESTs	7.2
		R44357	Hs.48712	ESTs; Wealdy similar to cONA EST EMB	8.6
		R63652	Hs.137190	ESTS	4.9
15		R88992	Hs.180612	ESTs	4.7
	124955	T10598	Hs.324841	ESTs; Wealty similar to IIII ALU SUBFA	4.4
	124958	T11134	Hs.431	murine leukemia viral (bmi-1) oncogene h	126
		178089	Hs.270134	ESTs	4.1
20		T92544	Hs.137548	CD84 antigen (leukocyta antigen)	14.8
20		W15495	Hs.129781	chromosome 21 open reading frame 5	6.7 4.8
		W37999	Hs.24336	ESTs ESTs	5.3
		W38419 W86423	Hs.105413	ESTS	6.6
		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	5.8
25		Z39436	Hs.102720	ESTS	122
		Z39821	Hs.288193	ESTs	10.2
	125304	Z39833	Hs.124940	GTP-binding protein	6.8
		AA151216		tyrosine 3-monooxygenase/tryptophan 5-m	8
20			Hs.288967	ESTs	5.4
30			Hs.267812	sorting nextin 4	4.1
		AA507383		cytochrome c oxidase subunit Vic	11.5 4
		A1432621	Hs.191356	CD47 antigen (Rh-related antigen; integri general transcription factor IIH; polypepti	9.4
		A1283493		ribophorin II	6.2
35		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	25.9
		AA434562		ESTs	4.1
	126160	N90960	Hs.265398	ESTs; Weakly similar to transformation-r	16.4
		N99638	Hs.124084	tumor necrosis factor receptor superfamily	9.5
40		A1066486		similar to S. cerevisiae RER1	5.6
40		U46278	Hs.122489	ESTS	7.5 4.1
		W40262 W78968	Hs.146310 Hs.181307	ESTs; Weakly similar to putative p150 [H H3 histone; family 3A	4.5
		AA205862		ESTs	5.2
		T72569	Hs.125359	Thy-1 cell surface antigen	4.4
45			Hs.102178	ESTs	4.6
	126804	A1203334	Hs.160628	ESTS	11.7
		AA305536		ESTs ·	4
		A)052047		ESTs	7
50		R31652	Hs.821	biglycan 4 (C. L. March 1)	5.6
50			Hs.179729	collagen; type X; alpha 1 (Schmid metaph	14.3 4.5
		W07286	Hs.204214 Hs.10340	ESTs ESTs; Wealdy similar to weak similarity t	5.1
		AA916752		ESTs; Highly similar to MEM3 [M.muscu	17.3
			· Hs.136713	ESTs; Weakly similar to V4-1 [H.saplens	4.1
55		A1281549		ESTs	5.5
	128092	AA904617	Hs.166229	EST8	5.8
		H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
		D59653	Hs.241471	EST	7.4
60		U83908	Hs.296251	programmed cell death 4	5.8
60		AA280617		ESTs; Weakly similar to p60 katanin (H.s	8.3 6.6
			Hs.183475 Hs.101448	Homo sapiens clone 25061 mRNA sequen metastasis associated 1	5.2
		AAA12048		keratin 8	5.1
		U31875	Hs.152677	short-chain alcohol dehydrogenase family	27.1
65		L38608	Hs.10247	activated leucocyte cell adhesion molecule	13.2
			Hs.102708	DKFZP434A043 protein	6.7
			Hs.103106	Homo saplens mRNA for G7b protein (G	4.5

	128651	AA446990	Hs.103135	ESTS	6.1
		R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
		AA458542		coatomer protein complex; subunit epsilon	14.3
		T30617	Hs.104222	Homo saplens mRNA; cDNA DKFZp566	24.5
5	128727	M64174	Hs.50651	Janus kinase 1 (a protein tyrosine kinase)	7.3
	128764	N49308	Hs.104938	ESTs; Wealty similar to alpha 1(XVIII) c	9.2
	128781	X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
	128793	W93562	Hs.105749	KIAA0553 protein	4.6
		W15528	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586	4
10		AA455658		basement membrane-induced gene	6.9
		AA400271		Homo saplens mRNA for putative Ca2+-1	4.5
		AA252023		ESTs; Wealdy similar to HRIHFB2157 [H	6.4
		D61676	Hs.21851	Homo saplens mRNA; cDNA DKFZp586	6.4
15		AA410325		ESTs	7 5.2
15		N29353	Hs.107318	kynurenine 3-monooxygenase (kynurenin	13.1
		AA485655 F10290	Hs.185807	proteasome (prosome; macropain) subunit Homo sapiens clone 24758 mRNA sequen	5.8
		AA460049		ESTs; Weakly similar to SODIUM-AND	12.6
		AA131421		ESTs	9.8
20		H13108	Hs.107968	ESTS	13.9
20		X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7
		AA129465		ESTs	4.7
		L12350	Hs.108623	thrombospondin 2	4.4
			Hs.108802	N-ethylmaleimide-sensitive factor	20.7
25	129160	AA131252	Hs.109007	ESTs	5.9
	129164	AA282183	Hs.109045	ESTs	5.8
	129180	R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6
		X89109	Hs.109606	coronin; actin-binding protein; 1A	12
~~			Hs.109643	polyadenylate binding protein-interacting	7.9
30		W24360	Hs.237868	interleukin 7 receptor	5.3
			Hs.109706	ESTs; Moderately similar to HN1 (M.mus	8.4
		H88033	Hs.109727	KIAA0733 protein	7.8
		AA151574		pilln-like transcription factor ESTs	6.4 6.2
35		Z35227	Hs.181385 Hs.109918	ras homolog gene family; member H	5.4
33		AA026318		glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosornal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7
		AA037467		ESTS	6
40		AA167268		Human ras inhibitor mRNA; 3' end	9.3
	129366	H18027	Hs.184697	plextn C1	18.2
	129383	W92984	Hs.288224	ESTs	5.9
	129388	AA151621	Hs.110964	ESTs	4.1
		T80814	Hs.11101	discs; targe (Drosophita) homolog 3 (neur	10.9
45		AA172056		ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4
		AA412087		EST; Highly similar to protein inhibitor o	8
		AA421213		Lsm3 protein	5.5
50		C00225	Hs.306163	ESTs; Wealthy similar to fos39554_1 [H.s	5.5 6.8
30		AA298786 R21443	Hs.166254	ESTs heat shock 90kD protein 1; alpha	u.o 5
		AA278243		ESTs	6.8
		AA447410		ESTs; Wealty similar to IIII ALU SUBFA	5.1
		AA258308		Homo sapiens mRNA; cDNA DKFZp564	5.3
55		U26727	Hs.1174	cyclin-dependent kinase inhibitor 2A (mel	8.2
		R50008	Hs.11806	7-dehydrocholesterol reductase	4.3
		AA442768		translocase of inner mitochondrial membr	4.4
	129665	M88458	Hs.118778	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4
	129691	X06700	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danios	6
60		AA454618		associated motecule with the SH3 domain	6.4
		AA252436		lysophospholipase I	7.7
		AA452161		YME1 (S.cerevislae)-like 1	5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
cr		AA102520		ESTs; Wealty similar to heat shock prote	5
65		AA043021	HS.13225	UDP-GathetaGicNAc beta 1;4- galactosy	6.6
		M87789	Lin 4404E0	immunoglobulin gamma 3 (Gm marker)	4
	1/29905	AA450045	ms.140452	cargo selection protein (mannose 6 phosp	5.8

	130029	AA236412	Hs.236510	ESTs; Moderately similar to PFT27 (M.m	5.6
	130033	M90696	Hs.181301	cathepsin S	5.4
	130036	AA195260	Hs.125849	ESTs; Moderately similar to IIII ALU SU	7.4
	130069	AA055898	Hs.146428	collagen; type V; alpha 1	7.6
5	130077	T24055	Hs.91379	ribosomal protein L26	4
-		X14850	Hs.147097	H2A histone family; member X	12.1
			Hs.197955	KIAA0704 protein	5
		AA234717		EST8	7.8
		M36803	Hs.1504	hemopexin	7.2
10		M61764	Hs.21635		5.6
10				tubulin; gamma 1	
			`Hs.151469	calcium/calmodulin-dependent serine pro	7.5
		D43947	Hs.151761	KIAA0100 gene product	6.4
		AA620556		perodsomal D3;D2-enoyl-CoA isomerase	6.4
		D50840	Hs.23703	UDP-glucose ceramide glucosyltransferas	4.5
15	130235	X14046	Hs.153053	CD37 antigen	9.1
	130276	S75295	Hs.169149	karyopherin alpha 1 (Importin alpha 5)	8.6
	130280	L13738	Hs.153937	activated p21cdo42Hs kinase	5
	130313	AA620323	Hs.154320	ubiquitin-activating enzyme E1C (homolo	6.1
	130314	D86967	Hs.154332	KIAA0212 gene product	10
20			Hs.154668	KIAA0391 gene product	6.1
		X84373	Hs.155017	nuclear receptor interacting protein 1	10.6
		Z38501	Hs.8768	ESTs; Weakly similar to IIII ALU SUBFA	8.3
		T47333	Hs.155188	TATA box binding protein (TBP)-associa	7.1
				cyclin-dependent kinase 5	5.6
25		X66364	Hs.166071		4.1
23		D13630	Hs.155291	KIAA0005 gene product	4.6
		AA449417		Homo sapiens mRNA for putative glucosy	
		N29888	Hs.155410	ESTs	7
		M21121	Hs.241392	small inducible cytokine A5 (RANTES)	4.1
20		U58522	Hs.155485	huntingtin-interacting protein 2	7.9
30		D21260	Hs.178710	clathrin; heavy polypeptide-like 2	4
		U35835	Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
		X17059	Hs.155956	N-acetyitransferase 1 (arylamine N-acetyl	26.4
	130498	L38951	Hs.180446	karyopherin (importin) beta 1	4.8
	130499	AA416723	Hs.158286	Homo sapiens mRNA for KIAA0446 prot	6.1
35		L32137	Hs.1584	cartilage offgomeric matrix protein (pseud	8.3
			Hs.252587	pituitary tumor-transforming 1	7.5
		H96654	Hs.15984	ESTs; Wealdy similar to gene pp21 protei	5.6
		AA232535		ESTs; Highly similar to CGI-13 protein [H	4
		W24957	Hs.293907	ESTs; Moderately similar to similar to C.e	13.3
40		H66211	Hs.16331	ESTs	10.1
		X03635	Hs.1657	estrogen receptor 1	39.9
		AA132007		ESTS	5.1
		AA477739	Hs.12532	ESTS	5.9
		AA235247		ESTs; Weakly similar to cytochrome P45	4.1
45		F03969	Hs.260720		8.3
40				matrix metalloproteinase 2 (gelatinase A;	-
		L23808	Hs.1695	matrix metalloproteinase 12 (macrophage	10.3
		M60346	Hs.1697	ATPase; H+ transporting; lysosomal (vacu	7
		M87503	Hs.1706	interferon-stimulated transcription factor	5.5
		D59711	Hs.17132	ESTs	7.2
50		H17861	Hs.17767	ESTs	13.5
	130681	D82808	Hs.17820	Rho-associated; coiled-coil containing pro	6
	130693	AA487202	Hs.17962	ESTs	6.1
	130703	N63295	Hs.18103	ESTs	4.3
	130706	AA488843	Hs.201673	comichon-like	4
55	130712	AA292066	Hs.279762	adenylate cyclase 7	5.1
		X92896	Hs.18212	DNA segment on chromosome X (unique)	8.4
		T98227	Hs.171952	occludin	5.7
		AA203527		POP7 (processing of precursor; S. cerevis	6.2
		AA471293		ESTs	8.2
60		AA435633		Homo sapiens clone 23965 mRNA sequen	8.3
W					
		R39390	Hs.19525	ESTS	4.5
		AA223386		ESTs; Wealdy similar to katanin p80 subu	7.7
			Hs.143323	putative DNA/chromatin binding motif	4.3
<i></i>		AA287327		ceroid-lipofuscinosis; neuronal 2; late infa	9.8
65		M58028	Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a	4.3
	130880	D14678	Hs.20830	kinesin-like 2	4.5
	130891	D31891	Hs.20991	SET domain; bifurcated; 1	4

	130905	AA056489	Hs.129998	ESTs	8.7
	130913	W03592	Hs.21198	translocase of outer mitochondrial membr	20.9
		AA291710		coffagen; type IV; alpha 3 (Goodpasture a	9
_			Hs.194688	bromodomain edjacent to zinc finger dom	5.3
5		M97935	Hs.21486	signal transducer and activator of transcrip	18.8
		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Wealty similar to cAMP inducible	8.5 7.2
		N48963 AA435748	Hs.21992	KIAA0689 protein ESTs; Wealdy similar to phosphatidic acid	5.2
10		X02530	Hs.2248	smell inducible cytokine subfamily B (Cy	10.1
10.		T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
		H11760	Hs.23606	ESTS	7.3
		M25753	Hs.23960	cyclin B1	6.2
		AA609427		ESTs; Moderately similar to IIII ALU SU	4.3
15		AA044078		ESTs	5.5
	131210	AA430047	Hs.95549	EST8	7.1
	131227	AA429472	Hs.236522	DKFZP434P106 protein	5.6
		D38076	Hs.24763	RAN binding protein 1	5.5
••		AA620599		DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stanniocalcin	8.9
		AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2 12.1
25		H84658 AA608962	Hs.279836	ESTS	18.1
23		Z39053	Hs.27263	calcyclin binding protein ESTs	7.5
		AA121127		H3 histone: family 3A	5.5
		X02152	Hs.2795	lactate dehydrogenase A	5.1
		N39152	Hs.301804	ESTs	4.3
30		D60856	Hs.28309	UDP-glucose dehydrogenase	8.4
	131544	N33236	Hs.28555	ESTs; Wealthy stmilar to B0511.8 [C.eleg	5.6
	131557	D30946	Hs.28707	signal sequence receptor; gamma (transloc	8.7
		U90551	Hs.28777	H2A histone family; member L	18.8
25		AA491465		ESTs	11.8
35		AA235385		ESTs; Moderately similar to alternatively	4.7
		M15182	Hs.183868	glucuronidase; beta	5.2
		U52100 D14533	Hs.29191 Hs.192803	epithelial membrane protein 2	4,4 4.6
		AA136126		xeroderma pigmentosum; complementatio mitogen-activated protein kinase-activated	4.3
40		AA136660		ESTS	9.4
40		U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
		L11066	Hs.3069	heat shock 70kD protein 98 (mortalin-2)	6.2
		AA599653		transcription factor-like 5 (basic helix-loo	8.3
		W60913	Hs.110796	ESTs; Wealty similar to cDNA EST yk45	9
45	131710	AA233225	Hs.30985	MRS1 protein	5.2
	131716	D49738	Hs.31053	cytoskeleton-associated protein 1	6.6
		D31352	Hs.31433	ESTs	11
		H46831	Hs.107767	ESTs; Moderately similar to CaM-KII inh	4.9
50		AA460450		DKFZP586G1722 protein	9.2
50		N32724	Hs.32317	Sox-like transcriptional factor	4.5
		L76517 AAA37226	Hs.3260	presentin 1 (Alzheimer disease 3)	5.4 4
		AA091932		interleukin 10 receptor; alpha dynamin-like protein	6.7
	131877		Hs.156346	topoisomerase (DNA) II alpha (170kD)	5
55		AA044095		ESTs	11.1
-		AA158258		heterogeneous nuclear protein similar to r	5.6
		AA248470		ESTs: Wealdy similar to RING finger pro	4.5
		AA205460		ESTs	14.3
		D62657	Hs.35086	ubiquifin-specific protease 1	6.2
60	131965	W90146	Hs.35962	ESTS	6.3
		D86960	Hs.3610	KIAA0205 gene product	4.2
		R70167	Hs.154938	ESTs	4.3
		AA410424		Homo sapiens mRNA; cDNA DKFZp586	4.6
CF		F09788	Hs.3622	procellagen-proline; 2-oxoglutarate 4-diox	6.4
65		AA479515		Human DNA sequence from clone 703H1	12
		D82399	Hs.136644	Homo sapiens clone 23714 mRNA sequen	10
	13201/	W67251	Hs.267659	Homo saplens vav 3 oncogene (VAV3) m	4.7

	132021 T68248 Hs.306079 132065 D82226 Hs.211594	chaperonin containing TCP1; subunit 5 (e proteasome (prosome; macropain) 26S sub		5.2 8.5
	132085 D44466 Hs.3887	proteasome (prosome; macropain) 26S sub		13.5
_	132089 AA131971 Hs.39122	ESTs'		4.8 6.2
5	132109 AA599801 Hs.40098	ESTS		14.6
	132143 AA257056 Hs.7972	KIAA0871 protein		5.3
	132149 T10822 Hs.324743	ESTs; Moderately similar to ELONGATI		9.2
	132153 N90141 Hs.41066 132160 AA281770 Hs.295923	seven in absentia (Drosophila) homolog 1		5.5
10	132164 U84573 Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy		8.1
10	132180 AA405569 Hs.418	Ebroblast activation protein; alpha; sepras		15.4
	132183 L19183 Hs.199695	hypothetical protein		12.2
	132225 AA128980	ESTs		5.6 6.7
	132227 AA412620 Hs.4248	ESTs		6.2
15	132235 F09058 Hs.42656	ESTs murine laukemia viral (bmi-1) oncogene h		6
	132256 AA608856 Hs.431 132298 N41849 Hs.7120	Homo sapiens cytokine receptor related p		5.6
	132298 N41849 Hs.7120 132314 AA285290 Hs.44499	small EDRK-rich factor 2		6.8
	132325 N37065 Hs.44856	ESTs		4.7
20	132384 AA479933 Hs.46967	Human DNA sequence from clone 167A1		4.2
	132387 R70914 Hs.281434	heat shock 70kD protein 1		9.1 4
	132393 W85888 Hs.47334	ESTs: Moderately similar to IIII ALLU SU		15
	132408 F09979 Hs.4774	ESTs ESTs		8
25	132407 AA431459 Hs.47783 132413 AA132969 Hs.260116	KIAA1104 protein		4
25	132446 AA426218 Hs.48764	ESTs		5.3
	132465 AAD47896 Hs.49169	ESTs		15.4
	132482 AA429478 Hs.238126	ESTs; Highly stmilar to CGI-49 protein [H		9 8.5
	132492 T03749 Hs.4990	KIAA1089 protein		4.3
30	132528 AA283006 Hs.50758	chromosome-associated polypeptide C		9.8
	132540 AA488987 Hs.5097	synaptogyrin 2 protein regulator of cytoldnesis 1		10.1
	132543 AA417152 Hs.5101 132580 L37042 Hs.283738	casein kinase 1; alpha 1		5.9
	132586 AA412452 Hs.52515	DKFZP434N024 protein		4.2
35	132608 AA199588 Hs.5321	ARP3 (actin-related protein 3, yeast) hom		4.2
	132616 AA386264 Hs.283558	isocitrate dehydrogenase 2 (NADP+); mit		5.2 10.1
	132617 AA171913 Hs.5338	carbonic anhydrase XII adaptor-related protein complex 1; gamma		4.8
	132618 AA253330 Hs.279916	Tax1 (human T-cell laukemia virus type I		5.7
40	132640 U33821 Hs.5437 132668 AA453614 Hs.5460	KIAA0776 protein	1	4.4
40	132694 M60830 Hs.5509	ecotropic viral integration site 2B		15.6
	132700 N47109 Hs.5521	ESTS		7
	132724 AA417962 Hs.55498	geranylgeranyl diphosphate synthase 1	Ì	5.6 4.9
	132738 W42674 Hs.264636	ESTs; Moderately similar to neuronal thre	A.	7.9
45	132742 AA490862 Hs.292812	ESTs; Wealthy similar to C43H8.1 [C.eleg glutamyl-prohyl-tRNA synthetase	•	4.1
	132744 X54326 Hs.55921 132795 H99152 Hs.57079	ESTs		8
	132795 H99152 Hs.57079 132807 AA331777 Hs.57301	muff. (E. coli) homolog 1 (colon cancer; n		8
	132811 U25435 Hs.57419	transcriptional repressor		4
50	132817 AB004884 Hs.57553	tousted-like kinase 2		6.5
	132840 N23817 Hs.5807	Homo saplens clone 23675 mRNA sequen		5.6 12.4
•	132845 D62588 Hs.5813	ESTs eukaryotic translation initiation factor 3; s		7
	132847 T48195 Hs.58189	glypican 4		6.2
55	132856 W79865 Hs.58367 132869 N26855 Hs.203961			6.5
33	132874 AA425776 Hs.58609	ESTs		5.6
	132880 AA444369 Hs.177537	ESTs		7.2
	132894 D82422 Hs.5944	ESTs		7.5 4.4
	132900 N56451 Hs.5978	LIM domain only 7		9.1
60	132903 AA235404 Hs.5985	Homo sapiens clone 25186 mRNA sequen 3-hydroxy-3-methylglutaryl-Coenzyme A		10.7
	132904 X83618 Hs.59889	ESTs; Highly similar to geminin (H.saple		10.2
	132905 AA142857 Hs.234896 132914 AA496037 Hs.60293	ESTS		4.7
	132918 AA252605 Hs.6051	KIAA0616 protein		7.1
65	132936 AB002305 Hs.6111	KIAA0307 gene product		8.3
JJ	132951 U04209 Hs.61418	microfibrillar-associated protein 1		4.3
	132957 AA234791 Hs.61469	Human gene from PAC 753P9; chromoso		13.2

	132959 AA02810	3 Hs.61472	ESTs; Wealdy similar to unknown [S.cere	18.9
	132968 N77151	Hs.61638	myosh X	5.8
	132984 H80409	Hs.62112	zinc finger protein 207	4.3
_	132990 AA45876		transcription factor AP-2 alpha (activating	4.2
5	132994 AA50513		solute carrier family 2 (facilitated glucose	26.4
	132998 Y00062	Hs.170121	protein tyrosine phosphatase; receptor typ	4.4
	133002 AF00608 133005 C21400	Hs.278605	ARP2 (actin-related protein 2; yeast) horn	4.7 6.6
	133015 AA04703		KIAA0970 protein ESTs	7.9
10	133016 W81298	Hs.6289	growth factor receptor-bound protein 2	5.2
10	133039 X62055	Hs.63489	protein tyrosine phosphatase; non-recepto	4
	133050 S67325	Hs.63788	propionyl Coenzyme A carboxylase; beta	5.2
	133056 AA07138		jumping translocation breakpoint	5
	133062 R33663	Hs.64056	ESTs	5.4
15	133083 N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
	133091 AA12214		KIAA0483 protein	5
	133093 AA59874	9 Hs.285996	ESTs	5.6
	133124 AA15604	9 Hs.267923	ESTs	4.1
	133126 D16469	Hs.6551	ATPase; H+ transporting; lysosomal (vacu	6.2
20	133196 R37367	Hs.6727	Ras-GTPase activating protein SH3 doma	5.1
	133214 Y10659	Hs.285115	Interleukin 13 receptor; alpha 1	6.2
	133225 Z41415	Hs.6823	ESTs; Wealdy similar to intrinsic factor-B	8.3
	133228 N90029	Hs.6831	Homo saplens clone 1400 unknown prote	4.7
06	133239 AA05940		Horno saplens clone 24655 mRNA sequen	5.5
25	133240 D31161	Hs.242894	ESTs	9
	133257 AF00608		actin related protein 2/3 complex; subunit	7.7 6.7
	133264 W72187 133274 AA48888		ESTs; Weakly similar to cDNA EST yk37 ESTs	4.2
	133281 AA42107		ESTs; Weakly similar to Sox-like transcri	4.9
30	133283 AA41050		ESTs	4.3
50	133287 L15702	Hs.69771	B-factor, properdin	9.3
	133294 R79723	Hs.69997	zinc finger protein 238	30.4
	133297 AA60005		KIAA0905 protein	10.4
	133318 AA25616	8 Hs.152316	ESTs	8.5
35	133362 H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
	133370 AA15689	7 Hs.72157	DKFZP564l1922 protein	5
	133391 X57579	Hs.727	inhibin; beta A (activin A; activin AB alp	13.9
	133395 AA49129		ESTs .	4.3
40	133422 N79516	Hs.73287	ESTs, Wealdy similar to eyelid [D.melano	4.5
40	133431 AA25543		Homo saptens mRNA; cDNA DKFZp568	8
	133435 T23983	Hs.323966	ESTS	5
	133449 AA09498		voltage-dependent anion channel 3	8.7
	133468 X03068 133484 X78710	Hs.73931 Hs.211581	major histocompatibility complex; class II	5 5.3
45	133506 AA31686		metal-regulatory transcription factor 1 ESTs; Weakly similar to 140G11.h [D.me	6.8
73	133517 X52947	Hs.74471	gap function protein; alpha 1; 43kD (conn	5.7
	133551 D63480	Hs.278634	KIAA0146 protein	4.8
	133569 AA31397		transcription elongation factor B (SIII); po	9.5
	133572 W94333		translocase of inner mitochondrial membr	5
50	133577 F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
	133589 L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5
	133608 D13315	Hs.75207	glyocalase l	4.2
	133617 AA14831	8 Hs.75249	KIAA0069 protein	4.5
	133627 U09587	Hs.75280	glycyl-IRNA synthetase	10
55	133633 D21262	Hs.75337	nucleolar phosphoprotein p130	4.5
	133634 U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15,2
	133640 D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
	133644 D89077	Hs.75367	Src-like-adapter	6.4
60	133649 AA47913		acid phosphatase 1; soluble	4.8
60	133652 AA28738		EST8	4.2
	133874 AA45894		ESTs	4.3 8.3
	133700 K01396 133705 N21648	Hs.297681 Hs.75659	protease inhibitor 1 (anti-elastase); alpha- MpV17 transgene; murine hornolog; glorn	4.6
	133716 Y00282	Hs.75722	ribophorin	7.5
65	133720 L27841	Hs.75737	pericentriolar material 1	9.4
43	133752 U49278	Hs.75875	ubiquitin-conjugating enzyme E2 variant	4.5
	133765 D21255	Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4

	133772	W73693	Hs.76038	isopentenyl-diphosphate delta isomerase	7.9
	133774	Z23090	Hs.76067	heat shock 27kD protein 1	4.1
	133776		Hs.177766	ADP-ribosyttransferase (NAD+; poly (AD	13
_			Hs.301064	ESTs	5.2
5		M33882		myxovirus (influenza) resistance 1; homol	11.7
		AA453783		Homo saplens mRNA; cDNA DKFZp564	9.4
			Hs.288660	serine protease; umbilical endothelium	4.8
		M59815	Hs.170250	complement component 4A	6.7 7.1
10		U73477	Hs.285013 Hs.76704	putative human HLA class II associated p ESTs	6.3
10		T68510 U86782	Hs.178761	26S proteasome-associated pad1 homolog	13.7
		D43948	Hs.76989	KIAA0097 gene product	4.1
		U58090	Hs.183874	cuilin 4A	4
			Hs.182793	ESTs	4.7
15		X01060	Hs.77356	transferrin receptor (p90; CD71)	8.3
		N32811	Hs.77542	ESTs	5
	-	W72783	Hs.58382	ESTs; Wealty similar to C13F10.5 (C.ele	4.5
	133944	AA045870	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564	6.3
	133946	AA156565	Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20	133963	L34587	Hs.184693	transcription elongation factor B (SIII); po	6.3
		D00760	Hs.250811	proteasome (prosome; macropaln) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2
		M28213	Hs.78305	RAB2; member RAS oncogene family	5.2
~~		J03077	Hs.78575	prosaposin (variant Gaucher disease and v	4.6
25		Z81326	Hs.78589	protease inhibitor 12 (neuroserpin)	6.5
		S82470	Hs.78768	BB1	11.9
		D28473	Hs.172801	isoleucine-tRNA synthetase	5.2 7.3
		D87685	Hs.78893	KIAA0244 protein cuitin 3	4.7
30		H98621 U51166	Hs.78946 Hs.173824	thymine-DNA glycosylase	7
30		M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	4.5
		X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	4.4
		U32519	Hs.220689	Ras-GTPase-activating protein SH3-doma	6.6
35			Hs.181634	Human Chromosome 16 BAC clone CIT9	8.6
	134170	M63138	Hs.79572	cathepsin D (lysosomal aspartyl protease)	9.3
	134208	U88871	Hs.79993	peroxisomal biogenesis factor 7	6.3
		L28010	Hs.808	heterogeneous nuclear ribonucleoprotein F	4.3
40		AA430008		ESTs	6.9
40		AA313414		Homo sapiens clone 24856 mRNA sequen	7.4
		U16306	Hs.81800	chondrollin sulfate proteoglycan 2 (versic	6.1
		D38551	Hs.81848	RAD21 (S. pombe) homolog	8.6
			Hs.111222	ESTs; Wealthy similar to CGI-128 protein	6.1 4.4
45		R82074 L43575	Hs.82109 Hs.82171	syndecan 1 Human clone 19187 placenta expressed m	6.6
43		M37033	Hs.82212	CD53 antigen	5.3
		X54199	Hs.82285	phosphoribosylg)ycinamide formyltransfe	4.8
		D62633	Hs.8236	ESTs	15.2
		AA412720		ESTs; Highly similar to CGI-118 protein	7.2
50		X02874	Hs.82396	2'5'-oligoadenylate synthetase 1	6.4
		U56637	Hs.184270	capping protein (actin filament) muscle Z-	4
	134388	-M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
	134395	L09717	Hs.8262	lysosomal-associated membrane protein 2	6.9
	134399	H99801	Hs.82689	tumor rejection antigen (gp96) 1	4.5
55			Hs.211577	kinectin 1 (kinesin receptor)	11.2
		J04177	Hs.82772	collagen; type XI; alpha 1	15.3
		AA329274		protein tyrosine phosphatase type IVA; m	4.1
		D87969	Hs.82921	solute carrier family 35 (CMP-stalic acid t	4.2
60		L08044	Hs.82961	trefoil factor 3 (intestinal)	5.9
60		AA122386 W96151		collagen; type V; alpha 2 ESTs; Highly similar to CGI-139 protein	5.8
			Hs.83006 Hs.246857	ESTs; Highly similar to CGI-139 protein ESTs; Highly similar to proteine kinase JN	4.4 7
		T25732	Hs.83419	KIAA0252 protein	<i>1</i> 4.6
		X70683	Hs.83484	SRY (sex determining region Y)-box 4	5.1
65		X54942	Hs.83758	CDC28 protein kinase 2	20.3
55		R38185	Hs.83954	Homo sapiens unknown mRNA	5
		D63477	Hs.84087	KIAA0143 protein	16.1
				-	

		M63180	Hs.84131	threonyl-IRNA synthetase	6.1
	134506	U45328	Hs.84285	ubiquitin-conjugating enzyme E21 (homol	4.6
	134529	H24460	Hs.848	FK508-binding protein 4 (59kD)	6.2
	134570	U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5	134582	AA234966	Hs.86041	CGG triplat repeat binding protein 1	4.7
	134600	R68884	Hs.86347	ESTs; Weakly similar to predicted using G	5.8
	134623	X74496	Hs.86978	prolyl endopeptidase	4.5
		W23625	Hs.8739	ESTs; Wealtly similar to ORF YGR200c [13.7
		AA454070		ESTs	5.8
10		AA250745		protein kinase; cAMP-dependent; catalyti	8.9
10		X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
		W47183	Hs.284226		8.1
		J05582	Hs.89603	ESTs; Wealdy similar to neural F box pro	6.2
15				mucin 1; transmembrane	
13		Z49099	Hs.89718	spermine synthase	4.2
		M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
		U51477	Hs.89981	diacytglycerol kinase; zeta (104kD)	4.1
		H60595	Hs.90061	progesterone binding protein	4.7
•		D82348	Hs.90280	5-aminolimidazole-4-carboxamide ribonuc	10.2
20		U84011	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotr	12.1
		Z39762	Hs.90419	KIAA0882 protein	6
		N27670	Hs.9071	progesterone membrane binding protein	5
	134982	N46086	Hs.92308	ESTs	4.1
	134989	AA236324	Hs.92381	Homo sapiens mRNA; chromosome 1 spe	16.8
25	134992	H05625	Hs.5831	ESTs	4
	134993	AA282343	Hs.301005	purine-rich element binding protein B	4.4
	135010	D59675	Hs.92927	ESTs	7
	135015	U54999	Hs.278338	LGN protein	4.8
	135029	AA224180		ESTs; Moderately similar to 17-beta-hydr	13.6
30			Hs.173685	Human DNA sequence from clone 30M3	4
	135037		Hs.278589	general transcription factor II; i	8
		AA598449		Homo sapiens clone 24483 unknown mRN	5.4
	135071		Hs.94	heat shock protein; DNAJ-like 2	9.3
		AA495950		ESTs	6.7
35		W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	10.2
55		AA044842		Homo saplens mRNA; cDNA DKFZp586	6.6
		AA126433		sorting nextn 4	7.4
	135218		Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
		AA454930		ESTs	19.5
40		AA215333		pulative G protein-coupled receptor	8.8
70	135335		Hs. 198281	pyruvale kinase; muscle	12.4
	135349				
		AA480109	Hs.9930	collagen-binding protein 2 (colligen 2)	5.5
				TYRO protein tyrosine kinase binding pro	5.4
45	135389		Hs.99872	fetal Alzheimer antigen	7.8
43		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
		L10333	Hs.99947	reticulon 1	5.3
		M97935		AFFX control: STAT1	8.3
		M97835		AFFX control: STAT1	7
50	300022			AFFX control: STAT1	14
50		AH99738		ESTs; Wealdy similar to IIII ALU CLASS	9.1
			Hs.270464	ESTs; Weakly similar to IIII ALU CLASS	7.4
		AW079607		ESTs; Wealdy similar to ZnT-3 [H.saplen	30.1
		AW015860		ESTs	11.9
		AA699328		ESTs	5.5
55		AM92179		ESTs; Wealthy similar to cDNA EST yk40	11
		AW293224	Hs.232165	ESTs	11
	301124	T79326	Hs.298262	ESTs; Wealthy strallar to dJ88J8.1 [H.sapi	8.8
	301165	N85789	Hs.150186	ESTs; Wealty similar to PTERIN-4-ALP	6
	301576	Al682905	Hs.270431	ESTs; Wealty similar to IIII ALU SUBFA	4.7
60		AA373124		ESTs; Wealthy similar to C17G10.1 [C.ele	8
		AA526313		ESTs	4.2
	301782		Hs.143046	EST cluster (not in UniGene) with exon h	18
		AA312082		GDNF family receptor alpha 1	20.7
		NM 004694		EST cluster (not in UniGene) with exon h	11.6
65		AF013956		chromobox homolog 4 (Drosophila Pc da	9.2
		NM_001992		EST cluster (not in UniGene) with exon h	4.3
	302052		Hs.222399		7.8
	302001	100000	119.444.933	ESTs; Weakly similar to protein-tyrosine	7.0

		NM_003613	3Hs.151407	EST cluster (not in UniGene) with exon h	15.1
		Al128606	Hs.6557	zinc finger protein 161	25.8
		NM_004448		EST cluster (not in UniGene) with exon h	21.6
_		AL117607		Homo sepiens mRNA; cDNA DKFZp564	41.4
5		NM_00427		EST cluster (not in UniGene) with exon h	8.9
		AB023141		KIAA0924 protein	5.4 8.9
		AL117406		Homo sapiens mRNA; cDNA DKFZp434	5.2
		AB021227		matrix metalioproteinase 24 (membrane-in	5.3
10			Hs.226434	EST cluster (not in UniGene) with exon h	9.9
10		AF022726		EST cluster (not in UniGene) with exon h	4.3
		AL049650		multiple UniGene matches	4.9
		L38149	Hs.248116	chemokine (C motif) XC receptor 1	5.3
		AA463798 AW293005		ESTs; Wealdy similar to C11D2.4 [C.eleg ESTs	8.4
15		ANY255005 AA343696		ESTs; Weakly similar to putative (H.saple	4.5
13		X04588	Hs.85844	EST cluster (not in UniGene) with exon h	6.8
		U66049	Hs.82171	EST cluster (not in UniGene) with exon h	8.4
		N58545	Hs.42346	histone deacetylase 3	22.8
		AW263124		EST cluster (not in UniGene) with exon h	6.8
20		N46406	Hs.84700	EST cluster (not in UniGene) with exon h	8.9
20		AA478876		pallid (mouse) homolog; pallidin	10.1
		AF140242		EST cluster (not in UniGene) with exon h	24.4
			Hs.103180	actin-like 6	6.3
		AI929819	Hs.4055	ESTs	17.7
25		U09759	Hs.246857	mitogen-activated protein kinase 9	11.4
	303387	AA908797	Hs.180799	ESTS	15.8
	303499	AJ815990	Hs.293515	ESTs	7.2
	303502	AA488528		EST cluster (not in UniGene) with exon h	5.3
		T07216	Hs.301226	EST cluster (not in UniGene) with exon h	16.2
30		AA397546		ESTs	8.9
		Al953377	Hs.28444	ESTs; Weakly similar to predicted using G	12
		AW299459		EST cluster (not in UniGene) with exon h	4.2
		AA436942		ESTS	8.4
25		AW502498		ESTs; Weakly similar to zinc finger prote	5.2 28.4
35		AI424014		ESTs; Moderately similar to KIAA0456 p	4.4
		C75094	Hs.199839	ESTs; Highly similar to NG22 (H.saplens ESTs; Wealdy similar to similar to PDZ d	8.1
		Al337304 AW475081	Hs.126268	collagen; type I; alpha 1	7.5
		AA421948	113.172320	EST singleton (not in UniGene) with exon	6.5
40		AA456426		EST	5.4
40		AA505702		EST singleton (not in UniGene) with exon	9.8
		AA507875		EST singleton (not in UniGene) with exon	7.5
		AA533185		EST singleton (not in UniGene) with exon	7
		AA630582	Hs,169476	glyceraldehyde-3-phosphate dehydrogena	124
45	305134	AA653159	Hs.179861	EST singleton (not in UniGene) with exon	8.7
	305415	AA725116	Hs.78465	EST singleton (not in UniGene) with excon	5.3
	305453	AA738110		EST singleton (not in UniGene) with exon	4.1
		AA872838		kerafin 8 .	7.7
	305913	AA876109		EST singleton (not in UniGene) with exon	6.3
50		AA884479		EST singleton (not in UniGene) with exon	5.6
		AA889992		EST singleton (not in UniGene) with excon	13.2
	,	AA894560		EST singleton (not in UniGene) with exon	4.4
		AA906161		EST singleton (not in UniGene) with exon	4.6
55		AA970548		EST singleton (not in UniGene) with exon	/.b
33			Hs.172928	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	19.7 5.5
		AJ184111	Hs.276092 Hs.76067	heat shock 27kD protein 1	7.7
		A)185516	Hs.172928	collagen; type I; alpha 1	8.8
		A1190870	Hs.276417	EST singleton (not in UniGene) with exon	4.1
60		Al280859	Hs.62954	EST singleton (not in UniGene) with exon	6
5 5		Al281603	Hs.172928	EST singleton (not in UniGene) with exon	10.8
		Al351739	Hs.276726	EST singleton (not in UniGene) with exon	4.7
	•••	A1472733	Hs.270208	ESTs	4.2
		Al581398	Hs.172928	collagen; type t; alpha 1	5.4
65		AI687580	Hs.169476	EST singleton (not in UniGene) with exon	10.1
		AI738593	Hs.101774	EST singleton (not in UniGene) with exon	15.1
		AI761173		EST singleton (not in UniGene) with exon	4.6

	308852	AI829848	Hs.182937	peptidytprotyt isomerase A (cyclophilin A	5.9
		Al872290	Hs.300697	immunoglobulin gamma 3 (Gm marker)	4.5
		AJ873242		EST singleton (not in UniGene) with exon	7.6
•		Al880172		EST singleton (not in UniGene) with exon	6.6
5		AI951118		EST singleton (not in UniGene) with exon	24.3
		A1952723 A1955915	Hs.90207	EST singleton (not in UniGene) with exon major histocompetibility complex; class i;	6.1 5.6
		Al969897		EST singleton (not in UniGene) with exon	6.2
		Al990102		EST singleton (not in UniGene) with exon	7.9
10		AW170035		EST	64.5
	309624	AW191929	Hs.252989	EST	5.3
		AW192764		collegen; type I; alpha 1	6.9
		AW194230		EST	11.4
15		AW238461		ribosomal protein; large; P0	4.3
13		AW241170 AI335004	Hs.148558	Homo saptens clone 24703 beta-tubulin m ESTs	11.9 4.2
		AW450967		ESTS	5.7
		AW080778		ESTS	4.8
		AW022192		ESTs	39.1
20		Al281848	Hs.194691	ESTs	4.9
		AW205632	Hs.211198	ESTs	7
		T47784	Hs.188955	ESTs	4.1
		Al587332	Hs.209115	ESTs	11.2
25		Al821294		ESTs	24.1
25		T57896	Hs.191095	EST cluster (not in UniGene)	5.7 15.7
		A1758660 A1828254	Hs.206132 Hs.271019	ESTs ESTs	6.4
		AA700870		ESTs	6.2
		Al056769	Hs.133512	ESTs ·	5
30		T60843	Hs.189679	ESTs	5.9
	311935	AA216387		EST cluster (not in UniGene)	5.5
		N51511	Hs.188449	ESTS	5.2
		Al435650	Hs.128778	ESTs	4.3
35		AA588275		ESTs	14.7
33		T89855	Hs.195648	EST cluster (not in UniGene)	9.8 27.1
		AA759250 T92251	Hs.198882	cytochrome b-561 ESTs	4.2
		Al222168	Hs.191168	ESTS	6.1
		AI796815	Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40	312292	AW451893	Hs.151124	ESTs	18.4
		A1080505	Hs.134529	ESTs	11.9
		AA582039		Homo sapiens mRNA; chromosome 1 spe	4
		R46180	Hs.153485	ESTs ESTs	13.6
45		AW139117 AW451347		ESTS	4.1 4.6
43		AM451547	Hs.7753	ESTs :	15.3
		AA033609		ESTs	12.5
		Al498371	Hs.183526	ESTs	14.6
	312638	AW439195		ESTs	5.3
50	312754	R99834	Hs.250383	ESTs	8.4
		H63791		EST cluster (not in UniGene)	4.3
•		AA699325		ESTs	8.3
		AW292286		ESTs	7.1
55		AA846353 AA828713		ESTs EST cluster (not in UniGene)	5.9 4.1
55		AA088446		ESTs	7.3
		Al422367		ESTs	6.1
		AA732534		ESTs	4.2
		AA720887		EST cluster (not in UniGene)	18.1
60			Hs.288010	ESTS	17
		Al738851		ESTs	12.9
			Hs.182099	ESTs	7.1
			Hs.183918	ESTS	13.7
65		AW449211		ESTs .	27.9 9.8
0 5		AW292127 AA741151		EST9	8.2
		AW081702		ESTs	6.9
	J. 10700	, . 1100 I 1 UZ	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		

	313590 AA804410 Hs.291677	EST cluster (not in UniGene)	5.3
	313663 Al953261 Hs.169813	ESTs	7.6
	313667 U69201 Hs.13684	ESTs; Wealdy similar to choline kinase is	12.5
	313749 AW450376 Hs.119004	ESTs	5.5
5	313832 AW271022 Hs.133294	. ESTs	4.3
	313881 AA535580 Hs.16331	ESTs	7.7
	313915 Al969390 Hs.163443	ESTs	27.1
	313955 Al858884 Hs.270647	ESTs	5.7
10	313974 Al310151 Hs.173524	ESTs	4.3
10	314097 AA648744 Hs.269493	EST8	14.5
	314129 AA228366 Hs.115122	ESTs	9.5
	314359 AA205569 Hs.194193	ESTS	5.4 5.3
	314384 AA535840 Hs.162203 314394 AI380563 Hs.130816	ESTs; Wealthy similar to alternatively spli ESTs	13.2
15	314462 AA347951 Hs.326413	ESTs	6.2
13	314465 AA602917 Hs.156974	ESTs	18.1
	314470 Al934422 Hs.30661	ESTs :	4.2
	314488 AA358265 Hs.182890	ESTs	6.1
	314506 AA833655 Hs.206868	ESTs	27.8
20	314510 Al204418 Hs.190080	ESTs	9.5
	314558 Al873274 Hs.190721	ESTs	22.5
	314661 AA436432 Hs.324239	EST cluster (not in UniGene)	13.3
	314691 AW207206 Hs.136319	ESTs	21.4
	314754 AW026761 Hs.134374	ESTs	4.4
25	314775 Al149880 Hs.188809	ESTs	4.4
	314943 Al476797 Hs.184572	cell division cycle 2; G1 to S and G2 to M	18.4
	314961 AW008061 Hs.231994	ESTs	10.2
	314963 Al689617 Hs.200934	ESTs	5.3
30	315006 Al538613 Hs.298241	ESTs	20.7
30	315010 AA531082 Hs.240049 315019 AA532807 Hs.105822	ESTs ESTs	5 6,1
	315033 Al493046 Hs.146133	ESTs	12
	315036 AA534953 Hs.163297	ESTs	8.3
	315037 AW205863 Hs.133988	ESTs; Weakly similar to gene MAC25 pr	6.1
3 5	315051 AW292425 Hs.163484	EST	12.7
-	315054 AI968598 Hs.78768	ESTs	7.6
	315073 AW452948 Hs.257631	ESTs	13.9
	315080 AA744550 Hs.136345	ESTs	4.4
	315083 Al221325 Hs.205442	ESTs	5.1
40	315088 AA557351 Hs.152448	ESTs; Moderately similar to MULTIFUN	4.7
	315175 Al025842 Hs.152530	ESTs	11.9
	315196 AA972756 Hs.44898	ESTs	28.8
	315296 AA876905 Hs.125286	ESTs	16.1 25.7
45	315303 AW194364 Hs.128022 315352 AA604799 Hs.136528	ESTs; Weakly similar to FIG-1 PROTEIN ESTs; Moderately similar to IIII ALU SU	12.3
43	315364 AA643602 Hs.155485	ESTs; Highly similar to serine protease (H	4.6
	315368 AW291563 Hs.104696	ESTs	4.8
	315390 Al801565 Hs.200113	ESTs; Weakly similar to alternatively spli	4.4
	315408 AW273261 Hs.216292	ESTs	5
50	315458 AA872000 Hs.116104	ESTs	7.6
	315472 AA828850 Hs.165469	ESTs	4.9
	315478 AA665612 Hs.120874	ESTs	5.2
	315498 AA628539 Hs.116252	ESTs; Moderately similar to IIII ALU SU	4.8
	315527 Al791138 Hs.116768	ESTs	4.4
55	315530 Al200852 Hs.127780	ESTs .	22.4
	315562 AA737415 Hs.152826	ESTs	5.9
	315634 AAB37085 Hs.220585	ESTs	8.8
	315647 AA648983 Hs.212911	ESTs	15
60	315652 Al521489 Hs.3053	ESTs	6.3
W	315676 AW002565 Hs.124660	ESTs ESTs	9,2 8,1
	315680 AA814309 Hs.123583 315735 Al831760 Hs.155111	ESTs	13.4
	315741 AA812168 Hs.122559	ESTs	5.4
	315769 AA744875 Hs.189413	ESTs	4.4
65	315978 AA830893 Hs.119769	ESTs	10.4
05	315984 Al015862 Hs.131793	ESTs	5
	316042 AW297979 Hs.170698	ESTs .	14.7
		•	

Ť

	316136 AA830808 Hs.1243	66 ESTs	4
	316177 Al908272 Hs.2931		32.6
	316313 AA741300 Hs.2025		4.8
_	316405 AA757900 Hs.2708		4.8
5	316480 AI749921 Hs.2053		12.9
	316564 AI743571 Hs.1687 316714 AA809792 Hs.1233		8.1 5
	316715 Al440268 Hs.1706		4.2
	316828 AA828116 Hs.1730		5.2
10	316869 Al954880 Hs.1346		13.3
	316905 AW138241 Hs.2108		6.2
	316943 AW014875 Hs.1370		5.3
	316949 AA856749 Hs.1246	20 ESTs	7.2
	317008 AW051597 Hs.1437	07 ESTs	4.1
15	317028 AA962623 Hs.1891		4.2
	317067 Al805392 Hs.3253		4.5
	317069 AI732892 Hs.1904	•	6.4
	317210 AA490718	EST cluster (not in UniGene)	4.4
20	317298 Al922374 Hs.1585 317658 AW139077 Hs.2022		5.9 4.6
20	317674 AW294909 Hs.1322		5.2
	317685 AI798630 Hs.1499		4.3
	317836 AA983913 Hs.1289		12.4
	317881 Al827248 Hs.2243		12.1
25	317902 AI828602 Hs.2112		8.8
	317916 Al565071 Hs.1599	83 ESTs	12.6
	318042 AW294522 Hs.1499	91 ESTs	5.6
	318053 AJ074465 Hs.1334		4
20	318064 AW296888 Hs.1709		5.2
30	318070 AJ024594 Hs.2489		4.7
	318073 AW167087 Hs.1315		15.7
	318146 Al040125 Hs.1505 318186 AW016773 Hs.3709		5.9 5.3
	318481 Al291584 Hs.1459		7.6
35	318566 Al335361 Hs.2263		5.8
	318617 AW247252 Hs.7551		11.1
	318662 Al285898 Hs.2940		16.3
	318691 AW192139 Hs.1813	07 H3 histone; family 3A	4
4.0	318740 NM_002543Hs.7772	9 EST cluster (not in UniGene)	21.3
40	318744 AI793124 Hs.1444		35
	318948 AA317274 Hs.1399		11.7
	319163 F15257 Hs.27	glycine dehydrogenase (decarboxylating;	7
	319478 R06841 Hs.2703		8.9
45	319545 R83716 Hs.1435 319668 NM_002731Hs.8777		8.2 25.4
73	319763 AA460775 Hs.6295		7
	319913 AA179304 Hs.2715		8.7
	319936 W22152 Hs.2829		5.6
	319951 AA307665 Hs.1455		4.9
50	319962 H06350 Hs.1350	56 EST\$	9.2
	319977 AA632632	EST cluster (not in UniGene)	4.6
	320074 AA321166 Hs.2782		16.7
	320092 AF022799 Hs.1132		5.4
55	320107 AA836481 Hs,2917		5.3
33	320133 D63271 320167 AA984373 Hs.9079	EST cluster (not in UniGene)	5.5
			15 6.7
	320187 T99949 Hs.3034 320211 AL039402 Hs.1257		24.3
	320401 U90449 Hs.1527		10
60	320458 Al884396 Hs.2413		5.4
	320488 R31386 Hs.1917		4.9
	320521 N31464 Hs.2474		. 9.5
	320661 AA864846 Hs.1151		6.6
	320691 R61576 Hs.3139		5.9
65	320699 R63161 Hs.1182		4
	320727 U96044 Hs.1811	· · · · · · · · · · · · · · · · · ·	15.3
	320993 AL050145 Hs.2259	66 Homo sapiens mRNA; cDNA DKFZp586	7.2

	321012	AA737314	Hs.194324	EST cluster (not in UniGene)	6.1
	321050	AW393497		EST cluster (not in UniGene)	5
		AF134149	Hs.240395	EST cluster (not in UniGene)	11.4
٠,		AI769410	Hs.221461	ESTs	7.7
5		AA295304	Hs.297939	ESTs; Wealdy similar to neogenin [H.sap	5.5
		AA078493		EST cluster (not in UniGene)	16.9
		H68014	Hs.141278	ESTs; Wealthy similar to IIII ALU SUBFA	4.2
		AW366305		EST cluster (not in UniGene)	6.3 9
10		AW392474 N98619	Hs.42915	ESTs; Moderately similar to IIII ALU SU ARP2 (actin-related protein 2; yeast) hom	11,3
10		H84762	Hs.253197	ESTs	10.4
		D28390	Hs.272897	EST cluster (not in UniGene)	19.9
		AW157424		ESTs	5.6
		H67065	Hs.271530	ESTs; Wealdy similar to !!!! ALU SUBFA	5.4
15		AW068268		ESTs; Weakly similar to !!!! ALU CLASS	6.5
		N77342	Hs.21851	EST cluster (not in UniGene)	10.2
		AA310039		ESTs	9.8
	322026	AA233527	Hs.283675	low density lipoprotein receptor (familial	27.8
	322035	AL137517	Hs.306201	EST cluster (not in UniGene)	40.2
20	322171	AF085968	Hs.48474	EST cluster (not in UniGene)	5.7
		AF085975		EST cluster (not in UniGene)	7.7
		AL134970		follistatin-like 1	14.4
		W07459	Hs.157601	EST cluster (not in UniGene)	13.4
25		AA086123		EST cluster (not in UniGene)	7.6
25		AA679082		ESTS	4.4
		AW043782		ESTs	21 15.3
		AW248508 C16391	ns.z/s/z/	DiGeorge syndrome critical region gene 2 EST cluster (not in UniGene)	21.3
		C18965	Hs.159473	ESTs	11.7
30		AA580288	110.100710	EST cluster (not in UniGene)	8.9
50		AW014094	Hs.210761	ESTs	10.8
		Al301107	Hs.150790	ESTs	6.5
		AL120351		EST cluster (not in UniGene)	5.5
	323168	AL120862	Hs.124165	ESTs	17.9
35	323195	A1064982	Hs.117950	multifunctional polypeptide similar to SA	5.8
			Hs.13350	Homo saptens mRNA; cDNA DKFZp586	11.6
		AA203135		ESTs	6.4
		W44372	Hs.110771	EST cluster (not in UniGene)	7.3
40		T70731	Hs.193620	EST cluster (not in UniGene)	15.8
40		AA228078		EST cluster (not in UniGene)	4.8 20.2
		Al829520 AA228883	Hs.227513	ESTs EST chaster (not in UniGene)	8.8
		AL038623		ESTs; Weakly similar to IIII ALLI SUBFA	5
		Al751438	Hs.41271	ESTs; Weakly similar to IIII ALU SUBFA	6.5
45		AA344205		EST cluster (not in UniGene)	7.1
		AA327102		EST cluster (not in UniGene)	6.1
		AA410943		EST cluster (not in UniGene)	16.8
	323845	AI684674	Hs.41127	ESTs; Weakly similar to waclaw (D.melan	10.1
	323930	AA570698	Hs.8173	ESTs	6.4
50	323997	AA844907	Hs.274454	EST cluster (not in UniGene)	8
		AA378201		EST cluster (not in UniGene)	6.3
		AL044891		EST cluster (not in UniGene)	50.1
		AA543008		ESTs; Weakly similar to IIII ALU SUBFA	5.7
55		AL138357		EST8	9.5
55		AW502000		EST cluster (not in UniGene)	4.4
		AA464510		EST cluster (not in UniGene)	16.7
		AW501411 AW152624		ESTs; Weakly similar to IIII ALU CLASS ESTs	5.5 5.4
		ANT 152024 AA502659		ESTs	5.4 8.8
60		AW016378		EST8	23.1
30		AA448021		EST cluster (not in UniGene)	21.2
		AI610425		EST8	5
			Hs.132586	ESTs	5
		AA640770		EST cluster (not in UniGene)	4.1
65		AJ826999		ESTs	6.3
		AA704806		ESTs	11.7
	324902	D31323	Hs.271492	ESTs	4.8

	202004 AAC40300		COT absetos (not in 1) niCono)	13.3
	324961 AA613792	Un 470004	EST cluster (not in UniGene)	19.6
	324987 T06882	Hs.172634	ESTs	24.5
	324988 T06997	Hs.121028	EST duster (not in UniGene)	
_	325146 Al064690	HS.1/11/6	ESTS	4.6
5	325622		CH.14_hs gij5867000	5.2
	326213		CH.17_hs gl 5867224	8.1
	326474		CH.19_hs gl 5867405	12.7
	326816		CH.20_hs gi 6552458	9.4
	326817		CH.20_hs glj6552458	11.7
10	327110		CH.21_hs gij6117842	14.7
	327196	•	CH.01_hs glj5867446	5.1 .
	327283		CH.01_hs gij5867478	4.3
	327313		CH.01_hs gij5887501	4.8
	327450		CH.02_hs gij5887766	4.1
15	328059		CH.06_hs gij6117819	6.2
	328304		CH.07_hs gij6004478	5.4
	328492		CH.07_hs glj5868455	7
	328857		CH.07_hs gif6381927	5.2
	329367		CH.X.) hs gij5868842	7.6
20	329373		CH.X_hs gij6682537	12
20	329655		CH.14_p2 gij6448516	4
				4
	329899		CH.15_p2 gij6563505	7.6
	329960		CH.16_p2 gij5091594	4
26	330084		CH.19_p2 gij6015302	5.8
25	330384 M23263		androgen receptor (dihydrotestosterone re	
	330385 AA449749		ESTs; Highly similar to secreted apoptosi	10.2
	330387 H14624		ESTs; Highly similar to secreted apoptosi	4.4
	330388 X03363		HER2 receptor tyrosine kinase (o-erbB-2;	17.7
	330409 D50692	Hs.78221	c-myc binding protein	10.1
30	330460 TIGR:HT54	4	Hs.73946	Endothelial Cell Growth Factor 1 5.5
	330486 M13755	Hs.833	interferon-stimulated protein; 15 kDa	67
	330494 M29696	Hs.237868	interleukin 7 receptor	6
-	330500 M34423	Hs.79222	galactosidase; beta 1	13.1
	330510 M75099	Hs.227729	FK506-binding protein 2 (13kD)	29
35	330513 M81057	Hs.180884	carboxypeptidase B1 (tissue)	38.5
	330541 U22970	Hs.265827	multiple UniGene matches	7.4
	330542 U23942	Hs.226213	cytochrome P450; 51 (lanosterol 14-alpha	15
	330547 U32989	Hs.183671	tryptophan 2,3-dloxygenase	11
	330551 U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	6.5
40	330562 U49082	Hs.76460	transporter protein	7.7
40	330573 U62800	Hs.83393	cystatin E/M	4
	330673 D57823	Hs.321403	Sec23 (S. cerevisiae) homolog A	10.5
	330711 AA164687		mannosyl (alpha-1;3-)-glycoprotein beta-1	24.3
	330814 AA015730		ESTs; Wealthy similar to transformation-r	44.1
45			ESTS	4.4
43	330850 AA075298			B.1
	330874 AA127474		ESTs; Wealty stratar to 1111 ALU SUBFA	5.2
	330884 AA133457		ESTS	5
	330912 AA195936	1 1	general transcription factor IIA; 1 (37kD a	
50	330924 AA232136		Homo sapiens mRNA; dDNA DKFZp434	9.1
50	330997 H55762	Hs.9302	ESTS	7.6
	331014 H98597	Hs.30340	ESTs	13.5
	331024 N32919	Hs.27931	ESTs	9.1
	331046 N66563	Hs.191358	ESTs	10.5
	331135 R61398	Hs.4197	ESTs	7.4
55	331145 R72427	Hs.129873	ESTs; Wealdy similar to CYTOCHROME	41.9
	331148 R73816	Hs.17385	ESTs	4.7
	331222 T98531	Hs.173904	ESTs	4.1
	331230 W69807	Hs.16537	hypothetical protein; similar to (U06944)	4.9
	331306 AA252079	Hs.63931	dachshund (Drosophila) homolog	15.1
60	331327 AA281076		ESTs	4.8
	331337 AA287662		ESTs	7.6
	331341 AA303125		ESTs; Wealty similar to IIII ALU SUBFA	13
	331344 AA357927		ESTs	12.4
	331362 AA417956		ESTs	6.5
65	331363 AA421582		anterior gradient 2 (Xenepus laevis) homo	28.2
03	331376 AA443802		ESTs; Weakly similar to dDNA EST yk47	15.1
	331384 AA456001		ESTS	7.9
	JODOCHMA POOLICE	10.55041	LUIO	•

	204.470	NOCOCO	11- A0000	CCTo	7
	331478		Hs.40539	ESTS	19.8
	331528		Hs.46624	ESTs	
	331533		Hs.47282	ESTS	6.5
_		W85712	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danios	13.8
5		W88502		ESTs	9.9
	331750	AA284372	Hs.111471	ESTs	5.6
	331751	AA284840	Hs.143818	ESTs	5.8
	331760	AA292721	Hs.154434	ESTs; Wealdy similar to unknown [H.sap	7.4
	331763	AA312861	Hs.96704	EST8	7.8
10		AA411144		ESTs	15.2
٠.		AA432166		succinate dehydrogenase complex; subuni	24.3
		AA454756		ESTS	5
		AA487910		ESTs: Weakly similar to !!!! ALU CLASS	10.5
		AA490831		ESTs	11.4
15		AA504779		ESTS	13.6
13				ESTS	9.1
		AA598594			8.8
			Hs.112592	ESTs	9
		AA620669		EST	
~~		N22508	Hs.139315	ESTs	7.1
20		N33213	Hs.100425	ESTs	12.2
		N57927	Hs.120777	ESTs; Wealthy similar to RNA POLYME	15.6
	332247	N58172	Hs.109370	ESTs .	16.9
	332260	N70088	Hs.138467	ESTs	4
	332269	N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.2
25	332336	T96130	Hs.137551	ESTs	7.7
	332340	W15495	Hs.129781	chromosome 21 open reading frame 5	14.1
	332347	W60326	Hs.288684	ESTS	4.4
		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	16.9
			Hs.119004	KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
-			Hs.154424	delodinase; lodothyronine; type II	5.8
		AA281753		Inositol 1,4;5-triphosphate receptor, type	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
		AA234896		E1A binding protein p300	12.3
35		R41791	Hs.36566	LIM domain kinase 1	11.1
ככ				protein regulator of cytokinesis 1	18.2
		AA417152		KIAA1067 protein	15.2
			Hs.243901		4.7
		H93968	Hs.75725	transgelin 2	5.5
40		T59161	Hs.76293	thymosin; beta 10	9.8
40		AA479968	HS.88201	arysulfatase A	17.7
	332927			CH22_FGENES.38_1	
	332929			CH22_FGENES.38_3	4.7
	332930			CH22_FGENES.38_4	7.A
	332955			CH22_FGENES.48_12	5.4
45	332958			CH22_FGENES.48_15	17.8
	332961			CH22_FGENES.48_18	10.6
	332983			CH22_FGENES.54_5	4.3
	333009			CH22_FGENES.61_1	5.2
	333010			CH22_FGENES.61_2	8.1
50	333013			CH22_FGENES.61_5	8.5
	333108			CH22_FGENES.79_14	5.6
	333139			CH22 FGENES.83 16	6.3
	333254			CH22_FGENES.118_2	6.8
	333305			CH22_FGENES.137_2	11.4
55	333343		•	CH22_FGENES.139_12	5.1
<i>JJ</i>	333388			CH22 FGENES.144_3	12.7
	333456			CH22_FGENES.157_5	4.2
				CH22_FGENES.157_8	7.6
	333459				8.2
6 0	333517			CH22_FGENES.173_2	5
60	333585			CH22_FGENES.203_4	4.3
	333679			CH22_FGENES.247_6	
	333743			CH22_FGENES.264_1	13.4
	333758			CH22_FGENES.268_1	4
<i>-</i> -	333767			CH22_FGENES.271_6	5.6
65	333768			CH22_FGENES.271_7	12.2
	333769			CH22_FGENES.271_8	48.3
	333795			CH22_FGENES.275_1	6.1

	333796	CH22_FGENES.275_3	6.8
	333892	CH22_FGENES.292_14	4.4
	333904	CH22_FGENES.294_2	6.5
_	333905	CH22_FGENES.294_3	9.3
5	333921	CH22_FGENES.296_12	9.6
	333968	CH22_FGENES.307_4	15.9
	334102	CH22_FGENES.327_60	7.1
	334222	CH22_FGENES.360_3	6.7
••	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1
	334360	CH22_FGENES.378_5	6.1
	334784	CH22_FGENES.432_9	4.8
15	334789	CH22_FGENES.432_14	5.1
15	334794	CH22_FGENES.434_2	7
	334889	CH22_FGENES.452_3	12.4
	335004 335445	CH22_FGENES.472_8	7.9
	335115 335287	CH22_FGENES.496_2 CH22_FGENES.526_11	18.8 4.5
20	335342	CH22_FGENES.536_1	5.3
20	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	7
	335498	CH22_FGENES.571_7	12.2
	335544	CH22_FGENES.576_5	8.4
25	335610	CH22_FGENES.583_4	12.9
	335653	CH22_FGENES.590_4	6.7
	335682	CH22_FGENES.595_2	12.1
	335687	CH22_FGENES.596_2	13.9
	335755	CH22_FGENES.604_4	11.5
30	335782	CH22_FGENES.609_4	17.9
	335791	CH22_FGENES.611_7	27.3
	335809	CH22_FGENES.617_6	19.2
	335822	CH22_FGENES.619_7	19.1
35	335823	CH22_FGENES.619_8	4.5
33	335824 335825	CH22_FGENES.619_11	40.2
	335895	CH22_FGENES.619_12 CH22_FGENES.635_3	34.3 10.2
	335917	CH22_FGENES.636_13	6
	335920	CH22_FGENES.636_16	8.8
40	336035	CH22_FGENES.678_6	5.9
	336042	CH22 FGENES.679 4	5.8
	336093	CH22_FGENES.691_2	11.6
	336096	CH22_FGENES.691_5	7.6
	336150	CH22_FGENES.706_6	6.3
45	336152	CH22_FGENES.706_9	10.5
	336416	CH22_FGENES.823_38	5
	336444	CH22_FGENES.827_10	4.8
	336449	CH22_FGENES.829_6	13.6
50	336471	CH22_FGENES.829_30	6.9
30	336512	CH22_FGENES.834_7	21.4
	336558	CH22_FGENES.842_3	8.2
	336560 336676	CH22_FGENES.842_5	9
	336959	CH22_FGENES.43-4 CH22_FGENES.367-13	9,4
55	337968	CH22_ENtAC005500.GENSCAN.103-2	19 13.4
•	338008	CH22 EMAC005500.GENSCAN.127-9	15.2
	338057	CH22 EN:AC005500.GENSCAN.160-1	13.9
	338410	CH22 EM:AC005500.GENSCAN.341-6	8
	338451	CH22_ENLAC005500.GENSCAN.359-3	11.6
60	338588	CH22_EM:AC005500.GENSCAN.432-1	10.3
	338665	CH22_EM:AC005500.GENSCAN.464-2	4.8
	338689	CH22_EM:AC005500.GENSCAN.475-3	6.7
	338832	CH22_DJ246D7.GENSCAN.6-9	4.8
65	338980	CH22_DA59H18.GENSCAN.2-4	5.1
65	339352	CH22_BA354I12.GENSCAN.29-7	6.9
	339373	CH22_BA232E17.GENSCAN.1-29	4.3

TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1.5	Pkey: CAT number: Accession:	Unique Eos probeset identifier number Gene cluster number Genbank accession numbers
15		

AACOOOCA AACOOOOO

Pkey (CAT number	Accession
--------	------------	-----------

	123619 3/1661_1 AA60	IZIO4 AAGUSZUU
20	103207 306354 X727	90
	103349 110522 X890	159
	110856 19346_14 AA99	92380 N33063 N21418 H79958 R21911 H79957
	113248 328626_1 T638	57 AW971220 AA493469 T63699
	123169 44573_2 Al956	0087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671
25	AA90	08598 AA251875 A820501 A820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517
	Al219	9788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964
	AA28	13144 A1890387 A1950344 A1741346 A1689062 AA282915 AW102898 A1872193 A1763273 AW173586 AW150329 A1653832
	A176	2688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970
	BE61	12881 AW276997 AW513801 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874
30	AI819	2225 AW205862 AI683338 AI868509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273
		9759 N75628 N22388 H84729 H60052 T92487 A1022058 AA780419 AA551005 W80701 AW613466 A1373032 A1564269
	. F005	31 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
	123533 genbank_AA608751	AA608751
~~	116480 genbank_C14088	C14088
35	132225 genbank_AA128980	AA128980 ,

	genbank_AA128980	AA128980 ,
125154	genbank_W38419	W38419
118475	genbank_N66845	N66845
102919	25180_2 M21191 AI	L035748 AA021266 AA323126 AA180515 Al613029 D28356 NM_000034 M11560 AW401425 AW248248 AA012956
	AA323294	W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW406575 AW404021 AW406207
	AA075752	AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367
	AW402140	AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804
	AA216544	AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385
	AA054395	H30840 AW498825 AA086141 Al557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257
	. AW176086	AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 C04921 AA345696 R89640 AA085425 AA481708
	AA313637	AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854
	AA192582	AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014
	AA001186	H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 AJ366131 H14328 AA197161
	AA379497	AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921
	AW380419	AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789
	AW362775	AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553
	R87925 AA	X292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750
	AA359270	AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267
•	AW372970	AA341973 AA346098 AW372969 AA337549 AA327342 H93855 A)074079 F29118 AA852940 F35696 AA345963
	AA079578	AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 AI909845 AW374374 AW374382
		AW374373 AW374370 AI909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 AI525039
		1007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131
		AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149
		AA481936 C04941 AW375299 M21190 AA410818 AA250940 AI354547 AA317422 AA250903 AI865497 AA890603
	AA366197	AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393
		AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811
	H44129 N8	4794 F01135 AA477852 AA293062 AW361595 H27194 AIB31650 H43253 H24797 AI564680 AA380090 W20057
	AI921586 A	N192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00948

	C03986 Al318091 Al860172 AA582179 Al633388 AA557193 R68075 F24105 AW518239 W56622 Al625219 Al925243 AW468046 Al921828 AA339164 Al144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 Al680458 AA159956 AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 Al630871 Al633128 AW514329 AA010455
_	AA563928 AI571596 AI128394 W73707 AM23575 AA583809 AA657988 AI950837 AA169782 AA600009 AI885540 AA771884
5	A1978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 A1905695 AA480115 AA574051 A1889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 A1038538 AA411329 AA781570 A1833176
	AA935520 AW074197 AA583063 AW073099 AW0D1198 AA948025 AA587857 AA191540 AH60085 AA193244 AL538037
	AA515572 AA758587 AI149311 AA508610 AA206409 AA534004 AA994600 AA827543 AI916349 AW245129 AW517804 D25663
10	AA781985 AA284536 AI819422 H16040 H27531 AA456564 AA845555 AI423596 AA012908 AA889439 AA716311 AA968868 AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 AI342442 AI003519 AI002503 AI347597
10	A1040946 AA197162 AA987883 AA292865 AW001944 A1640711 AW244044 AA456784 F30588 AA290829 H24754 A1978683
	AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204
	AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA477746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 Al569314 AA961665 Al922050 Al759000 AA555236 AA514432
15	AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 Al361315 AA284988 F36340 Al361322
	F26969 AA991922 AA021267 F26973 AI361314 F35891 AI918509 AA250964 AA190992 AA577139 AA865535 AA134324
	AW192842 AI224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007 AI830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921
	T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857083 AA017259
20	AA179789 AA088908 H43704 AA194320 F35950 A1880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390 A1302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28108 AA243301
	AI025737 AA101239 AA088887 AI214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715
	F37529 AI811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245
25	AA331222 F25634 F21996 W28215 F21911 R65793 Al192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411
23	H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455
	F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 F24835 F34672 F26474 Al926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297
	AIS37207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863
30	F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566
	F34230 F33258 F20860 F17998 Al695701 118600 genbank_NG9222 N69222
	118952 genbank_N92966 N92966
25	120873 genbank_AA358015 AA358015
35	113702 genbank_T97307 T97307 T97307 12982 221 267 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
	AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107
	Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190
40	AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991
	AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090
	AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526
40	AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506
45	X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957
	M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174057 UZ7189 Y09384
	U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AL006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519
50	796957 AF021986 792898 796956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520
	AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509
•	AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S58184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321
	AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115
55	AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702
	APG68669 APG66666 APG66667 APG6667 AWAST 1244 AWAG516 AWAG514 ANTHORY 3 AWAG515 AWAG5534 T93007 AW351514 D78345 T29140 J00231 NM_002179 AW465146 AA301091 X04648 H64660 AW402990 AW466534 T93007
	A1857980 AW368899 A1905833 AW406586 AA482084 A1872299 AA715266 AW404328 A1831674 A1709348 AA603112
60	AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 115763 genbank AA421560 AA421560
OU	115763 genbank_AA421560 AA421560 124357 genbank_N22401 . N22401
•	108733 504187_1 AA121022 AA126422
	101544 entrez_M31169 M31169 124447 genbank N48000 N48000
65	124677 genbank_R01073 R01073
-	124777 genbank_R41933 R41933
	119302 genbank_T25725 T25725

÷

```
103680 entrez Z93784Z93784
           135029 H58818_at
                                    H58818
           112253 genbank_R51818
                                                  R51818
           Pkey CAT number Accession
  5
           322175 46877_1
                                     AF085975 H53458 H53459
           323011 139750_1
                                     AA580288 AA315855 AA133031 AA377748
           322975 1510563_1
                                     C16391 C16413
                                     AW881145 AA490718 M85637 AA304575 T06067 AA331991
AA410943 AW948953 AA334202 AA332882
           317210 211994_1
           323817 233566_1
10
           309583 1046029_-2
                                     AW170035
           324961 376239_1
                                     AA613792 AW182329 T05304 AW858385
           303502 325188_1
                                     BE174240 AA488528 AL042253
           320133 447553_1
                                     BE151746 BE336853 D63271 T94955 AA774994
                                     AA216387 T63548 AA228676
           311935 174129_1
                                     C05928 AW393497
AA534222 AA632632 T81234
15
           321050 502195_1
           319977 345248_1
           312772 4380_7
                                     AW962299 AA310349 AW962294 H63791 H63751
           321354 116028 -2
                                     AA078493
           336512 CH22_3941FG_834_7_LINK_DJ
          336558 CH22 3992FG 842 3 LINK DJ
336560 CH22 3994FG 842 5 LINK DJ
20
           329367 c_x_hs
           329373 c_x_hs
           336676 CH22_4154FG_43_4_
25
           338008 CH22_6490FG__LINK_EM:AC00
           338057 CH22_6558FG__LINK_EM:AC00
           329655 c14_p2
           336959 CH22_4764FG_367_13_
           329899 c15_p2
30
           329960 c16_p2
           338410 CH22_7067FG__LINK_EM:AC00
          338451 CH22_7124FG_LINK_EM:AC00
338588 CH22_7331FG_LINK_EM:AC00
338665 CH22_7438FG_LINK_EM:AC00
338689 CH22_7464FG_LINK_EM:AC00
35
           308677 AI761173
           338832 CH22_7678FG_LINK_DJ246D7
338980 CH22_7859FG_LINK_DA59H18
          333009 CH22_233FG_61_1_LINK_EMA
333010 CH22_234FG_61_2_LINK_EMA
333013 CH22_237FG_61_5_LINK_EMA
40
          308981 Al873242
          308995 Al880172
          333108 CH22_336FG_79_14_LINK_EM:
45
          333139 CH22_368FG_83_16_LINK_EM:
          333254 CH22_495FG_118_2_LINK_EM:
333305 CH22_550FG_137_2_LINK_EM:
333343 CH22_589FG_139_12_LINK_EM:
333388 CH22_634FG_144_3_LINK_EM:
50
          326213 c17_hs
          333456 CH22_706FG_157_5_LINK_EM:
          333459 CH22_709FG_157_8_LINK_EM:
          333517 CH22_773FG_173_2_LINK_EM: 333585 CH22_846FG_203_4_LINK_EM:
55
          333679 CH22_941FG_247_6_LINK_EM:
          326474 c19_hs
          333743 CH22_1009FG_264_1_LINK_EM
          333758 CH22_1024FG_268_1_LINK_EM
          333767 CH22_1034FG_271_6_LINK_EM
333768 CH22_1035FG_271_6_LINK_EM
333769 CH22_1036FG_271_8_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
333796 CH22_1065FG_275_3_LINK_EM
60
          335004 CH22_2326FG_472_8_LINK_EM
          333892 CH22_1163FG_292_14_LINK_E
335115 CH22_2447FG_496_2_LINK_EM
333904 CH22_1176FG_294_2_LINK_EM
65
```

```
333905 CH22_1177FG_294_3_LINK_EM
          333921 CH22_1194FG_296_12_LINK_E
333968 CH22_1245FG_307_4_LINK_EM
           328059 c_6_hs
  5
           335287 CH22_2629FG_526_11_LINK_E
           326816 c20_hs
           326817 c20_hs
           335342 CH22_2689FG_536_1_LINK_EM
           335491 CH22_2843FG_570_23_LINK_E
10
           335495 CH22_2847FG_570_28_LINK_E
           335498 CH22_2850FG_571_7_LINK_EM
           328304 c_7_hs
305453 AA738110
           335544 CH22 2899FG_576_5_LINK_EM
335610 CH22_2969FG_583_4_LINK_EM
15
           335653 CH22_3013FG_590_4_LINK_EM
           335682 CH22 3043FG 595_2 LINK EM
335687 CH22 3048FG 596_2 LINK EM
           328492 c_7_hs
335755 CH22_3122FG_604_4_LINK_EM
335782 CH22_3151FG_609_4_LINK_EM
20
           335791 CH22_3160FG_611_7_LINK_EM
           335809 CH22 3181FG_617_6_LINK_EM
335822 CH22_3195FG_619_7_LINK_EM
          335823 CH22_3198FG_619_8_LINK_EM
335824 CH22_3197FG_619_11_LINK_E
335825 CH22_3198FG_619_12_LINK_E
25
           335895 CH22_3272FG_635_3_LINK_EM
335917 CH22_3294FG_636_13_LINK_E
30
           335920 CH22_3297FG_636_16_LINK_E
           305898 AA872838
           305913 AA876109
305950 AA884479
           328857 c_7_hs
35
           330084 с19_р2
           337968 CH22_6419FG__LINK_EM:AC00
           309177 Al951118
           309198 Al955915
           309226 Al969897
40
           339352 CH22_8317FG_'LINK_BA354I1
           309279 Al990102
           339373 CH22_8348FG__LINK_BA232E1
           325622 c14_hs
           334102 CH22_1380FG_327_60_LINK_E
45
           332927 CH22_148FG_38_1_LINK_C20H
          332939 CH22_150FG_38_3_LINK_C20H
332930 CH22_151FG_38_4_LINK_C20H
332955 CH22_179FG_48_12_LINK_EM:
332956 CH22_182FG_48_15_LINK_EM:
332951 CH22_182FG_48_18_LINK_EM:
50
           332983 CH22_207FG_54_5_LINK_EMtA
           334222 CH22_1506FG_360_3_LINK_EM
           334223 CH22_1507FG_360_4_LINK_EM
          334264 CH22_1551FG_367_15_LINK_E
55
           327110 c21_hs
           334343 CH22_1636FG_375_25_LINK_E
           334360 CH22_1654FG_378_5_LINK_EM
           327196 c_1_hs
          327283 c_1_hs
327313 c_1_hs
327313 c_1_hs
30465 AA421948
304507 AA456426
60
           327450 c_2_hs
           304591 AA505702
65
           304601 AA507875
           304659 AA533185
          334784 CH22_2096FG_432_9_LINK_EM
```

Í

334789 CH22_2101FG_432_14_LINK_E
334794 CH22_2106FG_434_2_LINK_EM
336035 CH22_3420FG_678_6_LINK_DJ
336032 CH22_3427FG_679_4_LINK_DJ
336093 CH22_3481FG_691_2_LINK_DJ
336096 CH22_3484FG_691_2_LINK_DJ
334889 CH22_2206FG_452_3_LINK_EM
336150 CH22_3540FG_706_6_LINK_DA
336152 CH22_3540FG_706_6_LINK_DA
336152 CH22_3543FG_706_9_LINK_DA
336444 CH22_3834FG_823_38_LINK_B
336444 CH22_3870FG_829_6_LINK_DJ
336447 CH22_3870FG_829_6_LINK_DJ
336471 CH22_3894FG_829_30_LINK_D

TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I, et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I, et al., Nature (1999) 402:489-495.		
	Strand: Nt position:	Indicates DNA strand from which exons were predicted. Indicates nucleofide positions of predicted exons.		

15	Diam.	Ref	Strand	Nt position
	Pixey	Kei	Suanu	Nt_position
	332955	Dunham, I. et.al.	Ptus	2508896-2508992
	332958	Dunham, I. et.al.	Plus	2516164-2516310
20	332961	Dunham, I. et.al.	Phus	2521424-2521555
~~	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et.al.	Phus	2521424-2521555
	333305	Dunham, I. et.al.	Plus	4630388-4630645
	333388	Dunham, I. et al.	Plus	4913749-4913805
25	333517	Dunham, I. et.al.	Plus	5570729-5570925
	333585	Dunham, i. et.ai.	Plus	6234778-6234894
	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333795	Dunham, I. et.al.	Ptus	7807688-7807795
	333796	Dunham, I. et.al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334102	Dunham, I. et.al.	Plus	9995140-9996373
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	334343	Dunham, I. et.al.	Plus	13655828-13656307
	334794	Dunham, I. et al.	Plus	16374312-16374458
40	334889	Dunham, I. et al.	Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et.al.	Plus	24140688-24140872
	335498	Dunham, I. et.al.	Plus	24172082-24172161
45	335653	Dunham, Letal	Plus	25329710-25329802
	335687	Dunham, I. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et.al.	Plus	26364087-26364196
	335823	Dunham, I. et.al.	Plus	26365925-26366004
50	335824	Dunham, I. et.al.	Plus	26376860-26376942
	335825	Dunham, I. et.al.	Plus	26378175-26378268
	336035	Dunham, I. et.al.	Plus	29016748-29017410
	336093	Dunham, I. et.al.	Plus	29556922-29557002
	336096	Dunham, I. et.al.	Plus	29578878-29579047
55	336444	Dunham, I. et.al.	Plus	34190585-34190718
	336959	Dunham, I. et.al.	Plus	13233040-13233126
	338008	Dunham, L. et.al.	Plus	7697068-7697236
	338057	Dunham, I. et.al.	Plus	8526397-8526522
	338410	Dunham, I. et.al.	Plus	19292807-19292916
60	338588	Dunham, I. et.al.	Plus	22896767-22896920
	338665	Dunham, I. et.al.	Plus	24472654-24472853
	338832	Dunham, i. et.al.	Plus	27775128-27775290
	338980	Dunham, I. et.al.	Plus	29896789-29896874
	339352	Dunham, I. et.al.	Plus	33544784-33545121
	338980	Dunham, I. et.al.	Plus	29896789-29896874
			. 443	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

	332929 Dur	iham, I. etal.	Minus	2020758-2020664
	332930 Dur	nham, I. et.al.	Minus	2022565-2022497
		ham, I. et.al.	Minus	2631933-2631797
		rham, Letal	Minus	2766043-2765856
5				2766207-2766119
)		nham, I. et.al.	Minus .	
		nham, I. et.al.	Minus	2772278-2772039
	333108 Dur	nham, I. et.al.	Minus	3240494-3240389
	333343 Dur	nham, l. et.al.	Minus	4692886-4692753
	333456 Dur	nham, I. et.al.	Minus	2631933-2631797
10		nham, I. et.ai.	Minus	5144548-5144344
10		nham, l. et.al.	Minus	7573218-7573060
			Minus	7666413-7666091
		nham, l. et.al.		8217374-8217261
		nham, I. etal.	Minus	
		nham, I. et.al.	Minus	8217796-8217670
15	334222 Dui	nham, I. etal.	Minus	12732417-12732289
	334223 Dur	nham, i. et.al.	Minus	12734365-12734269
	334360 Dur	nham, I. et.at.	Minus	13728850-13728751
	••••	nham, I. et.al.	Minus	16294548-16294360
		nham, I. et al.	Minus	16306095-16305998
20			Minus	20581911-20581794
20		nham, I. etal.		
		nham, l. et.al.	Minus	21388250-21388146
	335342 Du	nham, l. et.al.	Minus	22597448-22597284
	335544 Du	nham, I. et.al.	Minus	24650505-24650403
	335610 Du	nham, I. et.al.	Minus	25068943-25068841
25	335682 Du	nham, Letal	Minus	25421215-25421093
		nham, I. et.al.	Minus	25763806-25763747
		nham, I. etal.	Minus	25908578-25908440
				25948563-25948411
		nham, I. et.al.	Minus	
^^		nham, I. et.al.	Minus	26975307-26975239
30	335917 Du	nham, i. et.al.	Minus	27028481-27028377
	335920 Du	nham, I. et.al.	Minus	27034927-27034811
	336042 Du	nham, 1. et.al.	Minus	29041694-29041500
	336150 Du	nham, I. et.al.	Minus	30150423-30150256
		nham, I. et.al.	Minus	30156053-30155870
35		nham, I. et.al.	Minus	34047408-34047311
		nham, I. et.al.	Minus	34204707-34204577
		nham, I. et.al.	Minus	34215091-34214978
			Minus	34278373-34278275
		nham, Letal.		34375825-34375698
40		nham, i. etal.	Minus	
40		nham, i. etal.	Minus	34376814-34376596
	336676 Du	nham, I. et.al.	Minus	2022565-2022497
	337968 Du	nham, i. et.al.	Minus	7095797-7095680
	338451 Du	nham, I. et.al.	Minus	20174286-20174193
		nham, I. et.al.	Minus	24893073-24892972
45	••••	nham, l. et.al.	Minus	33860127-33860047
7.5		67000	Plus	69994-70075
		48516	Minus	35565-35843
		63505	Minus	111058-111783
<i></i> 0		91594	Minus	1031-1162
50	326213 58	8 72 24	Minus	60751-60927
	326474 58	67405	Plus	16995-18101
	330084 60	15302	Minus	57019-59337
	326816 65	52458	Plus	198354-198436
		52458	Plus	199909-200001
55	327110 61		Plus	94608-94785
<i>JJ</i>			Ptus	180921-181333
	327196 58			
	327283 58		Minus	567-962
	327313 58		Minus	89734-89838
	327450 58		Minus	47928-48076
60	328059 61		Plus	37052-37204
	328492 58	68455	Minus	46094-46241
		04478	Minus	3884-3952
		81927	Minus	80557-81051
		68842	Minus	87201-87587
65		82537	Minus	38950-39301
U.S	329373 66	الانتكار	iviii ius	30330-33301

TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast cancer cells.

10	Pkey: ExAcon: Unigene!D: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of humor to normal breast tissue
----	---	--

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100038	M97935		AFFX controt: STAT1	16.7
		D00596	Hs.82962	thymidylate synthetase	15.9
		J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin)	30.1
20	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelafinase B; 9	37.2
	101104	L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPYY	18.3
	101143	L12723	Hs.90093	heat shock 70kD protein 4	17:4
	101332	L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topols	18.9
	101378	M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.1
25	101809	M86849	Hs.323733	Homo saplens connexin 26 (GJB2) mRNA	22.5
		U65932	Hs.81071	extracellutar matrix protein 1	23.2
	102721	U79241	Hs.118666	Human clone 23759 mRNA; partial cds	15
		U90904	Hs.83724	Human cloine 23773 mRNA sequence	15.2
		X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
30		X17644	Hs.2707	G1 to S phase transition 1	20.6
		X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin 3	17.8
		X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); milo	18.9
		X72755	Hs.77367	monokine induced by gamma interferon	15.1
25			Hs.198793	KIAA0750 gene product	23.3
35		AA428090		ESTs	28.7
		AA007234		ESTs	16.6
		AA191512		Homo sapiens mRNA; cDNA DKFZp564G	19.3
		AA421104		ESTs	15.4
40		AA621169		ESTs	19
40			Hs.110826	trinucleotide repeat containing 9	20.1
		H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H59617	Hs.5199	ESTs; Wealty similar to UBIQUITIN-CON	19.5
		H98714	Hs.24131	ESTs ESTs	30.2 23.2
45		N46252	Hs.29724	ESTs ESTs	23.2 37
43		N67239 N91023	Hs.10760 Hs.87128	ESTS	37 15
		R46025	Hs.7413	ESTs .	17.4
		W86748	Hs.8109	ESTs	15
		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 protein	22
50		Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
50			Hs.196437	ESTs; Weakly similar to R26660_1; partial	16.9
		AA250737		ESTs	35.1
		AA405098		ESTs	16.1
		AA433943		ESTs; Weakly similar to Weak similarity t	33.5
55		H29532	Hs.101174	microtubute-associated protein tau	22.2
55		H72948	Hs.821	biglycan	20.7
		N26722	Hs.42645	ESTs	18.1
		Z41815	Hs.65948	ESTs	15.6
		AA195651		ESTs	15.2
60			Hs.174104	ESTS	22.6
		AA609200		ESTs	23.1
		D60302	Hs.270016	ESTs	20.6
		H09290	Hs.76550	Homo saplens mRNA; cDNA DKFZp564B	25.9
		N90960	Hs.265398	ESTs; Weakly similar to transformation-rel	16.4

PCT/US02/02242

			47.0
	127677 AA916752 Hs.26		17.3
	128595 U31875 Hs.15		27.1
	128717 T30617 Hs.10		24.5
_	129124 AA234530 Hs.10		20.7
5	129366 H18027 Hs.18		18.2 26.4
	130455 X17059 Hs.15		39.9
	130604 X03635 Hs.16		20.9
	130913 W03592 Hs.21		18.8
10	130944 M97935 Hs.21		18.1
10	131472 AA608962 Hs.27		18.8
	131562 U90551 Hs.28 132180 AA405569 Hs.41		15.4
	132406 F09979 Hs.47	• • • •	15
	132465 AA047896 Hs.49		15.4
15	132994 AA505133 Hs.27		26.4
13	133294 R79723 Hs.69		30.4
	133634 U24168 Hs.23		15.2
	134374 D62633 Hs.83	· ·	15.2
	134405 J04177 Hs.82		15.3
20	134470 X54942 Hs.83		20.3
	134495 D63477 Hs.84		16.1
	134714 U89922 Hs.89		35.7
	135237 AA454930 Hs.96		19.5
	301884 AA312082 Hs.10		20.7
25	302276 NM 004448Hs.32	3910 EST cluster (not in UniGene) with exon hit	21.6
	302290 AL117607 Hs.17	5563 Homo saplens mRNA; cDNA DKFZp564N	41.4
	309177 Al951118	EST singleton (not in UniGene) with exon	24.3
	309583 AW170035	EST	64.5
	310438 AW022192 Hs.20	0197 ESTs	39.1
30	311166 Al821294 Hs.11		24.1
	312153 AA759250 Hs.15		27.1
	313915 Al969390 Hs.10		27.1
	314506 AA833655 Hs.20		27.8
25	314558 AI873274 Hs.19		22.5
35	314691 AW207206 Hs.13		21.4 18.4
	314943 Al476797 Hs.18		28.8
	315196 AA972756 Hs.44		32.6
	316177 Al908272 Hs.25 318073 AW167087 Hs.13		15.7
40	318662 Al285898 Hs.25		16.3
40	318740 NM_002543Hs.77	The second secon	21.3
	318744 AI793124 Hs.14	· · · · · · · · · ·	35
	319668 NM_002731Hs.87		25.4
	320074 AA321166 Hs.27	1 1	16.7
45	320211 AL039402 Hs.12		24.3
	320727 U96044 Hs.18		15.3
	322818 AW043782 Hs.29		21
	322882 AW248508 Hs.27		. 153
	324261 AL044891 Hs.26	9350 EST diuster (not in UniGene)	50.1
50	324432 AA464510 Hs.15	2812 EST duster (not in UniGene)	16.7
	324603 AW016378 Hs.29	2934 EST8	23.1
	324620 AA448021 Hs.94		21.2
	324988 T06997 Hs.12		24.5
	330388 X03363	HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
55	330486 M13755 Hs.83		67
	330814 AA015730 Hs.20		44.1
		9873 ESTs; Weakly similar to CYTOCHROME	41.9
	331306 AA252079 Hs.63		15.1
C O	331890 AA432166 Hs.3		24.3
60	332526 AA281753 Hs.77		19 45 2
	332532 N63192 Hs.18		15.3 15.2
	332694 AA262768 Hs.24		15.2 17.8
	332958 333769	CH22_FGENES.48_15 CH22_FGENES.271_8	48.3
65	333769 333968	CH22_FGENES.271_0 CH22_FGENES.307_4	15.9
U.J	334223	CH22_FGENES.360_4	33.5
	334264	CH22_FGENES.367_15	18.5
	Wiles	01 Mail - Off 1840/1001 - 10	,020

335791	CH22_FGENES.611_7	27.2
336512	CH22_FGENES.834_7	21.4
338008	CH22_EM:AC005500.GENSCAN.127-9	15.3

TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	n	
1		

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene duster number

15

	Pkey	CAT number	Accession
	309583	10460292	AW170035
20	336512	CH22 3941FG	834_7_LINK_DJ
	338008	CH22_6490FG	LINK EM:ACOO
	333769	CH22_1036FG_	271_8_LINK_EM
	333968	CH22_1245FG_	307_4_LINK_EM
	335791	CH22_3160FG_	611_7_LINK_EM
25	309177	Al951118	
	332958	CH22_182FG_4	8_15_LINK_EM:
			360_4_LINK_EM
		CH22_1551FG_	
	123619	371681_1	AA602964 AA609200

TABLE 14B

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Sequen	orresponding to an Eos probeset 2. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publica the DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402-489-495.	xtion	
15	Strand: Nt_posit	Indicate	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.		
	Pkey	Ref	Strand	Nt_position	
	222050	Dumbon I of al	Dhie	2519404 2519240	

	PREY	Ker	2019110	MC posmon
	332958	Dunham, I. et.al.	Plus	2516164-2516310
20	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334264	Dunham, I. et.al.	Ptus	13234447-13234544
	338008	Dunham, I. et.al.	Ptus	7697068-7697236
	334223	Dunham, I. et al.	Minus	12734365-12734269
25	335791	Dunham, Letal.	Minus	25948563-25948411
		Dunham, I. et.al.	Minus	34278373-34278275

TABLE 15: Table 3 from BRCA 001-5 US

Table 15 shows genes downregulated in breast cancer cells.

5

10

R1

Pkey:	Unique Eos	probeset	ldentitie	er mu	mbe	r

ExAccn: Exemplar Accession number, Genbank accession number
UnigeneilD: Unigene number
Unigene Title: Unigene gene title

Ratio of normal breast tissue to tumor

R1 ExAccn UniGene IDUnigene Title Pkey 15 100115 D00632 Hs.172153 glutathione peroxidase 3 (plasma) 1.7 100499 TIGR:HT1428 Hs.283108 Globin, Beta 100502 TIGR:HT1496 Hs.169228 Adrenal-Specific Protein Pg2 L-Glycerol-3-PhosphatecNad+ Oxidoreduct 1.7 100815 TIGR:HT4268 Hs.9739 20 1.5 transmembrane 4 superfamily member 2 101125 L10373 Hs.82749 101367 M12963 Hs.4 alcohol dehydrogenase 1 (class I); alpha po 2.9 101397 M15856 Hs.180878 lipoprotein lipase 1.6 101883 M98399 Hs.75613 CD36 antigen (collagen type I receptor; thr Hs.93841 potassium large conductance calcium-activ 102227 U25138 25 retinal-binding protein 4; Interstitial Hs.76461 102857 X00129 1.8 Hs.288579 polymeric immunoglobulin receptor 103211 X73079 103496 Y09267 Hs.132821 flavin containing monooxygenase 2 1.8 103562 Z21966 Hs.2815 POU domain; class 6; transcription factor 1 104672 AA007629 glycerol-3-phosphate dehydrogenase 1 (sol 2.4 30 Hs.18791 ESTs: Weakly similar to CALCIUM-BIND 1.7 105083 AA146619 1.5 105138 AA164519 Hs.15248 **ESTs** 106075 AA417915 Hs.25930 **ESTs** Hs.26530 serum deprivation response (phosphatidyls 1.6 106870 AA487576 Hs.211568 eukaryotic translation initiation factor 4 gam 107099 AA609645 35 1.6 107616 AA004901 Hs.261164 ESTs 107997 AA037388 Hs.82223 Human DNA sequence from clone 141H5 o 108604 AA099820 Hs.49696 **ESTs** yz44h12.s1 Morton Fetal Cochlea Horno sa 111130 N64265 Hs.19515 Hs.24453 **ESTs** 1.6 111837 R36447 40 1.9 112538 R70255 **ESTs** Hs.281022 EST 1.5 112808 R97970 Hs.209100 DKFZP434C171 protein 1.9 113086 T40652 115740 AA418033 Hs.283559 ESTs 1.6 115949 AA443800 Hs.43125 ESTs 45 Hs.173233 ESTs 2.2 115965 AA446661 Hs.218707 EST8 1.7 117224 N20300 SRY (sex-determining region Y)-box 10 117513 N32174 Hs.44317 1.7 Friedreich ataxia region gene X123 1.7 119059 R15436 Hs.77889 Hs.301002 ESTs; Weakly similar to cell death activato 2.8 119175 R71792 50 119359 T71021 Hs.285681 ESTs; Highly similar to WS basic-helix-loo 1.9 119798 W73386 Hs.249129 ESTs Hs.97044 120889 AA365784 **ESTs** Hs.97984 121381 AA405747 ESTs; Weakly similar to WASP-family pro 1.8 121750 AA421184 1.5 Hs.97549 FST8 55 2.5 122127 AA434447 Hs.106771 **EST**9 2.1 122348 AA443695 Hs.293410 ESTs Hs.160318 phospholemman 122485 AÅ448300 1.5 123443 AA598841 Hs.167382 natriuretic peptide receptor Alguarylate cy 123505 AA600135 ESTs; Moderately similar to IIII ALU SUB 1.5 60 125284 W94688 Hs.103253 perilipin 1.7 126300 D81972 HUM427D08B Human fetal brain (TFujiw 1.8 Hs.160318 phosphotemman 126747 R72515 1.6 127218 AA309765 Hs.116017 ESTs; Wealthy similar to KIAA0795 protei 1.5 127357 AA452788 Hs.75432 zx39g11.rl Soares_total_fetus_Nb2HF8_9

PCT/US02/02242

	497000	A A CO A 40F	l I = 400000	EW-	4 5
		AA634405 AA972780	Hs.122608	ESTS; Wealdy similar to IIII ALU SUBFA	1.5 1.5
		Al092391	Hs.134886	•	1.5
		N44757	Hs.20340	ESTS	1.6
5		R71403	Hs.75309	eukaryotic translation elongation factor 2	1.7
•		AA459944		DKFZP586P1422 protein	1.5
		T62068	Hs.11006	ESTs	2.1
	129331	N93465	Hs.279772	ESTs; Highly similar to CGI-38 protein [H	1.5
	130085	M62402	Hs.274313	insulin-like growth factor binding protein 6	1.7
10		M25079		hemoglobin; beta	1.7
•		AA211776	Hs.2504	myornesin 1 (skelemin) (185kD)	3.8
		AA131466	Hs.23767	ESTs	1.9
		M12272	Hs.4	'alcohol dehydrogenase 3 (class I); gamma p	2.2
15		AA295848 D49487	Hs.25475	aquaporin 7	1.7 2.5
13		AA045503	Hs.56874	leptin (murine obesity homolog) ESTs: Wealdy similar to Homo saplens p2	1.6
		Z41452	Hs.6090	delated in bladder cancer chromosome regi	1.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
		U95367	Hs.70725	gamma-aminobulyric acid (GABA) A recep	1.5
20		X74295	Hs.74369	integrin; alpha 7	1.7
	133601	S95936	Hs.284176	transferrin	2.3
	133702	N56898	Hs.75652	glutathione S-transferase M5	1.9
		N79674	Hs.8022	TU3A protein	4.6
25		U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25		L10955	Hs.89485	carbonic anhydrase IV	1.6
		M72885	Hs.95910 Hs.156286	Human GOS2 protein gene; complete cds	1.9
		AW027556 Al369956	Hs.257891		1.7 1.5
		AA514805	Hs.293055		1.8
30		AI807692	Hs.129129		1.6
		AA923549	Hs.224121		2.1
	302910	N77978		hemoglobin; alpha 1	1.8
	303798	V00505	Hs.36977	hemoglobin; delta	1.6
~-		T04868	Hs.46780	EST cluster (not in UniGene) with exon hit	1.7
35		U94362	Hs.58589	glycogenin 2	1.5
		H91086		EST singleton (not in UniGene) with exon	1.5
		AA516384	•	EST singleton (not in UniGene) with exon	1.5 1.7
		AA550994 AA782347	He 272572	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	1.5
40		AA923457	1 ISLI ZSI Z	EST singleton (not in UniGene) with exon	1.5
,,,		Al192534		EST singleton (not in UniGene) with exon	1.6
		Al222691		EST singleton (not in UniGene) with exon	1.5
	308023	Al452732	Hs.251577	EST singleton (not in UniGene) with exon	1.9
	308359	Al612774	Hs.79372	retinoid X receptor; beta	1.5
45		AW296073	Hs.255504		1.5
		AI720978		ESTs; Moderately similar to alternatively s	1.8
		AW241947	Hs.232478		1.6
		AW238092	Hs.254759		2.1 1.9
50		T79860 H25237	Hs.118180 Hs.306814		2.3
50		N49684	Hs.143040		1.8
		W32480	Hs.157099		2.2
	313374	AW328672	Hs.132760		1.9
	314701	AI754634	Hs.131987		1.7
55	315391	AA759098	Hs.192007		1.8
		AA680055	Hs.264885		1.5
	316249	AA948612	Hs.130414		1.6
		Al205077	Hs.294065		1.7
60		AA837079	Hs.24647		1.5
W		A1480204 A1650625	Hs.177131 Hs.300756		1.5 1.6
		ANOSU023 AW206520	Hs.129621		1.5
		W26902	Hs.154085		1.7
		H22654	Hs.6382	EST cluster (not in UniGene)	1.5
65		AA021402	Hs.11067		1.7
	322102	H45589		EST duster (not in UniGene)	1.5
	322814	A1824495	Hs.211038	ESTs	2.2

	322929	A1365585	Hs.146246	ESTs	2.3
	323831	AA335715	Hs.200299	ESTs	1.7
	324044	AL045752	Hs.22350	ESTs	1.8
_	324675	AW014734	Hs.157969	ESTs	2.2
5	325272		•	CHL11_hs gl[5866902	1.5
	325558	•		CH.12_hs gij6056302	1.6
	325656			CH.14_hs gi[6056305	1.6
	326120			CH.17_hs glj5867194	1.5
	326139			CH.17_hs glj5867203	1.5
10	326855			CH_20_hs gi]6552460	1.5
	327438			CH.02_hs gti6004454	1.6
	329733			CH.14_p2 gij6065783	1.6
	330931	F01443	Hs.284256	ESTs	4.6
	331591	N71677	Hs.42146	ESTs	1.9
15	332159	AA621393	Hs.112984	EST	1.5
	332364	W94688	Hs.103253		2.1
	332502	H21819	Hs.14896	Homo saplens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
	336336			CH22_FGENES.814_B	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EN:AC005500.GENSCAN.110-1	2
20	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354112.GENSCAN.34-2	1.5

TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigeneID's for Table 15.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

```
Pkey: Unique Eos probeset identifier number 
CAT number: Gene cluster number 
Accession: Genbank accession numbers
```

15

50

```
Pkey CAT number Accession
```

336244 CH22_3642FG_746_2_LINK_DA

336336 CH22_3746FG_814_8_LINK_BA

306193 AA923457

```
126300 250375_2
                           D81972 BE003132
20
        112538 504579_1
                           AA908813 R70255
        123505 genbank_AA600135
                                    AA600135
                           AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263
        104672 6735_7
                           AIZ76281 R48205 AIZ45302 Al190036 AIZ81050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375
                           H45809 F33447 AA774528 AA007629 H42537 C01077 F32386
25
       322102 46708_1
                           H45589 H19807 AF075038 H19808 H42437
        336865 CH22_4590FG_305_1
       338192 CH22_6755FG_LINK_EM:AC00
        329733 c14_p2
       326120 c17_hs
30
       326139 c17_hs
       326855 c20_hs
       335352 CH22_2699FG_539_5_LINK_EM
        335639 CH22 2999FG 584 19 LINK E
       307206 Al192534
35
       307377 Al222691
       337494 CH22_5727FG_799_12_
       337764 CH22_6115FG__LINK_EM:AC00
       337983 CH22_6438FG__LINK_EM:AC00
       339366 CH22_8336FG__LINK_BA354H
40
       325272 c11_hs
       325558 c12 hs
       325656 c14_hs
       334175 CH22_1455FG_349_10_LINK_E
       304182 H91086
45
       334347 CH22_1640FG_375_31_LINK_E
       327438 c_2_hs
       304622 AA516384
       334737 CH22_2049FG_424_12_LINK_E
       304682 AA550994
```

TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham L et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham L et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15				
	Pkey	Ref	Strand	Nt_position
	334347	Dunham, I. et.al.	Plus	13663814-13663926
_	334737	Dunham, I. et.al.	Plus	15998517-15998685
20	335639	Dunham, I. et.al.	Plus	25173591-25173696
	337494	Dunham, I. et.al.	Plus	33339024-33339148
	334175	Dunham, I. et.al.	Minus	11668659-11668597
•	335352	Dunham, I. et.al.	Minus	22681512-22681384
	336244	Dunham, I. et.al.	Minus	31402729-31402583
25	336336	Dunham, I. et.al.	Minus	33797209-33797076
	336865	Dunham, I. et.al.	Minus	8622405-8622289
	337764	Dunham, I. et.al.	Minus	4035640-4035446
	337983	Dunham, I. et.al.	Minus	7275495-7275271
	338192	Dunham, I. et.al.	Minus	13248453-13248277
30	339366	Dunham, 1. et.al.	Minus	33647431-33647293
	325272	5866902	Minus	13247-13312
	325558	6056302	Plus	70930-71030
	325656	6056305	Minus	78190-78707
	329733	6065783	Plus	163237-163450
35	326120	5867194	Plus	36116-36276
	326139	5867203	Minus	218901-218960
	326855	6552460	Minus	111390-111463
	327438	6004454	Minus	199569-199692

TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in 5 breast cancer cells.

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor Pkey: ExAcon: UnigeneiD: Unigene Title: R1:

15	Pkey	ExAcon	UniGene ID	Unigene Title	R1
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha	2.9
	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
20	104672	AA007629		glycerol-3-phosphate dehydrogenase 1	2.4
	107099	AA609645	Hs.211568	eukaryotic translation initiation factor 4 gam	2.7
	108604	AA099820	Hs.49696	ESTs	2.4
	115949	AA443800	Hs.43125	ESTs	2
	115965	AA446661	Hs.173233	ESTs	2.2
25	119175	R71792	Hs.301002	ESTs; Weakly similar to cell death activator	2.8
	119798	W73386	Hs.249129	ESTs	3
	122127	AA434447	Hs.106771	ESTs	2.5
	122348	AA443695	Hs.293410	ESTs	2.1
	129285	T62068	Hs.11006	ESTs	2.1
30	131267	AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
	131282	M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma	2.2
	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
	133120	X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
~-	133601	S95936	Hs.284176	transferrin	2.3
35	134111		Hs.8022	TU3A protein	4.6
	301396	AA923549	Hs.224121	ESTs	2.1
	311794	AW238092	Hs.254759	ESTs	2.1
	312575	H25237	Hs.306814	ESTs	2.3
40	313283		Hs.157099	ESTs	2.2
40	322814	A1824495	Hs.211038	ESTs	2.2
	322929	Al365585	Hs.146246	ESTs	2.3
		AW014734	Hs.157969	ESTs	2.2
	330931	F01443	Hs.284256	ESTs	4.6
		W94688	Hs.103253	perliipin	2.1
45	337983			CH22_EN:AC005500.GENSCAN.110-1	2

TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Unique Eos probeset Identifier number

Pkey: CAT number: Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey CAT number Accession

104672 6735_7

AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263 Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigeneiD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1:	Ratio of himor to normal breast tissue

	Pkey	ExAcon	UnigenelD	Unigene Title	R1
20	100227	AV654694	Hs.82316	interferon-Induced, hepatitis C-associat	3
	100405	AW291587	Hs.82733	nldogen 2	3.2
	100406	A1962060	Hs.118397	AE-binding protein 1	3.6
	100420	D86983		Melanoma associated gene	3.2
	100911	X83300	Hs.289103	SMA4	5.2
25	100960	J00124	Hs.117729	keratin 14 (epidermolysis buliosa simple	4.3
	101011	BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3
	101183	AA442324	Hs.795	H2A histone family, member O	3.2
	101194	L20971	Hs.188	phosphodiesterase 4B, cAMP-specific (dun	3
	101329	U66042	Hs.82171	Homo sapiens clone 191B7 placenta expres	4.1
30	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
	101474	R07566	Hs.73817	small inducible cytokine A3 (homologous	3.9
	101491	M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5
	101530	M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
	101602	AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4
35	101663	NM 003528	Hs.2178	H28 histone family, member Q	5.6
		BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6
		M81057	Hs. 180884	carboxypeptidase B1 (tissue)	12
	101817	M89907		SWI/SNF related, matrix associated, acti	3.2
		BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1
40		M97815		cellular retinoic acid-binding protein 2	6.5
		NM 002038		Interferon, alpha-Inducible protein (clo	3
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	3
		NM_001504		G protein-coupled receptor 9	3.7
		NM 005824		37 kDa leucine-rich repeat (LRR) protein	3.7
45		NM 005651		tryptophan 2,3-dioxygenase	5.2
		AL043202	Hs.90073	chromosome segregation 1 (yeast homolog)	3.5
	102369			hepatocyte nuclear factor 3, alpha	3.9
		U62325		arnyloid beta (A4) precursor protein-bind	4
		H16646		hypothetical protein PP591	3.5
50		AA363025		Human done 23801 mRNA sequence	3.2
		AF080229	110.100012	abd-luman endogenous retrovirus K done 1	3
		NM_002318	Hs.83354	lysyl oxidase-like 2	3.2
		M73779		retinolc acid receptor, alpha	3.3
	103010			tyrosine aminotransferase	12.4
55	103042			ribosomal protein S3	4.5
-	103117			pavalbumin	3
	103207		16,250713	gbd-luman endogenous retrovirus mRNA for	5.9
		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.9
		AI751601	Hs.8375	TNF receptor-associated factor 4	3.3
60	103329		Hs.72984	refinoblastoma-binding protein 5	3.1
50	103364			gp25L2 protein	3.1
		NM 007069	Hs.37189	similar to rat HREV107	3.4
		AA496425	Hs.9629	papiliary renat cell carcinoma (transloc	3.4
	IMAGO	~~~~~(Z)	ns.5023	habinari i saugu cangunuma (nangioc	3.2

	103498	Y09306	Hs.30148	homeodomain-interacting protein kinase 3	3.4
	103558	BE616547	Hs.2785	keratin 17	3.7
		L02911		Activin A receptor, type I (ACVR1) (ALK	3.2
_		BE336654	Hs.70937	H3 histone family, member A	4.5
5		A1571835	Hs.55468.		4
	104073	AW779318	Hs.88417	ESTs	3.8
	104103	AW021102	Hs.21509	ESTs	4.3
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
10		AA461618	Hs.31704	ESTs, Wealdy similar to KIAA0227 [H.sapi	3.6
10	104173	AA084273	Hs.76561	ESTs, Wealtly similar to S47072 finger pr	4
	104181	AF173296	Hs.283740	DC6 protein	3
	104189	AB040927	Hs 301804	KIAA1494 protein	3.2
		AI559444	Hs.293960		4.3
1.5		Al929700		endosulfine alpha	3.1
15	104518	H20816	Hs.112423	Homo saplens mRNA; cDNA DKFZp58611420 (f	3.2
	104556	AV650851	Hs.96900	hypothetical protein; KIAA1830 protein	4.4
	104658	AA360954	Hs.27268	Homo saplens cDNA: FLJ21933 fis, clone H	3.2
		AA015879	Hs.33536	ESTs	3.2
20		T49951	Hs.9029	DKFZP434G032 protein	4.5
20	104825	AA035613	Hs.141883	ESTS	6.9
	104830	AW294092	Hs.21594	hypothetical protein MGC15754	11.
		T79340	Hs.22575	B-cell CLL/lymphoma 6, member B (zinc fi	3.5
•		BE298684	Hs.26802	protein kinase domains containing protei	6.5
05		H78517	Hs.33905	ESTs	3.6
25	105038	AW503733	Hs.9414	KIAA1488 protein	4.5
	105088	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.8
	105092	AA148982	Hs.29068	ESTs	3
		AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G0321 (f	4.8
			Hs.190325		8.2
20		AW134924			
30		AA814807	Hs.7395	hypothetical protein FLJ23182	3.1
	105409	AW505076	Hs.301855	DiGeorge syndrome critical region gene 8	4.2
	105431	AA252033	Hs.242413	hypothetical protein DKFZp434K1421	4.4
		AA256750	Hs.28802	centaurin-elpha 2 protein	3.2
		AA279439			3.5
25				hypothetical protein FLJ10504	
35		W16741	Hs.25635	HSPC003 protein	3.7
	105688	Al299139	Hs.17517	ESTs	5.5
	105808	Al133161	Hs.286131	CGI-101 protein	3.5
		AW973653	Hs.20104	hypothetical protein FLJ00052	3.3
		AA195191	Hs.5111		3.2
40				hypothetical protein FLJ20729	
40		AA131657	Hs.23830	ESTS	3.3
	106135	AL117474	Hs.41181	Homo saplens mRNA; cDNA DKFZp727C191 (fr	3.2
	106184	W28948	Hs.10762	EST8	3.3
	106293	N39842	Hs.301444	KIAA1673	4.1
		BE397649	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	3.1
45					3.2
4)		BE383668	Hs.42484	hypothetical protein FLJ10618	_
		AA351978	Hs.4943	hepatocellular carcinoma associated prot	7.8
	106533	AL134708	Hs.145998	ESTs	3
	106614	AA648459	Hs.335951	hypothetical protein AF301222	3.8
		AW958037	Hs.286	ribosomal protein L4	3.3
50		AW499914	Hs.7579	hypothetical protein FLJ10402	3
50					
		BE613328	Hs.21938	trypothetical protein FLJ12492	4.2
	106844	AA485055	Hs.158213	sperm associated antigen 6	3.4
	106864	AJ311928 .		gbcqo89h04_x1 NCL_CGAP_Kld5 Homo sapiens	4.4
		AW192535	Hs.19479		3.6
55		AW472981		hypothetical protein MGC2771	4.1
55					
		AA995351	Hs.31314	retinoblastoma-binding protein 7	3.6
	106968	AF216751	Hs.26813	CDA14	5.3
	107105	AW963419	Hs.155223	stanniocalcin 2	3.4
		N32849	Hs.31844	hypothetical protein FLJ12588	3.1
60		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.9
UU					
		BE379594	Hs.49136	EST's, Moderately similar to ALU7_HUMAN A	3.9
	107630	AW961576	Hs.60178	ESTs .	4.6
	107710	Al955040	Hs.265398	ESTs, Wealty similar to transformation-r	3
		AA025386	Hs.61311	ESTs, Wealdy similar to S10590 cysteine	3.1
65					4.8
UJ.		T40064	Hs.71968	Homo sapiens mRNA; cDNA DKFZp564F053 (fr	
		Al263307		H2B histone family, member L	3.3
	108217	AA058686	Hs.62588	ESTs	3.8

	40040-			11 1 mile 51 100000 5 -1 1	
		T82427		Homo saplens cDNA: FLJ20869 fis, clone A	3
	108591	AB033073	Hs.43857	similar to glucosamine-6-sulfatases	3.3
	108733	AA121022		gb:zn84f10.r1 Stratagene lung cardnoma	3.9
	108771	AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
5	108819	AA011449	Hs.271627		3.6
•		AA136674	Hs.118681		3.9
		AF186114		tumor necrosis factor (ligand) superfami	3.7
					3.1
		AK000684		hypothesical protein FLJ22104	
10		Al970536	Hs.16603	hypothetical protein FLJ13163	3.7
10		N23235 .	Hs.30567	ESTs, Wealty similar to B34087 hypotheti	4.5
	109277	AA196443	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	3.7
	109410	AW504732	Hs.21275	hypothetical protein FLJ11011	4.6
	109454	AA232255	Hs.295232	ESTs, Moderately similar to A46010 X-lin	6.4
		AA234087		ESTs. Weakly similar to \$72482 hypotheti	4.8
15		R45584	Hs.23025		3.3
13		AA325138		hypothetical protein FLJ22672	3
					3
		AW973964	H5.291331	ESTs, Highly similar to 1203217A dehydro	-
		F09609		gb:HSC33H092 normalized infant brain cDN	3.2
	109768	F06838	Hs.14763	ESTs	3.2
20	109807	R43646	Hs.12422	ESTs	3.8
	109842	AW818436	Hs.23590	solute carrier family 16 (monocarboxylic	3.3
	109895	AK001680	Hs.30488	DKFZP434F091 protein	3.6
		AW973152	Hs.31050	ESTs	4.2
		AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	5.1
25		H89355		adrenergic, alpha-2A-, receptor	5.3
23					3.7
		A)239832	Hs.15617		3.7
		BE092285	Hs.29724	hypothetical protein FLJ13187	
		N64683	Hs.290943		4
		N66563	Hs.191358		3.1
30	111199	AI767435	Hs.29822		4.5
	111336	AJ457338	Hs.29894	ESTs	5.4
	111510	R07856	Hs.16355	ESTs	3.2
		R08440		gb:yf19f09.s1 Soares fetal liver spleen	3.1
		AA602004	Hs.23260	ESTs	3.2
35		R35252	Hs.24944	ESTs, Weakly similar to 2109260A B cell	3.3
55		R38239		ESTs, Weakly similar to putative p150 [H	3.1
					3.4
		AA421081	Hs.12388		
		AF070526	Hs.13429		3.3
40		AW379029		ESTs, Wealdy similar to unnamed protein	4.4
40	112170	BE246743		hypothetical protein FLJ22635	7.3
	112287	AB033064	Hs.334806	KIAA1238 protein	3.2
	112300	H24334	Hs.26125	ESTs	4.4
	112303	R54797		gb:yg87b07.s1 Soares Infant brain 1NIB H	3.4
		R66067	Hs.28664	ESTs	8.2
45		AI791493		ESTs, Weakly similar to A36036 cytochrom	5.5
-13		R82040		gb:yj06b06.s1 Soares placenta Nb2HP Homo	3.9
			Hs.164599		5.4
		R82331			3.2
		AW844878	Hs.19769	hypothetical protein MGC4174	
50		Al418466	Hs.33665	ESTS	4.7
50		AA082465		choline/ethanolaminephosphotransferase	3.7
	113070	AB032977	Hs.6298	KIAA1151 protein	3.1
	113095	AA828380	Hs.126733	ESTs	3.4
	113117	AW813731	Hs.159153	ESTs, Moderately similar to S65657 alpha	3.4
	113187	BE613410	Hs.31575	SEC63, endoplasmic reticulum translocon	3.2
55		T57773	Hs.10263		3.5
J J		BE262470	Hs.241471		6.2
		179925		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
		U54727	Hs.191445		3
co .		T91451	Hs.86538		3.4
60		AW367788		postmelotic segregation increased 2-like	3.1
	113571	AI702609	Hs.15713	hypothetical protein MGC2776	3.1
	113822	NM_004585	Hs.17466	retinoic acid receptor responder (tazaro	3.9
		AI912410	Hs.27475	Homo saptens dDNA FLJ12749 fis, done NT	3
		W81598	,	gbzd88g02.s1 Soares_fetal_heart_NbHH19W	4.6
65		W84768		gb:zh53d03.s1 Soares_fetal_liver_spleen_	3.1
05		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
				hypothetical protein MGC3077	4.3
	114000	AA378776	15200048	in providural protest MCC3U//	4.3

	114148	AW470411	Hs.288433	neurotrimin	4.1
	114424	AW780192	Hs.267596	ESTs	3.4
		AW163267	Hs 106469	suppressor of var1 (S.cerevisiae) 3-like	3.1
		A1979168	Hs.82226	glycoprotein (transmembrane) nmb	4.8
5					
3		AI733881		BMP-R1B	10.1
	114995	AA769266	Hs.193657		3.6
	115121	AJ634549	Hs.88155	ESTs	3.2
		AW968073	He 194331	ESTs, Highly similar to A55713 Inositol	4.2
					3
10		AA749209	Hs.43728	hypothetical protein	
10	115253	BE149845		hypothetical protein MGC4126	3.6
	115277	AA814100	Hs.86693	ESTs	3.9
	115327	N46436	Hs.109221	ESTs	3.4
		AA281636	Hs.334827		4.8
1.5		AA405620	Hs.55158	ESTs, Wealdy similar to T29520 hypotheti	3.5
15	115676	AA953006	Hs.88143	ESTs	9.3
	115709	AW293849	Hs.58279	ESTs, Wealty similar to ALU7_HUMAN ALU S	3.4
	115729	AA417812	Hs.38775	ESTs	4
		Al126772	Hs.40479	ESTs	3.1
~~		AW970529	Hs.86434	hypothetical protein FLJ21816	3.6
20	115835	AA521410	Hs.41371	ESTs	3.1
	115850	NM_014937	Hs.52463	KIAA0966 protein	3
		AK001500	He 165186	hypothetical protein FLJ13852	3.2
					3
		AA354549	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	
		AL042465	Hs.43445	poly(A)-specific ribonuclease (deadenyla	3.1
25	116092	AB041035	Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (6.7
		AL042355	Hs.70202	WD repeat domain 10	3.6
		AW450737		CGI-09 protein	3.1
			Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.3
		AA464976			
20		Al219083	Hs.42532		3.2
30	116246	AF265555	Hs.250646	baculoviral IAP repeat-containing 6	3.6
	116443	AW962196	Hs.321264	LBP protein 32	4.1
	118470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.1
		AKD01114	Hs.53913	hypothetical protein FLJ10252	8.6
			נו פנכימו		
~~		AA649530		gb:ns44f05.s1 NCL_CGAP_Alv1 Homo sapiens	3.2
35	117026	H88256	Hs.50456	ESTs, Moderately similar to ZN75_HUMAN Z	3.5
	117216	Al569804	Hs.42792	ESTs, Wealdy similar to 178885 serine/th	3.1
		AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	3.2
		H84455	Hs.40639	ESTs	4.7
40		AB040959	Hs.93836	DKFZP434N014 protein	3
40	118229	AW968941	Hs.166254	hypothetical protein DKFZp566i133	3.3
	118363	Al183838	Hs.48938	hypothetical protein FLJ21802	4.3
		N66028	Hs.49105	FKBP-associated protein	3.1
		AW970584	Hs.291033		3.4
45		AL157488	Hs.50150	Homo saplens mRNA; cDNA DKFZp564B182 (fr	5.2
45	118695	AK000465	Hs.50081	KIAA1199 protein	3.4
	118925	N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	3.3
	119025	BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19.7
		R95872		chemokine binding protein 2	3.7
5 0		R16833	Hs.53106	ESTs, Moderately similar to ALU1_HUMAN A	4.1
50	119075	M10905		fibronectin 1	3.2
	119620	W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	3.3
	119741	AF041853	Hs.43670	kinesin family member 3A	3.1
		A1970797	Hs.64859	ESTs	5
	440000	***			
		ALU3/824		ras homolog gene family, member i	3.8
55	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	3.1
		W94472	Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	8.4
		AA825686		ESTs, Wealty similar to S65824 reverse t	3.6
				hypothetical protein RG083M05.2	3.2
		AA195300	Hs.21145		
~~		AA225084		gb:nc21d06.r1 NCI_CGAP_Pr1 Homo saplens	3.6
60	120870	AA357172		ESTs, Moderately similar to ALU1_HUMAN A	5.8
	120885	AA365515	Hs.301872	hypothetical protein MGC4840	3
		AA398118	Hs.97579	ESTs. Weakly similar to A46010 X-linked	3.7
					5.3
		AW976570	Hs.97387	ESTS	
		AA320134		Homo sapiens mRNA for KIAA1657 protein,	4
65	121103	AA398936	Hs.97697	EST	3.5
	121121	AA399371	Hs.189095	similar to SALL1 (sal (Drosophila)-like	6.3
		AW885727	Hs.301570		4.7
	12100/	, 1710001 &1			***

	121351	AW206227	Hs.287727	hypothetical protein FLJ23132	5
		M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
	121643	AA640987	Hs.193767	ESTs	5.6
_		NM_015902		progestin induced protein	3.4
5		AK000492		hypothetical protein	4.1
		AA443311	Hs.98998	ESTS	3
		AA446965 A1767879	Hs.112092 Hs.99214		4.7 3.8
		AW973253	Hs.292689		3
10		AA323296	Hs.97837		5.6
		AA526911	Hs.82772		3.2
	122851	AW205931	Hs.99598		8.6
	123105	AA487809	Hs.166011	catenin (cadherin-associated protein), d	3
		AA228776	Hs.191721		6.9
15		AA371307	Hs.125056		3.6
		AA491253		Empirically selected from AFFX single pr	7
	123385	BE149685		KIAA1554 protein Homo sapiens unknown mRNA sequence	3.1 3.4
		Al308876		hypothetical protein DKFZp761D112	3.1
20		A1675944		Homo sapiens cDNA FLJ12033 fls, clone HE	3.8
20		AA580082	Hs.112264		4.7
		AA352723	Hs.241471		3.8
	124243	H69125	Hs.133525	ESTs	4.1
		N22401		gb:yw37g07.s1 Morton Fetal Cochlea Horno	4.1
25		N22508		Homo sapiens cDNA: FLJ21479 fis, clone C	3.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1
	124911			interferon induced transmembrane protein	3.5
		R41396 BE065136		hypothetical protein FLJ23045 splicing factor (CC1.3)	4.3 6
30	125042			ESTs, Moderately similar to ALU1_HUMAN A	8.1
50		W60326		Homo sapiens cDNA FLJ11750 fis, clone HE	4.7
		AW970536	Hs.105413		3.1
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.3
	125304	AL359573	Hs.124940	GTP-binding protein	3
35		AW880562	Hs.114574		3
		AJ422996	Hs.161378		3.2
		A)924630	Hs.4943	hepatocellular carcinoma associated prot	3.2
	126257	N99638 AW975814	Lin 220744	gbzza39g11.r1 Soares fetal liver spleen Homo saplens clone IMAGE:713177, mRNA se	4
40		AA648886	Hs.151999		3.8
70		AW450979	1 10 10 1000	ghtUI-H-Bi3-ala-a-12-0-UL:s1 NCI_CGAP_Su	3
		AW771958	Hs.175437	ESTs, Moderately similar to PC4259 ferri	3.6
	127980	AA961459	Hs.125644		4.1
4.5		AW068311	Hs.311054	Homo sapiens mRNA full length insert cDN	3.3
45	•	AA650274	Hs.41296		4.6
		NM_003616		survival of motor neuron protein interac	3.9
	128946	113133 AA775076		kynurenine 3-monoxygenase (kynurenine 3	3.f
	129092		Hs.63525	Homo saplens, Similar to PRO0478 protein	3.9 3.3
50		AA357185		poly(rC)-binding protein 2 ras homolog gene family, member H	3.1
-		AF182277		cytochrome P450, subfamily IIB (phenobar	3.9
		AA172106		Rag C protein	6.2
	129619	AA209534	Hs.284243	tetraspan NET-6 protein	3.4
	120000	AK000398		hypothetical protein FLJ20391	3
55	129725		Hs.1219	alcohol dehydrogenase 4 (class II), pl p	3.2
		AI754813	Hs.146428	collagen, type V, alpha 1	5.4
	130092			v-erb-b2 avian erythroblastic leukemia v	4.4
		A1347487 NM_003450		class I cytokine receptor zinc finger protein 174	4.6
60		Al582291	Hs.16846	ESTs, Wealdy similar to 04HUD1 debrisogu	5.6 3
50	130703		Hs.18103	ESTs Weakly sinual to Ornoon debisoqui	3.8
		AA809875	Hs.25933	ESTs	4.2
	130954	AB014544	Hs.21572	KIAA0644 gene product	4.7
<i>-</i> -		A1399653	Hs.22917	ESTS	4.3
65	131153	H09048	Hs.23606	ESTs	3.8
	131253		Hs.24853	ESTs	3.5
	131372	AW293399	HS.144904	nuclear receptor co-repressor 1	3.6

	131507	A1826268	Hs.27769	ECTO Months similar in MCAT UI MAN MITOC	22
		A1695549		ESTs, Wealdy similar to MCAT_HUMAN MITTOC alucuronidase, beta	3.2 3.1
		AF017986	Hs.31386	secreted frizzied-related protein 2	3.2
		BE501849	Hs.32317		3.2
5		D86960	Hs.3610		3.6
•		NM_002314	Hs.36566	LIM domain kinase 1	3.2
		AA400091	Hs.39421	ESTS	3.2
		AA426202	Hs.40403	Cbp/p300-interacting transactivator, wit	3
		D76435	Hs.41154	Zic family member 1 (odd-paired Drosophi	3.2
10		AA192669 .	Hs.45032	ESTs	3.5
		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	9.2
	132482	AV660345		CGI-49 protein	8.2
	132543	BE568452	Hs.5101	protein regulator of cytokinesis 1	3.4
	132624	AA326108	Hs.33829	bHLH protein DEC2	3.2
15		AA319233 .		ESTs	4.8
		NM_005276		splicing factor, arginine/serine-rich 7	3.6
		W73311		SAC2 (suppressor of actin mutations 2, y	3.2
		T48195	Hs.58189	eukaryotic translation initiation factor	3.5
20		Y00272		cell division cycle 2, G1 to S and G2 to	4.4
20		AL120659 Al128606	Hs.6111 Hs.6557	aryl-hydrocarbon receptor nuclear transi	4.8
		AW952412	Hs.65874	zinc finger protein 161 ESTs, Wealdy similar to A40348 Elav/Sex-	3.3 3.5
		AW162840	Hs.6641	kinesin family member 5C	3.5 4.5
		AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25		AA085191	Hs.6949	hypothetical protein MGC11275	3
		Z93241		CGI-96 protein	4.5
	133287	AW797437	Hs.69771	B-factor, properdin	4.1
	133376	BE618768	Hs.7232	acetyl-Coenzyme A carboxylase alpha	5.1
••		AW675064	Hs.73875	furnarylacetoacetate hydrotase (furnarylac	3
30		AW162919		RAB2, member RAS oncogene family-like	3.4
		BE274552	Hs.76578	protein inhibitor of activated STAT3	3.9
		Al908165		GATA-binding protein 3 (T-cell receptor	6.2
		BE391929 Al433797	Hs.8752	transmembrane protein 4	3.1
35		D89377	Hs.8889 Hs.89404	serine hydroxymethyltransferase 1 (solub msh (Drosophila) homeo box homolog 2	3 5.8
55	134776		Hs.89603	mucin 1, transmembrane	4
		AF064804	Hs.96757	suppressor of Ty (S.cerevislae) 3 homolo	3.2
		R61253	Hs.98265	KIAA1877 protein	3.3
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	4.8
40	135411	L10333	Hs.99947	reticulon 1	3.8
•		AH99738		ESTs, Weakly similar to ALUA_HUMAN IIII	3.8
		AW614220	Hs.189402		4.2
		AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
45		AW591433		Transmembrane protease, serine 3	4.9 A
TJ .	300378	AA572949	Hs.207566	hypothetical protein FLI22672	
	301111		Hs.191990		3.5 3.8
		AA887801		G protein-coupled receptor	13.9
		Al091631	Hs.203845	two pore potasskem channel KT3.3	4.4
50		AA312082	Hs.105445	GDNF family receptor alpha 1	5.7
	301936	U79745	Hs.114924	solute carrier family 16 (monocarboxylic	8.6
	301976	T97905		gb:ye54c10.r1 Soares fetal liver spleen	3.9
		AB020711	Hs.278346	KIAA0904 protein	7.7
<u>سر</u> سر		BE542706	Hs.222399	CEGP1 protein	7.3
55		AW749321		ESTs	3.3
		AL049670		ribosomal protein L34 pseudogene 1	4.2
		NM_003813	HS.1014U/	cartilage intermediate layer protein, nu	7.9
		alo49987 aw057736	He 323010	Homo sapiens mRNA; cDNA DKFZp564F112 (fr HER2 receptor tyrosine kinase (o-erb-b2,	5.6 5.4
60 `		ANIO 130 AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (f	5.4 34.1
JU		AL117406	Hs.200102	ATP-binding cassette transporter MRP8	54.1 6.7
		AL109712	Hs.296506	Homo saplens mRNA full length insert cDN	4
		Al678059		synaptonemal complex protein 2	4.3
		AJ224172		lipophilin 8 (uteroglobin family member)	13.8
65		AW192334	Hs.38218 .	ESTs	9.6
		A1038997	Hs.132921	ESTs	5
	302857	AF282265	Hs.44836	inner centromere protein antigens (135kD	3.4

				and the second s	
	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
	302970	W05608	Hs.312679	ESTs, Wealdy similar to A49019 dynein he	5.1
	303271	AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
,-		AL121460		hypothetical protein FLJ20508	4.1
5		AW006352		ESTs, Wealdy similar to T32554 hypotheti	4.2
		AA355607		ESTs, Weakly similar to putative WHSC1 p	4.3
		AA367699	Hs. 10082	potassium intermediate/small conductance	3.3
		AW299459		gboxs50d08.x1 NCL_CGAP_Kid11 Homo saplen	4.2
10	303780 /	-	Hs.18995	KIAA1304 protein	3.6
10		AW629759	11. 00007	gbthh70e05.y1 NCL_CGAP_GU1 Homo sapiens	4.9
	303852		Hs.90207	hypothetical protein MGC11138	3.7
		AA149951	Hs.62112	zinc finger protein 207	3
		AA582081		gbmn32h08.s1 NCi_CGAP_Gas1 Homo sapiens	4.1
15		AA876109 AA876469		gbmx24h01.s1 NCL_CGAP_GC3 Homo sapiens	3
13	307010 /			gb:oe48b04.s1 NCi_CGAP_Pr25 Homo sapiens	3.1 3.5
	307041 /			gb:qa68f09.x1 Soares_fetal_heart_NbHi119W gb:qb65b12.x1 Soares_fetal_heart_NbHi119W	
	308106 /			gbttf/7e12.x1 Soares_NSF_F8_9W_OT_PA_P_S	3.9 4.3
	308307 /		He 172028	collagen, type i, alpha 1	4.6
20		AK000142		hypothetical protein FLJ23045	4.4
20	309177 /			Homo sapiens breast cancer antigen NY-BR	17.3
		AW024348		EST, Weakly similar to A27217 glucose tr	3.2
		AW168083		gbogg59g04.x1 NCL_CGAP_Ut4 Homo sapiens	3.1
		AW170035	Hs_326736	Homo sapiens breast cancer antigen NY-BR	57.6
25	310064 /			ESTs, Wealthy similar to 1917210A Pro/Arg	4.6
	310098 /	N685841	Hs.161354		3.6
	310438	AW022192	Hs.200197	ESTs	4.6
	310683 /	A1939456	Hs.160870	ESTs	3.2
	310727	4K000703	Hs.323822	Homo sapiens mRNA for KIAA1551 protein,	3.6
30	310781	AI380797	Hs.158992	ESTs	10.2
	310895 /			N-acetylgalactosamine-4-O-sulfotransfera	3.4
	310955 /		Hs.263912		10.9
	311117 /			Homo sapiens mRNA for KIAA1657 protein,	3.1
25	311166 /		Hs.118599		10.8
35		NA641098		ESTs, Moderately similar to ALU1_HUMAN A	4.3
	311465 /		Hs.206132		4.4
	311587 /	41020234 AW023595		ESTs, Wealdy similar to A47582 B-cell gr	5.1
		4WUZJJJJJ 4A700870	Hs.232048 Hs.14304	ESTs .	5.8 3.3
40	311785 /		Hs.133512	- -	3.9
	311872 F		Hs.194600	_:_	3.3
	311889 /			ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
	311913 /		Hs.270188		3
	311923 1		Hs.189679	=	5.6
45	311935 /	A216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
	312019 /	A373630	Hs.188750		3
	312021 A	VA759263	Hs.14041	ESTs	3.4
	312067 1	78968	Hs.14411	ESTs	3.5
	312090 7			similar to rat nuclear ubiquitous casein	3.8
50	312147 A			ESTs, Weakly similar to 138022 hypotheti	4.4
	312153 E			hexoldnase 1	5.2
	312168]		Hs.198882		3.3
	312182		Hs.326263		3.3
EE	312187		Hs.188490		3.4
55		W438602	Hs.191179		3.9
	312219 F 312226 A		Hs.117874		4
	312220 P		Hs.269737	ESTs, Wealdy similar to ALUB_HUMAN IIII	4.9
	312544 A			ESTs, Weakly similar to 138022 hypotheti	5.7 6.3
60		W439195		ESTs, Weakly similar to \$65657 alpha-1C-	6.3 4.9
50		W291545	Hs.185018		4.9
		W292286	Hs.255058		4.4
	312980 A		Hs.115685		3.1
	313070 A		Hs.161338		4.3
65	313079 N		Hs.1787	proteolipid protein 1 (Pelizaeus-Merzbac	3.3
	313089 A		Hs.293797		5.8
		W073310		Homo sapiens cDNA FLJ14142 fis, clone MA	4.5

	242420	44740000	II. 000040	rm.	40
		AA746503	Hs.283313		10
	313166	AI801098	Hs.151500	ESTs	3.5
	313197	AW979008	Hs.222487	ESTs	3.3
		AW960454	Hs.222830		4.7
5					
,		Al420611	Hs.127832		3,4
	313328	AW449211	Hs.105445	GDNF family receptor alpha 1	12.4
	313352	AW150945	Hs.144758	ESTs	4.1
		AI032087	Hs.269819		3
					5.2
10		AJ674685	Hs.200141		
10		AA741151 .	Hs.137323	ESIS	3.5
	313434	W92070		gb:zh48g05.r1 Soares_fetal_fiver_spleen_	3.7
	313569	Al273419	Hs.135146	hypothetical protein FLJ13984	. 3
		AA046309	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gbzf12f01.s1 Soares_fetal_heart_NbHH19W	5.6
			11- 004000		
1.5		AI540978		hypothetical protein FLJ13033	3.2
15	313915	C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
	313975	AW175896	Hs.65114	keratin 18	3
		Al535895	Hs.221024		4.9
					3.9
		AV657317		hypothetical protein MGC3077	
	314043	AA827082	Hs.291872	ESIS	3.1
20	314078	AW129357	Hs.329700	ESTs	8.3
	314097	AA648744	Hs.269493	FSTs	6.6
			Hs.187619		6.2
		Al732083			
		AA228366	Hs.115122		4
	314138	AA740616		gbmy97f11.s1 NCL_CGAP_GCB1 Homo saplens	5.9
25	314236	AA743396	Hs.189023	ESTs	3.1
		AL036450	Hs.103238		4
-	•				8
		Al280112		Homo sapiens cDNA FLJ13266 fis, clone OV	_
	314306	A1697901	Hs.192425	ESTS	3.7
	314322	AA907153	Hs.190060	ESTs	3.3
30	314394	AW961597	He 130816	ESTs, Moderately similar to 138022 hypot	4.2
-		Al660412	Hs.234557		3.3
		AA602917	Hs.156974		4.7
	314506	AA833655	Hs.206868	Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
	314510	Al204418	Hs.190080	ESTs	4
35		AW007211		hypothetical protein FLJ12876	3.4
33					
		AA399272	Hs.144341		6.7
		A1873274	Hs.190721	ESTS	27.4
	314627	AA425310	Hs.155766	ESTs, Weakly similar to A47582 B-cell gr	4.4
	314648	AW979268		gb:EST391378 MAGE resequences, MAGP Homo	4.6
40		AW207206	Hs.136319		20.7
70					
		AA457367	Hs.191638	<u> </u>	3.6
		AW026761	Hs.134374	ESTS	3.6
	314814	BE350122	Hs.157367	ESTs, Weakly striilar to 178885 serine/th	4.9
	314864	AW971198	Hs.294068	FSTs	4.3
45		Al095087		ESTs, Moderately similar to S65657 alpha	3.7
73					
		AA828032	Hs.189076		3.1
	314981	AW972359	Hs.293334	ESTs	3
	315006	AJ538613	Hs.298241	Transmembrane protease, serine 3	10.9
	315021	AA533447	Hs.312989		5.3
50		AW292425	Hs.163484		12.9
J U					
		AA551104		ESTs, Moderately similar to ALUC_HUMAN (5.8
	315073	AW452948	Hs.257631	ESTs	4.2
	315080	AA744550	Hs.136345	ESTs	3.7
	215175	A1025842	Hs.152530		6
55	245403	AIMM 20124			
JJ		AW136134	Hs.220277		3.9
	315193	Al241331	HS.131765	ESTs, Moderately similar to I38937 DNA/R	4.4
	315196	Al367347	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA sequ	8.2
		AI741506		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.6
		R38772		myelin transcription factor 1-like	3.4
60					
60		AW510994	Hs.220740		3.4
		Al222165	Hs.144923		4.9
	315296	AA876905	Hs.125286	ESTs	4
		AB037745		KIAA1324 protein	4.7
		AA218940			
C E				fidgefin-like 1	3.1
65	313489	Al378817	Hs.191847	E918	3.1
	315498	AA628539	Hs.116252	ESTs, Moderately similar to ALU1_HUMAN A	3.2
	315498	AA628539 Al193043		ESTs, Moderately similar to ALU1_HUMAN A ESTs, Weakly similar to T17226 hypotheti	3.2 4.1

	315530 AW015415	Hs.127780	ESTs	8.9
	315562 AA737415	Hs.152826	ESTs	5.5
	315634 AA837085	Hs.220585	ESTs	6.3
_	315647 AA648983	Hs.212911		3.6
5	315707 Al418055	Hs.161160	ESTs	5.1
	315772 AW515373	Hs.271249	Homo sapiens cDNA FLJ13580 fis, clone PL	3.1
	315850 AW270550	Hs.116957		3.8
	315858 AA737345	Hs.294041		5
4.0	315878 AA683336	Hs.189046		3.1
10	315977 AW865916	Hs.151206		4.7
	315978 AA830893	Hs.119769		4.1
	315995 Al217477	Hs.194591		4.1
	316012 AA764950	Hs.119898		7
15	315042 AI469960	Hs.170698		4.9
15	316052 Al962796	Hs.136754		4.1
	316072 AW517524		NOD2 protein	3.2
	316074 AW975114	Hs.293273		3.8
	316100 AW203986	Hs.213003	LUIS	3.7
20	316133 Al187742	Hs.125562		30.7
20	316177 Al904982	NS.2931U2	ESTs, Moderately similar to ALU1_HUMAN A gb:ti69g05.x1 NCI_CGAP_Kid11 Homo sapien	3.1
	316186 Al433540 316244 Al640761	Hs.224988		3.5
	316303 AA740994	Hs.209609		3.8
	316313 AA741300		ESTs, Weakly similar to 138022 hypotheti	4.4
25	316364 AA747807	Hs.149500		3.2
LJ	316580 AA938198		poly(A) polymerase gamma	9.4
	316697 AW293174	Hs.252627		4.4
	316715 AJ440266		ESTs, Wealdy similar to T24832 hypotheti	3
	316868 Al660898	Hs.195602		3.2
30	316869 Al954880	Hs.134604	ESTs	3.2
	316886 AA836331	Hs.134981	ESTs	4.4
	316897 AA838114	Hs.221612	ESTs	3.7
	316943 AW014875	Hs.137007	ESTs	4.6
	317069 AI732892	Hs.190489	ESTs	5.9
35	317194 AW445167	Hs.126036		4.1
	317360 Al125252	Hs.126419		3.5
	317404 AI808867	Hs.126594		5.1
	317452 AA972965	Hs.135568		6.9
40	317501 AJ822034	Hs.137097		4.6
40	317674 AW294909	Hs.132208		4.3
	317803 AW664964	Hs.128899		6.1 3.1
	317834 X56348		ret proto-oncogene (multiple endocrine n hypothetical protein FLJ13117	3.4
	317850 AJ681545 317881 AJ827248		Homo saplens cDNA FLJ11469 fis, done HE	9.6
45	317902 AW102941	Hs.211265		4.1
73	317916 Al565071	Hs.159983		10.3
	318042 AW294522	Hs.149991		3.1
	318223 Al077540	Hs.134090		3.9
	318327 AW294013	Hs.200942		3
50	318332 Al093930		Homo saplens cDNA: FLJ21000 fis, clone C	4.4
	318418 AF107493		Homo sapiens LUCA-15 protein mRNA, splic	5.4
	318558 AW402677		RNA binding motif protein, X chromosome	4.4
	318825 AA526235		Homo sapiens cDNA FLJ11983 fis, clone HE	5.9
	318634 T49598	Hs.156832	ESTs	4
55	318740 NM_002543	Hs.77729	oxidised low density tipoprotein (lectin	7.3
	318744 AI793124	Hs.144479	ESTs	17.8
	318781 F11802	Hs.6818	ESTs	3
	319191 NM_012391			3.6
	319478 AI524124	Hs.270307		4.6
60	319510 W88532	Hs.254562		3.3
	319551 AA761668		gbcnz24c08.s1 NCI_CGAP_GCB1 Homo saplens	3.2
	319745 T79366	Hs.108258	actin binding protein; macrophin (microf	3.3
	319834 AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
C F	319840 C19035	Hs.164259		3.3
65	319977 AA534222	Un arrange	gbm/21d02.s1 NCI_CGAP_AA1 Homo saplens	4.3
	320074 AA321166	Hs.278233		. 3.4
	320167 AA984373	H2"30\A0	Homo saplens cDNA: FLJ22930 fis, clone K	4.1

	320187	T99949	Hs.303428	Homo sapiens cDNA FLJ14832 ffs, clone OV	5.3
	320211	AL039402	Hs.125783	DEME-6 protein	9.2
		Al026984	Hs.293662		3.1
~		U78082		RNA polymerase II transcriptional regula	3.1
5	320635	N50617 .		small nuclear ribónucteoprotein polypept	6.1
	320654	Al160015	Hs.118112	ESTs	3.5
	320742	Al601188	Hs.120910	FSTe	3
	-				3.7
		AA214584	Hs.290167		
		A1359144	Hs.143688	Homo sapiens cDNA: FLJ23031 fis, clone L.	3.1
10	321016	BE144167 .	Hs.49994	hypothetical protein similar to RNA-bind	3.3
	321107	AI732643	Hs.144151	ESTs	12.3
		AI769410	Hs.221461		3.3
		AA610649	Hs.333239		3
	321318	AB033041	Hs.137507	vang (van gogh, Drosophila)-like 2	3.9
15	321642	Al432199	Hs.247084	ESTs	3
	321644	AW975944	Hs.237396	FSTs	11.7
		AJ471598	Hs.197531		3.8
		U29112	Hs.196151		4.4
	321811	D80630		gbdHUM091D02B Human fetal brain (TFujiwa	3.2
20	321828	R59890	Hs.83623	nuclear receptor subfamily 1, group 1, m	3.1
		H67065		ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
				Homo saplens mRNA; cDNA DKFZp566C093 (fr	3.5
		AL049351			
		N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, ctone NT	5
	322035	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19
25	322136	AF075083		gb:Homo sapiens full length Insert cDNA	3.6
		BE265745	He 194359	ESTs, Wealty similar to ALUC_HUMAN !!!!	3
			10.15-000	gb;zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
		W76326		·	
		Al357412	Hs.157601		11.5
	322476	AW963372	Hs.46677	PRO2000 protein	3
30	322520	T55958		gb:yb35f05.r1 Stratagene fetal spleen (9	3
	322521	AF147347		gbd-forno sapiens full length insert cDNA	4.2
		AF155108	He 256150	Homo sapiens, Similar to RIKEN cDNA 2810	4
		W92147	Hs.118394		5.4
	322675	AA017656		gb:ze39h01.r1 Soares retina N2b4HR Homo	3.1
35	322766	AW068805	Hs.288467	Homo sapiens dDNA FLJ12280 fis, clone MA	5.2
	322818	AW043782	Hs.293616		7.6
		AW248508		Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
			110210121		16.5
		C16391		gb:C16391 Clontech human aorta polyA mRN	
	323091	Al902456	HS.210761	ESTs, Wealdy similar to 138022 hypotheti	4
40	323131	AK002088	Hs.270124	Homo sapiens dDNA FLJ11226 fis, clone PL	3.3
	323168	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	6.3
		AW675572	Hs.193620		4.6
		AL133990	Hs.190642		10.5
			NS. 19004Z		
4 ~		AJ829520		gbowH9c06.x1 NCL_CGAP_Ut1 Homo sapiens	6.2
45	323333	AV651680	Hs.208558	ESTs	4.3
	323335	A1655499	Hs.161712	ESTs	9.2
		AW445014	Hs.197746	FSTs	3.1
		BE081058	Hs.243023		4
~ ^ ·		AA317962		ESTs, Moderately similar to PC4259 ferri	3
50	323782	AW961560	Hs.97600	ESTs	3.2
	323817	AA410943		BMP-R1B	8.4
		AL043683	Hs.8173	hypothetical protein FLJ10803	3.3
		AI825204	Hs.211408		4.5
		AL044949	Hs.116298		4.5
55	324036	AJ472078	Hs.303662	ESTS	8.4
	324261	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
		AA431159	Hs.122954		3
		AI524039			3
			Hs.192524		
C O		AA642007	Hs.116369		3.3
60		AA464510	Hs.152812	ESTS	16.5
	324585	AIB23969	Hs.132678	ESTs	3.3
		AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	5
		AW993522	Hs.292934		
					10.4
		AA937116	пз.255683	ESTs, Wealtly similar to 154374 gene NF2	3.3
65		BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.2
	324748	AW974941	Hs.292385	ESTs, Wealdy similar to 178885 serine/th	3
		AA631739	Hs.335440		3
	7///				•

PCT/US02/02242

	324774	A1031771	Hs.132586	ESTs	4.2	
		AW516704	Hs.208726		3 <i>A</i>	
	324824	A1826999	Hs.224624		3.1	
_ '	324826	AA704806	Hs.143842	ESTs, Wealdy similar to 2004399A chromos	4.4	
5	324961	AA613792		gbcno97h03.s1 NCI_CGAP_Pr2 Homo saplens	3.9	
		Al375572	Hs.172634		18.8	
		AJ805416	Hs.213897		3.3	
		A1064690	Hs.171176		4.2	
	325372			Phase 2 & 3 Exons	4.4	
10	325544			Phase 2 & 3 Exons	5.7	
•	327075			Phase 2 & 3 Exons	3.8	
	332798			C22000007;glj12314195 emb CAB99338.1 (A	4.3	
	334223			NM_005080*:Homo saplens X-box binding pr	26.2	
	334447			NM_012429*:Homo saplens SEC14 (S. cerevi	3.9	
15	335809			NM_014509*:Homo saptens kraken-like (BK1	10.1	
	335824			ENSP00000249072-DJ222E13.1 (N-TERMINAL	20	
	338255			NM_014323*:Homo saplens zinc finger prot	9	
	409430	R21945		splicing factor, arginine/serine-rich 5	4	
	428046	AW812795		ESTs, Moderately similar to 138022 hypot	4.6	
20	432558	R97268	Hs.177269	ESTs	3.2	
	436808	AA731602	Hs.120266		3.9	
	448569	BE382657		signal transducer and activator of trans	4.1	
	453542	AW836724	Hs.339660	Homo sapiens mRNA expressed only in plac	3.7	
		M97935		AFFX control: STAT1	3.2	
25		M97935		AFFX control: STAT1	3	
		M55150		furnarylacetoacetate	3	
		M13755		interferon stimulated protein; 15 kDa	4.5	
		AJ052047		EST8	6.7	
		AA252033		ESTs; Wealty similar to IIII ALU SUBFAMILY J	3.2	
30		AA401739		ESTS	3.3	
		H18459		hepatocellular carcinoma associated protein;	3	
	•	R48744		ESTs	4.2	
		M31682		inhibin; beta B (activin AB beta polypeptide)	3	
		AA416873		ESTs	3	
35		D80240		HUM5G11A Human fetal brain (TFujiwara) Homo	4	
		R49590		ESTs	3.2	
				CH22_FGENES.678_5	16.8	
				CH22_FGENES.619_7	12.9	
			•	CH22_FGENES.619_12	11.3	
40				CH22_EM:AC005500.GENSCAN.127 9	9.2	
				CH22_EM:AC005500.GENSCAN.304.2	8.5	
				CH22_FGENES.271_8	8.4	
				CH22_FGENES.619_13	8	
				CH22_FGENES.271_7	7.3	
45				CH22_FGENES.617_J	7.2	
				CH.07_hs gij6004473	7.1	
		-		CH22_FGENES.264_1	6.8	
		X03363		HER2 receptor tyrosine kinase (c erbB 2; ERBB2; a	neu) 6.6	
				CH22_FGENES.617_9	6.5	
50				CH.07_hs gl[5868264	5.8	
				CH.19_hs gij5867439	5.7	
	•			CH22_FGENES.63	5.3	
				CH.17_hs gi 5867230	5.1	
				CH.20_hs gl[6552458	5.1	
55				CH22_EM:AC005500.GENSCAN.148 22	4.7	
				CH22_FGENES.669_10	4.6	
		AA034918		KIAA1028 protein	4.6	
				CH22_FGENES.48_12	4.5	
				CH22_FGENES.118_2	4.5	
60		AF049569		ESTs	4.4	
~~		M13955		multiple UniGene matches	4.3	
				CH22 FGENES.619_8	4.3	
				CH22_FGENES.137	4.3	
		HG4126 HT43	396		Zinc Finger Protein Hzf4	4.3
65			-	CH22_FGENES.360_3	4.3	
				CH22_FGENES.706_9	4.3	
				CH.21_hs glj6531965	4.2	
				and the second s		

		CH.17_hs g][5867215	4.1	
		CH22 FGENES.669 8	4.1	
	HG2614 HT2710		Collagen, Type Viii, Alpha 1 4.1	
	11000111110	CH22_FGENES.48_18	4.1	
5	X83535	matrix metalloproteinase 14 (membrane inserted)	4	
•	740000	CH22 FGENES.271_6	3.9	
		CH22 FGENES.617.3	3.9	•
		CH22 FGENES.290_8	3.8	
	HG4716 HT5158		Guanosine 5' Monophosphate Synthase	3.8
10		CH22_FGENES.13 5	3.8	
	`	CH22_FGENES.13.2	3.8	
		CH_14_hs g26682474	3.8	
		CH.02 hs qii5867750	3.8	
	•	CH22 FGENES.617_8	3.7	
15	HG4677 HT5102		Oncogene Ret/Ptc2, Fusion Activated	3.7
		CH22 DJ32H0.GENSCAN.23 39	3.7	
		CH22_FGENES.543_20	3.7	
		CH22 EM:AC005500.GENSCAN.96 1	3.7	
		CH22 FGENES.204.2	3.5	
20		CH22 FGENES.619 4	3.5	
20		CH.16_hs gil5867087	3.5	
	AA714311	EST cluster (not in UniGene)	3.4	
	70.0 7.07.1	CH22_EM:AC005500.GENSCAN.1499	3.4	
		CH22 EM:AC005500.GENSCAN.421 5	3.4	
25		CH22_FGENES.134	3.3	
		CH.07_hs glj6004478	3.3	
		CH22_FGENES.360_1	3.3	
	HG2465 HT4871		Ona Binding Protein Ap 2, Alt. Splice 3	3.3
	V	CH22 FGENES.6 2	3.3	
30		CH22_C20H12_GENSCAN.16 2	3.2	
		CH22_C65E1.GENSCAN.8 1	3.2	
	AA707750	ESTs; Wealtly similar to cis Golgi matrix	3.1	
		CH22_FGENES.307_4	3.1	
		CH22_EM:AC005500.GENSCAN.248 14	3.1	
35		CH.06_hs gij5902482	3.1	
		CH22_FGENES.669_5	3.1	
		CH22_DJ32110.GENSCAN.198	3.1	
		CH22_FGENES.527_6	3.1	
		CH22_FGENES.330_10	3.1	
40		CH22_FGENES.14 2	3.1 '	
	AA976074	ESTs	3 3	
		CH22_FGENES.2267	3	
•		CH22_FGENES.13 3	3 1	
		CH22_EM:AC005500.GENSCAN.209 12	3 3 4	
45		CH22_FGENES.271_3	3 %	

TABLE 17A

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

15

```
Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers
```

```
CAT number Accession
        Pkey
                           AA649530 AA659316 H64973
        116845 393481_1
20
        103207 30635_4
                           X72790
                           N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
        126257 182217_1
                           AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AIG36743 AW614951 BE467547 AIG80833
        102791 37186 1
                           AJ633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AJ970376 AJ583718 AJ672574
                           N25695 AW665466 AIB18326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833
                           AW003247 AW496808 AI080480 AI631703 AI651023 AI867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030
25
                           A)652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048
                           AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 AI624817 BE466611 AI206344 AA574397
                           AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
        126872 142696 1
30
                            BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
        112631 1746257 1
                           R82040 R70934
                           AA225084 AA302713
        120742 176835_1
                           Al311928 AA936030 T51931 AA609816 AA487195 AA664207
        106864 324239_1
        109700 genbank_F09609
                                     F09609
35
        111532 genbank_R08440
                                     R08440
        113938 genbank_W81598
                                     W81598
        113947 genbank_W84768
                                     W84768
        124357
               genbank_N22401
                                     N22401
                           AA121022 AA126422
        108733 504187_1
40
        112303 genbank_R54797
                                     R54797
        322136 46802_1
                           AF075083 H52291 H52528
                            W76326 AF086341 W72300
        322296 47334_1
                           D80630 D80896 D80895
        321811 1527481 1
        314648 293660_1
                            AW979268 AA878419 AA431342 AA431628
45
        322520 38916_1
                           T55958 T57205 AF147346
                           AF147347 T55426 T55503
        322521 38917_1
                           AA017656 AA017374 AA019761
        322675 86787_1
                           AI829520 AI791832 AA228414 AI791823 AA229211 AA229315
        323332 179142_1
                           Al433540 AA728984 AA804981
        316186 425440_1
50
        322975 1510563_1
                           C16391 C16413
                            BE069341 AW748403 AL044891 Al908240 AA393080
        324261 273265 1
                           AA410943 AW948953 AA334202 AA332882
        323817 233566_1
        301976 128835_1
                           T97905 AA101672
        324961 376239_1
                           AA613792 AW182329 T05304 AW858385
55
        303642 284260_1
                           AW299459 AA417112
                           AW629759 AW749955 AA633408 Al651005
        303797 386364_1
                           AA761668 AA573621 R92814 R09670
        319551 357371 1
        311935 174129_1
                           AA216387 T63548 AA228676
                            AA071267 T65940 T64515 AA071334
        319834 112523_1
                            AA534222 AA632632 T81234
60
        319977 345248_1
```

AA740616 AA654854 AA229823

AAD46309 AI263500 AAD46397

314138 179960_1 313591 103087_1

308106 Al476803
338255 CH22_6856FG_LINK_EMAC00
335809 CH22_3181FG_617_6_LINK_EM
335824 CH22_3197FG_619_11_LINK_E

5 307010 Al140014
307041 Al144243
305913 AA876109
305917 AA876469
309574 AW168083

10 325372 c12_hs
325544 c12_hs
325544 c12_hs
327075 c21_hs
332798 CH22_14FG_6_5_LINK_C4G1.G
334223 CH22_1507FG_360_4_LINK_EM
327075 c21_hs
15 334447 CH22_1746FG_387_7_LINK_EM
304782 AAS82081
313434 441798_1 W92070 AW019952 W92053

TABLE 17B

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. "Durham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Durham I. et al., Nature (1999) 402:489-495.	
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.	

15	Pkey	Ref	Strand	Nt_position
	335809	Dunham, I. et.al. Dunham, I. et.al.	Plus	14308764-14308824 26310772-26310909
20		Dunham, Letal.		26376860-26376942
		Dunham, I. et.al. Dunham, I. et.al.	Minus Minus	232147-231974 12734365-12734269
		Dunham, I. et.al.	Minus	15242294-15242231
25	325372		Minus	1117061-1117304
25	325544 327075	6682452 6531965	Plus Plus	171228-171286 4041318-4041431
	OE 7 01 0	···		, , , , , , , , , , , , , , , , , , , ,

TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is

expressed in normal body tissues.

10	Pkey: ExAcon: UnigeneliD: Unigene Title:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title
	R1:	Ratio of tumor to normal body tissue

15	Pkey	ExAcon	UnigenelD	Unigene Title	R1
	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
		M81057	Hs.180884	carboxypeptidase B1 (fissue)	12
20		M97815	Hs.183650	cellular retinoic acid-binding protein 2	6.5
		X52509	Hs.161640	tyrosine aminotransferase	12.4
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
	104825	AA035613	Hs.141883	ESTs	6.9
	107105	AW963419	Hs.155223	stanniocalcin 2	5.3
25	108819	AA011449	Hs.271627	ESTs	6.1
	112287	AB033064	Hs.334806	KIAA1238 protein	7.3
	112561	AJ791493	Hs.129873	ESTs, Wealty similar to A36036 cytochrom	8.2
	112637	R82331	Hs.164599	ESTs	5.4
	113206	BE262470	Hs.241471	RNB6	6.2
30	113970	W27249	Hs.8109	hypothetical protein FLJ21080	6.9
	114965	AJ733881	Hs.72472	BMP-R1B	10.1
	118925	N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	8.4
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35	129301	AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	6.2
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2
	134731	D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
		AW183618		solute carrier family 30 (zinc transport	9.9
			Hs.105445	GDNF family receptor alpha 1	5.7
40	302001	AB020711	Hs.278346	KIAA0904 protein	7.7
	302067	BE542708	Hs.222399	CEGP1 protein	7.3
			Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.4
	-		Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N0763 (
			Hs.200102	ATP-binding cassette transporter MRP8	6.7
45			Hs.204096	lipophilin B (uteroglobin family member)	13.8
		A1951118		Homo saplens breast cancer antigen NY-BR	17.3
			Hs.326736	Homo saplens breast cancer antigen NY-BR	57.6
		A1380797	Hs.158992	ESTs	10.2
50		AJ821005	Hs.118599	ESTs	10.8
50	•	AA216387		gbmc16b02.s1 NCI_CGAP_Pr1 Homo saplens	5.2
			Hs.118625	hexokinase 1	5.2
	•		Hs.105445	GDNF family receptor alpha 1	12.4
		C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
			Hs.269493	ESTs	6.6
55		AA740616		gbmy97f11.s1 NCL_CGAP_GCB1 Homo saplens	
			Hs.206868	Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
		A1873274	Hs.190721	ESTs	27.4
			Hs.136319	ESTs	20.7
~		AI538613	Hs.298241	Transmembrane protease, serine 3	10.9
60	•		Hs.312989	ESTs	5.3
	315051		Hs.163484	ESTs	12.9
	315060	AA551104	Hs.189048	ESTs, Moderately similar to ALUC_HUMAN I	5.8

	315196	AI367347	Hs.44898	Homo sapiens cione TCCCTA00151 mRNA sequ	18.2		
	315530	AW015415	Hs.127780	ESTs	8.9		
	315634	AA837085	Hs.220585	ESTs	6.3		
	316012	AA764950	Hs.119898	ESTs	7		
5	316177	Al904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7		
	316580	AA938198	Hs.148123	poly(A) polymerase gamma	9.4		
	317803	AW664964	Hs.128899	ESTs	6.1		
	317881	A1827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	9.6		
		NM_00254		addised low density lipoprotein (lectin	7.3		
10		AI793124		ESTs	17.8		
	320211	AL039402	Hs.125783	DEME-6 protein	9.2		
	321107	AI732643	Hs.144151	ESTs	12.3		
	321644	AW975944	Hs.237396	ESTs	11.7		
	321978	N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5		
15	322035	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19		
	322766	AW068805	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.2		
	322818	AW043782	Hs.293616	ESTs	7.6		
	322975	C16391		gb:C16391 Clontech human aorta polyA mRN	16.5		
	323262	AL133990	Hs.190642	ESTs	10.5		
20		AI829520		gbowl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2		
	323817	AA410943		BMP-R1B	8.4		
	324261	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4		
	324432	AA464510	Hs.152812	ESTs	16.5		
	324598	AW972227	Hs.163986	Homo saplens cDNA: FLJ22765 fis, clone K	5		
25	324603	AW993522	Hs.292934	ESTs	10,4		
	324987	Al375572	Hs.172634	ESTs	18.8		
	325544			Phase 2 & 3 Exons	5.7		
	330388		Hs.46	HER2 receptor tyrosine kinase (c-erb-b2,	6.6		
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2		
30	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1		
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL			20
		A1052047		ESTs; Wealty similar to CYTOCHROME P450	6.7		
		R72427		CH22_EM:AC005500.GENSCAN.1279	5.5		
~ -				CH22_FGENES.619_13	9.2		
35				CH22_FGENES.617_9	8		
				CH22_FGENES.271_7	6.5		
					7.3		
				CH22_FGENES.271_8	12.9		
40					8.4	1	
40				CH22_EM:AC005500.GENSCAN.304 2	11.3	,	
					8.5		
					7.1		
				CH22_FGENES.678_5	7.2	Ĺ	
				CH22_FGENES.678_5	16.8	A	

TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

334223 CH22_1507FG_360_4_LINK_EM

Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accession
	323332	179142_1	Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
20	322975	1510563_1	C16391 C16413
	324261	273265 1	BE069341 AW748403 AL044891 Al908240 AA393080
	323817	233566 1	AA410943 AW948953 AA334202 AA332882
	311935	174129 1	AA216387 T63548 AA228676
	314138	179960_1	AA740616 AA654854 AA229923
25	335809	CH22_3181FG	617_6_LINK_EM
	335824	CH22_3197FG_	619_11_LINK_E
	325544	c12 hs	·

TABLE 18B

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 Pkey: Ref:			Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication				
15	Strand: Nt_position:		entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.				
	Pkey	Ref	Strand	Nt_position			

TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90th percentile value. The "average" normal adult tissue level was set to the 90th percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the 144 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

20	Unigene Title: R1:		Unigene gene title Ratio of tumor to normal body tissue			
20	Pkey	ExAccn	UnigeneiD	UnigeneTitle	R1	
	408591	AF01522	24 Hs.46452	mammaglobin 1	137.6	
25	406964	M21305		gb:Human alpha satellite and satellite 3	71.0	
	400291	AA40136	9 Hs.190721		68.4	
	407277	AW1700	35 Hs.326736	Homo saplens breast cancer antigen NY-BR	54.2	
	449746	Al668594	4 Hs.176588	ESTs, Wealthy similar to CP4Y_HUMAN CYTOC	46.4	
	426878	BE06934		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	44.8	
30	400292	AA25073	7 Hs.72472	BMP-R1B	37.4	
	427585	D31152	Hs.179729	cottagen, type X, alpha 1 (Schmid metaph	32.9	
	408045	AW1389	59 Hs.245123	ESTS	31,9	
	407178	AA19565	51 Hs.104106	ESTs	30.4	
	407377	C16391		gb:C16391 Clontech human aorta polyA mRN	27.]	
35	450705	U90304	Hs.25351	iraquais homeobox protein 5	24.8	
	407212	AA41210	18 Hs.269350	ESTs	22.0	
	428848	NM_000	230 Hs.194236	leptin (murine obesity homolog)	21.9	
	404561			trichorhinophatangeal syndrome I (TRPS1)	21.8	
	407980	AA04630		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8	
40	447350	AI375572	2 Hs.172634	ESTs	17.3	
	450375	AA00964	7 Hs.8850	a disintegrin and metalloproteinase doma	16.6	
	422109	S73265	Hs.1473	gastrin-releasing peptide	16.5	
	435496	AW8401			16.0	
	453160	A1263307	7 Hs.239884	H2B histone family, member L	15.B	
45	420813	X51501	Hs.99949	protactin-induced protein	15.8	
	415989	A1267700			15.5	
	422505	AL12086		programmed cell death 9 (PDCD9)	14.8	
	424399	A1905687	7 Hs.2533	aldehyde dehydrogenase 9 family, member	14.5	

Hs.163443 Homo saplens cDNA FLJ11576 fls, clone HE

C1001134:gij2117372[pir][i65981 fatty ac

gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi

glxzk15e04.s1 Soares_pregnant_utenis_NbH

Hs.204096 Ilpophilin B (uteroglobin family member)

Hs.151407 cartilage intermediate layer protein, nu

Hs.21572 KQAA0644 gene product

lysyl coddase

Hs.121017 H2A histone family, member A

Hs.190642 ESTs

Hs.144341 ESTs

Hs,102267

Unique Eos probeset identifier number

I Ininece number

Exemplar Accession number, Genbank accession number

15

Pkey:

ExAcon:

423575 C18863

429441 AJ224172

431474 AL133990

448595 AB014544 427217 AA399272

422805 AA436989

456207 AA193450

424086 Al351010

459587 AA031956

424634 NM_003613

402578

13.7

13.6

13.5

13.0

128

12.6

12.2

12.0

11.9

119

	416208	AW291168	Hs.41295	ESTs, Weakly similar to MUC2_HUMAN MUCIN	11.5
		NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
		Al951118		Homo sapiens breast cancer entigen NY-BR	11.4
_		AW137148		Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
5		AL035414		hypothetical protein	11.1
		NM_007115	Hs.29352	tumor necrosis factor, alpha-induced pro	11.0
		A1684808 N78223		programmed cell death 9 (PDCD9)	10.9
		N70223 AW873596		transcription factor calmodulin 2 (phosphorylase kinase, delt	10.7 10.6
10		H87879		lysyl oxidase	10.5
LO.	402606	1107075	15.102201	NM_024626:Homo sapiens hypothetical prot	10.4
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.3
	447033	Al357412	Hs.157601		10.2
15	400295	W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1
	424905	NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	10.1
		AW292425	Hs.163484		9.9
		AJ873274	Hs.190721		9.9
20		H23789	Hs.144530		9.8
20		BE218705		metallothioneth-like 5, testis-specific	9.7
		D90041 W20027	Hs.23439	N-acetyliransferase 1 (arylamine N-acety	9.7 9.6
		AL360204		Homo saplens mRNA full length insert cDN	9.6
		AI624342	Hs.170042		9.5
25		Al907673		gb:lL-BT152-080399-004 BT152 Homo saplen	9.3
	452744	Al267652	Hs.30504	· · · · · · · · · · · · · · · · · · ·	
	432596	AJ224741	Hs.278461		9.1
		Al127076		hypothetical protein DKFZp564O1278	9.1
20		D60730	Hs.57471	ESTs	9.1
30		AA410943		gb:zt32h03.r1 Soares ovary turnor NbHOT H	9.1
	406348	i Magre	II- 070400	Target Exon	9.0
		U31875 U23752	Hs.32964	short-chain alcohol dehydrogenase family SRY (sex determining region Y)-box 11	9.0 9.0
		AF026944	Hs.293797		8.8
35	405654		1,522,007,01	C12001521:pij7513934 phijT31081 cca3 pr	8.8
		AA279490	Hs.86368	calmegin	8.8
		A1955040			8.7
	408771	AW732573	Hs.47584	potassium voltage-gated channel, detayed	8.5
40		AB033025	Hs.50081		8.4
40		BE379594	Hs.49136		8.3
	451561		Hs.177403		8.2
		W67883		The state of the s	8.2
		NM_007050 AL080207			8.1 8.1
45	405095		ns. 134300		8.1
7,7		AA236115	Hs.120785		8.0
		AF026941	Hs.17518		8.0
		BE242870	Hs.75379		8.0
	416747	AW876523	Hs.15929		0.8
50	415385	R17798	Hs.7535	COBW-tike protein	7.9
		AJ811202			7.9
		AF044197			7.9
		M31126	HS.272620		7.8
55	400285		Un 45000		7.7 7.0
<i>J J</i>	437207 427110	AW880562	Hs.114574		7.6 7.5
		AW976987			7.5
	433426		Hs.133525	•	7.5
		A1222020			7.4
60	426214	H59846			7.4
	447475	Al380797	Hs.158992		7.3
		AA948033	Hs.130853	ESTS	7.2
		AW602166			7.2
65		AW368397			7.1
65		AW242243	HS. 1000/0	peroxisomal famesylated protein	7.0
		AK001468			6.9
	440000	AI734009	HS. 12/009	KIAA1603 protein	6.9

		A1678059	Hs.202676	synaptonemal complex protein 2	6.9
	410781	Al375672	Hs.165028	ESTs	6.9
	443788	Al732643	Hs.144151	ESTs	6.9
	421373	AA808229	Hs.167771	ESTs	6.8
5	451398	AI793124	Hs.144479	ESTs	6.8
	404253			NM_021058*:Homo sapiens H2B histone famil	6.8
		Al015591	Hs.131004	ESTs, Weakly similar to T17227 hypotheti	6.7
		AW963419		stanniocalcin 2	6.6
		AA321649	Hs.2248	small inducible cytoldne subfamily B (CX	6.6
10		BE545072		hypothetical protein FLJ10461	6.6
10		AW818127	113,122,013	gb:CM1-ST0277-061299-059-b07 ST0277 Home	
		AI418055	Hs.161160		
			Hs.130239		6.6
		A1733682			6.6
15		Al970394	Hs.197075		6.6
15		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	6.5
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	6.5
		BE041395		ESTs, Wealty similar to unknown protein	6.5
		X03635	Hs.1657	estrogen receptor 1	6.5
	427356	AW023482	Hs.97849	ESTs	6.5
20	425704	U79293	Hs.159264	Human clone 23948 mRNA sequence	6.4
	441134	W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
	424902	NM_003866	Hs.153687	Inositol polyphosphate-4-phosphatase, ty	6.4
	448693	AW004854	Hs.228320	hypothetical protein FLJ23537	6.4
	431448	AL137517		hypothetical protein DKFZp564O1278	6.2
25	444342	NM_014398	Hs.10887	similar to lysosome-associated membrane	6.1
		AA586894		S100 calcium-binding protein A7 (psorias	6.1
		A1240665	Hs.8895	ESTs	6.1
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; Inters	6.0
		AA972965	Hs.135568		6.0
30		R45154	Hs.106604		6.0
50		AA464510	Hs.152812		5.9
		AA310693	Hs.87329	HSPC072 protein	5.9
		AW975944	Hs.237396		5.9
	-	H39960		Homo saplans cDNA FLJ12280 fis. clune MA	5.9
35		AF115402			5.9
33		AW803341	Hs.11713	E74-like factor 5 (els domain transcript	
			U= 450000	gb:iL2-UM0079-090300-050-D03 UM0079 Homo	
		AL049689		hypothetical protein similar to tenascin	5.9
		X72755	Hs.77367	monokine induced by gamma interferon	5.8
40		R20991	11. 405404	gb:yg05h01.r1 Soares infant brain 1NIB H	5.8
40		N28519		ESTs, Wealty similar to unnamed protein	5.8
		AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.8
		W52854	Hs.27099	hypothetical protein FLJ23293 similar to	5.7
		AW162916		hypothetical protein PRO2577	5.7
40		AI733881	Hs.72472	BMP-R18	5.6
45		AW016531	Hs.122147	ESTS	5.6
•		AW067903	Hs.82772	collagen, type XI, alpha 1	5.5
		AA463893	Hs.220933	ESTs	5.5
		R41396	Hs.101774	hypothetical protein FLJ23045	5.5
	423811	AW299598	Hs.50895	homeo box C4	5.4
50	434539	AW748078	Hs.214410	ESTs, Wealdy similar to MUC2_HUMAN MUCIN	5.4
	439138	AI742605	Hs.193696		5.4
	453931	AL121278	Hs.25144	ESTs	5.4
	444078	BE246919	Hs.10290	U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
	447102	BE167434	Hs.98471	ESTs, Wealdy similar to T18712 hypotheti	5.4
55		A1879148	Hs.26770	fatty acid binding protein 7, brain	5.4
-		AW067800		stanniocalcin 2	5.3
		AA291553	Hs.190086		5.3
		AW970060		gb:EST382140 MAGE resequences, MAGK Horn	
		AA421081	Hs.12388	ESTs	5.3
60		U65011	Hs.30743	preferentially expressed antigen in meta	5.3
50		AB028945	Hs.12696	cortactin SH3 domain-binding protein	
					5.3
	456938			tyrosine aminotransferase	5.3
	422867		Hs.1584	cartilage oligomeric matrix protein (COM	5.2
65	438167	•	Hs.24286	ESTs	5.2
65		AW207084		hypothetical protein MGC14801	5.2
		N92293		ESTs, Moderately similar to ALUB_HUMAN A	5.2
	416276	U41060	Hs.79136	LIV-1 protein, estrogen regulated	5.2

	400300			HER2 receptor tyrosine kinase (o-erb-b2,	5.2
	418004	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
	439840	AW449211	Hs.105445	GDNF family receptor alpha 1	5.2
	428771	AB028992	Hs.193143	KIAA1069 protein	5.2
5	455047	AW852530		gb:PM1-CT0243-071099-001-g06 CT0243 Homo	5.2
	419169	AW851980	Hs.262346	ESTs, Wealthy similar to S72482 hypotheti	5.2
		AJ916269		ESTs, Wealdy similar to ALU5_HUMAN ALU S	5.1
		AA032279	Hs.61635	six transmembrane epithelial antigen of	5.1
		Al283133	Hs.297420		5.1
10		Al791495		calmodulin-like skin protein	5.1
10		AI798680	Hs.25933		5.1
		AA642007	Hs.116369		5.1
		AW207206	Hs.136319		5.1
	405494		110.100010	C2001837°:pi 12697903kib jBAB21770.1 (A	5.1
15		AW195285	Un 104007	ESTs, Wealthy similar to (38022 hypotheti	5.1
13		Al201849	115, 154051	gb:gs76g04.r1 NCI_CGAP_Pr28 Homo sapiens	
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
		BE387335		ESTs, Weakly similar to S64054 hypotheti	5.0
			Hs.12422		5.0
20		R43646	Hs.38383		5.0
20		W02414			5.0
		AW665281	Hs.224625		5.0
		AA236776		MAD2 (mitotic arrest deficient, yeast, h	5.0
		AK000713		hypothetical protein FLJ20706	4.9
26		AW512260	Hs.87767		
25		XB2125	Hs.25040		4.9
		AJ003029	Hs.65792		4.9
		M30703		amphiregulin (schwannoma-derived growth	4.8
		A)655499	Hs.161712		4.8
20		Al820682	Hs.129598		
30		AF220050	HS.181365	uncharacterized hematopoletic stem/proge	4.8
	400286			C16000922:gi7499103 ph T20903 hypothe	4.8
		U71600		gb:Human zinc linger protein zip31 (zi31	
		Al831190	Hs.166676		4.8
25		BE218239	Hs.202656		
35		A1217477	Hs.194591		4.8
		AW997556		KIAA1717 protein	4.8
		BE440042	Hs.83326	•	4.7 4.7
		A1349764	Hs.217081	-	4.7
40		AA191493	Hs.48778	•	4.7
40	400284		11- 020207	estrogen receptor 1	4.7
		AW248508		Horno saplens cDNA FLJ14035 ffs, clone HE	4.7
		R42185	Hs.274803	· · · · · · · · · · · · · · · · · · ·	4.7
		BE062109		chloride channel, calcium activated, fam	4.7
15		AW961489	Hs.154116		4.7
45		NM_003462	Hs.33846	· ·	4.6
		AF077345	Hs.177936		4.6
		AW813731		ESTs, Moderately similar to \$65657 alpha	4.6
		R63503	Hs.28419	ESTS	4.6
60	405718		11- 407000	C4000799*:gij6330365 dbjjBAA86508.1 (AB	4.6
50		AW207523	Hs.197628		4.6
		Z40313		Homo sapiens done IMAGE:23371, mRNA seq	4.6
		M81057	HS.160884	carboxypeptidase B1 (fissue)	4.6
			HS.19322	Homo sapiens, Similar to RIKEN cDNA 2010	4.6
<i></i>		AK000282	HS.239681	hypothetical protein FLJ20275	
55		AW855717	11. 70400	gb:RC1-CT0279-081299-013-b01 CT0279 Homo	
		AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
		AA808189	Hs.272151	ESIS	
		AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	
C 0		AL036877	Hs.282878		4.5
60		AA514660	Hs.128443		4.6
		H15261	Hs.21948	ESTs	4.
		AW246333	Hs.17901	Homo sapiens, done IMAGE:3937015, mRNA,	4.0
		AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6)	4.
CF		AW966399	Hs.46821	hypothetical protein FLJ20086	4.
65		W68815	HS.3U1685	Homo saplens cDNA FLJ11346 fis, clone PL	4.5
		AW503329	11-01-100	gb:UI-HF-BN0-alox-e-02-0-ULr1 NIH_MGC_50	4.5
	4007/7	- HY35-157	-c /17/172	Company 67	- 4.

		H56435		9-7-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	4.5
		D89053	Hs.268012		4.5
		AW814902	•	gb:MR1-ST0206-120400-022-f08 ST0206 Homo	4.5
_	401418				4.5
5		AK001074			4.5
		AKD01581		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	4.4
		AA135257	Hs.47783	90,	4.4
		AA335497			4.4 4.4
10		AW419196		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	4.4 4.4
10		AW664964	Hs.128899		4.4
		BE463857		2,,	4.4
		R31178 AW905138	Π3,201 OZU	fibronectin 1 gb:QVO-NN1071-280400-207-g07 NN1071 Homo	
	405196	•		C2000662*:gij7512792jpir]]T12482 hypothe	4.4
15		N47863	He 336001		4.4
13	401793	1441000	10.0000		4.4
		AA381209			4.4
		AB007975	Hs.131454		4.4
	400238			C19000274*:gil12741327 reffXP_008833.2	4.4
20		AF019612	Hs.297007	membrane-bound transcription factor prot	4.4
	400608				4.4
		AV657310	Hs.282898	20.0	4.3
		AL138272	Hs.62713		4.3
25	405906			Target Exon	4.3
25	405925		4000000		4.3 4.3
		BE247684	Hs.103070		4.3
		H57646	Hs.42586		4.3
		N63855 AA603305	IS. 142004	zinc finger protein gbcnp12d11.s1 NC1_CGAP_Pr3 Homo sapiens	4.3
30		N71277		ghtza36e03.s1 Soares fetal liver spleen	4.3
50		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	4.2
		AI266484	Hs.31570	ESTs, Weakly similar to KIAA1324 protein	4.2
		AA291377	Hs.50831	ESTs	4.2
		AA033714		hypothetical protein FLJ14260	4.2
35		NM 001898		cystafin SN	4.2
	413043	BE158766			4.2
	413499	BE144884		gb:CM0-HT0182-041099-065-e11 HT0182 Homo	4.2
		BE538082	Hs.8172		4.2
40		AF123050	Hs.44532	diubiquitin	4.2
40		S82472		ghtbeta -pol=DNA polymerase beta (exon a	4.2 4.2
	404285		11- ACE 20A	C6001909:gip704441 dbj BAA18909.1 (D298	4.2
		NM_005940		matrix metalioproteinase 11 (MMP11; stro ESTs, Moderately similar to 138022 hypot	4.2
		AW812795 AA026880	Hs.25252	prolactin receptor	4.2
45		AW592187	Hs.293299		4.2
73		A1908165		GATA-binding protein 3 (T-cell receptor	4.2
		AW821113	Hs.72402	ESTs	4.2
		AA024538		Human DNA sequence from done RP1-28H20	4.2
		AW378065	Hs.8687	ESTs	4.2
50		AJ085198	Hs.164226	ESTs	4.2
	425523	AB007948	Hs.158244	KIAA0479 protein	4.1
		J05070		matrix metalloproteinase 9 (gelatinase B	4.1
	430009	AA894564	Hs.22242	ESTs	4.1
	434469	AA634806		gb:ab28c02_r1 Stratagene lung (937210) H	4.1
55		BE241831		hypothetical protein MGC2705	4.1
	450229	R18717	Hs.8929	hypothetical protein Ft.J11362 gb:CM1-BT0368-061299-060-g07 BT0368 Homo	4.1
	455700	BE068115	LL- 777202	· Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
	431924	AK000850	Hs.184987		4.1
60		A1886558	(TS. 104307	NM_004496*Homo saplens hepatocyte nucle	4.1
UU	401451	A1685464		gb:ti88i04.x1 NCI_CGAP_Pr28 Homo sapiens	4.1
	421010	AI735283	Hs.172608	-	4.1
	40303Z 42077N	W60379	Hs.57773		4.1
	VVSGUS	AI220547	Hs.135223		4.1
65	427122	AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	4.1
J U		U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.1
		BF007371	Hs.200313		4.1

	403585			Target Exon	4.1
		AJ394151	Hs.37932	ESTs	4.1
		AA640891	Hs.102406	ESTs	4.1
		BE264901		carbonic anhydrase VIII	4.1
5		NM_004354	Hs.79069		4.1
•		AA296520	Hs.89546		4.1
	400555			Target Exon	4.1
		U94362	Hs.58589	glycogenin 2	4.0
		NM 003528	Hs.2178	H2B histone family, member Q	4.0
10		AA448460		GE36 gene	4.0
		AL359055		Homo sapiens mRNA full length insert cDN	4.0
		AL117408		ATP-binding cassette transporter MRP8	4.0
		NM_002666	Hs.103253	perilipin	4.0
		AA228776	Hs.191721		4.0
15	424188	AW954562	Hs.142634	zinc finger protein	4.0
		AW938484		gb:CMO-DT0057-290200-253-d06 DT0057 Homo	4.0
	404142			Target Exon	4.0
	441143	Al027604	Hs.159650	ESTs	4.0
	444540	AJ693927	Hs.265165	ESTs	4.0
20	415579	AA165232	Hs.222069	ESTs	4.0
		N75582	Hs.212875	ESTs, Weakly similar to DYH9_HUMAN CILIA	4.0
		BE390440		gb:601283601F1 NIH_MGC_44 Homo sapiens c	4.0
	452281	T93500	Hs.28792	Homo saptens cDNA FLJ11041 fis, clone PL	4.0
	417801	AA417383	Hs.82582	Integrin, beta-like 1 (with EGF-like rep	4.0
25	446232	A1281848	Hs.194691	retinoic acid induced 3	4.0
	447377	X77343	Hs.334334	transcription factor AP-2 alpha (activat	4.0
	437854	AL119723		gb:DKFZp761A2124_r1 761 (symonym: harmy2)	4.0
	446140	AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
	452240	AJ591147	Hs.61232	ESTs	4.0
30	459574	A1741122	Hs.101810	Homo sapiens cDNA FLJ14232 fis, clone NT	4.0
	458673	N99626		gb:za39d11.r1 Soares fetal liver spleen	4.0
	444858	Al199738		ESTs, Wealthy similar to ALUA_HUMAN IIII	4.0
		AI948607	Hs.264680		4.0
~~		AF153330	Hs.30246		3.9
35		AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554		:	Target Exon	3.9
		AA573006	Hs.19173	ESTs	3.9
		Z42023	HS.1065/6	alanine-glyoxylate aminotransferase 2-li	3.9 3.9
40		AA442176	11. 75040	gbczw63b08_r1 Soares_total_fetus_Nb2HF8_	3.9
40		M86153	Hs.75618	RAB11A, member RAS oncogene family	3.9
	401781	E05000	11- 200440	Target Exon	3.9
		F05086	Hs.328142	gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
		AA026777	Hs.209122		3.9
45		AI819068		actin related protein	3.9
43		Z21336 AJ472106	Hs.49303		3.9
		AF086534	110.45000 14e 487561	ESTs, Moderately similar to ALU1_HUMAN A	3.9
		AA419529	Hs.76391		3.9
		AB037791	Hs.29716	hypothetical protein FLJ10980	3.9
50		BE537217	Hs.30343	ESTs	3.9
J 0		BE568414	He 145407	Homo sapiens cDNA: FLJ22097 fis, clone H	3.9
		AI073512	Hs.133916		3.9
		BE152428	152,1000,10	gb:CMO-HT0323-151299-126-b04 HT0323 Home	
	401785			NM_002275°:Homo saplens keratin 15 (KRT1	3.9
55		M86699	Ho 169840	TTK protein kinase	3.9
<i></i>		AI989885	Hs.231926		3.9
		H75391	Hs.255748		3.9
		BE172186	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:MR0-HT0559-110300-005-h11 HT0559 Homo	
		AA236645	Hs.98274		3.8
60		AH84268	Hs.339665	EST8	3.8
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.8
	403593			Target Exon	3.8
		AW018669	Hs.29190	ESTs	3.8
		AW664873	Hs.87836	Homo sapiens PAC clone RP5-1087M19 from	3.8
65		W02410	Hs.205555		3.8
		Al217928	Hs.144762		3.8
		A A E CO COOR	Un 20502	hunothotical protein El 122418	3 8

		T49951	Hs.9029	DKFZP434G032 protein	3.8
		AW383618		ESTs, Moderately similar to ALU2_HUMAN A	3.8
		AL359938		Meis (mouse) homolog 3	3.8
_		AA904244	Hs.153205		3.8
5		A1476732	Hs.263912		3.8
	403426	44470450	11- 00000	Target Exon	3.8
		AA470158	Hs.98202	ESTS	3.8 3.8
		BE222648 AW206942	Hs.253594	ESTs, Highly similar to c380A1.1b [H.sap	3.8
10.		AW105231	Hs.192035		3.8
10.		AW794600	110.132000	gb:RC6-UM0014-170300-022-C05 UM0014 Horr	
		NM_005758	Hs.184942	G protein-coupled receptor 64	3.8
		BE622641		ESTs, Wealdy similar to 138022 hypotheti	3.8
		Al742618		ESTs, Wealdy similar to nitrilase homolo	3.7
15	401747			Homo sepiens keratin 17 (KRT17)	3.7
		NM_014581		odorant-binding protein 2A	3.7
		AP000692		chromosome 21 open reading frame 5	3.7
		AB029496	Hs.59729	semaphorin sem2	3.7
20		BE005346	Hs.116410		3.7 3.7
20		AK001666 AA018534	Hs.103334	similar to SALL1 (sal (Drosophila)-like	3.7
	402696		113.100334	C3002523:gij6686211 sp 027533 YH2M_CAEEI	
		AV660737	Hs.135100		3.7
		AW816379	Hs.335018	— - · · -	3.7
25	422026	U80736	Hs.110826	trinucleotide repeat containing 9	3.7
	419440	AB020689	Hs.90419	KIAA0882 protein	3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648		3.7
20	401508			NM_024817:Homo saplens hypothetical prot	3.7
30		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7 3.7
		U79734 AI021992	Hs.97206 Hs.124244		3.7
		AA629065	Hs.116301		3.7
		R55373	Hs.20864	ESTS	3.7
35		BE623004	11045001	gb:601441282F1 NIH_MGC_72 Homo saplens c	
	458712	Al347502	Hs.107872	hypothetical protein FLJ20761	3.7
	433404	T32982	Hs.102720		3.7
	405232			NM_015832:Homo saplens methyl-CpG bindin	3.7
40		AL109791	Hs.241559	Homo sapiens mRNA full length insert cDN	3.7
40		BE011668	Hs.30098	gb:CM3-BN0223-100500-177-a04 BN0223 Home	3.7
		Al239923 Al970797	Hs.64859	ESTs ESTs	3.7
		Al248584		Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
	401049		110.1007-10	Target Exon	3.6
45		D31771	Hs.89404	rnsh (Drosophila) homeo box homolog 2	3.6
	420179	N74530	Hs.21168	ESTs	3.6
		AV658444		tankyrase, TRF1-interacting ankyrtn-rela	3.6
		A)377755	Hs.120695		3.6
50		M97815	Hs.183650	cellular retinolc acid-binding protein 2	3.6
50		Al698839 AL120173	Hs.301663	gbrwd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	3.6
		AW901458	HS.30 1003	gb:RC0-NN1012-270300-031-c07 NN1012 Homs	
		AA352111		ob:EST60061 Activated T-cells XX Homo sa	3.6
		Al142095	Hs.143273	•	3.6
55		BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	3.6
	414869	AA157291	Hs.21479	ubinuciein 1	3.6
		AA062954	Hs.141883		3.6
		Y12735		dual-specificity tyrosine-(Y)-phosphoryl	3.6
<i>c</i> n		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091		Un COAAF	Target Exon	3.6 3.6
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast Target Exon	3.6
	405153 423248	AA380177	Hs 125945	ribulose-5-phosphate-3-epimerase	3.6
	403639		10.12000	ENSP00000233023°:CDNA FLJ12662 fis, clon	3.6
65	404360			C7001385:gil12082809lgbjAAG48618.1jAF315	3.6
		AA766296	Hs.99200	ESTS	3.6
	423338	AB007961	Hs.127338	KIAA0492 protein	3.6

	424202	BE350295	Hs.15032		3.6
		AA514986	Hs.283705		3.6
		AA853978	Hs.124577		3.6
_		AA441838	Hs.62905		3.6
5	406446			·	3.6
		AA315308		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3.6
		AW015415	Hs.127780		3.6
		W87707			3.6
10		A1697121			3.6
10		AW291095			3.6
		AW297920	Hs.130054		3.5
		AW860158	11- 00700	gb:RC0-CT0379-290100-032-b04 CT0379 Homo	
		AW968226	Hs.60798		3.5 3.5
15	402820	AA191719	Hs.314714		3.5
13		AW393080			3.5
		AV1353000 Al806335			3.5
		AA420683	Hs.98321		3.5
		NM 015368	Hs.30985	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3.5
20	400610				3.5
		W07361	Hs.22545		3.5
		AW960146			3.5
		AI805416	Hs.213897		3.5
		NM_004272	Hs.337737	Homer, neuronal immediate early gene, 18	3.5
25	423948	AW392342	Hs.283077		3.5
	449424	AW448937	Hs.197030		3.5
		AW753967		gbdRC2-CT0304-080100-011-h12 CT0304 Homo	
		NM_000288	Hs.79993	201011111111111111111111111111111111111	3.5
30		R20893			3.5
30		AL043002			3.5
		H84847	Hs.49391	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3.5 3.5
		AW316843	Hs.66309 Hs.42645	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3.5
		N32536 AB17494	Hs.9812		3.5
35		AI057094	Hs.96867	***************************************	3.5
<i></i>		Al370876	Hs.79090		3.5
		AW850178	1 10.1 3000		3.5
		AA314337	Hs 301547		3.5
		AA877124	Hs.172844		3.5
40		N25521	Hs.25275	Kruppel-type zinc finger protein	3.5
	440623	Al935016	Hs.216639	ESTs	3.5
	455838	BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	3.5
	458771	AW295151	Hs.163612		3.5
	442942	AW167087	Hs.131562		3.5
45	436550	Z50158			3.5
		AW474547			3.5
		BE614743			3.5
		AW505021	Hs.88414		3.5
50		Al908400	Hs.143789		3.5
50		AF086224	Hs.55238		3.5 3.5
	405917		Hs.176220		3.5
		AW993582 W47595			3.4
		AA283185	Hs.19327	ESTs	3.4
55		AW904466			3.4
<i></i>		BE252383			3.4
		BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	3.4
		U92649	Hs.64311		3.4
		AW073310	Hs.163533		3.4
60		AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	3.4
	404097			C5000242*:gij9369379jgbl/AAF87128.1/AC006	3.4
		AF119861		.,,	3.4
		Al215069	Hs.89113		3.4
	402421				3.4
65	405248				3.4
		AJ404672			3.4

		AF038564	Hs.98074	itchy (mouse homolog) E3 ubiquitin prote	3.4
	432239		Hs.2936	matrix metalloproteinase 13 (collagenase	3.4
		BE618395		hypothetical protein DKFZp761J1523	3.4
_		R41823	Hs.7413	ESTs; calsyntenin-2	3.4
5		AA210765		gbczr90c06.r1 NCI_CGAP_GCB1 Homo sapiens	
		AI346468	Hs.145789	guanine nucleotide binding protein (G pr	3.4 3.4
		Al613276	Hs.5662 Hs.232168		3.4
		Al247716		hypothetical protein FLJ23511	3.4
10		AA164366 Al971313		KIAA0551 protein	3.4
10		AF102546	Hs.63931	dachshund (Drosophila) homolog	3.3
	405460			Target Exon	3.3
		AW503603	Hs.129915	phosphotriesterase related	3.3
		AL037925		ab:DKFZp564M037_r1 564 (synonym: hfbr2)	3.3
15		AW885727	Hs.301570	- , -	3.3
	441690	R81733	Hs.33106	ESTs	3.3
		AA814043	Hs.88045	ESTs	3.3
	418478	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.3
	408908	BE296227		serine/threonine kinase 15	3.3
20		A)160386	Hs.125087		3.3
		AF055575	Hs.23838	calcium channel, voltage-dependent, i. ty	3.3
		NM_000685	Hs.89472	angiotensin receptor 1	3.3
		AA160079		Homo sapiens mRNA for partial 3UTR, seq	3.3
25		AW503857	Hs.4007	Sarcolemnal-associated protein	3.3 3.3
25		NM_005982	Hs.54416 Hs.135288	sine ocuiis homeobox (Drosophila) homolo	3.3
		AW138872 AA280627	Hs.57848	ESTs	3.3
		AA296961	13.37040	qb:EST112514 Adrenal gland tumor Homo sa	3.3
		AJ936450	Hs.147482		3.3
30	402892		110.111110	Target Exon	3.3
50		AA994896	Hs.22514	ESTs	3.3
		AA741545		ESTs, Weakly similar to T24961 hypotheti	3.3
		R21945	Hs.166975	splicing factor, arginine/serine-rich 5	3.3
_	443194	A1954968	Hs.279009	matrix Gla protein	3.3
35	445432	AV653771		gbcAV653771 GLC Homo sapiens dDNA done	3.3
		AA121686	Hs.10592	ESTs _	3.3
	406151			Target Exon	3.3
		AW511956	Hs.293261	ESIS	3.3
40		AW820260	11- 000044	gb:QV2-ST0296-150200-040-c10 ST0296 Homo ESTs, Weakly similar to A43932 mucin 2 p	3.3
40		T16971 AF086120	Hs.102793	•	3.3
	401575		NS. 102/33	Target Exon	3.3
		AL045633	Hs.44269	ESTs	3.3
		AI344166	Hs.155743		3.3
45		AW369771	Hs.52620	integrin, beta 8	3.3
		AW204610	Hs.22270	ESTs	3.3
		AA976718	Hs.202242	ESTs	3.3
	416783	AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.3
	435039	AW043921	Hs.130526		3.3
50		T70874	Hs.207636		3.2
		T10213		gycosyltransferase	3.2
		A1824009	Hs.44577	ESTs	3.2
		R60336	Hs.52792	Homo sapiens mRNA; cDNA DKFZp586l1823 (f	
55		W88774	Hs.118370		3.2
22		BE336654	Hs.70937 Hs.26040	H3 histone family, member A ESTs, Wealdy similar to fatty acid omega	3.2
		AA863360 BE311926	Hs.15830		3.2
	403637		113,13000	C3001106":pij10047201jdbjjBAB13394.1j (A	3.2
	405547			NM_018833*:Homo saplens transporter 2, A	3.2
60		C05766	Hs 181022	CGI-07 protein	3.2
00		AI821005	Hs.118599		3.2
		R10305	Hs.185683		3.2
	416856	N27833		ESTs, Weakly similar to I38022 hypotheti	3.2
		A)652777	Hs.197069		3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
	440684	Al253123	Hs.127356	ESTs, Highly similar to S21424 nestin [H	3.2
	459055	N23235	Hs.30567	ESTs. Wealdy similar to R34087 hypotheti	3.2

	452190	H26735	Hs.91668	Homo sapiens cione PP1498 unknown mRNA	3.2
		AA489732	Hs.154918	_ 	3.2
	405394			Target Exon	3.2
_		BE169810	Hs.47557	ESTs	3.2
5		H03556		ESTs, Weakly similar to thyroid hormone	3.2
		AA765917	Hs.122840		3.2
		AK000684		hypothetical protein FLJ22104	3.2
		AL121282	Hs.257786		3.2
10		AW856552 NM_005429	No 70444	gb:RC1-CT0294-080100-012-a04 CT0294 Home	
10		AA758239	Hs.79141 Hs.180330	vascular endothelial growth factor C	3.2 3.2
		A1249368	Hs.98558		3.2
		H38857		Homo sapiens cDNA FLJ20738 fis, clone HE	3.2
		Al904743		hypothetical protein FLJ10292	3.2
15		A)016377	Hs.131693		3.2
		AB033052	Hs.22151		3.2
	419519	AI198719	Hs.176376		3.2
	404580			NM_014112*Homo sapiens trichorhinophala	3.2
	447046	AA326187	Hs.17170	G protein-coupled receptor 4	3.2
20	457473	AW974903	Hs.291231	· · •	3.1
		AW904907	Hs.30732	hypothetical protein FLJ13409; KIAA1711	3.1
		Al204995		gbcan03c03.x1 Stratagene schizo brain S1	3,1
	400195			NM_007057*:Homo saptens ZW10 interactor	3.1
25		AW408557		hypothetical protein FLJ14075	3,1
25		AW974175		ESTs, Weakly similar to MAPB_HUMAN MICRO	
		AA312735	Hs.30512		3.1
		AA701327 AA906366	Hs.17949	ESTS	3.1
		D38122	Hs.190535 Hs.2007		3.1
30		AW891294		tumor necrosis factor (ligand) superfami solute carrier family 4, sodium bicarbon	3.1 3.1
50		R82331	Hs.164599		3.1
		AJ638627		KIAA1688 protein	3.1
		AA503653		ESTs, Moderately similar to ALU2_HUMAN A	3.1
		AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	3.1
35	430264	AA470519		gb:nc71f10.s1 NCI_CGAP_Pr1 Homo sapiens	3.1
	418827	BE327311	Hs.47166	HT021	3.1
	410835	AW806906		gb:QV4-ST0023-160400-172-d12 ST0023 Homo	3.1
		H15302	Hs.168950	Homo saplens mRNA; cDNA DKFZp566A1046 (f	3.1
40	405336			Target Exon	3.1
40		Al683150			3.1
		Al583052	Hs.270058		3.1
		BE160636 Al768801	LL- 400042	gb:PM1-HT0422-291299-002-c08 HT0422 Homo	
	405848		ITS.108943		3.1
45		BE066976		gb:PM0-8T0340-211299-003-c12 BT0340 Homo	3.1
10		M29994		T	3.1
		W26713	Hs.256972		3.1
	423518	,•			3.1
		AI065104			3.1
50		BE165753	Hs.250528		3.1
	433805	AA706910	Hs.112742		3.1
	437152	AL050027		gbdHomo saplens mRNA; cDNA DKFZp566C0324	13.1
		AI541305	Hs.48778		3.1
		AW407181	Hs.218377	Homo saptens cDNA FLJ11927 fis, clone HE	3.1
55		AF026942		gbi-liomo sapiens cig33 mRNA, partial sequ	3.1
		AW807227		gb:MR4-ST0062-180200-001-e10 ST0062 Homo	
		NM_002914		replication factor C (activator 1) 2 (40	3.1
	416790		Hs.7043		3.1
۲۸		BE295866	Hs.94382		3.1
60		W94997	Hs.189917	combination /098 Management	3.1
	426968	00/616 AL117431	IIS. 1/3034	emphiphysin (Stiff-Mann syndrome with br	3.1
		BE466639	10.112100 He 61770		3.1
		AW138413	He 130332		3.1
65		AA382814	. 10, 10,000		3.1 3.1
JJ		Al248013	Hs.106532		3. I 3. 1
•		AW135274	Hs.12433		3. i 3.1
				•	

	446466	H38026	Hs.308	arrestin 3, retinal (X-arrestin)	3.1
	457888	BE219794		ESTs	3.1
	420058	AKD01423	Hs.94694	Homo saplens cDNA FLJ10561 fis, clone NT	3.0
	409248	AB033035	Hs.51965	KIAA1209 protein	3.0
5		BE153855	Hs.61460	ig superfamily receptor LNIR	3.0
,		AA232658	He 105794	UDP-glucosecglycoprotein glucosyttransfe	3.0
		AI830417	Hs.44143	polybromo 1	3.0
		N93266	Hs.40747	ESTs	3.0
				Homo sapiens mRNA; cDNA DKFZp761C1712 (I	
10		AL133731	Hs.4774		3.0
10		NM_005357	Hs.95351	lipase, hormone-sensitive	
•	405609	NA `		ENSP00000241065*:CDNA	3.0
	404274			NM_602944*Homo sapiens v-ros avian UR2	3.0
	449777	Al971362	Hs.231945	ESTs	3.0
	415459	H07118	Hs.6099	ESTs ·	3.0
15		N59650	Hs.27252	ESTs	3.0
1.7	406291			Target Exon	3.0
		BE383592		gb:601297871F1 NIH_MGC_19 Homo sapiens of	3.0
			Hs.293334		3.0
		AW972359			3.0
00		AI791988	Hs.129115		3.0
20		N21043	Hs.42932	ESTs	
	451177	Al969716	Hs.13034	ESTs	3.0
	418026	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326	NA	•	C10000447*:gij1168375 sp P43467 AGA1_PED	3.0
	409920	BE169746	Hs.12504	Exely ortholog of mouse Arkadia	3.0
25	432887	AJ926047	Hs.162859	ESTs	3.0
		AF245505	Hs.72157	DKFZP564H922 protein	3.0
	401045			C11001883*:gij6753278 ref NP_033938.1 c	3.0
		AA584062	Hs.272798		3.0
		A1221894	Hs.39311	ESTS	3.0
30			Lie 477527	hypothetical protein DKFZp761B1514	3.0
30		BE077155	Hs.270535		3.0
		AW958879			3.0
		H91882		Dyl-binding protein IDAX (inhibition of	3.0
		NM_014711		KIAA0419 gene product	
		R13474	Hs.290263	ESTs, Weakly similar to 138022 hypotheti	3.0
35	416173	R52782		gb:yg99d09.r1 Soares infant brain 1NIB H	3.0
	408155	AB014528	Hs.43133	KIAA0628 gene product	3.0
	453913	AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
	435495	AI754212	Hs.21951	Homo saplens Xq pseudoautosomal region;	3.0
	423629	AW021173	Hs.18612	Homo saplens cDNA: FLJ21909 fls, ctone H	3.0
40		AW901879	Hs.314453		3.0
		D31118	Hs. 191735	hypothetical protein MGC10520	3.0
		AW294795	Hs.198529		3.0
		AA878939	Hs.125406		3.0
		A1375957		F-box only protein 22	3.0
45				hypothetical protein FLJ14681	3.0
43		AA281279	Hs.23317	GPI-anchored metastasis-associated prote	3.0
		NM_014400	Hs.11950		3.0
		AA701259	Hs.189299		3.0
		AJ041793	Hs.42502	ESTS	
		BE175605		gb:RC5-HT0580-100500-022-H07 HT0580 Hom	
50		AW295923		KIAA1843 protein	3.0
	427711	M31659	Hs.180408	solute carrier family 25 (mitochondrial	3.0
	450382	2 AA397658	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3.0
	424866	W01938	Hs.337243	ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
	433043	W57554		hymphoid nuclear protein (LAF-4) mRNA	2.9
55		2 U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.9
-		BE246743	Hs 288529	hypothetical protein FL122635	2.9
	403677			C4001462:nij4887715jgbjAAA79329.2j (L088	2.9
		BE067650		gb:MR4-BT0358-090300-003-e01 BT0358 Hom	
			Un 400040	ESTs, Moderately similar to ALU1_HUMAN A	2.9
C O		5 W87434	115.100013	ESIS, MODERATED SHIRLE TO ALCO IS TOURSELY	2.9
60		7 BE568102	HS.180312	milochondrial ribosomal protein S16	
		Al674818	Hs.316433	Homo sapiens cDNA FLJ11375 fis, clone HE	2.9
		5 AA179949		Homo saplens mRNA; cDNA DKFZp564N0763	(1 Z.Y
		4 AW365665	Hs.120388		2.9
) A1633559	Hs.310359	ESTs	2.9
65	458562	2 N34128	Hs.145268	B ESTs	2.9
	40210			Target Exon ·	2.9
		9 BE501732	Hs.30622	Homo sapiens cDNA FLJ13010 fis, clone NT	2.9

	442205	A10077040	Lie novenno	Name and an abita El 144400 for alone HE	20
		A1827248		Homo sapiens cDNA FLJ11469 fis, clone HE	2.9
		AA249573	ns.102010	ESTs, Moderately similar to ZN91_HUMAN Z	2.9 2.9
	404721	A 10000404	11- 447040	NM_005596*:Homo saplens nuclear factor I	
5		Al208121	ns.14/313	ESTs, Weakly similar to 138022 hypotheti	2.9 2.9
,	401987	AA481282	Hs.190149	NM_002737*:Homo sapiens protein kinase C	29
				20.0	2.9
		A1939339	Hs.146883		2.9
		AW873606	Hs.149006		2.9
10		AW194426	Hs.20726	ESTS	2.9
IV		AI868634	TBLZ40330	ESTs, Weakly similar to T32250 hypotheti	29
	401458	NR4 000470	Lla 404200	Target Exon	
		NM_003478	Hs.101299		2.9
		BE514127	U- 453054	gb:601315974F1 NIH_MGC_8 Homo saplens cD	
15		NM_012288		TRAM-like protein Homo saptens mRNA; cDNA DKFZp434K0514 (I	29
13		BE003760	Hs.55209 Hs.80485	adipose most abundant gene transcript 1	2.9
		D45371	U2'00'5	gb:PMO-HTD425-141299-001-F08 HT0425 Home	
		BE161151	Un CC4AD		2.9
		NM_016122 AA743991	Hs.56148	NY-REN-58 antigen gbony57g01.s1 NCI_CGAP_Pr18 Homo saptens	2.9
20		AI193043	Lie 420006	ESTs, Weakly similar to T17226 hypotheti	2.9
20		Z45439	Hs.270425		2.9
		Y15221		small inducible cytokine subfamily B (Cy	2.9
		AF015592	Hs.28853	CDC7 (cell division cycle 7, S. cerevisi	2.9
		AW452648		activation-induced cytidine deaminase	2.9
25		AW961400		HER2 receptor tyrosine kinase (o-erb-b2,	2.9
23		AA057264		ESTs. Wealty similar to (define not ava	2.9
	401093	AAU31 204	TIS,230930	C12000586*:gij6330167 dbijBAA86477.1] (A	2.9
		Al651474	Hs.163944		2.9
		Al681475	Hs. 200949		2.9
30		AW235786		hypothetical protein MGC10954	2.9
50		AM72078	Hs.303662		29
		BE265067	15550002	gb:601193893F1 NIH_MGC_7 Homo sapiens cD	
	405953			Target Exon	2.8
		AW296927		ob:UI-H-BWO-aic-c-07-0-ULs1 NCI_CGAP_Su	2.8
35		AA846811	Hs 130554	Homo sapiens cDNA: FLJ23089 fis, done L	2.8
33		AA295331		Homo saplens cDNA FLJ20042 fis, clone CO	2.8
		AA243837	Hs.57787	· ·	2.8
		AW206453	Hs.3782	ESTs	2.8
		AW452434	Hs.58006	ESTs, Weakly similar to ALU5_HUMAN ALU S	2.8
40		BE176480		gb:RC3-HT0585-160300-022-c02 HT0585 Homo	2.8
		AL039852	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	28
		Al038997	Hs.132921		2.8
		T97490	Hs.50002	small inducible cytoldine subfamily A (Cy	28
	454545	AW806899		gb:QV4-ST0023-160400-172-c12 ST0023 Homo	2.8
45	439842	Al910896	Hs.132413	ESTs	2.8
	428479	Y00272	Hs.184572	cell division cycle 2, G1 to S and G2 to	2.8
	424800	AL035588	Hs.153203	MyoD family inhibitor	2.8
	411086	BE070800		gb:RC3-BT0502-251199-011-c07 BT0502 Homo	2.8
	400250	NA		Eos Control	2.8
50	449168	NM_016206	Hs.23142	colon carcinoma related protein	2.8
	456482	AA485224		gb:aa41b12.s1 NCL_CGAP_GCB1 Homo sepiens	2.8
	426044	AA502490	Hs.336695		2.8
	431854	AA383550	Hs.271699	polymerase (DNA directed) lota	2.8
				Tomol Evan	2.8
55	405873	NA		Target Exon	
	440400	AA994364		ESTs, Wealdy similar to T25472 hypotheti	2.8
	440400 458265	AA994364 Al075375		ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU	2.8 2.8
	440400 458265	AA994364		ESTs, Wealdy similar to T25472 hypotheti	2.8 2.8
-	440400 458265 413708	AA994364 Al075375		ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROCU gb:1L2-HT0397-091299-025-002 HT0397 Homo	2.8 2.8
	440400 458265 413708 423739 424408	AA994364 Al075375 BE158791 AA398155 AI754813	Hs.128193 Hs.97600 Hs.146428	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1	2.8 2.8 2.8
60	440400 458265 413708 423739 424408	AA994364 AI075375 BE158791 AA398155	Hs.128193 Hs.97600 Hs.146428 Hs.11325	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROCU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs	2.8 2.8 2.8 2.8
60	440400 458265 413708 423739 424408 453096 421825	AA994364 Al075375 BE158791 AA398155 AI754813 AW294631 AA298758	Hs.128193 Hs.97600 Hs.146428 Hs.11325	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gbcll2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs ESTs, Moderately similar to CALB_HUMAN C	2.8 2.8 2.8 2.8 2.8 2.8 2.8
60	440400 458265 413708 423739 424408 453096 421825	AA994364 AI075375 BE158791 AA398155 AI754813 AW294631	Hs.128193 Hs.97600 Hs.146428 Hs.11325	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs ESTs, Moderately similar to CALB_HUMAN C gb:EST22d11 WATM1 Homo saplans cDNA clon	2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8
60	440400 458265 413708 423739 424408 453096 421825 417742 402765	AA994364 AI075375 BE158791 AA398155 AI754813 AW294631 AA298758 R64719	Hs.128193 Hs.97600 Hs.146428 Hs.11325 Hs.183747	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs, Moderately similar to CALB_HUMAN C gb:EST22d11 WATM1 Homo sapians cDNA clon C1003621*gi]12407405[gb]AAG53491.1]AF22	2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8
	440400 458265 413708 423739 424408 453096 421825 417742 402765 444378	AA994364 Al075375 BE158791 AA398155 AI754813 AW294631 AA298758 R84719 R41339	Hs.128193 Hs.97600 Hs.146428 Hs.11325 Hs.183747 Hs.12569	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs ESTs, Moderately similar to CALB_HUMAN C gb:EST22111 WATM1 Homo saplans cDNA clon C1003621*gi 12407405 gb AAG53491.1 AF22 ESTs	2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8
60	440400 458265 413708 423739 424408 453096 421825 417742 402765 444378 419172	AA994364 AI075375 BE158791 AA398155 AI754813 AW294631 AA298758 R64719	Hs.128193 Hs.97600 Hs.146428 Hs.11325 Hs.183747	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROCU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs ESTs, Moderately similar to CALB_HUMAN C gb:EST22d11 WATM1 Homo saplans cDNA clon C1003621*gi]12407405[gb]AAG53491.1]AF22 ESTs ESTs	2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8
	440400 458265 413708 423739 424408 453096 421825 417742 402765 444378	AA994364 Al075375 BE158791 AA398155 AI754813 AW294631 AA298758 R84719 R41339	Hs.128193 Hs.97600 Hs.146428 Hs.11325 Hs.183747 Hs.12569	ESTs, Wealdy similar to T25472 hypotheti ESTs, Wealdy similar to IRX2_HUMAN IROQU gb:IL2-HT0397-091299-025-D02 HT0397 Homo ESTs collagen, type V, alpha 1 ESTs ESTs, Moderately similar to CALB_HUMAN C gb:EST22111 WATM1 Homo saplans cDNA clon C1003621*gi 12407405 gb AAG53491.1 AF22 ESTs	2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8

	405041	NA		C3001706*gli1345652[sp]P15989[CA36_CHIC	2.8
	408758	NM_003686	Hs.47504	exonuclease 1	2.8
	431917	D16181	Hs.2868	peripheral myelin protein 2	2.8
_		AA761190	Hs.244627		2.8
5		AA744862	Hs.194293	ESTs, Wealdy similar to I54374 gene NF2	2.8
	_	AF086325		gitchomo sapiens full length insert cDNA	2.8 2.8
	401283	NA AW803201		Target Exon gb:11.2-UM0077-070500-080-E06 UM0077 Homo	
		NM_014735	Hs.82292	KIAA0215 gene product	2.8
10		AW994005	Hs.337534		28
10		AW291488		Homo sapiens, clone IMAGE:3682908, mRNA	2.8
		AW815098	,	gb:QV4-ST0212-091199-023-f10 ST0212 Homo	2.8
	418629	BE247550	Hs.86859	growth factor receptor-bound protein 7	2.8
	442101	Al651930	Hs.135684	ESTs	2.8
15		AK000375	Hs.88820	HDCMC28P protein	2.8
	414661		Hs.21929	ESTs	2.8
		A1650633		Homo sapiens cDNA: FLJ23031 fis, clone L	2.8
		Al916662		kinectin 1 (kinesin receptor)	2.7
20	_	W23624	Hs.173059 Hs.1395		2.7 2.7
20		NM_000399 BE386870	HS. 1383	early growth response 2 (Krox-20 (Drosop gb:601275271F1 NIH_MGC_20 Homo sapiens c	
	440868		He 263339	ESTs, Moderately similar to 138022 hypot	2.7
		BE247449	Hs.31082	hypothetical protein FLJ10525	2.7
		AV646449	Hs.282872		2.7
25		Al378562	Hs.159585	ESTs	2.7
	430375	AW371048	Hs.93758	H4 histone family, member H	2.7
	406504			C5000558:gi]4504675[ref]NP_002175.1] int	2.7
		AW959861	Hs.290943		2.7
20		NM_004525		low density lipoprotein-related protein	2.7
30		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, comp	2.7 2.7
	423961 422156	D13666	HS.130340	osteoblast specific factor 2 (fasciclin pbcyy56d10.s1 Seares_multiple_sclerosis_	2.1 2.7
		BE314524	Hs.78776	putative transmembrane protein	2.7
		NM_005014	Hs.94070	osteomodulin	2.7
35	406182		,	Target Exon	2.7
	416495		Hs.79350	RYK receptor-like tyrosine kinase	2.7
	444701	AI916512	Hs.198394	ESTs .	2.7
		AA301228	Hs.43299	hypothetical protein FLJ12890	2.7
40		AW968128	Hs.336679		2.7
40		AA128978		hypothetical protein FLJ14917	2.7
		M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	2.7
		BE563085	Hs.833	Interferon-stimulated protein, 15 kDa	2.7 2.7
		AB026264 AA742577	Hs.303781	hypothetical protein IMPACT	2.7
45		AF075079	11000701	gbd-lomo sapiens full length insert cDNA	2.7
		W74653	Hs.271593	ESTs, Moderately similar to A47582 B-cel	2.7
	406153				2.7
	406625	Y13647	Hs.119597	stearoyl-CoA desaturase (delta-9-desatur	27
		AH88139	Hs.147050		2.7
50		Al572739		6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
	429628		Hs.13268	ESTs .	2.7
		AA255920 AA495925	Hs.88095 Hs.9394	ESTs	2.7 2.7
		RF379623	Hs.27693	ESTs peptidytprolyt isomerase (cyclophilin)-l	2.1 2.7
55		A1050073	Hs.135338	ESTs	2.7
<i></i>		Al741320		Homo sapiens dDNA: FLJ23228 fis, done C	2.7
		AA054726	Hs.285574		2.7
	416515			ESTs, Wealdy similar to 138022 hypotheti	2.7
	429922		Hs.226117	H1 histone family, member 0	2.7
60	418203			· · · •	2.7
		AF086332	Hs.58314	ESTs	2.7
•	402184		11- 0cm-10 :	ENSP00000245238*:CDNA FLJ10922 fis, clon	2.7
	450496	AW449251	Hs.257131		2.7
65	451963	A1825440	Hs.224952		2.7
UJ		A1373638 AA938663	Hs.133900 Hs.199828		2.7 2.7
	441041	A1806867	Hs.126594		2.1 2.7

	423020	AA383092	Hs.1608	replication protein A3 (14kD)	2.7
	445354	AV653485	Hs.6390	Homo saptens clone FLB3344 PRO0845 mRNA,	2.7
	427961	AW293165	Hs.143134		2.7
	410889	X91662	Hs.66744	twist (Drosophila) homolog (acrocephalos	2.7
5	445234	AW137636	Hs.146059	ESTs	2.7
	413903	AA496493	Hs.23136	ESTs	2.7
	406069	NA		Target Exon	2.7
		A1470235	Hs.172698		2.7
4.0	401256			NM_024089*:Homo sapiens hypothetical pro	2.7
10	-	AW975942	Hs.48524	ESTs	2.7
		AW958037	Hs.286		2.7
		BE144762	11. 30070	gb:CMD-HT0180-041099-065-b04 HT0180 Homo	
		BE327427	Hs.79953	ESTS	2.6 2.6
15		AA045857	Hs.54943 Hs.5534	fracture callus 1 (rat) homolog Homo sapiens cDNA FLJ12961 fis, done NT	2.6 2.6
13		AL121053 AF160477	Hs.61460	Ig superfamily receptor LNIR	26
		AK001122		hypothetical protein FLJ10260	2.6
		AW893940	Hs.59698	ESTs	26
	-	Z30201		gb:HHEA22G Atrium cDNA library Human hea	2.6
20		D38299	Hs.170917	prostaglandin E receptor 3 (subtype EP3)	2.6
		NM_006456		sialyltransferase	2.6
		AA300900	Hs.98849	ESTs, Moderately similar to AF161511 1 H	2.6
	429208	AA447990	Hs.190478	ESTs	2.6
	430733	AW975920	Hs.283361	ESTs	2.6
25	441720	A1346487	Hs.28739	ESTs	2.6
		AJ123555	Hs.81796	ESTS	2.6
		AW451645	Hs.151504	Homo saplens cDNA FLJ11973 fis, clone HE	2.6
•		AW754311) - 400004	gb:CM1-CT0337-141299-068-07 CT0337 Homo	2.6 2.6
30		AI875944	MS.166691	Homo sapiens cDNA FL/12033 fis, clone HE	2.6
30		M25809 AK002016	NS.04173	ATPase, H transporting, lysosomal (vacuo Homo saplens, clone MGC:16327, mRNA, com	2.6
•		NM_013989		delodinase, iodothyronine, type II	2.6
		AW292286	Hs.255058		2.6
		AA018311	Hs.114762		2.6
35	405822	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Target Exon	2.6
		AW976201	Hs.53913	hypothetical protein FLJ10252	2.6
	417315	Al080042	Hs.336901	ribosomal protein S24	2.6
	434699	AA643687		Homo saplens cDNA FLJ11980 fis, clone HE	2.6
	443204	AW205878	Hs.29643	Homo sapiens cDNA FLJ13103 fis, clone NT	2,6
40	405638			Target Exon	2.6
		AW812256		gb:RC0-ST0174-191099-031-a07 ST0174 Homo	
	403943	707001	11-404400	C5000355:gi 4503225 ref NP_000765.1 cyt	2.6
		Z25884	HS.121463	chloride channel 1 , skeletal muscle (Th	2.6 2.6
45	402800		Hs.233405	Target Exon	2.6
43		AJ989503 AW846080	Hs.314324		2.6
		H03754		wingless-type MMTV integration site famil	2.6
		AW974476		regulator of G-protein signalling 16	2.6
		AA418187	Hs.330515		2.6
50		AK001826	Hs.25245	hypothetical protein FLJ11269	2.6
		BE246010	Hs.271468	Homo saplens mRNA for FLJ00038 protein,	2.6
	455097	AW855802		gb:RC1-CT0279-170200-023-d08 CT0279 Homo	2.6
		AB028955	Hs.175780	KIAA1032 protein	2.6
		NM_015434	Hs.48604	DKFZP434B168 protein	2.6
55		Z47542		small nuclear RNA activating complex, po	2.6
		NM_000163	Hs.125180	growth hormone receptor	2.5
	406271	DEFCC000	11- 7000	Target Exon	2.6
		BE566982	Hs.7063	Homo saptens cDNA: FLJ20913 fis, clone A	2.6 2.6
60		AW016892 Algorests	Hs.100855 Hs.59203		2.6
υU		AI928513 AA121098	Hs.3838	ESTs	2.6
		BE069326	120000	serum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo	
		W24320	Hs 102044	Homo sapiens cDNA: FLU21531 fis, done C	2.6
		X64984	· ros + 46071	githLaptens mRNA HTPCRX10 for olfactory	2.6
65	425101	AA830431	Hs.180811	ESTs	2.6
55		AA668763	Hs.291939		2.6
	409139	A1681917			2.6

	ASS100	BE160198		gb:QV1-HT0413-010200-059-h03 HT0413 Homo	2.6
		BE274552	Hs.76578	protein inhibitor of activated STAT3	2.6
		Al732892			2.6
		AA831267	Hs.12244	hypothetical protein FLJ20097	2.6
5	431473	AA825686	Hs.321176	ESTs, Wealthy similar to S65824 reverse t	2.6
	404440			NM_021048:Homo saptens metanoma antigen,	2.6
	403388			C3001398*:gi 12248917 db BA820375.1 (A	2.6
	403775			Target Exon	2.6 2.6
10	405037			NM_021628*Homo sapiens arachidonate lip qb:Homo sapiens aminopeptidase mRNA, par	2.6
10		AF290544 AA282067	Hs.88972	ESTs, Moderately similar to A46010 X-lin	2.6
		AM202007 AI8772932	113.00372		2.6
		AW516211	Hs.125300	ring finger protein 21, Interferon-respo	26
		AI702885	Hs.145568	<u> </u>	2.6
15		BE391727	Hs.102910	general transcription factor IIH, polype	2.6
	414870	N72264	Hs.300670	KIAA1204 protein	2.6
	457411	AW085961	Hs.130093		2.6
		Y08565	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6 2.6
20	404443		11- 00777	C8001428*;gij6572242jembjCAB62951.1] (Z9	2.6
20		NM_003512	Hs.28777	H2A histone family, member L ESTs, Weakly similar to JE0350 Anterior	26
		AI073913 AI192105	Hs.147170		2.6
		AW963372	Hs.46677	PRO2000 protein	2.6
		F13036	Hs.27373	Homo sapiens mRNA; cDNA DKFZp564O1763 (2.6
25		R36075		gbcyh88b01.s1 Soares placenta Nb2HP Homo	2.6
		AW081681		ESTs, Weakly similar to T42689 hypotheti	2.6
		NIM_000169	Hs.69089	galactosidase, alpha	2.6
		S70284		gb:stearoyl-CoA desaturase [human, adipo	2.6 2.6
20		H62943	Hs.154188	gb:RC2-BT0318-110100-012-g12 BT0318 Homo	
30		BE065837	No 12/027	SELENOPHOSPHATE SYNTHETASE; Human	selen2.6
		NM_012247 A)538613		Transmembrane protease, serine 3	2.5
		AF012023	Hs.173274	integrin cytoplasmic domain-essociated p	2.5
		AK001058	Hs.12680	Homo saplens cDNA FLJ10196 ffs, clone HE	2.5
35		BE245652		zinc finger protein 266	2.5
	428330	L22524	Hs.2256	matrix metalloprotelnase 7 (MMP7; uterln	2.5
		AB020641	Hs.57856	PFTAIRE protein kinase 1	2.5 2.5
		NW_000909	Hs.169266	neuropeptide Y receptor Y1	2.5 2.5
40		AW973708	Hs.122897	Homo sapiens cDNA FLJ13446 fis, clone PL	2.5
40		AA767881 AK001741	Hs.8739	hypothetical protein FLJ10879	2.5
		AL042306	Hs.97689	VASA protein	25
		AW628666	Hs.98440	ESTs, Wealty similar to 138022 hypotheti	2.5
		AK002032		Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45	455732	BE080908		gb:QV1-BT0631-280200-084-h07 BT0631 Homo	2.5
		Al362790		KIAA1684 protein; likely homolog of mous	2.5
		BE394723		S100 calcium-binding protein A6 (calcycl	2.5 2.5
		NM_002318	Hs.83354	lysyl oxidase-like 2 hypothetical protein FLJ13046 similar to	2.5
50		AW375610 AM24899	Hs.188211		2.5
30		BE091089	1100100211	gb:PM4-BT0724-130400-006-c07 BT0724 Homo	2.5
		U64820	Hs.66521	Machado-Joseph disease (spinocerabellar	2.5
		AW972565	Hs.32399	ESTs, Wealdy similar to S51797 vasodilat	2.5
	440029	AW089705		ESTs, Wealdy similar to S64329 probable	2.5
55		A)471598	Hs.197531	ESTS	2.5
		AA065081	Un 44000	gbczm13e03.s1 Stratagene pancreas (93720	2.5 2.5
		BE178536	Hs.11090	membrane-spanning 4-domains, subfamily A prostate cancer associated protein 1	2.5 2.5
		AF109298 AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.5
60		BE158687	: 10,07 00	gb:CM0-HT0395-280100-169-b09 HT0395 Hom	
-		AW953168	Hs.12407	ESTs	2.5
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	2.5
	404826	i		Target Exon	2.5
~ =	422938	NM_001809	Hs.1594	centromere protein A (17kD)	2.5
65	421991	NM_014918		KIAA0990 protein	2.5 2.5
	417404	NM_007350	Hs.82101	pleckstrin homology-like domain, family gb:RC1-NN0073-260400-011-g09 NN0073 Hom	
	448516	AW898595		And to the test of	

	403356	NA			2.5
	404983				2.5
		AA215535		20.0	2.5
_	427409	AW467143	Hs.135411		2.5
5		AF186114			25
		AW071349	Hs.215937		2.5
		AW582962		OC. II Protoni	2.5
		AF086041	Hs.42975		2.5 2.5
10	400925				
10	404552		1)- 04976	ENSP00000220888*:ZINC FINGER TRANSCRIP Homo sapiens mRNA; cDNA DKFZp586L1121 (f	112. 25
		AL133117:			2.5
		NM_002332	Hs.89137		2.5
	426853			opposition and report annual series	2.5
15		NM_000318	Hs.15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (f	
13		AA501760 Al271898	Hs.164866		2.5
		AW813428	115.10-1000	gbcMR3-ST0192-010200-210-c05 ST0192 Homo	
		AA641876	Hs.191840		2.5
	402077		113.131010	Target Exon	2.5
20		X07820	Hs.2258		2.5
20		AW885757	Hs.257862		2.5
•		T27308	Hs.16986	hypothetical protein FLJ11046	2.5
		AJ807894	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr	25
		A1024353		hypothetical protein FLJ14298	2.5
25		AA059013	Hs.22607	ESTs	2.5
		AA122393	Hs.70811	hypothetical protein FLJ20516	2.5
	426504	AW162919	Hs.170160	RAB2, member RAS oncogene family-like	2.5
		A1128772	Hs.40479	ESTs	2.5
		A1580090	Hs.48295	RNA helicase family	2.5
30		N80077	Hs.24792	chromosome 12 open reading frame 5	2.5
		AA449644		Homo saplens cDNA FLJ14201 fis, clone NT	2.5 2.5
		AW297921	Hs.255703		2.5
		AA256769	Hs.94949	methylmalonyl-CoA epimerase	2.5
25		AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein tally acid symihase	2.5
35		U29344 AA356923	Hs.83190	nuclear cap binding protein subunit 2, 2	2.5
		AL039402		DEME-6 protein	2.5
•		N52639	Hs.32683	ESTS	2.5
		AI743977	Hs.205144		2.5
40		AA740875	Hs.44307	ESTs, Moderately similar to 138022 hypot	2.5
,,		AW500507		KIAA1600 protein	2.5
		AI920783	Hs.191435	ESTS	2.5
	408877	AA479033	Hs.130315	ESTs, Wealdy similar to A47582 B-cell gr	2.5
	445150	AJ446747	Hs.338704	olfactory receptor, family 7, subfamily	2.5
45	407756	AA116021	Hs.38260	ubiquitin specific protease 18	2.5
	407633	NM_007069	Hs.37189	similar to rat HREV107	2.5
		H00820	Hs.30977	ESTs, Wealty similar to B34087 hypotheti	2.5
		AA236255	Hs.298419		2.5
		H20669	Hs.35406	ESTs, Highly similar to unnamed protein	25
50		AL046412	Hs.202151		2.5 2.5
		AI640355	Hs.312691		2.5
		AW298631	Hs.27721	Wolf-Hirschhom syndrome candidate 1-lik	2.5
		AI937547	MS. 1249 10	hypothetical protein MGC2601 gb:QV2-LT0038-270300-108-d12 LT0038 Homo	
55		AW837349 AA843719	Hs.122341		2.5
<i>JJ</i>	408414		113.122271	C5000506*gij124941 spjP18614 jTA1_RAT i	2.5
		AB033043	He 149377	hypothetical protein DKFZp761L0424	25
		BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	
		AA347746	Hs.9521	ESTs, Wealth similar to ZN43_HUMAN ZINC	2.5
60		BE159984	Hs.125395	ESTs	2.5
		AA635062	Hs.50094	Homo sapiens mRNA; cDNA DKFZp43400515 (
		D86983		Melanoma associated gene	2.5
		AL135623		KIAA0575 gene product	2.5
		AA442324	Hs.795	H2A histone family, member O	2.5
65		D13752		cytochrome P450, subfamily XIB (steroid	2.5
		AA081395	Hs.42173	Homo saplens cDNA FLJ10366 fis, clone NT	2.5
	403433			Tarnet Exon	2.5

413189	BE070231		gb:QV4-BT0407-260100-087-f12 BT0407 Homo	2
400346	AB041269	Hs.272263	Homo sapiens mRNA for keratin 19, partia	2.
435509	AI458679	Hs.181915	ESTs	2.
458145	A1239457	Hs.130794	ESTs	2.

TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Unique Eos probeset Identifier number

Pkey: CAT number: Accession:

Gene cluster number Genbank accession numbers

15

10

5

	Pikey	CAT number	Accessions
	407647	1007366_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062666
20	407980	103087 1	AAN46309 A1263500 AA046397
	408254	1049346_1	AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801
			AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424
			AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390
			AW807395 AW845789 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098
25			AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807166 AW807501
			AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807158 AW845800
			AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141
			AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211 AW807498 AW807086 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807087 AW845784
20			AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160
30			AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103
			AW845870 AW177099 AW177101 AW807528 AW807338 AW807038 AW177100 AW807411 AW807088 AW845865
			AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521
			AW807488 AW807385 AW807223 AW807125
35	409163	110418_1	AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457
55	103100		AAD64704 AA082878 AA075742 AA069182
	409695	114876 1	AA296961 AA296889 AA076945 AA077528 AA077497
	410534	1207247_1	AW905138 AW753008 R13818 Z43519
	410672	1214882_1	AW794600 AW794730 g
40	410784	1221005_1	AW803201 BE079700 BE062940
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
	410835	1223785_1	AW806906 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604 AW814902 BE156656 BE156667 BE156590 BE156441 BE156447
	411050	1230330_1	AVIV149U2 BE130000 BE130007 BE130090 BE130091 BE130097 BE1370800 AWIX75228 BE149115
45	411086	1231500_1 1231970_1	BED67650 AW817053
43	411093 411111	1231970_1	AW818127 AW818161 R09719
	411171	1234393_1	AWR20260 AWR20332 R94406 ·
•	411337	1239217 1	AW837349 AW837355 AW882717
	411514	1248638_1	AW850178 AW850233 AW850445 AW850446
50	411670	1253680_1	AW856552 AW881101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562
	411905	1265181_1	BE265067 BE264978 AW875420
	412102	1277395_1	H56435 H56572 AW892929
	412209	1283610_1	AW901456 AW901450 AW901441
	412248	1285000_1	BE176480 AW903298 AW903313
55	413043	1346556_1	BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678 BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065789 BE065792
	413111	1349546_1	BE070231 BE070229 BE070255
	413189 413221	1352723_1 1353887 1	BE161151 BE162495 BE161002 BE072205 BE160989 BE162482
	413499	1373910_1	BE144884 H97942
60	413708	1384140 1	BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685
UU	414210	1426051 1	BE383592 BE281671
	414596	1465004_1	BE386870 Z41986 H08501

```
414605
                 1465790_-1
                             RE300440
                              AA381209 AA381245 AA167683
        415747
                 155189_1
        416173
                 1574973_1
                              R52782 R17313 H24192 R19876
                 1696282_1
                              R64719 Z44680 R12451
        417742
 5
                 171237_1
                              AA210765 T95700 H94407
       417974
                              AW749855 AA225995 AW750208 AW750206
        418636
                 177402_1
                              AA603305 AA244095 AA244183
        419536
                 185688_1
                              AW296927 Al684514 Al263168 AA281079
        420854
                 197072_1
                              N34524 AA305071 AW954803 AA502335 AI433430 AI203597 AW026670 AW265323 AW850787 AA317554 AW993643
        422156
                 212379_1
10
                              AW835572 AW385512 AK334968 W32951 H62656 H53902 R88904 AW835732
                              BED91089 BE091123 AA319959
        422996
                 223666_1
                              AW503329 N46610 AA331571
        423833
                 232451_1
                              AW753967 AA370795 AA331630 AW962550
        423841
                 232507_1
                              AA410943 AW948953 AA334202 AA332882
        423945
                 233566_1
                              AA352111 AW962247 AA429695
15
        425201
                 247933_1
                              AA382814 AA402411 AA412355
        426650
                 270283_1
                              BE069341 AW748403 AL044891 AI908240 AA393080
                 273265_1
        426878
                              AA470519 BE303010 BE302954 BE384120
        430264
                 315008_1
                              Z30201 AA486132 T72025
        430785
                 323486_1
20
        431676
                 336411_1
                              A1685464 AW971336 AA513587 AA525142
                 373061_1
                              AA743991 AA604852 AW272737
        433687
                              AW754311 AA630185 AW803285
        434338
                 383982_1
                              AA634806 C18732 AA729161 AA729860
        434469
                 387447_1
                  406400_1
                              AI872932 AA682306 BE220163 W88695 T81307 H91447
        435447
                              AL050027 BE089051
25
        437152
                  43386_1
                              AL119723 AL119874 Al909018 U50537
                  44418_1
        437854
                              AF075079 H48601 H48795
        439031
                  46798 1
                              BE164500 AA832198 BE164502
                  470321_1
        439255
        444910
                 624951_1
                              Al201849 BE069007 AW946544
30
                 63943_1
                              AV653771 BE089370
        445432
                 69865_1
                              BE175605 Z43529 F06610 BE175602 AV661027
        446922
                              R36075 Al366546 R36167
        447197
                 711623_1
                              BE623004 AA380669 BE263627 BE246433
        448420
                  76273_1
                              AW898595 AW898588 AW898590 AW898663 AW898592 AI525093
        448516
                  766241_1
35
                              Al698839 Al909260 Al909259
        450522
                  837264 1
                 844652_1
                              AW970060 AI732368 AI792313 AW839644
        450736
                              AA442176 AA259181
                  85565_1
        451024
                              BE172186 AA059279 AA020815 AA013437
                  85759_1
        451057
                              AW936273 AW340350 AA017208
        451340
                  86640_1
40
                              AW812256 AW812257 Al906423 Al906422
        452542
                  921410_1
        452564
                              AA026777 N50065 R09961 N54721
                  92227_1
                  968371_1
                              AL037925 AL037931 AL037957
        453472
                  1106070_1
                              AW855717 AW382452 AW362443
        454307
                              N71277 AW390764
                  1130674_1
        454359
                              AW806899 AW866451 AW866393 AW866297 AW817869
45
                  1223779_1
        454545
                              AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
        454693
                  1229132_1
                              AW815098 BE154843 BE154831
        454714
                  1230493 1
                              AW852530 AW852527 AW852526
        455047
                  1250536_1
                              BE152428 AW855572 AW855607
        455092
                  1252971_1
                              AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
50
                  1253130_1
        455097
                              BE160198 AW935898 T11520 AW935930 AW856073 AW861034
                  1253334_1
        455100
                              AW938484 BE001245 BE001190
        455431
                  1289854_1
                              BE144762 AW979091
        455511
                  1321229_1
                              BED11668 BED11689 BED11627 BED11679 BED11699 BED11678 BED11696 BED11675 BED11622 BED11635
                  1337548_1
        455609
                              BE064962 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
55
                  1348732_1
        455651
                              BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
        455685
                  1350393 1
                              BE066976 BE066928 BE066927
                              BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198
                  1351264_1
        455700
                              BE069326 BE069290 BE069352
        455708
                  1352232_1
                              BE080908 BE072258 BE072190 BE072236
60
                  1353874_1
        455732
        455838
                  1374605_1
                              BE145808 BE145807 BE181883
        455935
                  1384144_1
                              BE158687 BE158688
        455945
                  1385588_1
                              BE160636 BE160606 BE160703
                  165078_-1
                              AA193450
        456207
                              AA485224 AA287308 AA258121
65
                  192289_1
        456482
        458094
                  47311_1
                               AF086325 W72956 W73221 AA219112
                              N99626 Al302701
        458673
                  679507_1
```

TABLE 19B

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkev:		Unique	number corresponding to an Eos probeset
10	Ref:	S	equence so	urce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
			entitied	"The DNA sequence of human chromosome 22." Dunham L et al., Nature (1999) 402:489-495.
	Strand;			es DNA strand from which exons were predicted.
	Nt_positi	ion:	Indicat	es nucleotide positions of predicted exons.
15				
				MA was fell on
	Pkey	Ref	Strand	Nt_position
	400555	9801191	Minus	134694-134817
20		9887666	Minus	96756-97558
	400610	9887671	Minus	117606-117928,124040-124147
	400925	7651921	Plus	38183-38391,43900-44086
	401045	8117619	Plus	90044-80184,91111-91345
	401049	7232177	Phis	149157-150692
25	401093	8516137	Minus	22335-23166
	401256	9796573	Minus	45482-45620
	401283	9800093	Minus	47256-47456
		9212516	Minus	226246-227505
	401418	7452889	Minus	124865-125075
30		6634068	Minus	119926-121272
	401458	9187886	Plus	76485-77597
	401497	7381770	Plus	92607-92813
		7534110	Minus ·	110779-110983
		7229804	Minus	76253-76364
35	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-
				131258,131866-131932,132451-132575,133580-134011
		7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
		7249190	Minus	165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942
		7263888	Minus	102945-103083
40		4406829	Minus	72893-73021,76938-77049
		8117414	Plus	65014-65195
		8131678	Minus	171722-171859,173197-173303
		8576001	Minus	112844-112986,113505-113636
45		9625329	Minus	21753-22385
45		9796341	Minus	46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924
		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		7328818	Minus	23500-23731
50		9367757	Plus	109588-109726
20		6010175	Plus	43921-44049,46181-46273
		6456853	Minus	82274-82443 194384-194645
		8086844	Minus	38314-38634
		7331427 8569930	Plus	92839-63036
55			Plus	112733-113001,114599-114735
22		9438331 9719529	Ptus Minus	157156-158183
			*******	131266-131769
		8101208 6862650	Minus Minus	62554-62712,69449-69602
		8671936	Minus	142647-142771,145531-145762
60		8671948	Plus	13234-113326,115188-115287,119649-119786
W		7331517	Pius Minus	55008-55083,62860-63051
		7770580	Minus	102247-102326,103095-103148
			Milnus Plus	100742-100904,101322-101503
	403943	7711864	rius	1007-92-10030-0-10-1000-0-10-1000-0-10-1000-0-10-1000-0-10-1

```
82121-83229
        404091 7684554
                         Minus
        404097 7770701
                         Phys
                                   55512-55781
        404142 9856692
                                   80316-80459
                         Minus
        404253 9367202
                                   55675-56055
                         Minus
 5
        404274 9885189
                                    104127-104318
                         Plus
        404285 2326514
                         Plus
                                   32282-32416
        404360 9858450
                         Minus
                                   122873-122966,151324-151469,153093-153253
        404440 7528051
                                   80430-81581
                         Plus
        404443 7579073
                                   87198-87441
                         Minus
        404552 7243881
10
                         Phis
                                    19854-20010
                                   69039-70100
        404561 9795980
                         Minus
        404580 6539738
                         Minus
                                   240588-241589
        404721 9856648
                                    173763-174294
                         Minus
        404826 6572184
                                   47726-48046
                         Plus
        404983 4432779
15
                                   51178-51374,52000-52173
                         Minus
                                    127374-127578
        405037 7543748
                         Minus
        405041 7547195
                                    121230-121714
                         Plus
        405095 8072599
                         Plus
                                    138877-139066
        405153 9965565
                         Minus
                                    175317-175500
20
        405196 7230083
                         Minus
                                    135716-135851
                                    125904-126063
        405232 7249042
                         Phis
        405248 7259728
                                    637-777
                         Phis
                                   33267-33563
        405336 6094635
                         Plus
        405394 6624123
                         Minus
                                   31900-32373
25
        405460 7684569
                         Minus
                                    52223-52389
        405494 8050952
                                   70284-70518
                         Minus
                                    124361-124520,124914-125050
        405547 1054740
                         Plus
                                    42814-43010,43583-43783,44863-45033,46429-46554,47815-48018,49961-50153,51624-51727,51823-51959,52702-
        405609 5757553
                         Minus
                                   52918.55469-55601.57111-57307.58169-58296,60215-60332,61482-61727
30
                                    199260-199372,199826-199929
        405638 6289229
                         Plus
                                    53624-53759
        405654 4895155
                         Minus
        405718 9795467
                                    113080-113266
                         Plus
        405822 6273498
                         Minus
                                    154660-154974,155203-155379
        405848 7651809
                         Minus
                                   28135-28244
35
                                   32129-32764
        405873 6758747
                         Minus
                                    10835-11059
                         Minus
        405906 7705124
                                    106829-107213
        405917 7712162
                          Minus
        405925 6758795
                         Plus
                                    129935-130282
        405953 7960374
                         Minus
                                    65101-65574
40
        406069 9117732
                                   68880-69374
                         Plus
                                   94087-94285
        406151 7144806
                         Minus
        406153 9929734
                                    12902-13069
                         Minus
                         Minus
                                    28256-28935
        406182 5923650
                                    36179-36692
        406271 7534217
                         Plus
                                   9562-9867
45
        406291 5686274
                         Phrs
                                   71754-71944
        406348 9255985
                         Minus
        406414 9256407
                         Plus
                                    49593-49850
        406446 9454509
                         Minus
                                    116424-116527,118721-118859,121187-121364
        406504 7711360
                                    107068-107277
                         Minus
50
                                    106956-107121
        406554 7711566
                         Plus
```

WO 02/059377

TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

5

Pkey: ExAcon: Unique Eos probeset Identifier number

Exemplar Accession number, Genbank accession number

Unigene number UnigenelD:

20 Predicted Protein Domains Pred.Prot.Domains:

Unigene Title: Unigene gene title

Ratio of 93rd percentile of turnor to 85th percentile of normal body tissue

25	Pkey	ExAccn	UnigenelD	Pred.Prot.Domains	UnigeneTitle	R1
	408591	AF015224	Hs.46452	SS,Uteroglobin,SS,Uteroglobin	mammaglobin 1	168.6
		AA401369			ESTs	73.2
		Al668594	Hs.176588	,SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
30		AW170035		TM	Homo sapiens breast cancer antigen NY-BR	57.6
		AA250737		death_ZU5,TM_Activin_recp_pkinase,	BMP-R1B	55.9
		U31875	Hs.272499	,SS,TM	short-chain alcohol dehydrogenase family	53.8
		BE069341		TM	gb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
		NM_000236	OHs.194236	SS.Leptin.SS.Leptin.	leptin (murine obesity homolog)	40.8
35 '		AA195651		.SS.Dihydroorotase.	ESTs	39.3
		L11690	Hs.620	Plectin_repeat.SH3.spectrin_SS,Plectin_r	bullous pemphigoid antigen 1 (230/240kD)	37.3
		D31152	Hs.179729	SS,C1g,Collagen,SS,C1g,Collagen,	collagen, type X, alpha 1 (Schmid metaph	35.2
		AJ224172	Hs.204096	,SS,Uteroglobin,	lipophilin B (uteroglobin family member)	30.0
		AA009647		,SS,TM,disintegrin,Pep_M12B_propep,Repro	a disintegrin and metalloproteinase doma	25.7
40	420931	AF044197	Hs.100431	SS, B.B.SS	small inducible cytokine B subfamily (Cy	25.2
	422109	S73265	Hs.1473	SS_Bombesin,SS	gastrin-releasing peptide	24.8
		AI624342	Hs.170042	.SS.TM.Cation_efflux	ESTS	24.1
		AI955040	Hs.265396	SS	ESTs, Wealdy similar to transformation-r	24.0
	400297	Al127076	Hs.334473	TM	hypothetical protein DKFZp564O1278	23.8
45		X51501	Hs.99949	SS.SS	protactin-induced protein	22.8
	452744	A1267652	Hs.30504	,SS,TM,GNS1_SUR4,cNMP_binding,Rila	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
	424634	NM 00361	3Hs.151407	in tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
	420757	X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
		Al905687	Hs.2533	SS	aldehyde dahydrogenase 9 family, member	20.3
50		Al375572	Hs.172634	.pkinase.	ESTs	19.2
	456207	AA193450		.SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
	431448	AL137517	Hs.334473	TM	hypothetical protein DKFZp564O1278	18.2
	427217	AA399272	Hs.144341	SS	ESTs	18.2
	456938	X52509	Hs.161640	.SS.TM.aminotran_1_2,Cadherin_C_term,cad	i tyrosine aminotransferase	18.1
55	435496	AW840171	Hs.265398	SS	ESTs, Wealdy similar to transformation-r	17.9
	402578			SS,p450,SS,TM,p450	C1001134:qi[2117372[pir]][65981 falty ac	17.8
		A1263307	Hs.239884	SS	H2B histone family, member L	17.8
		AL120862		SS	programmed cell death 9 (PDCD9)	17.7
	444342	NM_01439	8Hs.10887	Lamp,SS,TM,Lamp,	similar to lysosome-associated membrane	17.5

	449765	N92293	Hs.206832	SS	ESTs, Moderately similar to ALU8_HUMAN A	17.3
		AA321649		SS,IL8,	small inducible cytokine subfamily B (CX	17.0
		D90041	Hs.155956	,SS,Acetyltranst2,	N-acetyltransferase 1 (arylamine N-acety	16.7
,,		W67883	Hs.137476	,planase,	paternally expressed 10	16.5
5		AB014544		LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.3
		D60730	Hs.57471	SS	ESTs 4 0 0 0 0 1	16.2
			Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase		15.7
		AA296520		SS,lectin_c,sushl,EGF,SS,EGF,lectin_c,su	selectin E (endothelial adhesion molecul	15.5
10		AA441838		SS ON OUR VIEW	hypothetical protein FLJ 14834	15.5
10		NM_007115		,SS,CUB,Xiink,	tumor necrosis factor, alpha-induced pro	15.0 14.9
		H44186	Hs.15456	PDZ,SS	PDZ domain containing 1	14.8 14.8
		AA236115 U65011		SS cc cc	ESTs preferentially expressed antigen in mela	14.7
		AA436989	Hs.30743	SS,SS histone,SS,histone,histone	H2A histone family, member A	14.3
15		AL035414		SS	hypothetical protein .	14.2
13		Al199268		,SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
		W20027	Hs.23439	,SS,Pepiidase_M1,	ESTs	13.9
		Al082692		,SS,TM,SNF	ESTs	13.7
		AA031956	113, 13, 10	SSLIM	gbczk15e04.s1 Soares_pregnant_uterus_NbH	13.7
20		AI733682	Hs 130239	SS	ESTs	13.5
LU		X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
		BE336654		histone, SS, histone, histone	H3 histone family, member A	13.3
		AA948033		,SS,histone,histone,linker_histone	ESTs	13.2
		AA706910		,SS,Ribosomal_L7Ae,	ESTs	13.1
25		AI951118		TM	Homo saplens breast cancer antigen NY-BR	13.1
	443348	AW873596	Hs.182278	,SS,DENN	calmodulin 2 (phosphorylase klnase, delt	13.0
	421037	A1684808	Hs.197653	SS	programmed cell death 9 (PDCD9)	12.9
	424086	Al351010	Hs.102267	,SS,Lysyl_oxidase	lysyl oxidase	12.8
	400295	W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
30		N78223	Hs.108106	,SS,G9a,PHD,	transcription factor	12.5
		A1873274		TM	ESTs	12.4
		AF026944		,SS,TPR	ESTs	12.3
		AA576953		SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	12.0
25		AJ224741		SS,EGF,vwa,SS,TM,vwa,	matriin 3	11.9
35		AW732573		TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		BE007371		,SS,TM,Folate_carrier	ESTs ESTs	11.9 11.8
		Al357412		SSd culdens Aldress coin Februares S	lysyl oxidase	11.8
		H87879 NM_002497	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S pkinase,SS,TM,pkinase,polypremyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40		AL049689		SS SS TWITHINGS TO SHELL STUT	hypothetical protein similar to tenascin	11.6
70		R28363	Hs.24286	,SS,TM,7tm_1,p450,rrm	ESTs	11.5
		Al907673	I KAZTZOO	pkinase,	gb:ttBT152-080399-004 BT152 Homo saplen	11.5
		AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.rl Soares ovary tumor NbHOT H	11.4
		AL360204	Hs.283853	SS	Homo sapiens mRNA full length insert cDN	11.4
45	402606			SS	NM_024626:Homo sapiens hypothetical prot	11.3
	445263	H57646	Hs.42586	,SS,Acyliransferase,	KIAA1560 protein	11.2
	430217	N47863	Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24	ie,ribosomal protein S24	11.1
	447164	AF026941	Hs.17518	,TM,IBR	Homo saplens cig5 mRNA, partial sequence	11.1
	431385	BE178536	Hs.11090	,SS,TM	membrane-spanning 4-domains, subfamily A	11.1
50	423887	AL080207	Hs.134585	,SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
	415385	R17798	Hs.7535	,SS,Fork_head,	COBW-like protein	10.9
•	425704		Hs.159264	SS	Human clone 23948 mRNA sequence	10.7
		NM_007050		,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
		AB007948		,SS,laminin_B,laminin_EGF,laminin_Nterm	KIAA0479 protein	10.3
55		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
		NM_000685		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
	422026		Hs.110826	SS - No. of the same	trinucleotide repeat containing 9	10.3
		AL120173 AW016531		,SS,pkinase,	ESTs ESTs	10.3 10.2
60	400608	MMO10001	NS. 122 147	,SS,ArfGap,	C10001899:gi[7508633 pht][T25392 hypothe	10.2
UU		BE242870	He 75270	SS,TM,SS,TM	solute carrier family 1 (glia) high affi	10.0
		W68815	Hs.301885	SS SS	Homo sapiens cDNA FLJ11346 fis, clone PL	9.9
	402408		1 2201003	.SS.carb anhydrase	NIM_030920*;Homo saptens trypothetical pro	9.8
		AJ245671	Hs 12844	,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65			Hs.26770	SS, lipocalin, lipocalin,	fatty acid binding protein 7, brain	9.6
00	405654			BTB,SS	C12001521pji7513934 pirj[T31081 cca3 pr	9.6
		AI418055	Hs.161160	SS	ESTs	9.6
					•	

	416220		Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
		M30703	Hs.270833	SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
		AW368397		,SS,UDPGT	Homo saplens cDNA FLJ14438 fis, clone HE	9.4
_		AA032279		TM_	six transmembrane epithelial antigen of	9.4
5		AA279490		SS,TM,calreticutin,SS,TM,calreticutin,	calmegin	9.4
		AI733881		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4
		AA291377		TM	ESTs	9,3
		Al678059		SS	synaptonemal complex protein 2	9.3
10		AI820662		SS	ESTs	9.1
10		X73114	Hs.169849	,SS,TM,fn3,fg,	myosin-binding protein C, slow-type	9.1
		M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase		9.1
		AW004854		SS	hypothetical protein FLJ23537	9.1
		AB041035		Ferric_reduct, TM, Ferric_reduct,	NM_016931:Homo saplens NADPH oxidase 4 (9.1
	426214		Hs. 128355	SS	ESTs, Moderately striitar to ALU7_HUMAN A	9.0
15		A1798680		,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
		X72755	Hs.77367	SS,IL8,SS,IL8	monoidine induced by gamma interferon	8.8
	400285			,TM,ABC_tran,ABC_membrane,	Eos Control	8.8
			Hs.115263	SS,TM,EGF,SS,TM	epiregulin	8.8
~~	416182	NM_004354	Hs.79069	cyclin,SS	cyclin G2	8.8
20		AW512260		SS	ESTs	8.7
		T93500	Hs.28792	,SS,TGF-beta,TGFb_propeptide,	Homo sapiens cDNA FLJ11041 fis, clone PL	8.7
		AA642007		SS	ESTs	8.6
		AF123050		,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6
~~		AJ732643		TM	ESTs	8.6
25		A1222020		SS,SS	CoccaCrisp	8.5
		BE622641			mis_reESTs, Weakly similar to 138022 hypotheti	8.5
		H69125	Hs.133525	,SS,TM	ESTs	8.5
		NM_00452		SS,EGF,kdl_recept_a,kdl_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
	426215	AW963419	Hs.155223	SS .	stannlocalcin 2	8.4
30		AA635062		TM	Homo saplens mRNA; cDNA DKFZp434O0515 (f	8.4
	435525	AJ831297	Hs.123310	TMI .	ESTs	8.3
	409203	AA780473	Hs.687	SS,p450,SS,p450	cylochrome P450, subfamily IVB, polypept	8.3
		NM_003866	5Hs.153687	SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
		X65724	Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
35		R45154	Hs.106604	,death,ZL15,pklnase,Activin_recp,	ESTs	8.3
	439840	AW449211		SS	GDNF family receptor alpha 1	8.2
		M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_N		8.2
		AA280627		SS,cpn10	ESTs	8.2
40		W47595	Hs.169300	SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		,SS,kazal,	ESTS	8.1
		AW419196		SS	hypothetical protein FLJ13782	8.1
		AW248508	Hs.279727	SS	Homo saplens cDNA FLJ14035 ffs, clone HE	8.0
	404347			SS	Target Exon	8.0
		AA743991		TM	gbmy57g01,s1 NCI_CGAP_Pr18 Homo saplens	8.0
45		AA808229		,ss,impdH_c,impdH_n,cbs	ESTs	8.0
		NM_016010		SS	CGI-62 protein	7.9
		X70697	Hs.553	TM,SNF,SS,TM,SNF,	solute carrier family 6 (neurotransmitte	7.9
		N39015	Hs.190368	,SS,TM	ESTs	7.8
		AL138272		,TM,cpn60_TCP1,Sema,	ESTs	7.8
50		AJ085198		,TSPN,vwc,tsp_1,EGF,thiored,	ESTs	7.8
		Al754693		,TM,cadherin,Cadherin_C_term,	ESTs	7.7
		AW207523		,SS,rm,	ESTs	7.6
		AL133731			Homo sapiens mRNA; cDNA DKFZp761C1712 (f	7.6
		AI742605		TM .	ESTs	7.6
55		AW207206		SS	ESTs	7.6
		AK000713		,SS,UDPGT	hypothetical protein FLJ20706	7.5
		AL031224	Hs.33102	SS,SS	transcription factor AP-2 beta (activati	7.5
		R41396	Hs.101774	SS	hypothetical protein FLJ23045	7.5
		AA157291		SS	ubhuciein 1	7.5
60		U41060	Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065		,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
		Al742170	Hs.31297	,SS,TM	duodenal cytochrome b	7.4
		Al240665	Hs.8895	,SS,TM,disIntegrin,Pep_M12B_propep,Repro		7.3
		U22376	Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65		R43646	Hs.12422	SS	ESTs	7.2
	422867		Hs.1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
	418004	U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2

	426451 AI908165	Hs.169946	SS,GATA,	GATA-binding protein 3 (T-ceil receptor	7.1
	450701 H39960	Hs.288467	,SS,LRR	Homo saplens cDNA FLJ12280 fls, clone MA	7.1
	419519 Al198719	Hs.176376	SS	ESTs	7.1
	410555 U92649		,TM,disintegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
5	433138 AB029496		SS, ig, Sema, SS, Sema, ethand	semaphorin sem2	7.0
	411558 AA102670		SS,TM,SS,TM	gamma-aminobutyric acid (GABA) A recepto	7.0
	409079 W87707		,TM,fn3,	interleukin 6 signal transducer (gp130,	7.0
	417275 X83578	Hs.295449	SS,ethand,SS,ethand,ras	parvalbumin	7.0
4.0	432731 R31178	Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10	442818 AK001741		WD40,SS	hypothetical protein FLJ10879	6.9
	407366 AF026942		,TM,IBR	gbd·lomo saplens dig33 mRNA, partial sequ	6.8
	427427 AF077345		SS, lectin_c, SS	ESTS	6.8
	410785 AW803341		SS	gbdt_2-UM0079-090300-050-D03 UM0079 Homo	6.7
15	401045	36-367E3770L	ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE	p 6.7	
13		••	#[NP_033938.1] c	ESTs	6.7
	418986 Al123555 442082 R41823	Hs.7413	,SS,Reprolysin,isp_1, ,TM,EPH_lbd,pkinase,SAM,in3,	ESTs; calsyntenin-2	6.7
	442861 AA243837		SS	ESTS .	6.6
	418836 AI655499		,TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
20	422060 R20893	Hs.325823	SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	6.6
20	444381 BE387335		,SS,mito_carr	ESTs, Weakly similar to S64054 hypotheti	6.6
	404091 NA	1220110	,TM,7tm_3,ANF_receptor,	Target Exon	6.6
	417866 AW067903	Hs 82772	SS, Collagen, COLFI, TSPN, SS, TSPN	collagen, type XI, alpha 1	6.6
	428819 AL135623		SS,SS	KIAA0575 gene product	6.5
25	410275 U85658	Hs.61796	,SS,Ribosomai_S4e	transcription factor AP-2 gamma (activat	6.4
	425236 AW067800	Hs.155223	SS	stanniocalcin 2	6.2
	415669 NM_00502		,SS,serpin,	serine (or cysteine) proteinase inhibito	6.2
	416319 AI815601		SS,TM,jg,SS,TM	CD83 antigen (activated B lymphocytes, i	6.2
	412140 AA219691	Hs.73625	,SS,kinesin,	RAB6 Interacting, kinesin-like (rabkines	6.2
30	442942 AW167087		,SS,Ig,Sema,pkinase,	ESTs	6.2
	446163 AA026880		,SS,TM,fn3,	protectin receptor	6.1
	443162 T49951	Hs.9029	filament,SS,filament,filament	DKFZP434G032 protein	6.1
	409602 W26713	Hs.256972	,SS,TM,DAGKa,DAGKc,	ESTS	6.1
25	428479 Y00272	Hs.184572	,SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	6.1
35	400300 X03363	11- 400000	,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fi		6.1 6.1
	433404 T32982	Hs.102720	SS Characteristics	ESTs	6.1
	410079 U94362	Hs.58589	Glyco_transf_8,SS	glycogenin 2 Target Exon	6.1
	401781 447359 NM_01209	2Un 19209	,SS,filament,Pribosyltran,filament,Armad SS,adenylatekinase,	adenylate kinase 5	6.1
40	402230 NA	S/15. 10200	,SS,TM,p450,	Target Exon	6.1
70	427674 NM_00352	RHe 2178	histone, SS, histone,	H2B histone family, member Q	6.1
	428398 Al249368		,SS,TM	ESTs ·	6.0
	458098 BE550224		SS	metallothionein 1E (functional)	6.0
	419968 X04430	Hs.93913	SS.II.6.II.6.	Interleukin 6 (Interferon, beta 2)	6.0
45	416636 N32536	Hs.42645	,SS,TM	solute carrier family 16 (monocarboxylic	6.0
_	419703 AI793257	Hs.128151	,SS,zf-C2H2,	ESTs	5.8
	424687 J05070	Hs. 151738	SS,Peptidase_M10,In2,hemopexin,SS,TM,Pe	epmatrix metalloproteinase 9 (gelatinase B	5.8
	449679 AI823951	Hs.129700	SS	tolloid-like 1	5.8
	421296 NM_00268		SS	perilipin	5.8
50	442117 AW664964		,SS,TM	EST8	5.7
	400303 AA242758		,SS,TM	LIV-1 protein, estrogen regulated	5.7
	419440 AB020689		SS	KIAA0882 protein	5.7
	444858 Al199738		SS	ESTs, Wealdy similar to ALUA_HUMAN IIII	5.7
E E	432239 X81334	Hs.2936	SS,Peptidase_M10,hemopexin,SS,Peptidase		5.6
55	440705 AA904244	HS.153205	TM	ESTS	5.6
	400286 NA	U- 200	SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gi[7499103 pir [T20903 hypothe	5.6 5.5
	446466 H38026 423201 NM_00016	Hs.308	arrestin,SS	arrestin 3, retinal (X-arrestin) growth hormone receptor	5.5
	433043 W57554	Hs.125019	SS,TM,fn3,SS	lymphoid muclear protein (LAF-4) mRNA	5.5
60	439509 AF086332		SS ,SS,TM,Syntaxin	ESTs	5.4
UU	425247 NM_00594		SS,Pepildase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
	409757 NM_00189		,SS,cystatin,	cystafin SN	5.4
	425292 NM_00582		SS	37 kDa leucine-rich repeat (LRR) protein	5.4
	448045 AJ297436		,SS,TM	prostate stem cell antigen	5.4
65	452681 AF153330		,SS,TM	solute carrier family 19 (thiamine trans	5.3
-5	452243 AL355715		SS	programmed cell death 9	5.3
	439310 AF086120		,SS,TM,UDPGT,casein_kappa	EST8	5.2
			· · · · · - · ·	•	

**

	AA4444	A1000007	Hs.126594	SS TM Discentaglicet	ESTs	5.2
		A1806867 N54926	Hs.29202	,SS,TM,Phosphodiest, TM,7tm_1,TM	G protein-coupled receptor 34	5.2 5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
		AW749855	TIS. 100400	,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5		AL117406	Hs.200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
,		R81733	Hs.33106	,SS,HECT,zFUBR1,PABP,14-3-3,	ESTs	5.1
		W17064	Hs.332848	SS 1400,	SWI/SNF related, matrix associated, acti	5.1
		A1685086		"SS.ras.	ESTs, Weakly similar to S21348 probable	5.1
		X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_1		•••
10	120020		notamine N-met		5.1	
~~	423600	Al633559		SS	ESTs	5.1
			Hs.125087	SS	ESTs	5.1
	403593			,CIDE-N,pktnase	Target Exon	5.1
	407758		Hs.38365	SS,SS	KIAA0125 gene product	5.0
15		AW137636		,SS,TM	ESTs	5.0
	411165	NM_000169	Hs.69089	SS, Meliblase, BTK, PH, pkinase, SH2, SH3, Ribo	galactosidase, alpha	4.9
	420633	NM_014581	Hs.274480	SS,lipocalin,SS,lipocalin	odorant-binding protein 2A	4.9
	414117	W88559	Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	416783	AA206186	Hs.79889	SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093			TM,LRRCT,TM,LRRCT,	С12000586°-ыіј8330167 dbj[BAA88477.1] (A	4.9
	411096		Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs	4.9
		Al247716		,SS,adh_zinc,	ESTs	4.9
0.5		NM_004460		SS,DPPIV_N_term.Peptidase_S9,SS,DPPIV_		4.9
25		AA641836		,SS,trypsin	hypothetical protein FLJ23186	4.9
		Al215069		SS	ESTs	4.8
		AF012023		,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
		M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
20	403199		11- 222040	SS,TM,Folate_carrier,SS,TM,Folate_carrie	NM_025243*Homo saplens solute carrier f	4.8 4.8
30		AW057736		,SS,TM,pkinase,Recep_L_domain,SH2,PH,Ft	Homo sapiens clone 24787 mRNA sequence	4.5 4.7
		AF070526 M93221	Hs.75182	,SS,Ca_channel_B, SS,TM,lectin_c,fn2,Ricin_B_lectin,SS,TM	mannose receptor, C type 1	4.7
		AA526235		SS	Homo saplens cDNA FLJ11983 fis, clone HE	4.7
		BE093589		SS	hypothetical protein FLJ23468	4.6
35		AA447453		,SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
-		AW016669		,SS,TM,CBS,voltage_CLC	ESTs	4.6
		Al668605		,TM,Glyco_hydro_1	ESTs, Moderately similar to ALU6_HUMAN A	4.6
		AA687376		,SS,pklnase,RhoGEF,ig,PH,SH3,	ESTs	4.6
		AA339449		AIRS, formyl_transf, GARS, SS, GARS, AIRS, for	phosphoribosylglycinamide formyltransfer	4.6
40	446089	A1860021	Hs.270651	,pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
	445413	AA151342	Hs.12677	SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
		BE614743		,SS,TM,MAPEG,	prostaglandin E synthase	4.5
		A1493046		,SS,TM,UDPGT	ESTs	4.5
	452190		Hs.91668	,SS,TM,PH,SH2,Furin-like,pidnase,Recep_L	Homo sapiens clone PP1498 unknown mRNA	4.5
45		AA831879		,SS,Hist_deacetyl,	ESTs '	4.5
		Al345455		ptinase,OPR,	GA-binding protein transcription factor,	4.5
		Al910275		SS, trefoil, SS, TM, bil_recept_a, SRCR, byps	trefoil factor 1 (pS2)	4.5
		BE391804		SS,TM,GBP,TM,GBP	guanylate binding protein 1, interferon-	4.5 4.5 ·
50			Hs.44898	SS SS.SS.Ja.	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5
50	406639	MB7711 Al638627	Lin 40ECCE	ss,ss,y, ,ss,dead,fork_head	gbd-luman T-cell receptor (V beta 18.1, J KIAA1688 protein	4.5
		AA179949			Homo saplens mRNA; cDNA DXFZp564N0763 (f	4.4
		AA863360		,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AA976718		ig,Sema,	ESTs	4.4
55		AA312082		SS	GDNF family receptor alpha 1	4.4
-		AW294092		,SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
		BE466639			Homo saplens cDNA FLJ13591 fis, clone PL	4.4
		AK000136		SSLRRSS	asporin (LRR class 1)	4.4
	453619		Hs.33922		Homo saplens, clone MGC:9084, mRNA, comp	4.3
60		NM_000248	iHs.3076		MHC class II transactivator	4.3
		AI472078			ESTs	4.3
	431701	AW935490	Hs.14658	,SS,BIR	Human chromosome 5q13.1 done 5G8 mRNA	4.3
	416931		Hs.80485	SS,C1q,Collagen,SS,C1q,	adinose most abundant gene transcript 1	4.3
		AW296927		,SS,TM,Peptidase_M1,	ab:UJ-H-BWO-ajo-c-07-0-ULs1 NCL_CGAP_Su	4.3
65	418867		Hs.89404		msh (Drosophila) homeo box homolog 2	4.3
		BE464288			ESTS	4.3
	447499	AW262580	HS.14/6/4	,SS,TM,cadherin,cadherin	protocadheith beta 16	4.3

	441560 F13386 Hs.7888	pkinase,	Homo sapiens done 23736 mRNA sequence	4.3
	409064 AA062954 Hs.141883	,SS,CUB,	ESTs	4.3
	422667 H25642 Hs.133471	,SS,TM,FMO-like	ESTs	4.3
_	454032 W31790 Hs.194293	,SS,TM	ESTs, Wealty similar to 154374 gene NF2	4.3
5	432663 Al984317 Hs.122589	TM	ESTs	4.3
	401747	,SS,filament,filament	Homo saplens keratin 17 (KRT17)	4.3
	432882 NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2 4.2
	437036 Al571514 Hs.133022 447754 AW073310 Hs.163533	,SS,TM	ESTs Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
10	443194 Al954968 Hs.279009	,pktnase, ,SS,TM	matrix Gla protein	4.2
10	451871 Al821005 `Hs.118599	,SS,GDNF,	ESTs	4.2
	457211 AW972565 Hs.32399	WH1,WH1	ESTs. Weakly similar to S51797 vasodilat	4.2
	421566 NM_000399Hs.1395	zi-C2H2,SS	early growth response 2 (Krox-20 (Drosop	4.2
	431657 Al345227 Hs.105448	,SS,TM,pkinase	ESTs, Wealty similar to B34087 hypotheti	4.1
15	427899 AA829286 Hs.332053	,SS,SAA_proteins,ABC_membrane,ABC_tra	n,serum emyloid A1	4.1
	444779 Al192105 Hs.147170	SS	ESTs	4.1
	442295 AI827248 Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fis, clone HE	4.1
	436396 Al683487 Hs.152213	,wnt,	wingless-type MMTV integration site fami	4.1
20	446039 Al150491 Hs.90756	,TM,Glyco_hydro_1	ESTS	4.1
20	422938 NM_001809Hs.1594	,SS,TM,thiolase,	centromere protein A (17kD)	4.1 4.1
	406922 S70284 439285 AL133916 Hs.172572	SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo hypothetical protein FLJ20093	4.1
	424800 AL035588 Hs.153203	,SS,ig,pkinase,LRRNT,LRRCT, HLH,SS	MyoD family inhibitor	4.1
	429922 Z97630 Hs.226117	,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
25	447178 AW594641 Hs.192417	SS.TM	ESTS	4.0
	409038 T97490 Hs.50002	SS,ILB,SS,ILB	smail inducible cytokine subtamity A (Cy	4.0
	452747 BE153855 Hs.61460	,SS,HLH	lg superfamily receptor LNIR	4.0
	420139 NM_005357Hs.95351	,SS,TM,p450,	lipase, hormone-sensitive	4.0
20	408877 AA479033 Hs.130315	,SS,TM	ESTs, Wealthy similar to A47582 B-cell gr	4.0
30	403329 NA	SS,SS	Target Exon	4.0
	439926 AW014875 Hs.137007 430832 Al073913 Hs.100686	SS SS	ESTs ESTs, Weakly similar to JE0350 Anterior	4.0 4.0
	432481 AW451645 Hs.151504	,SS,Collagen,COLFI,TSPN,	Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
	452410 AL133619 Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35	418661 NM_001949Hs.1189	SS	E2F transcription factor 3	4.0
•-	431958 X63629 Hs.2877	SS,TM,Cadherin_C_term,cadherin,SS,TM,ca	the contract of the contract o	4.0
	425071 NM_013989Hs.154424	SS,T4_delodinase,T4_delodinase,	deiodinase, lodothyronine, type II	4.0
	447197 R36075	,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
40	428722 U76456 Hs.190787	,SS,TIMP,	tissue inhibitor of metalloprotelnase 4	3.9
40	428330 L22524 Hs.2256		opematrix metalloproteinase 7 (MMP7; uterin	3.9
	423242 AL039402 Hs.125783	SS	DEME-6 protein	3.9 3.9
•	449048 Z45051 Hs.22920 414831 M31158 Hs.77439	SS,SS,TM ,SS,cNMP_binding,Rila,HMG_box	similar to S68401 (catile) glucose induc protein kinase, cAMP-dependent, regulato	3.9
	413589 AW452631 Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 nonci	3.8
45	408875 NM_015434Hs.48604	SS	DKFZP434B168 protein	3.8
	418629 BE247550 Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furtn-like,pktnas		3.8
	450787 AB006190 Hs.25475	SS,TM,MiP,SS,TM,MIP,	aquaporin 7	3.8
	414870 N72264 Hs.300670	SS .	KIAA1204 protein	3.8
	450325 Al935962 Hs.26289	SS	ESTs	3.8
50	407633 NM_007069Hs.37189	TM,TM	similar to rat HREV107	3.8
	426172 AA371307 Hs.125056	,SS,DENN	ESTs	3.8
	442262 BE170651 Hs.8700	,ss,start,	deleted in liver cancer 1	3.8 3.8
•	427961 AW293165 Hs.143134 445563 AW873606 Hs.149006	,SS,WH1,WH1	ESTS	3.8
55	403943	p450,SS,p450	C5000355;gi[4503225]ref[NP_000765.1] cyt	3.8
33	408761 AA057264 Hs.238936	,SS,TM,7tm_1,	ESTs, Weakly similar to (define not ava	3.8
	423279 AW959861 Hs.290943	SS	ESTs	· 3.8
	420440 NM_002407Hs.97644	,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
	445107 Al208121 Hs.147313	,SS,TM	ESTs, Wealtly similar to I38022 hypotheti	3.7
60	428303 AW974476 Hs.183601	SS,RGS,RGS,RGS	regulator of G-protein signalling 16	3.7
	411667 BE160198	TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
	427809 M26380 Hs.180878	,SS, Jipase, PLAT, Sec7, PH,	lipoprotein lipase	3.7
	418203 X54942 Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7
65	430376 AW292053 Hs.12532	SS SS	chromosome 1 open reading frame 21	3.7 2.7
UJ	444190 A1878918 Hs.10526 433495 AW373784 Hs.71		cysteine and glycine-rich protein 2 alpha-2-glycoprotein 1, zinc	3.7 3.7
	429638 Al916662 Hs.211577	SS,1g,MHC_J,connexin,SCAN,SS,TM SS,TM,SS	apna-2-gycoprotein 1, 2nc kinectin 1 (kinesin receptor)	3.7 3.7
		,	unicoms s functions sometimes)	J.,

	454071 Al041793 Hs.42502	,TM,7tm_1,	ESTs	3.7
	451859 H44491 Hs.252938	,SS,TM,EGF,ldt_recept_a,ldt_recept_b,EGF	ESTs. Weakly similar to ALU1_HUMAN ALU S	3.7
	420281 AJ623693 Hs.191533	SS,AAA.	ESTs	3.7
	427691 AW194426 Hs.20726	SS.Glycos transf 2.	ESTs	3.7
5			ESTs	3.7
J	428824 W23624 Hs.173059	SS		
	424676 Y08565 Hs.151678	Glycos_trans(_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
	418026 BE379727 Hs.83213	lipocalin,SS,lipocalin,lipocalin,ferriti	fatty acid binding protein 4, adipocyte	3.7
	457465 AW301344 Hs.122908	SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
	417601 NM_014735Hs.82292	PHD pkinase,SS	KIAA0215 gene product	3.7
10	407999 Al126271 Hs.49433	SS	ESTs, Wealty similar to YZ28_HUMAN HYPOT	3.7
10	425548 AA890023 Hs.1906	SS,TM,fn3,SS,TM,fn3,	protactin receptor	3.7
	446619 AU076643 Hs.313	,SS,TM,ethand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	411213 AA676939 Hs.69285	SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CU	JB,F5_neuropMn 1	3.6
	406625 Y13647 Hs.119597	SS,TM,Desaturase,SS	stearoyl-CoA desaturase (delta-9-desatur	3.6
15	417511 AL049176 Hs.82223	SS	chordin-like	3.6
	428769 AW207175 Hs.106771	,SS,7tm_1,SPRY,	ESTs	3.6
	407137 T97307	,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal liver spicen	3.6
		and the state of t	- ·	3.6
	401866	,SS,filament,	Target Exon	
00	451195 U10492 Hs.438	SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20	426044 AA502490 Hs.336695	SS	ESTs	3.6
	426310 NM_000909Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
	440029 AW089705 Hs.293711	SS	ESTs, Wealtly similar to S64329 probable	3.6
	408573 AA284775 Hs.43148	SS,TM,PMP22_Claudin,	ESTs	3.6
	431830 Y16645 Hs.271387	,SS,TM,IL8	small inducible cytokine subfamily A (Cy	3.6
25			GPI-anchored metastasis-associated prote	3.6
23	444781 NM_014400Hs.11950	,SS,PH,lactamase_B		
	431493 AI791493 Hs.129873	,SS,p450,p450	ESTs, Wealthy similar to A36036 cytochrom	3.6
	414175 Al308876 Hs.103849	,TM,hemopexin,Peptidase_M10,hemopexin,I		3.6
	411789 AF245505 Hs.72157	b,LRRCT,	DKFZP564l1922 protein	3.6
	418851 Al417828 Hs.192435	,SS,TM	ESTs	3,5
30	453968 AA847843 Hs.62711	,SS,HMG_box,	Homo saplens, clone IMAGE:3351295, mRNA	3.5
	407104 S57296 Hs.323910	,SS,TM,SH2,PH,pkinase,Recep_L_domain,F	urv-erb-b2 avlan ervihroblastic leukemia v	3.5
	449051 AW961400 Hs.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
				3.5
	434398 AA121098 Hs.3838	pkinase,POLO_box,SS,pkinase,POLO_box,		
25	454042 H22570 Hs.172572	,SS,lg,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
35	459498 AA808940 Hs.274450	,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
	414998 NM_002543Hs.77729	,SS,TM	oxidised low density lipoprotein (lectin	3.5
	407756 AA116021 Hs.38260	SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
	442101 Al651930 Hs.135684	SS	ESTs	3.5
	449722 BE280074 Hs.23960	cyclin,SS,TM,cyclin,	cyclin B1	3.5
40			ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
40	452554 AW452434 Hs.58006	SS		
	421991 NM_014918Hs.110488	SS	KIAA0990 protein	3.4
	420058 AKD01423 Hs.94694	SS	Homo sapiens cDNA FLJ10561 fis, clone NT	3.4
	425776 U25128 Hs.159499	SS,TM,7km_2,SS,TM,7km_2	parathyrold hormone receptor 2	3.4
	407846 AA426202 Hs.40403	,TM,ABC_membrane,ABC_tran,Ribosomal_S	S4eCbp/p300-Interacting transactivator, wit	3.4
45	406925 L34041 Hs.9739	SS TM transport prof SWIB RhoGAP DAG	PEplycerol-3-phosphate dehydrogenase 1 (so	3.4
	445873 AA250970 Hs.251946	,SS,mm,PABP,pkinase,14-3-3,mm	poly(A)-binding protein, cytoplasmic 1-l	3.4
	418054 NM_002318Hs.83354	,SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	3.4
		OO OTADT OO OTADT MINUT DAILIT TELIT	desidencele emis remistras remisir e	3.4
	414921 BE390551 Hs.77628	SS, START, SS, START, NNMT_PNMT_TEMT	, Serologene acue regulatory protein r	
5 0	452268 NM_003512Hs.28777	SS,histone,Calc_CGRP_IAPP,lg,MHC_I,SPF	(Y,HZA nistone family, member L	3.4
50	428862 NM_000346Hs.2316	SS,HMG_box,	SRY (sex determining region Y)-box 9 (ca	3.4
	412520 AA442324 Hs.795	histone,SS,histone,BolA	H2A histone family, member O	3.4
	410530 M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	401780	filament, SS, filament, filament	NM_005557*:Homo sapiens keratin 16 (foca	3.4
	447131 NM_004585Hs,17468	TM	retinols acid receptor responder (tazaro	3.4
55		,SS,TM,Ribosomal_L27e,		3.4
33	418334 AA319233 Hs.5521		ESTS	
	415138 C18358 Hs.295944	,Kunitz_BPT1,	tissue factor pathway inhibitor 2	3.4
	421168 AF182277 Hs.330780	SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
	431473 AA825686 Hs.321176	SS	ESTs, Wealdy similar to S65824 reverse t	3.4
	421379 Y15221 Hs.103982	SS,ILB,	small inducible cytokine subfamily B (Cy	3.4
60	411984 NM_005419Hs.72988	SH2.STAT,SS,STAT	signal transducer and activator of trans	3.4
•		"pkinase,	CDC2-related protein kinase 7	3.4
	408101 AW968504 Hs.123073		NM_003371*:Homo saplens vav 2 oncogene (
	405366	RhoGEF,PH,SS,RhoGEF,PH,		3.4
	414612 BE274552 Hs.76578	SAP,SS,FG-GAP,vwa	protein inhibitor of activated STAT3	3.4
	411393 AW797437 Hs.69771	SS,sushi,trypsin,vwa,rm,fibrinogen_C,fn	B-factor, properdin	3.3
65	435767 H73505 Hs.117874	,SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
	416406 D86961 Hs.79299	,SS,TM	lipoma HMGIC fusion partner-like 2	3.3
	433068 NM_006456Hs.288215	,SS,Pribosyltran,	slalyltransferase	3.3
	TOURS TRITE VOUCHOUS IDLE VOUCHO	lank impalings)		

	44			20.00	hand to the table to be a second	
		AA378776		SS,SS	hypothetical protein MGC3077	3.3
		AA918317		SS,SS	B-cell CLL/lymphoma 11B (zinc finger pro	3.3
		AF109302		SS	prostate cancer associated protein 7	3.3
_		AK000725		SS	hypothetical protein FLJ20718	3.3
5		Al141031		SS	ESTS	3.3
			Hs.339665	SS	ESTs	3.3
		AF037062		,SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-cls and 9-cl	3.3
		BE327427		,SS,TM,histone,ANF_receptor,guarrylate_cy	ESTS	3.3
10		H11257	Hs.22968	,SS,pkinase,kg,	Homo saplens clone IMAGE:451939, mRNA se	3.3 3.3
10		AL079905	HS.1103	SS,TGFb_propeptide,TGF-beta,SS	transforming growth factor, beta 1	3.3
		AW881145	LI- 470000	SS SS SS Francisco DI AT	gb:QV0-OT0033-010400-182-a07 OT0033 Hamo ESTs	3.3
		Al267371		SS,SS,lipoxygenase,PLAT	ESTs	3.3
		AM23317		,SS,T-box,UDPGT SS,SS,Peptidase_M1,EGF,ig,tectin_c,sushi	amhopeptidase	3.3
15		Al161293 Al547306		SS Tehtoase_M1,cor,ig,tecat_c,scsni	ESTs	3.3
13		AF052152		"pkinase,	Homo saplens clone 24628 mRNA sequence	3.3
		APU02102 AWD43782		SS .	ESTS	3.3
		AA502764		SS	ESTs, Wealdy similar to AF208855 1 BM-01	3.3
			Hs.283978	,SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
20		BE314524		TM	putative transmembrane protein	3.3
20		AF084545	115.70770	,SS,Peptidase_M1,	Target	3.3
			Hs.57664 .	,TM,Integrin_B,Ricin_B_lectin,rm	Homo sapiens mRNA full length insert cDN	3.3
		AL137326		,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	3.3
		AW236861		,SS,START,NNMT_PNMT_TEMT,	EST8	3.3
25		AA852773		SS	KIAA1866 protein	3.3
23			Hs.22785	SS,TM,TM	gamma-aminobutyric acid (GABA) A recepto	3.3
			Hs.269109	Sema.lg,	ESTs	3.3
		BE270266		SS,TM,LRRCT,LRRNT,LRR,TM,LRRCT,	5T4 oncofetal trophoblast glycoprotein	3.3
		AI694413		,SS,TM,7lm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
30			Hs.10247	,SS,lg,	activated leucocyte cell adhesion molecu	3.2
		AW015140		SS,CUB,	ESTs	3.2
		A1921270		SS,TM,SS,TM,G-patch	hypothetical protein FLJ14251	3.2
		NM_003654		SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
	431104	AW970859	Hs.313503	,Sema,ig,	ESTs	3.2
35	443767	BE562136	Hs.9736	,SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
	419589	AW973708	Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 fis, ctone PL	3.2
	415447	Z97171	Hs.78454	SS,OLF,OLF,OLF,Ribosomal_L4	myodilin, trabecular meshwork inducible	3.2
	443464	BE548446	Hs.5167	SS,TM,SSF,SS,TM	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	3.2
		AA326062		,SS,p450,p450	gb:EST29171 Cerebellum II Homo saplens c	3.2
40		BE563085		,SS,TM,ubiquitin,taminin_G,taminin_EGF,k	interferon-stimulated protein, 15 kDa	3.2
		AW297181		,SS,Ribosomal_L14	EST8	3.2
		AA885430		,FGF,	Home saplens cDNA FLJ13446 fls, clone PL	3.2
			Hs.75517	SS, taminin_EGF, taminin_Nterm, adh_short, S		3.2
45		AF160477		,SS,HLH	lg superfamily receptor LNIR	3.2
45		AF213457		SS,Jg,SS,TM	triggering receptor expressed on myeloid	3.2
			Hs.324725	,SS,TM,Ribosomal_S3Ae,G-gamma	ESTs, Moderately similar to A47582 B-cel	3.2
		AV658411		SS	KIAA1681 protein	3.2 3.2
		NM_003155		,SS,homeobox,	stanniocalcin 1	3.2 3.2
50		AW513691		,SS,fn3,	ESTs, Weakly similar to 2109260A B cell	3.2
30	452110		Hs.28005	,SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
		AW247529	U2'01	,TM,p450,Ets SS	platelet activating factor acetylhydrola	3.2 3.2
	402837 420454		Na 77055A		ENSP00000241312*:DJ947L8.1.8 (novel Sush heterochromatin-like protein 1	3.1
	406664	AF086270	Hs.9739	,SS,Chromo_shadow,chromo,	Eglycerol-3-phosphate dehydrogenase 1 (so	3.1
55		AJ080042		SS.RNA_pol_A.RNA_pol_A2.Ribosomal_S24		3.1
33		AW068115		SSLRRLRRNT.SSLRRNTLRR.	biglycan	3.1
	A14097	AA524394	He 204027	.SS.connexin.hormone_rec.zf-C4.connexin	hypothetical protein FLJ14950	3.1
			Hs.26930	,SS,Gelsolin,	ESTs, Wealthy similar to T20272 hypotheti	3.1
•			Hs.325960	,SS,TM	membrane-spanning 4-domains, subfamily A	3.1
60		AW191962		"SS,TM,C1g.	collagen, type VIII, alpha 2	3.1
	419092		Hs.89603	SS,TM,SEA.	much 1, transmembrane	3.1
		AK002016		,SS,PK,PK	Homo saplens, clone MGC:16327, mRNA, com	3.1
		BE281128		SS,TM,7tm_1,mm,SS	TONDU	3.1
		AK000933		,TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
65		Al538613		SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
		AJ245210		SS	gb:Homo sapiens mRNA for immunoglobulin	3.1
	400903			SS	Target Exon	3.1
					-	

	424400	A1004774	11- 400FDD	00.01 11 0	Prov.	24
			Hs.132586	,SS,Glyco_hydro_2	ESTs	3.1
		AW962597		SS,WD40,SS,WD40,	KIAA1547 protein	3.1
		AJ347487		fn3,SS,TM,EF1BD	class I cytokine receptor	3.1
_			Hs.201189	SS	ESTs, Wealty similar to G01763 atrophin-	3.1
5		A1936442		UBACT_repeat,SS,UBACT_repeat,ThiF_fami		3.1
		T29618	Hs.89640	,TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		AA587773		,SS,SRCR,	Homo saplens, Similar to RIKEN cDNA 5830	3.1
	418624	AJ734080	Hs.104211	,Sema,ig,	ESTs	3.1
	436291	BE568452	Hs.5101	,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10	411000	N40449	.Hs.201619	SS	ESTs, Wealthy similar to S38383 SEB4B pro	3.1
	412519	AA196241	Hs.73980	SS, Troponin, Hemagglutinin, SS, TM, C2, Tropo	troponin T1, skeletal, slow	3.1
	450223	AA418204	Hs.241493	,SS,pro Isomerase,	natural killer-tumor recognition sequenc	3.1
	422790	AA809875	Hs.25933	.TM.histone.Sect_histone.sugar_tr	ESTs	3.1
	424269	AW137691	Hs.199754	SS,TM,7tm 2,GPS	ESTs	3.1
15	435854	AJ278120	Hs.4996	.SS,WD40	putative ankyrin-repeat containing prote	3.1
		AW630534		,SS,TM,rrm,coddored_q6,coddored_q6	Homo sapiens, clone MGC:9381, mRNA, comp	3.1
		R00866		SS	above79c02.s1 Soares fetal liver spicen	3.0
			Hs.298241	,SS,TM,trefoll,trypsin,trefoll	Transmembrane protease, serine 3	3.0
			Hs.126730	,TM.PH.	ESTs, Weakly similar to KIAA1214 protein	3.0
20		AA593731		.SS.TM.CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
20		R91600			gb:yq10c02.r1 Soares fetal liver spleen	3.0
			Hs.162209	SS,TM,SS,TM,PMP22_Claudin,PMP22_Claur		3.0
		H58373	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
	401197	, 1000.0		art.art.	ENSP00000229263":HSPC213.	3.0
25		AW204256	Hs 291887	,wnt,	ESTs	3.0
		BE077084		,SS_mm_zf-RanBP_pkinase,C2_pkinase_C,DA		3.0
		AA381807		SS,SS	hypoxia-inducible protein 2	3.0
		W27249	Hs.8109	SS	hypothetical protein FLJ21080	. 3.0
	404826	*****	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,SS,TM	Target Exon	3.0
30		H70284	Hs.160152	.SS.RA	ESTs. Weakly similar to FPHU alpha-fetop	3.0
20		AL034548		HMG_box.pkinase.zf-CCHC.SS,TM.HMG_box		3.0
		AW977653			ribonucleofide reductase M2 polypeptide	3.0
		Al820961			ESTs	3.0
		AI868872			hypothetical protein FLJ22704	3.0
35			Hs.145807	,SS,TM	hypothetical protein FLJ13593	3.0
33		AA688021			ESTs	3.0
		AW103364		SS,TGF-beta,TGFb_propeptide,SS,TGF-beta,		3.0
		AU077005			a disintegrin and metalloproteinase doma	3.0
		AA374569			ESTs, Moderately similar to 2109260A B c	3.0
40		AB032417			frizzied (Drosophila) homolog 4	3.0
-70			Hs.1707	SS,SS	cocaine- and amphetamine-regulated trans	3.0
		AW385224			ectonucleotide pyrophosphatase/phosphodi	3.0
		AW300118			ESTs	3.0
		AA532807			ESTS	3.0
	432204	MN33200/	FT3. 1U3022	, SO, I MILITALIZACI,	EOIO	3,0

TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

R	"
Ł	
_	•

Picey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accessions
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
20	411667	1253334_1	BE160198 AW935898 T11520 AW935930 AW856073 AW861034
	418636	177402_1	AW749855 AA225995 AW750208 AW750206
	420854	197072_1	AW296927 Al684514 Al263168 AA281079 .
	422128	211994 1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
	423431	228162 1	AA326062 AA325758 AW962182
25	423945	233566 1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	433687	373061 1	AA743991 AA604852 AWZ/72737
	447197	711623 1	R36075 Al366546 R36167
	451631	878098_1	R00866 R01523 Al806815
30	456207	165078 -1	AA193450
	456592	202684_1	R91600 T87079 AA291455

TABLE 20B

405654 4895155 Minus 53624-53759

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Ref:		Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402-489-495. Indicates DNA strand from which exons were predicted.			
	Nt_post	ion:	Indicates n	ucleofide positions of predicted exons.		
1.5						
15	Pkey	Ref	Strand	Nt_position		
	400608	9887666	Minus	96756-97558		
		2911732		59112-59228		
20		8117619		90044-90184.91111-91345		
		8516137		22335-23166		
		9719705		176341-176452		
	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-		
				131932.132451-132575.133580-134011		
25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573		
	401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814		
	401866	8018106	Plus	73126-73623		
	402230	9966312	Minus	29782-29932		
	402408	9796239	Minus	110326-110491		
30	402578	9884928	Plus	66350-66496		
	402606	9909429	Minus	81747-82094		
	402837	9369121	Minus	2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320		
	403199	9958183	Minus	58895-59036,66618-66789		
		8516120		96450-96598		
35		6862650		62554-62712,69449-69602		
		7711864		100742-100904,101322-101503		
		7684554		82121-83229		
		9838195		74493-74829		
40		6572184		47726-48046		
40	405366	2182280	Plus	22478-22632		

TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, peptidase, phosphatase, ATPase, or ion transporter domains). The predicted protein domains are noted.

20	Pkey: ExAccn: UniveneliD:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number
	Unigene Title:	Unigene gene title

R1:

5

10

15

Ratio of 93rd percentile tumor to 85th percentile of normal body tissue

25						
	Pkey	ExAcen	UnigeneiD	Predicted Protein Domains	UnigeneTitle	R1
			Hs.176588	SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
		AA250737		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
30	424735	U31875	Hs.272499	\$S,TM	short-chain alcohol dehydrogenase family	53.8
			Hs.104106	SS,Dihydroorotase,	ESTs	39.3
		AW138959		Phosphodlest,Somatomedin_B,	ESTs	34.9
		AA009647		SS,TM,distntegrin,Pep_M12B_propep,Reprol	a disintegrin and metalloproteinase doma	25.7
0.5		NM_00139		DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
35			Hs.170042	SS,TM,Cation_efflux	ESTs	24.1
		NM_00361	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
		A1905687		SS	aldehyde dehydrogenase 9 family, member	20.3
40		A1375572	Hs.172634	pkinase,	ESTs	19.2
40		AA193450		SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Horno sapi	18.3
		X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cadi	htyrosine aminotransferase	18.1
	402578			SS,p450,SS,TM,p450	C1001134:gij2117372[pir][l65981 fatty ac	17.8
		D90041	Hs.155956	SS,Acetyftransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
4-		W67883	Hs.137476	pktnase,	paternally expressed 10	16.5
45		M13509	Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_	matrix metalloproteinase 1 (MMP1; Inters	15.7
		Y13153	Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
		W20027	Hs.23439	SS,Peptidase_M1,	ESTs	13.9
		X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	Omatrix metalloproteinase 10 (MMP10; str	13.5
~~		AW873596		SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
50			Hs.102267		lysyl oxidase	12.8
		W72838	Hs.2533		aldehyde dehydrogenase 9 family, member	12.7
	408771	AW732573	Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
		NM_002497		pkinase,SS,TM,pkinase,polyprenyL_synt,	NIMA (never in mitosis gene a)-related k	11.7
55		R28363	Hs.24286		ESTs	11.5
		Al907673		pkinase,	gb:fL-87152-080399-004 BT152 Homo sapien	11.5
		AA410943			gbczt32h03.r1 Soares ovary turnor NbHOT H	11.4
	445263	H57646	Hs.42586		KIAA1560 protein	11.2

		AL080207		SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
	429859	NM_00705	0Hs,225952	SS,TM,Y_phosphatase,WAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
	428368	BE440042	Hs.83326	SS,Peptidase_M10,hemopexin,SS,Peptidase	_matrix metalloproteinase 3 (stromelysin	10.3
	418912	NM_00068	5Hs.89472	SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
5	451952	AL120173	Hs.301663 .	SS,pkinase,	ESTs	10.3
	402408			SS,carb_anhydrase	NM_030920°:Homo sapiens hypothetical pro	9.8
		AJ733881	Hs.72472	death, ZU5, TM, Activin_recp, pkinase,	BMP-R1B	9.4
		M31126	Hs.272620	SS Peptidase M10 hemopedn SS Peptidase		9.1
		AB041035		Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (9.1
10	400285		118.33047			8.8
10	400200	A CARROLLE	11- 44599	TM,ABC_tran,ABC_membrane,	Eos Control	
		AF123050		SS,TM,ublquitin,7tm_3,ANF_receptor,sushi	dubiquitin	8.6
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_00386		SS,SS	Inositol polyphosphate 4-phosphatase, ty	8.3
	431725	X65724	Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
15	418092	R45154	Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	8.3
	427811	M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_M	#14carboxypeptidase B1 (tissue)	8.2
	423554	M90516	Hs.1674	GATase 2.SIS.	glutamine fructose 6-phosphate transamin	8.1
	426261	AW242243	Hs.168670	SS,TM,WD40,ubiquittn,E1-E2_ATPase,Cation	peroxisomal famesylated protein	7.8
		NM_00103		SS	ribonucleotide reductase M2 polypeptide	7.8
20		NM_00448		SS,TM,Glycos_transf_2,Ricin_B_lectin,DPP		7.6
20		D38299	Hs.170917	SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
		A1240665		SS,TM,dishtegrin,Pep_M12B_propep,Reprol		7.3
		Y12735	Hs.38018	pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2
25		U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2
25		U92649	Hs.64311	TM, disintegrin, Reprolysin,	a disintegrin and metalloproteinase doma	7.1
		AW204099			ESTs, Wealty similar to AF126780 1 retin	6.9
		AP000692	Hs.129781	GAF,PDEase	chromosome 21 open reading frame 5	6.8
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_	.p	
		C11001883	1*gi 6753278 re	fNP_033938.1 c	6.7	
30	442082	R41823	Hs.7413	TM,EPH_lbd_pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
	418836	A1655499	Hs.161712	TM, Activin_recp, planase, death, ZU5,	ESTs	6.6
	404091			TM,7tm_3,ANF_receptor,	Target Exon	6.6
		Al248013	Hs.106532	zf-C2H2	ESTs, Weakly similar to 138588 reverse t	6.5
		NIM_002914		SS,AAA,Viral_helicase1,rm,	replication factor C (activator 1) 2 (40	6.5
35		AF055575		TM,ion_trans,SS,TM,ion_trans,	caldum channel, voltage-dependent, L ty	6.4
33		AA932186		TM,7tn_1,	ESTs	6.2
						6.2
		NM_00502		SS,serpin,	serine (or cysteine) proteinase inhibito	
		AW167087		SS,ig,Sema,pkinase,	ESTs	6.2
40		R45503	Hs.97469	SS,TM	ESTs, Highly similar to A39769 N-acetyll	6.1
40		Y00272	Hs.184572	SS,pktnase,pktnase	cell division cycle 2, G1 to S and G2 to	6.1
		X03363		SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
	447359	NM_012093	3Hs.18268	SS,adenytatekinase,	adenylate kinase 5	6.1
	402230	NA		SS,TM,p450,	Target Exon	6.1
	424687	J05070	Hs.151738	SS,Peptidase_M10,fn2,hemopedn,SS,TM,Pe	pmatrix metalloproteinase 9 (gelatinase B	5.8
45	432328	AJ572739	Hs.195471	6PF2K.PGAM	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
	432239	X81334	Hs.2936	SS,Peptidase_M10,hemopadn,SS,Peptidase_		5.6
	400286			SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gij7499103 pirijT20903 hypothe	5.6
		NM_005940	1Hs 155324		matrix metalloproteinase 11 (MMP11; stro	5.4
		AA828246		UCH-1,pkinase,OPR,Rhodanese,AMP-binding		5.4
50		AF086120			EST8	5.2
30						
			Hs.126594	SS,TM,Phosphodiest,	ESTs	5.2
		N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408		solute carrier family 25 (milochondrial	5.2
		AL117406		SS,TM,ABC_train,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
55	425325		Hs.1892 ·	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_T	EMT,STAR	
			notamine N-met		5.1	
	448706	AW291095	Hs.21814	SS,TM,pkinase,	interleukin 20 receptor, alpha	5.1
	403593	NA -		CIDE-Nupltinase	Target Exon	5.1
	432777	AA564991	Hs.269477	alpha-amylase.	ESTs	5.0
60		Al281848			retinoic acid induced 3	4.9
		NM_000169		SS,Melibiase,BTK,PH,pkmase,SH2,SH3,Ribo	nalarineiriaea alnha	4.9
		W88559	Hs.1787	TMJon_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	411096		Hs.68583	Peptidase M3.	proteoripid protein r (r excepts-marzoac mitochondria) intermediate peptidase	4.9
		NIM_004460		SC DDDIV N from De-Educa On On Proper	HOMERANDER OFFICER ACTION ACTION ACTION	
65				SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		4.9
65		AA641836		SS,trypsin	hypothetical protein FLJ23186	4.9
		M73700	Hs.105938		lactotransferrin	4.8
	427122	AW057738	HS.3Z3910	SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu	iHER2 receptor tyrosine lunase (c-erb-b2,	4.8

	400404 N		_	CO TM 2D-1- LICD	ENSP00000171555:CDNA FLJ10727 fis, clone	4.6
	400181 N			SS,TM,3Beta_HSD,		
	452093 AA	V44 7453	Hs.27860	SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
	435542 A	4687376		SS,phinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
	417576 A	4339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
5	446089 All	860021		pldnase	ESTs, Moderately similar to A47582 B-cel	4.6
_	424420 BE			SS.TIMMAPEG.	prostaglandin E synthase	4.5
	452190 H2			SS,TM,PH,SH2,Furin-Eke,phinase,Recep_L_	Homo sapiens clone PP1498 unknown mRNA	4.5
						4.5
	419986 AL			pldnase,OPR,	GA-binding protein transcription factor,	
	421582 A			SS,trefoil,SS,TM,tdLrecept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
10	446733 A	4863360	Hs.26040	SS,TM,p450,	ESTs, Wealdy shrifar to fatty acid omega	4.4
	453080 AV	N294092	Hs.21594	SS,ras,Y_phosphatase,ras	hypotheEcal protein MGC15754	4.4
	400205 N/	A		• • •	NIM_006265°:Homo saptens RAD21 (S. pombe)	4.4
	420854 AV			SS,TM,Peptidase_M1,	gbtUI-H-BWO-alc-c-07-O-UI.s1 NCI_CGAP_Su	4.3
				SS.pyr_redox.SS.Ribosomal_L39	prenylcysteine lyase	4.3
15	432690 AF			22/byl_tenny22/umpanist_ma	Henry contract data 22726 mDNA company	4.3
15	441560 F1				Homo saptens clone 23736 mRNA sequence	
	416445 AL	.043004	Hs.79337	SS,phinase,	KIAA0135 protein	4.3
	439024 RS	98698	Hs.35598	SS,TM,trypsin,vad,ig	ESTs .	4.3
	432882 NI	M 013257	Hs.279696	pidnase,pidnase_C,	serum/glucocorticold regulated kinase-li	4.2
	447754 AV			phinase,	Homo sactens cONA FLJ14142 fis, clone MA	4.2
20	453775 NR		Lle 25120	SS,AAA,PI3_PI4_binasa,PI3Ka,PI3K_rbd,PI3		4.2
20					ESTs, Westly similar to B34087 hypotheti	4.1
	431657 AL		HS.1U0446	SS,TM,pt/mase		
	427899 A			SS,SAA_proteins,ABC_membrane,ABC_tran,		4.1
	422938 NA	VL 00 1809	Hs.1594	SS,TM,thiolase,	centromere protein A (17hD)	4.1
	418478 U3	38945	Hs.1174	ank ank	cyclin-dependent binase inhibitor 2A (me	4.1
25	408922 S7			SS,TM,Desaturase,SS	ob:stearoyl-CoA desaturase [human, adipo	4.1
	439285 AL			SS_by_obtmase_LRRNT_LRRCT,	hypothetical protein FLJ20093	4.1
	429922 Z9			SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
						4.0
	420139 N			SS,TM,p450,	lipase, hormona-sensitiva	
	425071 NA		Hs.154424		deiodinase, lodothyronine, type II	4.0
30	424511 BE	E300512	Hs.193557	SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
	428722 U7	76456	Hs.190787	SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
	428330 12		Hs.2256	SS.Peptidase_M10,SS,Peptidase_M10,hemop	pematrix metalloproteinase 7 (MA/P7; uterin	3.9
	414831 M			SS_cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
	413589 AV			SS.abtwdrotese	ESTs, Highly similar to AF157833 1 noncl	3.8
25						
35	418629 BE				growth factor receptor-bound protein 7	3.8
	413453 AA	1129640	Hs.128085	SS,Pepiidase_C1,gpdh	ESTs	3.8
	403943			p450,SS,p450	C5000355:gij4503225jrefjNP_000765.1j cyt	3.8
	444618 AV	/653785	Hs.173334	•	ELL-RELATED RNA POLYMERASE II, ELONGATIO	3.8
	408761 AA			SS,TM,7tm_1,	ESTs, Wealtly similar to (defilne not ava	3.B
40	427809 M			SS Epase PLAT, Sec7, PH,	Epoprotein Epase	3.7
70					CDC28 protein kinese 2	3.7
	418203 X5			CKS,SS,CKS,		
	454071 AM				ESTS	3.7
	424676 YO				UDP-M-acetyl-alpha-D-galactosamine:polyp	3.7
	457465 AV	N301344	Hs.122908		DNA repContion factor	3.7
45	417601 NA	4 014735	Hs.82292	PHD,pktnase,SS	KIAA0215 gene product	3.7
	446619 AL			SS,TM,ethand.lon_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	406625 Y1			SS,TM,Deseturase,SS	stearoyl-CoA desaturase (delta 9 desatur	3.6
	428769 AV				ESTS	3.6
					neuropepäde Y receptor Y1	3.6
50	426310 NA					
50	417531 NA				serine/threonine kinase 2	3.6
	444781 NA	V_014400	Hs.11950		GPI-anchored metastasis-associated prote	3.6
	431493 AT	791493	Hs.129873	SS,p450,p450	ESTs, Wealdy similar to A36036 cytochrom	3.6
	428966 AF	059214	Hs.194687	•	cholasteral 25-hydroxylase	3.6
	414175 AL		Hs 103849	TM,hemopexin,Peptidase_M10,hemopexin,Pe	ohyoothatical proje'n DKFZo761D112	3.6
55	455325 AV		113,100010	TM.ion_trans.K_tetra.	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
33						
	429597 NA				a disintegrin and metalloproteinase doma	3.6
	425320 U2			,, -, -, -, -, -, -, -, -, -, -, -, -, -,	fatty ecid synthase	3.5
	431854 AA		Hs.271699	ims,ss	polymerase (DNA directed) lota	3.5
	407104 S5	7296	Hs.323910	SS,TM,SH2,PH,pldnase,Recep_1_domain,Fui	iv-erb-b2 avian erythroblastic laukemia v	3.5
60	449051 AV			SS	HER2 receptor lyrosina trinase (c-erb-b2,	3.5
	434398 AA			pkinase,POLO_box,SS_pkinase,POLO_box,	serum-inducible hinese	3.5
					hyposheccal protein FLJ20093	
	454042 H2					3.5
	407756 AA				ubiqu'iin specific protease 18	3.5
	401464 AF				histone deacelylase 5	3.5
65	412970 AB	3026436	Hs.177534	DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
	412049 N5	3437	Hs.18268	SS adenylatekinase,	adenylate kinase 5	3.5
	425776 U2				parathyroid homone receptor 2	3.4
					, , , , , , , , , , , , , , , , , , , ,	

	407846 AA426202 Hs.40403	TM,ABC_membrane,ABC_tran,Ribosomal_9	S4eCbp/p300-interacting transactivator, wit	3.4
	406925 L34041 Hs.9739		PE-glycerol-3-phosphate dehydrogenase 1 (so	3.4
	445873 AA250970 Hs.251946	SS,rm,PABP,pkinase,14-3-3,rm	poly(A)-binding protein, cytoplasmic 1-l	3.4
_	418054 NM_002318Hs.83354	SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	. 3.4
5	406815 AA833930 Hs.288036	SS,IPPT,	tRNA Isopentenytpyrophosphate transferas	3.4
	410530 M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	407021 U52077	• • • • •	gbt luman marinert transposase gene, comp	3.4
	421168 AF182277 Hs.330780	SS,p450,SS	cylochrome P450, subfamily IIB (phenobar	3.4
	431473 AA825686 Hs.321176	SS	ESTs, Wealdy similar to \$65824 reverse t	3.4
10	408101 AW968504 Hs.123073	pkinase,	CDC2-related protein kinase 7	3.4
	422083 NM_001141Hs.111256	lipoxygenase PLAT,	arachidonate 15-lipoxygenase, second typ	3.3
	411393 AW797437 Hs.69771	SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	3.3
	435767 H73505 Hs.117874	SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
	433068 NM_006456Hs.288215	SS.Pribosyltran.	sialyltransferase	3.3
15	426928 AF037062 Hs.172914	SS,adh short,TGF-beta,TGFb propeptide	retinol dehydrogenase 5 (11-cis and 9-ci	3.3
	414575 H11257 Hs.22968	SS pkinase k	Homo sapiens clone IMAGE:451939, mRNA se	3.3
	445941 Al267371 Hs.172636	SS,SS,lipoxygenase,PLAT	ESTS	3.3
	444542 Al161293 Hs.280380	SS,SS,Peptidase_M1,EGF,ig,lectin_c,sushi	aminopeptidase	3.3
	425741 AF052152 Hs 159412	pkinase.	Homo saplens clone 24628 mRNA sequence	3.3
20	434228 Z42047 Hs.283978	SS,TM,7tm_1	Homo saplens PRO2751 mRNA, complete cds	3.3
_•	433264 D85782 Hs.3229	00)	cysteine dioxygenase, type I	3.3
	400419 AF084545	SS.Peptidase_M1,	Target	3.3
	439750 AL359053 Hs.57664	TM Integrin_B Rich_B lectin.rm	Homo saplens mRNA full length insert cDN	3.3
	417757 R19897 Hs.106604	death, ZU5, pkinase, Activin_reco,	ESTs	3.3
25	452194 Al694413 Hs.332649	SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
	421458 NM_003654Hs.104576	SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
	443767 BE562136 Hs.9736	SS,PCLRasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropaln) 26S subu	3.2
	422648 D86983 Hs.118893	peroxidase,LRRCT,	Melanoma associated gene	3.2
	423431 AA326062	SS.p450.p450	gb:EST29171 Cerebellum II Homo seplens c	3.2
30	451264 Al768235	SS,Trehalase	gbwg82g08x1 Soares_NSF_F8_9W_OT_PA_P_S	3.2
	452110 T47667 Hs.28005	SS,TM,Activin_recp,pkinase	Homo saplens cDNA FLJ11309 fis, done PL	3.2
	439963 AW247529 Hs.6793	TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
	453941 U39817 Hs.36820	SS.DEAD.HRDC.helicase_C.	Bloom syndrome	3.1
	406664 L34041 Hs.9739	SS,TM,transport_prot,SWIB,RhoGAP,DAG_F		glycerol-3-
35	phosphate dehydrogenase 1 (so	3.1	•	9,,0000
	453487 R31770 Hs.23540	TM,7tm_1,	ESTa	3.1
	420911 U77413 Hs.100293		O-linked N-acetylglucosamine (GlcNAc) tr	3.1
	443171 BE281128 Hs.9030	SS,TM,7tm_1,rm,SS	TONDU	3.1
	452256 AK000933 Hs.28661	TM.GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
40	432201 Al538613 Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protesse, serine 3	3.1
. •	419150 T29618 Hs.89640	TM.pkinase.fn3.	TEX lyrosine kinase, endothelial (venous	3.1
	444443 Al149286 Hs.55099	SS	rab6 GTPase activating protein (GAP and	3.1
	426283 NM 003937Hs.169139	•	kynureninase (L-kynurenine hydrolase)	3.1
	436291 BE568452 Hs.5101	SS, abinydrolase,	protein regulator of cytokinesis 1	3.1
45	450223 AA418204 Hs.241493	SS,pro Isomerase.	natural killer-tumor recognition sequenc	3.1
	424269 AW137691 Hs.199754	SS,TM,7tm_2.GPS	ESTs	3.1
	448105 AW591433 Hs.298241	SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
	452560 BE077084 Hs.336432	SS,rm,zf-RanBP,pkinase,C2,pkinase_C,DAG		3.0

TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accessions
	420854	197072_1	AW296927 Al684514 Al263168 AA281079
20	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566 1	AA410943 AW948953 AA334202 AA332882
	451264	863988_1	AI768235 R31400 H29082 H23107
	455325	1279475_1	AW895719 N31451 N41451
	456207	1650781	AA193450

TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref;	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham L et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham L et al., Nature (1999) 402-489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.
15		

13	Pkey	Ref	Strand	Nt_position
20	402230 402408 402578 403593 403943	8117619 9966312 9796239 9884928 6862650 7711864 7684554	Phis Minus Minus Phis Minus Phis Minus	90044-90184,91111-91345 29782-29932 110326-110491 66350-66496 62554-62712,69449-69602 100742-100904,101322-101503 82121-83229

TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 22 shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85th percentile value for 12 non-malignant breast specimens, and the 96th percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10

5

Pkey: Unique Eos probeset Identifier number

ExAcon: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene titte

15 Unigene Title

Ratio of 90th percentile tumor to 85th percentile normal breast tissue

	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	,			•	
	400292	AA250737	Hs.72472	BMP-R1B	51.5
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	38.3
	400297	Al127076	Hs.334473	hypothetical protein DKFZp564O1278	29.9
	431448	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	26.9
25		Al955040		ESTs, Wealty similar to transformation-r	25.8
		M86849		gap junction protein, beta 2, 26kD (conn	23.2
		X54942	Hs.83758	CDC28 protein kinase 2	22.6
	407980	AA046309		abczf12f01.s1 Soares, fetal heart NbHH19W	19.8
	414646	AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
	409041	AB033025	Hs.50081	KIAA1199 protein	17.6
	412140	AA219691	Hs.73625	RAB6 Interacting, kinesin-like (rabkines	17.6
	407824	AA147884	Hs.9812	Homo sapiens dDNA FLJ14388 ffs, clone HE	17.1
	453160	Al263307	Hs.239884	H2B histone family, member L	17.0
35	407137	T97307		gbcye53h05.s1 Soares fetal liver spleen	16.1
	425692	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	16.1
	438533	Al440266	Hs.170673	ESTs, Wealty similar to T24832 hypotheti	16.0
	428227	AA321649	Hs.2248	small inducible cytokine subfamily 8 (CX	15.5
	444342	NM_014398	8Hs.10887	similar to lysosome-associated membrane	15.1
40	422505	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.9
	430515	AA746503	Hs.283313	ESTs	14.7
	417308	H60720	Hs.81892	KIAA0101 gene product	14.4
	452744	AI267652	Hs.30504	Homo saptens mRNA: cDNA DKFZp434E082	(fr14.4
	412446	Al768015	Hs.92127	ESTs	14.2
45	415539	AI733881	Hs.72472	BMP-R1B	14.1
	435496	AW840171	Hs.265398	ESTs, Weakly similar to transformation-r	13.8
	438209	AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	13.8
	400205	NA		NIM_006265":Home saplens RAD21 (S. pomb	e)13.5
	430965	AA489732	Hs.154918		13.4
50	415263	AA948033	Hs.130853	ESTs	13.3
	451952	AL120173	Hs.301663	ESTs	13.2
		BE280074	Hs.23960	cyclin B1	13.2
	406685	M18728		gb:Human nonspecific crossreacting antig	13.0
	406690	M29540	Hs.220529	carcinoembryonic antigen-related cell ad	12.8
55		NM_000788			12.8
-		U33632	Hs.79351	potassium channel, subfamily K, member 1	12.7
		Al493046	Hs.146133		125
		BE218239	Hs.202656		12.5
		AA193450		gbzzr40e07.r1 Soares_NhHMPu_S1 Homo sa	
60		AA436989	Hs.121017	H2A histone family, member A	12.2
		AW190902		cysteine knot superfamily 1, BMP antagon	12.2
			Hs.104106		12.2
	TUITIO	1,0000		20.4	

PCT/US02/02242

	420024	AED44407	No 400424	small inducible cytokine B subfamily (Cy	12.1
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	12.0
	434408	Al031771	Hs.132586	ESTs	12.0
	446591	H44186	Hs.15456	PDZ domain containing 1	11.9
5	431385	BE178536		membrane-spanning 4-domains, subfamily A	11.8
•				calmodulin 2 (phosphorylase kinase, delt	11.7
		NM_00615		nel (chicken)-like 2	11.7
	433365	AF026944	Hs.293797	ESTS	11.6
	437866	AA156781	Hs.74170	metallothionein 1E (functional)	11.5
10	412472	AW975398	Hs. 293836		11.4
			Hs.21948	ESTs	11.3
					11.3
		AW600291		hypothetical protein FLJ10430	44.0
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	11.3
		BE336654		••	11.2
15	423600	A1633559	Hs.310359	ESTs	11.2
	430770	AA765694	Hs.123296	ESTs	11.0
	421037	A1684808	Hs.197653	programmed cell death 9 (PDCD9)	10.9
		N78223		transcription factor	10.7
		AA576953		hypothetical protein FLJ13352	10.6
20		AW965339			10.6
20					
		Al370413		hypothetical protein FLJ22418	10.4
		W67883		paternally expressed 10	10.4
	447342	Al199268	Hs.19322	Homo saplens, Similar to RIKEN cDNA 2010	
	424905	NM_002497	7Hs.153704	NIMA (never in mitosis gene a)-related k	10.1
25	453619	H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, com	p10.1
		AW167087			10.1
	42A277	AW427449	He 306603	Homo sapiens cDNA FLJ11382 fis, clone HE	
					10.1
		AA399272			
20		A1624342	Hs.170042		10.0
30		A1926047	Hs.162859		10.0
		AL355715		programmed cell death 9	9.9
	424590	AW966399	Hs.46821	hypothetical protein FLJ20086	9.9
	432169	Y00971	Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
	438950	H23789	Hs.144530		9.9
35		Al655499	Hs.161712	The state of the s	9.8
JJ					9.8
					9.7
			(15.411.03	gb:C16391 Clontech human aorta polyA mRN	
		C16391	11- 40077		
40		AA151342		CGI-147 protein	9.7
40		AJ064690	Hs.171176		9.7
	442145	AJ022650	Hs.8117	erbb2-Interacting protein ERBIN	9.7
	435570	AF212222	Hs.177812	uncharacterized bone marrow protein BM04	9.7
	439820	AL380204	Hs.283853	Homo sapiens mRNA full length insert cDN	9.6
				cholesterol 25-hydroxytase	9.6
45		D60730	Hs.57471		9.6
73		A1375499	Hs.27379		9.5
		R31178			9.3
					9.3
	415385	R17798	Hs.7535		9.3
50	422026	U80736	Hs.110826	trinucleolide repeat containing 9	9.2
	432596	AJ224741	Hs.278461	matriin 3	9.2
	439451	AF086270	Hs.278554	heterochromatin-like protein 1	9.2
		AA410943		gb:zl32h03.rl Soares ovary tumor NbHOT H	9.1
			He 38178	hypothetical protein FLJ23468	9.1
55				ESTs, Moderately similar to ZN91_HUMAN Z	
<i>JJ</i>					
		AW732573			9.0
		AI076089	Hs.292239		9.0
		Y00272	Hs.184572		8.9
		A1767756	Hs.82302	Homo sapiens cDNA FLJ14814 fls, clone NT	8.9
60	402408	NA		NM_030920*Homo saplens hypothetical pro	8.9
	418601	AA279490	Hs.86368		8.8
		W03242	Hs.44898	Homo saplens clone TCCCTA00151 mRNA se	
		Al198719	Hs.176376		8.8
CE		AW296024			8.8
65			Hs.145968		8.8
		AI745649	Hs.26549		8.7
	AA717R	AW504641	He 102417	FSTe	87

	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	8.6
	415857	AA866115		Homo saplens cDNA FLJ11381 fis, clone HE	8.6
		AJB51474	Hs.163944		8.6
_				CTP synthase	8.4
5		AW067903		collagen, type XI, alpha 1	8.4
		AA382207		ecotropic viral integration site 28	8.3
		AA767373		ESTs, Moderately similar to ALU1_HUMAN A	
		BE268362		DKFZP434G232 protein COBW-like protein	8.2 8.2
10				protein tyrosine phosphatase, receptor t	8.2
10		AJ132592		zinc finger protein 281	8.2
		X65724	Hs.2839	Nomie disease (pseudoglioma)	8.1
	446258	AI283476	Hs.263478		8.1
		AW876523		hypothetical protein FLJ12910	8.1
15				Homo saplens cDNA: FLJ23523 fis, clone L	8.1
		AA781795			8.0
				ESTs, Wealdy similar to 2109260A B cell	8.0
				DNA replication factor	8.0
20		AW293165 AA379597		HSPC150 protein similar to ubiquitin-con	8.0 8.0
20				AF15q14 protein	8.0
		U29926	Hs.83918	adenosine monophosphate deaminase (isofo	
	400285			Eos Control	7.9
		AF039241	Hs.9028	histone deacetylase 5	7.9
25		M18728		gbd-luman nonspecific crossreacting antig	7.8
		D43945		transcription factor EC	7.8
		AA99352/ Al161293		hypothetical protein FLJ23403 aminopeptidase	7.8
		A1683487		wingless-type MMTV integration site famil	7.8 7.7
30		AL110216			7.6
		H69912	Hs.48269		7.6
	437207	T27503	Hs.15929	hypothetical protein FLJ12910	7.6
		AK001741			7.6
35		J05070			7.5 7.5
55		NM_016293		matrix metalioproteinase 9 (gelatinase 8 bridging integrator 2	7.5 7.5
		H69125	Hs.133525		7.5
		M97711			7.5
40		AW512260			7.4
40					7.4
		NM_001809 Al391662		centromere protein A (17kD) Homo saplens, clone MGC:12318, mRNA, cor	7.4 -7.4
				ELL-RELATED RNA POLYMERASE II, ELON	
		BE391804			7.3
45	400268			NM_003292:Homo sapiens translocated prom	
		AF086332			7.3
		AL138272			7.3
			Hs.109370		7.3 7.2
50					7.2 7.1
					7.1
				ESTs, Weakly similar to LEU5_HUMAN LEUK	
		AA398155	Hs.97600		7.0
<i>e e</i>		A)475858		gb:to87d07.x1 NCL_CGAP_CLL1 Homo sapier	
55				Homo sapiens breast cancer antigen NY-BR	
		BE062906 AK001468			7.0 7.0
		AA808229			6.9
		AW241821			6.9
60					8.8
	449517	AW500106	Hs.23643	serine/threonine protein kinase MASK	8.8
					8.8
		AA135257	Hs.47783 Hs.193002		6.8
65		AI767056 AF123050			6.7 6.7
5 5					6.7 8.7
		AA393907			6.7

	419839	U24577	Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
	437740	AA810265	Hs.122915		6.7
		Al910275	Hs.1406	trefolf factor 1 (pS2)	6.7
5		AW023482		ESTS	6.6
3		NM_00381		a disintegrin and metalloprotetnase doma CGI-62 protein	6.6 6.6
		Al215069	Hs.89113	ESTS	6.5
		Al798680	Hs.25933	ESTs	6.5
		N40449		ESTs, Wealthy similar to S38383 SEB4B pro	6.5
10		Al151418		protein phosphatase 3 (formerly 2B), cat	6.4
				cystatin SN	6.4
		AF026941		Homo sapiens cig5 mRNA, partial sequence	6.4
		X52509 AJ820961	Hs.193465	tyrosine aminotransferase	6.4 6.4
15				inositol polyphosphate-4-phosphatase, ty	6.4
		U65011	Hs.30743	preferentially expressed antigen in mela	6.4
•	439452	AA918317	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro	6.4
		AJ235664		gbd-lomo sapiens mRNA for immunoglobulin	6.3
20		Al222020		CoccaCrisp	6.3
20				clone HQ0310 PRO0310p1 ESTs, Wealdy similar to T17226 hypotheti ,	6.3 6.2
		Al193043 AA394183	Hs.26873	ESTS Vecasity Series to 117220 hypothes	6.2
	402578	70007100	, DILLOUTO	C1001134:glj2117372 plr 65981 fatty ac	6.2
		AW161391	Hs.709	deoxycytidine klnase	6.1
25		W17064		SWI/SNF related, matrix associated, acti	6.1
		T16971		ESTs, Weakly similar to A43932 mucin 2 p	6.1
		A1082692 A1694143	Hs.134662	programmed cell death 4	6.1 6.1
		BE440042		matrix metalloproteinase 3 (stromelysin	6.1
30		Al126772	Hs.40479	ESTs	6.0
-		BE463721		putative G protein-coupled receptor	6.0
		U23752	Hs.32964		6.0
		J04088		topolsomerase (DNA) il alpha (170kD)	6.0
35		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters KIAA0403 protein	6.0 6.0
33				ESTs, Weakly similar to ALU1_HUMAN ALU	
		AA583206	Hs.2156	RAR-related orphan receptor A	6.0
		M31126		matrix metalloproteinase 11 (MMP11; stro	6.0
40		R45154	Hs.106604		6.0
40				ESTs, Weakly similar to Con1 [H.sapiens]	6.0
		AA972965 X81334	Hs.2936		6.0 6.0
		AA100847		matrix metalloproteinase 13 (collagenase ESTs, Highly similar to AF174600 1 F-box	5.9
		AI831297	Hs.123310		5.9
45		AW972512		sin3-associated polypeptide, 30kD	5.9
		AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Hc	
				CGI-83 protein	5.9
		AI793124 AWGERONA	Hs.144479	hypothetical protein FLJ22624	5.9 5.8
50		A1005043	Hs.24143	Wiskoti-Aldrich syndrome protein interac	5.8
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	5.8
		A1375572	Hs.172634		5.8
	434094	AA305599	Hs.238205	hypothetical protein PRO2013	5.8
55				SEC22, vesicle trafficking protein (S. c	5.8
<i>)</i>		AI571940 T93500	Hs.7549 Hs.28792	ESTs Homo sapiens cDNA FLJ11041 fis, clone PL	5.8 5.8
		Al299139	Hs.17517		5.8
		AJ033965		sterol-C4-methyl oxidase-like	5.8
		X07820	Hs.2258		5.7
60				ESTs, Moderately similar to \$65657 alpha	5.7
		AA831879			5.7 5.7
		W47595 NM 00711!		transforming growth factor, beta 2 furnor necrosis factor, alpha-induced pro	5.7 5.7
				hypothetical protein MGC14797	5.7
65		AW016531			5.7
	446203	Z47553	Hs.14286	flavin containing monooxygenase 5	5.7
	428336	AA503115	Hs.183752	microseminoprotein, beta-	5.6

	430379	AF134149	Hs.240395	potassium channel, subfamily K, member 6	5.6
	422835	BE218705	Hs.121378	metallothionein-like 5, testis-specific	5.6
	444758	AL044878	Hs.11899	3-hydroxy-3-methylglutaryi-Coenzyme A re	5.6
	443426	AF098158	Hs.9329	chromosome 20 open reading frame 1	5.6
5	400301	X03635	Hs.1657	estrogen receptor 1	5.6
	447078	AW885727	Hs.301570		5.6
	432015	AL157504	Hs.159115	Homo sapiens mRNA; cDNA DKFZp5860072	24 (15.5
			Hs.212184		5.5
	439809	R41396	Hs.101774	hypothetical protein FLJ23045	5.5
10	415786	AW419198	Hs.257924	hypothetical protein FLJ13782	5.5
•	456373	BE247706	Hs.89751	membrane-spanning 4-domains, subfamily A	5.5
	401645	NA		C16001440 gij12330704 gbjAAG52890.1 jAF	35.5
	437967	BE277414	Hs.5947	mel transforming oncogene (derived from	5.5
	445885	AI734009	Hs.127699	KIAA1603 protein	5.4
15	439138	AJ742605	Hs. 193696	ESTS	5.4
	440270	NM_01598	6Hs.7120	cytokine receptor-like motecule 9	5.4
	437536	X91221	Hs.144465	ESTs	5.4
	438167	R28363	Hs.24286	ESTs	5.4
	452741	BE392914		Homo sapiens cDNA FLJ11344 fls, clone PL	
20		H59846		ESTs, Moderately similar to ALU7_HUMAN A	5.4
	413554	AA319146	Hs.75426	secretogranin II (chromogranin C)	5.4
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648	ESTs	5.4
0.5	446382	AW205168	Hs.150823	ESTs	5.4
25	422406	AF025441	Hs.116206	Opa-interacting protein 5	5.3
		AA576635		CGI-48 protein	5.3
			Hs.86693		5.3
		U91616	Hs.91640	nuclear factor of kappa light polypeptid	5.3
20		H39960		Homo saplens cDNA FLJ12280 fis, clone MA	
30			Hs.13429	Homo sapiens clone 24787 mRNA sequence	
				HER2 receptor tyrosine kinase (c-erb-b2,	5.2
				hypothetical protein DKFZp434J037	5.2
				transcription factor 19 (SC1)	5.2
35		U65590	Hs.81134		5.2
33	420004	APO00742	13.103043 13.402720	polyadenylate binding protein-interactin	5.2
	4200U4 A27A27	ADDITION	Hs.177936	hypothetical protein FLJ20706	5.2
•	403485	AFUI1343	ns. 177330	C3001813*:gi]12737279]ref[XP_012163.1] k	5.2 5.2
		A A SREROA	No 112/02	S100 calcium-binding protein A7 (psorias	5.2 5.1
40	421937	Al878857		hematological and neurological expressed	5.1
70		X69490	Hs.172004		5.1
		X70697	Hs.553		5.1
		M81933	Hs.1634		5.1
		AJ810054	Hs.14119		5.1
45				ESTs, Moderately similar to ALU7_HUMAN A	
		AL121278			5.1
	404347				5.1
		M30703	Hs.270833	~	5.1
	429113				5.1
50	436291	BE568452			5.1
	450603	R43646	Hs.12422		5.1
	434725	AK000796	Hs.4104	hypothetical protein .	5.0
	435981		Hs.188620		5.0
	407376	AA993138	Hs.142287	ESTs, Weakly similar to ALUF_HUMAN IIII	5.0
55	431689	AA305688	Hs.267695	UDP-GatbelaGlcNAc beta 1,3-galactosyltr	5.0
	405348			C7001684:gl[12698061]db[[BAB21849.1] (AB	5.0
	436196	AK001084	Hs.333498	Homo saplens cONA FLJ10222 fis, clone HE	5.0
			Hs.103238		5.0
	410196	A1936442	Hs.59838	hypothetical protein FL110808	5.0
60		NM_006235	Hs.2407	POU domain, class 2, associating factor	5.0
		AU076643	Hs.313	secreted phosphoprotein 1 (osteopontin,	4.9
	403329			Target Exon	4.9
		BE623003		Homo sapiens done TCCCTA00142 mRNA se	qu4.9
~=			Hs.129598		4.9
65		AW371048	Hs.93758	H4 histone family, member H	4.9
	424128	AW966163		gb:EST378236 MAGE resequences, MAGI Hor	mo4.9
	408873	ALU46017	Hs.182278	calmodulin 2 (phosphorylase kinase, delt	4.9

	401 2 IV	MY0000214 113,41230	involcent recens in raignounding h	4.3
	432606	NM_002104Hs,3066	granzyme K (serine protease, granzyme 3;	4.9
		R10799 Hs.191990		4.8
			ESTs, Weakly similar to AT2A_HUMAN POT	
_				
5		Z45051 Hs.22920		4.8
	408369	R38438 Hs.182575	solute carrier family 15 (H??? transport	4.8
	431645	AF078849 Hs.266483	dynein light chain-A	4.8
			Homo sapiens cDNA FLJ11576 fis, clone HE	AR
				4.8
10		H93281 Hs.10710		
10			GDNF family receptor alpha 1	4.8
	452827	A1571835 Hs.55468	ESTs	4.8
	414222	AL135173 Hs.878	sorbital dehydrogenase	4.8
		AL161999 Hs.77324		4.8
		M93119 Hs.89584	insulinoma-associated 1	4.8
15				
15		AA233056 Hs.191518		4.8
	447033	Al357412 Hs.157601		4.8
	451621	AJ879148 Hs.26770	fatty acid binding protein 7, brain	4.7
	419968	X04430 Hs.93913	Interleukin 6 (Interferon, beta 2)	4.7
		NM_014479Hs.145296		4.7
20			hypothetical protein FLJ10326	4.7
20	401000	DCZ4ZDU3 113.ZUZUZU	Home contact and the Party of the state of	
			Homo saplens cDNA: FLJ22463 fis, clone H	4.7
	416814	AW192307 Hs.80042	dolichyl-P-Gic:Man9GlcNAc2-PP-dolichylgl	4.7
	439897	NM_015310Hs.6763	KIAA0942 protein	4.7
			nucleoporin 153kD	4.7
25			glutathlone reductase	4.7
23		AF220104 113.121324		
	405801		NM_000390:Homo saplens choroideremia (R	
	432435	BE218886 Hs.282070		4.6
	439544	W26354 Hs.28891	hypothetical protein FLJ11360; artemis p	4.6
	425354	U62027 Hs.155935	complement component 3a receptor 1	4.6
30	436027	Al864053 Hs.39972		4.6
-		AW963062 Hs.337404		4.6
				4.6
	403366	NA	Target Exon	
	402542		Target Exon	4.6
	450193	Al916071 Hs.15607	Homo sapiens Fanconì anemia complementa	t 4.6
35	411678	Al907114 Hs.71465	squalene epoxidase	4.6
			CDP-diacytglycerol synthase (phosphatida	4.6
		Al459306 Hs.24908	EST8	4.5
				4.5
		AW138959 Hs.245123		
40		AM72209 Hs.323117	ESIS	4.5
40	447388	AW630534 Hs.76277	Homo sapiens, clone MGC:9381, mRNA, con	np4.5
	448140	AF146761 Hs.20450	BCM-like membrane protein precursor	4.5
	452561	A)692181 Hs.49169	KIAA1634 protein	4.5
		AW962128	gb:EST374201 MAGE resequences, MAGG I	
				4.5
AE		AW277121 Hs.254881		
45			fatty acid desaturase 2	4.5
	426075	AW513691 Hs.270149	ESTs, Wealdy stmilar to 2109260A B cell	4.4
	437259	Al377755 Hs.120695	ESTs	4.4
	400409	AF153341 Hs.283954	Homo sapiens winged helix/forkhead trans	4.4
		AA121673 Hs.59757		4.4
50				4.4
J U		AJ815206 Hs.99395	ESTS	
	401868		Target Exon	4.4
	418819	AA228776 Hs.191721	ESTs	4.4
	406348		Target Exon	4.4
		AW895387	gb:QV4-NN0038-300300-157-c10 NN0038 H	omo4.4
55	AZREEN	AW297880 Hs.98661		AA
<i>JJ</i>			-LOTS CTOOCA SOARRO DTA LOT CTOSCA LL	T.T
		AW862214	gb:QV4-CT0361-301299-074-b05 CT0361 He	
		BE081342 Hs.283037		4.4
	423291	NM_004129Hs.126590	guanytate cyclase 1, soluble, beta 2	4.4
	423456	AL110151 Hs.128797	DKFZP586D0824 protein	4.4
60		H26735 Hs.91668	Homo saplens done PP1498 unknown mRN/	
J			low density lipoprotein-related protein	4.3
		AA706003 Hs.99387		4.3
	429922	Z97630 Hs.226117	H1 histone family, member 0	4.3
	421379	Y15221 Hs.103982	small inducible cytokine subfamily B (Cy	4.3
65		X03363	HER2 receptor tyrosine kinase (c-erb-b2,	4.3
55		AL041243 Hs.174104		4.3
	446595	15/448 Hs.15467	hypothetical protein FLJ20725	4.3

	403011	NA		ENSP00000215330*:Probable serine/threoni	
		Al365384		Homo sapiens cDNA FLJ11570 fis, clone HE	4.3
		NM_00194		E2F transcription factor 3	4.3
~		AA687538		tetraspan 1	4.3
5		-		KIAA0704 protein	4.3
		AW188551		hypothetical protein FLJ14007	4.3
		Al091795			4.3
		AJ694413		olfactory receptor, family 2, subfamily	4.3
10		M63835	Hs.77424		4.2
10				Homo sapiens cDNA FLJ14035 fis, clone HE	
			Hs.28005		
				nucleolar phosphoprotein Nopp34	4.2
		AW953937		ESTS	4.2
15				ESTs, Weakly similar to T47184 hypotheti	4.2
15		AI085198	Hs.164226		4.2
				ESTs, Wealdy similar to S72482 hypotheti	4.2
		BE091926		mitotic spindle colled-coll related prot DEME-6 protein	4.2 4.2
		AA902953			4.2
20		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	4.2
20				hypothetical protein FLJ22635	4.2
				protease, serine, 23	4.2
		BE247676		E-1 enzyme	4.2
		AK001376		hypothetical protein FLJ10514	4.1
25		AW779318		ESTs	4.1
				chloride channel, calcium activated, fam	4.1
		AW294909			4.1
	410129	BE244074	Hs.58831	regulator of Fas-Induced apoptosis	4.1
	427521	AW973352	Hs.290585	ESTs	4.1
30				matrix metalloproteinase 11 (MMP11; stro	4.1
	-	AF041163	Hs.74647		4.1
		BE562826		gb:601336534F1 NIH_MGC_44 Homo saplen	
		AK000136		asporin (LRR class 1)	4.1
25			Hs.180669	conserved gene amplified in osteosarcoma	4.1
35	405850		I h- 400400	Target Exon	4.1
		Al732892 AW292425	Hs.190489		4.0
	400284		NS. 103404		4.0 4.0
		N91453	Hs.102987		4.0
40		U20158	Hs.2488		4.0
. •		AW797437			4.0
		U79293			4.0
		AA013051			4.0
	419092	J05581	Hs.89603		4.0
45	443147	Al034351	Hs.19030	ESTs	4.0
	408633	AW963372	Hs.46677	PRO2000 protein	4.0
		T32982	Hs.102720	ESTs	4.0
					4.0
5 0		BE250127			3.9
50		AW630088		Homo saplens mRNA; cDNA DKFZp564B1264	
		AW411479	HS.848		3.9
	404580	4 DO4 DO 4 F	11- 07057	NM_014112*:Homo saplens trichorhinophala	
		AB018345	HS.2/00/		3.9
55		AA031956 U03272	He 70/22	gb:zk15e04.s1 Soares_pregnant_uterus_NbH fibrillin 2 (congenital contractural ara	
<i>))</i>	410000 426647	AADADARA	110.7 0-10.C 140 20.4101		3.9
	4200H	AI 117/06	He 200102		3.9 3.9
		AW134924			3.9
					3.9
60			Hs.110165		3.9 3.9
		Al201183	Hs.130251		3.9
					3.9
		AW935490	Hs.14658	Human chromosome 5q13.1 clone 5G8 mRNA	3.9
		BE019020	Hs.85838	solute carrier family 16 (monocarboxylic :	3.9
65	414998	NM_002543	Hs.77729		3.9
		AA809875	Hs.25933	ESTs	3.9
	419741	NM 007019	Hs.93002		20

				Address of the first of the second		
		AA263172 Hs		protein tyrosine phosphatase, non-recept	3.9	
				ESTs, Wealdy similar to Z195_HUMAN ZINC	3.8	
	428514	AW236861 Hs	s.193139	ESTs	3.8	
	434521	NM_002267Hs	s.3886	karyopherin alpha 3 (importin alpha 4)	3.8	
5	409425	U40462 Hs	s.54452	zinc finger protein, subfamily 1A, 1 (lk	3.8	
	439560	BE565647 Hs	s.74899	hypothetical protein FLJ12820	3.8	
				Homo sapiens cDNA FLJ14354 fis, clone Y7	3.8	
	400021			AFFX control - HUMISGF3AM97935_MA	3.8	
		BE466639 Hs		Homo saplens cDNA FLJ13591 fs, done PL	3.8	
10		Al267371 · Hs			3.8	
10					3.8	
		AA631739 Hs				
		AW207206 Hs			3.8	
		AM46444 He		ESTs, Weakly similar to B28096 line-1 pr	3.8	
	401045			C11001883*:gij6753278 ref NP_033938.1 c	3.8	
15		AW449612 Hs			3.8	
	423397	NM_001838Hs	s.1652	chemokine (C-C motif) receptor 7	3.8	
•	447630	A1660149 Hs	s.44865	lymphoid enhancer-binding factor 1	3.8	
	436391	AJ227892 H:	s.146274		3.8	
	413011	AW068115 Hs	s.821	biglycan	3.8	
20		Al767949 Hs		_===	3.8	
		NM_003512H		H2A histone family, member L	3.8	
				carboxypeptidase B1 (tissue)	3.8	
		AA165232 Hs			3.8	
				Homo sapiens mRNA; cDNA DKFZp761J1112		3.8
25		AL353944 Hs			3.7	3.0
25			5.3239 10	HER2 receptor tyrosine kinase (c-erb-b2,		
	400286		404500	C16000922:gi[7499103[pir]]T20903 hypothe	3.7	
			s.191533		3.7	
		AW900992 Hs		DKFZP586D2223 protein	3.7	
20				hypothetical protein FLJ22439	3.7	
30		AA371307 H			3.7	
				kinectin t (kinesin receptor)	3.7	
	457001	J03258 Hs	s.2062	vitamin D (1,25-dihydroxyvitamin D3) re	3.7	
		AW406878		gb:UI-HF-BLO-adg-g-06-0-UILr1 NiH_MGC_37		
•	417022	NM_014737Hs		Ras association (RalGDS/AF-6) domain fam		
35	436222	Al208737 H:	s.122810	Homo sapiens cDNA FLJ11489 fls, clone HE	3.7	
	430448	Al633553 Hs	s.13303	Homo sapiens cDNA: FLJ21784 fis, clone H	3.7	
	432729	AK000292 H:	s.278732	hypothetical protein FLJ20285	3.7	
	413916	N49813 H:	s.75615	apolipoprotein C-II	3.7	
	421662	NM 014141H	s.106552	cell recognition molecule Caspr2	3.7	
40				normal mucosa of esophagus specific 1	3.7	
				ESTs, Wealdy similar to (defline not ava	3.7	
	406153	70.007.207. 17.		Target Exon	3.7	
		AW873606 H	3000M		3.7	
			s.32989	receptor (calcitonia) activity modifying	3.7	
45		AB011152 H		KIAA0580 protein	3.7	
73				serine (or cysteine) proteinase inhibito	3.6	
				seven in absentia (Drosophila) homolog 2	3.6	
			s.20191		3.6	
				hypothetical protein FLJ22490		
EΛ				ESTs, Wealdy similar to 138022 hypotheti	3.6	
50			s.93837	phosphalidylinositol transfer protein, m	3.6	
				phospholipase A2, group IID	3.6	
			s.2556	turnor necrosis factor receptor superfami	3.6	•
			s.171941		3.6	
	426431	NM_000458H:	s,169853	transcription factor 2, hepatic; LF-B3;	3.6	
55	431843	AA516420 Hs	s.183526	ESTs, Wealdy similar to 138022 hypotheti	3.6	
	426878	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Ho	a.com	i
	434061	AW024973 H	s.283675	NPD009 protein	3.6	
		AV653264 H		Homo saplens cDNA FLJ14666 fis, clone NT		
			s,10844	Homo sapiens cDNA FLJ14476 fis. clone MA		
60				KIAA0129 gene product	3.6	
		AW961434 H		ESTs	3.6	
		NM_000402H		glucose-6-phosphate dehydrogenase	3.6	
			s.3327	Homo sapiens cDNA: FLJ22219 fis. clone H	3.6	
			s.161	cadherin 2, type 1, N-cadherin (neurona)	-	
65		AW015415 H			3.6	
UJ				retinoic acid induced 3	3.6	
					3.6	
	4150/9	R43179 H	s.22895	hypothetical protein FLJ23548	3.6	

3.4

	409619	AK001015	Hs.55220	BCL2-associated athanogene 2	3.6
	430044	AA464510	Hs.152812	ESTS	3.6
	430829	AW451999	Hs.194024		3.6
_		AA380731		Interleukin 2 receptor, gamma (severe co	3.6
5		AF088020		EST	3.6
		H63010	Hs.5740	ESTs	3.5
		AA351647		eukaryotic translation elongation factor	3.5
		AJ418055	Hs.161160		3.5
10		AF234882		suppression of turnorigenicity 7	3.5
10		AA284166		cyclin-dependent kinase Inhibitor 3 (CDK	3.5
		A1907673	113.222355	CEGP1 protein gb:IL-BT152-080399-004 BT152 Homo sapia	3.5
	403212			NM_019595:Homo sapiens intersectin 2 (IT	3.5
		AK000725	Hs 50579	hypothetical protein FLJ20718	3.5
15		AA847843		Homo sapiens, clone IMAGE:3351295, mRN	
		W92147	Hs.118394		3.5
		Z43784	Hs.75893	ankyrin 3, node of Ranvier (ankyrin G)	3.5
•	442295	Al827248	Hs.224398		
	417975	AA641836	Hs.30085	hypothetical protein FLJ23186	3.5
20	433730	AK002135	Hs.3542	hypothetical protein FLJ11273	3.5
			Hs.137007		3.5
				poly(A)-binding protein, cytoplesmic 1-l	3.4
		BE311926		hypothetical protein FLJ12691	3.4
25		AW881145		gb:QV0-OT0033-010400-182-a07 OT0033 H	
23		BE390551 W29092		steroidogenic acute regulatory protein r	3.4
		AJ167877	Hs.7678 Hs.143716	cellular retinoic acid-binding protein 1	3.4
	402470		115.145710	Target Exon	3.4 3.4
			Hs.192249		3.4
30		AW875237		ESTs	3.4
		AI681545		hypothetical protein FLJ13117	3.4
		U61412	Hs.51133	PTK6 protein tyrosine kinase 6	3.4
	422611	AA158177	Hs.118722	fucosyltransferase 8 (alpha (1,6) fucosy	3.4
0.5	423554	M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	3.4
35		AA447492	Hs.20183	ESTs, Wealdy similar to AF164793 1 prote	3.4
	402359			C19001991 gi]12656111[gb AAK00751.1]AF	
			Hs.221504		3.4
		F01020 AA812633	Hs.172004		3.4
40		R11141		ESTs hypothetical protein	3.4 3.4
-10		AJ271216	Hs.22880	dipeptidylpeptidase III	3.4
		AK001763		hypothetical protein FLJ10901	3.4
		Y18418		RuvB (E coli homolog)-like 1	3.4
			Hs.194698		3.4
45		U58766		tissue specific transplantation antigen	3.4
	418286	AA622528	Hs.319825	Homo saplens, clone IMAGE:3616574, mRN/	4,3.4
		AF037335		carbonic enhydrase XII (turnor antigen H	3.4
		AW392550		proteasome (prosome, macropain) subunit,	3.4
50				KIAA0175 gene product	3.3
3 0			Hs.200266		3.3
		A1335773 NM_000505	Hs.270123		3.3
		AW160375		coagulation factor XII (Hageman factor) amyloid beta (AA) precursor-like protein	3.3 3.3
	418327		Hs.84136	paired-like homeodomain transcription ta	3.3
55		AI627393	Hs.258998	ESTs, Wealthy similar to high mobility gr	3.3
	425999	AW513051	Hs.332981	ESTs, Wealdy similar to 138022 hypotheti	3.3
	430280	AA361258	Hs.237868	interleukin 7 receptor	3.3
	407777	AA161071	Hs.71465	squalene enoxidase	3.3
~ ^	426516	BE262660	Hs.170197	glutamic-oxaloacetic transaminase 2, mit	3.3
60	414361	AI086138	Hs.204044	ESTs	3.3
	427080	AW068287	Hs.173466	ras-related C3 botulinum toxin substrate	3.3
•	426429	X73114	HS.169849	myosin-binding protein C, slow-type	3.3
		AA026880		prolactin receptor	3.3
65	428566	U41/63 BE243136	FIS. 104910	clathrin, heavy polypeptide-like 1	3.3
ری			Hs.120910	a disintegrin and metalloproteinase doma	3.3
	430233 411257	AARZROR7		ESTS, Highly similar to IHH_HUMAN INDIAN	3.3
	711231			Andrew Caller on ILIA LANDAN INDIAN	ふむ

	430253	AKUU1514	HS.230844	nypometicai protein FLJ 10002	J.J
	430066	Al929659	Hs.237825	signal recognition particle 72kD	3.3
	436469	AK001455	Hs.5198	Down syndrome critical region gene 2	3.3
				polymerase (DNA directed), eta	3.3
5		H09048	Hs.23606	ESTs	3.3
,		H91882		Dvl-binding protein IDAX (Inhibition of	3.3
	424245	A A 400070	15.110505	Human DNA sequence from clone RP11-2180	
	401210	AA4500/0	HS. 121004	TRUMENT DAY SEQUENCE BOTH COME TO 11-2100	210~
				ret finger protein 2	3.3
4.0		AW270655			3.3
10	408652	R43409 .	Hs.6829	Homo sapiens mRNA for KIAA1644 protein,	3.3
	445142	AW978484	Hs.93842	Homo sapiens cDNA: FLJ22554 fls, clone H	3.3
	426761	AI015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022	(13.3
				ESTs, Wealdy similar to A47582 B-cell gr	3.3
				selenophosphate synthetase 2	3.3
15				c-Myc target JPO1	3.3
13					3.3
		U24683		immunoglobutin heavy constant mu	
	43413/	AA907734	HS.124895	ESIS	3.3
				ESTs, Wealthy similar to A47582 B-cell gr	3.3
		C01765	Hs.38750	hypothetical protein FLJ11526	3.3
20 -	408221	AA912183	Hs.47447	ESTs	3.3
	447519	U46258	Hs.339665	ESTs	3.3
	404755	NA		Target Exon	3.3
		AI821005	Hs 118599		3.2
		AW406289		and the second s	3.2
25				immunoglobulin heavy constant gamma 3 (G	
23			15.300037	NM_002795*:Homo saplens proteasome (pro	33
	400202				
	400222			NM_002082*1-forno sapiens G protein-couple	
				ESTs, Weakly similar to 138022 hypotheti	3.2
••		BE550224			3.2
30		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	3.2
	431563	A1027643	Hs.120912	ESTs	3.2
	442353	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	3.2
	422309	U79745	Hs.114924	solute carrier family 16 (monocarboxylic	3.2
	419703	Al793257	Hs.128151	ESTs	3.2
35	420380	AA640891	Hs.102406	ESTs	3.2
		H04588	Hs.30469	ESTs	3.2
		Al244459		trinucleotide repeat containing 9	3.2
		Al821926	12.710020	gb:nf78f05.x5 NCL_CGAP_Pr3 Homo sapiens	
			Uc 4400E7	polymerase (RNA) III (DNA directed) poly	3.2
40					3.2
40		NM_015156		KIAA0071 protein	3.2
		Al472078	Hs.303662		
		N30714		membrane-spanning 4-domains, subfamily A	
	418739	AA310964	Hs.88012	SHP2 interacting transmembrane adaptor	3.2
	442053	R35343	Hs.24968	Human DNA sequence from clone RP1-233G	
45	434747	AA837085	Hs.220585	ESTs	3.2
	427297	AW292593	Hs.334907	Homo saplens, clone MGC:17333, mRNA, co	m3.2
		AW503785		complement component (3d/Epstein Barr vi	3.2
		AA025386		ESTs, Wealdy similar to \$10590 cysteine	3.2
		AW408337		CD7 antigen (p41)	3.2
50			Hs.38365	KIAA0125 gene product	3.2
J 0		D50915			3.2
		AL047586		RNA binding motif protein 88	
		AW768399			3.2
		W20128	Hs.296039	_	3.2
	418334	AA319233	Hs.5521	ESTs	3.2
55	450223	AA418204	Hs.241493	natural killer-tumor recognition sequenc	3.2
	454365	AW966728	Hs.54642	methlonine adenosyltransferase II, beta	3.2
		AL118668		gb:DKFZp761i0310_r1 761 (synonym: harny2	33.2
		AW405434	Hs. 82575	small nuclear ribonucleoprotein polypept	3.2
		U22029	Hs.334345	cytochrome P450, subfamily IIA (phenobar	3.2
60		BE244638		steroi regulatory etement binding transc	3.2
W					3.2
		NM_003613			
		AI345455	Hs.78915	GA-binding protein transcription factor,	3.2
	416714	AF283770	HS./9630	CD79A antigen (immunoglobulin-associated	3.2
		NM_004380		CREB binding protein (Rubinstein-Taybi s	3.2
65	422166	W72424	Hs.112405		3.2
	409079	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.2
			Hs.233785		3.2

	45358	3 AA03684	9 Hs.61829	Homo saplens cDNA FLJ12763 fis, clone N	TT 32
	44258	0 AI73368	Hs.13023		3.2
	45807	9 AI796870			1923.2
_	42570	0 AF07629	2 Hs.15925	1 forkhead box H1	3.2
5			2 Hs.25338	ESTs	3.2
		4 S57296	Hs.32391	0 v-erb-b2 avian erythroblastic leukernia v	3.2
		5 AJ703172	Hs.12900	5 ESTs, Wealthy similar to 2109260A B cell	3.1
		1 T06199	Hs.23750	6 Dna.J (Hsp40) homolog, subfamily B, memb	e 3.1
10	42031	/ AWZU51		6 interleukin 21 receptor	3.1
10		5 Al278023 3 BE38889		2 1 1 1 2	3.1
		9 AL13758		hypothetical protein FLJ11307	3.1
		1 BE37933	7 NS. 102 14 5 No 24150	9 hypothetical protein DKFZp434K0410 4 proteasome (prosome, macropain) 26S sub	3.1
				3 ESTs, Weakly similar to KIAA1074 protein	
15	43157	4 AW5726	9 Hs 26137	3 hypothetical protein dJ434O14.3	3.1 3.1
	43687	6 Al124756	Hs.5337	isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	40501	7 NA		Target Exon	3.1
	43380	5 AA70691	Hs.11274		3.1
		2 AL353957	7 Hs.28418	hypothetical protein DKFZp434P0531	3.1
20		5 X70297	Hs.2540	cholineroic receptor, nicofinic, alpha p	3.1
	42208	3 NM_0011	41Hs.111250	arachidonate 15-lipoxygenase, second typ	3.1
	41350	7 BE14536	Hs.190064	ESTs, Wealthy similar to 138022 hypotheti	3.1
		9 Al267700			3.1
25		7 A1879263 8 AA89002		Human glucose transporter pseudogene	3.1
23		BE38720		protactin receptor non-metastatic cells 1, protein (NM23A)	3.1
		3 AW24752		platelet-activating factor acetylhydrola	3.1 3.1
		Al638516	Hs.22630	colactor required for Sp1 transcriptiona	3.1
		Al885190		ESTs, Wealthy similar to repressor protei	3.1
30	418478	3 U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
	400814			Target Exon	3.1
	402327			Target Exon	3.1
		AA190712		gb:zp87f09.r1 Stratagene HeLa cell s3 93	3.1
35		AL355722			3.1
33		Al571514	Hs.133022 79Hs.54443		3.1
		AJ245210		chemoldne (C-C motif) receptor 5 gbd-lomo sapiens mRNA for immunoglobutin	3.1
		AF052762		gb:Homo saplens clone csneg8-1 immunogk	3.1
				coronin, actin-binding protein, 1A	3.1
40	414523	AU076633	Hs.76353	serine (or cysteine) proteinase inhibito	3.1
		N38857	Hs.203933		3.1
		D89974	Hs.121102		3.1
		Al399956	Hs.208956		3.1
45	4219U 4 420034	AW/900742		hypothetical protein FLJ20035	3.1
73				ESTs Homo sapiens cDNA FLJ12136 fis, clone MA	3.1
	452823	AB012124	Hs 30698	transcription factor-like 5 (basic helix	
	405381			Target Exon	3.1 3.1
	428746	AW503820	Hs.192861	Spi-B transcription factor (Spi-1/PU.1 r	3.1
50	435147	AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C17:	2 (13.1
		U66468	Hs.159525	cell growth regulatory with EF-hand doma	3.1
-		W88562	Hs.108198	ESTs	3.1
		AA234276		ESTs	3.1
55	438581	AW9///66	HS.292133	ESTs, Moderately similar to 178885 serin	3.1
<i>J J</i>		X60992	Hs.81226	CD6 antigen transcriptional intermediary factor 1	3.0
	420001 417880	BE241595	He RORAR	selectin L. (lymphocyte achesion molecute	3.0
:	402606	000	1 10-020-10	NM_024626:Homo sapiens hypothetical prot	3.0
	401451			NM_004496*:Homo sapiens hepatocyte nucle	
60		AA299652	Hs.111496	Homo sapiens cDNA FLJ11643 fis, clone HE	3.0
	409518	BE384836	Hs.3454	KIAA1821 protein	3.0
		BE561850	Hs.80508	small nuclear ribonucleoprotein polypept	3.0
		Y14768	Hs.890	lymphotoxin beta (TNF superfamily, membe	3.0
c e		X74794	Hs.154443	minichromosome maintenance deficient (S.	3.0
65	401519	41400000		C15000476 - gl 12737279 refpxP_012163.1	3.0
		AM99220		hypothetical protein FLJ10074	3.0
	420013	AL135623	ns.193914	KIAA0575 gene product	3.0

	428423	AU076517	Hs.184276	solute carrier family 9 (sodium/hydrogen	3,0	
	413835	A1272727		fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo santens done 25218 mRNA sequence	3.0	
5	433658	L03678	Hs.156110	immunoglobulin kappa constant	3.0	
_	427666	AI791495	Hs.180142	calmodulin-like skin protein	3.0	
	452514	A1904898		gb:RC-BT068-130399-085 BT068 Homo sapt	en3.0	
	429500	X78565	Hs.289114	hexabrachion (tenascin C, cytotactin)	3.0	
	432485	N90866	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Wealdy similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 Ho	omo	3.0
	453216	AL137566	Hs.32405	Homo saplens mRNA; cDNA DKFZp586G032		3.0
	400929			ENSP00000252232*:Sterol regulatory eleme	3.0	
15	445145	Al961702	Hs.147434	ESTs	3.0	
	432615	AA557191	Hs.55028	ESTs, Wealdy similar to 154374 gene NF2	3.0	
	423279	AW959861	Hs.290943		3.D	
	429392	AL109712	Hs.296506	Homo saptens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Wealty similar to ALUC_HUMAN !!!!	3.0	
20			8Hs.26312		3.0	
	413109	AW389845	Hs.110855	ESTs	3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C	LON	3.0
	421462	AF016495	Hs.104624	aquaporin 9	3.0	
	421750	AK000768	Hs.107872	hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
	438930	AW843633	Hs.306163	hypothetical protein AL110115	3.0	

TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey: CAT nu Accessi	mber:	Unique Eos probeset Identifier number Gene cluster number Genbank accession numbers	ne cluster number	
15	Pkey	CAT num	ber Accessions	Accessions	
20	411743 412138 413269	1221055 1256098 1279172 1356961	1 AW803341 AW803365 AW803403 AW803466 AW803402 AW803413 AW803396 AW803334 AW80335 1 AW862214 AW859811 AW882215 1 AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538 1 BE167526 BE167651 BE076401 R24654	AW803341 AW8 AW862214 AW8 AW895387 AW8 BE167526 BE16	N803355
25	422128	163179_1 211994_1 233566_1		AW881145 AA4	

AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537

424109 235506_1

TABLE 22B

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. "Durnham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Durnham I. et al., Nature (1999) 402:489-495.	
	Strand: Ni_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.	

15				374
	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
	401645	7657839	Minus	34986-35133
	401714	6715702	Plus	96484-96681
25	401866	8018106	Plus	73126-73623
	402327	7656695	Minus	108675-108770,109801-109910
	402359	9211204	Minus	40403-41961
	402408	9796239	Minus	110326-110491
	402470	9797107	Plus	195129-195776
30	402542	9801558	Minus	67076-67594 ·
	402578	9884928	Plus	66350-66496
	402606	9909429	Minus	81747-82094
	403011	6693597	Minus	3468-3623
	403212	7630897	Minus	156037-156210
35	403329	8516120	Plus	98450-96598
	403366	8783692	Minus	49323-49652
	403485	9966528	Plus	2888-3001,3198-3532,3655-4117
	404347	9838195	Plus	74493-74829
	404580	6539738	Minus ·	240588-241589
40	404755	7706327	Minus	53729-53846
	405017	6532084	Plus	35551-35690
	405348	2914717	Minus	43310-43462
	405381	6006920	Minus	7636-8054
	405801		Ptus	63469-63694
45	405850		Phis	13871-14110
	406153	9929734	Minus	12902-13069
	406348	9255985	Minus	71754-71944

TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90th percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0 (i.e. 4-fold down-regulated in tumor vs. normal breast).

Pkey:	Unique Eos probeset identifier number
ExAccn:	Exemplar Accession number, Genbank accession number
UnigeneiD:	Unigene number
Halanaa Tibaa	11-1

Unigene Title: Unigene gene title
R1: Ratio of 50th perce

15

Ratio of 50th percentile normal body tissue to 75th percentile turnor

20	Pkey	ExAcen	UnigeneID	UnigeneTitle	Ratio
•	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	22.4
	428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
	445263	H57646	Hs.42586	KIAA1560 protein	15.4
25	418935	T28499	Hs.89485	carbonic anhydrase IV	15.0
	407228	M25079	Hs.155376	hemoglobin, beta	14.6
	417511	ALD49176	Hs.82223	chordin-like	14.6
	439285	AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
	412442	Al983730	Hs.26530	serum deprivation response (phosphatidy)	13.6
30	410544	A)446543	Hs.95511	ESTs	126
	412047	AA934589	Hs.49696	ESTs	12.2
	422667	H25642	Hs.133471	ESTs	12.0
	406664	L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
	423201	NM 000163	Hs.125180	growth hormone receptor	11.7
35		AF027208	Hs.112360	prominin (mouse)-like 1	10.8
	428769	AW207175	Hs.106771	ESTs	10.6
		X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
		AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
		N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40		Al220684	Hs.272572	hemoglobin, alpha 2	9.5
	447471	AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
	451533	NM 004657	Hs.26530	serum deprivation response (phosphatidy)	9.4
		AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
		Al365585	Hs.146246	ESTs	9.0
45		T53088	Hs.155376	hemoglobin, beta	8.9
		AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
		X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
		D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
		AA779958	Hs.185932	ESTs	8.5
50		AU076442	Hs.117938	collagen, type XVII, alpha 1	8.4
•		AB029496	Hs.59729	semaphorin sein2	8.3
	402195	712020700	110,007.20	NM_004497*:Homo sapiens hepatocyte nucle	8.1
		A1754634	Hs.131987	ESTs	8.1
		Al208121	Hs.147313	ESTs, Weakly similar to 138022 hypotheti	8.1
55		N77976	Hs.272572	hemoglobin, alpha 2	8.0
"		AW377424	Hs.205126	Homo saplens cDNA: FLJ22667 fis, clone H	8.0
•		AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
		AA760849	Hs.294052	ESTs	7.0 7.5
		AK000027	Hs.98633	ESTs	7.5 7.5
60		NM 002599	Hs.154437	phosphodiesterase 2A, cGMP-stimulated	7.5
50		AW973636	Hs.55931	ESTs	7.3 7.4
	430327	WAS 2000	1 13,0000 1	LOIS	1.4

				· ·	
		Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Al150491	Hs.90756	ESTS	7.2
		R20893 AA452006	Hs.325823 Hs.333199	ESTs, Moderately similar to ALU5_HUMAN A ESTs	7.2 7.1
5		AA452006 AW956360	Hs.4748	adenylate cyclase activating polypeptide	7.1
,		Al352340	Hs.131194	ESTs	7.0
		Al219304	Hs.283108	hemoglobin, gamma G	6.9
		AJ446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	6.8
		AA346839	Hs.209100	DKFZP434C171 protein	6.7
10		AJ478427	Hs.43125	esophageal cancer related gene 4 protein	6.7
		AB002058	Hs.113275	purinergic receptor P2X-like 1, orphan r	6.7
	420205	AA256395	Hs.88156	ESTs	6.6
	404368	NA		ENSP00000241075":TRRAP PROTEIN.	6.6
	447261	NM_006691	Hs.17917	extracellular link domain-containing 1	6.5
15		AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
		AL119798	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		AW963085	11- 70400	gb:EST375158 MAGE resequences, MAGH Horr	
20		S72043	Hs.73133 Hs.15463	metallothionein 3 (growth inhibitory fac	6.4 6.4
20		BE250659 AA701483	Hs.36341	Homo sapiens, clone IMAGE:2959994, mRNA ESTs	6.3
	402779		na.Jooy i	Target Exon	6.3
		AA213626	Hs.136204	EST	6.3
		AA742697	Hs.62492	ESTs, Weakly similar to B39066 proline-r	6.3
25		AA001732	Hs.173233	hypothetical protein FLJ10970	6.2
		BE143068		gb:MR0-HT0158-030200-003-b09 HT0158 Homo	
	452654	BE004783		gb:MR2-BN0114-270400-004-e11 BN0114 Homo	
	447359	NM_012093	Hs.18268	adenylate kinase 5	6.1
		NM_014759	Hs.334688	KIAA0273 gene product	6.1
30		H15968	Hs.293845	Homo sapiens, clone IMAGE:3502329, mRNA,	6.1
		F08212	Hs.234898	ESTs, Wealdy similar to 2109260A B cell	6.0
	400089		II. 077404	Eos Control	6.0
		W07475 N92818	Hs.277101 Hs.64754	cytochrome c oxidase subunit IV isoform ESTs, Wealthy similar to potential COS (H	5.9 5.9
35		N92010 BE067414	NS.04/04	gh:MR4-BT0355-200100-201-e05 BT0355 Homo	
33		AA062610	Hs.148050	EST	5.9
	406563		113.170000	Target Exon	5.9
		AW451023	Hs.65848	hypothetical protein DKFZp761O132	5.9
		AA843387	Hs.87279	ESTs	5.9
40	409196	NM_001874	Hs.334873	carboxypeptidase M	5.8
•		AW809163		gb:MR4-ST0118-261099-012-a03 ST0118 Homo	
		AB014533	Hs.33010	KIAA0633 protein	5.8
		Al372588	Hs.8022	TU3A protein	5.8
15		AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
45		BE063555	Un 2242	gb:CM1-BT0283-081199-033-d09 BT0283 Homo	
		AW876813 AW014486	Hs.3343 Hs.22509	phosphoglycerate dehydrogenase ESTs	5.7 5.7
		AW452355	Hs.256037	ESTS	5.7
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5.7
50		Al695473	Hs.298006	ESTs	5.7
	428553	AA181641	Hs.184907	G protein-coupled receptor 1	5.6
	404689	NA		Target Exon	5.6
	438887	R68857	Hs.265499	ESTs	5.6
	406082	\$47833	Hs.82927	adenosine monophosphate deaminase 2 (iso	5.6
55		H23963	Hs.32043		5.6
		R50253	Hs.249129		5.5
		C15819	II- connec		5.5
		AW444613	Hs.288809		5.5
60		AB020629	Hs.38095 Hs.60380		5.5 E E
60		A1668605 AA345824	Hs.76688		5.5 5.5
	414623	PARTICIET	1 10.1 0000		5.5 5.5
		T99079	Hs.191194		5.5
		AJ161428	Hs.75916		5.5
65		BE005346	Hs.116410	_• •	5.5
		BE617015	Hs.11006		5.5
		AJ432652	Hs.42824		5.5

	454016	AWU16806	HS.233108	ESIS	0.0
	414913	R25621		gb:yh45f06.r1 Soares placenta Nb2HP Homo	5.4
	459033	AA017590	Hs.129907	ESTs	5.4
	441003	BE172240	Hs.126379	ESTs, Wealdy similar to 138022 hypotheti	5.4
5		N49826	Hs.18602	ESTs	5,4
•		AA994520	110.10002	gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	
					5.3
	403612		41 0700	Target Exon	
		AA007629	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	5.3
	410057	R66634	Hs.268107	multimerin	5.3
10	428232	BE272452	Hs.183109	monoamine oxidase A	5.3
	432769	AA620814	Hs.144959	ESTs	5.3
		R99530	Hs.272572	hemoglobin, alpha 2	5.3
		AF012023	Hs.173274	integrin cytoplasmic domain-associated p	5.3
		BE261320	Hs.158196	transcriptional adaptor 3 (ADA3, yeast h	5.3
15				ESTs	5.3
15		AW613948	Hs.194915		5.3
		AI809481	Hs.131227	ESTs	
	402054			Target Exon	5.3
	432085	AF212829	Hs.272406	potassium channel, subfamilly K, member 9	5.3
	415313	R59638	Hs.6181	ESTs	5.2
20	459159	Al904646		gh:QV-BT065-020399-103 BT065 Homo sapien	5.2
		AB037721	Hs.173871	KIAA1300 protein	5.2
		BE467930	Hs.170381	ESTs	5.2
		Al285901	Hs.181297	ESTs	5.2
			143.1012.07	ENSP00000251335*:DJ1003J2.1 (sodium and	5.2
25	402698				5.2
25	401810		11- 400070	Target Exon	5.2
		AA827674	Hs.189073	ESTs	
		AA424074	Hs.76780	protein phosphatase 1, regulatory (inhib	5.2
	427809	M26380	Hs.180878	Itpoprotein lipase	5.1
	456063	NM_006744	Hs.76461	retinol-binding protein 4, interstitial	5.1
30	451186	AW023469	Hs.65256	ESTs, Wealdy similar to leucine-rich gli	5.1
	451882	AI821324	Hs.100445	ESTs	5.1
	402583	NA		NM_021620:Homo saptens PR domain contain	5.1
		NM_006103	Hs.2719	HE4: WFDC2: putative ovarian carcinoma m	5.1
		AJ435179	Hs.126820	ESTs	5.1
35		R53467	Hs.269122	ESTs, Wealthy similar to ALU1_HUMAN ALU S	5.1
55		BE143867	1 10200 122	gb:MR0-HT0164-070100-013-h02 HT0164 Homo	
		X03350	Hs.4	alcohol dehydrogenase 1B (class i), beta	5.1
				natriuretic peptide receptor A/guanylate	5.1
		BE244537	Hs.167382		5.0
40		AA486620	Hs.41135	endomucin-2	
40		AW026692	Hs.224829	ESTs	5.0
		D59597	Hs.118821	CGI-62 protein	5.0
		AI524307	Hs.162870	ESTs	5.0
	437526	Al076012	Hs.121388	ESTs, Wealthy similar to MDHC_HUMAN MALAT	5.0
	454775	BE160229		gb:QV1-HT0413-090200-062-a12 HT0413 Homo	5.0
45	409451	AF012626	Hs.54472	fragile X mental retardation 2	5.0
		AW502327		gb:UI-HF-BR0p-aka-a-07-0-UI.r1 NIH_MGC_5	5.0
	405062			Target Exon	5.0
		AK000706	Hs.15125	hypothetical protein FLJ20699	5.0
		AW298163	Hs.82318	WAS protein family, member 3	5.0
50		AJ243662	Hs.110196	NICE-1 protein	5.0
J U					5.0
		R62431	Hs.12758	EST8	
		R35009	Hs.24903	ESTs (1) III	5.0
		R00348		gb:ye69e06.r1 Soares fetal liver spieen	5.0
	409882	AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55		A1768289	Hs.304389	ESTs	4.9
	445613	BE550889	Hs.158491	ESTs	4.9
		AW341470	Hs.144907	ESTs	4.9
	451324	Al783600	Hs.208052	ESTs	4.9
		AW014734	Hs.157969	ESTs	4.9
60		AI989812	Hs.199850	ESTs	4.9
55			Hs.55063	ESTs	4.9
		AW973716	Hs.13913		4.9
				KIAA1577 protein	4.9
		AA682722	Hs.192725	ESTs	
CF		AF026263	Hs.247920	cholinergic receptor, muscarinic 5	4.8
65		AW137094	Hs.97990	ESTs	4.8
		AA868510	Hs.112496	ESTs	4.8
	420334	Al349351	Hs. 118944	hynothetical orotein FLJ22477	4.8

	421795		Hs.283822		4.8
	427138		Hs.173717		4.8
		BE063965		gb:QV3-BT0296-140200-085-h01 BT0296 Homo	
_		AW450451	Hs.266355		4.8
5		AW139474	Hs.246862		4.8
		AA843716	Hs.177927		4.7 4.7
		Al025499	Hs.132238		4. <i>1</i> 4.7
		AI383475	Hs.171697	ESTs, Wealdy similar to T13924 sdk prote gb:601273249F1 NIH_MGC_20 Homo sapiens c	
10		BE386764	Un 07419	ESTs	4.7
10		AA398716 AW292618	Hs.97418 Hs.113011		4.7
	401590		TIS. LISOTT		4.7
		AW134679	Hs.242849		4.7
		AK000123	Hs.180479		4.6
15		AA045290	Hs.25930		4.6
10		R49187	Hs.6659	ESTs	4.6
		AA972327	Hs.142903	ESTs	4.6
	441499	AW298235	Hs.101689		4.6
	447517	Al382726	Hs.182434		4.6
20	403017			. mg	4.6
	450580	N40087	Hs.15248		4.6
		H58589	Hs.35156	The section of the se	4.6
		M31158	Hs.77439	processing p	4.6 4.6
25		NM_001546	Hs.34853	managed at a contract of the c	4.6 4.6
25		Al142027 Al.137698	Hs.146650 Hs.46531	Homo sapiens mRNA; cDNA DKFZp434C1915 (f	
	-	AW204277	Hs.250723		4.6
		AF134707	Hs.278679	,,,poundation products	4.6
		Al375984	Hs.167216		4.6
30		F00312		gbdHSBB0D101 STRATAGENE Human skeletal r	п4,6
	440698	Al348455	Hs.147492	Homo saplens cDNA FLJ11777 fis, clone HE	4.6
	451199	Al290653	Hs.124758		4.6
	438338	NM_014861	Hs.6168		4.6
25		AW015933	Hs.112654	tionic capitality manifest and the contract of the capitality of t	4.5
35		S67580	Hs.1645	0,000,000,000,000,000,000,000,000,000	4.5
		H88385	Hs.81737	, parameter 1	4.5 4.5
		AL389981 AA335769	Hs.149219 Hs.16262	Transcription in a contract to the contract of	4.5
		H73444	Hs.394		4.5
40		N94835	Hs.283828		4.5
70		AF035303	TALLOCAL		4.5
		NM_012190	Hs.9520		4.5
		AA169114	Hs.12247	hypothetical protein FLJ11413	4.5
	415986	Z43619			4.5
45	457416	BE142052	Hs.62654		4.5
		BE387287	Hs.83384		4.4
		Al356125	Hs.157767	ESTs, Wealdy similar to HXA2_HUMAN HOMEO	
		AA156998	Hs.211568	7	4.4
50	401093	AMPROCADA	LL DESECO	0.12000000	4.4 4.4
20		AW206494	Hs.253560 Hs.321717		4.4
		AW842353 AL133112	Hs.183085	Homo sapiens mRNA; cDNA DKFZp434K098 (fr	
		AI264634	Hs.131127		4.4
		AL359599	Hs.283850	Homo sapiens mRNA; cDNA DKFZp547C126 (fr	
55		Al380906	Hs.158436		4.4
		H03589		gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
	416069	R37101	Hs.20982	ESTs	4.4
	438463	AA807958	Hs.314232		4.4
	444043	AI499723	Hs.135089		4.4
60		H87407	Hs.172944		4.4
		AF147401	Hs.23917		4.3
	400870		16 00027		4.3
		AA933590	Hs.28937	homeobox protein from AL590526 absyn99c10.r1 Soares adult brain N2b5HB5	4.3 4.3
65		H45384		gbdynesetu. 1 Soeres adult drain N2054185 gbdynnan ig rearranged H-chain mRNA VDJ4	4.3
UJ		M12873 AV654020	Hs.184261	ESTs, Wealthy similar to T26686 hypotheti	4.3
	444567		153.10-1201	Target Exon	4.3
	400200	19/3		· mg-, mm,	1.0

	410034	BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Homa	04.3
		Al421645	Hs.139851	caveolin 2	4.3
		BE395260	Hs.309438	EST	4.3
	416931	D45371	Hs.80485	adipose most abundant gene transcript 1	4.3
5	421296	NM_002666	Hs.103253	perilipin	4.3
	400973	NA		ENSP00000236667*:Mucin 5B (Fragment).	4.3
	452602	AW366194	Hs.55962	ESTS	4.3
	412330	NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3
	405016			CY000171 pip280405jjbjAAF86402.1JAF245	4.3
10	435104	AI475671 :	Hs.88607	ESTs, Highly similar to F-box protein FB	4.3
	406118			ENSP00000246632:CDNA FLJ20261 fis, clone	4.3
		T02850		gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818	Hs.221736	ESTs	4.3
4.5		AW451206	Hs.115899	ESTs	4.3
15		AA342329	Hs.115920	Homo saplens cDNA: FLJ22816 fls, clone K	4.3
		Al803166	Hs.28462	ESTs, Weakly similar to 138022 hypotheti	4.3
		Al377221	Hs.40528	ESTs	4.2
		BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
20		AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921		11- 40740	С5000212°:gi 10047237 db BAB13407.1 (A	4.2 4.2
		AI798425	Hs.42710	ESTS	4.2
	406344	AA404204	Hs.35861	C5001660:gi[11611537 dbj]BAB18935.1] (AB	4.2
		AA191201 BE155866	Hs.25522	DKFZP586E1621 protein	4.2
25		AW070634	Hs.144794	KIAA1808 protein ESTs	4.2
23	404682		H3.144/34	C9001188*:aii12738842trefiNP_073725.1 p	4.2
		N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433	umaiá	113.000	NM_001622:Homo saplens alpha-2-HS-glycop	4.2
		AW975460	Hs.143563	ESTs	4.2
30		Al309298	Hs.279898	Horno saplens cDNA: FLJ23165 fis, clone L	4.2
		A)871247	Hs.6262	hypothetical protein MGC8407	4.2
	419589	AW973708	Hs.201925	Homo sapiens cDNA FLJ13446 fis, clone PL	4.2
	457029	AA397789	Hs.161803	ESTs	4.2
	447860	AF193807	Hs.131835	Rhesus blood group, B glycoprotein	4.2
35	448988	Y09763	Hs.22785	gamma-aminobutyric acid (GABA) A recepto	4.2
		AI733098	Hs.130800	ESTs	4.2
		AF086410		gb:Homo sapiens full length Insert cDNA	4.2
		AA399975	Hs.274151	ligatin .	4.2
40		AW594172	Hs.278513	TP53TG3 protein	4.2
40		T77545	Hs.187559	ESTs	4.2
		Al144152	Hs.58246	ESTs	4.2
		AA318060	Hs.135121	hypothetical protein FLI22415	4.2
		NM_015977	Hs.285681	Williams-Beuren syndrome chromosome regi	4.2
45	400545	R57171	Hs.57975	calsequestrin 2 (cardiac muscle)	4.1 4.1
73	403051			Target Exon Target Exon	4.1
		NM 005357	Hs.95351	lipase, hormone-sensitive	4.1
		AA007534	Hs.125062	ESTs	4.1
		AA034116	Hs.118494	ESTs	4.1
50		W52010	Hs.191379	ESTs	4.1
		Al307802	Hs.135560	ESTs, Weakly similar to T43458 hypotheti	4.1
		Al150595	Hs.122226	ESTs	4.1
		AA082947		gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
		BE270758	Hs.69428	hypothetical protein MGC3020	4.1
55	441871	Al306150	Hs.153450		4.1
	426411	AK000708	Hs.169764	hypothetical protein FLJ20701	4.1
	453692	AL110416		gbtDKFZp434K0431_r1 434 (synonym: htes3)	4.1
	448640	AW817177	Hs.102558		4.1
	417481	AA203281	Hs.21798	ESTs	4.1
60		AW118878	Hs.110835		4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	
		AW631296		gb:hh83c09.y1 NCt_CGAP_GU1 Homo sapiens	
		R06285	Hs.191215		4.1
CE	417629				4.1
65	403593	NA		_ ~	4.0
	402690	D40504			4.0
	418190	K49091	Hs.270425	ESTs	4.0

PCT/US02/02242

	408641 AW245207	Hs.5555	hypothetical protein MGC5347	4.0
	427899 AA829286	Hs.332053	serum amyloid A1	4.0
	445975 Al811536	Hs.145734	ESTs	4.0
	438831 BE263273	Hs.6439	synapsin II	4.0
5	455578 BE006350	Hs.14355	Homo sapiens cDNA FLJ13207 fts, clone NT	4.0
•	401840 NA		Target Exon	4.0
	413753 U17760	Hs.75517	taminin, beta 3 (niceln (125kD), kalinin	4.0
	445030 Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873 AW156913	Hs.150478	ESTs, Wealthy similar to A Chain A, Cryst	4.0
10	456736 AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
10	450112 BE047734	Hs.5473	ESTs, Moderately similar to ALU5_HUMAN A	4.0
	AARONG AISROSET	Hs.309719	ESTs	4.0

TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers

15

Pkey CAT number Accessions

```
AW502327 AW502488 AW501829 AW502625 AW502687
       409853 1156226_1
                          BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
20
       410034 1170594_1
                          AANROQAT AANRONGS
       410233 118656_1
                          H03589 AW750687 AW750688
        410490 1205347_1
                          AW809163 AW809247 AW809177 AW809190 AW809225
       410882 1225686_1
                          BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005
       411478 1247073_1
                          BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322
25
       413065 1347960 1
                          BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884
       413072 1348163_1
       414593 1464909_1
                          BE386764 BE387560
                          R25621 C03959 C04010
        414913 1506721_1
                          AW963085 AA159005 AW963073
        415011 151328_1
30
       415986
              1564410_1
                          Z43619 R61274 H12206 R12883
               1583547_1
                          H45384 H49125 H41699
        416267
                          R00348 R09593
        417574 1687770_1
              1690392 1
                           T76945 R20210 R05755
        417629
        418556 1767866_-1
                          T02850
35
        419583 186198_1
                          F00312 AA247490 F31427 AA383663 F22045
                          AW631296 AA375484
        426328 264901_1
        439590 47413_1
                          AF086410 W94386 W74609
        442398 541271_1
                          AA994520 AW393574
                          C15819 AA024741 AA024742
        452205 90415 1
40
        452654 925931_1
                          BE004783 BE004947 AI911790
                          AL110416 AW876759
        453692 977825 1
                          AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807058 BE141561
        4541B3 1049636_1
                           BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345
                           AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399
                           AW807064 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216
45
                           AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308
                           AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433
                           AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019
                           AW807238 AW807201 BE141590 AW807302 AW807323 AW807380 AW807109 BE141588 AW845877 AW807418 AW807407
                           AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350
50
                           AW807028 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198
                           AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131
                           AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921
                           BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353
        454404 1170594_1
                           BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
55
                           BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911
        454775 1234106_1
               1273020_1
                           BE143867 AW935060 AW886684
        459159 919998_1
                           Al904646 BE179494 BE179421
```

TABLE 23B

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Plæy: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham t. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Mt_position
	400545	9800107	Minus	124618-124881
	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25 '	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
	406118	9143818	Phus	53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

TABLE 24:

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAccn for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10	Pkey: ExAccn:	Unique Eos probeset trentifier number Exemplar Accession number, Genbank accession number				
	UnigenelD:	Unigene numbe				
	Unigene Titla:	Unigene gene fi				
	Pred.Cell.Loc.:	Predicted Cellul	ar Locanzation Identification Number found in Table 25			
15	Seq.ID.No.:	Sequence	Remarkation Number today in Table 25			
15	Pkey ExAcc	n UnigenelD	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.	
	449746 Al6685	94 Hs.176588	ESTs, Wealthy similar to CP4Y_HUMAN CYT	00	Seq ID 1 & 2	
	407276 Al9511		Homo sapiens breast cancer antigen NY-BR		Seq ID 3 & 4	
20	415539 AI7338		BMP-R1B		Seq ID 5 & 6	
	400297 Al1270	776 Hs.334473	hypothetical protein DKFZp564O1278		Seq ID 7 & 8	
	450375 AA009	647 Hs.8850	a disintegrin and metalloproteinase doma	_	Seq ID 9 & 10	
	102457 NM_00)1394Hs.2359	dual specificity phosphatase 4	uncjear.	Seq ID 11 & 12	
	429170 NM_00)1394Hs.2359	dual specificity phosphatase 4	nuclear	Seq ID 11 & 12	
25	424399 Al9056		aldelryde dehydrogenase 9 family, member	cytoplasm	Seq ID 13 & 14	
	422505 AL120	862 Hs.124165	ESTs		Seq ID 15 & 16	
	449765 N9229	3 Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A		Seq ID 17 & 18	
	425692 D9004	1 Hs.155956	N-acetyitransferase 1 (arylamine N-acety		Seq ID 19 & 20	
	426215 AW963	3419 Hs.155223	stanniocalcin 2		Seq ID 21 & 22	
30	439840 AW449	9211 Hs.105445	GDNF family receptor alpha 1		Seq ID 23 & 24	
	410102 AW24	8508 Hs. <i>27</i> 9727	Homo sapiens cDNA FLJ14035 fis, clone HE		Seq ID 25 & 26	
	429220 AW207	7206 Hs.136319	ESTs		Seq ID 27 & 28	
	416276 U4106		LIV-1 protein, estrogen regulated		Seq ID 29 & 30 Seq ID 31 & 32	
	409079 W8770		interleutin 6 signal transducer (gp130,		Seq ID 33 & 34	
35	442818 AKD01		hypothetical protein FLJ10879		Seq ID 35 & 36	
	442082 R4182		ESTS		Seq ID 37 & 38	
		7335 Hs.283713	ESTs, Wealdy similar to \$64054 hypotheti		Seq ID 39 & 40	
	446163 AA026		Homo sapiens cDNA FLJ13603 fis, clone PL		Seq ID 41 & 42	
40	416636 N3253		solute carrier family 16 (monocarboxylic		Seq ID 43 & 44	
40		4964 Hs.128899	ESTs lymphoid nuclear protein (LAF-4) mRNA		Seq ID 45 & 46	
	433043 W575		ATP-binding cassette transporter MRP8		Seq ID 47 & 48	
		406 Hs.200102	Homo sapiens clone PP1498 unknown mRN	Δ	Seq ID 49 & 50	
	452190 H2673		ESTs, Weakly similar to fatly acid omega	•	Seq ID 51 & 52	
45	446733 AA863		ig superfamily receptor LNIR		Seq ID 53 & 54	
43	452747 BE153	9402 Hs.125783	DEME-6 protein		Seq ID 55 & 56	
		0266 Hs.82128	5T4 oncofetal trophoblast glycoprotein		Seq ID 57 & 58	
		613 Hs.298241	Transmembrane protease, serine 3		Seq ID 59 & 60	
	423961 D1366		osteoblast specific factor 2 (fasciclin		Seq ID 61 & 62	
50		2166 Hs.222399	CEGP1 protein		Seq ID 63 & 64	
30		6778 Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp		Seq ID 65 & 66	
	404561	0110 113.101010	NM_014112*:Homo sapiens trichorhinophala	mitochodrla	Seq ID 67 & 68	
	325372 NA		Phase 2 & 3 Exons	nuclear	Seq ID 69 & 70	
		3064 Hs.334806	KIAA1238 protein		Seq ID 71 & 72	
55	335824 NA	0001 155501000	ENSP00000249072*:DJ222E13.1 (N-TERMI	NAL	Seq ID 73 & 74	
33	424735 U3187	75 Hs.272499	short-chain alcohol dehydrogenase family		Seq ID 75 & 76	
	400289 X078		matrix metalloproteinase 10 (stromalysin		Seq ID 77 & 78	
	427585 D3115		collagen, type X, alpha 1 (Schmid metaph		Seq ID 79 & 80	
*		00786Hs.226213	cytochrome P450, 51 (lanosterol 14-alpha	ER	Seq ID 81 & 82	
60	429441 A.I224	172 Hs.204096	lipophilin B (uteroglobin family member)		Seq ID 83 & 84	
00	421155 H878		lysyl oxidase	extracellular	Seq ID 85 & 86	
		4197 Hs.100431	small inducible cytokine B subfamily (Cy		Seq ID 87 & 88	
	420813 X5150		protectin-induced protein	nuclear	Seq ID 89 & 90	
	452744 Al267		Homo sapiens mRNA; cDNA DKFZp434E08	2 (fr	Seq ID 91 & 92	

	420757 X7859	02 Hs.9991	androgen receptor (dihydrotestosterone r	cytoplasm S	eq ID	93 & 9	94
	424905 NM 0	02497Hs.1537		nuclear S	eq ID	95 & 9	96
		07050Hs.2259		S	eq ID	97 & 9	98
	446921 AB01			extracellular S	ea ID	99 & 1	100
5	445537 AJ24				eo ID	101 &	102
<i>J</i> .	428227 AA32		small inducible cytokine subfamily B (Cy			103 &	
	424001 W678					105 &	
						107 &	
	421727 Y131					109 &	
10	452838 U650						
10	419667 AU07			-		111 &	
	414812 X727	55 Hs.7736				113 &	
	426320 W475	95 Hs.1693				115 &	
	422867 L3213	7 Hs.1584	cartilage oligomeric matrix protein (pse			117 &	
	411558 AA10	2670 Hs.7072	gamma-aminobutyric acid (GABA) A recepto			119 &	
15	417866 AWO	7903 Hs.8277	collagen, type XI, alpha 1	S	eq ID	121 &	122
	428398 Al249	368 Hs.9855	B ESTs	, 8	eq ID	123 &	124
	431958 X636	29 Hs.2877	cedherin 3, type 1, P-cadherin (placenta	plasma membraneS	eq ID	125 8	126
	428722 U764			· S	eq ID	127 &	128
	412970 AB02			S	ea ID	129 &	130
20	421379 Y152			extracellular S	eo ID	131 &	132
20	415752 BE31					133 &	
	444051 N483					135 &	
						137 &	
	451110 AI955	040 Hs.2653	98 ESTs. Wealdy similar to transformation-r		ᄱᄱ	ioi u	

TABLE 24A

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15 Pkey CAT number Accession 335824 CH22_3197FG_619_11_LINK_E 325372 c12_hs

TABLE 24B

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: 10 Ref:

Unique number corresponding to an Eos probeset

Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand:

Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

Nt_position:

Pkey

Nt_position Strand

404561 9795980

Ref


69039-70100

20

15

Table 25

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (nr and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522)



70

75

Seq ID NO: 4 <u>Protein sequence:</u>
Protein Accession #: NP_443723.1

	AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAA GCAA AATCAGAGAT AGTTGGCATG 600
	AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAAA TGCAATGAGAT AGTTGGCATG 600 TATAAATGCA CAGCCCTCAT GCTTGCTGTA TGTCATGGAT CATCAGAGAT AGTTGGCATGAACAT 660
_	
5	
_	
10	
U	
15	
IJ	
	CAAAAAGTAA TGGAGATAAA TAGAGAAGTA CAAAAAG CCTTTGAATT GAAGAATGAA 1560 AAGCCTGCCA TTGAAATGCA AAACTCTGTT CCAAATAAAG CCTTTGAATT GAAGAATGAA 1620
	AAGCCTGCCA TTUAAATUCA AAACTCTGTT CCAAAAATCCA AACAAAAGGA CTATGAAGAA 1620 CAAACATTGA GAGCAGATCC GATGTTCCCA CCAGAATCCA AACAAAAGGA CTATGAAGAA 1620
	CAAACATTGA GAGCAGATCC GAIGHTCLCAC AGAAGGATGT GTGTTTACCC 1680
20	CAAACATTGA GAGCAGATCC GATGT TCCAC ACAGCATGT GAGAAGGATGT GTGTTTACCC 1680 AATTCTTGGG ATTCTGAGAG TCTCTGTGAG ACTGTTTCAC AGAAGGATGT GTGTTTACAA 1740
	AATTCTTGGG ATTCTGAGAG TCTCTGAGAG ACTOTTCCAAAATGGAAAAATGAAAAATGAAAAAAAAAAA
25	
30	
-	
35	
55	
40	
. •	
15	
45	
	CAATACCAGG AAAAGGAAAA TAAATACTTI GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420 GCTGAACTTC AGATGACCCT AAAACTGAAA GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420
50	
50	TATAGTGGGC AGCTTAAAGT TC IGATAGCG CAGAAATTGAAT CACACCATCC TAGACTGGCT 3540 GAAAAACAAG ACAAAGAAAT ACTAGAGGCG GAAAATTGAAT CACACCATCC TAGACTGCTTC 3600
	GAAAACAAG ACAAAGAAAT ACTAGAACAA GAAA AAAGTTAAGA ACCTGCTTTC 3600
	GAAAACAAG ACAAAGAAAT ACTAAACACA CAAATTAGAA AAAGTCAAGA ACCTGCTTTC 3600 TCTGCTGTAC AAGACCATGA TCAAATTGTG ACATCAAGAA AAAGTCAAGA ACCTGCTTTC 3660
	TCTGCTGTAC AAGACCATGA TCAAATTATA AAAATGAATG TTGATGTGAG TAGTACGATA 3660 CACATTGCAG GAGATGCTTG TTTGCAAAAGA AAAATGAATG TTGATGTGAG TAGTACGATA 3720
55	
60	
	ATATATCAAT ATGAAAAAGA GAAGCCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200 AAACTTCTTT TGGAGAAACA ACAGACCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200
65	
55	AGCAGACATC ATTCAATCCA ACCAGAATCT COCTCTGCAC TCCAGCCTAG GTGACAGAGT 4440
	GAGACTCCAC CTCGGAAA
	Onunciosis of the second

CGVTAEHYAV TCGFHHIHEQ IMBYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240 SLVEKTPDEA APLVEKTPDT AESLVEKTPD EAASLVEGTS DKIQCLEKAT SGKFEQSAEE 300 TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360 IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420 DEEYSCDSRS LFESSAKIQV CIPÉSIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480

AFELKNEQTI. RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540

KLEESPNKDG LIKATCGMKV SIPTKALEIK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA 600

LEIKNEQTWR ADEILPSESK QKDYEENSWD TESLCETVSQ KDVCLPKATH QKEIDKINGK 660

LEIKNEQTWR ADEILPSESK QKDYEENSWD TESLCETVSQ KDVCLPKATH QKRIDKINGK 660

LEGSPVKDGL LKANCGMKVS IPTKALEILMD MQTFKAEPPE KPSAFEPAIE MQKSVPNKAL 700 5 LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIB MQKSVPNIKAL 720
ELKNEQTLRA DEILPSESKQ KDYEESSWDS ESLCEITVSQK DVCLPKATHQ KEIDKINGKL 780
EESPDNIDGFL KAPCRMKVSI PTKALELMDM QTFKAEPPEK PSAFEPAIBM QKSVPNIKALE 840
LKNBQTLRAD QMFPSESKQK KVEBNSWDSE SLREITVSQKD VCVPKATHQK EMDKISGKLE 900
DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960
DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960
EVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020
DIELKSVESN LNQVSHTHEN ENVILHENCM LKKEIAMIKL ELATILKHQYQ EKENKYFEDI 1080
EKIKEKNAEL QMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILBAEIB 1140
SHIPPKLASAV QDHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTIYNN EVLHQPLSEA 1200
QRKSKSLKIN LNYAGDALRB NTLVSEHAQR DQRETQOMK BAEHMYQNEQ DNVNKHTEQQ 1260
ESLDOKLFOL OSKOMWLOOO LVHAHKKADN KSKITIDHF LERKMQHHLL KEKNEEIFNY 1320 10 15 ESLDOKLFOL OSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320 20 NNHLKNRIYO YEKEKAETEN S Seq ID NO: 5 DNA sequence none found Nucleic Acid Accession #: 273-1785 (underlined sequences correspond to start and stop codons) Coding sequence: 25

. 41 51 21 31 CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGCG AGTGCGGAGA CCGCGGCGCT 60 CAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 30 GIGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCG TCCAAAAGGTC 360 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAAACAATAT TTGCAGCACA 420 GACGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTATCT 480 GGTTGCCTAG GACTAGAAGAG CTCAGAATTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540 AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCTACA 660 ATATCTGTGA CTGCTCTGT GAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660 ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTTTACT TACATCACAG GGCTTTACTT 660 35 ATATCTOTOA CTOTCTOTAG TITGCTCTTO GTOCTTATCA TATTATTTTG TTACTTCCGG 720
TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780
ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA 840 40 TEAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900
ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960
GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AAATATATCAG 1020
ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080
GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140
TATCTGAAGT CCACCACCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200
AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260
CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320
ACTCGAGTTG GCACCAAACG CTATATGCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440
AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTTGGGAG 1500
GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTGTGGAG 1500
CTAGTGGCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620
CCCCCCTCAT TCCCAAAACCG GTGGAGCACT GATGAGTGTC TAAGGCAGAT GGGAAAACT TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900 45 50 55 60 CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG 1980 TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

65 Seq ID NO: 6 Protein sequence: Protein Accession #:

51 21 31 41 11 70 MLLRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED 60 DSGLPVVTSG CLGLEGSDFQ CRDTPPHQR RSIECCTERN BCNKDLHPTL PPLKNRDFVD 120
GPHHRALLI SVTVCSLLV LIILFCYRY KRQETPRYKS IGLEQDETYI PPGESLRDLI 180
EQSQSSGSG GLPLLVQRTI AKQQMVKQI GKGRYGEVWM GKWGEKVAV KVFFTTEEAS 240 EUSUSSUSSI SULFILL VOKII AKORUMYKUI SKOKTOBY WM GAWGUEVAY KYFTI IEBAS 340 WFRETEIYOT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTILDAKS 300 MLKLAYSSVS GLCHLHTEIF STQGKPAIAH RDLXSKNILV KKNGTCCIAD LGLAVKFISD 360 TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV 420 75


PCT/US02/02242

EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS 480 RLTALRVKKT LAKMSESQDI KL

Seq ID NO: 7 DNA sequence

Nucleic Acid Accession #: none found

Coding sequence: 482-3007(underlined sequences correspond to start and stop codons)



Seq ID NO: 8 <u>Protein sequence:</u>
Protein Accession #: none found

PCT/US02/02242

PPQNPRKLIL AGNIIHSLMK SDLVEYFTLB MLHLGNNRIB VLEEGSFMNL TRLQKLYLNG 420
NHLTKLSKGM FLGLHNLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPPHIPS 480
GVPLTKVNLK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540
TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600
LTDAVPLSVL ILGLLIMPTI IVFCAAGIVV LVLHRRRRYK KKQVDEQMRD NSPVHLQVSM 660
YGHKTTHHTT ERPSASLYEQ HMVSPMVHVY RSPSFGPKHL BEBEBRNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL BKERELQQLG ITEYLRKNIA 780
QUQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840

Seq ID NO: 9 DNA sequence Nucleic Acid Accession #: NM_003474

5

10

Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons)

15 11 21 31 41 CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60
TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACACACACACACACGGGGGGAAA 120
CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT 180 20 COGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC GCCGCTTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300 GCGACGATGG CAGCGCGCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCT GCTCGCCCTG 360 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 25 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600
TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660
TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 30 TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780 AGTGCACCA ACAGATACAA ACTCTTCCCA GCGAGAAGAGC TGAAAAGGT CCGGGGATCA 840
TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900
CAGACATGGG CAAGAAGGCA TAAAAGGAGA ACCTCAAGG CAACTAAGTA TGTGGAGCTG 960
GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAAAGTTAAG 1020 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1880
ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140
CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 35 CCATICACCA GCCICCATIGA ATTICIGAC IGOAGGAAXA IGAAGCAICI ACCECCAATICA TOCCATIGACA ATGCGCAGGT TGTCAGTGGG GTTTATTICC AAGGGACCAC CATCGGCATG 1260
GCCCCAATCA TGAGCATGTG CACCGCAGAC CAGTCTGGGG GAAATTGTCAT GGACCATTCA 1320
GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380
AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440 40 ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 45 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 AGGCGGACU CIGITATECCE ACAIGGCTO TOCHICARD ACHOCCACT GACAGGGGCC 1800
GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800
AGCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860
GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920
CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980 50 TATGCAACT GTOGCAAAGT CTOGAAGAGT TOCTITGCCA AATGCGAGAT GAGAGATGCT 2040
AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100
GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160
CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 GCAGATGGAA AAATCTGCCT GAATCGTCAA TOTCAAAAATA TTAGTGTCTT TGGGGTTCAC 2280
GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340
GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400
GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460 55 TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520 60 TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580
CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640
CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CITICATICA UNICCUTAN CONCITANT OF OCCUPANT 65 GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060 TGAAGACAGA AGTITIGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTGTA CCAACTTTTA 3120 GGATTTTTTT TAATGTTAA AACATCATTA CTATAAGAAC TTTGAGCTAC TGCCGTCAGT 3180 GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240 70 GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300 CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360
CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360
CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480
CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540 75 TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600

ACACCTGGGA GAAATCTGGC TTCTGGCCAO GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGACAGGGG TCTGTAGTGT CACTCAAGGC 3780
GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840 5 CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TOTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TITCCATGGG ACCACAACTA TITTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 10 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 CATCCTCTTT TICCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260
ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320
CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 15 AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 AAACACACA AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800
TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAAGCCAT GCTGGAAAAT AATACTGCTG 4860
AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920
TATATACTAT TAAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTT 4980 20 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 АССАЛАЛАЛ ЛАЛАЛАЛАЛ ЛА

Seq ID NO: 10 Protein sequence: Protein Accession #: NP_003465.2

1 11 21 31 41 51

MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNIEGRAD EVVSASVRSG DLWIPVKSFD 60
SKNIHPEVINI RIQRESKELI INLERNEGIL ASSFITHYL QDGTDVSLAR NYTVILGHCY 120
YHGHVRGYSD SAVSLSTCSG LEGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180
SHINTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240
LIEJANHVDK FYRPLNIRIV LVGVSVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300
DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLJAAAVTLAH ELGHINFGMNH 360
DTLDRGCSCQ MAVEKGGCIM NASTGYPFFM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420
SFGGQKCGNR FYEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480
ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGCQTHE QQCVTLWGPG 540
AKPAPGICTE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600
IETNIPLQQG GRILCRGTHY YLGDDMPDPG LVLAGTKCAD GKICLNRQQQ NISVFGYIEIC 660

AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720
LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQFCQAHLGH LGKGLMRKFP 780
DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840
ALRQAQTICK PNPPQKPLPA DPLARITRLT HALARTPGQW BTGLRLAPLR PAPQYPHQVP 900
RSTHTAYIK

Seq ID NO; 11 DNA sequence
Nucleic Acid Accession #: NIM_001394
Coding sequence: 400-1584(underlined sequences correspond to start and stop codons)

31 41 51 55 GGAGCCGCGC GACCGGCAAA AATACACGGG AGGCCGTCGC CGAAAAGAGT CCGCGGTCCT 120 CTCTCGTAAA CACACTCTCC TCCACCGGCG CCTCCCCCTC CGCTCTGCGC GCCGCCCGGC 180 TIGGGCGCCCG AGGCCGCTCC GACTGCTATG TGACCGCCAG GCTGCGGGAG GAAGGGGACA 20 GGGAAGAAGA GGCTCTCCCG CGGGAGCCCT TGAGGACCAA GTTTGCGGCC ACTTCTGCAG 300 60 GGGAAGAAGA GGCTCTCCCG CGGGAGGCCT TGAGGACCAA GTGCGGCCCA GGTTCTCTTC 360
GCGTCCCTTC TTAGCTCTCG CCTGCCCCTT TCTGCAGCCT AGGCGGCGCCAA GGTTCTCTTC 360
TCTTCCTCGC GCGCCAGCC GCCTCGGTTC CCGGCGACCA TGGTGACGAT GGAGGAGCTG 420
CGGGAGATGG ACTGCAGTGT GCTCAAAAGG CTGATGAACC GGGACGAGAA TGGCGGCGCC 480
GCGGGCGGCA GCGCCAGCCA CGGCACCCTG GGGCTGCCGA GCGGCGCAA GTGCCTGCTG 540 65 CTGGACTGCA GACCGTTCCT GGCGCACAGC GCGGGCTACA TCCTAGGTTC GGTCAACGTG 600 CTGGACTGCA GACCUTTCCT GGGGCACAGC GCGGGCTACA TCCTAAGGTC GCACACGTG CGCTGTAACA CCATCGTGCG GCGGCGGGCT AAGGGCTCCG TGAGCCTGGA GCAGATCCTG 60 CCCGCCGAGG AGGAGGTACG CGCCGCTTG CGCTCCGGCC TCTACTCGGC GGTCATCGTC 720 TACGACGAGC GCAGCCCGCG CGCCGAGAGC CTCCGCCGAGG ACAGCACCGT GTCGCTGGTG 780 GTGCAGGCGC TGCGCCGCAA CGCCGAGCGC ACCGACATCT GCCTGCTCAA AGGCGGCTAT 840 70 GAGAGGTTTT CCTCCGAGTA CCCAGAATTC TGTTCTAAAA CCAAGGCCCT GGCAGCCATC 900 CCACCCOGG TTCCCCCAG CGCCACAGAG CCCTTGGACC TGGGCTGCAG CTCCTGTGGG 960
ACCCCACTAC ACGACCAGGG GGGTCCTGTG GAGATCCTTC CCTTCCTCTA CCTCGGCAGT 1020
GCCTACCATG CTGCCCGGAG AGACATGCTG GACGCCCTGG GCATCACGGC TCTGTTGAAT 1080 GTCTCCTCGG ACTGCCCAAA CCACTTTGAA GGACACTATC AGTACAAGTG CATCCCAGTG 1140 GAAGATAACC ACAAGGCCGA CATCAGCTCC TGGTTCATGG AAGCCATAGA GTACATCGAT 1200 GCCGTGAAGG ACTGCCGTGG GCGCGTGCTG GTGCACTGCC AGGCGGGCAT CTCGCGGTCG 1260 GCCACCATCT GCCTGGCCTA CCTGATGATG AAGAAACGGG TGAGGCTGGA GGAGGCCTTC 1320 75

CTGCAGTTCG AGTCCCAGGT GCTGGCCACG TCCTGTGCTG CGGAGGCTGC TAGCCCCTCG 1440 GGACCCCTGC GGGAGCGGGG CAAGACCCCC GCCACCCCCA CCTCGCAGTT CGTCTTCAGC 1500 GUACCCCTGC GGGAGCGGGG CAAGACCCCCC GCCACCCCCAGTT CGTCTTCAGC 1500
TITCCGGTCT CCGTGGGCGT GCACTCGGCC CCCAGCAGCCC TGCCCTACCT GCACAGCCCC 1560
ATCACCACCT CTCCCAGCTG TAGAGCCGC CCTGGGGGGCC CCAGAACCAG AGCTGGCTCC 1620
CAGCAAGGGT AGGACGGGCC GCATGCGGCA GAAAGTTGGG ACTGAGCAGC TGGGAGCAGG 1680
CGACCGAGCT CCTTCCCCAT CATTTCTCCT TGGCCAACGA CGAGGCCAGC CAGAATGGCA 1740
ATAAGGACTC CGAAATACATA ATAAAAGCAA ACAGAACACT CCAACTTAGA GCAATAACCG 1800 5 ATAAGGACTC CGAATACATA ATAAAAGCAA ACAGAACACT CCAACTTAGA GCAATAACAT 1800
GTGCCGCAGC AGCCAGGGAA GACCTTGGTT TGGTTTATGT GTCAGTTTCA CTTTTCCGAT 1860
AGAAATTTCT TACCTCATTT TTTTAAGCAG TAAGGCTTGA AGTGATGAAA CCCACAGATC 1920
CTAGCAAATG TGCCCAACCA GCTTTACTAA AGGGGGGGGA AGGGAGGGCA AAGGGATGAG 1980
AAGACAAGTT TCCCAGAAGT GCCTGGTTCT GGGTACTTGT CCCTTTGTTG TCGTTGTTGT 2040
AGTTAAAGGA ATTTCATTTTT TAAAAGAAAT CTTCGAAGGT GTGGTTTCA TTTCTCAGTC 2100 10 15 AGAAAAAGAC AGCATCTCAC TATGTTGCCA AGGCTCATCT TGAGAAGCAG GCGGGTTGGG 2460 TGGGAGGAGG AAGAAAGGGA AGAATTAGGT TTGAATTGCT TTTTTAAAAA AAAA 20 Seq ID NO: 12 Protein sequence:
Protein Accession #: NP_001385 25 MYTMEELREM DCSVLKRLIM RDENGGGAGG SGSHGTLGLP SGGKCLLLDC RFFLAHSAGY 60
LGSVNVRCN TIVRRAKGS VSLBQILPAB EBVRARLRSG LYSAVIVYDE RSPRAESLRE 120
DSTVSLVVQA LRRNAERTDI CLLKGGYERF SSEYPEFCSK TKALAAIPPP VPPSATEPLD 180 LGCSSCGTPL HDQGGPVEIL PFLYLGSAYH AARRDMLDAL GITALLNVSS DCPNHFEGHY 240 30 QYKCIPVEDN HKADISSWFM BAIEYIDAVK DCRGRVLVHC QAGISRSATI CLAYLMMKKR 300 VRLEBAFEFV KQRRSIISPN FSFMGQLLQF ESQVLATSCA ABAASPSGPL RERGKTPATP 360 TSQFVFSFPV SVGVHSAPSS LPYLHSPITT SPSC 35 Seq ID NO: 13 DNA sequence Nucleic Acid Accession #: none found Coding sequence: 68-340(underlined sequences correspond to start and stop codons) 40 31 11 21 AGCGCCTTGC CTTCTCTTAG GCTTTGAAGC ATTTTTGTCT GTGCTCCCTG ATCTTCAGGT 60 AGESCUTTGE CITULITIAN SCITTURAGE ATTITUSTED INCIDENCE AND ILCACCACTAG ANGITICATOR 180
CACCACCATG AAGTICITAG CAGTCCTGGT ACTCTTGGGA GTITICCATCT TICTIGGTCTC 120
TGCCCAGAAT CCGACAACAG CTGCTCCAGC TGACACGTAT CCAGCTACTG GTCCTGCTGA 180
TGATGAAGCC CCTGATGCTG AAACCACTGC TGCTGCAACC ACTGCGACCA CTGCTGCTCC 240
TACCACTGCA ACCACCGCTG CTTCTACCAC TGCTCGTAAA GACATTCCAG TTTTACCCAA 300
ATGGGTTGGG GATCTCCCGA ATGGTAGAGT GTGTCCCTGA GATGGAATCA GCTTGAGTCT 360 45 TCTGCAATTG GGTCACAACT ATTCATGCTT CCTGTGATTT CATCCAACTA CTTACCTTGC 420 CTACGATATC CCCTTTATCT CTAATCAGTT TATTTTCTTT CAAATAAAAA ATAACTATGA 480 50 GCGAGCTAAC AT Seq ID NO: 14 Protein sequence: none found Protein Accession #: 55 21 31 11 60 ATTAASTTAR KDIPVLPKWV GDLPNGRVCP Seq ID NO: 15 DNA sequence NM 016640.2 Nucleic Acid Accession #: 39-1358(underlined sequences correspond to start and stop codons) Coding sequence: 65 41 51 21 31 11 GCTTAAGTTG ACCTCTGGGT CCGGAATCGC GGGCAAAG<u>AT G</u>GCCGCGGCC AGGTGTTGGA 60 GGCCTTTGCT ACGCGGTCCG AGGCTTTCAT TGCACACCGC GGCTAATGCC GCCGCCACGG 120 CTACAGAAAC GACCTCCCAA GACGTCGCGG CGACCCCCGT CGCCGGGTAC CCGCCGATTG 180 70 TGGCCTCCAT GACAGCCGAC AGCAAAGCTG CACGGCTGCG GCGGATCGAG CGCTGGCAGG 240 COACCGTGCA CGCTGCGGAG TCGGTAGACG AGAAGCTGCG AAATCCTCACC AAGATGCAGT 360
TTATGAAGTA CATGGTTTAC CCGCAGACCT TCGCACTGAA TGCCGACCGC TGGTACCAGT 360
ACTTCACCAA GACCGTGTTC CTGTCGGGTC TGCCGCCGCC CCCAGCGGAG CCCGAGCCCG 420 75 AGCCCGAACC CGAACCTGAA CCTGCGCTGG ACCTCGCGGC GCTGCGTGCG GTCGCCTGCG ACTGCCTGCT GCAGGAGCAC TTCTACCTGC GGCGCAGGCG GCGCGTGCAC CGTTACGAGG 540

GAGTTCGTTA AGCAGCGCCC CAGCATCATC TCGCCCAACT TCAGCTTCAT GGGGCAGCTG 1380

353

PCT/US02/02242

Seq ID NO: 16 Protein sequence; Protein Accession #: NP_057724.1

25

40

MAAARCWRPL LRGPRLSLHT AANAAATATE TTSQDVAATP VARYPPIVAS MTADSKAARL 60
RRIERWQATV HAAESVDEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120
PPAEPEP PEPEPALDLA ALRAVACDCL LQEHFYLRR RRVFRYEESE VISLPFLDQL 180
VSTLVGLLSP HNPALAAAAL DYRCPVHFYW VRGEEIIPRG HRRGRIDDLR YQIDDKPNNQ 240
IRISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300
LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFVSQAV 360
ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420
IVHFLLNRPK EPKSQLLEN

Seq ID NO: 17 DNA sequence
Nucleic Acid Accession #: NM_025059.1
Coding sequence: 3-2150 (underlined sequences correspond to start and stop codons)

41 51 21 31 GCATGAGCCT GGACTGCACC AGCCATATCG CGCTGGGTGC CGCTTCGCCA GCGCCCGAGG 60
AAACTTACGA TCATCTTTCG GAAGTCCCGG TCACGCGGGA GCAGTTAAAC CACTATCGGA 120
ATGTGGCTCA AAATGCTCGA AGTGAACTTG CAGCAACTTT GGTCAAATTT GAATGTGCTC 180 45 AGTCTGAGCT TCAAGACCTC CGATCCAAGA TGCTTTCTAA AGAAGTCTCC TGTCAAGAAC 240 AGICTIGAGCI ICAAGACCIC GIATCLAAGA TICTITICTAA AGAAGICICC IGICAAGACC 240
TGAAAGCTGA AATGGAGAGC TACAAGGAAA ACAATCACC CTCCTTACCT 300
CTTTGAGAGA CAGAGTTCAG GAACTAGAAG AAGAATCAGC AGCACTTTCC ACTICTAAAA 360
TCAGAACAGA AATCACAGCT CACGCTGCAA TCAAGGAGAA CCAGGAATTA AAGAAGAAAG 420
TTGTAGAGTT AAATGAAAAA TTACAAAAGT GTTCAAAAGA AAATGAGGAG AATAAGAAAAC 480
AAGTTTCAAA GAATTGCAGG AAACATGAGG AATTTCTGAC TCAACTGCOT GACTGCTTGG 540 50 ATCCAGATGA GAGGAATGAC AAGGCATCAG ATGAAGATTT AATTTTAAAG CTTAGAGACC 600
TGCGCAAAAGA AAATGAATTC GTGAAAAGGAC AAATTGTTAT TCTTGAAGAG ACTATAAATG 660
TCCATGAGAT GGAAGCAAAA GCTAGCAGAG AAACGATCAT GAGGCTGGCT TCAGAAGTCA 720 55 ICLATUAGA I UGAAGCAAAA GUTAGCAGAG AAACUATUAT UAGGCTGCT TCAGAGTCA 789
ACAGAGAGCA GAAAAAAACT GCCTCCTGTA CTGAAGAGAA AGAGAAGCTG AACCAGGACC 780
TGCTCAGTGC TGTAGAAGCA AAAGAAGCTC TTGAAAGCGA AGTTAAGATC TTCCAAGAAA 840
GGCTGCTTGC TGGCCAGCAG GTCTGGGATG CCTCAAAGCA GGAAGTGAGC CTCCTGAAGA 900
AAAGCTCTTC TGAGTTGGAG AAGAGTTTGA AGGCCAGTCA GGATGCAGTC ACAACCTCAC 960 AAAGCAGTA CTCATTT AGGGAGAAAA TCGCAGCCT CCTTAGGGGC AGATTGAGCA 1020
AAAGCAGTA CTCCTCATTT AGGGAGAAAA TCGCAGCCT CCTTAGGGGC AGATTGAGCA 1020
TGACTGGGTC CACTGAGGAC ACCATTTTGG AGAAGATTCG AGAAATGGAC AGCCGGGAAG 1080
AAAGCAGGA CCGGATGGTC TCCCAGCTTG AAGCCCAAAT ATCTGAGCTT GTTGAACAGT 1140
TGGGAAAGGA GTCTGGGTTT CACCAGAAAG CTCTCCAGAG GGCCCAGAAA GCAGAGAAAT 1200 60 65 AGACCATTIC CCACAATTIG CAGAGAAAGC TAAAGACACA GAAAGAGAG CTGGAGAGCA 1500
AGACTTACA CATGAGCCTC CTCCGGCAGA AAATAGCCCA GCTGGAGAGG GAGAAGCAGG 1560
CACGCACGGC CTTGGTGGTT GAGAGGGACA ACACGGCATCT TACCATCAGG AACTTGCAGA 1620
AGAAGGTGGA GAGGCTGCAG AAAGAGCTGA ACACGTGTCG AGACTTGCAC ACCGAGCTCA 1680
AAGCCAAACT GGCCGACACC AATGAACTGA AGATTAAAAC TTTGGAACAG ACTAAAGCCA 1740 70 AMBULANACI GGUGALAU. AATGAACTGA AGAT HAAAC TITOUAACAG ACTANAGU TAGAGATCT AAACAAATCC AGAGACCAAC TGGAGAACA TGAGGAGAAA GCTGAGAAAA GCTGAGAAAA GCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860 AAAGGGCCAG AAACATGATA GAAGTGGTAA CCAGTGAAAT GAAGACACTA AAAAAATCTC 1920 TGGAAGAAGC AGAAAAAGAGA GAAAAAGCAGC TGGCAGACTT CAGGGAGGTG TGTTCGCAGA 1980 75 TICTAGGETT GAACGTGACC AGCETTGETE TICCTGATTA TOAAATCATE AAGTGTETTI 2040

PCT/US02/02242

19 205

AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100 CTACTGGGCA AGAGAGGCA CCACAAGGCC ATTTACAGCT TCTTCATTGA ACACTGTATC 2160
TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220
TCTTGAGAT TIGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280
CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340 5 CAAAAAAA AAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400 AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460 AUA ITGGUAA A IUGUAUIUG GAGAIAATAI IUGUAGUIAI CIAIIIIAAU ICAGOOUCII 2400 TACTAGCCGA TITAGTICTC ACAATAACCA TGTGGAGAAG CTGTGACATT TITAATITAC 2520 AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAGG TTGCAGTTGG GTAGTGGTGG 2580 GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATGC 2640 10 GACLAGGATG GACAACICAT TIGGCUCIGC TCAAAAGCCA TACULTIC CCUCIATIOC 2040
AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGAA TTGTTTGCAT AGAGGAAGGA 2700
CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760
CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820
CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880
GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGGAGG 2940 15 UTGCATUACT GTAATCUAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGAGG 2940
CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000
CTCAGAAAA AAAAAAAA AAAAAAAAA AAGTTAATGT CCAAAAATGA CAGATTTACA 3060
AGTGTAAGCT ATATGATTTC TTCAAAAAGC AAAAGCAATA TACCTAATTC ATTTGGATCA 3120
AACTTACATA GGTCTCAGGT CCTGTAAGAA ACTTGCCTGT TCTAACTGTT GCTACCAGAT 3180 TATATCTGGT GGTAATTGTT AATGTTTCAG CAGGGCTGGT CTCAGTCCTT TAAAATGGAA 3240 20 AGCTITATIT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTT TATCACCAA 3300
TATATCCAAT ACACCCACAG CAATGGTACC TITTAAGAT CAGGATITIA TIATGAATTC 3360
CTGTCACTIT CTGTTTTCCA TITAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420 CITIAACITIA CIGITITICA ITIAAAATI IC TATITIACAA ATTITICAGGIGAATCATATT 3420
CITAACITICA CIGAGAAAAA TGTGTTACTICTTTTIGGACAA TITATCITAT TATCATA 3480
TAAGATGAT TITTITATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540
AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATAC AACCAACCGT 3600
TCGTGAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAACAT GGCAAAACTC CGTCTCCTGCA 3660 25 AAAAATACAA AAATGAGCCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720 AAAATACAA AAATGAGCCCGGTATGTTGG CATATGCCTG TAATCCCAGC TACTCCAGAG 3720
GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780
CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAAACA ACAACAACAA 3840
AAAGTCAAAG TCATAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAATTAA 3900
AGAGATGAAA CAATCAATTG CAAGGGTCAA AACTAGATTG GATCTTGGTT TGAATGAAAA 3960 30 AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020 ATATTAAAAT ATTITTAAAT TITTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080 AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140 35 *************

Seq ID NO: 18 <u>Protein sequence:</u>
Protein Accession #: NP_079335.1

60

Seq ID NO: 19 DNA sequence
Nucleic Acid Accession #: AF071552, NM_000662
Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons)

PCT/US02/02242 WO 02/059377


TTGATGGCAG GAACTACATT GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CICTGGAGTT AATTICTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900
AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960
AATTICTTCA TTCTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020
TTAAGCCTCG AACAATTGAA GATTITGAGT CTATGAATAC ATACCTGCAG ACATCCCAT 1080 5 CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC CCCAGATGGG GTTCACTGTT 1140
TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATAA GGACAATACA GATCTAATAG 1200 AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260 CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTTACTATT <u>TAG</u>AATAAGG 1320 AGTAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380 10 TOTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440 TATAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACAAACCTT 1500 TTCAAATAAT AATAATAATA ATAATAATAA ATGTATTTTA AAGATGGCCT GTGGTTATCT 1560 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 Protein sequence: NP_000653.1 20 41 51 11 21 31 MDIBAYLERI GYKKSRNKLD LETLTDILQH QIRAVFFENL NIHCGDAMDL GLEAIFDQVV 60 RRNRGGWCLQ VNHLLYWALT TIGFETTMLG GYVYSTPAKK YSTGMIHLLL QVTIDGRNYI 120 VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL 180 LEDSKYRKIY SFILKPRITE DESMINTYLQ TSPSSVFTSK SFCSLQIPDG VHCLVGFTLT 240 HRRPNYKDNT DLIEFKTLSE EEIEKVLKNI FNISLQRKLV PKHGDRFFTI 25 See ID NO: 21 DNA sequence Nucleic Acid Accession #: NM 003714 30 Coding sequence: 123-1031 (underlined sequences correspond to start and stop codons) 21 31 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60 -35 GAGGAGGAAG AGGGGAGCAC AAAGGATCCA GGTCTCCCGA CGGGAGGTTA ATACCAAGAA 120 CCATGTGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTG GCCACCTTTG 180 ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240
AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300
CTGGCGATGT GGGGTGTGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360 40 GCTTACATGG GATTTGCATG ACTITTCTGC ACAACGCTGG AAAATTTGAT GCCCAGGGCA 420 AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480 GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540 ACCTCAAGCA CGACCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGA 600 45 TOCATTICAA GGACTIGCTG CTGCACGAAC OCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660 CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCACAGCGT GCAGGTTCAG TGTGAGCAGA 720
ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780
CGGCGCCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900 OTGAGCGAGG TAGCAAGAGC CACCCAAACG CCAATGCCCG AGGCAGAGTC GGGGGCCTTG 960
GGGCTCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACGA ACAGTCTGAG TATTCTGATA 1020
TCCGGAGGTG AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080 50 ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGGG GATGTCACAC GCAGGATTCT 1140 OTOGGGGCC GGGGTTATCCI CGTACCTTIG TCTCCTTCC ATCIGGGG TCAGTGGGTG 1320 55 TYMGCCGCTC TGTTGTGGGG GAGGTGAACC AGGGAGGGC AGGGCAAGGC AGGGCCCCCA 1380 GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440 GGTGCTGTCT CCGCGGAAGT CAGGGCCGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500 AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGGCCGAG GGGGTGCTTG 1560 60 OTGCCAAACT GAAATICAGT TTCTTGTGTG GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680
GGGGGACACT GTCCAAGGGA GTGGCCCCTA TQAGTTTATA TTTTAACCAC TGCTTCAAAT 1740
CTCGATTTCA CTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 Seq ID NO: 22 Protein sequence:
Protein Accession #: NP_003705 Protein Accession #: 70 41 51 31

75

356

*

RR



CAGGGCGGC GAGGACGGGG GAGGTGGGGG GGGCGGCGCC CCCGCGCAGC CGACAGCCCC 240 5 GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT 540 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TICTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGGGCCG CCTTTGGTGT 660 GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG 720 GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACATA 780 10 CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840
CGTGGAGCGT GCGCGCGAGG AGATCGAGAC GCACATCGCG GTGCGCACTG GCAAGATCCT 900 CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCG 960
CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCTCTCCA CCTTCCGGCA 1020
GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCCACGCCT 1080 15 GAACAGCCTG GGCTGCATCG GCGAGTGCGG AUTGGACTC TGGCTTTAAGCGTGGG 1160
GGGTGAGCAG GGCGGGGACT TTGGCTACGG CGGTACCTC TTTCCGGGCT ATGGCGTGGG 1140
CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGCCAGGA 1200
GAACGCCACG CCCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCCTCCT CCTCTTCCGC 1260
CAAGGCCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCCT GCCACTTCCG CGGGACCCGA 1320
GCTGGCCGGA CTCCCGAGGC GCCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTCAAACTTGG 1380 20 TIGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440
AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25

Seq ID NO: 26 Protein sequence:
Protein Accession #: FGENESH predicted

30

1 11 21 31 41 51

FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP 60
RAGEDGGGG GGAPAQPTAP PQPAPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC 120
ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEPPV 180

FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240
LVVGPKGATI KRIQQQTINTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL 300
EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360
GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSS 420
KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLQGFSKLG GGGLRSPGGG RDCMVCFESE 480

VTAALVPCGH NLFCMECAVR ICERTDPBCP VCHITATQAI RIFS

Seq ID NO: 27 DNA sequence
Nucleic Acid Accession #: FGENESH predicted
Coding sequence: 1-2070 (underlined sequences correspond to start and stop codons)

45 31 ATGAGCGOTO COGGGGTGGC GGCTGGGACG CGGCCCCCA GCTCGCCGAC CCCGGGCTCT 60 ATMADEDIGITU CHRISOFTIGIC UNCLUGARIA CUSTICACA SCRUCTURA COCUCATA SCRUCTURA COCOCA CASTERIA CONTROL CASTERIA COCOCA CASTERIA COCACA CASTERIA CAST 50 GAAAACAAGG GTGAGCOGG GGGGGCCC1 AGGCCGGCCC TGCCCTCCCA 360
ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGCCTCA 360
GGGGGAACAC AGGACGGGGA GCCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGCC 420
CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480
AGCCGTGGCT GGACGATGTT ATGCAGCCAA GCACAGCACG TGCTGCTCTC GGGAAGCCCA 540
GGGCCTGAGG TCATTGCAGG GCGCCAGGTG GCCACAGGGT GCTCCCTCCT 600 55 60 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840 GCARTACCA IGGGGAAAAA GGGAGGAACAA CAGCCCAG ATCCTGGGCT GTGGTCTCAA 900
GCACTTCCCC ATCCTGACAG CGGCCCCAC CCAGCCCAGG ATCCTGGGCT GTGGTCTCAA 900
GCTCACTTCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGGA 960
TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTGCCTA GGGCTCTCCC TTCCCAGGGA 1020
GACATGGAGA AGGGGGTTGA GGGAGGGCCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 65 UNIATIONADA AUGUSTITUA GISAAGGULEE TECLETAGUE GETSTUGGAA CIUZAGITGAS 1080 CTGTTCTGGG CAAAGTGTGG CCCAAGTCGG CAGCCCCAGC CCTGCAGTGC T9GGGACGT 1140 GACAGGACAC GGGAAGAGGC CATGCTTTCC CTCSGGACCT GCTGTTCCAT GTGTCCCAAG 1200 CCCTCCTGCT TTCCAGATGG CCCCTCAGGA AACCACCTTT CCAGGGCCTC TGCTCCCTTG 1260 GGCGCTCGCT GGGTCTGCAT CAACGGAGTG TGGGTAGAGC CGGGAGGACC CAGCCCTGCC 1320 AGGCTGAAGG AGGGCTCCTC ACGGACACAC AGGCCAGGAG GCAAGCGTGG GCGTCTTGCG 1380 70 TOCTTCAACA AGCAAGATTC AAAAGCTGAC GTCTCCCAGA AGGCGGACCT GGAAGAGGAG 1560
CCCCTACTTC ACAACAGCAA GCTGGACAAA GTTCCTGGGG TACAAGGGCA GGCCAGAAAG 1620 GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTGTATGG GGAACAGCCA GCACCAGGGC 1680 75 AGGCAGATGG GGGCGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740

5

25

ACCEAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGGCCCC TGCATCGCTC AGTGCTTTGA

Seq ID NO: 28 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted

1 11 21 31 41 51

| MSGAGVAAGT RPPSSPTPGS RRRRQRPSVG VQSLRPQSPQ LRQSDPQKRN LDLEKSLQFL 60
QQQHSEMLAK LHEEIEHLKR ENKGEPARGP RPALPPQAHS TLPLPQHRNT AINSSTRLGS 120

GGTQDGEPLQ TVLAHLAALA PVCQPSGYRF WGTWTDAATS SRGWTMLCSQ AQHVLLSGSP 180
GPEVIAGRQV ATGCSPDLPP PSRAEMGRNP WDSPCPARSL PQIAAVARPR ISSEMALSPH 240
MLGAQGIWTH SIQGSLPAIW AATMGTKGGS RVLFPCHLSK ALPHPDSGPH PAQDPGLWSQ 300
AHFPLSLGLG LTSGGHLTGG WSQPGNIAAG AVPRALPSQG DMEKGVEGGF FFSRCGNSSE 360
LFWAKCOPSR QPQPCSAGDA DRTREEAMLS LGTCCSMCPK PSCFPDGPSG NHLSRASAPL 420
GARWVCINGV WVEPGGPSPA RLKEGSSSTH RPGGKRGRLA GGSADTVRSP ADSLSMSSFQ 480
SVKSISNSAN SQGKARPQPG SPNKQDSKAD VSQKADLEEE PILHNSKLDK VPGVQGQARK 540
EKAEASNAGA ACMGNSQHQG RQMGAGAHPP MILPLPLRKP TTLRQCEVIL RELWNTNLLQ 600
TQBLRHLKSL LEGSQRPQAA PEEASFPRDQ EATHFPKVST KSLSKKCLSP PVAERAILPA 660
LKOTPKNNFA ERQKRLQAMQ KRRLHRSVL

Seq ID NO: 29 DNA sequence
Nucleic Acid Accession #: NM_012319.2
Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons

138-2405 (underlined sequences correspond to start and stop codons) Coding semence: 30 21 31 CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA CICUTUCUA AT ICUGUACIA AGACUSCUTU TICUCUCUTU GIAGAGATTI CICUGAGUACA


60
CCAGTIGGGCC CGTGTGGAAC CAAACCTGCG CGCGTGGCCG GGCCGTGGGA CAACGAGGCC

120
GCGGAGACGA AGGCSCAATE GCGAGGAAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC

180
TCTCTGTCAC AAATCCCCTT CATGAACTAA AAGCAGCTGC TITCCCCCAG ACCACTGAGA

240
AAATTAGTCC GAATTGGGAA TCTGGCATTA ATGTTGACTT GGCAATTTCC ACACGGCAAT

300 35 ATCATCTACA ACAGCTITTC TACCGCTATG GAGAAAATAA TICTTIGTCA GTIGAAGGGT 360 ACADANAT ACTICANAT ATAGGCATAG GABARAHA HOLLIGICA GLORAGUGI 300
TCAGAAAAT ACTICAAAAT ATAGGCATAG ATAAGAATAA AAGAATCAT ATACACCATG 420
ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCAT GAGCGTCAC TCAGACCATG 480
AGCATCACTC AGACCACGAG CATCACTCTG ACCATGATCA TCACTCTCAC CATAATCATG 540
CTGCTTCTGG TAAAAATAAG CGAAAAAGCTC TTTGCCCAGA CCATGACCAC GATAGTTCAG 600 40 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCO ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720 TCTCTGAAGG AACTCACTTT CTAGAGACAÁ TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 45 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 TIGGCTIGGTAG GAAAACAAT GAATCTIGTIGA GTGAGCCCCG AAAAGGCTTT ATGTATTICCA 900
GAAACACAAN TIGAAAATCCT CAGGAGTIGTT TCAATGCATC AAAGCTACTIG ACATCTCATG 960
GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCTCTIGT CCAGCCATCA 1020 TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080 50 CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140
TCAGTTICCT GICTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTCA 1200
AATTCCCCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTT 1260 TACACCTICT TOCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320 CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAAA 1380 GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGGCCTG TATTTCATGT 1440 TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 AGAAGAAACC TGAAAATGAT GATGATGGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560 55 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620 GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680 AAGAGGTCAT GATAGCTCAT GCTCATCCAC AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740 60 GGTGCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1800 UDIGUANIAA IAAATOUAT ILACATTRU: AGIATACACI CEGCUAGICA GACUATUTCA 1800
TICACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACCAA AACCACCATC 1860
CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATGCCGGG GTCGCCACTT 1920
TIGGCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980
GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTGTC 2040 65 GIGCTGCITT TACIGAAGGC TIATCAAGTG GITTAAGTAC TICTGTTGCI GIGTTCTGC 2040
ATGAOTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100
AGCAGGCTGT CCTTTATAAT GCATTGTCAG CCATGCTGGC GTATCTTGGA ATGGCAACAG 2160
GAATTTCAT TGGTCATTAT GCTGAAAAATG TTTCTATGTG GATATTTGCA CITACTGCTG 2220
GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC AATGATGCTA 2280 70 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 OTTTIGGAAT TATOTTACTT ATTTCCATAT TIGAACATAA AATOGTGTIT CGTATAAATT 2400
TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTIG TCATAGTTIC AGTAGGTCAT: 2460
AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAA GTTAGTGGGT TITGTGATTI 2520 TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTTA ATATTTAAGT 2580 75 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAATGT CTTTAATGCT 2700



11

21

31

41 51

ß

AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360 PGNSCPCPGP APAKTCIMEA STDFLPGLNF SNCSRRALEK ALLDGMGSCL FERLPSLPPM 420 AAFCGNMFVE PGEOCDCGPL DDCVDPCCDS LTCQLRPGAQ CASDGPCCQN CQLRPSGWQC 480 AAPCGMMPVE PGBQCLCOPL DICVPPCLTS LIQLERGAQ CASIAR-CAN CQLAR-SWAC 540
PAPICALOTA NTRGNAFGSC GRNPSGSYVS CIPRDAICGQ LQCQTGRTQP LLGSIRDLLW 600
ETIDVNGTEL NCSWVHLDLG SDVAQPLLTL PGTACGPGLV CIDHRCQRVD LLGAQECRSK 660
CHGHGVCDSN RHCYCEEGWA PPDCTTQLKA TSSLTTGLLL SLLVLLVLVM LGAGYWYRAR 720
LHQRLQQLKG PTQQYRAAQS GPSERPGPPQ RALLARGTKS QGPAKPPPPR KPLPADPQGR 780 5 CPSGDLPGPG AGIPPLVVPS RPAPPPPTVS SLYL 10 Seq ID NO: 113 DNA sequence NM_002416 Nucleic Acid Accession #: Coding sequence: 40-417 (underlined sequences correspond to start and stop codons) 15 31 41 51 ATCCAATACA GGAGTGACTT GGAACTCCAT TCTATCACTA TGAAGAAAAG TGGTGTTCTT 60
TTCCTCTTGG GCATCATCTT GCTGGTTCTG ATTGGAGTGC AAGGAACCCC AGTAGTGAGA 120
AAGGGTCCCT GTTCCTGCAT CAGCACCAAC CAAGGGACTA TCCAACTACA ATCCTTGAAA 180 GACCTTAAAC AATTTIGCCC AAGCCCTTCC TGCGAGAAAA TTGAAATCAT TGCTACACTG 240
AAGAATGGAG TTCAAACATG TCTAAACCCA GATTCAGCAG ATGTGAAGGA ACTGATTAAA 300 20 AAGTGGGAGA AACAGGTCAG CCAAAAGAAA AAGCAAAAGA ATGGGAAAAA ACATCAAAAA 360 AAGAAAGTTC TGAAAGTTCG AAAATCTCAA CGTTCTCGTC AAAAGAAGAC TACA<u>TAA</u>GAG 420 ACCACTICAC CAATAAGTAT TCTGTGTTAA AAATGTTCTA TTTTAATTAT ACCGCTATCA 480
TTCCAAAGGA GGATGGCATA TAATACAAAG GCTTATTAAT TTGACTAGAA AATTTAAAAC 540 25 ATTACTCTGA AATTGTAACT AAAGTTAGAA AGTTGATTTT AAGAATCCAA ACGTTAAGAA 600 TIGITAAAGG CTATGATIGT CITTGTTCTT CTACCACCCA CCAGTTGAAT TICATCATGC 660 TTAAGGCCAT GATTTTAGCA ATACCCATGT CTACACAGAT GTTCACCCAA CCACATCCCA 720 CTCACAACAG CTGCCTGGAA GAGCAGCCCT AGGCTTCCAC GTACTGCAGC CTCCAGAGAG 780 TATCTGAGGC ACATGTCAGC AAGTCCTAAG CCTGTTAGCA TGCTGGAG CCAAGCAGTT 840 30 TGAAATTGAG CTGGACCTCA CCAAGCTGCT GTGGCCATCA ACCTCTGTAT TTGAATCAGC 900
CTACAGGCCT CACACACAAT GTGTCTGAGA GATTCATGCT GATTGTATT GGGTATCAGC 960
ACTGGAGATC ACCAGTGTGT GGCTTTCAGA GCCTCCTTTC TGGCTTTGGA AGCCATGTGA 1020
TTCCATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATTC 1080 35 AAGTCAGCTC TTCTCCATCC TACCACAATG CAGTGCCTTT CTTCTCTCCA GTGCACCTGT 1140 CATATGCTCT GATTTATCTG AGTCAACTCC TTTCTCATCT TGTCCCCAAC ACCCCACAGA 1200
AGTGCTTTCT TCTCCCAATT CATCCTCACT CAGTCCAGCT TAGTTCAAGT CCTGCCTCTT 1260
AAATAAACCT TTTTGGACAC ACAAATTATC TTAAAACTCC TGTTTCACTT GGTTCAGTAC 1320 CACATGGGTG AACACTCAAT GGTTAACTAA TTCTTGGGTG TTTATCCTAT CTCTCCAACC 1380 40 AGATTGTCAG CTCCTTGAGG GCAAGAGCCA CAGTATATTT CCCTGTTTCT TCCACAGTGC 1440 CTAATAATAC TGTGGAACTA GGTTTTAATA ATTTTTTAAT TGATGTTGTT ATGGGCAGGA 1500 TGGCAACCAG ACCATTGTCT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 TIGGCAACAG ACEATTRICT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 CTAGGCTACTGCTG GTAACCTCTT ACTTATTATC TTCAGGACAC TCACTACAGG ACCAGGGAT 1620 GATGCAACAT CCTTGTCTTT TTATGACAGG ATGTTTGCTC AGCTTCTCCA ACAATAAGAA 1680 GCACGTGGTA AAACACTTGC GGATATTCTG GACTGTTTTT AAAAAATATA CAGTTTACCG 1740 AAAATCATAT AATCTTACAA TGAAAAGGAC TTTATAGATC AGCCAGTGAC CAACCTTTTC 1800 45 CCAACCATAC AAAAATTCCT TITCCCGAAG GAAAAGGGCT TICTCAATAA GCCTCAGCTT 1860 TCTAAGATCT AACAAGATAG CCACCGAGAT CCTTATCGAA ACTCATTTTA GGCAAATATG 1920 AGTTTATTG TCCGTTTACT TGTTTCAGAG TTTGTATTGT GATTATCAAT TACCACACCA 1980 TCTCCCATGA AGAAAGGGAA CGGTGAAGTA CTAAGCGCTA GAGGAAGCAG CCAAGTCGGT 2040 50 TAGTGGAAGC ATGATTGGTG CCCAGTTAGC CTCTGCAGGA TGTGGAAACC TCCTTCCAGG 2100
GGAGGTTCAG TGAATTGTGT AGGAGAGGTT GTCTGTGGCC AGAATTTAAA CCTATACTCA 2160
CTTTCCCAAA TTGAATCACT GCTCACACTG CTGATGATTT AGAGTGCTGT CCGGTGGAGA 2220
TCCCACCCGA ACGTCTTATC TAATCATGAA ACTCCCTAGT TCCTTCATGT AACTTCCCTG 2280 55. AAAAATCTAA GTGTTTCATA AATTTGAGAG TCTGTGACCC ACTTACCTTG CATCTCACAG 2340 GTAGACAGTA TATAACTAAC AACCAAAGAC TACATATTGT CACTGACACA CACGTTATAA 2400 TCATTTATCA TATATATACA TACATGCATA CACTCTCAAA GCAAATAATT TTTCACTTCA 2460 AAACAGTATT GACTTGTATA CCTTGTAATT TGAAATATTT TCTTTGTTAA AATAGAATGG 2520 TATCAATAAA TAGACCATTA ATCAG 60 Seq ID NO: 114 <u>Protein sequence:</u>
Protein Accession #: NP_002407 31 51 65 MKKSGVLFLL GITLLVLIGV OGTPVVRKGR CSCISTNOGT IHLOSLKDLK OFAPSPSCEK 60 IEIIATLKNG VQTCLNPDSA DVKELIKKWE KQVSQKKKQK NGKKHQKKKV LKVRKSQRSR 120 **`70** Seq ID NO: 115 DNA sequence NM 003238.1 Nucleic Acid Accession #: Coding sequence: 182-1426 (underlined sequences correspond to start and stop codons) 21 31 75 AAAACAAACA ACAACAACAA AAAACCAAAC AACTCTCCTT GATCTATACT TTGAGAATTG 120

WO 02/059377

À

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180 AATGCACTAC TGTGTGCTGA GCGCTTTTCT GATCCTGCAT CTGGTCACGG TCGCGCTCAG 240 CCTGTCTACC TGCAGCACAC TCGATATGGA CCAGTTCATG CGCAAGAGGA TCGAGGCGAT 300 CCGCGGGCAG ATCCTGAGCA AGCTGAAGCT CACCAGTCCC CCAGAAGACT ATCCTGAGCC 360
CGAGGAAGTC CCCCCGGAGG TGATTTCCAT CTACAACAGC ACCAGGAGACT TGCTCCAGGA 420
GAAGGCGAGC CGGAGGGCGG CCGCCTGCGA GCGCGAGAGAG AGCGACGAAG AGTACTACGC 480
CAAGGAGGTT TACAAAATAG ACATGCCGCC CTTCTTCCCC TCCGAAAATG CCATCCCGCC 540 5 CACTITICTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600 TGCTTCCAAT TTGGTGAAAG CAGAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660 AGTGCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAGATT TAACATCTCC 720
AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780
CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840
TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900 10 AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCACCT CCACATATAC 960 15 CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAAA AACAGTGGGA AGACCCCACA 1020 TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080 GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTITAC ATTGATTTCA AGAGGGATCT AGGGTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATTTA TGGAGTTCAG ACACTCAGCA 1260 20 CAGCAGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320 CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380 TGAACAGCTT TCTAATATGA TTGTAAAAGTC TTGCAAAATGC AGC<u>TAA</u>AATT CTTGGAAAAG 1440 TOGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG ACGACGACAA CGATGATGCT 1500 TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAAATTT TTGAAAAGGC 1560 GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTGTTTG TTAAAAACTGG CATCTGACAC 1620 25 AAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTITI TTAAA Seq ID NO: 116 <u>Protein sequence:</u>
Dentein Accession #: NP_003229.1 30 21 31 41 MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIFAI RGQILSKLKL TSPPEDYPEP 60 35 EEVPPEVISI YNSTROLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFOVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180 TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240 NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300 KRALDAAYCF RNYODNCCLR PLYIDFKRDL GWKWIHIPKG YNANFCAGAC PYLWSSDTQH 360 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS 40 Seq ID NO: 117 DNA sequence Nucleic Acid Accession #: NM_000095.1 Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons) 45 41 11 21 31 CAGCÁCCIÁG CTCCCCGCCÁ CCGCC<u>ATG</u>GT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCGCGT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120 50 GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT 180 GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240 CCCCTGCCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420 55 CGCCCACCCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480 GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGC GTGGGGCTGG CTTTCGCCAA 540 GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCAAC ATAACTGCGT 600 CCCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660 CTTOGTGGGC GACCAGGCGT COGGCTGCCA GCGCGGCGCA CAGCGCTTCT GCCCCGACGG 720 60 CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC 780 GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840 AGACGGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG 900 COTGACTOTO CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960 CGATCTGG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960
CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAG GACAACTGCC CGCTGGTGCG 1020
GAACCCAGAC CAGCGCAACA CGGACGAGGAC CAAGTGGGGC GATGCGTGCG ACAACTGCCC 1080
GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA 1140
CGACGACATC GACGGCGACC GGATCCGCAA CCAGGCCCGAC AACTGCCCTA GGGTACCCAA 1200
CTCAGACCAG AAGGACAGTG ATGGCQATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA 1260
GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GTGGGAAGTG CTTGTGACAG 1320
-CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC 1380
TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACCACGA 1440 65 70 CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500 GGAGGACGC GACAGGGACG GCOTTGGGCGA COTTOTGCCAG GACGACTTTG ATGCAGACAA 1560 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620 GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGC CAGATTGACC CCAACTGGGT 1680 75 GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 GGOTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC 1800

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860 CATGTGGAAG CAGATGGAGC AAACOTATTG GCAGGCGAAC CCCTTCCGTGG CTGTGGCCGA 1920 GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGAAC AGCTGCGGA 1980 CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG 2040 AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100 GGGCTACATC AGGGTGGCAT TCATGAGGG CCTTGGATCTG GTGGCCGACA GCAACGTGGT 2160 CTTGGACACA ACCATGCGGG GTGGCCGCCT GGGGGTCTTC TGCTTCTCCC AGGAGAACAT 2220 CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCA 2280 TCAGCTGCGG CAAGCCTAGG AGACAGTGGC GACCCCCCC 2340 CCGCCTGGAT GGGGGCTCTT CACCAGGGCT AGACAGGGCT CCCCCACC 2340 AAGGGCTCAG AGAGGACAAAA ATAAAGTGTG TGTGCAGGG

Seq ID NO: 118 Protein sequence:

Devotein Accession #: NP_000086.1

15

10

70

75

20
ELKNTVMECD ACOMQQSVRT GLPSVRPILH CAPGFCFFGV ACIQTESGGR CGPCPAGFTG 120
NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180
NECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH 240
ADCVLERDGS RSCVCRVGWA GNGILLGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSQG 300
EDVDRDGIGD ACDPDADGIG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQRNDDQK 360
DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420
VDHDFVGDAC DSDQDQDGD HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS 480
BDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENABVTLTD FRAFQTVVLD 540
PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI 600
FGYQDSSSFY VVMWKQMEQT YWQANFFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660
ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG 720
RLGVFCFSQE NIIWANLRYR CNDTIPEDVB THQLRQA

Seq ID NO: 119 DNA sequence
Nucleic Acid Accession #: NM_014211
Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons)

35 31 GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60 GTCCTGCCTG TAGGCCTGAA GGACTTGCCC TAACAGAGCC TCAACAACTA CCTGGTGATT 120 CCTACTTCAG CCCCTTGGTG TGAGCAGCTT CTCAAC<u>ATG</u>A ACTACAGCCT CCACTTGGCC 180 TTCGTGTGTC TGAGTCTCTT CACTGAGAGG ATGTGCATCC AGGGGAGTCA GTTCAACGTC 240 40 ACAAGTA TCTCTAGCAT TTCAGAGAGT ACACTGGCT GAACCCAC CATATACCTC 420
CGACAGCGCT GGATGGACA GCGCCTGGT TTTGAGAGCT ACACAAGCCCT CACTCTGGAC 360
ATTGCAAGTA TCTCTAGCAT TTCAGAGAGT AACATGGACT ACACAGCCAC CATATACCTC 420
CGACAGCGCT GGATGGACCA GCGGCTGGTG TTTGAAGGCA ACAAGAGCTT CACTCTGGAT 480 45 GCCCGCCTCG TGGAGTTCCT CTGGGTGCCA GATACTTACA TTGTGGAGTC CAAGAAGTCC 540 TTCCTCCATG AAGTCACTGT GGGAAACAGG CTCATCCGC TCTTCTCCAA TGGCACGGTC 600 CTGTATGCCC TCAGAATCAC GACAACTGTT GCATGTAACA TGGATCTGTC TAAATACCCC 660 ATGGACACAC AGACATGCAA GTTGCAGCTG GAAAGCTGGG GCTATGATGG AAATGATGTG 720 50 GAGTTCACCT GGCTGAGAGG GAACGACTCT GTGCGTGGAC TGGAACACCT GCGGCTTGCT 780 CAGTACACCA TAGAGOGGTA TITCACCTTA GTCACCAGAT CGCAGCAGGA GACAGGAAAT 840 TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900 ACCTACGTTC CTTCCACTTT CCTGGTGGTG TTGTCCTGGG TTTCATTTTG GATCTCTCTC 960 GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGACGACCG TGTTATCAAT GACCACACTG 1020 ATGATOGGGT CCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGC CATCGATGTG 1080
TACCTGGGGA TCTGCTTTAG CTTTGTGTTT GGGCCTTGC TAGAATATGC AGTTGCTCAC 1140
TACAGTTCCT TACAGCAGAT GGCAGCCAAA GATAGGGGGA CAACAAAGGA AGTAGAAGAA 1200
GTCAGTATTA CTAATATCAT CAACAGCTCC ATCTCCAGCT TTAAACGGAA GATCAGCTTT 1260 55 GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320 GACAAGTTCA AGITTGTCTT CCGAGAAAG ATGGGCAGGA TTGTTGATTA TTTCACAATT 1380
CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTGAT TTTTATGGTA 1440
GCCAATGTAT TTTACTGGGC ATACTACATG TATTTTTGAG TCAATGTTAA ATTTCTTGCA 1500
TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTTTAGG CCAAGTGTGC 1560 60 ACCEACATCE AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAGA 1620
ATGAAGCTCC AACCATTGTT CTAAGCTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680
TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740
TTACAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800 65

TATACATOTT TITTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920
GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TATGGGCTTA TGTCAATTCA 1980
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAATAATGA ATATTATTTA 2040
ATACCACAAC AGAATTATCC CCAATTTCCA ATAAGTCCTA TCATTGAAAA TTCAAAATATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TTTATTCCCC CACTATGCAT ATCTTATCAT 2220

AAGAATGGGA AGGAGACCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CTAAAGTAAC 1860

AGTGAAGAAA AAAATTAGTAG ATCAACAATC TAAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCCA TACTGGAAGG ACTCTGAGGC TITATTCCCC CACTATGCAT ATCTTATCAT 2220
TITATTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280
GGAAATGGAA GATTTTTTTTG TAACTTGTTC TAGAAGTCTT AATATGGGCT GTTGCCATGA 2340
AGGCTTGCAG AATTGAGTCC ATTTTCTAGC TGCCTTTATT CACATAGTGA TGGGGTACTA 2400

GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520 TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAC TGCTTGACCC AGGAACAAGT 2580 GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640 TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 5 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGIGIGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TITAGACAAT CTCGCCATCT 2880
TTAATTICTT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940
ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000
CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTTA 3060 10 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120 TATGAGCCAA TCATATTTGT GATTTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180 AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAA CTGTGAAATA 3240 15 AATATACCAT ATTAGCTACC CACC Seq ID NO: 120 <u>Protein sequence:</u> Protein Accession #: NP_055026.1 20 11 41 21 31 MNYSLHLAFV CLSLFTERMC IQGSQFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60 VOJALITOIA SISSISSIM DYTATIYIRQ RWMDQRLVFE GNKSTIDAR LVEFLWYPDT 120
YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITITVAC NMDLSKYPMD TQTCKLQLES 180 25 WGYDGNDVEF TWLRGNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240 NVLYFILETY VPSTFLVVLS WVSFWISLDS VPAKTCIGVT TVLSMTTLMI GSRTSLPNTN 300 CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNUNSSIS 360 SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 LEPIJEMIAN VEYWAYYMYE 30 Seq ID NO: 121 DNA sequence NM 001854 Nucleic Acid Accession #: Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons) 35 31 41 51 AAOCATCAAA TITAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TOTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120
TTCGTGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180
GGTGGAAAAC GAAACGGTGG CTCTGGGATT TCACCGTAAC AACCCTCGCA TTGACCTTCC 240
TCTTCCAAGC TAGAGAGGGTC AGAGGAGCTG CTCCAGTTGA TGTACTAAAA GCACTAGATT 300 40 TITCACAATE TOCAGAGGGA ATATCAAAAA CAACGGGATT TIGCACAAAC AGAAAGAATT 360
CTAAAGGCTC AGATACTGCT TACAGAGTTT CAAAGCAAGC ACAACTCAGT GCCCCAACAA 420
AACAGTTATT TOCAGGTGGA ACTITCCCAG AAGACTTTTC AATACTATTT ACAGTAAAAC 480
CAAAAAAAAG 45 TIGGTGTTGA GGTTGGGAGA TCACCTGTTT TTCTGTTTGA AGACCACACT GGAAAACCTG 600 TIGGIGITIGA GGTIGGGAGA TCACCIGITI' TICIGITIGA AGACCACACI GAAAAACLI 600
CCCCAGAAGA CTATCCCCTC TICAGAACTG TTAACATCGC TGACGGGAAG TGGCATCGGG 660
TAGCAATCAG CGTIGGAGAAG AAAACTGTIGA CAATGATTGT TGATTGTAAG AAGAAAACCA 720
CGAAACCACT TGATAGAAGT GAGAGAGCAA TTGTTGATAC CAATGGAATC ACGTTTTTTG 780
GAACAAGGAT TTTGGATGAA GAAGTTTTTTG AGGGGGACAT TCAGCAGTTT TTGATGACAG 840
GTIGATCCCAA GGCAGCATAT GACTACTGTG AGCATTATTAG TCACAGACTGT GACTCTTCAG 900
CACCCAAGGG TGCTCAAGCT CAGGAACCTC AGATAGATGA GTATGCACCA GAGGATATAA 960
TCGAATATGA CTATGAGTAT GGGGAAGCAG AGTATAAAGA GGCTGAAAAGT GTAACAGAGG 1020 50 GACCCACTGT AACTGAGGAG ACAATAGCAC AGACGGAGGC AAACATCGTT GATGATTTTC 1080 55 AAGAATACAA CTATGGAACA ATGGAAAGTT ACCAGACAGA AGCTCCTAGG CATGTTTCTG 1140 GGACAAATGA GCCAAATCCA GTTGAAGAAA TATTTACTGA AGAATATCTA ACGGGAGAGG 1200 ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAAACAAA GAAATAGACG 1260 GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTTAGGCGA ATATGATTTT TATGAATATA 1320 AAGAATATGA AGATAAACCA ACAAGCCCC CTAATGAAGA ATTTGGTCCA GGTGTACCAG 1380
AAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATG TGCATATGGA GAGAAAGGAC 1440
AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500
CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACAAGG CCCCACTGGA CCCCCTGGTG 1560 60 ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACC AGGGGCTGAT GGTCTACCTG 1620
ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACC AGGGGCTGAT GGTCTACCTG 1620
CTCCTCGG TACTATGTTG ATGTTACCGT TCCGTTATGG TGGTGATGGT TCCAAAAGGAC 1680
CAACCATCTC TGCTCAGGAA GCTCAGGCTC AAGCTATTCT TCAGCAGGCT CGGATTGCTC 1740
TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCTG 1800 65 GTTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTCC TCAGGGCCCT CGAGGCGTCC 1860 AGGGTCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920 GAAGAGGAAT GCCAGGAGAA CCTGGGGCAA AGGGAGATCG AGGGTTTGAT GGACTTCCGG 1980 GTCTGCCAGG TGACAAAGGT CACAGGGGTG AACGAGGTCC TCAAGGTCCT CCAGGTCCTC 2040 70 CTGGTGATGA TGGAATGAGG GGAGAAGATG GAGAAATTGG ACCAAGAGGT CTTCCAGGTG 2100 AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGGAACTCC AGGAGCTCCA GGGCAGCCTG 2160 AGACTOSCO ACAGOTTO COOCCAGAC CAAAAGGAAA CATGGGTCCC CAAGGGAGC 2220
CTGGGCCTCC AGGTCAACAA GGGAATCCAG GACCTCAGGG TCTTCCTGGT CCACAAGGTC 2280
CAATTGGTCC TCCTGGTGAA AAAGGACCAC AAGGAAAACC AGGACTTGCT GGACTTCCTG 2340
GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAGAAGGCCA GTCTGGAGAA AAGGGGGCTC 2400 75 TGGGTCCCCC TGGTCCACAA GGTCCTATTG GATNNCCGGG CCCCCGGGGA GTAAAGGGAG 2460


AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460

PCT/US02/02242 WO 02/059377


CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGGT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAGA TOGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640 CTTCAGGTCA AGCAGGAGAA AAGGGAAAAC TTGGAGTTCC AGGATTACCA GGATATCCAG 2700 5 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAGA 2760 AAGGTGCACG GGGAGTAGCT OGCAAACCAG GCCCTCGGGG TCAGCGTGGT CCAACGGGTC 2820 CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880 GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940 TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGGC TGCCCAGGAC 3000 10 ACCCTGGGCA ACGTGGGGAG ACTGGATTTC AAGGCAAGAC CGGCCCTCCT GGGCCAGGGG 3060 GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240 GTTTCCCAGG GGAAAGAGGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 15 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGCC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480 AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 20 GCCCTCCCGG TCCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660 ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGGTG 3720 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780 GTGAAAAAGG TGAAAATGGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840 GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900 25 CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140 GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACGAGGT CCTCCTGGAG 4260 30 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 OTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTETTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440
AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500
GCTCCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560 35 AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 40 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATICT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 CTIGCATITIA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 AACCAGGAAG TIGGTTTAGT GAATTTAAGA GGGGAAAACT GCFTTCATAC TTAGATGTTG 5220 45 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340 GGTAAATTT CACTACAC TOTCATCAGA CAGAGC TOTATOATOTO TOTATCAGAA 5940
GTTATOACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5460
ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460
TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TOTTGATGTC ATGATCAGTG 5520
ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT 5580 50 ACTITIGATION ICAGAACTA AGAICAGAA TIGAATI TOGATI TOGATITICA CACCAACOCCA 5640
TITTOTICCCA CATGCAAGTI TITGAATAAGG ATGTATGGAA AACCACCTG CATATACAGG 5760
TACCATITAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760
ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 55 TICTICAACTC TOCTITITOCT ATTIGACTTT CTITGGTGCT GTAGAAAACA AAAAAGAAA S880
AATATATT CATAAAAAAA ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAAACAG 5940
TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000
CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 60 GATGGCAATA ATATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 TTICTTIGGT TAATGATGAA ATTCCTTTGT GTGTGTTT


Seq ID NO: 122 Protein sequence 65 NP 001845 Protein Accession #:

11 21 31 41 51 MEPWSSRWKT KRWLWDFTVT TLALTFLFQA REVRGAAPVD VLKALDFHNS PEGISKTTGF 60 CTNRKNSKGS DTAYRVSKQA QLSAPTKQLF PGGTFPEDFS ILFTVKPKKG IQSFLLSIYN 120 EHGIQQIGVE VGRSPVFLFE DHTGKPAPED YPLFRTVNIA DGKWHRVAIS VEKKTVTMIV 180 70 EHRIQQUOTE VORSETYLLE DHIGKPAPED ITHEN I VAIA DORWHAVAIS VERRI VIRIAT 180
DCKKKTTKPL DRSERAIVDT NGITVFGTRI LDEBVFEGDI QQFLITGDPK AAYDYCEHYS 240
PDCDSSAPKA AQAQEPQIDE YAPEDIIEYD YBYGEABYKE AESVTEGPTV TEBITAQTEA 300
NIVDDFQEYN YGTMESYQTE APRHVSGTNE PNPVEEFTE EYLTGEDYDS QRKNSEDTLY 360
ENKEIDGRDS DLLVDGDLGE YDFYBYKEYE DKPTSPPNEE FGPGVPAETD ITETSINGHG 420
AYGEKGQKGE PAVVEPGMLV EGPPGPAGPA GIMGPPGLQG PTGPPGDPGD RGPPGRPGLP 480 75



WO 02/059377





75


METRISHIQU AVILINCANI SKRKUQQKI I VIDISACIB DIDARKHI'S KEHV I ISAI 1841 PAPEN MPSRVMPSQ PLHIVLESI.K REGKEPLVI.K GGLSSFKQNH ENILCDNSIQL QECREVGGGA 300 SAASSI JPQP BYTTPDIENA ELTPILPFLF LGNEQDAQDL DTMQRINIGY VINVTTHILPL 360 YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420 AYLMKHTRMT MTDAYKFVKG KRPIISPNI.N FMGQILIEFEE DLNNGVTPRI LTPKLMGVET 480 5 Seq ID NO: 131 DNA sequence NM 005409.3 Nucleic Acid Accession #: Coding sequence: 94-378 (underlined sequences correspond to start and stop codons) 10 31 41 TICCTITCAT GITCAGCATT TCTACTCCTT CCAAGAAGAG CAGCAAAGCT GAAGTAGCAG 60 15 CAACAGCACC AGCAGCAACA GCAAAAAACA AACATGAGTG TGAAGGGCAT GGCTATAGCC 120 TTGGCTGTGA TATTGTGTGC TACAGTTGTT CAAGGCTTCC CCATGTTCAA AAGAGGACGC 180 TGTCTTTGCA TAGGCCCTGG GGTAAAAGCA GTGAAAGTGG CAGATATTGA GAAAGCCTCC 240
ATAATGTACC CAAGTAACAA CTGTGACAAA ATAGAAGTGA TTATTACCCT GAAAGAAAAT 300
AAAGGACAAC GATGCCTAAA TCCCAAATCG AAGCAAGCAA GGCTTATAAT CAAAAAAGTT 360
GAAAGAAAAAA ATTTTTAAAA ATATCAAAAC ATAFGAAOTC CTGGAAAAGAG GCATCTGAAA 420 20 AACCTAGAAC AAGTITAACT GTGACTACTG AAATGACAAG AATTCTACAG TAGGAAACTG 480
AGACTITICT ATGGTTTTGT GACTTTCAAC TTTTGTACAG TATGTGAAG GATGAAAGGT 540
GGGTGAAAGG ACCAAAAACA GAAATACAGT CTTCCTGAAT GAATGACAAT CAGAATTCCA 600 CTGCCCAAAG GAGTCCAGCA ATTAAATGGA TTTCTAGGAA AAGCTACCTT AAGAAAGGCT 660 CIGOCCAAAG GAGTICAGCA ATTAAATIGAA TTICTAGGAA AAGTIACTT ATAAATICAT 720
GGITTACCATC GGAGTITACA AAGTIGCITTC ACGTICTTAC TIGTIGTATT ATACATICAT 720
GCATTICTAG GCTAGAGAAC CITCTAGATT IGATGCITAC AACTATICIG TIGTIGACTAT 780
GAGAACATTI CIGTICTCTAG AAGTIATCTG TICTGATTGA TCTITATGCT ATATTACTAT 840
CIGTIGGITAC AGTIGGAGACA TTGACATTAT TACTGGAGTC AAGCCCTTAT AAGTICAAAAG 900 25 CATCTATUTG TCGTAAAGCA TTCCTCAAAC ATTTTTTCAT GCAAATACAC ACTTCTTTCC 960 CCAAATATCA TGTAGCACAT CAATATGTAG GGAAACATIC TTATGCATCA TTTIGGTTTGT 1020
TTTATAACCA ATTCATTAAA TGTAATTCAT AAAATGTACT ATGAAAAAAA TTATACGCTA 1080 30 TGGGATACTG GCAACAGTGC ACATATTTCA TAACCAAATT AGCAGCACCG GTCTTAATTT 1140 GATGTTTTIC AACTITTATT CATIGAGATG TITTGAAGCA ATTAGGATAT GTGTGTTTAC 1200 TGTACTITIT GITTIGATCC GTTIGTATAA ATGATAGCAA TATCTTGGAC ACATTTGAAA 1260 TACAAAATGT TTTTGTCTAC CAAAGAAAAA TGTTGAAAAA TAAGCAAATG TATACCTAGC 1320 AATCACTITI ACTITTIGTA ATTCTGTCTC TTAGAAAAAT ACATAATCTA ATCAATTTCT 1380 35 TIGTICATGC CTATATACTG TAAAATTTAG GTATACTCAA GACTAGTTTA AAGAATCAAA 1440 Seq ID NO: 132 <u>Protein sequence:</u>
Protein Accession #: NP_005400.1 40 31 41 21 45 MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI 60 EVITTLKENK GORCLNPKSK QARLIIKKVE RKNF Seq ID NO: 133 DNA sequence NM_012342 Nucleic Acid Accession #: 50 Coding sequence: 373-1155 (underlined sequences correspond to start and stop codons) 21 31 41 CTGGCGCGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGAGACCC TACTCTCTTC 60 GCTGAGAACG GCCGCTAGCG GGGACTGAAG GCCGGAGCC CACTCCCGAC CCGGGGCTAG 120 CGTGCGTCCC TAGAGTCGAG CGGGGCAAGG GAGCCAGTGG CCGCCGACGG GGGACCGGGA 180 55 AACTITICTG GGCTCCTGGA GAGCCCTGTA GCCGCGCTCC ATGCTCCGGC AGCGGCCCGA 240 AACCCAGCCC CGCCGCTGAC GGAGCCCGCC GCTCCGGGCA GGGCCCATGC CCTGCGCGCT 300
CCGGGGGTCG TAGCTGCCGC CGAGCCGGGG CTCCGGAAGC CGGCGGGGGC GCCGCGCCG 360
TGCGGGGGCT CAATGGATCG CCACTCCAGC TACATCTTCA TCTGGCTGCA GCTGGAGCTC 420 60 TGCGCCATGG CCGTGCTGCT CACCAAAGGT GAAATTCGAT GCTACTGTGA TGCTGCCCAC 480 TOTOTAGCCA CTGGTTATAT GTGTAAATCT GAGCTCAGCG CCTGCTTCTC TAGACTTCTT 540 GATCCTCAGA ACTCAAATTC COCACTCACC CATGGCTGCC TGGACTCTCT TGCAAGCACG 600
ACAGACATCT GCCAAGCCAA ACAGGCCCGA AACCACTCTG GCACCACCAT ACCCACATTG 660
GAATGCTGTC ATGAAGACAT GTGCAATTAC AGAGGGCTGC ACGATGTTCT CTCTCCCC 720 65 AGGGGTGAGG CCTCAGGACA AGGAAACAGG TATCAGCATG ATGGTAGCAG AAACCTTATC 780 ACCAAGGTGC AGGAGCTGAC TTCTTCCAAA GAGTTGTGGT TCCGGGCAGC GGTCATTGCC 840 GTGCCCATTG CTGGAGGGCT GATTTTAGTG TTGCTTATTA TGTTGGCCCT GAGGATGCTT 900 CGAAGTGAAA ATAAGAGGCT GCAGGATCAG CGGCAACAGA TGCTCTCCCG TTTGCACTAC 960 70 AGCTTTCACG GACACCATTC CAAAAAGGGG CAGGTTGCAA AGTTAGACTT GGAATGCATG 1020 OTGCCGGTCA GTGGGCACGA GAACTGCTGT CTGACCTGTG ATAAAATGAG ACAAGCAGAC 1080 CTCAGCAACG ATAAGATCCT CTCGCTTGTT CACTGGGGCA TGTACAGTGG GCACGGGAAG 1140 CTGGAATTCG TA<u>TGA</u>CGGAG TCTTATCTGA ACTACACTTA CTGAACAGCT TGAAGGCCTT 1200 TTGAGTTCTG CTGGACAGGA GCACTTTATC TGAAGACAAA CTCATTTAAT CATCTTTGAG 1260

MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240

AGACAAAATG ACCTCTGCAA ACAGAATCTT GGATATTTCT TCTGAAGGAT TATTTGCACA 1320

5

TAAACAAAAA TOTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500 AAATATATAT ATTITGTCTG A



45

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADBISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA

5 Seq ID NO: 137 DNA sequence XM_030559 Nucleic Acid Accession #: Coding sequence: 1-119 (underlined sequences correspond to start and stop codons) 31 41 51 10 ATGAACCGCA GCCACCGGCA CGGGGCGGGC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG 60 AGCAAGTITG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACC TGGAAAATTT 120
GAGGAGGTTTT ATGGATTACT ACAACATGTT CATAAAGATC CCAATGTTGA CGTTTTGGTA 180
GGCTATGCAG ACATCCATGG AGACTTACTA CCTATAAATA ATGATGATAA TTATCACAAA 240
GCTGTTTCAA CGGCCAATCC ACTGCTTAGG ATATTTATAC AAAAGAAGGA AGAAGCAGAC 300 15 TACAGTGCCT TIGGTACAGA CACGCTAATA AAGAAGAAGA ATGTTTTAAC CAACGTACTC 360
CGTCCTGACA ACCATAGAAA AAAGCCACAT ATAGTCATTA GTATGCCCCA AGACTTAGA 420
CCTGTGTCTT CTATTATAGA CGTGGATATT CTCCCAGAAA CGCATCGTAG GGTACGTCTT 480
TACAAATACG GCACGGAGAA ACCCCTAGGA TICTACATCC GGGATGGCTC CAGTGTCAGG 540 20 GTAACACCAC ATGGCTTAGA AAAGGTTCCA GGGATCTTTA TATCCAGGCT TGTCCCAGGA 600 GIACACCAC A RIGICI ROBA ACRASTIAGCT GITAATGATG AAGTITAAGG AGTTAATGGC 660
ATAGAAGTIT CAGGGAAGAG CCTTGATCAA GITAATGATG AAGTITAAGA GTTAATGGC 660
ATAGAAGTIT CAGGGAAGAG CCTTGATCAA GITAACAGACA TGATGATTGC AAATAGCCGT 720
AACCTCATCA TAACAGTGAG ACCGGCAAAC CAGAGGAATA ATGITGTGAG GAACAGTCGG 780
ACTTCTGGCA GTTCCGGTCA GTCTACTGAT AACAGCCTTC TTGGCTACCC ACAGCAGATT 840 ACTICITICA GETTACAGATA GASTACAGA ACAGACTIC TIGOCIACAC ALAGCAGATI 840
GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCGAAGAAG ATGACATTAT CATTGAAGAC 900
AATGGAGTGC CACAGCAGAT TCCAAAAAGCT GTTCCTAATA CTGAGAGCCT GGAGTCATTA 960
ACACAGATAG AGCTAAGCTT TGAGTCTGGA CAGAATGGCT TTATTCCCTC TAATGAAGTG 1020
AGCTTAGCAG CCATAGCAAG CAGCTCAAAC ACCGGAATTTG AAACACATGC TCCAGATCAA 1080 25 AAACTCTTAG AAGAAGATGG AACAATCATA ACATTA<u>TGA</u> 30 Seq ID NO: 138 Protein sequence: 21 35 GYADIHGDLL PINNDDNYHK AVSTANPLLR IFIQKKEEAD YSAFGTDTLI KKKNVLTNVL 120 TI ADMIDDLE PINNDDIN HIS AVSTANTLIK ENGRADDAD TSANDLID RESEAVE THE PROBLEM STREET OF THE RESEAVE THE PROBLEM STREET OF THE RESEAVE THE RES 40 KLLEEDGTII TL

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

12.

1

1	1.	A method of detecting a breast cancer-associated transcript in a cell	
2	from a patient, the method comprising contacting a biological sample from the patient with a		
3	polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence		
4	as shown in Tables 1-25.		
1	2.	The method of claim 1, wherein the biological sample comprises	
2	iselated nucleic acid		
1	3.	The method of claim 2, wherein the nucleic acids are mRNA.	
1	4.	The method of claim 2, further comprising the step of amplifying	
2	nucleic acids before	the step of contacting the biological sample with the polynucleotide.	
1	5.	The method of claim 1, wherein the polynucleotide comprises a	
2	sequence as shown	in Tables 1-25.	
1	6.	The method of claim 1, wherein the polynucleotide is immobilized on	
2	a solid surface.		
1	7.	The method of claim 1, wherein the patient is undergoing a therapeutic	
2	regimen to treat breast cancer.		
1	8.	The method of claim 1, wherein the patient is suspected of having	
2	breast cancer.		
1	9.	An isolated nucleic acid molecule consisting of a polynucleotide	
2	sequence as shown	in Tables 1-25.	
1	10.	The nucleic acid molecule of claim 9, which is labeled.	
1	11.	An expression vector comprising the nucleic acid of claim 9.	
	· ·	- • • •	

A host cell comprising the expression vector of claim 11.

1		13.	An isolated polypeptide which is encoded by a nucleic acid molecule
2	having polynucleotide sequence as shown in Tables 1-25.		
1	•	14.	An antibody that specifically binds a polypeptide of claim 13.
1		15.	The antibody of claim 14, further conjugated to an effector component.
1 2	fluorescent la	16. bel.	The antibody of claim 15, wherein the effector component is a
1 2		17.	The antibody of claim 15, wherein the effector component is a stoxic chemical.
1		18.	The antibody of claim 15, which is an antibody fragment.
1	1	19.	The antibody of claim 15, which is a humanized antibody
1		20.	A method of detecting a breast cancer cell in a biological sample from
2	a patient, the method comprising contacting the biological sample with an antibody of claim		
3	14.		
1		21.	The method of claim 20, wherein the antibody is further conjugated to
2	an effector co	mpone	nt.
1		22.	The method of claim 21, wherein the effector component is a
2	fluorescent la	bel.	
1		23.	A method for identifying a compound that modulates a breast cancer-
2	associated polypeptide, the method comprising the steps of:		
3		(i) con	ntacting the compound with a breast cancer-associated polypeptide, the
4	polypeptide e	ncoded	by a polynucleotide that selectively hybridizes to a sequence at least
5	80% identical to a sequence as shown in Tables 1-25; and		
6		(ii) de	stermining the functional effect of the compound upon the polypeptide.
1		24.	A drug screening assay comprising the steps of

2	(i) administering a test compound to a mammal having breast cancer or a cell		
3	isolated therefrom;		
4	(ii) comparing the level of gene expression of a polynucleotide that selectively		
5	hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a		
6	treated cell or mammal with the level of gene expression of the polynucleotide in a control		
7	cell or mammal, wherein a test compound that modulates the level of expression of the		
8	polynucleotide is a candidate for the treatment of breast cancer.		

楼

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760 TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820 5 AAATATATTT AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TTTCAAAATG 3120 TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180 TATTGCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240
CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300
TCATTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360
GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 10 GATGITICIT TITTACACAA TAAATTOCTT ATATCAGCTT G

Seq ID NO: 30 Protein sequence:
Protein Accession #: NP_036451.2 15

70

21

MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL 60 20 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHES HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180

EHHSDHDHIHS HINHAASGKN KRKALCPDHD SDSSGKDFRN SQGKGAHRPE HASGRRNVKD 180
SVSASEVTST VYNTVSEGTH FLETIETPRP GKLIPKDVSS STYPSVTSKS RVSRLAGGKT 240
NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300
RSCLHITSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360
LVALAVGTLS GDAFLHLLPH SHASHHHISHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420
TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480
EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEVMIA HAHPQEVYNE YVPRGCKNKC 540
HSHFHDTLGQ SDDLIHHHHD YHHILHEHHH QNEHPHSHSQ RYSREFLKDA GVATLAWMVI 660
MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHEIPHE LGDFAVLLKA GMTVKQAVLY 660
NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720
RWGYFFLQNA GMLLGFGIML LISHEHKIV FRINF 25 30

RWGYFFLONA GMLLGFGIML LISTFEHKIV FRINF

Seq ID NO: 31 DNA sequence 35 NM_002184.1 Nucleic Acid Accession #: 256-3012(underlined sequences correspond to start and stup codons) Coding sequence:

41

GAGCAGCCAA AAGCCCCCCG GAGTCGCCCT GGGCCCCCCC GGCGCAGCTG AACCGGGGGC 60
CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCCCC AAGGGGTTCG TGCGCTGTGG 120
AGACGCCGAG GGTCGAGGCC GCGCGGCCTG AGTGAAAACCC AATGGAAAAA GCATGACATT 180
TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTGG 240
AAATATCCGC GCAAGATGTT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300
CTCACCACTG AATCTACAGG TGAACTTCTA GATCCATGTG GTTAATATCAG TCCAATCTAAATTT TGTGATTTC 360 40 45 CCAGTTGTAC AACTICATC TAATTICACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420
CCAGTTGTAC AACTICATTC TAATTICACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420
GATTATTTTC ATGTAAATGC TAATTACATT GTCTGGAAAA CAAAACCATTT TACTATTCCT 480
AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540
TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600 50 TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAC CTAAAAATTT GAGTTGCATT 660 GTGAACGAGG GGAAGAAAT GAGGTGTGAG TGGGATGGTG GAAGGGAAAC ACACTTGGAG 720
ACAAACTTCA CTTTAAAATC TGAATGGGCA ACACACAAGT TTGCTGATTG CAAAGCAAAA 780
CGTGACACCC CCACCTCATG CACTGTTGAT TATTCTACTG TGTATTTGT CAACATTGAA 840 GTCTGGGTAG AAGCAGAGAA TGCCCTTGGG AAGGTTACAT CAGATCATAT CAATTTTGAT 900 CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960 CTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960 AAATATAACA TCTAAAAATT GACATGGACC AACCCAAGTA TTAAGAGTGT TATAATACTA 1020 AAATATAACA TTCAATATAG GACCAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCTGAA 1080 GACACAGCAT CCACCGGATC TTCATTCACT GTCCAAGAACC TTAAACCTTT TACAGAATAT 1140 55 GAGCAAGCAI CCACCUGATE TICATI CACI GICLAGAGC TIAAACCTI TACACAGAA TOGATGAA 1200
GAGCAAGTG GGATCACCTA TGAAGGAATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260
ATAGATCCAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320
CCITTIGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380 60 65

CATTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440
TATCTAGCAA CCTTAACAGT AAGAAATCTT GTTGGCAAAT CAGATGCAGC TGTTTTAACT 1500
ATCCCTGCCT GTGACTTTCA AGCTACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560
GATAACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAGAA ATATATACTT 1620 GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGATGGT 1680 ACCITICANA TATAGCACCE TOTAL AND ACTION ACTIO

ATATTTATA GAACCATCAT TOGAAATGAA ACTGCTGTGA ATGTGGATTC TTOCCACACA 1980
GAATATACAT TGTCCTCTTT GACTAGTGAC ACATTGTACA TGGTACGAAT GGCAGCATAC 2040
ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100
GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160 75 GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGTT 2220 CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTCC AAGGCACAAT 2280

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340 ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTCAAA 2400 AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460 TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CITCACAAAA CACTTCGAGC 2520 5 ACTOTOCAGT ATTOTACCGT GGTACACAGT GGCTACAGAC ACCAAGTTCC GTCAGTCCAA 2580 GTCTTCTCAA GATCOGAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640 CTACAATTAG TAGATCATGT AGATGGCOGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA AAGGTCAAAG 2760 CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820 10 ATTTCACAAT CCTGTGGATC TGGGCAAATG AAAATGTTTC AGGAAGTTTC TGCAGCAGAT 2880 GCTTTTGGTC CAGGTACTGA GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT 2940 CTAAAATGAT TITATCTGTG AATTC 15 Seq ID NO: 32 Protein sequence:
NP_002175.1 31 41 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV 60 NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL 240 KLIWINPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSTTVQDLK PFTBYVFRIR 300 CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360 25 GKILDYEVTL TRWKSHLONY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD 420 FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480 YLRGNIAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540 QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600 KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK 660 30

SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPPPEDLKS LDLFKKEKIN 720 TBGHSSGIGG SSCMSSSRPS ISSSDENBSS QNTSSTVQYS TVVHSGYRHQ VPSVQVPSR8 780 ESTOPLLDSE ERPEDLQLVD HVDGGDGILP RQQVPKQNCS QHESSPDISH FESKQVSSV 840 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900

Seq ID NO: 33 DNA sequence
Nucleic Acid Accession #: NM_018255.1
Coding sequence: 11-2491 (underlined sequences correspond to start and stop codons)

35

MPKSYLPQTV RQGGYMPQ

31 AGTTIGGOGAC <u>ATG</u>GTIGGCAC COGTIGCTIGGA GACTTCTCAC GTIGTTTTIGCT GCCCAAACCG 60 45 GGTGCGGGGA GTCCTGAACT GGAGCTCTGG GCCCAGAGGA CTICTGGCCT TTGGCACGTC 120 CTGCTCCGTG GTGCTCTATG ACCCCCTGAA AAGGGTTGTT GTTACCAACT TGAATGGTCA 180 CACCGCCCGA GTCAATTGCA TACAGTGGAT TTGTAAACAG GATGGCTCCC CTTCTACTGA '240 ATTAGTTTCT GGAGGATCTG ATAATCAAGT GATTCACTGG GAAATAGAGG ATAATCAGCT 300 TTTAAAAGCA GTGCATCTTC AAGGCCATGA AGGACCTGTT TATGCGGTGC ATGCTGTTTA 360 CCAGAGGAGG ACATCAGATC CTGCATTATG TACACTGATC GTTTCTGCAG CTGCAGATTC 420 TGCTGTTCGA CTCTGGTCTA AAAAGGGTCC AGAAGTAATG TGCCTTCAGA CTTTAAACTT 480 50 TGGAAATGGA TTTGCTTTGG CTCTCTGCTT ATCTTTTTTG CCAAATACTG ATGTACCAAT 540 55 GCTGTATATA AAGTCAACAT CTTTAGAAAC TCAGGATGAC GATAACATAA GACTGAAAGA AAATACTTTT ACCATAGAAA ATGAAAGTGT TAAAATAGCA TITGCTGTTA CTCTGGAGAC 840 AGTGCTAGCC GGTCATGAAA ACTGGGTAAA TGCAGTTCAC TGGCAACCTG TGTTTTACAA 900 AGATGGTGTC CTACAGCAGC CAGTGAGATT ATTATCTGCT TCCATGGATA AAACCATGAT 960 60 TCTCTGGGCT CCAGATGAAG AGTCAGGAGT TTGGCTAGAA CAGGTTCGAG TAGGTGAAGT 1020 AGGTGGGAAT ACTTTGGGAT TTTATGATTG CCAGTTCAAT GAAGATGGCT CCATGATCAT 1080 TGCTCATGCT TTCCACGGAG COTTGCACCT TTGGAAACAG AATACAGTTA ACCCAAGAGA 1140 GTGGACTCCA GAGATTGTCA TTTCAGGACA CTTTGATGGT GTCCAAGACC TAGTCTGGGA 1200 TCCAGAAGGA GAATITATTA TCACTGTTGG TACTGATCAG ACAACTAGAC TTTTTGCTCC 1260 65 ATGGAAGAGA AAAGACCAAT CACAGGTGAC TTGGCATGAA ATTGCAAGGC CTCAGATACA 1320 TGGGTATGAC CTGAAATGTT TGGCAATGAT TAATCGGTTT CAGTTTGTAT CTGGAGCAGA 1380 TGAAAAAGTT CTTCGGGTTT TTTCTGCACC TCGGAATTTT GTGGAAAATT TTTGTGCCAT 1440 TACAGGACAA TCACTGAATC ATGTGCTCTG TAATCAAGAT AGTGATCTTC CAGAAGGAGC 1500 CACIGICACIA ICALIGNATE AIGUICILIG INAICAGAT AGIGATUTIC CAGAAGGAGE 1500
CACIGICCCT GCATIGGGAT TATCAAATAA AGCTGTCITT CAGGGAGATA TAGCTTCTCA 1560
GCCTTCTGAT GAAGAGGAGC TGTTAACTAG TACTGGTTTT GAGTATCAGC AGGTGGCCTT 1620
TCAGCCCTCC ATACTTACTG AGCCTCCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1680
GCCTGAAGTT CAAAAACTAT ATGGGCACGG TTATGAAATA TTTTGTGTTA CTTGTAACAG 1740
TTCAAAGACT CTGCTTGCCT CAGCTTGTAA GGCAGCTAAG AAAGAGCATG CAGCTATCAT 1800 70 TCTTTGGAAC ACTACATCTT GGAAACAGGT GCAGAATTTA GTTTTCCACA GTTTGACAGT 1860 CACGCAGATG GCCTTCTCAC CTAATGAGAA OTTCTTACTA GCTGTTTCCA GAGATCGAAC 1920 CTGGTCATTG TGGAAAAAGC AGGATACAAT CTCACCTGAG TTCGAGCCAG TTTTTAGTCT 1980 75 TITIGCCITC ACCAACAAAA TTACTTCTGT GCACAGTAGA ATTATTTGGT CITGTGATTG 2040

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGGTGG TTGTCTGGGG 2100
TGAGTGCGAC TOCACTGATG ACTGTATTGA GCACAACATT GGCCCCTGCT CCTCAGTCCT 2160
GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCAC CTTCTCAACG 2220
ATACGTGGTT GCAGTAGGAT TGGAGTGTGG AAAGATTTGC TTATATACCT GGAAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2240
TCATACACTG GCTATCAGAA AATTATGCTG GAAGAATTGC AGTGGAAAAA CTGAACAGAA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAGATC ACACTGTGAA 2460
GATACACAGA GTCAATAAAAT GTGCACTGTAATTGG

Seq ID NO: 34 Protein sequence: Protein Accession #: NP_060725.1

5

75

15
MVAPVLETSH VFCCPNRVRG VLNWSSGPRG LLAFGTSCSV VLYDPLKRVV VTNLNGHTAR 60
VNCIQWICKQ DGSPSTELVS GGSDNQVIHW EIEDNQLLKA VHLQGHEGPV YAVHAVYQRR 120
TSDPALCTLI VSAAADSAVR LWSKKGPEVM CLQTLNFGNG FALALCLSFL PNTDVPILAC 180
GNDDCRIHF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240
KSTSLETQDD DNIRLKENTF TIENESVKIA FAVTLETVILA GHENWVNAVH WQPVFYKDGV 300
LQQPVRLLSA SMDKTMILWA PDEESGVWLE QVRVGEVGGN TLGFYDCQFN EDGSMILAHA 360
FHGALHLWKQ NTVNPREWTP EIVISGHFDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420
KDQSQVTWHE IARPQHIGYD LKCLAMINRF QFVSGADEKV LRVFSAPRNF VENFCAITGQ 480
SIJNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540
ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600
TTSWKQVQNL VPHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660
TNKITSVHSR IIWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720
GAYTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PENDWTHCV ETSQSQSHTL 780
AIRKLCWKNC SGKTEQKEAB GAEWLHFASC GEDHTVKHRV VNKCAL

Seq ID NO: 35 DNA sequence
Nucleic Acid Accession #: NM_022131
Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)

11 21 31 51 35 TGCTGCGAGG ATGCTGCCTG GGCGGCTGTG CTGGGTGCCG CTCCTGCTGG CGCTGGGCGT 60 GGGGAGCGC AGCGGCGGTG GCGGGGACAG CCGGCAGCGC CGCCTCCTCG CGGCTAAAGT 120 CAATAAGCAC AAGCCATGGA TCGAGACTTC ATATCATGGA GTCATAACTG AGAACAATGA 180 CACAGTCATT TTGGACCCAC CACTGGTAGC CCTGGATAAA GATGCACCGG TTCCTTTTGC 240 AGGGGAAATC TGTGCGTTCA AGATCCATGG CCAGGAGCTG CCCTTTGAGG CTGTGGTGCT 300 40 CAACAAGACA TCAGGAGAGG GCCGGCTCCG TGCCAAGAGC CCCATTGACT GTGAGTTGCA 360 GAAGAGACH ICAGGACAGC 420
GAAGAGACHAC ACATTCATCA TCCAGGCCTA TGACTGTGGT GCTGGGCCCC ACGAGACAGC 420
CTGGAAAAAG TCACACAAGG CCTTGGTCCA TATACAGGTG AAGGATGTCA ACGAGTTTGC 480
TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540
CATTCTGCAG GTGGAGGCCA TTGACGAGGA CTGCTCCCCA CAGTACAGCC AGATCTGCAA 600 45 CTATGAANTC GTCACCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 660 CACTGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACGA 720 CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTAA AGCCAGTTTG 780 CAAGCCTGGC 50 GCCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTCTT CCCTCCAGAT 900 COTCACAGAG CTGCAGACTA ATTACATTGG GAAGGGTTGT GACCGGGAGA CCTACTCTGA 960
GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCC 1020
TAGCGCTGCC ACCAACTGGA CTGCAGGACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1080 OTTTGACGC AGGCAGGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1140 TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200 GGAAACCATC CTCTGCAACT CAGACAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA 1260 TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCAGG CTGACACCTT 1320 55 TOGCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA 1380 TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440 ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCCATGC AACTCACAGT 1500 CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAACCACAG TTTGCTCAGT TCTTTCATGG 1560 60 AAGCCTGGCC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCCTG 1620 CCTGCAGGCC TGCAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680
AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGTGACG ACATTGGGAA 1740
CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGG 1800 65 TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGCTTT GGGGAAGACG TATGCATCAG 1860 TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATGGAGCCCC GGATCACCCT 1920 CCGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980 CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040 GAAAACCACA GACCCCAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100 70 TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAGGCAG GAGTGCTTGG AGCTCAACCA 2160 CAGTGAGCTC CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220
CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340

CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAGA 2400

TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460
TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520

CATCATCTCC GTGTGCATGC TTGTGTTTGT CGTGGCCATG GGTGTGTACC GGGTCCGGAT 2580
CGCCCACCAG CACTTCATCC AGGAGACTGA GGCTGCCAAG GAATCTGAGA TGGACTGGGA 2640
CGATTCTGCG CTGACTATCA CAGTCAACCC CATGGAGAAA CATGAAGGAC CAGGGCATGG 2700
GGAAGATGAG ACTGAGGGAG AAGAGGAGGA AGAAGCCGAG GAAGAAATGA GCTCCAGCAG 2760 TGGCTCTGAC GACAGCGAAG AGGAGGAGGA GGAGGAAGGG ATGGGCAGAG GCAGACATGG 2820 GCAGAATGGA GCCAGGCAAG CCCAGCTGGA GTGGGATGAC TCCACCCTCC CCTAC<u>TAG</u>TG 2880 CCCAGGGGTC TGCTGCCTGG CCCACATGTC CCTTTTGTAA ACCCTGACCC AGTGTATGCC 2940 CATGTCTATC ATACCTCACC TCTGATGTCT GTGACATGTC TGGGAAGGCC TTCTCCAGCT 3000 TCCTGGAGCC CACCCTTTAA GCCTTGGGCA CTCCCTGTGT TTCATCCATG GGGAAGTTCC 3060 AAGAAGOCCA GCATGGCCAT CAGTGAGGAC TTCAGGGTAG ACTTTGTCCT GTAGCCTCCA 3120 10 . CTTCTGCCCT AAGTTCCCCA GCATCCTGAC TACCTGTCTG CAGAGTTTGC CTTTGTTTTT 3180 TOCTGCAGGG AAGAAGGCCC ACCTTTGTGT CACTCACCTC CCCAGGCTCA GAGTCCCCAA 3240 GGCCCTGGGG TTCCAACTCA CTGTGCGTCT CCTCCACACA GACCAGTAGG TTCTCCTATG 3300 CTGACTCCAG GTTGCTTCAT ACAAGGAGGG TGGTTGAACT TCACACACGT AAGGTCTTAG 3360 15 TGCTTAACAG TTTAAAGGAA AGTCCTTGTT GAGGCAGAAC TAAGTTTACA GGGAAAGGTA 3420 CACACATICT CTCTCTCTCT CTCTCTCTGT CTATCTAGTT CCCCAGCTTG GAGAGCCTTT 3480 COCCTTGCTT CTTTCTOAGG CEATATAAGC TTATAAGAAA AGTCCCAAAC CAAGAATAGG 3500 TCCTTGGCCA CAAGCAGGGT CTGATCCCC ATCAGAGCTA TCTGAGCCTG CCTGTCTGGG 3600 CACCTGCTGC AACCATGCAG CTACCCTGCC AGGGGCACTC AGCAAACAGA ACCACAGGGC 3660 CCAGGAGGCA TICCACACAG GCACTGCCCC AGGACAACAC AACAAGGACA GTCACAACAA 3720
GGACAACAAG GACACAACAC AACACACAAC AAGGACAGTC ACAACAAGGACA GTCACAACAA 3780
AAGCAGATGG AAATGCTAAT GAGGTCAAAC GTAGGCTTCA TGGTGGGTGG AGTGGGGTTG 3840
GCTGGGCTCC CCCAGGACAG AGGGGACCCT GAGGTTGGCA AGGCTCTAC CACTCAGCCT 3900 20 TATGGTCCCT TATCTCCTAT CTTCCCTCTT GAGAAAATAC ACGCTTTCTG CATGTATTAG 3960 25 AAACGCACGA GCTCCACCAA GTCTACAATG AAAGTTTGAA ATTTAACTGC AAGGAATTAG 4020 AAGCATATTT GCAATCATTG CAGCTTCTTC TTTCTTCTGC TCATAAAAGG AGGAACACTT 4080 TAGATAGAGG GCAAATATAT CTGAAAACCT AATTICTTTC TTTTTTTGAT AAGGAAATCT 4140 TITICCATCTC CATCCTAACA TGCACAACCT GTGAAGAGAA TTGTTTCTAT AGTAACTGGT 4200 CTGTGATCIT TIGTGGCCAA GAGAATAGCA GGCAAGAATT AGGGCCTIGA CAGAATTICC 4260
ACGAAGCTCT GAGAACATGT TIGTTTCGAA TGTCTGATTC CTCTTTGTCA TCAATGTGTA 4320
TGCTCTGTCC CCATCCTTCA CTCCTCCICA AGCTCACACC AATTGGTTTG GCACAGGCAC 4380
AGAGCTGGTC CCTAGTTAAG TGGCATTTAT GTTAAAAAAA AATAGTTCAG AATCTCAGCC 4440 30 TTTTCTTTGT GTCATCAAAA CAGCTTAAGA AGGGGACTAC TGCCAATGTC CTCTAGTCTG 4500 ACCTCCACCC AGGGAGGACC CATGGCAGGT CTITTCAACT TTCTGATTCA TGAGAACAAC 4560 CTTGTGAAGC TTTTCCCACC TCCTAAAGTG TTTTCTGCAT CTGTTCCTTC CTTTGGACCT 4620 CACAACAAAT CCTGTGAAGT AACTGAGACA TCTGTTGTTA GATACATTTT TGTGATGAGT 4680 35 AAACTGAGGC TTCG Seq ID NO: 36 Protein sequence:
Protein Accession #: NP 071414.1 40 31 41 MLPGRLCWVP LLLALGVGSG SGGGGDSRQR RLLAAKVNKH KPWIETSYHG VITENNDTVI 60 MIPGRICKWY ILLAIDYUSG SOUGDSKOK KILAAKVIRH REWEISTED VIERIOITU LDPPLVALDK DAPVPFAGEI CAPKIHGQEL PFEAVVLIKT SGEGRLRAKS PIDCELQKEY 120 TPIIQAYDOG AGPHETAWKK SHKAVVHIQV KDVNEFAPTF KEPAYKAVVT EGKIYDSILQ 180 VEALDEDCSP QYSQICNYEI VTTDVPFAID RIIGNIRNTEK LSYDKQHQYE ILVTAYDCGQ 240 KPAAQDTLVQ VDVKPVCKPG WQDWTKRIEY QPGSGSMPLF PSIHLETCDG AVSSLQIVTE 300 45 LOTNYIGKOC DRETYSHKSL OKLOGASSOI IDLLPSPSAA TNWTAGLLVD SSEMIFKFDG 360 LQTINYIGKGC DRETYSEKSL QKLCGASSGI IDLI PSPSAA TNWTAGLLVD SSEMIKH-IJG 360
RQGAKIPDGI VPKNLTDQFT ITMWMKHGPS PGVRAEKETI LCNSDKTEMN RHHYALYVHN 420
CRLVFLLRKD FDQADTFRPA EPHWKLDQIC DKEWHYYVIN VEFFVVILYM DGATYEPYLV 480
TNDWPIHPSH IAMQLTVGAC WQGGEVTKPQ FAQFFHGSLA SLTIRFGEME SQKVISCLQA 540
CKEGLDINSL ESLQQGIKYH FNPSQSILVM EGDDIGNINR ALQKVSTYNS RQFPTAGVRR 600
LKVSSKVQCF GEDVCISIPE VDAYVMVLQA IEPRITLRGT DHFWRPAAQF ESABGVTLPP 660
DIKIVSTFAK TEARGDVKTT DPKSEVLEEM LENLDFCDIL VIGGDLDPRQ ECLELNHSEL 720
HQRHLDATNS TAGYSIYGVG SMSRYBQVLH HRYRNWRPA SLHARRFRIK CSELNGRYTS 780 50 55 NEFNLEVSIL HEDQVSDKEH VNHLIVQPPF LQSVHHPESR SSIQHSSVVP SIATVVIIIS 840 VCMLVFVVAM GVYRVRIAHQ HFIQETEAAK ESEMDWDDSA LTTTVNFMEK HEGPGHGEDE 900 TEGEEEEEAE EEMSSSSGSD DSEEEEEEEG MGRGRHGQNG ARQAQLEWDD STLPY 60 Seq ID NO: 37 DNA sequence Nucleic Acid Accession #: none found 143-874 (underlined sequences correspond to start and stop codous) Coding sequence: 65 51 21 31 41 70 ATTGAATTAT GGCATAGATC TTGGGAAAAT TGCGGAGTGT ACATTTACAA AGATGCGTTC 540
AAATAGTGCT CTAAGAGTTT TGTTCAGTGG CTCACTTCGG CTAAAATGCA GAAATGCATG 600
CTGTCAGCGT TGGTATTTCA CATTCAATGG AGCTGAATGT TCAGGACCTC TTCCCATTGA 660 75

叠

AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG 720 CACTICTICT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT 780 CTGGGTTGGC ACTIGTTCAG ATTACCCAAA AGAAGATGCT TCACTGGAT GGAATTCAGT 840
TCTCGCATC ATTATTGAAG AACTACCAAA ATAAATGCTT TAATTGGAT GGAATTCAGT 900
TTTTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TITAAATAAG TTTATGTATA 960
CATCTGAATG AAAAGCAAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT 1020 5 TITAAATCTA GCATTATTCA TITTGCTTCA ATCAAAAGTG GTTTCAATAT TITTTTTAGT 1080 TGGTTAGAAT ACTITICTICA TAGTICACATT CTCTCAACCT ATAATTIGGA ATATTGTTTGT 1140
GGTCTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT 1200 TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA 1260 **10**. **CAACCTTAAA ΑΑΛΑΑΑΑΑΑΑΑ ΑΑΑΑ** Seq ID NO: 38 Protein sequence:

Protein Accession #:

15 51 21 31 41 MRPQGPAASP QRLRGILILL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA 60 GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFIE SWTPNYKQCS WSSLNYGIDL 120 GKIAECTFIK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIRAIIYLDQ 180 20 GSPEMINSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240

Seq ID NO: 39 DNA sequence 25 NM 000949 Nucleic Acid Accession #: 285-2153 (underlined sequences correspond to start and stop codons) Coding sequence:


51 30 CTCCCTCTTT CTGGATTTTA CCGACCGTTC GCGAAACAGC TTTCCACACA ATGGAGCTTC 120 ATGTCCTCGT GCAGGAAGTA CTCATCGACT GATGTGGCAG ACTTTGCTCC CTGACAAAAC 180 TAAAGAACTC TCCTATTCAT GGAGGCGAAC ACTGAGGATG CTTTCCACAT GAACCCTGAA 240 GTGAACTTCT GATACATTTC CTGCAGCAAG AGAAGGCAGC CAACATGAAG GAAAATGTGG 300 GTGAACTICT GATACATTIC CTGCAGCAAG AGAAGGCAGC CAACATGAAG GAAAATGTGG 300
CATCTGCAAC CGTTTTCACT CTGCTACTIT TTCTCCAACAC CTGCTTCTG AATGGACAGT 360
TACCTCCTGG AAAACCTGAG ATCTTTAAAT GTCGTTCTCC CAATAAGGAA ACATTCACCT 420
GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTT ACTTACCACA 480
GGGAAGGAGA GACACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540
GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600
CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660
AGCCAGACCC TCCTTTGGAG CTGGCTGTGG AAGTAAAACA GCCAGAAGACA CAGAAAACCCT 720 35 40 ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780
TCCTGTATGA AATTCGATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840
GGCAGCAAAC AGAGTTTAAG ATTCTCAGCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900
TTCGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGCGACC TTCATTCAGA 960 45 TICGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGGGACC TICATICAGA 960
TACCTAGTGA CTTCACCATG AATGATACAA CCGTGTGGAT CTCTGTGGCT GTCCTTTCTG 1020
CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080
GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140
AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200
ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAAGTAA TAGTGAGGAC CACACTCTAA 1260
TGTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGGTATGAA ACCCCAAGTCAAC CTGGATCCTG 1320
ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380
AACCCCAGGC CAATCCCTCC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCAGAGAATC 1440
CTGAAACAAC CCACACCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCCTATT 1500 50 TICATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACO 1560 CCAGATCCTC TTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620 CACCGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTCT CAAACCATTA 1680 55 AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740 CTGACCAGGA TACGCCCTGG CTGCCTGCCCC AGGAGAAAC CCCCTTTGGC TCCGCTAAAC 1860
CTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860
AACAGAGAGA GAACAGCGGC AAGCCCAAGA AGCCCGGGAC TCCTGAGAAC AATAAGGAGT 1920
ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980 60 CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCAAAGAGGC CCCACCATCA CTTGAACAGA 2040 ATCAAGCTGA GAAAGCCCTG GCCAACTTCA CTGCAACATC AAGCAAGTGC AGGCTCCAGC 2100
TGGGTGGTTT GGATTACCTG GATCCCGCAT GTTTTACACA CTCCTTTCAC TGATAGCTTG 2160
ACTAATGGAA TGATTGGTTA AAATGTGATT TTTCTTCAGG TAACACTACA GAGTACCTGA 2220 65 AATGCTCAAG AATGTAGTCA GACTGACACT ACTAAAGCTC CCAGCTCCTT TCATGCTCCA 2280 AATIC-TCAAG AATGTAGTCA UNCTGACACT ACTAMAGGTC CCAGATCAT TCATGCTCCC 2280
TTTTTAACCA CTTGCCTCTT TCTCCAGCAG CTGATTCCAG AACAAATCAT TATGTTTCCT 2340
AACTGTGATT TGTAGATTTA CTTTTTGCTG TTAGTTATAA AACTATGTGT TCAATGAAAT 2400
AAAAGCACAC TGCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460
GCTTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTG TCAAAATTGT TTACCATAGA 2520 70


AAGATGACAA AAGAAAATTT TOCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580 AACTGCATAA CCTTTACACT CCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640 AAAGAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TCCTATACCT TACTGACACA 2700 TIGCTGATAT GCAAGTAAGA AAT


Ø.

Protein Accession #:

NP_000940.1








QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EPSRSGETNS 300
CVEHIREMT WLPPLSAIQA PGKVEPTKFP FPNKDSQLVS SGINNPKKGD AEPESPDNGT 360
SNTSMLEDDL KLSSDEEPNE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSG 420
TSSSSSDESS SSGSDEBTES SSSESEGSKP PHFSSPEAPP ASSNKWQLDK WLNKVNPHKP 480
5 PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540
GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600
NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660
KSKEFIETES SSSSSSSDS LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGPR 720
APVGSINART TSDIAKELEE QFYTLVFFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780
HLPQEPGVLS APATKDSESA PPSHTSDTPA EKALPKSKRK RKCDNEDDYR EIKKSQGEKD 840
SSSRLATSTS NTLSANHCNM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900
RPNGNSLFTS ASSSKKPKAD SQLQPHGGDL TKAAHNNSEN IPLHKSRPQT KPWSPGSNGH 960
RDCKRQKLVF DDMPRSADYF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FECGNAMEQ 1020
GPMESKSPYY LMYSSTVELI RYAMRIKTHS GPNATPEDKQ LAALCYRCLA LLYWRMFRLK 1080
15 RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTPSP ISPNFFFGSS VGSQGSLSNA 1140
SALSPSTIVS IPQRIHQMAA NHVSTTNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200
TLHSSMEHLV QYSQQGLHWL RNSAHLS

Seq ID NO: 47 DNA sequence
Nucleic Acid Accession #: NM_033151
Coding sequence: 351-4499(underlined sequences correspond to start and stop codons)

41 51 21 31 25 ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT 60
GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC 120 GCCLAGGATC AAGGGTGCGG TGT IGGGGGT GGGTGCGCGCGGGGATC AAGCACAGGC 180
TAAGGAGAGTTTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGGC 180
TAAGGAGAGG AAAGAGCAGG CACCCAAAACC TCTGCATGGC CCCAAATATGC TCCCTGCAGG 240
GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300
CTTTTCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA ATGACTAGGA 360
AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC ATCGACATAG 420 30 AGAGGACATA CTGOGTICCC ACCUTTETO TO TO TO TO TO THE TOTAL CONTROL AND ASSOCIATION OF THE TOTAL CONTROL AND ASSOCIATION OF THE TOTAL CANCEL AND ASSOCIATION OF THE TOTAL CONTROL CONTROL ASSOCIATION OF THE TOTAL CONTROL CONT 35 TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720 ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 780
GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840
TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900 40 TITATACCAAA GATCCIGGGA TATICAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960
GACTCTGCTT TGCCCTTTTTCTCCCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020
GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTG 1080
AGAAGCTCAT CCAATTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140 TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200 CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA TACACTGCAT 1260 TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320 45 CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT GTGACCAGTG 1380 AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA TTTGCAAAAA 1440 TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500 GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCA 1560 50 TCCACACATC CTTAAAGCTG AAACTCACAG CGTCAATGGC CTTCAGCATG CTGGCCTCCT 1620 TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680 CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCCA GGAGAGCCCT GTTTTCTATG 1740
TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTGA GGAGGCCACC TTGTCATGGC 1800
AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGGAAC GGGCATGCTT 1860 55 CTGAGGGGAT GACCAGGCCT AGAGATGCCC TCGGGCCAGA GGAAGAAGGG AACAGCCTGG 1920 GCCCAGAGTT GCACAAGATC AACCTGGTGG TGTCCAAGGG GATGATGTTA GGGGTCTGCG 1980 GCAACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAGCCAT CCTGGAGGAG ATGCACTTGC 2040 TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCAGCAG GCCTGGATCG 2100 60 TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGCGC ATATGACAAG GCCCGATACC 2160 TCAGGGGAA CATCAGGAG AACATCLICA TIGGAGGGA ACTICTICCC TTTGGAGACA 2220
TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280
TGGCCCCCCC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCC CTGTCTGCTG 2340
TGGACGCCCA CGTGGGGAAG CACATTITTG AGGAGTCCAT TAAGAAGACA CTCAGGGGGA 2400 65 AGACGGTCGT CCTGGTGACC CACCAGCTGC AGTACTTAGA ATTTTGTGGC CAGATCATTT 2460 TGTTGGAAAA TGGGAAAATC TGTGAAAATG GAACTCACAG TGAGTTAATG CAGAAAAAGG 2520 GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATGTTGCAGG 2580 ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGTCA GGCTCTGGCC ACCTCCCTGG 2640 70 AAGAGTCTCT CAACGGAAAT GCTGTGCCGG AGCATCAGCT CACACAGGAG GAGGAGATGG 2700 AAGAAGGCTC CTTGAGTTGG AGGGTCTACC ACCACTACAT CCAGGCAGCT GGAGGTTACA 2760
TGGTCTCTTG CATAATTTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG GCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880 ATGGAACCAT GGCAGACCTG GGCAACATTG CAGACAATCC TCAACTGTCC TTCTACCAGC 2940 75 TGGTGTACGG GCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAGGGATTT 3000 TCACCAAAGT CACGAGGAAG GCATCCACGG CCCTGCACAA CAAGCTCTTC AACAAGGTTT 3060

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180 TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240 TAATGGGAGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3300 TCGGTGTGTT CAAGAGACTG GAGAACTATA GCCGGTCTCC TTTATTCTCC CACATCCTCA 3360 ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420 5 AGTTTAAGAG GCTGACTGAT GCGCAGAATA ACTACCTGCT GTTGTTTCTA TCTTCCACAC 3480 GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540 TCGTGGCTTT TGGCATTTCC TCCACCCCCT ACTCCTTTAA AGTCATGGCT GTCAACATCG 3600 TGCTGCAGCT GGCGTCCAGC TTCCAGGCCA CTGCCCGGAT TGGCTTGGAG ACAGAGGCAC 3660 AGTTCACGGC TGTAGAGAGG ATACTGCAGT ACATGAAGAT GTGTGTCTCG GAAGCTCCTT 3720 10 TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATATITC 3780 AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCACGGC ATCAACCTGA 3840 CCATCCGCGG CCACGAAGTG GTGGGCATCG TGGGAAGGAC GGGCTCTGGG AAGTCCTCCT 3900
TGGGCATGGC TCTCTTCCGC CTGGTGGAGC CCATGGCAGG CCGGATTCTC ATTGACGGCG 3960
TGGACATTTG CAGCATCGGC CTGGAGGACT TGCGGTCCAA GCTCTCAGTG ATCCCTCAAG 4020 15 ATOCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTTGAC CGTCACACTG 4080 ACCAGCAGAT CTGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAGTTCC 4140 CCAAAAAGCT OCATACAGAT GTGGTGGAAA ACGGTGGAAA CTTCTCTGTG GGGGAGAGGC 4200 AGCTGCTCTG CATTGCCAGG GCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAG 4260 20 CCACAGCCTC CATTGACATG GAGACAGACA CCCTGATCCA GCGCACAATC CGTGAAGCCT 4320 TCCAGGGCTG CACCGTGCTC GTCATTGCCC ACCGTGTCAC CACTGTGCTG AACTGTGACC 4380 ACATCCTGGT TATGGGCAAT GGGAAGGTGG TAGAATTTGA TCGGCCCGGAG GTACTGCCGA 4440
AGAAGCCTGG GTCATTGTTC GCAGCCCTCA TGGCCACAGC CACTTCTTCA CTGAGA<u>TAA</u>G 4500
GAGATGTGGA GACTTCATGG AGGCTGGCAG CTGAGCTCAG AGGTTCACAC AGGTGCAGCT 4560 25 TCGAGGCCCA CAGTCTGCGA CCTTCTTGTT TGGAGATGAG AACTTCTCCT GGAAGCAGGG 4620 GTAAATGTAG GGGGGGTGGG GATTGCTGGA TGGAAACCCT GGAATAGGCT ACTTGATGGC 4680 TCTCAAGACC TTAGAACCCC AGAACCATCT AAGACATGGG ATTCAGTGAT CATGTGGTTC 4740 TCCTTTTAAC TTACATGCTG AATAATTTTA TAATAAGGTA AAAGCTTATA GTTTTCTGAT 4800 CTGTGTTAGA AGTGTTGCAA ATGCTGTACT GACTTTGTAA AATATAAAAC TAAGGAAAAC 4860 30 Seq ID NO: 48 <u>Protein sequence:</u>
Protein Accession #: NP_149163.2 MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPBAPGRAAVPPWGKYDAALRT MIPFRPKPRFPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPPLSVHDASDKNVQRLHRLWEEE VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEBQLGNVVHGVGLCFALF 35 LSECVKSLSPSSSWIINORTAIRFRAAVSSFAFEKLIOFKSVIHITSGEAISFFTGDVNYLFEGVCYGFL VLITCASLVICSISSYFIIGYTAFIAILCYLLVFPLAVFMTRMAVKAQHHTSEVSDQRIRVTSEVLTCIK LIKMYTWEKPFAKIIEDLRRKERKLLEKCGLVQSLTSTILFIIPTVATAVWVLIHTSLKLKLTASMAFSM 40 LASLNILRISVFFVPIAVKGLTNSKSAVMRFKKFFLQESPVFYVQTLQDPSKALVFEEATLSWQQTCPGI VNGALELERNGHASEGMTRPRDALGPEEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE MHILEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLEILPFGDMTEIGER GLNLSGGQKQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHIFEECIKKTLRGKTVVLVTHQLQYLEFCG 45 OILLENGKICENGTHSELMOKKGKYAQLIQKMHKEATSDMLQDTAKIAEKPKVESQALATSLEESLNGN AVPEHOLTQEEEMEEGSLSWRVYHHYIQAAGGYMYSCIIFFFVVLIVFLTIFSFWWLSYVLEQGSOTINSS RESNOTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF FDTIPIGRLLNCFAGDLEQLDQLLPIFSEQFLVLSLMVIAVLLIVSVLSPYILLMGAIIMVICFTYYMMF KKAIGVFKRLENYSRSPLFSHILNSLQGLSSIHVYGKTEDFISQFKRLTDAQNNYLLLFLSSTRWMALRL EIMTNI.VTI.AVAI.FVAFGISSTPYSFKVMAVNIVI.QI.ASSFQATARIGI.BTBAQFTAVERII.QYMEMCVS EAPI.HMEGTSCPQGWPQHGEIIFQDYHMKYRDNTPTVLHGINLTIRGHEVVGIVGRTGSGKSSLGMALFR LVEPMAGRILIDGVDICSIGLEDLRSKLSVIPQDPVLLSGTIRFNLDPFDRHTDQQIWDALERTFLTKAI 50 SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL VIAHRYTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR 55 Seq ID NO: 49 DNA sequence Nucleic Acid Accession #: NM 033419 Coding sequence: 18-980 (underlined sequences correspond to start and stop codons) 60 31 41 51 COAGCCAGGG AGAAAGGATG GCCGGCCTGG CGGCCCGGTT GGTCCTGCTA GCTGGGGCAG 60 CGGCGCTGGC GAGCGGCTCC CAGGGCGACC GTGAGCCGGT GTACCGCCAC TGCGTACTGC 120
AGTGCGAAGA GCAGAACTGC TCTGGGGGCG CTCTGAATCA CTTCCGCTCC CGCCAGCCAA 180
TCTACATGAG TCTAGCAGGC TGGACCTGTC GGGACGACTG TAAGTATGAG TGTATGTGGG 240
TCACCGTTGG GCTCTACCTC CAGGAAGGTC ACAAAGTGCC TCAGTTCCAT GGCAAGTGGC 300
CCTTCTCCCG GTTCCTGTTC TTTCAAGAGC CGGCATCGGC CGTGGCCTGG TTTCTCAATG 360 65 GOCTGGCCAG CCTGGTGATG CTCTGCCGCT ACCGCACCTT CGTGCCAGCC TCCTCCCCCA 420
TGTACCACAC CTGTGTGGCC TTCGCCTGGG TGTCCCTCAA TGCATGGTTC TGGTCCACAG 480
TTTTCCACAC CAGGGACACT GACCTCACAG AGAAAATGGA CTACTTCTGT GCCTCACTG 540 70 TCATCCTACA CTCAATCTAC CTGTGCTGCG TCAGGACCGT GGGGCTGCAG CACCCAGCTG 600 TGGTCAGGC CTCCGGGGCT CTCCTGCTGC TCATGCTGAC CGTGCACGTC TCCTACCTGA 660
GCTCATCCG CTTCGACTAT GGCTACAACC TGGTGGCCAA CGTGGCTATT GGCCTGGTCA 720
ACGTGGTGTG GTGGCTGGCC TGGTGCCTGT GGAACCAGCG GCGCTGCCT CACGTGCGCA 780
AGTGCGTGGT GGTGGCTTG CTGCTGCAGG GGCTGTCCCT GCTCGAGCTG CTTGACTTCC 840 75 CACCECTCTT CTGGGTCCTG GATGCCCATG CCATCTGGCA CATCAGCACC ATCCCTGTCC ACGTCCTCTT TTTCAGCTTT CTGGAAGATG ACAGCCTGTA CCTGCTGAAG GAATCAGAGG 960

蝬



Seq ID NO: 53 DNA sequence

NM_030916 Nucleic Acid Accession #: Coding sequence: 1-1533 (underlined sequences correspond to start and stop codons) 5 31 41 51 ATGCCCCTGT CCCTGGGAGC CGAGATGTGG GGGCCTGAGG CCTGGCTGCT GCTGCTGCTA 60 CTGCTGGCAT CATTTACAGG CCGGTGCCCC GCGGGTGAGC TGGAGACCTC AGACGTGGTA 120 ACTOTGOTOC TOGGCCAGGA CGCAAAACTG CCCTGCTTCT ACCGAGGGGA CTCCGGCGAG 180 CAAGTGGGCC AAGTGGCATG GGCTCGGGTG GACGCGGGGCA AAGGCGCCC AGGAACTAGCG 240
CTACTGCACT CCAAATACCG GCTTCATGTG AGCCCGGGTT ACGAGGGCCG CGTGGAGCA 300
CCGCCGCCCC CACGCAACCC CCTGGACGGC TCAGTGCTCC TGCGCAACGC AGTGCAGGCG
GATGAGGGCG AGTACGAGTG CCGGGTCAGC ACCTTCCCCG CCGGCAGCTT CCAGGCGCGG
420 10 CTGCGGCTCC GAGTGCTGGT GCCTCCCCTG CCCTCACTGA ATCCTGGTCC AGCACTAGAA 480 15 GAGGGCCAGG GCCTGACCCT GGCAGCCTCC TGCACAGCTG AGGGCAGCCC AGCCCCCAGC 540 GTGACCTGGG ACACGAGGT CAAAGGCACA ACGTCCAGCC GTTCCTTCAA GCACTCCCGC 600
TCTGCTGCCG TCACCTCAGA GTTCCACTTG GTGCCTAGCC GCAGCATGAA TGGGCAGCA 660
CTGACTTGTG TGGTGTCCCA TCCTGGCCTG CTCCAGGACC AAAGGATCAC CCACATCCTC 720 CACGTGTCCT TCCTTGCTGA GGCCTCTGTG AGGGGCCTTG AAGACCAAAA TCTGTGGCAC 780 ATTIGCAGAG AAGGAGCTAT GCTCAAGTIGC CTGAGTGAAG GGCAGCCCC TOCCTCATAC 840
AACTIGACAC GGCTGGATGG GCCTCTGCCC AGTIGGGATG GGCAGCCCC TOCCTCATAC 840
GGCTTTCCCC CACTGACCAC TGAGCACAGC GGCATCTACG TCTGCCATGT CAGCAATGAG 960
TTCTCCTCAA GGGATTCTCA GGTCACTGTG GATGTTCTTG ACCCCCAGGA AGACTCTGGG 1020 20 AAGCAGGTGG ACCTAGTGTC AGCCTCGGTG GTGGTGGTGG GTGTGATCGC CGCACTCTTG 1080 25 GAGGGCCGCA GTTACTCCAC GCTGACCACG GTGAGGGAGA TAGAAACACA GACTGAACTG 1380 CTGTCTCCAG GCTCTGGGCG GGCCGAGGAG GAGGAAGATC AGGATGAAGG CATCAAACAG 1440 GCCATGAACC ATTTTGTTCA GGAGAATGGG ACCCTACGGG CCAAGCCCAC GGGCAATGGC 1500 30 ATCTACATCA ATGGGCGGGG ACACCTGGTC TGA Seq ID NO: 54 Protein sequence 35 NP_112178.1 Protein Accession #: 31 41 MPLSIGAEMW GPRAWLLLL LLASFTGRCP AGELETSDVV TVVLGQDAKL PCFYRGDSGE 60 40 OVGOVAWARY DAGEGAQELA ILHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA 120 QVGQVAWARV DAGGGAQELA ILHSKYGLHV SFAYEGKVDQ FFFFRNILDG SYLEARAVQA 12 DEGEYECRVS TFFAGSFQAR LRLRVLVPPL PSINPGPALE EGQGLTLAAS CTAEGSPAPS 180 VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNQOP LTCVVSHIFGL LQDQRITHIL 240 HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL 300 GFPPLTTEHS GIYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV VVVGVIAALL 360 45 FCLLVVVVVL MSRYHRRKAQ QMTQKYHEEL TLTRENSIRR LHSHHTDPRS QPEESVGLRA 420 EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEB EEDQDEGIKQ 480 AMNHFVQENG TLRAKPTGNG IYINGRGHLV Seq ID NO: 55 DNA sequence 50 AF007170.1 leic Acid Accession #: Coding sequence: 73-1725 (underlined sequences correspond to start and stop codons) 31 41 21 AAGGAGGGG CTTCCGGGAA AAGCGACCGC AGGACTCCTG AGAGCAGCCT CCATGAGGCC 60 CTGGACCAGT GCATGACCGC CCTGGACCTC TTCCTCACCA ACCAGTTCTC AGAAGCACTC 120 AGCTACCTCA AGCCCAGAAC CAAGGAAAGC ATGTACCACT CACTGACATA TGCCACCATC 180 55 CTGGAGATGC AGGCCATGAT GACCTTTGAC CCTCAGGACA TCCTGCTTGC CGGCAACATG 240 ATGAAGGAGG CACAGATGCT GTGTCAGAGG CACCGGAGGA AGICTTCTGT AACAGATTCC 300 TTCAGCAGCC TGGTGAACCG CCCCACGCTG GGCCAATTCA CTGAAGAAGA AATCCACGCT 360 60 GAGGTCTGCT ATGCAGAGTG CCTGCTGCAG CGAGCAGCCC TGACCTTCCT GCAGGACGAG 420 AACATGGTGA GCTTCATCAA AGGCGGCATC AAAGTTCGAA ACAGCTACCA GACCTACAAG 480
GAGCTGGACA GCCTTGTTCA GTCCTCACAA TACTGCAAGG GTGAQAACCA CCCGCACTTT 540
GAAGGAGGAG TGAAGCTTGG TGTAGGGGCC TTCAACCTGA CACTGTCCAT GCTTCCTACT 600
AGGATCCTGA GGCTGTTGGA GTTTGTGGGG TTTTCAGGAA ACAAGGACTA TGGGCTGCTG 660 65 CAGCTGGAGG AGGGAGCGTC AGGGCACAGC TTCCGCTCTG TGCTCTGTGT CATGCTCCTG 720 CTGTGCTACC ACACCTTCCT CACCTTCGTG CTCGGTACTG GGAACGTCAA CATCGAGGAG 780
GCCGAGAAGC TCTTGAAGCC CTACCTGAAC CGGTACCCTA AGGGTGCCAT CTTCCTGTTC 840
TTTGCAGGGA GGATTGAAGT CATTAAAGGC AACATTGATG CAGCCATCCG GCGTTTCGAG 900 70 QAGTGCTGTG AGGCCCAGCA GCACTGGAAG CAGTTTCACC ACATGTGCTA CTGGGAGCTG 960 ATGTGGTGCT TCACCTACAA GGGCCAGTGG AAGATGTCCT ACTTCTACGC CGACCTGCTC 1020
AGCAAGGAGA ACTGCTGGTC CAAGGCCACC TACATTTACA TGAAGGCCGC CTACCTCAGC 1080
ATGTTTGGGA AGGAGGACCA CAAGCCGTTC GGGGACGACG AAGTGGAATT ATTTCGAGCT 1140 GTGCCAGGCC TGAAGCTCAA GATTGCTGGG AAATCTCTAC CCACAGAGAA GTTTGCCATC 1200 75 CGGAAGTCCC GGCGCTACTT CTCCTCCAAC OCTATCTCGC TGCCAGTGCC TGCTCTGGAA 1260 ATGATGTACA TCTGGAACGG CTACGCCGTG ATTGGGAAGC AGCCGAAACT CACGGATGGG 1320

ENSDVLE

Seq ID NO: 59 DNA sequence Nucleic Acid Accession #:

75

TCAGTGGATG ACGAGTGCTT GGTGAAATTG TTGAAAGGCC TGTGTCTGAA ATACCTGGGC 1440 COTOTOCAGG AGGCCGAGGA GAATTITAGG AGCATCICTG CCAATGAAA AAACATTAAA 1500
TATGACCACT ACTTGATCCC AAACGCCCTG CTGGAGCTGG CCCTGCTGCT TATGGAGCAA 1560
GACAGAAACG AAGAGGCCAT CAAACTTTTG GAATCTGCCA AGCAAAACTA CAAGAATTAC 1620
TCCATGGAGT CAAGGACCA CTTTCGAATC CAGGCAGCCA CACTCCAAGC CAAGTCTTCC 1680
CTAGAGAACA GCAGCAGATC CATGGTCTCA TCAGTGTCCT TGTAGCTTTG TGCAGCAGTT 1740 5 CCGGGCTGGA AGACAGAGAC AGCTGGACAG AGCTCCTGAA AACATTCAA AATACCCCT 1800
CCCCTGCCC TGCCTGCCT TTGGGGTCCA CCGGCACTCC AGTTGGATGG CACAACATAG 1860
TGTATCCGTG CAGAAGCCGA GCTGGCATTT TCACCAGTGT AGCCAAGGGC CTTTGCCAAG 1920
GGCAGAGCAG GTGGAGCCCT CTGCCTGCCC TATCACACAT ACGGGTACTT GCTTTTCACT 1980 10 OTGATGITTA AGAGAATGTA TGAACAGTTT ACATTTTCCT TAGAAATACA TTGATGGGAT 2040 CACAGITIGGC TITAAAAACC AACAACAATC AACCACTGT AAGTCTITGT CITCACCTAT 2100
TATCATCTGG AGGTAAATCT CITTATATGA TGATGCCAAA GGGCAAATTG CTITTCAAAT 2160
TCAGCAAGIT CTCAGCTTGT GTGACGGAAG GTCCTTCAGA GGACCTGAGG AATGCCTGGG 2220 15 AGAGGCTAAG CCTCAGGCTT CAATGCTTCT GGGGTTGGGC ATGAGGATGT ACACAGACAC 2280 CCACTACCTT ACTACTCACA CITCATTICA CTCCTTTGT AAATTICCAA TITAAAAATC 2340
AGCACGTCT TITTAGTGAG ATAAAATCTG AGCTCTTCTT TAGAAAAATC ATCCTACC 2400
AGTAGAAAAT GCCAGGGCTT GATGGAAGAG CTGTGTAGCC CTTTCTATGC CAAAGCCAGG 2460
AAATTTGGGG GGCAGGAGGA GGTTCTCAGA ATCCAGTCTG TATCTTTGCT GTATGCCAAA 2520 CTGAAACCAC TGGGAATAAT TTATGAAACA TAAAAATCTT CTGTACTTCA CTCCAAGGTA 2580 20 CATTTGCTTA CTGACAGCAT TTTTGTTAAA ACTGTTATTC TTGAAAAAAA AAAAAAAAA 2640 Seq ID NO: 56 Protein sequence:
Protein Accession #: AAC39582.1 25 21 31 41 MTALDIFLTN OFSEALSYLK PRTKESMYHS LTYATILEMQ AMMTFDPQDI LLAGNMMKEA 60
QMLCQRHRRK SSVTDSFSSL VNRPTLGQFT BEBHABVCY ABCILQRAAL TFLQDENMVS 120
FIKGGIKVRN SYQTYKELDS LVQSSQYCKG ENHPHFEGGV KLGVGAFNLT LSMLPTRILR 180
LLEFVGFSGN KDYGLLQLEE GASGHSFRSV LCVMLLLCYH TFLTFVLGTG NVNIEEAEKL 240 30 LLEP VISSUN KDYGLLQLEE GASURISPRSY LCVMLLLCTH IPLIFYLDTG NYNIEEAERL 240
LKPYLNRYPK GAIPLFFAGR IEVIKGNIDA AIRRFEBCCE AQQHWKQFHH MCYYWELMWCF 300
TYKGQWKMSY FYADLLSKEN CWSKATYIYM KAAYLSMFGK EDHRYFGDDE YELFRAVPGL 360
KLKIAGKSLP TEKFAIRKSR RYFSSNPISL PVPALEMMYI WNGYAVIGKQ PKLTDGILEI 420
ITKAEEMLEK GPENEYSVDD ECLVKLLKGL CLKYLGRVQE AEENFRSISA NEKKIKYDHY 480 35 LIPNALLELA LLLMEODRNE EAIKLLESAK QNYKNYSMES RTHFRIQAAT LQAKSSLENS 540 40 Seq ID NO: 57 DNA sequence NM_006670,1 Nucleic Acid Accession #: Coding sequence: 1-927 (underlined sequences correspond to start and stop codons) 51 21 31 41 45 ATGCCTGGGG GGTGCTCCCG GGGCCCCGCC GCCGGGGACG GGCGTCTGCG GCTGGCGCGA 60 CTAGCCCTGG TACTCCTGGG CTGGGTCTCC TCGTCTTCTC CCACCTCCTC GGCATCCTCC 120 TTCTCCTCCT CGGCGCCGTT CCTGGCTTCC GCCGTGTCCG CCCAGCCCCC GCTGCCGGAC 180 CAGTGCCCC GCTGTGCGA GTGCTCCGAG GCAGCGCGCA CAGTCAAGTG CGTTAACCGC 240
AATCTGACCG GCGACCACCA CTTCCTTTAC CTGCCGCGGG ATGTGCTGGC CCAACTGCCC 360
AACCAGCTGG CCAGCAACCA CTTCCTTTAC CTGCCGCGGG ATGTGCTGGC CCAACTGCCC 360
AGCCTCAGGC ACCTGGACTT AAGTAATAAT TCGCTGGTGA GCCTGACCTA CGTGTCCTTC 420 50 CGCAACCTGA CACATCTAGA AAGCCTCCAC CTGGAGGACA ATGCCCTCAA GGTCCTTCAC 480 AATGGCACCC TGGCTGAGTT GCAAGGTCTA COCCACATTA GGGTTTTCCT GGACAACAAT 540
CCCTGGGTCT GCGACTGCCA CATGGCAGAC ATGGTGACCT GGCTCAAGGA AACAGAGGTA 600
GTGCAGGGCA AAGACCGGCT CACCTGTGCA TATCCGGAAA AAATGAGGAA TCGGGTCCTC 660 55 TIGGAACTCA ACAGTGCTGA CCTGGACTGT GACCCGATTC TICCCCCATC CCTGCAAACC 720 TCTTATGTCT TCCTGGGTAT TGTTTTAGCC CTGATAGGCG CTATTTTCCT CCTGGTTTTG 780 TATTTGAACC GCAAGGGGAT AAAAAAGTGG ATGCATAACA TCAGAGATGC CTGCAGGGAT 840 CACATGGAAG GOTATCATTA CAGATATGAA ATCAATGCGG ACCCCAGATT AACAAACCTC 900 AGTTCTAACT CGGATGTCCT CGAG<u>TGA</u> 60 Seq ID NO: 58 <u>Protein sequence</u> Protein Accession #: NP_006661.1 65 41 51 21 31 11 70 OCPALCECSE AARTYKCVNR NLTEVPTDLP AYVRNLFLTG NQLASNHFLY LPRDVLAQLP 120 SYPILGIVIA LIGAIFILVL YLNRKGIKKW MHNIRDACRD HMEGYHYRYE INADPRLITIL 300

NM 024022

Coding sequence: 1-1362(underlined sequences correspond to start and stop codons) ATGGGGGAAA ATGATCCGCC TGCTGTTGAA GCCCCCTTCT CATTCCGATC GCTTTTTGGC 5 CTIGATGATT TGAAAATAAG TCCTGTTGCA CCAGATGCAG ATGCTGTTGC TGCACAGATC 120 CTGTCACTGC TGCCATTGAA GTTTTTTCCA ATCATCGTCA TTGGGATCAT TGCATTGATA 180 TTAGCACTGG CCATTGGTCT GGGCATCCAC TTCGACTGCT CAGGGAAGTA CAGATGTCGC 240 TCATCCTTTA AGTGTATCGA GCTGATAGCT CGATGTGACG GAGTCTCGGA TTGCAAAGAC 300 GGGGAGGACG AGTACCGCTG TGTCCGGGTG GGTGGTCAGA ATGCCGTGCT CCAGGTGTTC 360 10 ACAGCTGCTT CGTGGAAGAC CATGTGCTCC GATGACTGGA AGGGTCACTA CGCAAATGTT 420 GCCTGTGCCC AACTGGGTTT CCCAAGCTAT GTGAGTTCAG ATAACCTCAG AGTGAGCTCG 480 CTGGAGGGGC AGTTCCGGGA GGAGTTTGTG TCCATCGATC ACCTCTTGCC AGATGACAAG 540
GTGACTGCAT TACACCACTC AGTATATGTG AGGGAGGGAT GTGCCTCTGG CCACGTGGTT 600
ACCTTGCAGT GCACAGCCTG TGGTCATAGA AGGGGCTACA GCTCACGCAT CGTGGGTGGA 660 15 AACATGTCCT TGCTCTCGCA GTGGCCCTGG CAGGCCAGCC TTCAGTTCCA GGGCTACCAC 720 CTGTGCGGGG GCTCTGTCAT CACGCCCCTG TGGATCATCA CTGCTGCACA CTGTGTTTAT 780
GACTTGTACC TCCCCAAGTC ATGGACCATC CAGGTGGGTC TAGTTTCCCT GTTGGACAAT 840
CCAGCCCCAT CCCACTTGGT GGAGAAGATT GTCTACCACA GCAAGTACAA GCCAAAGAGG 900 20 CTGGGCAATG ACATCGCCCT TATGAAGCTG GCCGGGCCAC TCACGTTCAA TGAAATGATC 960 CAGCCTGTGT GCCTGCCCAA CTCTGAAGAG AACTTCCCCG ATGGAAAAGT GTGCTGGACG 1020
CAGCCTGTGT GCCTGCCCAA CTCTGAAGAG AACTTCCCCG ATGGAAAAGT GTGCTGGACG 1020
GTCCCTTTGA TTTCCAACAA GATCTGCAAC CACAGGGACG TGTACCGGTGC CATCATCTCC 1140
CCCTCCATGC TCTGCGCGGG CTACCTGACG GGTGGCGTGG ACAGCTGCCA GGGGGACAGC 1200 25 GGGGGCCCC TGGTGTGTCA AGAGAGGAGG CTGTGGAAGT TAGTGGGAGC GACCAGCTTT 1260 GGCATCGGCT GCGCAGAGGT GAACAAGCCT GGGGTGTACA CCCGTGTCAC CTCCTTCCTG 1320 GACTGGATCC ACGAGCAGAT GGAGAGAGAC CTAAAAACCT GA Seq ID NO: 60 <u>Protein sequence</u> Protein Accession #: NP_076927 30 Protein Accession #: 41 11 21 MGENDPPAVE APPSFRSLFG LDDLKISPVA PDADAVAAQI LSLLPLKFFP IIVIGIIALI 60 TALS HATCH SERVICE SERVICE SERVICE A RCDGYSDCKD GEDEYRCYRV GGONAVLQVF 120
TALSWKTMCS DDWKGHYANV ACAQLGFPSY VSSDNLRVSS LEGQFREEFV SIDHLLYDDK 180 35 VTALHHSVYV REGCASGHVV TLQCTACGHR RGYSSRIVGG NMSLLSQWPW QASLQFQGYH 240 LCGGSVITPL WIITAAHCVY DLYLPKSWTI QVGLVSLLDN PAPSHLVEKI VYHSKYKPKR 300 LGNDIALMKL AGPLTPNEMI QPVCLPNSEE NFPDGKVCWT SGWGATEDGG DASPVLNHAA 360 VPLISNKICN HRDVYGGIIS PSMLCAGYLT GGVDSCQGDS GGPLVCQERR LWKLVGATSF 420 40 GIGCAEVNKP GVYTRVTSFL DWIHEQMERD LKT Seq ID NO: 61 DNA sequence NM 006475 Nucleic Acid Accession #: 45 Coding sequence: 28-2538 (underlined sequences correspond to start and stop codons) 51 41 AACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA TIGCTGCTTA TIGTTAACCC TATAAACGCC AACAATCATT ATGACAAGAT CTTGGCTCAT 120
AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC 180
ACCAAAAAGA AATACTTCAG CACTTGTAAG AACTGGTATA AAAAGTCCAT CTGTGGACAG 240 50 AAAACGACTG TITTATATGA ATGTTGCCCT GGTTATATGA GAATGGAAGG AATGAAAGGC 300 AAAACGACIG TITTATATOA ATGITOCCCI GGTTATATA GAAACGACG ATGATAAA GAACGACGAG TITTGCCCAT TGACCATGIT TATGCACTC TGGGCATCT TGGGCATCT TGGGAGCACC 360
ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAGG AGATCGAGGG AAAGGGATCC 420
TTCACTTACT TTGCACCGAG TAATGAGGCT TGGGACAACT TGGATTCGA TATCCGTAGA 480
GGTTTGGAGA GCAACGTGAA TGTTGAATTA CTGAATGCTT TACATAGTCA CATGATTAAT 540 55 AAGAGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTA TTCCTTCAAT GTATAACAAT 600 TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC 660 ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA 720 CAAATTGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA 780 60 GCAGCTGCCA TCACATCGGA CATATTGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC 840 TITGCTCCCA CCAATGAGGC TITTGAGAAA CITCCACGAG GTGTCCTAGA AAGGTTCATG 900
GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACCACA TCTTAAATAC TCTCCAGTGT 960
TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC AATTGAGATA 1020 65 GGATGTGACG GTGACAGTAT AACAGTAAAT GGAATCAAAA TGGTGAACAA AAAGGATATT 1080 GTGACAAATA ATGGTGTGAT CCATTTGATT GATCAGGTCC TAATTCCTGA TTCTGCCAAA 1140
CAAGTTATTG AGCTGGCTGG AAAACAGCAA ACCACCTTCA CGGATCTTGT GGCCCAATTA 1200
GGCTTGGCAT CTGCTCTGAG GCCAGATGGA GAATACACTT TGCTGGCACC TGTGAATAAT 1260
GCATTTTCTG ATGATACTCT CAGCATGGTT CAGCGCCTCC TTAAATTAAT TCTGCAGAAT 1320 70 CACATATTGA AAGTAAAAGT TGGCCTTAAT GAGCTTTACA ACGGGCAAAT ACTGGAAACC 1380 ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCGTACAG CTGTCTGCAT TGAAAATTCA 1440 TGCATGGAGA AAGGGAGTAA GCAAGGGAGA AACGGTGCGA TTCACATATT CCGCGAGATC 1500

ATCAAGCCAG CAGAGAAATC CCTCCATGAA AAGTTAAAAC AAGATAAGCG CTTTAGCACC 1560

3

AAAATCTITC TGAAAGAAGT AAATGATACA CTICTGGTGA ATGAATGAA ATCAAAAGAA 1860
TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920
GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980
CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACCAACT 2040 5 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 AMATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TIGAAGGCAG TICAGGCO 2000
ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TIGAAGGGTGA ACCTGAAATC 2160
AGACTGATTA AAGAAGGTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220
AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280
GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340 10 ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400 GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460 ACACCCOTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520 ACACUCATION OURAGINA ATCCAAAAAC CAGAAAAAAA TOTTTATACA ACCCTAAGTC 2580
AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCIGAA CACAAATTTA ATATTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880 20 CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT 2940 TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000 TCAAAAGGCT TIGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060 CAACTAATTT TGTACTCTCA GAATGTTTGT CATATGCTTC TIGCAATGCA TATTTTTTAA 3120 TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 25 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA Seq ID NO: 62 Protein sequence:
Protein Accession #: NP_006466 30 MIPFI PMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60 KNWYKKSICG OKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TTTQRYSDAS 120 KUREEIEGKG SFTYFAPSNE AWDNILDSDIR RGLESNVNVE LINALHSHMI NKRMLTKDLK 180 NGMIPSMYN NIGLFINHYP NGVVTVNCAR IHGNQIATN GVVHVIDRVL TQIGTSIQDF 240 IEAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300 35 MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360 IDQVLIPDSA KQVIBLAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420 VQRLLKLILQ NHILKVKVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480 RNGAIHIFRE IIKPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQFGD WTLFVPTNDA 540 40 FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND 600 TILVNELKSK ESDIMTINGV IHVVDKILLYP ADIPVGNDQL LEILNKLIKY IQIKFVRGST 660 FKEIPVTVYT TKITKVVEP KIKVIEGSLQ PIIKTEGPTL TKVKIEGEPE FRLIKEGETI 720 TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKILL 780 45 QEEVIKVIKF IEGGDGHLFE DEEIKRLLQG DIPVRKLQAN KKVQGSRRRL REGRSQ Seq ID NO: 63 DNA sequence NM 020974 Nucleic Acid Accession #: Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 51 31 41 GGCGTCCGCG CACACCTCCC CGCGCCGCCGCCCACCGC CCGCACTCCG CCGCCTCTGC 60 COGCAACOGC TEAGOCATOC <u>ATE</u>GGGGTCG CGGGCCGCAA COGTCCCGGG GCGGCCTGGG 120 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGGCGGGG GCCGTCCCGC 180 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 55 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360
TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420
TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480 60 AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 GCAAGGAGGG GITTITCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 720 65 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780 GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGAGG AGCTGCCTTG 840
AGCGAGGG CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900
ATAAACGGGT GAAACGCCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960
ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020 70 TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080 OTGATCATT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CCGCTGCAG AAAGGATTT 1880
ATTATTACA AAATGATGAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140
AATTATAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200
GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CGAGGGTACA 1260
CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGCT 1320 75 OTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380 AGCTCCACTG GAATAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500

TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800

GTCACTCTGG CATTCACCTC TCTTCAGATG TCACCACCAT CAGGACAAGT GTAACCTTTA 1560 AGCTAAATGA AGGCAAGTGT AGTTTGAAAA ATGCTGAGCT GTTTCCCGAG GGTCTGCGAC 1620 CAGCACTACC AGAGAAGCAC AGCTCAGTAA AAGAGAGCTT CCGCTACGTA AACCTTACAT 1680
GCAGCTCTGG CAAGCAAGTC CCAGGAGCCC CTGGCCGACC AAGCACCCCT AAGGAAATGT 1740
TTATCACTGT TGAGTTTGAG CTTGAAACTA ACCAAAAGGA GGTGACAGCT TCTTGTGACC 1800
TGAGCTGCAT CGTAAAAGCGA ACCGAGAAGC GGCTCCGTAA AGCCATCCGC ACGCTCAGAA 1860 5 AGGCCGTCCA CAGGGAGCAG TITCACCTCC AGCTCTCAGG CATGAACCTC GACGTGGCTA 1920 AAAAGCCTCC CAGAACATCT GAACGCCAGG CAGAGTCCTG TGGAGTGGGC CAGGGTCATG 1980 CAGAAAACCA ATGTGTCAGT TGCAGGGCTG GGACCTATTA TGATGGAGCA CGAGAACGCT 2040 GCATTTTATG TCCAAATGGA ACCTTCCAAA ATGAGGAAGG ACAAATGACT TGTGAACCAT 2100 10 GCCCAAGACC AGGAAATTCT GGGGCCCTGA AGACCCCAGA AGCTTGGAAT ATGTCTGAAT 2160 GTGGAGGTCT GTGTCAACCT GGTGAATATT CTGCAGATGG CTTTGCACCT TGCCAGCTCT 2220 GTGCCCTGGG CACGTTCCAG CCTGAAGCTG GTCGAACTTC CTGCTTCCCC TGTGGAGGAG 2280 GCTTGCCAC CAAACATCAG GGAGCTACTT CCTTTCAGGA CTGTGAAACC AGAGTTCAAT 2340 GTTCACCTGG ACATTTCTAC AACACCACCA CTCACCGATG TATTCGTTGC CCAGTGGGAA 2400 CATACCAGCC TGAATTTGGA AAAAATAATT GTGTTTCTTG CCCAGGAAAT ACTACGACTG 2460 15 ACTITIGATEG CTCCACAAAC ATAACCCAGT GTAAAAACAG AAGATGTGGA GGGGAGCTGG 2520
GAGATTTCAC TGGGTACATT GAATCCCCAA ACTACCCAGG CAATTACCCA GCCAACACCG 2580
AGTGTACGTG GACCATCAAC CCACCCCCA AGCGCCGCAT CCTGATCGTG GTCCCTGAGA 2640 20 TCTTCCTGCC CATAGAGGAC GACTGTGGGG ACTATCTGGT GATGCGGAAA ACCTCTTCAT 2700 CCAATTCTGT GACAACATAT GAAACCTGCC AGACCTACGA ACGCCCCATC GCCTTCACCT 2760 CCAGGTCAAA GAAGCTGTGG ATTCAGTTCA AGTCCAATGA AGGGAACAGC GCTAGAGGGT 2820 TCCAGGTCCC ATACGTGACA TATGATGAGG ACTACCAGGA ACTCATTGAA GACATAGTTC 2880 GAGATGGCAG GCTCTATGCA TCTGAGAACC ATCAGGAAAT ACTTAAGGAT AAGAAACTTA 2940 25 TCAAGGCTCT GTTTGATGTC CTGGCCCATC CCCAGAACTA TTTCAAGTAC ACAGCCCAGG 3000 AGTCCCGAGA GATGTTTCCA AGATCGTTCA TCCGATTGCT ACGTTCCAAA GTGTCCAGGT 3060 TTTTGAGACC TTACAAATGA CTCAGCCCAC GTGCCACTCA ATACAAATGT TCTGCTATAG 3120 GGTTGGTGGG ACAGAGCTGT CTTCCTTCTG CATGTCAGCA CAGTCGGGTA TTGCTGCCTC 3180 CCGTATCAGT GACTCATTAG AGTTCAATTT TTATAGATAA TACAGATATT TTGGTAAATT 3240 30 GAACTTGGTT TTTCTTTCCC AGCATCGTGG ATGTAGACTG AGAATGGCTT TGAGTGGCAT 3300 CAGCTTCTCA CTGCTGTGGG CGGATGTCTT GGATAGATCA CGGGCTGGCT GAGCTGGACT 3360 TTGGTCAGCC TAGGTGAGAC TCACCTGTCC TTCTGGGGTC TTACTCCTCC TCAAGGAGTC 3420 TGTAGTGGAA AGGAGGCCAC AGAATAAGCT GCTTATTCTG AAACTTCAGC TTCCTCTAGC 3480 CCGGCCCTCT CTAAGGGAGC CCTCTGCACT CGTGTGCAGG CTCTGACCAG GCAGAACAGG 3540 35 CAAGAGGGGA GGGAAGGAGA CCCTTGCAGG CTCCCTCCAC CCACCTTGAG ACCTGGGAGG 3600 ACTCAGTTTC TCCACAGCCT TETCCAGCCT GTGTGATACA AGTTTGATCC CAGGAACTTG 3660 AGTTCTAAGC AGTGCTCGTG AAAAAAAAA GCAGAAAGAA TTAGAAATAA ATAAAAACTA 3720 AGCACTTCTG GAGACAT Seq ID NO: 64 <u>Protein sequence;</u>
Protein Accession #: NP_066025.1 40 31 45 MGVAGRNRPG AAWAVLLLLL LLPPLLLLAG AVPPGRGRAA GPQEDVDECA QGLDDCHADA 60 LCQNTPTSYK CSCKPGYQGE GRQCEDIDEC GNELNGGCVH DCLNIPGNYR CTCFDGFMLA 120 HDGHNCLDVD ECLENNGGCQ HTCVNVMGSY ECCCKEGFFL SDNQHTCHR SEEGLSCMNK 180 DHGCSHICKE APRGSVACEC RPGFELAKNQ RDCILTCNHG NGGCQHSCDD TADGPECSCH 240 PQYKMHTDGR SCLEREDTVL EVTESNTTSV VDGDKRVKRR LLMETCAVNN GGCDRTCKDT 300 50 STGVHCSCPV GFTLQLDGKT CKDIDECQTR NGGCDHFCKN IVGSFDCGCK KGFKLLTDEK 360 SCODVDECSL DRTCDHSCIN HPGTFACACN RGYTLYGFTH CGIDTNECSIN NGGCQQVCVN 420 TVGSYECQCH PGYKLHWNKK DCVEVKGLLP TSVSPRVSLH CGKSGGGDGC FLRCHSGIHL 480 SSDVTTIRTS VTFKLNEGKC SLKNAELFPE GLRPALPEKH SSVKESFRYV NLTCSSGKQV 540 PGAPGRPSTP KEMFTTVEFE LETNQKEVTA SCDLSCIVKR TEKRLRKAIR TLRKAVHREQ 600 FHIQLSGMINL DVAKKPPRTS ERQAESCGVG QGHAENQCVS CRAGTYYDGA RERCILCPNG 660
TFQNEEGQMT CEPCPRFGNS GALKTPEAWN MSEGGLCQP GEYSADGFAP CQLCALGTFQ 720
PEAGRTSCFP CGGGLATKHQ GATSFQDCET RVQCSPGHFY NTTTHRCRC PVGTYQPEFG 780
KNNCVSCPGN TTTDFDGSTN ITQCKNRRCG GELGDPTGYI ESPNYPGNYP ANTECTWIN 840 55 PPPKRRILIV VPEIFLPIED DCGDYLVMRK TSSSNSVTTY ETCQTYERPI AFTSRSKKLW 900

Seq ID NO: 65 DNA sequence
Nucleic Acid Accession #: NM_007210
Coding sequence: 1-1869 (underlined sequences correspond to start and stop codons)

LAHPONYFKY TAQESREMFP RSFIRLLRSK VSRFLRPYK

41

31

11

60

70

| | | | | | | | | | |
ATTGAGGCTCC TCCGCAGACG CCACATGCCC CTGCGCCTGG CCATGGTGGG CTGCGCCTTT 60
GTGCTCTTCC TCCTCCT GCATAGGGAT GTGAGCAGCA GAGAGGAGGC CACAGGAAG 120
CCGTGGCTGA AGTCCCTGGT GAGCCGGAAG GATCACGTCC TGGACCTCAT GCTGGAGGCC 180
ATGAACAACC TTAGAGATTC AATGCCCAGG CTCCAAATCA GGCCTCAGAA AGCCAGCAG 240
ACTCTGTTCT CCATAAACCA GTCCTGCCTC CCTGGGTTCT ATACCCCAGC TGAACTGAAG 300
CCCTTCTGGG AACGGCCACC ACAGGACCCC AATGCCCCTG GGGCAGATGG AAAAGCATTT 360
CAGAAGAGCA AGTGGACCCC CCTGGAGACC CAGGAAAAGG AAGAAGGCTA TAAGAAGCAC 420
TGTTTCAATG CCTTTGCCAG CGACCGGATC CCCCGACTGGC CCCCACTGGC CACCACCAGC 540
CGACCACCTG AGTGTGTGTGA CCAGAAGTTC CGGCGCTGCC CCCCACTGGC CACCACCAGC 540

IQFKSNEGNS ARGFQVPYVT YDEDYQELIE DIVRDGRLYA SENHQEILKD KKLIKALFDV 960

OTGATCATTG TGTTCCACAA CGAAGCCTGG TCCACACTGC TGCGAACAGT GTACAGCGTC 600 CTACACACCA COCCTGCCAT CITGCTCAAG GAGATCATAC TGGTGGATGA TGCCAGCACA 660 CIACACACA COLLIGICAL CHIGALANA GAGAICATAC HIGHIGARIA IGULAGICACA 680
GAGGACCACC TAAAGGAGAA GCTGGAGCAG TACGTGAAGC AGCTGCAGGT GTGAGGGTG 720
GTGCGGCAGG AGGAGCOGAA GGGGTTGATC ACCGCCCGGC TGCTGGGGGC CAGCGTGGCA 780
CAGGCGGAGG TGCTCACGTT CCTGGATGCC CACTGTGAGT GCTTCCACGG CTGGCTGGAG 840
CCCCTCCTGG CTCGAATCGC TGAGGACAAG ACAGTGGTGG TGAGCCCAGA CATCGTCACC 900 5 ATCGACCTTA ATACTITTGA GTTCGCCAAG CCCGTCCAGA GGGGCAGAGT CCATAGCCGA 960 GGCAACTTTG ACTGAGCCT GACCTTCGGC TGGGAAACAC TTCCTCCACA TGAGAAGCAG 1020
AGGCGCAAGG ATGAAACATA CCCCATCAAA TCCCCGACGT TTGCTGGTGG CCTCTTCTCC 1080
ATCCCCAAGT CCTACTTTGA GCACATCGGT ACCTATGATA ATCAGATGGA GATCTGGGGA 1140
GGGGAGAACG TGGAAATGTC CTTCCGGGTG TGGCAGTGTG GGGGCCAGCT GGAGATCATC 1200 10 CCCTGCTCTG TCGTAGGCCA TGTGTTCCGG ACCAAGAGCC CCCACACCTT CCCCAAGGGC 1260 - 15 ATCAAGAACC TCGGCACCAA CCAATGCCTG GATGTGGGTG AGAACAACCG CGGGGGGAAG 1560 CCCCTCATCA TGTACTCCTG CCACGGCCTT GGCGGCAACC AGTACTTTGA GTACACAACT 1620
CCGGGGGACC TTCGCCACAA CATCGCAAAG CAGCTGTGTTC TACATGTCAG CAAGGGTGCT 1680
CTGGGCCTTG GGAGCTGTCA CTTCACTGGC AAGAATAGCC AGGTCCCCAA GGACGAGGAA 1740
TGGGAATTGG CCCAGGATCA GCTCATCAGG AACTCAGGAT CTGGTACCTG CCTGACATCC 1800 20 CAGGACAAAA AGCCAGCCAT GGCCCCCTGC AATCCCAGTG ACCCCCATCA GTTGTGGCTC 1860
TTTGTCTAGG ACCCAGATCA TCCCCAGAGA GAGCCCCCAC AAGCTCCTCA GGAAACAGGA 1920
TTGCTGATGT CTGGGAACCT GATCACCAGC TTCTCTGGAG GCCGTAAAGA TGGATTTCTA 1980 AACCCACTGG GTGGCAAGGC AGGACCTTCC TAATCCTTGC AACAACATTG GGCCCATTTT 2040 25 AACUTALING UTGGCAAGGC AGGACCTTUC TAATCTTUC AACAACTTUC COCCATTUCTTC 2100
CTTTCCTTCA CACCGATGGA AGAGACCATT AGGACATATA TTTAGCCTAG CGTTTTCCTG 2100
TCCTAGAAAT AGAGGCTCCC AAAGTAGGGA AGGCAGCTGG GGGAGGGTTC AGGCCAGCAA 2160
TGCTGAGTTC AAGAAAAGTA CTTCAGGCTG GGCACAGTGG CTCATGCCTG AAATCCTAGC 2220
ACTTTGGGAA GACAATGTGG GAGAATGGCT TGAGCCCAGG AGTTCAAGAC CGGCCTGAGC 2280 ACATAGTGA GGATCCCATC TCTACGCCCA CCCTCCCCC GGCAAAAAAA AAAGCTGGGT 2340
AACATAGTGA GGATCCCATC TCTACGCCCA CCCTCCCCC GGCAAAAAAA AAAGCTGGGT 2340
ATGGTGGCTT ATGCCTGTAG TCGCAGCTAC TCAGAAGGCT GAGGTGGAG GATTGCTTGT 2400
TCCCCGGAGG TTGAAGCTAC AGTGAGCCTT GATTGTGTCA CTGCACTCCA GCCTGGGCAA 2460
CAGGTAAGAC TCTGTCTCAA AAAAAAAACA AAAAAGAAGA AGAAAAGTAC TTCTACAGCC 2520 30 ATGTCCTATT CCTTGATCAT CCAAAGCACC TGCAGAGTCC AGTGAAATGA TATATTCTGG 2580 AUTUCLATI OUTUATICAT CLARAGUACU TICAGAGRICO AUTUARATA TATATTOTIGI 2380
CTGGGCACAG TGGCTCACAC CTGTAATOCT AGCACTTTGG GAGGCCAAGG CAGGTGGATC 2640
ACCTGAGGTC AGAAGTTTGA AACCAGCCTG GACTACATGG TGAAACTCCA TCTCTACTAA 2700
AAGTACAAAA ATTAGCTGGG CATGATGGCA CGCACCTGCA GTCCCAGCTA CTTGGGAGGC 2760
TGAGGCAGGA GAATCACTCG AACCCAGGAG GCAGAGGTTG CAGTGAGCCA AGACAGCACC 2820 35 ATTGCACCCC AGCCTGAGCA ACAAGAGCGA AACTCCATCT CAGGAAAAAA AAAAAAAAA 2880 40 Seq ID NO: 66 Protein sequence: Protein Accession #: NP 009 NP_009141 45 21 31 41 MRLLRRRHMP LRLAMVGCAF VLFLFLLHRD VSSREEATEK PWLKSLVSRK DHVLDLMLEA 60 MNNIRDSMPK LQIRAPEAQQ TLFSINQSCL PGFYTPAELK PFWERPPQDP NAPGADGKAF 120 QKSKWTPLET QEKEEGYKKH CPNAFASDRI SLQRSLGPDT RPPECVDQKF RRCPPLATTS 180 50 VIIVFHNEAW STLLRTVYSV LHTTPAILLK EIILVDDAST EEHLKEKLEQ YVKQLQVVRV 240 VRQEERKGLI TARLLGASVA QAEVLTFLDA HCECFHGWLE PILARIABIK TVVVSPDIVT 300
DLMTFEFAK PVQRGRVHSR GNFDWSLTFG WETLPPHEKQ RRKDETYPIK SPTFAGGLFS 360
PKSYFEHIG TYDNQMEIWG GENVEMSFRV WQCGGQLEII PCSVVGHVFR TKSPHTPPKG 420 TSVIARNOVR LAEVWMDSYK KIFYRRNLQA AKMAQEKSFO DISERLQLRE QLHCHNFSWY 480 LHNVYPEMFV PDLTPTFYGA IKNLGTNQCL DVGENNRGGK PLIMYSCHGL GGNQYFEYTT 540 55 QRDLRHNIAK QLC1HVSKGA LGLGSCHPTG KNSQVPKDEE WELAQDQLIR NSGSGTCLTS 600 QDKKPAMAPC NPSDPHQLWL FV Seq ID NO: 67 DNA sequence 60 NM_014112 Nucleic Acid Accession #: Coding sequence: 600-4484 (underlined sequences correspond to start and stop codons) 41 31 21 TTCCTCCGCG AAGGCTCCTT TGATATTAAT AGTGTTGGTG TCTTGAAACT GACGTAATGC 60
GCGGAGACTG AGGTCCTGAC AAGCGATAAC ATTTCTGATA AAGACCCGAT CTTACTGCAA 120 65 TCTCTAGCGT CCTCTTTTTT GGTGCTGCTG GTTTCTCCAG ACCTCGCGTC CTCTCGATTG 180 CTCTCTCGCC TTCCTATTIC TITTTTTTTTTTTTTTAACAA AAACAACAC CCCCTCCCCC 240
CTCCCACCCG GCACCGGCA CATCCTTGCT CTATTCCTT TCTCTTTCTC TCTCTCTCCC 300
TCTCTTTTTT AATAAGGTTG GGGGAGGAA AGGGGGGGGA GGCAGGAAAG ACCTTTTCT 360
CTCCCCCCCG CAATAATCCA AGATCAACTC TGCAAACAAC AGAAGACGGT TCATGGCTTT 420 70 GGCCGCCGCG CCACCATCTT TCGGGCTGCC GAGGGTGTTC TTGACGATTA ATCAACAGAT 480 GTACAGATCA GCICTCAAAA TGTCTTCTGT GTCTTCTAGA CGTCTCAAAA AAGAACTGCA 540
TTAGCCTCCT GCTAGTTGAC TAATAGAATT AATAATTGTA AAAAGCACTC TAAAGCCACA 600
TGCCTTATGA AGTCAATGCT GGGTATGATT TTACAAATAT GGTCCGGAAA AAGAACCCCC 660
CTCTGAGAAA CGTTGCAAGT GAAGGCGAGG GCCAGATCCT GGAGCCTATA GGTACAGAAA 720
GCAAGGTATC TGGAAAGAAC AAAGAATTCT CTGCAGATCA GATGTCAGAA AATACCGATC 780 75

WO 02/059377 PCT/US02/02242

AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840 CTICTAGCAG TAAGAAGGAC TIGAAAAGCG CAGTICTGAG TGAGAAGGCT GGCTICAATT ATGAAAGCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA 960
GAAATATGTT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020
CGCAAAGAGC AGAGGCAGAT GACCCTCAAG ATATGGCCTG CACCCCTCA GGGGACTCAC 1080 5 TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140 AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200 AAGTOCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260 ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320 GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 10 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440 ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500 CTGGTGGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 15 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 ACACTCCTGT TGGGTACTCA GTGCCCATAA AGCCCCTCGA TTCCTCTAGA CAAAATGGTA 1920 20 CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980 CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACGGAGC AGTGCAGTCA GGCGGCCTTA 2040 ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100 AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAGA 2160 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 AGGACTICIC CAGCAAGGA GCCUAGGATA ATATIGGTAAC GAGCTAAAT TOTACATTC 2280
GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTICTCC 2280
GTCATTATCA ACAGCTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGC 2340
CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400
GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460 25 GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520 30 TACTICTICTT TICACTATIGAA AGTOTIGCATIG AGTOCICAAGC ATCGGATGTC AAACAAGAAG 2580 CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTIGTCAA GGAAAGCAAA GAACACTCAT 2640 GTACCAAATIG TIGATTITTATT ACCCAAGTIGO AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 CACACAGCTG CTACAAATGC COTCAGTGCA GTTTTACAGC TGCCGATACT CAGTCACTAC 2760
TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820
AGGACGGTCA TGCCATATCC ACCATCAAAG AGGAGCCCAA AATTGACTTC AGGGTCTACA 2880
ATCTGCTAAC TCCAGACTCT AAAATGGGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940 35 AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGAGT TCCAGTGATG 3000 ACCTTOGCAA TOTGACTTOG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060
AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120
GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGCACC TATTTATGGC TTGGCTGTGG 3180 40 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240 AGCAGTATCC TOCATCOGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300 GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360 GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420 45 CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480 GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAGA 3540 GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660 GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720 50 TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780 ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAGA GGCAGTCCTA 3840 TAGAAAAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900 AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960 CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020
TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080
ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140 55 TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200 CACCAAATGT AAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAA GTTGATAGAA 4260
GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320
TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380
GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440 60 GCAGCATET TTGCACGGAC AAATATGACT ICACAACACA TATCADAGG GGCTGCATA 4440
GGAACAATGC ACAAGTGGAA AAAAATGGAA AACC<u>TAA</u>AGA GTAAAACCTT AGCACTTAGC 4500
ACAATTAAAT AGAAATAGGT TTTCTTGATG GGAATTCAAT AGCTTGTAAT GTCTTATGAA 4560
GACCTATTAA AAAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCCTTCTTT 4620
GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680 65 AGAAAGAATG GAAGATGGTA AACAATCACT TTITAAAACC TGTTAAGTCA AAACCATCTT 4740 GGCTAATATG TACTGGGGAA ATAATCCATA AGAGATATCA CCAGACTAGA ATTAATATAT 4800 TTATAAAGAA AGAGACCAAA ACTGTCTAGA ATTTGAAAGG GTTTACATAT TATTATACTA 4860 AAGCAGTACT GGACTGGCCA TTGGACCATT TGTTCCAAAA CCCATAAATT GTTGCCTAAA 4920 70 TITATAATGA TCATGAAACC CTAGGCAGAG GAGGAGAAAT TGAAGGTCCA GGGCAATGAA 4980 AGAAAATGG CGCCTCTCA ATTTAGTCTT CTCTCATTGG CAATGTTCA GATTTTGACC 5040
TAGAAATGG CACCTGTT AGCCTGGTT AGAGTGCAGC AAGCAACATG ACAGATGGTO 5100
GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160
TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGGTTTAGA TTCATTTTGT 5220 CCACACATOT ACCCATTITA AAAAACAATG TCCTCGATGC TTCTGTAGTG ATTTCATTTT 5280
AGCCAGGTAT TTCTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340
TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400 75

2

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460 CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTGGTT AAATATAATT TCCAAACTTT 5520 GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580 CAATCCCTTC ATTANATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCATTAGAA 5640
GTATGTCCTC ATGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700
GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760
TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820
TTTAATAATT TGCACTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAATGTAG 5880 5 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 AGAACAAATA GGAAAAAAA AACTTATTT TCTAGTAAAT ATTAATGTAT TACATTCAA 6000
AGAACAAATA GGACATATT GAATAATTAT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000
ATAATGGTGC CTGACATATT GAATAATTAT TTTCTACAGT GTACGTATGC AACAAAGATA 6060
TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATTT GCAAATGTAG 6120
CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGGTAGAT ATCCTTTTGT GTGTGTGT 6180 10 GTGCATTAAA GTTGTAAACG GTAACATGAA ACAAATGAAA GTTCTTGCTA TAATGGTATG 6240 GAAAACAAGA AGGAAATGAA AATATTTTTA TGCCTACTTA GGAAAAAAAG GGTAGCACTT 6300 15 TAGTCGCATT TGCACTCCAT TTTTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 INGICICAL I INCACICAL ITTIACATIA ATTOCAMIT GETTAGRICA GATGGCAGGT 6600
TIGGGTTTIG TTTCTTTTIC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600
AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660
TIGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAAGAG 6720
AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTCGCTTCA GTTTCATTGT TAACGGGCCT 6780 20 TATTCTGATC TCACCTGTCG CGTAGCTCTA ATATTCACAT AAACTGAAAT AAAGAAGTGG 6840 AATGAGGAGC TITGACATTC AAATTATGTG ATGTAATTTA TCTTCCTTAG GAATTTTGAT 6900 GGATGCATCT CAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAT CTAAAAAAGA 6960 GAGGAGATTC CCCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAGAATA ACAGAATGCA 7020 25 TOTTOGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCAGA 7880
TOTTOGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCACAGA 7880
AGTITGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAACT ACTCATTAAG 7140
CAATTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7209
ATTTTCATC AATTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 30 AATACATATC ACTATICTIG GAATATTTAT GGTCAGTCTA CITTITAGTA AAATATTITT 7320 CATTITITIGE TITCATTATT ATACATATTT TGGTGGAGAA GAGGTTGGGC TTTTTTGAAA 7440 GAGACAAAAA TITATTATAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500 35 CATCICICAA GATATATTAT AAAATTTATT TTTTTAATTT AAGATTTCTG AATTATTTTA 7560 TCITAAATIG TGATTITAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 CATGATGATT TAGGAATITI CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TTGTGTGCCA TTTAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800 40 THITCHACT CTITCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAAA 7860
AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920
CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAAAA 7980 CAAGIATATU AGAAAAGGAU AGAGCICHAA HUAHAACIC IGHAGICAA AAGAAAAA 786 GTATGCCCAA TICTCTCTAC ATGACATATT GAGATTITTT TTAATCAACT TITAAGATAG 8040 GGGATTCTTT TCTAAACTG TICTGTTTTA GTGAAGGTAG ATTITTATAA AACAAGCATG 8100 GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTATCTTTA ACAGCICTTT 8160 GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220 45 GITGAAGC: T GIGGIAGCAC ATTATOTTA TAATIGCACCA TOTOCACATA ATGCTTATATAT AND ATGCTTGAGG 8280 ATCCAATGCA AATACAGCT CAAAAATATT AAATGTATAT ATATTITAAA ATGCCTGAGG 8280 CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400 GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460 50 GCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGGG 8800
TGGAAATGTG GAGTAAAGAA GCTGGTGGTC TGCTTCTGTG CTGTATGCCA GCCTTTTGCC 8520
TAAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTTGGT TTGAGAGCCA TGGCAAAAAA 8580
AAAAAAAGAA AAAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640
TGTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAAATGCAA CCTGAGTATC AAACTAAATA 8700 55 TICTAATCAA AGGTAGGTAC TUTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760 AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTCC CAAAGAAAGA 8820 CGGCCAAGGG CAGAGGCATG GATTCTTTGC AGAGCACTTC CTTTTGGTTT TTCAGTACTG 8880 COGLANGIA CATROCATO CATOTICCTO ATAGTICCTGC AGTTGCTTAG AAAGCATCCC 8940
AGTTAATTGC AGTAATTAGA ACTICTGGAA TATGCTAGGG CAGAAGTATG TCAAGTATGT 9000 60 CACATGAAGA AAATGTGAAA TTCAAGAGTA ATCCACACGT GAGAAACTAG ACAATGTACA 9060 TICATOTOTT CICTIGAAAG GAAAGGGAGA GCTGTAAGCT TCACTCTGTC CTACACCGGA 9120
GAAAAGCAGG AATAACTITA CCGTGGAAAT AATGTTTAGC TTTTATCAGA GAAAATTGTC 9180 CTTCTAGAGC ATAGAGTCCC AAAACTCAAT TCTGGTTTTC CCCTGTTTTT TTTTTTTTT 9240 TITTICCCAA CATATGAACT GCAGCATATC ACTITTICIT TITGIGCCIC AGGITCCICA 9360
CCIGIAAAAT IGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360 .65 GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGT 9420 ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480 GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATA GTGTTGACTA 9540 TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAG TTCTTAATGG CTACCAATA 9600 GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9600 GAAAACTTTG GGGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720 70 TACAGCAATA TTCACCAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGCTAAGA 9780 AAAAGAATIC AATTIGTAGT CCTGATTIGA ATACTAGAAT GTIGGCTATA ATAGTTCTGT 9840 TCTTACAACA CATGAAATTI TTICGITTTA TITTATTITG TITTCATAGT GCATGTTCAT 9900 TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 75 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A

Seq ID NO: 68 Protein sequence: Protein Accession #:

NP_054831

5 41 . 51 31. MPYEVNAGYD FINNVRKINP PLRNVASEGE GQILEPIGTE SKVSGKNKEF SADQMSENTD 60 QSDAAEINHK EEHSLHVQDP SSSSKKDLKS AVLSEKAGFN YESPSKGGNF PSFPHDEVTD 120 RNMLAFSFPA AGGVCEPLKS PQRAEADDPQ DMACTPSGDS LETKEDQKMS PKATEETGQA 180 RNMLAFSFPA AGGVCEPLKS PQRAEADDPQ DMACTPSGDS LETKEDQKMS PKATEETGQA 180
QSGQANCQGL SPVSVASKNP QVPSDGGVRL NISKTDLLVN DNPDPAPLSP BLQDFKCNIC 240
GYGYYGNDPT DLIKHFRKYH LGLHNRTRQD AELDSKILAL HNMVQFSHSK DFQKVNRSVF 300
SGVLQDRISS RPVLLNGTYD VQVTSGGTFI GIGRKTPDCQ GNTKYFRCKF CNFTYMGNSS 360
TELEQHFLQT HPNKIKASLP SSEVAKPSEK NSNKSIPALQ SSDSGDLGKW QDKITVKAGD 420
DTPYGYSYPI KPLDSSRQNG TEATSYYWCK FCSFSCESS SLKLLEHYGK QHGAVGSGL 480
DPPH NIKLSB GSVINTADI A KSSEGEFTMTK TDKSSSGAKK KIDSSKGA BI NAAUTSVACOB 540 10 DIPYGYSVPI KPLDSSKQING TEATSYT W.C.R. K.S.PSLESSS SLÆLLEHTGIR QHRJAVQSOGL 480
NPERDIMLISE GSVINQNIDLA KSSEGETMTK TDKSSSGAKK KDPSSKGAED NMVTSYNCQF 540
CDFRYSKSHG PDVIVVGPLL RHYQQLHNIH KCTIKHCPFC PRGILCSPEKH LGEITYPFAC 660
RKSNCSHCAL LLLHLSPGAA GSSRVKHQCH QCSFTTPDVD VLLFHYESVH ESQASDVKQE 660
ANHLQGSDGQ QSVKESKEHS CTKCDPTTQV EEEISRHYRR AHSCYKCRQC SFTAADTQSL 720 15 ANHLQGSDGQ QSVKESKEHS CTKCDFTTQV EEEISRHYRR AHSCYKCRQC SFTAADTQSL 720
LEHFNTVHCQ EQDITTANGE EDGHAISTIK EEPKIDFRVY NILLTEDSKMG EPVSESVVIR 780
EKLERKDGLK EKVWTESSSD DLRNVTWRGA DILRGSPSYT QASLGILITPV SGTQEQIKTL 840
RDSPNVEAAH LARPIYGLAV ETKGFLQGAP AGGEKSGALP QQYPASGEINK SKDESQSLLR 900
RRRGSGYFCA NCLTTKTSLW RKNANGGYVC NACGLYQKLH STPRPLNIIK QNNGEQIIRR 960
RTRKRLNPEA LQAEQLNKQQ RGSNEEQVNG SPLERRSEEDH LTESSHQREIP LPSLSKYRAQ 1020
GSLTKSHSAQ QPVLVSQTLD HKKNAQPLHI QKSPQESTG DPGNSSSVSE GKGSSERGSP 1080
HEKYMADDAKU BAIVGDBGSDE HEKYOVDE EGI BEVLINTEDGER ADMIT BUNGETV ET CUPCANDIN 11A0 20 USLIKSHDAQ QYVLYSQILD HIRANGYLIII QIASYQESIG DI'GHSOYS GAWLRIYSKY KLSYPGNPHY 1140 LSHYMPAKH PNYSPPGSPI EKYQYPLFGL PFVHIDPOSE ADWLRIYSKY KLSYPGNPHY 1140 LSHYMJIYN CQNYVPYPH NLPPHIFSAVG SONDIPLDLA IKHSRPGPTA NGASKEKTKA 1200 PPNVKNBGPL NVVKTEKVDR STQDELSTKC VHCGIVFLDE VMYALHMSCH GDSGPFQCSI 1260 25 CQHLCTDKYD PTTHIQRGLH RNNAQVEKNG KPKE 30 Seq ID NO: 69 DNA sequence XM_073879. leic Acid Accession #: Coding sequence: 1-387(underlined sequences correspond to start and stop codons) 31 51 21 35 ATGGGGTTTG GAGACCAGGG AACGGTGGAA GGGAGCCTAG GAACGTCGAA AAAACCACCT 60 GAAGTGAAAA TGTTTGGAGC CAGTCAAGGT TTGCTGACAA TGGAAACAAA CCAGTCCCTG 120
GCACAAGGCA CAGGCTGCTC AGTAGTAAAG GTAGACACTG TTCTCTTCGA GAGTTTATAC 180
CACTGCGGCT TTGAACACACG GAGCGTGATG CACTGCCTTG GGGATGATCA CCCCCAGGAA 240 GACAGGAAGG CTCACTTCTC TGCCCCAGTT GCAGCCATCG CCTCTCCAGC ACCGACTCCT 300 40 GTCTGTCCTG CACACCACTC AACACAGAGC ATCTGCCAGT TTCTACAGCA CTGCAGGCAG 360 AACACTCACT TGCAGGCTGC TAACTAA Seq ID NO: 70 Protein sequence: Protein Accession #: XP_073879 45 31 41 MGFGDQGTVE GSLGTSKKPP EVKMFGASQG LLTMETNQSL AQGTGCSVVK VDTVLFESLY 60 HCGFEHGSVM HCLGDDHPQE DRKAHFSAPV AAIASPAPTP VCPAHHSTQS ICQFLQHCBQ 120 50 NTHLQAAN Seq ID NO: 71 DNA sequence Nucleic Acid Accession #: AB033064 55 Coding sequence: 826-1986 (underlined sequences correspond to start and stop codons) 41 31 GGGGAACAGC AAATTCAGTC ACAGACAATC CTCCACTCGG TCAAGAGCCA CTTTTCTCTT 60 CCTGCCTTGC CCCCCCGCAG GGGGTAAGGA ACTGAGCGTT TAATCTTTAG CCGGTTGGCT 120 60 ACCAGCTAAA ATTCTACTTA TCTTAGTTTC TAGTGGATAG CTTTCTTATT TTGCCCATGT 180 TITICTTAGAA TOCCIGITTA ATATACTITT GICAGTAGTA GTATCTAGGA GTAGCAGGGA 240
GAGTGACAAT AAATTAGCCC CITCTTITT COCTAGTCAT TCAGGCCCT TITICTCTCC 300
AGAGGGAAAT TACCAGTAAA CICTICTAAA TCTTCCACCC CITCTCAGTC ATACTGTGAA 360 AGAGGGAAAT TACLAGTAAA CICTICTAAA TUTICLACXX CITICICAGIC ATACIGIGAA 360 GAAACACACT AAAGTGGACA TTATTTGACC AGTGAACACG AACCCAGCTT CAGGCATTGG 420 TITIGTTGTGG CACATGGAGA AACATCTCTT TTAAAATATC TCCCAATTAC CCTTTTCACA 480 ATTTGTATCC ACCTAGGATT TGCTGCTGGG GTAAGTCACT AGATTTATTT CTCAAAGCTC 540 CCCTCTCTAT GAGCTGAAAG ACTGACCAAC CATGAACACT AGTAGGGGAT GGGGAAAGGG 600 65 CCCICICTAT GAGCTGAAAG ACTGACCAAC CATGAACACT AGTAGGGGAT GGGGAAAGGG 600
GACAGAGCAG AGCCAGTIGT TCCACACTTT GGGAAGCAGG AGTAGCTTT ATCATCTICC 660
TCTGGGGAGC AGGCATAGAG ACATAAACTG AGTGAAAATG GGTGGAGGAA GAACTTCTAT 720
ACCCACGAAC AACATGTGAA GAGAGAAC CAAACATAAA GTAAGGAGGG TAGACGTTAC 780
ATCCAAGAGG AAATAATCCA GGCAAGGAAG CACAAGCTGA TCCAAGATGTO TAGTTCTGTG 840
GCTGCCAAGT TGTGGTTTTT GACAGATCGT CGCATCAGGG AAGACTATCC TCAAAAAGAG 900
ATTTTACGAG CATTGAAGGC CAAATGTTGT GAGGAGGAC TGGACTTTAG GGCTGTGTGTG 960
ATGGATGAGG TGGTGCTGAC AATCGAGCAA GGAAACCTGG GTCTGCGGAT CAATGGAGAG 1020
CTAATCACTG CCTACCCACA AGTGGTGTA GTCAGAGTAC CAACCCCTTG GGTGCAAAGT 1080
GATAGTGGACA TCACTGTTTT GCGCCATCTA GAGAAGATGG GATGTCCGTT AATGAACCGA 1140 70 75 GATAGTGACA TCACTGTTTT GCGCCATCTA GAGAAGATGG GATGTCGGTT AATGAACCGA 1140

Seq ID NO: 72 Protein seque

11 21 31 1 1 1 1

Protein Accession #:

75

BAA86552

```
CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200
           GOTGTTCCTC TGCCGGATAC TITCTCTTAT GGTGGCCACG AAAATTTGC TAAAATGAT 1260
GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAGA ATACCCGGGG TCACAGAGGT 1320
AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCCA TCTTATTCGC 1380
CATGAAGCG
 5
           OTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTTCAAC AGATGGGAGA 1500
           ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1560
            AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
            CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680
           GOCITTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740
10
           CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800
           AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1800
GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920
CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980
GACTGACTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTTTCT 2040
15
            ATTITITAAAA CCAACITGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAT 2100
           TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160
TICATTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATTAGAA AAATCTCAGG 2220
CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGTAT GCTCATAGGC CATGAGGAAC 2280
AAATACTTTT TTTTTTTCAT GGTCCCTTGC TTTTGTTTTT GTACAAAAAAA AAATGGTTTT 2340
20
           GCTACAAATA TCCAAGTAGC ATAACTTCAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400
AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460
TCCTTATTAA CTAGCAGCTT TAGTTTGTAG TTTATGAAAT CTTGAGGGGC TCTTTTACTG 2520
            GGATTTCTTA TITTTTGTT TTTTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
           CCCAATAAAG GCTTCTTAAT GAGAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640
25
           AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGTAGATAAA ATTACCTAG 2700
TTTAAAAATA GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTG AAAGATGTGC 2760
TCTGTTAATG TGCTTTTT TTTTTTTTT TAATACATGC TAGTCTAACA TTTCCTGCTC 2820
            TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880
           ACACTGACTT GAAACATGTA CATTTAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940
TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000
30
            TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060
            TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120
            TIGITITCCAT CAACTAATCA AAAAGGATAA TITAGAAAAT GGAGCATGAT GGGAAACAGA 3180
            GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240
35
            TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300
            GITGITIGIT TITTICCITT IGITICIAGC CIGITCAGIG TACAGITTAT TCAAGGCTAC 3360
            ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480
CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540
40
            AAAAGCCCC AAACTGCATA TAATATGAGC CTITAAAACA TGGGTAAAAC TAATCCATT 3600
GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCAACG TAATTTTTTA 3660
AACÁGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TTTACCCAAG CCCTTTCTTG 3720
CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATTTCTTGG ACACTACTAG 3780
            AGAGACTICG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTGATCA 3840
45
            TGCTTACTTG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900
            CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960
CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020
            TAATTTATCT TAGGATATIC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080
            GGGACTCAC ATACATATAT TAATACCICT GACTCATTAA CAGAAAGAAA TACTIGGTAC 4400
TICTITICGCT GAATGACCAT ACTGGGAGG ATGCATAACA TTTTGGTATAG AGAAATAAAT 4200
GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACAATCTGG 4260
TIGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320
·50
            ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
            ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440
TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500
GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
55
            AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620
            TAAACTTATT TICATAATIG TITAATAACT TITGTATAAT CTICATIGCT ATTATGAGAG 4680
AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TIGTAAAATT TITGTATATT 4740
60
            GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800
            TCACCCATGA TGAAAACTGG ACTITATATA TCTAAACATA CAAGTATGAA CTATTCTATT 4860
TAAAATTITT AATAGTTITT TTCTTTTTTG GTGCCTATAA TTGATTGGTC ATTTCTGCTG 4920
            GCTTTTCTCC AATGAACATT GAAATCTTCC TGTATATGTT ACCAATAAGA AAACTACCCT 4980
GGAACAGTAG AAAAACCCAA CAAGAGACTT GGCATTCATC AAGCACATTA TCAGACTTTG 5040
65
            AGAACATATT GAAGGCATTG ACTITGAAAA TCATCTCTTT TTCTCAAGAA GAAAGCAATG 5100
            AGAAACAAA TTIGTTTCAT TCAGTGAATC CCCAGTTTGG GCTTTGGG GCTTAGAGAC 5160
ATTGTGAAAT CAAATCTTG GTTATACTTT TCCTGGCT CACTTTTTT GAGAAGGTTT 5220
ATGGGCTATT TGGCTGGTGA GACACGATCC CCTCCTAAGA AAATGTAGGT GCTCAGACAG 5280
GTAACCACTG CTGCTACTGT TTTTATTTGT TTGTTTGTT CAATTTTATTT AAGATTTGTT 5340
70
            TTTGTTGTAC TAGGATTTTA AAAAATGTAA TATATTGCAG GATTTATAAC CAG
```

380

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60 RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120 ELAGHGVPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHBAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 5 LSEQGKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NVGFIAFDKA CNLDVAGIIA 300 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 ELLTKLPGGL FNMNQLLANE IKLLVD Seq ID NO: 73 DNA sequence XM_040080.2 10 Nucleic Acid Access Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons) CTGAGTGGGG GCGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120 15 GTGAGGGAGT GACAGCAGCG CATTCGCGGG ACGAGAGCGA TGAGTGAGAA CGCCGCACCA 180 UTUAUUJAUT DALAUCAUCAU CA LICULUSUS ACUAGABISTIA TEJAGTGAGAA CGCCGCACCA 18
GGICTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCCAGCGC CAAAGCCTGG 240
GGCTCCCTGC AGGCCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGCTCC 300
TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360
GGTCATGGGC TCTCGTCCCA TTACAGCCCA GGTGTCCCAT ATTACCTCCA GACTTTTGTG 420 20 AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480 AGITICGATG GCGCAGGCTTG AAATGGAATC UATTCCAT TCGGCCAC 480
AGCTTCGGTG GCGCAGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540
CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600
ACCTACAAGC GGAGAGCCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660
CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA AGAGCAATAG CCACTTGAGT 720 25 GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGAACCACGA AGGTGGCCAC AGGTCTGGTT 780 CTGAACAGAG ACCAGAGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840 CTGTGTGCGC ATTCCATCAG GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900 GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960 30 ACCATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATCACTGT 1020 GTCCACATGA GCGAACCCCA GCACGTGGCC AGTATCATCA GCTCCTTCTT ACAGTGCACA 1080 CACATGCTCC CAGCCCAGCT GTAGCTCTGG GCCTGGAACT ATGAAGACCT AGTGCTCCCA 1140 GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200 35 AGGCCTCACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260 AACTTCAACA TCTGTGACCT CAAGGGGGAG ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320 CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380 CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A 40 Seq ID NO: 74 Protein sequence: XP_040080.1 Protein Accession #: 41 21 31 MSENAAPGIL SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPILPQDFY 60
MSENAAPGIL SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPILPQDFY 60
YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSSG GVVGGMFFCT 120
FPEMYDKLIL LDTPLFLLES DEMERILLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRIL 180
KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISREICA HSIRKLQAHV 240
LLIKAVHGYF DSRQNYSEKE SLSFMIDTMK STLKEQFQFV EVPGNHCVHM SEPQHVASII 300 45 50 SSFLOCTHML PAQL Seq ID NO: 75 DNA sequence leic Acid Accession #: NM_005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons) 55 21 31 GGITICCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 60 CACCATCTIT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240
GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300
TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360 CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAG AAGCATCTCA 420
GACACCAAC ACTATGCTGT CAGCAGTTGC CGGGGCTAC CAGGGCTGGT TTCATCCCTG 480
TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGC TCCTGGCTAA 540 65 COGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACGTCT 600 GGCCCGGGAC GGGGCCCACG TGGTCATCAG CAGCCGGAAG CAGCAGAACG TGGACCGGGC 660 CATGGCCAAG CTGCAGGGGG AGGGGCTGAG TGTGGCGGGC ATTGTGTGCC ACGTGGGGAA 720

GGCTGAGGAC CGGGAGCAGC TGGTGGCCAA GGCCCTGGAG CACTGTGGGG GCGTCGACTT 780
CCTGGTGTGC AGCCCAGGGG TCAACCCTCT GGTAGGGAGC ACTCTGGGGA CCAGTGAGCA 840
GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900

GCTGCCCTAC ATGGAGAACA GGAGGGGTGC TGTCATCCTG GTCTCTTCCA TTGCAGCTTA 960

70

75

CTICCTGTGC TCTCCAGATG CCAGCTACGT CAACGGGGAG AACATTGCGG TGGCAGGCTA 1260 CTCCACTCGG CTCTGAGAGG AGTGGGGGGCG GCTGCGTAGC TGTGGTCCCA GCCCAGGAGC 1320 CTGAGGGGGT GTCTAGGTGA TCATTTGGAT CTGGAGCAGA GTCTGCCATT CTGCCAGACT 1380 AGCAATTTGG GGGCTTACTC ATGCTAGGCT TGAGGAAGAA GAAAAACGCT TCGGCATTCT 1440 5 Seq ID NO: 76 <u>Protein sequence</u> Protein Accession #: NP_005 NP_005785 10 21 31 MLSAVARGYO GWFHPCARLS VRMSSTGIDR KGVLANRVAV VTGSTSGIGF AIARRLARDG 60 AHVVISSRKQ QNVDRAMAKL QGEGLSVAGI VCHVGKAEDR EQLVAKALEH CGGVDFLVCS 120 AGVNPLVGST LGTSEQIWDK ILSVNVKSPA LLLSQLLPYM ENRRGAVILV SSIAAYNPVV 180 ALGVYNVSKT ALLGLTRTLA LELAPKDIRV NCVVPGIIKT DFSKVFHGNE SLWKNFKEHH 240 15 QLQRIGESED CAGIVSFLCS PDASYVNGEN IAVAGYSTRL Seq ID NO: 77 DNA sequence 20 Nucleic Acid Accession #: NM 002425 Coding sequence: 26-1453 (underlined sequences correspond to start and stop codons) 21 31 25 AAAGAAGGTA AGGGCAGTGA GAATGATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC . 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TIGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180
AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAGGAATG CAGAAGTTCC TTGGGTTGGA 240
GGTGACAGGG AAGCTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300 GGTGACAGGG AAGCTAGACA CTOALACTET GGAGTGATG AAGTGGAGGA AAACCCACCT 360
TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420
TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGTATGA 480
AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAGAA CATGGAGACT TTTACTCTTT 540 30 AGRAGAGGET GATATAATUA TETETTICOE AGTIMAAGAA CATGUAGGET TITATGGAGA 600
TGATGGCCEA GGACCACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TITATGGAGA 600
TATTCACTTT GATGATGATG AAAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT 660
CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGCTCTTT CACTCAGCCA ACACTGAAGC 720
TTTGATGTAC CCACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780 35 TIGATOTICA TO GEOATICAGI CICTICTACOG ACCTICCCCT GCCTCTACTG AGGAACCCCT 840
GGTGCCCACA AAATCTGTTC CITCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900
GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 900 40 TIGGOGAAGA TOOCACTGGA ACCCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 TIGGGJAAGA TOCCACIGGA ACCCIGAACC IGAACT IGAATITACT TIGGAT TOCACIGGACA COCTITITAT 1080
TITTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140
AGGCATCCAT ACCCTGGGTT TICCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200
CAAGGAAAAG AAGAAAACAT ACTTCTTTGC AGCGGACAAA TACTGGAGAT TTGATGAAAA 1260 45 TAGECAGATEC ATGGAGGAAG CETTECETAG ACTAATAGET GATGACTTTC CAGGAGTTGA 1320
GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTTTC TACTTCTCA GTGGATCATC 1380
ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440
GTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500
ATTATTCATC TAATGTATTA TGAGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTACT 1560 50 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTIC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740 55 Seq ID NO: 78 Protein segmence NP_002416 Protein Accession #: 41 21 60 KIQGMQKFLG LEVTGKLDTD TLEVMRKPRC GYPDVGHFSS FPGMPKWRKT HLTYRIVNYT 120 PDLPRDAVDS AIEKALKYWE EVTPLTFSRL YEGEADIMIS FAVKEHGIFY SFDGFGHSLA 180 HAYPFGFGLY GDHIFDDDEK WTEDASGTNL FLVAAHELGH SLGLFHSANT EALMYPLYNS 240 FTELAQFRLS QDDVNGIQSL YGPPPASTEB PLVPTKSVPS GSEMPAKCDP ALSFDAISTL 300 65 RGEYLFFKDR YFWRRSHWNP EPEFHLISAF WPSLPSYLDA AYEVNSRDTV FIFKGNEFWA 360 IRGNEVOAGY PRGIHTLGFP PTIRKIDAAV SDKEKKKTYF FAADKYWRFD ENSQSMEQGF 420 PRLIADDFPG VEPKVDAVLQ AFGFFYFFSG SSQFEFDPNA RMVTHILKSN SWLHC 70 Seq ID NO: 79 DNA sequence Nucleic Acid Accession #: NM_000493.1 Coding sequence: 1-2043 (underlined sequences correspond to start and stop codons) 21 31 75 ATTICTIGGCAC AAATACCCTT TTTGCTGCTA GTATCCTTGA ACTTGGTTCA TGGAGTGTTT 60

TACGCTGAAC GATACCAAAC GCCCACAGGC ATAAAAGGCC CACTACCCAA CACCAAGACA 120

á

CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240
GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300
GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAGA 360 GGACCATATG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420 5 CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACAA 480 CAGGGACCCA CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAGGG TGCACCAGGA 540 GICCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600
GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660
AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAGGTGATAG AGGTTTTCCG 720 10 GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780 GAAGGCATTG GAAAGCCAGG AGCTGCTGGA GCCCCAGGCC AGCCAGGGAT TOCAGGAACA 840
AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900
CCAGGCTTGC CAGGCCTGAA GGGAGAAAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960
GCCAAAGGGG AACAAGGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020 15 GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCCT 1080 AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAGGG TGAAAGGGT 1180
TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200 GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260 20 CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320 CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCCTA TTGGGCCACC AGGCATTCCA 1380 GGATTCCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGGCATA 1440 GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AAGAGGCCCC 1500 TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 25 ATGCCTGAGG GTTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAA TTTTGTATAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTTCA 1800 TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860 GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920
ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAATGC CGAGTCAAAT 1980
GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCTCAG GATTCCTAGT GGCTCCAATG 2040 30 TGAGTACACC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100 TOCCACCETA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATTIT TATTITCTGA 2160
AATACAGATI TGAGCTATCA GACCAACAAA CCTTCCCCCT GAAAAGTGAG CAGCAACGTA 2220
AAAACGTATG TGAAGCCTCT CTTGAATTIC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280
TTCTCCAATA TTAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAAA 2240 35 AAACAAAGCA ACAAAAAAA AAATTAAAAA AAAAAACAGA AATAGAGCTC TAAGTTATGT 2400 GAAATTIGAT TIGAGAAACT CGGCATTICC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAA CTTTGTAGAA CTTAAATACT 2520 40 TGAATATICA AATTIAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 TGAAGGCCTGT ATGCCCCTT TCATCAATAT CTATTCAATA ATACAGGTGC ATATATACTT 2640
GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700
TTTCATCAAT GAACCTTTTC AAAACTTTTC TATGATGCA GAGAAGCTTT TTATATACCC 2760
AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTTA GTTAACACAA GTGTGATTAA 2820 45 AGCATAACTI GGAAACAGT ATGAATCTT ATGTGATATG ATTTTCTGGA TTTACAGAAC 2880
ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940
CAAAATTCGA CTAGAAGTGG AGATATATTA TITATTTATG CACTGTACTG TATTTTATA 3000
TTGCTGTTTA AAACTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3660 50 TCCTTATITA CGACACAATA AAATAACATC AATAGATTTT TAGGCTGAAT TAATTTGAAA 3120 CATCAATAGA TITITAGG

Seq ID NO: 80 <u>Protein sequence:</u>
Protein Accession #: NP_000484.1

Seq ID NO: 81 DNA sequence
Nucleic Acid Accession #: NM_000786
Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51

75

75


Seq ID NO: 83 DNA sequence

Nucleic Acid Accession #:

CGCGATTCTC AGGGATTGAT CCGCCTCTTC AGGTAAGTTA TCTTCCGGCC CCGTACCACT 60
GTGCCACAGG CGCAGCCCGC TTCCTCAGGT GCCCTATCCC GCGCAGAAGA CCACGGCTTC 120
ACAGAGTGTT ATTTAAGGGC GTGGCCAGCG GAACATCCCG CCCCATTCTG TGACGCACGG 180 5 GUTGOCGCGC GTGGGACCCG AGGGGTGGGG CTGGGTTTAG TAGGAGACCT GGGGCAAGGC 240 CCCTGTGGA CGACCATCTG CCAGCTTCTC TCGTTCCGTC GATTGGGAGG AGCGGTGGCG 300 ACCTCGGCCT TCAGTGTTTC CGACGGAGTG AATGGCGGCG GCGCCTGGGA TGCTGCTGCT 360 GGGCTTGCTG CAGGCGGGTG GGTCGGTGCT GGGCCAGGCG ATGGAGAAGG TGACAGGCGG 420 CAACCTCTTG TCCATGCTGC TGATCGCCTG CGCCTTCACC CTCAGCCTGG TCTACCTGAT 480 CONTINUED TO THE CONTINUE TO THE CONTINUE TO THE CONTINUE TO THE CONTINUE TH 10 CCTGAATGCA GAAGATGTCT ACAGTCGCCT GACAACACCT GTGTTTGGGA AGGGAGTTGC 780 15 ATACGATGTG CCTAATCCAG TTTTCTTGGA GCAGAAGAAA ATGTTAAAAA GTGGCCTTAA 840 CATAGCCCAC TITAAACAGC ATGTITCTAT AATTGAAAAA GAAACAAAGG AATACTITGA 900 GAGTTGGGGA GAAAGTGGAG AAAAAAATGT GTTTGAAGCT CTTTCTGAGC TCATAATTTT 960 AACAGCTAGC CATTGTTTGC ATGGAAAGGA AATCAGAAGT CAACTCAATG AAAAAGTAGC 1020
ACAGCTGTAT GCAGATTTGG ATGGAAGGTTT CAGCCATGCA GCCTGGCTCT TACCAGGTTG 1080 20 GCTGCCTTTTG CCTAGTTTCA GACGCAGGGA CAGAGCTCAT CGGGAAATCA AGGATATTTT 1140 CTATAAGGCA ATCCAGAAAC GCAGACAGTC TCAAGAAAAA ATTGATGACA TTCTCCAAAC 1200 TTTACTAGAT GCTACATACA AGGATGGGCG TCCTTTGACT GATGATGAAG TAGCAGGGAT 1260 GCTTATTGGA TTACTCTTGG CAGGGCAGCA TACATCCTCA ACTACTAGTG CTTGGATGGG 1320 CTTCTTTTTG GCCAGAGACA AAACACTTCA AAAAAAATGT TATTTAGAAC AGAAAACAGT 1380 CTGTGGAGAG AATCTGCCTC CTTTAACTTA TGACCAGCTC AAGGATCTAA ATTTACTTGA 1440 TCGCTGTATA AAAGAAACAT TAAGACITAG ACCTCCTATA ATGATCATGA TGAGAATGGC 1500 25 CAGAACTCCT CAGACTGTGG CAGGGTATAC CATTCCTCCA GGACATCAGG TGTGTGTTTC 1560 TOCCACTGTE AATCAAAGAC TTAAAGACTE ATGGGTAGAA COCCTGGACT TTAATCCTGA 1620
TOGCTACTTA CAGGATAACC CAGCATCAGG GGAAAAGTTT GCCTATGTGC CATTTGGGC 1680
TGGGCGTCAT CGTTGTATTG GGGAAAAGTTT TGCCTATGTT CAAATTAAGA CAATTTGGTC 1740
CACTATGCTT CGTTTATATG AATTTGATCT CATTGATGGA TACTTTCCCA CTGTGAATTA 1800 30 TACAACTATG ATTCACACCC CTGAGAACCC AGTTATCCGT TACAAACGAA GATCAAAATG 1860 AAAAAGGTTG CAAGGAACGA ATATATGTGA TTATCACTGT AAGCCACAAA GGCATTCGAA 1920 GAGAATGAAG TGTACAAAAC AACTCTTGTA GTTTACTGTT TTTTTAAGTG TGTAATTCTA 1980 AAAGCCAGTT TATGATTTAG GATTTTGTTA ACTGAATGGT TCTATCAAAT ATAATAGCAT 2040 35 TTGACACATT TTCTAATAGT TATGATACTT ATACATGTGC TTTCAGGAAG TTCCTTGGTG 2100 AAACAATTGT TGAGGGGGGA TCTAGGTAAT TGGCAGATTC TAAATAATAT AATTTCCAGA 2160 TAGTAATTTT AAGAGTACTC ATCGCTCTTG CCAAATAAGT TCAGGGTATT CAAATCTTGG 2220 ACTAGTCCTG CAAGGTATAA AGAATAAAAA TCCCAGTGAG ATACTTGGAA ACCACAGTTT 2280 40 ATTATTATTT ATCTGGGCAA TTATTGTGTG TGTGAGGATG GAAGGGTAGG GAATAATCGA 2340 ACATCTAAAG CCTTGAATAA GAGAATACTA ATTGTTTTGG TATGATGATA CTCAGAAATG 2400 GAGATATTAT AGGAAAAAGA AATCCTTTGG AATTTTAACT AAAATCACTG CATATGGGAA 2460 ATTAAGAGAT CCAGGACCAT ATTTGATAAG AGTTCCTAAA AATAATGTAA TTATTAATGC 2520 TAAAGACTGC TCATGTATCT TGATCTAATT ACTAAATAAA TTACATATTT ATTTACCTGA 2580 TAAATATGTA TCTAGTTCTA CAAGGTCACA TTTATOTGGA AGTCCAAAGT CAAGTCCTTA 2640 GGGGATAATT TTGTTTTGGG CTCAGTTGTT CCCTGCTTCC TTTTTTTTT TTTTTTTTT 2700 45 TTGAGATGGA GTCTCGCTCT GTTGCCCAGG CTGGAGTGCA GTGGTGCGAT CTCAGCTCAC 2760 TIGARATGUA VICTUCICI OTTUCAGCANT TUTUTGUA GIOCITUCA GIOCITUCA GIOCITUCA GALLAGO PER A TRACAGCANT CICACANTA CALAGORA CALA 50 CTAGAATCA ATTAGGGATG TTTGTTACTA CTCATATTGA TTAAAACAGT TAACAAACTT 3060
CTTGGGAGTA ATAAATGGGAG ATCAGTGAAC TCTGGTTTTA AGATAATCTG AAACAAGGTC 3120
CTTGGGAGTA ATAAAATTGG TCACATTCTG TAAAGCACAT TCTGTTTAGG AATCAACTTA 3180
TCTCAAATTG TAACTCGGGG CCTAACTATA TGAGATGGCT GAAAAAATAC CACATCGTCT 3240 55 GTTTTCACTA GGTGATGCCA AAATATTTTG CTTTATGTAT ATTACAGTTC TTTTTAAAAC 3300 ACTGGAAGAC TCATGTTAAA CTCTAATTGT GAAGGCAGAA TCTCTGCTAA TTTTTCAGAT 3360 TAAAATICTC TTTGAAAAAA T 60 Seq ID NO: 82 Protein sequence Protein Accession #: NP_000777 21 31 41 65 MAAAAGMILL GILQAGGSVL GQAMEKVTGG NILSMILIAC AFTLSLVYLI RLAAGHLVQL MAAAAGMILI GILQAGGSYL GGAMEK YIGZ NILSMILIAC AFIISLYYLI KIAAGHLVQL OO PAGYKSPPYI FSPIPFIGIHA IAFGKSPIEF LENAYEKYEQ YESTIMVGKT PTYLLGSDAA 120 ALLFNSKNED LNAEDVYSRL TIPVFGKGVA YDVPNPVFLE QKKMLKSGLN IAHFKQHVSI 180 IEKETKSYFE SWGESGEKNV FEALSELJIL TASSECLHGKB IRSQLNEKVA QLYADLDGGF 240 SHAAWILIPGW LPLPSFRRRD RAHREIKDIF YKAIQKRRQS QEKIDDLIQT LLDATGKDGR 300 PI.TDDEVAGM LIGILLAGQH TSSTTSAWMG FFIARDKTIQ KKCYLEQKTV CGENLPPLTY 360 DQLKDLNILD RCIKETLRLR PPIMIMMRMA KTPQTVAGYT IPPGHQVCVS PTVNQRLKDS 420 WVERLDFNPD RYLQDNPASG EKFAYVPFGA GRHRCIGENF AYVQIKTIWS TMLRLYEFDL 480 70 IDGYFPTVNY TTMIHTPENP VIRYKRRSK

NM 006551.2

Coding sequence: 64-336 (underlined sequences correspond to start and stop codons)




Â

5	GCTCAAGTCT GAACTCTACC TCCAGACAGA ATGAAGTTCA TCTCGACATC TCTGCTTCTC 120 ATGCTGCTGG TCAGCAGCCT CTCTCCAGTC CAAGGTGTTC TGGAGGTCTA TTACACAAGC 180 TTGAGGTGTA GATGTGTCCA AGAGAGCTCA GTCTTTATCC CTAGACGCTT CATTGATCGA 240 ATTCAAATCT TGCCCCGTGG GAATGGTTGT CCAAGAAAAA AAATCATAGT CTGGAAGAAG 300 AACAAGTCAA TTGTGTGTGT GGACCCTCAA GCTGAATGGA TACAAAGAAT GATGGAAGTA 360 TTGAGAAAAA GAAGTTCTTC AACTCTACCA GTTCCAGTGT TTAAGAGAAA GATTCCCTGA 420
10	TIGCTOATATT TOCACTAAGA ACACCTGCAT TOTTOCOTTA TOCCTGCTCT GGATTITAGT 480 TITTGTGCTTA GTTAAATCTT TTCCAGGGAG AAAGAACTTC COCATACAAA TAAGGCATGA 540 GGACTATGTG AAAAATAACC TTGCAGGAGC TGATGGGGCA AACTCAAGCT TCTTCACTCA 660
10	CAGCACCCTA TATACACTTG GAGTTTGCAT TCTTATTCAT CAGGGAGGAA AGTTTCTTTG 660 AAAATAGTTA TTCAGTTATA AGTAATACAG GATTATTTTG ATTATACT TGTTGTTTAA 720 TGTTTAAAAT TTCTTAGAAA ACAATGGAAT GAGAATTTAA GCCTCAAATT TGAACATGTG 780 GCTTGAATTA AGAAGAAAAT TATGGCATAT ATTAAAAGCA GGCTTCTATG AAAGACTCAA 840
15	AAAGCTOCCT GGGAGGCAGA TGGAACTTGA GCCTGTCÁAG AGGCAAAGGA ATCCATGTAG 90 TAGATATCCT CTGCTTAAAA ACTCACTACG GAGGAGAATT AAGTCCTACT TTTAAAGAAT 960 TTCTTTATAA AATTTACTGT CTAAGATTAA TAGCATTCGA AGATCCCAG ACTTCATAGA 1020 ATACTCAGGG AAAGCATTTA AAGGGTGATG TACACATGTA TCCTTTCACA CATTTGCCTT 1080 GACAAACTTC TTTCACTCAC ATCTTTTTCA CTGACTTTTT TTGTGGGGGG GGGCCCGGGG 1140 GGACTCTGGT ATCTAATTCT TTAATGATTC CTATAAATCT AATGACATTC AATAAAGTTG 1200
20	AGCAAACATT TTACTT
	Seq ID NO: 88 Protein sequence: Protein Accession #: NP_006410.1
25	1 11 21 31 41 51
	MKFISTSILL MILLVSSLSPV QGVLEVYYTS LRCRCVQESS VFIPRFIDR IQILPRGNGC 60 PRKEIIVWKK NKSIVCVDPQ AEWIQRMMEV LRKRSSSTLP VPVFKRKIP
30	Seq ID NO: 89 DNA sequence
	Nucleic Acid Accession #: NM_002652 Coding sequence: 37-477 (underlined sequences correspond to start and stop codons)
35	1 11 21 31 41 51
33	CTICTOTGGG ACACATIGCC TICTGTTTTC TOCAGCATGC GCTTGCTCCA GCTCCTGTTC 60 AGGGCCAGCC CTGCCACCCT GCTCCTGGTT CTCTGCCTGC AGTTGGGGGGC CAACAAAGCT 120 CAGGACAACA CTCGGGAAGAT CATAATAAAG AATTTTGACA TICCCAAGTC AGTACGTCCA 180 AATGACGAAG TCACTGCAGT GCTTGCAGTT CAAACAGAAT TGAAAGAATG CATGGTGGTT 240
40	AAAACITACC TCATTAGCAG CATCCCTCTA CAAGGTGCAT TTAACTATAA GTATACTGCC 300 TGCCTATGTG ACGACAATCC AAAAACCTTC TACTGGGACT TTTACACCAA CAGAACTGTG 360 CAAATTGCAG CCGTCGTTGA TGTTATTCGG GAATTAGGCA TCTGCCCTGA TGATGCTGCT 420 GTAATTCYCA TCAAAAACAA CCGGTTTTAT ACTATTGAAA TCCTAAAGGT AGAATAATGG 480
45	AAGCCCTGTC TOTTTGCCAC ACCCAGGTGA TTTCCTCTAA AGAAACTTGG CTGGAATTTC 540 TGCTGTGGTC TATAAAATAA ACTTCTTAAC ATGCTT
	Seq ID NO: 90 Protein sequence: Protein Accession #: NP 002643.1
50	i ii 21 31 41 51
55	GICPDDAAVI PIKNNRFYTI EILKV
	Seq ID NO: 91 DNA sequence Nucleic Acid Accession #: AK000341 Coding sequence: 85-975 (underlined sequences correspond to start and stop codons)
60	1 11 21 31 41 51 1 1 1 1 1 1
	GATAGOGCOG GGCAGAGGGA COCGGCTACC CTGGACAGCG CATCGCCGCC CGCCCGGGTC 60 GCCGCGCCAC AGCCGCTGCG GATCATGGAA CATCTAAAGG CCTTTGATGA TGAAATCAAT 120
65	GCTTTTTTGG ACAATATGTT TGGACCGCGA GATTCTCGAG TCAGAGGGTG GTTCACGTTG 180 GACTCTTACC TTCCTACCTT TTTTCTTACT GTCATGTATC TGCTCTCAAT ATGGCTGGGT 240
	AACAAGTATA TGAAGAACAG ACCTGCTCTT TCTCTCAGGG GTATCCTCAC CTTGTATAAT 300 CTTGGAATAC ACCTTCTCC CGCGTACATG CTGGCAGAGC TCATTCTCTC CACTTGGGAA 360 CGAGGCTACA ACCTTCACAGTG TCAAGATCTT ACCAGCGCAG GGGAAGGTGA CATCCGGGTA 4
70	GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCCTGGA CACAATTTTC 480 TTCGTTTTGC GGAAAAAAAC GAGTCAGATT ACTTTTCTC ATGTATATCA TCATGCTTCT 540
	ATGTTTAACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTTCTTTGGA 600 CCAACACTGA ACAGTTTTGT CCACATTCTT ATGTACTCCT ACTATGGACT TTCTGTGTTT 660 CCATCTATGC ACAAGTATCT TTGGTGGAAG AAATATCTCA CACAGGCTCA GCTGGTGCAG 720
75	TTOGTGCTCA CCATCACGCA CACCATGAGC GCCGTCGTGA AACCGTGTGG CTICCCCTTC 780
75	GGTTGTCTCA TCTTCCAGTC ATCTTATATG CTAACGTTAG TCATCCTCTT CTTAAATTTT 840 TATGTTCAGA CATACCGAAA AAAGCCAATG AAGAAAGATA TGCAAGAGCC ACCTGCAGGG 90 AAAGAAGTGA AGAATGGTTT TTCCAAAGCC TACTTCACTG CAGCAAATGG AGTGATGAAC 960
	INDIMARCIAL URINIAATT TO THE PROPERTY OF THE P

TIGITITIANA GCANAGACTO ANTIGAAGGI TACATGITIT AGGATANACT ANTITCITIT 1080
GAGTICATAA ATCATTIGIA CCCAGAATGI ATTAATATAT TGCTATTAGG TIAATCTGIT 1140
AACTGAATGC TITGATCAGC ATTGAGGTGA TGCTCACCTC CGAGGACCTC AGAACTGGTG 1200 CAGCTTCTCT CTCCCTCCCT CCCACAGACT GAACCTTTCG CCAGAAGCTG TCCTTATAAC 1260 GCCTTATACG CATACACAGC CAGGAAACGT GGAGCATTGT TTCTCACAGA GAGTCTCCAA 1320 ATAAAAAGGG TTTTGTTCAG ATTAAAATGT TTACAACAAA ATGTTAATTA TATTCTAAAT 1380 ACAGGGTATG TTCTAATCTA TATTAAGCAA TAATGCCAGT GCATAATCAT TCCATTTGTT 1440 CCTITAGCAA TCAACCCCAG AAAATATTAA AATGGGATCA TACACAGAAG ATAGAAAAAT 1500 10 CTAGCAAAAC TICTCTTTCT GTAAGCCAGA GTCTTGTCTA TCAGATTCCC ACAACCACTC 1560 CTGATTCTAA ATITAGTGAT ATGGTAATGA AATTGGTATT TATTTTAAAT ATTAGTTATT 1620 CTAAGGAGAA AAAAATGCTT CTGCAAGATT TTCATAATTC AGGGGCTGTG GATAGGATTG 1680
TTCCTCTGTT TCCCTAATCA TTCATCTGTT CATGTCTCCC TCTTGTGCCA GTCAGCCTAG 1740
GTTATACAGA TGCCATGCTC CACACCACGA GCAGTGTACA AATCTGGCTG CCCGTTTACT 1800 15 TTCTGAGCAA GCACTGGAGT CCACTCCGAC CTTTTTCTTT GAACATGCAT GCTGCTGGAA 1860 TATGTATAAA TCAGAACTAG CAGAAGTAGC AGAGTGATGG GAGCAAAATA GGCACTGAAT 1920
TCGTCAACTC TTITTTGTGA GCCTACTTGT GAATATTACC TCAGATACCT GTTGTCACTC 1980
TTCACAGGTT ATTTAAGTTC TTGAAGCTGG GAGGAAAAAG ATGGAGTAGC TTGGAAAGAT 2040 TCCAGCACTG AGCCGTGAGC CGGTCATGAG CCACGATAAA AAATGCCAGT TTGGCAAACT 2100 CAGCACTOCT GTFOCCTGCT CAGGTATATG CGATCTCTAC TGAGAAGCAA GCACAAAAGT 2160
AGACCAAAAGT ATTAATGAGT ATTTCCTTTC TOCATAAGTG CAGGACTGTT ACTCACTACT 2220
AAACTCTACC AAGAATGGAA ACCAAGAATA TITTCTGAAG ATTTTTTTGA AGATTAATTT 2280 20 ATACCCTATA AAATAAAACT TOTTAGCTTC GATGAAGTCA AAAAAAAAAA AAAAAAAAA 25 Seq ID NO: 92 Protein sequence: tein Accession #: BAA91096.1 31 41 MEHLKAFDDE INAFLDNMFG PRDSRVRGWF TLDSYLPTFF LTVMYLLSIW LGNKYMKNRP 60 30 ALSLRGILTL YNLGITLLSA YMLAELILST WEGGYNLQCQ DLTSAGEADI RVAKVLWWYY 120 FSKSVEFLDT IFFVLRKKTS QITPLHVYHH ASMFNIWWCV LNWIPCGQSF FGPTLNSFVH 180 ILMYSYYGLS VFPSMIKYLW WKKYLTQAQL VQFVLITTHT MSAVVKPCGF PFGCLFQSS 240 YMLTLVILFL NFYVQTYRKK PMKKDMQEPP AGKEVKNGFS KAYPTAANGV MNKKAQ 35 Seq ID NO: 93 DNA sequence NM_000044 Nucleic Acid Accession #: Coding sequence: 1115-3874 (underlined sequences correspond to start and stop codons) 40 31 21 41 CGAGATCCCG GGGAGCCAGC TTGCTGGGAG AGCGGGACGG TCCGGAGCAA GCCCACAGGC 60 AGAGGAGGCG ACAGAGGGAA AAAGGGCCGA GCTAGCCGCT CCAGTGCTGT ACAGGAGCCG 120 AAGGGACGCA CCACGCCAGC CCCAGCCCGG CTCCAGCGAC AGCCAACGCC TCTTGCAGCG 180 45 CGGCGGCTTC GAAGCCGCCG CCCGGAGCTG CCCTTTCCTC TTCGGTGAAG TTTTTAAAAG 240 CTGCTAAAGA CTCGGAGGAA GCAAGGAAAG TGCCTGGTAG GACTGACGGC TGCCTTTGTC 300 CTCCTCCTCT CCACCCCGCC TCCCCCCACC CTGCCTTCCC CCCCTCCCCC GTCTTCTCTC 360 COGCAGCTGC CTCAGTOGGC TACTCTCAGC CAACCCCCCT CACCACCCTT CTCCCCACCC 420 GCCCCCCCC CCCCGTCGGC CCAGCGCTGC CAGCCCAAGT TTGCAGAAGAG GTAACTCCCT 480
TTGGCTGCGA GCGGGCGAGC TAGCTGCACA TTGCAAAGAA GGCTCTTAGG AGCCAGGCGA 540
CTGGGGAGCG GCTTCAGCAC TGCAGCCACG ACCCGCCTGG TTAGAATTCC GGCGGAGAGA 600 50 ACCCTCTGTT TTCCCCCACT CTCTCTCCAC CTCCTCCTGC CTTCCCCACC CCGAGTGCGG 660 AGCAGAGATC AAAAGATGAA AAGGCAGTCA GGTCTTCAGT AGCCAAAAAA CAAAACAAAC 720
AAAAACAAAA AAGCCGAAAT AAAAGAAAAA GATAATAACT CAGTTCTTAT TTGCACCTAC 780
TTCAGTGGAC ACTGAATTTG GAAGGTGGAG GATTTTGTTT TTTCTTTTA AGATCTGGGC 840 55 ATCITITGAA TCTACCCTTC AAGTATTAAG AGACAGACTG TGAGCCTAGC AGGGCAGATC 900 TIGHTCACCE TOTGTCTTCT TCTGCACGAG ACTTTGAGGC TGTCAGAGGC CTITTTGCGT 960
GGTTGCTCCC GCAAGTTTCC TTCTCTGGAG CTTCCCGCAG GTGGGCAGCT AGCTGCAGCG 1020
ACTACCGCAT CATCACAGCC TGTTGAACTC TTCTGAGCAA GAGAAGGGGA GGCGGGGTAA 1080
GGGAAGTAGG TGGAAGATTC AGCCAAGCTC AAGGATGGAAA GTGCAGTTAG GGCTGGGAAG 1140 60 GGTCTACCCT CGGCCGCCGT CCAAGACCTA CCGAGGAGCT TTCCAGAATC TGTTCCAGAG 1200 CGTGCGCGAA GTGATCCAGA ACCCGGGCCC CAGGCACCCA GAGGCCGCGA GCGCAGCACC 1260 TCCCGGCGCC AGTTTGCTGC TGCTGCAGCA GCAGCAGCAG CAGCAGCAGC AGCAGCAGCA 1320 GCAGCAGCAG CAGCAGCAGC AGCAGCAAGA GACTAGCCCC AGGCAGCAGC AGCAGCAGCA 1380 65 GGGTGAGGAT GGTTCTCCCC AAGCCCATCG TAGAGGCCCC ACAGGCTACC TGGTCCTGGA 1440 TGAGGAACAG CAACCTTCAC AGCCGCAGTC GGCCCTGGAG TGCCACCCCG AGAGAGGGTTG 1500 CGTCCCAGAG CCTGGAGCCG CCGTGGCCGC CAGCAAGGGG CTGCCGCAGC AGCTGCCAGC 1560 ACCTCCGGAC GAGGATGACT CAGCTGCCCC ATCCACGTTG TCCCTGCTGG GCCCCACTTT 1620 CCCCGGCTTA AGCAGCTGCT CCGCTGACCT TAAAGACATC CTGAGCGAGG CCAGCACCAT 1680 GCAACTOCTT CAGCAACAGC AGCAGGAAGC AGTATCCGAA GGCAGCAGCA GCGGGAGAGC 1740
GAGGGAGGCC TCGGGGGCTC CCACTTCCTC CAAGGACAAT TACTTAGGGG GCACTTCGAC 1800
CATTTCTGAC AACGCCAAGG AGTTGTGTAA GGCAGTGCG GTGTCCATGG GCCTGGGTGT 1860
GGAGGCGTTG GAGCATCTGA GTCCAGGGGA ACAGCTTCGG GGGGATTGCA TGTACGCCCC 1920 70 ACTITIGGGA GITCCACCCG CTGTGCGTCC CACTCCTTGT GCCCCATTGG CCGAATGCAA 1980 AGGITCTCTG CTAGACGACA GCGCAGGCAA GAGCACTGAA GATACTGCTG AGTATTCCCC 2040 TTTCAAGGGA GGTTACACCA AAGGGCTAGA AGGCGAGAGC CTAGGCTGCT CTGGCAGCGC 2100 TGCAGCAGGG AGCTCCGGGA CACTTGAACT GCCGTCTACC CTGTCTCTCT ACAAGTCCGG 2160 75

AAGAAAGCAC AA<u>TAA</u>AAATG AGTAACAGAA AAAGCACATA TACTAGCCTA ACAGATTGGC 1020



TIGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA 720 AATCAGATAT CTGGTCATTG GGCTGCTTGC TGTATGAGTT ATGTGCATTA ATGCCTCCAT 780
TTACAGCTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGGCAAA TTCAGGCGAA 840
TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG 900 ATTACCATCG ACCTICTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG 960 CAGACGAGCA AAGAAGAAAT CTTGAGAGAA GAGGGCGACA ATTAGGAGAG CCAGAAAAAT 1920 CGCAGGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC 1980 GAGAGGGAGC TCTCAAAGCA AGAGAAAGAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG 1140 TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA 1200 GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC 1260 10 CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA 1320 GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA 1380 GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC 1440 TGAAAAGCAG ACAGATCCTG GGCATGCGCT AGCCAGGTAG AGAGACACAG AGCTGTGTAC 1500 AGGATGTAAT ATTACCAACC TTTAAAGACT GATATTCAAA TGCTGTAGTG TTGAATACTT 1560 15 GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG 1620 TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC 1680 ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG 1740 GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAATATT 1800 TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT 1860 20 TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTAAA TGTTTTTGAG CTTAGAAAAC 1920 CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC 1980 TETISTAGTIC AAATCIGTTA GETTISTIGAA AATTCATCAC TISTIGATIGTT GTATTCTTTT 2040
TITTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA 2100 25 TAAAAGAATT CTTCAGTTA

Seq ID NO: 96 Protein sequence NP 002488 Protein Accession #:

45

30 31 41 GIREFNPNIM ANEVERINMI TOSISGENEA RELATEDKIN ASEHOMOSAP IENSMPSRAE 60 DYEVLYTIGT GSYGRCOKIR RKSDGKILVW KELDYGSMTE AEKOMLVSEV NILRELKHPN 120 IVRYYDRIID RTNTTLYIVM EYCEGGDLAS VITKGTKERQ YLDEEFVLRV MTQLTLALKE 180 CHRRSDGGHT VLHRDLKPAN VFLDGKQNVK LGDFGLARIL NHDTSFAKTF VGTPYYMSPE 240 35 OMNRMSYNEK SDIWSLGCLL YELCALMPPF TAFSQKELAG KIREGKFRRI PYRYSDELNE 300 ITRMI NIKO YHRPSVEEL ENPLIADI.VA DEQRRNIERR GRQLGEPEKS QDSSPVLSEL. 360 KIKEIQLQER ERALKAREER LEQKEQELCV RERLAEDKIA RAENILKNYS LIKERKFISI. 420 ASNPELINIP SSVIKKKVHF SQESKENIMR SENSESQLTS KSKCKDIKKR LHAAQIRAQA 480 40 LSDIEKNYQL KSRQILGMR

Seq ID NO: 97 DNA sequence NM_007050.2 Nucleic Acid Accession #: Coding segmence: 185-4576 (underlined sequences correspond to start and stop codons)

51

41

31 CCTCCCCCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60
CCCGAGCGGA GCCAGCCGCG CGCACAGCCA GCGGCCGCCC CGGCGATGCG GGGCCACCCC 120
GCGCCCGCCC CAGTCCCGGC CCCGGCCCCC GCGGAAGGG GCTGAGCTGC CCGCCCCCC 180
CCGGATGGCG AGCCTCCCCG CGCTCGCCCT CAGCTGCTC CTGAGGCTGC AGCTGCCGCC 240 50 ACTGCCCGGC GCCCGGGCTC AGAGCGCCCC AGGTGGCTGT TCCTTTGATG AGCACTACAG 300 CAACTGTGGT TATAGTGTGG CTCTAGGGAC CAATGGGTTC ACCTGGGAGC AGATTAACAC 360
AACGGAGAAA CCAATGCTGG ACCAGGCAGT GCCCACAGGA TCTTTCATGA TGGTGAACAG 420
CTCTGGGAGAA CCCTCTGGCC AGAAGGCCCA CCTTCTCCTG CCAACCCTGA AGGAGAATGA 480
CACCCACTGC ATCGACTTCC ATTACTACTT CTCCAGCCGT GACAGGTCCA GCCCAGGGGC 540 55 CTTGAACGTC TACGTGAAGG TGAATGGTGG CCCCCAAGGG AACCCTGTGT GGAATGTGTC 600
CGGGGTCGTC ACTGAGGGCT GGGTGAAGGC AGAGCTCGCC ATCAGCACTT TCTGGCCACA 660
TTTCTATCAG GTGATATTTG AATCCGTCTC ATTGAAGGGT CATCCTGGCT ACATCGCCGT 720
GGACGAGGTC CGGGTCCTTG CTCATCCATG CAGAAAAGCA CCTCATTTTC TGCGACTCCA 780 60 AAACGTGGAG GTGAATGTGG GGCAGAATGC CACATTTCAG TGCATTGCTG GTGGGAAGTG 840 GTCTCAGCAT GACAAGCTTT GGCTCCAGCA ATGGAATGGC AGGGACACGG CCCTGATGGT 900
CACCCGTGTG GTCAACCACA GGCGCTTCTC AGCCACAGTC AGTGTGGCAG ACACTGCCCA 960
GCGGAGCGTC AGCAAGTACC GCTGTGTGAT CCGCTCTGAT GGTGGGTCTG GTGTGTCCAA 1020 CTACGCGGAG CTGATCGTGA AAGAGCCTCC CACGCCCATT GCTCCCCCAG AGCTGCTGGC 1080 65 TOTOGGGGC ACATACCTOT GGATCAAGCC AAATGCCAAC TOCATCATCG GGGATGGGCC 1180
TOTOGGGGCC ACATACCTOT GGATCAAGCC AAATGCCAAC TOCATCATCG GGGATGGCCC 1180
CATCATCCTG AAGGAAGTGG AATATCGCAC CACCACAGGC ACGTGGGCAG AGACCCACAT 1200
AGTCGACTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260
AGTGCTCCTC ACACGACCAG GTGAGGGGGGG TACGGGACCG CCAGGGGCTC CCCTCACCAC 1320 70 CAGGACCAAG TOTGCAGATC CGGTACATGG CCCACAGAAC GTGGAAATCG TAGACATCAG 1380 AGCCCGGCAG CTGACCCTGC AGTGGGAGCC CTTCGGCTAC GCGGTGACCC GCTGCCATAG 1440 CTACAACCTC ACCGTGCAGT ACCAGTATGT GTTCAACCAG CAGCAGTACG AGGCCGAGGA 1500 GGTCATCCAG ACCTCCTCCC ACTACACCCT GCGAGGCCTG CGCCCCTTCA TGACCATCCG 1560 GCTGCGACTC TTGCTGTCTA ACCCCGAGGG CCGAATGGAG AGCGAGGAGC TGGTGGTGCA 1620 75 GACTGAGGAA GACGTTCCAG GAGCTGTTCC TCTAGAATCC ATCCAAGGGG GGCCCTTTGA 1680 GGAGAAGATC TACATCCAGT GGAAACCTCC CAATGAGACC AATGGGGTCA TCACGCTCTA 1740 CGAGATCAAC TACAAGGCTG TCGGCTCGCT GGACCCAAGT GCTGACCTCT CGAGCCAGAG 1800

GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860 GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920 CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980 ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040 TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100 AGCTGACATT ATTGAGTGCT TITICGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160 TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220
TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTCT CTCCCCTGAA 2280
AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340 10 TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400 CTIGOCTIC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460
GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520
TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAT GCTTATTCCT ACTCCTATTA 2580
CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640 15 GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700 TGAAGGCTTC TCTTCTAGTT CTCAGGAAGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760
GCTTTCCCAG CCCACCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820
GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880 CATCACGCAG ATGAAGAGAG GCCAGGGCTA CGGGTTCAAG GAGGAATACG AGGCCTTACC 2940 20 AGAGGGGCAG ACAGCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000 ATATGGGAAC ATCATATCCT ACGACCATTC CCGGGTGAGG CTGCTGGTGC TGGATGGAGA 3060 CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120 CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTGGAGAA TGATCTGGCA 3180 GGAGAACTCC GCCAGCATCG TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAATG 3240 25 TGTGCGATAC TGGCCAGATG ACACGGAGGT CTACGGAGAC ATTAAAGTCA CCCTGATTGA 3300 AACAGAGCCC CTGGCAGAAT ACGTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTTCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TOGGCCCATA OTGGTCCACT GCAGTGCTGG GGCTGGGCGG ACTGGCTGCT TCATTGCCAT 3540 TGACACCATG CTTGACATGG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600 TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660 30 CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTGT GTGAGTTCCG 3720 TTCTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780 TGAATTICAG ACCETCAACA TIGTGACACC COGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA AFCCAGCAAT TACATCAACG CAGCACTGAT 3960 35 GGATAGCCAC AAGCAGCCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCCT 4020 GGCAGACTTC TGGAGGCTGG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080 GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCG GGTGCTATGG 4140 GCCCATCCAG GTGGAGTTCG TCTCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200 40 COGCATCTGT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260
CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCTCTCTGC TCAAAGTGGT 4320
CCGACGACTG GAGAAGTGGC AGGAGCAGTA TGACGGGAGG GAGGACGTA CTGTGGTCCA 4380 CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440 45 GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500 ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTGTA TACGAGGTGG CACTGGAATA 4560 TITAAGCTCC TTTTAGCTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620 CAAGCCCCCT TTTGTGTGAA TGGCAGTAAC TGGGCTCAGG AGCTCTGAGG TGGCACCCTG 4680 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740 GGGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAGGC CCAGGCTTCC TTTTCAACCT 4860 AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCCAC AAGCAAGGCC TTGGATTTCT 4860 GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920 50 AGGTGCTGGG GAGTGGGAGG CTCCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980 TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040 CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 CCTTACQATG TTCCCTAGGC CACAAGAGAG GCCCCCATC CTCACACCTA ACCTGCATGG 5160 55 GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT 5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTTGT 5280 GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCTT GTCTTTGTAA 5340 AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA 5460 60 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA 5520 AGAAGGGGC GGGGAGTTT GAGTATOTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT 5880
TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640
AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700 65 TGCATAATIT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820 GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940 70 CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTTATCAT CTCCATTTGA TCATCTCCTC 6000 CAATGAGGAA ACCCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060 AATGGCAATG AGACTICTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120
TATGGAGGGA AAATAAGGCC AGAAACTICT GAGCAGATAA CTCCACAAAT GGAAATTTTAG 6180
TACTTTCTTC CTGATGCCAG TICTTCTGGG AAGCGCAGAA TITCAGATAT ATTTTAGTAA 6240
CACATTCCCA GCTCCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300 75 TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360 CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420

WO 02/059377 PCT/US02/02242

TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600 AGAAGGGGAC GTCCATTCCT GCTGGGTCTT AACAAGCATA AAAAGGAAAA AAAGGAAACT 6660 5 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 OTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTOCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GGCCAAGACT CCTTCTGGGC 6900 CAATGGGGCT GCCTCTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960 10 CTTTTTAATA TCACATCTAT TIGTCTGTCT GCTCATTGTT TIGTTGCTGG AACTAAATAT 7020 GCAATGGATC ATGAGACTCA GATTCTATGA GAAACCCAGG GTCTCTGCTT TACCACGGAG 7080 CAGGGTCACC AACCCAGATC TCCAGGCCCA TGAGGATGGA ACATGAAAGG AGCCGACAAA 7140 AGTTGCTTCC ATTGGCATGG GCTCTGGAGC TGTCCAGAAG TCCAGGGACA CCAGACTTGA 7200 TCAAGGAAGG GCTGTCACTT TAGAGGTTCA AAAGGAAGTG CCTCAAAGCA AAGGCAAGCA 7260 AAGGAACCCC ACGATGAACT TECTCTTTC CTTTGATGAG CCTCTCCCCA GGTGTATTTC 7320
AGCAGACCCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380 15 GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440 ATGCTATTTT CTTAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTIT TITCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560 AGACAGTGGC TITTATCATI TIAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620 AAACTTGCAA AAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680 20 GATTICCCCC AGCTCATCCC CTTATITTCC CACAACCCAA CCATTCTCTA AAGCAGGACA 7740 GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAATTGA GGCTTATGGA TGGGGATGAC '7800 TTCCCTAAGA TCCCATGGGA CAAGGATGTG GCAAGGCTTG GATGAGATGG GGCACCAGTG '7860 CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCCC '7920 25 CAGGGGGTCT CCCCACCCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980 AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8040 CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT. 8160 TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160 GGGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 30 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 TTCCAGCATT CTAAAGGAGG GTTTGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 35 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520
CCCAGGAGGT TACCCATAAC AGAAGAGACT AGAGTGGAAC AGATACGTCA GTGGATAAAG 8580
CTCAAAGCAA ACAACAGTAA GCTTAAAATT CCTTCATAGT CTCATGTTTT ACGTTCACAA 8640 TTCATGCAAA ATTTGCATTC CACITTCTGA TITAGCCTTG TTGGTTTTAA TATGACTCTA 8700 40 TATGACGGAC CCTAGGTCAG CTGGTCTTCA GCTTGACCCT AGAATTGACT CTAGGAGCAG 8820 TGACCCTGCT GCCTCCCAGA GCCAGTTATA GGCTCAAGAT CAAGACCAAC TGACCTTCTC 8880 CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000 ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAGAAGC 9060 TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120 45 CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 50 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 55 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720 ACCOCTTAGA GTACATAGAG GTATCAGTOC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780 GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9440
CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9400 ATGAAGAAAG CCACCCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960 60 CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020 AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 AGGGAAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 CTTCTTAGCC TGTGACCAGC TTCAAATCAC AGCCAAGTAA AACAAGGAAA TAGGAAAAGT 10200
AAATCCAACT AGAAGAGACA AGCTGAGATT CAGATTTGTT TACTCCTCCC ATGCAAAAGT 10200
TCCCTGTTGG AGGTTTTCCA TGTATACATG TCTAGAAGTG ATAGAATGCA AGGCCTTGGC 10380
TTTGTCTTGC AGGGATCTGC CTTTGAGGTC ATAGACTGAA CAGCAGGGAG AGAGGTTAGT 10440 65 GGTGGAGTGT GGGGGGAGCT GTTCTAGCTC CAGTTTCTTC TGACACATA TICAGGATCA 10500
TGGATCTGAT CCTCCGAAGC ACAGCAGAGA TATCTAAGCC ATATTTGTGC ACATGAGCAG 10500
ACTCTTCTAG TTTTTTAGTA ACCAGGGATG GGCTTTTGCA TGGCACTGAC TATAGAGATG 10620
TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680 70 AAAGGICATC AAAGGGCATT CACCAACTGA AATCCACTCA TGAATGTTAG GTCTCTAAAA 10740 AAAGGICATC AAAGGGCATI CACCAACIGA AATCCACICA IOAAIGITAG GICICTAAAA IU/AU
GGAGGGATGA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800
CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860
CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATGGGGCT TCCTTCTATA TCTGAGAACT 10920
GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980 75 TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040

Ī

WO 02/059377 PCT/US02/02242

TTAATGTAGT TCATGGTTCC TTAGTGAGCA GGACTCTTGG ATGTGGAGGA GAAAGGGTCA 11100 TAGGAAGTAA ACCACCAAAA TTACAAAATT GAGTCTCTGT ACAATTACTT CAGTGCCTTT 11160 GGGCTTATGA ATACAAATCA GTGGGCCTTC TCTATGATGG TCCAACAAAC TCTCAGTGTC 11220 CACCCTGTCC CTGTATCTCC CATGGAAGAT GAATAATGTC AGGTGTTCTT TGGGTCAAAG 11280 5 GCCCCAGGGC AGTCTGGAGG CTTAGAGGGC AGAGTGGTGT CATTCCATGT AAAGTTAGGC 11340 TTCTGAGGGG TCAGGCAGAA TATGGTGTCC ATATCTTCCA TAGCTCTGCA GATTCTTGGA 11400 TGAAGTCAAG CACAGTTTGC TAGACCCAGG TCACTCCTCT GAGTATAACT AGGACCCATG 11460 AGTGAAACTT AATAGCTGTA AGGAAGAACC TGCTGTCTGC CAGAGAGGAT AAGCTGCCCA 11520 TCTCAGCAGC TGTCTAAAAG AAGGCAGGTG TCTCTTTAAA GGGAAGAGAA GCATTGGTGA 11580 10 AATGGATITC AGGTCACTTC CATTCCAGAT GGGTGAGATC TTGTGGAGCT GGGATCATGT 11640 TTGAACTCAT TCATACCTGT AGAGCACGAA TCCAAGTAGA TTGTGTTTGG TCTGTACAGG 11700 CTGAAGCCCC CTGCTCTCCC ACCCAAGTGC CCCCACTGAG CAGGCCAACA TGCTGTTGTG 11760 GCCACATATA CTGGGCTGAT CCAGGCTGGT TATCACCAAA CAGCAAACCA TAGGGAACAG 11820 CTGCTTTGCC ATAGACCCAA TACCCATGTA GATCTCTCAT GAGAGCAGCC ATAACTCAGA 11880 15 CCCACTGACC AACAGGGCCA TGAGTGACAG CCAGAACCAG TGAAGGTCCA AGTAGGACAC 11940 AGAGCAGGGC TITTCTTACC ATACACATTA TCTCCAGAGG TTATTTCTAC CCCACTCCCT 12000 ATTCAAGGCC TGTTGGAGCA CACTGCAAAA GCAAAAGCAC AGTAACTCAA TITACACATG 12060 ATTATAATCA TTTCCAGTGC ACACATTTCA TCACCAGGTG GATCCTGAGC TAGCCCATGT 12120 AAATCCGGGT TAACCCATAT TGGTAATCAT ACTCAAAAGC ACTTTTCACC CTACATTCTA 12180 20 CTAGCCAATC AAAGACAAAG AGTTGTGGCC TCTACCATTG CCTTGGCTTC TGGACACCCT 12240 CACAAGCTAT COCAAGGTTC CCGCTCAACT CCAGGGAGGC TGACATCTTC ACATCACTG 12300
GGCATATAAT ATTGCATGAG ACCAAAGTCT CCACACTCTT TGCAGCCTCC TCCATGAATC 12360
CCAATGGCCT GCACTTGTAC AGTTTGGGTG TTTGATAGAT AAAGCACGTA TGAGAAGAGA 12420
AAACAAAATA AATCAACTTT TTAAAAAAAGC CAGCACTGTG CTGTCAATGT TTTTTTTTTC 12480 25 TTTTCAATTC TAGCTCAGAA AAGCAGAAGG TAAATAATGT CAGGTCAATG AATATCAGAT 12540 ATATTTTTTG ACTGTACATT ACAGTGAAGT GTAATCTTTT TACACCTGCA AGTCCATCTT 12600 ATTTATTCTT GTAAATGTTC CCTGACAATG TTTGTAATAT GGCTGTGTTA AAAAATCTAT 12660 ACAATAAAGC TGTGACCCTG 30 Seq ID NO: 98 Protein sequence: NP_008981.1 Protein Accession #: 31 41 35 LAALALSLLL RLQLPPLPGA RAQSAPGGCS FDEHYSNCGY SVALGTNGFT WEQINTTEKP 120 MALDQAVPTGS FMMVNSGRA SGQKAHLLLP TLKENDTHCI DFHYYFSSRD RSSPGALNY 180
VKVNGGPQGN PVWNVSGVVT EGWVKAELAI SITWPHFYQV IFESVSLKGH PGYIAVDEVR 240
VLAHPCRKAP HFLRLQNVEV NVGQNATFQC IAGGKWSQHD KLWLQQWNGR DTALMVTRVV 3
NHRRFSATVS VADTAQRSVS KYRCVIRSDG GSGVSNYAEL IVKEPPTPIA PPELLAVGAT 360 40 YLWIKPNANS IIGDGPIILK EVEYRTTTGT WAETHIVDSP NYKLWHILDPD VEYEIRVLLT 420 RPGEGGTGPP GAPLTTRTKC ADPVHGPQNV EIVDIRARQL TLQWEPFGYA VTRCHSYNLT 480 VQYQYVFNQQ QYEAEEVIQT SSHYTLRGLR PFMTIRLRLL LSNPEGRMES EELVVQTEED 540 VPGAVPLESI QGGPFEEKIY IQWKPPNETN GVITLYEINY KAVGSLDPSA DLSSQRGKVF 600 45 KLRNBTHHILF VGLYPGTTY'S FTIKASTAKG FOPPVTTRIA TKISAPSMPB YDTIDTPLNET 660 DTTTTVMLKP AQSRGAPVSV YQLVVKEERL QKSRRAADII ECFSVPVSYR NASSLDSLHY 720 FAAELKPANL PVTQPFTVGD NKTYNGYWNP PLSPLKSYSI YFQALSKANG ETKINCVRLA 780 TKAPMGSAQV TPGTPLCLLT TGASTQNSNT VEPEKQVDNT VKMAGVIAGL LMFIILLGV 840 MI.TIKRRRNA YSYSYYI.SQR KLAKKQKETQ SGAQREMGPV ASADKPTTEL SASRNDEGFS 900 SSSQDVNGFT DGSRGELSQP TI.TIQTHPYR TCDPVEMSYP RDQFQLAIRV ADLLQHITQM 960 KRGQGYGFKE BYEALPEGQT ASWDTAKEDE NRNKNRYGNI ISYDHSRVRL LVLDGDPHSD 1020 50 YINANYIDGY HRPRHYIATQ GPMQETVKDF WRMIWQENSA SIVMVINLVE VGRVKCVRYW 1080 PDDTEVYGDI KVTLIBTEPL ABYVIRTFTV OKKGYHEIRE LRLPHFTSWP DHGVPCYATG 1140 LLGFVRQVKF LNPPEAGPIV VHCSAGAGRT GCFIAIDTML DMAENEGVVD IFNCVRELRA 1200 QRVNLVQTEE QYVFVHDAIL EACLCGNTAI PVCEFRSLYY NISRLDPQTN SSQIKDEFQT 1260 55 LNIVTPRVRP EDCSIGLLPR NHDKNRSMDV LPLDRCLPFL ISVDGESSNY INAALMDSHK 1320 QPAAFVVTQH PLPNTVADFW RLVFDYNCSS VVMLNEMDTA QFCMQYWPEK TSGCYGPIQV 1380 EFVSADIDED IHRIFRICN MARPODGYRI VOHLQYIGWP AYRDTPPSKR SILKVVRRLE 1440 KWQEQYDGRE GRTVVHCLNG GGRSGTFCAI CSVCEMIQQQ NIIDVFHIVK TLRNNKSNMV 1500 60 RTLEOYKFVY EVALEYLSSE Seq ID NO: 99 DNA sequence Nucleic Acid Accession #: NM_002988.1 Coding sequence: 71-340 (underlined sequences correspond to start and stop codons) 65 31 COGGCACGAG AGGAGTTGTG AGTTTCCAAG CCCCAGCTCA CTCTGACCAC TTCTCTGCCT 60 GCCCAGCATC ATGAAGGCCC TTGCAGCTGC CCTCCTTGTC CTCGTCTGCA CCATGGCCCT 120 GCCAGAAA TACATCAGCG ACCTGAAGCT GAATGCCTGA GGGGGCCTGGA AGCTGCAGGG

GGGCCAGAAA TACATCAGCG ACCTGAAGCT GAATGCCTGA GGGGCCCCAGT GCCCAAGCC

AGGTGTCATC CTCCTAACCA AGAGAGGCCG GCAGATCTGT GCTGACCCCA ATAAGAAGTG

GGTCCAGAAA TACATCAGCG ACCTGAAGCT GAATGCCTGA GGGGCCTGGA AGCTGCGAGG

300 70 GCCCAGTGAA CTTGGTGGGC CCAGGAGGGA ACAGGAGCCT GAGCCAGGGC AATGGCCCTG 420 75 CCACCCTGGA GGCCACCTCT TCTAAGAGTC CCATCTGCTA TGCCCAGCCA CATTAACTAA 480 CTTTAATCTT AGTTTATGCA TCATATTTCA TTTTGAAAATT GATTTCTATT GTTGAGCTGC 540 ATTATGAAAT TAGTATTTTC TCTGACATCT CATGACATTG TCTTTATCAT CCTTTCCCCT 600

WO 02/059377

TICCCTICAA CTCTTCGTAC ATTCAATGCA TGGATCAATC AGTGTGATTA GCTTTCTCAG 660 CAGACATTGT GCCATATGTA TCAAATGACA AATCTTTATT GAATGGTTTT GCTCAGCACC 720 ACCTITTAAT ATATTGGCAG TACTTATTAT ATAAAAGGTA AACCAGCATT CTCACTGTGA 780 ΑΛΑ ΑΛΑΛΑΛΑ ΑΛΑΛΑΛΑΑ ΑΛΑ 5 Seq ID NO: 100 Protein sequence: Protein Accession #: 11 21 31 41 10 MKGLAAALLV LVCTMALCSC AQVGTNKELC CLVYTSWQIP QKFIVDYSET SPQCPKPGVI 60 LLTKRGRQIC ADPNKKWVQK YISDLKLNA Seq ID NO: 101 DNA sequence 15 NM_015507.2 Nucleic Acid Accession #: Coding sequence: 241-1902 (underlined sequences correspond to start and stop codons) 21 31 41 20 CCGCAGAGGA GOCTOGGCCA GGCTAGCCAG GGCGCCCCCA GCCCCTCCCC AGGCCGCGAG 60 CGCCCCTGCC GCGGTGCCTG GCCTCCCCTC CCAGACTGCA GGGACAGCAC CCGGTAACTG 120 CGAGTGGAGC GGAGGACCCG AGCGGCTGAG GAGAGAGGAG GCGGCGGCTT AGCTGCTACG 180 ATQCTCTGC CCTGGAGCCT TGCGCTCCCG CTGCTGCTCT CCTGGGTGGC AGGTGGTTCC 300 25 GGGAACGCGG CCAGTGCAAG GCATCACGGG TTGTTAGCAT CGGCACGTCA GCCTGGGGTC 360 TGTCACTATO GAACTAAACT GGCCTGCTGC TACGGCTGGA GAAGAAACAG CAAGGGAGTC 420
TGTGAAGCTA CATGCGAACC TGGATGTAAG TTTGGTGAGT GCGTGGGACC AAACAAATGC 480
AGATGCTTTC CAGGATACAC CGGGAAAACC TGCAGTCAAG ATGTGAATGA GTGTGGAATG AAACCCCGGC CATGCCAACA CAGATGTGTG AATACACACG GAAGCTACAA GTGCTTTTGC 600 30 CTCAGTGGCC ACATGCTCAT GCCAGATGCT ACGTGTGTGA ACTCTAGGAC ATGTGCCATG 660 ATAAACTGTC AGTACAGCTG TGAAGACACA GAAGAAGGGC CACAGTGCCT GTGTCCATCC 720 TCAGGACTCC GCCTGGCCCC AAATGGAAGA GACTGTCTAG ATATTGATGA ATGTGCCTCT 780 GGTAAAGTCA TCTGTCCCTA CAATCGAAGA TGTGTGAACA CATTTGGAAG CTACTACTGC 840 AAATGTCACA TIGGTTTCGA ACTGCAATAT ATCAGTGGAC GATATGACTG TATAGATATA 900
AATGAATGTA CTATGGATAG CCATACGTGC AGCCACCATG CCAATTGCTT CAATACCCAA 960
GGGTCCTTCA AGTGTAAATG CAAGCAGGGA TATAAAGGCA ATGGACTTCG GTGTTCTGCT 1020 35 ATCCCTGAAA ATTCTGTGAA GGAAGTCCTC AGAGCACCTG GTACCATCAA AGACAGAATC 1080 AAGAAGTTGC TTGCTCACAA AAACAGCATG AAAAAGAAGG CAAAAATTAA AAATOTTACC 1140 CCAGAACCCA CCAGGACTCC TACCCCTAAG GTGAACTTGC AGCCCTTCAA CTATGAAGAG 1200 ATAGTTTCCA GAGGCGGGAA CTCTCATGGA GGTAAAAAAG GGAATGAAGA GAAAATGAAA 1260 40 GAGGGGCTTG AGGATGAGAA AAGAGAAGAG AAAGCCCTGA AGAATGACAT AGAGGAGCGA 1320 AGCCTGCGAG GAGATGTGTT TTTCCCTAAG GTGAATGAAG CAGGTGAATT CGGCCTGATT 1380 CTGGTCCAAA GGAAAGCGCT AACTTCCAAA CTGGAACATA AAGATTTAAA TATCTCGGTT 1440. GACTGCAGCT TCAATCATGG GATCTGTGAC TGGAAACAGG ATAGAGAAGA TGATTTTGAC 1500 45 TGGAATCCTG CTGATCGAGA TAATGCTATT GGCTTCTATA TGGCAGTTCC GGCCTTGGCA 1560 GGTCACAAGA AAGACATTGG CCGATTGAAA CTTCTCCTAC CTGACCTGCA ACCCCAAAGC 1620 AACTTCTGTT TGCTCTTTGA TTACCGGCTG GCCGGAGACA AAGTCGGGAA ACTTCGAGTG 1680 TTTGTGAAAA ACAGTAACAA TGCCCTGGCA TGGGAGAAGA CCACGAGTGA GGATGAAAAG 1740 TGGAAGACAG GGAAAATTCA GTTGTATCAA GGAACTGATG CTACCAAAAG CATCATTTTT 1800 50 GAAGCAGAAC GTGGCAAGGG CAAAACCGGC GAAATCGCAG TGGATGGCGT CTTGCTTGTT 1860 TCAGGCTTAT GTCCAGATAG CCTTTTATCT GTGGATGACT GAATGTTACT ATCTTTATAT 1920
TTGACTTTGT ATGTCAGTTC CCTGGTTTTT TTGATATTGC ATCATAGGAC CTCTGGCATT 1980 TTAGAATTAC TAGCIGAAAA ATTGTAATGT ACCAACAGAA ATATTATTGT AAGATGCCIT 2040 TCTTGTATAA GATATGCCAA TATTTGCTTT AAATATCATA TCACTGTATC TTCTCAGTCA 2100 TTTCTGAATC TTTCCACATT ATATTATAAA ATATGGAAAT GTCAGTTTAT CTCCCCTCCT 2160 CAGTATATCT GATTTGTATA AGTAAGTTGA TGAGCTTCTC TCTACAACAT TTCTAGAAAA 2220 55 TAGAAAAAA AGCACAGAGA AATGTTTAAC TGTTTGACTC TTATGATACT TCTTGGAAAC 2280 TATGACATCA AAGATAGACT TTTGCCTAAG TGGCTTAGCT GGGTCTTTCA TAGCCAAACT 2340 TGTATATITA AATTCTTTGT AATAATAATA TOCAAATCAT CAAAAAAAA AAAAAAAA 60 Seq ID NO: 102 Protein sequence Protein Accession #: NP_056 NP 056322.2 11 21 31 41 65 MPLPWSLALP LLLSWYAGGF GNAASARHHG LLASARQPGV CHYGTKLACC YGWRRNSKGV 60 CEATCEPGCK FOECVOPNIC RCFPGYTUKT CSQDVNECGM KPRPCQHRCV NTHOSYKCFC 120 LSGHMLMPDA TCVNSRTCAM INCQYSCEDT EEGPQCLCPS SGLRLAPNGR DCLDIDECAS 180 GKVICPYNRR CVNTFGSYYC KCHIGFELQY ISGRYDCIDI NECTMDSHTC SHHANCFNTQ 240 70 GSPKCKCKQG YKGNGLRCSA IPENSVKEVL RAPOTIKDRI KKLLAHKNSM KKKAKIKNVT 300 ISSTRUKCKOGO TRUNGIRUSA IPERSYASY LAWY IRANG KRELAHKASA KRARUKAY 1 300
PEPTRIPTPIK VNLQPFNYEG IVSRGGNSHG GKKGNBEKMK BGLEDEKREE KALKNDIEER 360
SLRGDVFFFK VNEAGEPGLI LVQRKALTSK LEHKDINISY DCSFNHGICD WKQDREDDFD 420
WNPADRDNAI GFYMAVPALA GHKKDIGRLK LLLPDLQPQS NFCLLFDYRL AGDKVGKLRV 480
FYKNSNNALA WEKTTSEDEK WKTGKIQLYQ GTDATKSIIF EAERGKGKTG EIAVDGVLLV 540 75 SGLCPDSLLS VDD

Seq ID NO: 103 DNA sequence

Nucleic Acid Accession #:

51 21 31 41 5 GAGACATTCC TCAATTGCTT AGACATATTC TGAGCCTACA GCAGAGGAAC CTCCAGTCTC 60 AGCACCATGA ATCAAACTGG GATTCTGATT TGCTGCCTTA TCTTTCTGAC TCTAAGTGGC 120
ATTCAAGGAG TACCTCTCTC TAGAACCGTA CGCTGTACCT GCATCAGCAT TAGTAATCAA 180
CCTGTTAATC CAAGGTCTTT AGAAAAACTT GAAATTATTC CTGCAAGCCA ATTTTGTCCA 240 10 COTOTTGAGA TCATTGCTAC AATGAAAAAG AAGGGTGAGA AGAGATGTCT GAATCCAGAA 300 TCGAAGGCCA TCAAGAATTT ACTGAAAGCA GTTAGCAAGG AAATGTCTAA AAGATCTCCT 360 TAAAACCAGA GGGGAGCAAA ATCGATGCAG TGCTTCCAAG GATGGACCAC ACAGAGGCTG 420 CCTCTCCCAT CACTTCCCTA CATGGAGTAT ATGTCAAGCC ATAATTGTTC TTAGTTTGCA 480 GTTACACTAA AAGGTGACCA ATGATGGTCA CCAAATCAGC TGCTACTACT CCTGTAGGAA 540 15 GGTTAATGTT CATCATCCTA AGCTATTCAG TAATAACTCT ACCCTGGCAC TATAATGTAA 600 GCTCTACTGA GGTGCTATGT TCTTAGTGGA TGTTCTGACC CTGCTTCAAA TATTTCCCTC 660 ACCTTTCCCA TCTTCCAAGG GTACTAAGGA ATCTTTCTGC TTTGGGGTTT ATCAGAATTC 720 TCAGAATCTC AAATAACTAA AAGGTATGCA ATCAAATCTG CTTTTTAAAG AATGCTCTTT 780 ACTICATGGA CTICCACTGC CATCCTCCCA AGGGGCCCAA ATTCTTTCAG TGGCTACCTA 840 CATACAATIC CAAACACATA CAGGAAGGTA GAAATATCTI AAAATGTATG TGTAAGTATT 900
CTTATTIAAT GAAAGACTGT ACAAAGTATA AGTCTTAGAT GTATATATTT CCTATATIGT 960
TTTCAGTGTA CATGGAATAA CATGTAATTA AGTCTTAGAT GTATATATTT CCTATATIGT 960
TTTCAGTGTA CATGGAATAA CATGTAATTA AGTACTATGT ATCAATGAGT AACAGGAAAA 1020
TTTTAAAAAT ACAGATAGAT ATATGCTCTG CATGTTACAT AAGATAAATG TGCTGAATGG 1080 20 TTTTCAAATA AAAATGAGGT ACTCTCCTGG AAATATTAAG 25 Seq ID NO: 104 <u>Protein sequence:</u>
Protein Accession #: NP_001556.1 31 41 30 EIIATMKKKG EKRCLNPESK AIKNLLKAVS KEMSKRSP Seq ID NO: 105 DNA sequ 35 NM 015068.1 Nucleic Acid Accession #: Coding sequence: 1170-2243 (underlined sequences correspond to start and stop codons) 31 41 51 40 GTAACAACCG TCACCCTGGG TCCCGACTGC CCACCTCCTC CTCCTCCCCC TCCCCCCAAC 60 AACAACAACA ACAACACTC CAAGCACACC GGCCATAAGA GTGCGTGTGT CCCCAACATG 120 ACCGAACGAA GAAGGGACGA GCTCTCTGAA GAGATCAACA ACTTAAGAGA GAAGGTCATG 180 AAGCAGTCGG AGGAGAACAA CAACCTGCAG AGCCAGGTGC AGAAGCTCAC AGAGGAGAAC 240 ACCACCCTTC GAGAGCAAGT GGAACCCACC CCTGAGGATG AGGATGATGA CATCGAGCTC 300 CGCGGTGCTG CAGCAGCTGC TGCCCCACCC CCTCCAATAG AGGAAGAGTG CCCAGAAGAC 360 CTCCCAGAGA AGTTCGATGG CAACCCAGAC ATGCTGGCTC CTTTCATGGC CCAGTGCCAG 420 ATCTTCATGG AAAAGAGCAC CAGGGATTTC TCAGTTGATC GTGTCCGTGT CTGCTTCGTG 480 45 ACAAGCATGA TGACCGGCCG TGCTGCCCGT TGGGCCTCAG CAAAGCTGGA GCGCTCCCAC 540 TACCTGATGC ACAACTACCC AGCTTTCATG ATGGAAATGA AGCATGTCTT TGAAGACCCT 600 CAGAGGCGAG AGGTTGCCAA ACGCAAGATC AGACGCCTGC GCCAAGGCAT GGGGTCTGTC 660 ATCGACTACT CCAATGCTTT CCAGATGATT GCCCAGGACC TGGATTGGAA CGAGCCTGCG 720 50 CTGATTGACC AGTACCACGA GGGCCTCAGC GACCACATTC AGGAGGAGCT CTCCCACCTC 780 GAGGTCGCCA AGTCGCTGTC TGCTCTGATT GGGCAGTGCA TTCACATTGA GAGAAGGCTG 840
GCCAGGGCTG CTGCAGCTCG CAAGCCACGC TCGCCACCC GGGCGCTGGT GTTGCCTCAC 900
ATTGCAAGCC ACCACCAGGT AGATCCAACC GAGCCGGTGG GAGGTGCCCCG CATGCGCCTG 960 55 ACGCAGGAAG AAAAAGAAAG ACGCAGAAAG CTGAACCTGT GCCTCTACTG TGGAACAGGA 1020 60 ATGTTGCTCA AAATGGAATT CCTCTAAGAA TCAAGGACTG GCCAATACTT GTGGAAGCAA 1320 TIGATGGGCG CCCCATAGCA TCGGGCCCAG TIGTCCACGA AACTCACGAC CTGATAGTTG 1380
ACCTGGGAGA TCACCGAGAG GTGCTGTCAT TIGATGTGAC TCAGTCTCCA TICTTCCCTG 1440
TCGTCCTAGG GGTTCGCTGG CTGAGCACAC ATGATCCCAA TATCACATGG AGCACTCGAT 1500 65 CTATCGTCTT TGATTCTGAA TACTGCCGCT ACCACTGCCG GATGTATTCT CCAATACCAC 1560 CATCGCTCCC ACCACCAGCA CCACAACCGC CACTCTATTA TCCAGTAGAT GGATACAGAG 1620
TTTACCAACC AGTGAGGTAT TACTATGTCC AGAATGTGTA CACTCCAGTA GATGAGCACG 1680
TCTACCCAGA TCACCGCCTG GTTGACCCTC ACATAGAAAT GATACCTGGA GCACACAGTA 1740 TTCCCAGTGG ACATGTGTAT TCACTGTCCG AACCTGAAAT GGCAGCTCTT CGAGATTTTG 1800 TIGGCAGAAA TIGTAAAAGAT GGGCTAATTA CTICCAACGAT TIGCACCTAAT GGAGCCCCAAG 1860
TITCTCCAGGT GAAGAGGGGG TIGGAAACTGC AAGTITICTTA TIGATIGCCGA GCTICCAACA 1920
ATTTTACTAT CCAGAATCAG TATCCTCGCC TATCTATTCC AAATTTAGAA GACCAAGCAC 1980
ACCTGGCAAC GTACACTGAA TTCGTACCTC AAATACCTGG ATACCAAACA TACCCCACAT 2040 70 ATGCCGCGTA CCCGACCTAC CCAGTAGGAT TCGCCTGGTA CCCAGTGGGA CGAGACGGAC 2100 AAGGAAGATC ACTATATGTA CETGTGATGA TCACTTGGAA TCCACACTGG TACCGCCAGC 2160 CTCCGGTACC ACAGTACCCG CCGCCACAGC CGCCGCCTCC ACCACCACCA CCGCCGCCGC 2220 CTCCATCTTA CAGTACCCTG TAAATACCTG TCATGTCCTT CAGGATCTCT GCCCTCAAAA 2280 75

NM_001565.1

Coding sequence: 67-363 (underlined sequences correspond to start and stop codons)

TTTATTCCTG TTCAGCTTCT CAATCAGTGA CTGTGTGCTA AATTTTAGGC TACTGTATCT 2340 TCAGGCCACC TGAGGCACAT CCTCTCTGAA ACGCTATGG AAGGTTAGGG CCACTCTGGA 2400
CTGGCACACA TCTTAAAGCA CCAAAAGACC TTCAACATTT TCTGAGAGCA ACAGAGTATT 2460
TGCCAATAAA TGATCTCTCA TTTTTCCACC TTGACTGCCA ATCTAACTAA AATAATTAAT 2520
AAGTTTACTT TCCAGCCAGT CCTGGAAGTC TGGGTTTTAC CTGCCAAAAAC CTCCATCACC 2580 5 ATCTAAATTA TAGGCTGCCA AATTTGCTGT TTAACATTTA CAGAGAAGCT GATACAAACG 2640 CAGGAAATGC TGATTTCTTT ATGGAGGGGG AGACGAGGAG GAGGAGGACA TGACTTTTCT 2700 TGCGGTTTCG GTACCCTCTT TTTAAATCAC TGGAGGACTG AGGCCTTATT AAGGAAGCCA 2760 AAATTATOGG TGCAGTGTGG AAAGGCTTCC GTGATCCTCT CGCTGCACCC TTAGAAACTT 2820 CACCGTCTTC AAACTCCATT TCCATGGTTC TGTTAATTCT CAAGGAGCAG CAACTCGACT 2880 10 GGTTCTCCCA GGAGCAGGAA AAACCCTTGT GACATGAAAC ATCTCAGGCC TGAAAAGAAA 2940 GTGCTCTCTC AGATGGACTC TTGCATGTTA AGACTATGTC TTCACATCAT GGTGCAAATC 3000 ACATGTACCC AATGACTCCG GCTTTGACAC AACACCTTAC CATCATCATG CCATGATGGC 3060 TTCCACAAAG CATTAAACCT GGTAACCAGA GATTACTGGT GGCTCCAGCG TTGTTAGATG 3120 15 TTCATGAAAT GTGACCACCT CTCAATCACC TTTGAGGGCT AAAGAGTAGC ACATCAAAAG 3180 GACTCCAAAA TCCCATACCC AACTCTTAAG AGATTTGTCC TGGTACTTCA GAAAGAATTT 3240
TCATGAGTGT TCTTAATTGG CTGGAAAAGC ACCAGCTGAC GTTTTGGAAG AATCTATCCA 3300
TGTGTCTGCC TCCATATGCA TCTGGGCATT TCATCTTCAG TCCCTCATT AGACTGTAGC 3360 ATTAGGATOT GTGGAGAGAG GAGAAATGAT TTAGCACCCA GATTCACACT CCTATGCCTG 3420 GAAGGGGAC ATCTTTGAAG AAGAGGAATT AGGGCTGTGG ACACTGTCTT GAGGATGTGG 3480 ACTTCCTTAG TGAGCTCCAC ATTACTTGAT GGTAACCACT TCAAAAGGAT CAGAATCCAC 3540 20 GTAATGAAAA AGGTCCCTCT AGAGGATGGA GCTGATGTGA AGCTGCCAAT GGATGAAAAG 3600 CCTCAGAAAG CAACTCAAAG GACTCAAAGC AACGGACAAC ACAAGAGTTG TCTTCAGCCC 3660 AGTGACACCT CTGATGTCCC CTGGAAGCTT TGTGCTAACC TGGGACTGCC TGACTTCCTT 3720 AGIGACACUT CIGARGICU CIGGARGUT I GIGUTACAC TROCATOCA TRACTICATA 3780
TAGCCTGGTC CCTTGCTACT ACCTTGAACT GTTTTATCTA ACCTCTCTTT TCTGTTTAA 3780
TCTTTGCTA CTGCCATTGA CCCTGCTGCA GGATTTGTGT CATTTTCCTG CCTGGTTGCT 3840
GAGACTCCAT TTTGCTGCCA CACACAGAGA TGTAAGAGGC AGGCTTTAAT TGCCAAAGCA 3960
CAGTTTGAGC AGTAGAAAAC AACATGGTGT ATATCTCAAA TTGCCTGACA TGAAGAGGAG 3960 25 TCTAACGGTG AAGTTTCACT TTTCATCAGC ATCATCTTTC ACATGTTCAT TATCATCCGC 4020
TCTTATICTT GCATGTTTAA ACACTTAAAA TTTTTAGTAT AATTTTTAGT GTGTTTTGAA 4080
GTGGTGACTA GGCTTTCAAA AACTTCCATT GAATTACAAA GCACTATCCA GTTCTTATTG 4140 30 TTAAACTAAG TAAAAATGAT AAGTAACATA GTGTAAAATA TTCCTTTACT GTGAACTTCT 4200 TACAATGCTG TGAATGAGAG GCTCCTCAGA ACTGGAGCAT TTGTATAATA ATTCATCCTG 4260 TICATCITCA ATTITAACAT CATATATAAT TICAATTCTA TCAATTGGGC CTITAAAAAT 4320 CATATAAAAG GATATAAAAT TIGAAAAGAG AAACCTAATT GGCTATTTAA TCCAAAACAA 4380 CITTTTTTT TCCTTCAATG GAATCAGAAA GCTTGTCAAT CACTCATGTG TTITAGAGTA 4440 35 ATTACTITTA AAATGGTGCA TTIGTGCTIC TGAACTATTI TGAAGAGTCA CTTCTGTTTA 4500
CCTCAAGTAT CAATTCATCC TCCATACATT TGAATTCAAG TTGTTTTTTG TCAAATTTAC 4560
AGTTGTCAAT TGATCTTCAA GCTGCAGGGT GCCTAGAAAT GGGCCGTTGT CTGTAGCCCT 4620
GGCATGTGCA CACGGACATT TGCCACCACT GCAAGCAAAA GTCTGGAGAA GTTCACCAAC 4680 40 GACAAGAACG ATTAGGGAAA ATATGCTGCT GTGGGTTAAC AACTCAGAAA GTCCCTGATC. 4740
CACATTIGGC TGTTTACTAA AGCTTGTGAT TAACTTTTTG GCAGTGTGTA CTATGCTCTA 4800
TTGCTATATA TGCTATCTAT AAATGTAGAT GTTAAGGATA AGTAATTCTA AATTTATTAT 4860
TCTATAGTTT TGAAGTTTGG TTAAGTTTCC TTTCACTCAA TTGATTTATT TTGTTGTTAA 4920 TCAAATITAT GITAATIGGA TCCITTAAAT TITTITIGGC ATTITCCAAC AAAAATGGCT 4980 TTATTCATAA GAAAGGAAAA AAATCAATGG AATITGATAT CTAAAGAAGT TAGAAAGGGA 5040 GCAAAATAAA AAACATAAAG GAGATAGATG AATTAGTAAG CAAATCAGTA GTCGAGTTIT 5100 45 TCAAACTGGC AAAATTAATT AATTGACTTT TAGCCCAAAT TTACATTGTT AATTAAATCA 5160 AGAAGGAAGA AGATCTAAGA GCTCCCATTG ATAGGCAAGC CTAGAGAGAA CTAGGTAAAT 5220 TTATCATGCT AGGATATTGA AACACAGAAA GTTTACATAC ATTTATGAAG GGTCAATTTA 5280 GTTTGGACAG TGAGGTATTT GTCTTAGTGG AAAAAAGGAG AATTAGTCTG ATCAAATCGT 5340 50 GAAGTAATAC AGTGAACTTG CAGGTGCACA AAATAAGAGG GCCACATCTA TATGGTGCAG 5400 TCTGGAATTC TOTTTAAGTT TGTAGGTACC TCTTGGACTT CTGAATTGAT CCAGTTGTCA 5460 TOCACCACAG ACATOTCACA TOAGATACAG ACAGTTOCAA GATTGACAAC AGAGAACAAC 5520 CTGCTGGAAA GACCTGGGCA GAAATGGAGA GCCCTGCGGG AACCATGCTA CATTTTCATC 5580 TAAAGAGAGA ATGCACATCT GATGAGACTG AAAGTTCTTT GTTGTTTTAG ATTGTAGAAT 5640 55 GOTATIGAAT TGGTCTGTGG AAAATTGCAT TGCTTTTATT TCTTTGTGTA ATCAAGTTTA 5700 AGTAATAGGG GATATATAAT CATAAGCATT TTAGGGTGGG AGGGACTATT AAGTAATTIT 5760 AAGTGGGTGG GUTTATTTAG AATGTTAGAA TAATATTATG TATTAGATAT CGCTATAAGT 5820 GGACATGCGT ACTTACTTGT AACCCTTTAC CCTATAATTG CTATCCTTAA AGATTTCAAA 5880 60 TAAACTCGGA GGGAACTGCA GGGAGACCAA CTTATTTAGA GCGAATTGGA CATGGATAAA 5940 AACCCCAGTO GGAGAAAGTT CAAAGGTGAT TAGATTAATA ATTTAATAGA GGATGAGTGA 6000
CCTCTGATAA ATTACTGCTA GAATGAACTT GTCAATGAT AGTTAAAAAT TITCATGGAA 6060
GTTATAAAAG TGATAAATAA AAACCCTTGC TTTTACCCCT GTCAGTAGCC CTCCTCCTAC 6120
CACTGAACCC CATTGCCCCT ACCCCTCCTT CTAACTTTAT TGCTGTAATTC TCTTCACTCT 6180 65 ATATTICICT CTATTIGCTA ATATTGCATT GCTGTTACAA TAAAAATTCA ATAAAGATTT 6240 AGTGGTTAAG TGC

70 Seq ID NO: 106 Protein sequence:
Protein Accession U: NP_055883.1

21 31 41

MTERROBLS BEINNLREKV MKQSEENNNL QSQVQKLTEB NTTLREQVEP TPEDEDDDIE 60
LRGAAAAAAP PPPEEECPE DLPEKFDGNP DMLAPFMAQC QIPMEKSTRD FSVDRVRVCF 120
VTSMMTGRAA RWASAKLERS HYLMHNYPAF MMEMKHVFED PQRREVAKRK IRRLRQGMGS 180
VIDYSNAFQM IAQDLDWNEP ALIDQYHEGL SDHIQEELSH LEVAKSLSAL IGQCIHIERR 240

di.

LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

Seq ID NO: 107 DNA sequence
Nucleic Acid Accession #: NM_003679.1
Coding sequence: 47-1507(underlined sequences correspond to start and stop codons)

51

31

10 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTT<u>ATG</u>G ACTCATCTGT 60 CATTCAAAGG AAAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG CTTTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT 180
GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240
CTTGAAAGCT GTTGGCCTGG AAGATCAGAT TGTATCCCAA GGTATTCCCA TGAGAGCAAG 300
AATGATCCAC TCTCTTTCAG GAAAAAAGTC TGCAATTCCC TATGGGACAA AGTCTCAGTA 360 15 TATTCTTTCT GTAAGCAGAG AAAATCTAAA CAAGGATCTA TTGACTGCTG CTGAGAAATA 420 CCCCAATGTG AAAATGCACT TTAACCACAG GCTGTTGAAA TGTAATCCAG AGGAAGGAAT 480 GATCACAGTG CITGGATCTG ACAAAGTTCC CAAAGATGTC ACTTGTGACC TCATTGTAGG 540 ATGTGATGGA GCCTATICAA CTGTCAGATC TCACCTGATG AAGAAACCTC GCTTTGATTA 600 20 CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660 THATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720
ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780
AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCCAG AAATACTTTC CGGATGCCAT 840
CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900 25 GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020 GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTGTC TTCCTGTGTT 1080 CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200 30 TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260
AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 ACTOTITITO TIGGGATCAC TGATAGOCAT CAGCAGTACO TACOTACITA TACACTACAT 1380 GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCTC ACTTCCGGAA 1440 TACAACATGT TICCCCGCAA AGGCCGTGGA CTCCCTAGAA CAAATTTCCA ATCTCATTAG 1500 CAGGTGATAG AAAGGTTTTG TGGTAGCAAA TGCATGATTT CTCTGTGACC AAAATTAAGC 1560 ATGAAAAAAA TGTTTCCATT GCCATATTTG AFTCACTAGT GGAAGATAGT GTTCTGCTTA 1620 35 TAATTAAACT GAATGTAGAG TATCTCTGTA TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 ATTITAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740
AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800
TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860 40 TGACTCAACA CCTAGGACTA AAAATCACAA CTTAACTAGC ATGTTAACTG CACTTTTCAT 1920 TACOTGAATG GAACTTACCT AACCACAGGG CTCAGACTTA CTAGATAAAA CCAGAAATGG 1980 AAATAAGGAA TTCAGGGGAG TTCCAGAGAC TTACAAAATG AACTCATTTT ATTTTCCCAC 2040 CTTCAAATAT AAGTATTATC ATCTATCTGT TTATCGTCTA TCTATCTATC ATCTATCTAT 2100 45 TCTATTTATT TATGTATTTA GAGATCAGGT CTCACTCTGT TGACCAGGCT GGAGTGCAGT 2220 GGTGAGATCT GGGTTCACTG CAACCTCTGC CTCCTGGGCT CAAGCAATCC TCCCACTTCA 2280 GCCTCCCAAA TAGCTGGGGC TACCATGGTA TTTTTCAGTA GAGACCGGGT CTTGCCATGC 2340 TGCCCAGGCC AGTCTCAAAC TCCTGGCCTC ATGTGATCTG CCCACCTCAG CCTCCCAAAG 2400 50 TACAGGGATT AGAGTTUTGA GOCACOGCTG OCAGCOCAGA GTTACCCTCT AAAGATAAGA 2460 AAAAGGCTAT TAATATCATA CTAAGTGAAG GACAGGAAAG GGTTTTATTC ATAAATTAAA 2520 TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTTATA GAAATACAAA 2580 GOCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640 CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700 55 ATGATTCAGT GTTTCTTTC TATATTOTCA ATGAAAACCT TGAGTTCTAA TAATCCATGT 2880 TCAGTTTGTA GGGAAAGAAA AAATAATTIT TOCTTCTACC CACTTTAGGT TCCTTGGCTG 2940 GGGCCCCTAT AACAAAAGAC AGATTGACAA GAGAAAAACA AACATAAATT TATTAGCGGG 3000 TATATGTAAT ATATATGTGG GAAATACAGG GGAATGAGCA AATCTCAAAG AGCTGGCGTC 3060 TTAGAACTCC CTGGCTTATA TAGCATCGAC AAAGAACAGT AAATTTTTAG AGAAACAACA 3120 60 AAACAAAGAA AAAGAGCTTT GAGTCTGTAG GGGCAGCAAT TTGGGGGAAG CAAATATATG 3180 GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240 TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTTT CCAACAAGAG 3300 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420 65 TACGCGACAG TTATTTTTAC AGTAAGGTAT TITCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATTTAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGTTAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600 ATTAAAAGAA TTTGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCCAATTC 3660 70 GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720 CTICTTATGA TGAAAGTCCA AAAGTGCAT CCAATTTAAG GCCCCATCTT TCGTTGCCAT 3780
TCTTCATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTTGGACCCAT TGGTTTTGTC 3840
GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3960
GAAAGTCACT TTTTTCTTTTG GCCTGTCCCC ATCTTTCTGT GACATCACA TGGGTCTGAT 3960
CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020 75 GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAT AAAGTGGAAT 4080 WO 02/059377 PCT/US02/02242

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TITGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TTTATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ANGTAGACC ATTICAATAC CTIGTAATCC TOCAAGCTIC AATOTGCACA CACTITCTAT 4320
GAGGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCCACAA ATATTCAGTG 4380
GOCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTITTTACTA TAAGCATCAA 4440
AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500 5 AATTAGGTGA AGAATTTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560 TATAGEAGAC AGEACTAATG TEATEAACAA ACATTGTTET TETECOTGTC ETGGGTACAA 4620 CATCGAATAA TATTTETTGG CETCETTTCC GETTCTCCTC TETGCTGTTC CTCTCTACAA 4680 10 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740 AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800 GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 15 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 TAAAAATATA ATAAATAGCT Seq ID NO: 108 Protein sequence: NP_003670.1 Protein Accession #: 20 41 31 21 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 MISSYIGKAY AVIOUGUV SUQATTARKA MISSI SGKKSAIPYG TKSQYILSVS REDIANKDILLT 120
AAEKYPNYKM HFNHRLIKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180 25 PRFDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP 240 FEEFEKILTS NOVYDFFOKY FPDAIPLIGE KLLVQDFFIL PAQFMISVKC SSFHFKSHCV 300 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYTEMRAH VNSSWFTFOK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 30 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 SNLISR Seq ID NO: 109 DNA sequence NM_006115.1 teic Acid Acces 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) 51 21 31 41 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCCGGCCT GCAGCCCCTC AGCACCGCTC 60
CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120
ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT 180 40 GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATGGA 240 ACGAAGGCTT TTOTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 45 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540
TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600
GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 50 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TIGITTEGAC ACAGAGGCAG AGCAGCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGT 780
CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840
GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900
TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG 960 55 TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 GCGTAGACTE CICCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080
GCAGTATATE GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140
TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 60 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 CONGICTIT ARGAGING GGALACOGA HARCACOGA ANTICACTIC ARGAGINATORA TOCATACTIC 1500
CITGCAGAGI CICCTGCAGC ACCITATAGG CITGAGCAAT CIGACCACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620
TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680
TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCC 1740 65 GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 70 GTTCAGTGAG GAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 **GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100** TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAA AAAAAAA

Seq ID NO: 110 Protein sequence:
Protein Accession #: NP_006106.1

75

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.